FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Satre, DD Manuel, JK Larios, S Steiger, S Satterfield, J AF Satre, Derek D. Manuel, Jennifer K. Larios, Sandra Steiger, Scott Satterfield, Jason TI Cultural Adaptation of Screening, Brief Intervention and Referral to Treatment Using Motivational Interviewing SO JOURNAL OF ADDICTION MEDICINE LA English DT Editorial Material DE alcohol; cultural competence; hazardous drinking; motivational interviewing; SBIRT; substance use disorder ID PRIMARY-CARE; DRUG-USE; TREATMENT SBIRT; CLINICAL-TRIAL; ILLICIT DRUG; ALCOHOL-USE; ACCULTURATION; CALIFORNIA; CESSATION; DRINKING AB This clinical case presentation and discussion illustrates a culturally adapted alcohol and drug use intervention using the Screening, Brief Intervention, and Referral to Treatment (SBIRT) approach, incorporating motivational interviewing skills. This case conference serves to complement the accompanying review article on SBIRT with diverse cultural groups, placing information from the reviewin the context of a typical clinical setting. In this example, SBIRTis provided in a primary care clinic to a Latino patient who reports hazardous drinking, depression, chronic pain and use of prescription opioids. C1 [Satre, Derek D.] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave,Box 0984, San Francisco, CA 94143 USA. [Satre, Derek D.] Kaiser Permanente Northern Calif Reg, Div Res, Oakland, CA USA. [Manuel, Jennifer K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Larios, Sandra] San Francisco Gen Hosp, Dept Psychiat, San Francisco, CA USA. [Steiger, Scott; Satterfield, Jason] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Satre, DD (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave,Box 0984, San Francisco, CA 94143 USA. EM dereks@lppi.ucsf.edu FU NIDA NIH HHS [T32 DA007250, P50 DA009253, P50DA09253, U10 DA015815, U10DA015815] NR 35 TC 1 Z9 1 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD SEP-OCT PY 2015 VL 9 IS 5 BP 352 EP 357 DI 10.1097/ADM.0000000000000149 PG 6 WC Substance Abuse SC Substance Abuse GA DC9CK UT WOS:000369518300002 PM 26428360 ER PT J AU Jones, AL Hanusa, BH Appelt, CJ Haas, GL Gordon, AJ Hausmann, LRM AF Jones, Audrey L. Hanusa, Barbara H. Appelt, Cathleen J. Haas, Gretchen L. Gordon, Adam J. Hausmann, Leslie R. M. TI Racial Differences in Veterans' Satisfaction With Addiction Treatment Services SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE healthcare disparities; patient satisfaction; substance abuse treatment services ID SUBSTANCE-ABUSE TREATMENT; HEALTH-CARE; PATIENT-SATISFACTION; UNITED-STATES; TREATMENT COMPLETION; OUTPATIENT TREATMENT; ETHNIC DISPARITIES; OUTCOMES; RACE/ETHNICITY; PERCEPTIONS AB Objectives: Racial minorities experience lower rates of alcohol treatment completion than whites. Treatment satisfaction is an important factor in alcohol treatment retention, yet few studies have explored the satisfaction of racial minorities while in treatment. This study examined racial differences in addiction treatment satisfaction and explored factors that might mediate or moderate racial differences in satisfaction. Methods: We surveyed non-Hispanic black and non-Hispanic white veterans with an alcohol-related diagnosis about addiction treatment services at a large Veterans Affairs medical center. Treatment satisfaction was measured using the 8-item Client Satisfaction Questionnaire, dichotomized as low versus non-low satisfaction in analyses. The chi(2) and logistic regression methods were used to test for associations of race and sociodemographic characteristics with treatment satisfaction. Results: Among 271 black and 304 white veterans with an alcohol-related diagnosis, race was not statistically associated with treatment satisfaction in bivariate analyses (P > 0.05). However, we identified significant interactions of race with mental health diagnoses in predicting treatment satisfaction in multivariable analyses (adj odds ratio = 0.55; 95% confidence interval [CI] = 0.39-0.78). In post hoc comparisons among veterans with zero mental health diagnoses, black veterans had a greater probability of reporting low satisfaction than whites (marginal difference = 0.13; 95% CI = 0.04-0.22). In veterans with 4 or more diagnoses, whites had a greater probability than blacks of reporting low satisfaction (marginal difference = 0.28, 95% CI = 0.10-0.46). Regardless of race, past homelessness was associated with low satisfaction (adj odds ratio = 2.09; 95% CI = 1.19-3.67). Conclusions: Racial minorities, veterans with unstable housing, and white veterans with co-occurring mental health disorders may be at risk of experiencing low treatment satisfaction. C1 [Jones, Audrey L.; Gordon, Adam J.; Hausmann, Leslie R. M.] Vet Affairs Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hanusa, Barbara H.; Appelt, Cathleen J.; Haas, Gretchen L.] Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Appelt, Cathleen J.] Duquesne Univ, Dept Sociol, Pittsburgh, PA 15219 USA. [Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Gordon, Adam J.; Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Jones, AL (reprint author), VAPHS, VA Ctr Hlth Equ Res & Promot CHERP, Univ Dr,151C,Bldg 30, Pittsburgh, PA 15240 USA. EM Audrey.Jones3@va.gov FU Department of Veterans Affairs Substance Use Disorder Quality Enhancement Research Initiative [SUDQ-LIP1411]; VISN4 Mental Illness Research, Education and Clinical Center at the Veterans Affairs Pittsburgh Healthcare System FX Supported by the Department of Veterans Affairs Substance Use Disorder Quality Enhancement Research Initiative (SUDQ-LIP1411) and the VISN4 Mental Illness Research, Education and Clinical Center at the Veterans Affairs Pittsburgh Healthcare System. NR 41 TC 1 Z9 1 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD SEP-OCT PY 2015 VL 9 IS 5 BP 383 EP 390 DI 10.1097/ADM.0000000000000144 PG 8 WC Substance Abuse SC Substance Abuse GA DC9CK UT WOS:000369518300006 PM 26335005 ER PT J AU Kaunitz, AM Kaunitz, JD AF Kaunitz, Andrew M. Kaunitz, Jonathan D. TI Compounded bioidentical hormone therapy: time for a reality check? SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material ID UNITED-STATES C1 [Kaunitz, Andrew M.] Univ Florida, Coll Med, Dept Obstet & Gynecol, Jacksonville, FL USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. RP Kaunitz, AM (reprint author), Univ Florida, Coll Med, Dept Obstet & Gynecol, Jacksonville, FL USA. FU NIDDK NIH HHS [R01 DK054221] NR 6 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1072-3714 EI 1530-0374 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD SEP PY 2015 VL 22 IS 9 BP 919 EP 920 DI 10.1097/GME.0000000000000484 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DD0IL UT WOS:000369603500001 PM 26035149 ER PT J AU Reese, SR Wilson, NA Huang, GW Redfield, RR Zhong, WX Djamali, A AF Reese, Shannon R. Wilson, Nancy A. Huang, Gengwen Redfield, Robert R., III Zhong, Weixiong Djamali, Arjang TI Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model SO TRANSPLANTATION LA English DT Article ID RELAPSED/REFRACTORY MULTIPLE-MYELOMA; CHRONIC ALLOGRAFT NEPHROPATHY; DONOR-SPECIFIC ANTIBODIES; KIDNEY-TRANSPLANTATION; PLASMA-CELLS; RENAL-TRANSPLANTATION; BORTEZOMIB; BAFF; DIAGNOSIS; RAT AB Background. There is a need for new immunosuppression strategies to minimize calcineurin inhibitor (CNI) toxicity while effectively preventing antibody-mediated rejection (AMR). Methods. We tested the efficacy of an investigational proteasome inhibitor, ixazomib, alone and in a CNI minimization strategy in a rat kidney transplant model of transfusion-elicited acute AMR. Nonsensitized (naive) and sensitized allograft recipients were randomized into 4 treatment groups (8 groups total, n = 3 to 6 in each group) and treated for 1 week. Groups included: no treatment, full dose cyclosporine (CsA, 10 mg/kg per day), ixazomib (0.25 mg/kg on days -5, -2 and +2) alone, and half dose CsA (5 mg/kg per day) + ixazomib. Results. Compared to untreated animals, ixazomib alone or in combination with 1/2 dose CsA reduced donor-specific antibody, intragraft transcripts for chemokines CCL-21 and CXCL-13, and CD19 expression in both sensitized and naive transplants. Compared to full dose CsA, the CNI minimization strategy with ixazomib inhibited AMR and allograft injury as evidenced by reduced C4d staining in peritubular capillaries, microcirculation inflammation, splenic plasma cells, circulating B cell activating factor, and intragraft transcripts for major histocompatibility complex class II, Toll-like receptors (TLR-1, TLR-10, and TLR-12) and CCL-21 and CXCL-13 in sensitized animals, indicating downregulation of B cell activation, antigen presentation and T-cell and B-cell signaling. Conclusions. These studies suggest that CNI minimization strategies including ixazomib are effective to prevent AMR including in sensitized kidney allograft recipients. Clinical studies are needed to determine the role of novel proteasome inhibitors for the prevention and treatment of AMR. C1 [Reese, Shannon R.; Wilson, Nancy A.; Djamali, Arjang] Univ Wisconsin, Dept Med, Div Nephrol, Sch Med & Publ Hlth, Madison, WI USA. [Huang, Gengwen; Redfield, Robert R., III; Djamali, Arjang] Univ Wisconsin, Dept Surg, Div Transplantat, Sch Med & Publ Hlth, Madison, WI USA. [Zhong, Weixiong] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI USA. [Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Serv, Madison, WI USA. RP Djamali, A (reprint author), UWSMPH, 5142 MFCB,1685 Highland Ave, Madison, WI 53705 USA. EM axd@medicine.wisc.edu NR 37 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD SEP PY 2015 VL 99 IS 9 BP 1785 EP 1795 DI 10.1097/TP.0000000000000736 PG 11 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DC2YV UT WOS:000369086000024 PM 25919767 ER PT J AU Bowen, ME Rowe, MA Hart-Hughes, S Barnett, S Ji, M AF Bowen, Mary Elizabeth Rowe, Meredeth A. Hart-Hughes, Stephanie Barnett, Scott Ji, Ming TI Characteristics of and Barriers to Functional Status Assessment in Assisted Living SO RESEARCH IN GERONTOLOGICAL NURSING LA English DT Article ID CLINICALLY IMPORTANT DIFFERENCE; PHYSICAL PERFORMANCE; BARTHEL INDEX; NURSING-HOMES; FACILITIES; STROKE; IMPAIRMENT; INSTRUMENT; RESIDENTS; ADMISSION AB The most commonly used functional status (FS) instruments were examined to determine the validity, reliability, sensitivity, and specifi city to change and feasibility in residents in an assisted living facility (ALF). Twenty-six ALF residents were assessed weekly for up to 8 months using six instruments. Group and single-subject analyses were used to examine associations between instruments and acute events. Two were problematic initially (Katz Index of Independence in Activities of Daily Living and hand grip) and were excluded early in the study. Of the remaining instruments, only the Barthel Index and Resident Assessment Instrument had acceptable psychometric profi les. However, these instruments were either not feasible in this environment or did not capture the full range of FS in this population. The current study's fi ndings suggest that instruments commonly used to measure FS may be inadequate for this population and environment. These fi ndings may be used to develop assessment methods for ALF residents that capture both the full range of FS in ALF settings as well as acute and long-term changes in functioning. C1 [Bowen, Mary Elizabeth] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Bowen, Mary Elizabeth] West Chester Univ Penn, Dept Hlth, W Chester, PA 19383 USA. [Bowen, Mary Elizabeth] West Chester Univ Penn, Gerontol Certificate Hlth Aging, W Chester, PA USA. [Rowe, Meredeth A.; Ji, Ming] Univ S Florida, Coll Nursing, Tampa, FL USA. [Hart-Hughes, Stephanie] James A Haley Vet Hosp, Patient Safety Ctr Inquiry, Tampa, FL 33612 USA. [Barnett, Scott] Amer Nurses Credentialing Ctr, Res, Silver Spring, MD USA. RP Bowen, ME (reprint author), West Chester Univ Penn, Sturzebecker Hlth Sci Ctr 315, Dept Hlth, W Chester, PA 19383 USA.; Bowen, ME (reprint author), West Chester Univ Penn, Sturzebecker Hlth Sci Ctr 315, Gerontol Certificate Hlth Aging, W Chester, PA 19383 USA. EM mbowen@wcupa.edu FU Rehabilitation Research and Development Career Award at the Department of Veterans Affairs (VA) [E7503W] FX The authors have disclosed no potential conflicts of interest, financial or otherwise. This work was supported by a Rehabilitation Research and Development Career Award at the Department of Veterans Affairs (VA; E7503W). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or the United States government. The authors acknowledge Dr. Susan C. McMillan for her helpful comments and suggestions in the early stages of this study, Mr. Robert Byrd for his help with data management, Ms. Lisa Goff and Ms. Raquel Elliot for data collection, and Dr. Mary Ersek for her editorial comments. The authors also acknowledge the University of Pennsylvania, School of Nursing and the anonymous reviewers of Research in Gerontological Nursing for their valuable comments and suggestions that helped improve the manuscript. NR 33 TC 1 Z9 1 U1 2 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1940-4921 EI 1938-2464 J9 RES GERONTOL NURS JI Res. Gerontol. Nurs. PD SEP-OCT PY 2015 VL 8 IS 5 BP 220 EP 230 DI 10.3928/19404921-20150406-01 PG 11 WC Nursing SC Nursing GA DB7AK UT WOS:000368666600003 PM 25893725 ER PT J AU Sacks, GD Lawson, EH Dawes, AJ Russell, MM Maggard-Gibbons, M Zingmond, DS Ko, CY AF Sacks, Greg D. Lawson, Elise H. Dawes, Aaron J. Russell, Marcia M. Maggard-Gibbons, Melinda Zingmond, David S. Ko, Clifford Y. TI Relationship Between Hospital Performance on a Patient Satisfaction Survey and Surgical Quality SO JAMA SURGERY LA English DT Article ID CLINICAL-QUALITY; MORTALITY-RATES; HEALTH OUTCOMES; CLAIMS DATA; ACS NSQIP; CARE; COMPLICATIONS; PERSPECTIVES; PERCEPTION; EXPERIENCE AB IMPORTANCE The Centers for Medicare and Medicaid Services include patient experience as a core component of its Value-Based Purchasing program, which ties financial incentives to hospital performance on a range of quality measures. However, it remains unclear whether patient satisfaction is an accurate marker of high-quality surgical care. OBJECTIVE To determine whether hospital performance on a patient satisfaction survey is associated with objective measures of surgical quality. DESIGN, SETTING, AND PARTICIPANTS Retrospective observational study of participating American College of Surgeons National Surgical Quality Improvement Project (ACS NSQIP) hospitals. We used data from a linked database of Medicare inpatient claims, ACS NSQIP, the American Hospital Association annual survey, and Hospital Compare from December 2, 2004, through December 31, 2008. A total of 103 866 patients older than 65 years undergoing inpatient surgery were included. Hospitals were grouped by quartile based on their performance on the Hospital Consumer Assessment of Healthcare Providers and Systems survey. Controlling for preoperative risk factors, we created hierarchical logistic regression models to predict the occurrence of adverse postoperative outcomes based on a hospital's patient satisfaction scores. MAIN OUTCOMES AND MEASURES Thirty-day postoperative mortality, major and minor complications, failure to rescue, and hospital readmission. RESULTS Of the 180 hospitals, the overall mean patient satisfaction score was 68.0% (first quartile mean, 58.7%; fourth quartile mean, 76.7%). Compared with patients treated at hospitals in the lowest quartile, those at the highest quartile had significantly lower risk-adjusted odds of death (odds ratio = 0.85; 95% CI, 0.73-0.99), failure to rescue (odds ratio = 0.82; 95% CI, 0.70-0.96), and minor complication (odds ratio = 0.87; 95% CI, 0.75-0.99). This translated to relative risk reductions of 11.1%(P = .04), 12.6%(P = .02), and 11.5%(P = .04), respectively. No significant relationship was noted between patient satisfaction and either major complication or hospital readmission. CONCLUSIONS AND RELEVANCE Using a national sample of hospitals, we demonstrated a significant association between patient satisfaction scores and several objective measures of surgical quality. Our findings suggest that payment policies that incentivize better patient experience do not require hospitals to sacrifice performance on other quality measures. C1 [Sacks, Greg D.; Lawson, Elise H.; Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Lawson, Elise H.; Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Sacks, GD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-215 CHS, Los Angeles, CA 90095 USA. EM gsacks@mednet.ucla.edu OI Dawes, Aaron/0000-0003-4574-6765 FU Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles FX Drs Sacks and Dawes were supported by the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles. NR 38 TC 13 Z9 13 U1 2 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD SEP PY 2015 VL 150 IS 9 BP 858 EP 864 DI 10.1001/jamasurg.2015.1108 PG 7 WC Surgery SC Surgery GA DA1VR UT WOS:000367584100008 PM 26108091 ER PT J AU Scott, VCS Haake, DA Churchill, BM Justice, SS Kim, JH AF Scott, Victoria C. S. Haake, David A. Churchill, Bernard M. Justice, Sheryl S. Kim, Ja-Hong TI Intracellular Bacterial Communities: A Potential Etiology for Chronic Lower Urinary Tract Symptoms SO UROLOGY LA English DT Review ID UROPATHOGENIC ESCHERICHIA-COLI; ADULT FEMALE BLADDER; INTERSTITIAL CYSTITIS; OVERACTIVE BLADDER; YOUNG-WOMEN; FOLLOW-UP; INFECTIONS; PATHOGENESIS; DIAGNOSIS; CULTURE AB Patients with persistent lower urinary tract symptoms and negative urine cultures are often difficult to treat. Infection may go undetected in these patients because the concentrations of bacteria in their urine are beneath the threshold of standard urine culture techniques. Empiric treatment may result in temporary relief, followed by recurrent symptoms. Occult and recurrent urinary tract infection may be due to both invasion of the bladder wall by uropathogenic Escherichia coli and the formation of biofilm-like intracellular bacterial communities. This review examines emerging evidence for a role of intracellular bacterial communities in human infection. (C) 2015 Elsevier Inc. C1 [Scott, Victoria C. S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. Hosp Columbus, Res Inst Nationwide Childrens, Ctr Microbial Pathogenesis, Columbus, OH USA. Ohio State Univ, Sch Med, Columbus, OH 43210 USA. RP Scott, VCS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, 10833 Le Conte Ave,Box 951738, Los Angeles, CA 90095 USA. EM vscott@mednet.ucla.edu RI Justice, Sheryl/E-3329-2011 OI Justice, Sheryl/0000-0002-7059-3759 FU NIAID NIH HHS [U01 AI075565, R21 AI109889] NR 47 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD SEP PY 2015 VL 86 IS 3 BP 425 EP 431 DI 10.1016/j.urology.2015.04.002 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CY5RA UT WOS:000366463700004 PM 26189137 ER PT J AU Chen, XQ Wang, LX Loh, DH Colwell, CS Tache, Y Reue, K Arnold, AP AF Chen, Xuqi Wang, Lixin Loh, Dawn H. Colwell, Christopher S. Tache, Yvette Reue, Karen Arnold, Arthur P. TI Sex differences in diurnal rhythms of food intake in mice caused by gonadal hormones and complement of sex chromosomes SO HORMONES AND BEHAVIOR LA English DT Article DE Food intake; Sex differences; Testosterone; Estradiol; Sex chromosomes; Four Core Genotypes; Body composition; Circadian rhythm; Night eating; Obesity; Adiposity ID NIGHT-EATING SYNDROME; OVARIECTOMIZED MICE; METABOLIC SYNDROME; OBESITY; ASSOCIATION; ESTRADIOL; WEIGHT; MOUSE AB We measured diurnal rhythms of food intake, as well as body weight and composition, while varying three major classes of sex-biasing factors: activational and organizational effects of gonadal hormones, and sex chromosome complement (SCC). Four Core Genotypes (FCG) mice, comprising XX and XY gonadal males and XX and XY gonadal females, were either gonad-intact or gonadectomized (GDX) as adults (2.5 months); food intake was measured second-by-second for 7 days starting 5 weeks later, and body weight and composition were measured for 22 weeks thereafter. Gonadal males weighed more than females. GDX increased body weight/fat of gonadal females, but increased body fat and reduced body weight of males. After GDX, XX mice had greater body weight and more fat than XY mice. In gonad-intact mice, males had greater total food intake and more meals than females during the dark phase, but females had more food intake and meals and larger meals than males during the light phase. GDX reduced overall food intake irrespective of gonad type or SCC, and eliminated differences in feeding between groups with different gonads. Diurnal phase of feeding was influenced by all three sex-biasing variables. Gonad-intact females had earlier onset and acrophase (peak) of feeding relative to males. GDX caused a phase-advance of feeding, especially in XX mice, leading to an earlier onset of feeding in GDX XX vs. XY mice, but earlier acrophase in GDX males relative to females. Gonadal hormones and SCC interact in the control of diurnal rhythms of food intake. (C) 2015 Elsevier Inc. All rights reserved. C1 [Chen, Xuqi; Arnold, Arthur P.] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA. [Chen, Xuqi; Loh, Dawn H.; Colwell, Christopher S.; Arnold, Arthur P.] Univ Calif Los Angeles, Brain Res Inst, Neuroendocrinol Lab, Los Angeles, CA 90095 USA. [Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Dept Med,Div Digest Dis, Los Angeles, CA 90095 USA. [Wang, Lixin; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Loh, Dawn H.; Colwell, Christopher S.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA. RP Arnold, AP (reprint author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 610 Charles Dr South, Los Angeles, CA 90095 USA. EM xuqichen@physci.ucla.edu; LixinWang@mednet.ucla.edu; hloh@mednet.ucla.edu; ccolwell@mednet.ucla.edu; ytache@mednet.ucla.edu; reuek@ucla.edu; arnold@ucla.edu OI Loh, Dawn/0000-0001-7876-5757 FU NIH [DK083561, NS043196, DK041301]; VA Career Scientist Award; O'Keefe Foundation FX Supported by NIH grants DK083561 (APA, XC, KR), NS043196 (APA), DK041301 (YT, Animal Models Core), VA Career Scientist Award (YT), and the O'Keefe Foundation (CSC). Thanks to Rebecca McClusky, Maureen Ruiz-Sundstrom, and Shawn Aarde for assistance. NR 32 TC 4 Z9 4 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0018-506X EI 1095-6867 J9 HORM BEHAV JI Horm. Behav. PD SEP PY 2015 VL 75 BP 55 EP 63 DI 10.1016/j.yhbeh.2015.07.020 PG 9 WC Behavioral Sciences; Endocrinology & Metabolism SC Behavioral Sciences; Endocrinology & Metabolism GA CY1EQ UT WOS:000366149900008 PM 26226656 ER PT J AU Langer-Gould, AM Lucas, R Chen, LH Xiang, A Barcellos, L AF Langer-Gould, A. M. Lucas, R. Chen, L. H. Xiang, A. Barcellos, L. TI Vitamin D, race/ethnicity and the risk of multiple sclerosis SO MULTIPLE SCLEROSIS JOURNAL LA English DT Meeting Abstract CT 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) CY OCT 07-10, 2015 CL Barcelona, SPAIN SP European Comm Treatment & Res Multiple Sclerosis C1 [Langer-Gould, A. M.; Chen, L. H.; Xiang, A.] Kaiser Permanente So Calif, Res & Evaluat, Pasadena, CA 91101 USA. [Langer-Gould, A. M.] W Los Angeles Vet Affairs Med Ctr, Neurol, So Calif Permanente Med Grp, Los Angeles, CA USA. [Lucas, R.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia. [Barcellos, L.] Univ Calif Berkeley, Sch Publ Hlth, Genet Eopidemiol & Genom Lab QB3, Berkeley, CA 94720 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD SEP PY 2015 VL 21 SU 11 MA P280 BP 100 EP 100 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CX5GF UT WOS:000365729400171 ER PT J AU Hughes, AJ Turner, AP Alschuler, KN Beier, M Atkins, D Amtmann, D Ehde, DM AF Hughes, A. J. Turner, A. P. Alschuler, K. N. Beier, M. Atkins, D. Amtmann, D. Ehde, D. M. TI Association between sleep disturbance and perceived cognitive dysfunction over 12 months in individuals living with multiple sclerosis SO MULTIPLE SCLEROSIS JOURNAL LA English DT Meeting Abstract CT 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) CY OCT 07-10, 2015 CL Barcelona, SPAIN SP European Comm Treatment & Res Multiple Sclerosis C1 [Hughes, A. J.; Turner, A. P.; Alschuler, K. N.; Beier, M.; Amtmann, D.; Ehde, D. M.] Univ Washington, Rehabil Med, Seattle, WA 98195 USA. [Hughes, A. J.; Turner, A. P.] VA Puget Sound Hlth Care Syst, MS Ctr Excellence West, Seattle Div, Seattle, WA USA. [Beier, M.] Johns Hopkins, Rehabil Med, Baltimore, MD USA. [Atkins, D.] Univ Washington, Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD SEP PY 2015 VL 21 SU 11 MA P302 BP 113 EP 114 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CX5GF UT WOS:000365729400193 ER PT J AU Oldenburg, O Teerlink, JR AF Oldenburg, Olaf Teerlink, John R. TI Screening for Sleep-Disordered Breathing in Patients Hospitalized for Heart Failure SO JACC-HEART FAILURE LA English DT Editorial Material DE acute decompensated heart failure; hospitalized patients; oxygen desaturation index; plethysmography; sleep-disordered breathing ID PROGNOSTIC IMPACT; APNEA; PREVALENCE C1 [Oldenburg, Olaf] Ruhr Univ Bochum, Dept Cardiol, Heart & Diabet Ctr North Rhine Westphalia, D-32545 Bad Oeynhausen, Germany. [Teerlink, John R.] San Francisco VA Med Ctr, Sect Cardiol, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. RP Oldenburg, O (reprint author), Ruhr Univ Bochum, Dept Cardiol, Heart & Diabet Ctr North Rhine Westphalia, Univ Hosp, Georgstr 11, D-32545 Bad Oeynhausen, Germany. EM akleemeyer@hdz-nrw.de NR 14 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD SEP PY 2015 VL 3 IS 9 BP 732 EP 733 DI 10.1016/j.jchf.2015.07.006 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CX4FU UT WOS:000365655300013 PM 26362450 ER PT J AU May, P Garrido, MM Cassel, JB Kelley, AS Meier, DE Normand, C Smith, TJ Stefanis, L Morrison, RS AF May, Peter Garrido, Melissa M. Cassel, J. Brian Kelley, Amy S. Meier, Diane E. Normand, Charles Smith, Thomas J. Stefanis, Lee Morrison, R. Sean TI Prospective Cohort Study of Hospital Palliative Care Teams for Inpatients With Advanced Cancer: Earlier Consultation Is Associated With Larger Cost-Saving Effect SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID LENGTH-OF-STAY; PROPENSITY SCORES; IMPACT; MEDICINE; ONCOLOGY; HEALTH AB Purpose Previous studies report that early palliative care is associated with clinical benefits, but there is limited evidence on economic impact. This article addresses the research question: Does timing of palliative care have an impact on its effect on cost? Patients and Methods Using a prospective, observational design, clinical and cost data were collected for adult patients with an advanced cancer diagnosis admitted to five US hospitals from 2007 to 2011. The sample for economic evaluation was 969 patients; 256 were seen by a palliative care consultation team, and 713 received usual care only. Subsamples were created according to time to consult after admission. Propensity score weights were calculated, matching the treatment and comparison arms specific to each subsample on observed confounders. Generalized linear models with a distribution and a log link were applied to estimate the mean treatment effect on cost within subsamples. Results Earlier consultation is associated with a larger effect on total direct cost. Intervention within 6 days is estimated to reduce costs by -$1,312 (95% CI, -$2,568 to -$56; P = .04) compared with no intervention and intervention within 2 days by -$2,280 (95% CI, -$3,438 to -$1,122; P < .001); these reductions are equivalent to a 14% and a 24% reduction, respectively, in cost of hospital stay. Conclusion Earlier palliative care consultation during hospital admission is associated with lower cost of hospital stay for patients admitted with an advanced cancer diagnosis. These findings are consistent with a growing body of research on quality and survival suggesting that early palliative care should be more widely implemented. (C) 2015 by American Society of Clinical Oncology C1 [May, Peter; Normand, Charles] Univ Dublin Trinity Coll, Ctr Hlth Policy & Management, Dublin 2, Ireland. [May, Peter; Garrido, Melissa M.; Kelley, Amy S.; Meier, Diane E.; Stefanis, Lee; Morrison, R. Sean] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Garrido, Melissa M.; Stefanis, Lee; Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Cassel, J. Brian] Virginia Commonwealth Univ, Richmond, VA USA. [Smith, Thomas J.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. RP May, P (reprint author), Univ Dublin Trinity Coll, Ctr Hlth Policy & Management, 3-4 Foster Pl, Dublin 2, Ireland. EM mayp2@tcd.ie RI May, Peter/B-2107-2017 OI May, Peter/0000-0001-8501-6500; Normand, Charles/0000-0002-0885-5754 FU National Cancer Institute (NCI); National Institute of Nursing Research in the United States; Health Research Board (Ireland); NCI [P30 CA 006973]; Veterans Affairs Health Services Research and Development career development award [CDA 11-201/CDP 12-255]; Midcareer Investigator Award in Patient-Oriented Research [5K24AG022345]; Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai [5P30AG028741]; National Palliative Care Research Center; National Institute on Aging [1K23AG040774-01A1] FX Supported by the National Cancer Institute (NCI) and the National Institute of Nursing Research in the United States. P.M. is sponsored by a health economics fellowship from the Health Research Board (Ireland) and NCI. M.M.G. is supported by a Veterans Affairs Health Services Research and Development career development award (CDA 11-201/CDP 12-255). T.J.S. is supported by NCI Grant No. P30 CA 006973 to Sidney Kimmel Comprehensive Cancer Center. R.S.M. was the recipient of a Midcareer Investigator Award in Patient-Oriented Research (5K24AG022345) during the course of this work. This work was supported by the National Institute on Aging, Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai (Grant No. 5P30AG028741), and the National Palliative Care Research Center. A.S.K. time was funded by the National Institute on Aging (Grant No. 1K23AG040774-01A1). NR 39 TC 28 Z9 28 U1 4 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD SEP 1 PY 2015 VL 33 IS 25 BP 2745 EP U47 DI 10.1200/JCO.2014.60.2334 PG 10 WC Oncology SC Oncology GA CX4ST UT WOS:000365691300008 PM 26056178 ER PT J AU Williams, GD AF Williams, Glynne D. TI Two Cases of Urinary Tract Infection Caused by Propionimicrobium lymphophilum SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ANAEROBIC-BACTERIA AB The first case reports involving Propionimicrobium lymphophilum, a rarely encountered anaerobic Gram-positive non-sporeforming rod, are presented here as urinary tract infections. Initial detection of these bacteria required urine Gram stains. Comparison of the type strain to the two isolates by various methods is depicted and includes antimicrobial susceptibility data. C1 [Williams, Glynne D.] VA Cent Western Massachusetts Healthcare Syst, US Dept Vet Affairs, Pathol & Lab Med Serv, Leeds, MA 01053 USA. RP Williams, GD (reprint author), VA Cent Western Massachusetts Healthcare Syst, US Dept Vet Affairs, Pathol & Lab Med Serv, Leeds, MA 01053 USA. EM glynne.williams@va.gov NR 14 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2015 VL 53 IS 9 BP 3077 EP 3080 DI 10.1128/JCM.00438-15 PG 4 WC Microbiology SC Microbiology GA CW6TE UT WOS:000365129900046 PM 26135862 ER PT J AU Friedman, MJ AF Friedman, Matthew J. TI Improving Our Understanding of Posttraumatic Trajectories SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Editorial Material ID VIETNAM C1 [Friedman, Matthew J.] US Dept Vet Affairs, White River Jct, VT USA. [Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Psychiat & Pharmacol Toxicol, Hanover, NH USA. RP Friedman, MJ (reprint author), VA Med Ctr, Natl Ctr PTSD, 215 North Main St, White River Jct, VT 05009 USA. EM Matthew.Friedman@Dartmouth.edu NR 9 TC 0 Z9 0 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD SEP PY 2015 VL 76 IS 9 BP E1153 EP E1154 DI 10.4088/JCP.14com09488 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CX0UM UT WOS:000365412500019 PM 26455689 ER PT J AU Das, A Miller, R Lee, P Holden, CA Lindhorst, SM Jaboin, J Vandergrift, WA Banik, NL Giglio, P Varma, AK Raizer, JJ Patel, SJ AF Das, Arabinda Miller, Rickey Lee, Philip Holden, Chrysanthe Alyssa Lindhorst, Scott M. Jaboin, Jerry Vandergrift, William A., III Banik, Naren L. Giglio, Pierre Varma, Abhay K. Raizer, Jeffery J. Patel, Sunil J. TI A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/beta-catenin signaling pathway SO TUMOR BIOLOGY LA English DT Article DE Meningioma; Apoptosis; Wnt; Catenin; Lemon; Ginger; Mushroom ID BREAST-CANCER CELLS; HUMAN GLIOBLASTOMA T98G; MALIGNANT MENINGIOMA; INDUCED APOPTOSIS; OXIDATIVE STRESS; GANODERIC ACID; U87MG CELLS; IOMM-LEE; KAPPA-B; INHIBITION AB Recurrent meningiomas constitute an uncommon but significant problem after standard (surgery and radiation) therapy failure. Current chemotherapies (hydroxyurea, RU-486, and interferon-alpha) are only of marginal benefit. There is an urgent need for more effective treatments for meningioma patients who have failed surgery and radiation therapy. Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM are some of the plant derivatives that have anti-tumorgenic properties and cause cell death in meningioma cells in vitro. Due to its ease of administration, long-term tolerability, and low incidence of long-term side effects, we explored its potential as a therapeutic agent against meningiomas by examining their efficacy in vitro against meningioma cells. Treatment effects were assessed using MTT assay, Western blot analysis, caspases assay, and DNA fragmentation assay. Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3 beta) via inhibition of the Wnt5/beta-catenin pathway. These drugs did not induce apoptosis in normal human neurons. Other events in apoptosis included downregulation of tetraspanin protein (TSPAN12), survival proteins (Bcl-XL and Mcl-1), and overexpression apoptotic factors (Bax and caspase-3). These results provide preliminary strong evidence that medicinal plants containing Limonin, Tangeritin, 6-Gingerol, Zerumbone, Ganoderic Acid A, and Ganoderic Acid DM can be applied to high-grade meningiomas as a therapeutic agent, and suggests that further in vivo studies are necessary to explore its potential as a therapeutic agent against malignant meningiomas. C1 [Das, Arabinda; Miller, Rickey; Lee, Philip; Holden, Chrysanthe Alyssa; Lindhorst, Scott M.; Vandergrift, William A., III; Banik, Naren L.; Giglio, Pierre; Varma, Abhay K.; Patel, Sunil J.] Med Univ S Carolina, Dept Neurosurg, Charleston, SC 29425 USA. [Jaboin, Jerry] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Giglio, Pierre] Ohio State Univ, Dept Neurol Surg, Wexner Med Coll, Columbus, OH 43210 USA. [Raizer, Jeffery J.] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Raizer, Jeffery J.] Northwestern Univ, Northwestern Brain Tumor Inst, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA. [Das, Arabinda] Med Univ S Carolina, Dept Neurosurg, MUSC Brain & Spine Tumor Program CSB 310, Neurooncol Div, Charleston, SC 29425 USA. RP Das, A (reprint author), Med Univ S Carolina, Dept Neurosurg, Charleston, SC 29425 USA. EM dasa@musc.edu FU Jerry Zucker Fund for Brain Tumor Research at the MUSC Foundation; Department of Neurosurgery (MUSC); American Brain Tumor Association; NIH [NS-38146, NS-41088]; Office of Research and Development, Department of Veterans Affairs [101BX001262] FX This investigation was supported by the Jerry Zucker Fund for Brain Tumor Research at the MUSC Foundation, Department of Neurosurgery (MUSC), American Brain Tumor Association (Medical Student Summer Fellowship in Honor of Paul Fabri), NIH grants (NS-38146, NS-41088), and also, this work in part was supported by a merit award from the Office of Research and Development, Department of Veterans Affairs (101BX001262). NR 36 TC 4 Z9 4 U1 2 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1010-4283 EI 1423-0380 J9 TUMOR BIOL JI Tumor Biol. PD SEP PY 2015 VL 36 IS 9 BP 7027 EP 7034 DI 10.1007/s13277-015-3388-0 PG 8 WC Oncology SC Oncology GA CW5KA UT WOS:000365033100051 PM 25864108 ER PT J AU Lee, DC Long, JA Wall, SP Carr, BG Satchell, SN Braithwaite, S Elbel, B AF Lee, David C. Long, Judith A. Wall, Stephen P. Carr, Brendan G. Satchell, Samantha N. Braithwaite, Scott Elbel, Brian TI Determining Chronic Disease Prevalence in Local Populations Using Emergency Department Surveillance SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID PUBLIC-HEALTH; DIABETES CARE; IMPROVE; OBESITY; SYSTEM; IMPACT; STATES AB Objectives. We sought to improve public health surveillance by using a geographic analysis of emergency department (ED) visits to determine local chronic disease prevalence. Methods. Using an all-payer administrative database, we determined the proportion of unique ED patients with diabetes, hypertension, or asthma. We compared these rates to those determined by the New York City Community Health Survey. For diabetes prevalence, we also analyzed the fidelity of longitudinal estimates using logistic regression and determined disease burden within census tracts using geocoded addresses. Results. We identified 4.4 million unique New York City adults visiting an ED between 2009 and 2012. When we compared our emergency sample to survey data, rates of neighborhood diabetes, hypertension, and asthma prevalence were similar (correlation coefficient = 0.86, 0.88, and 0.77, respectively). In addition, our method demonstrated less year-to-year scatter and identified significant variation of disease burden within neighborhoods among census tracts. Conclusions. Our method for determining chronic disease prevalence correlates with a validated health survey and may have higher reliability over time and greater granularity at a local level. Our findings can improve public health surveillance by identifying local variation of disease prevalence. C1 [Lee, David C.; Wall, Stephen P.] NYU, Sch Med, Ronald O Perelman Dept Emergency Med, New York, NY USA. [Braithwaite, Scott; Elbel, Brian] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Carr, Brendan G.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Emergency Med, Philadelphia, PA 19107 USA. [Satchell, Samantha N.] George Washington Univ, Milken Inst, Sch Publ Hlth, Washington, DC USA. RP Lee, DC (reprint author), Dept Emergency Med, 462 First Ave,Room A345, New York, NY 10016 USA. EM david.lee@nyumc.org OI Wall, Stephen/0000-0003-3965-5074; Elbel, Brian/0000-0003-1615-9430 FU University of Pennsylvania; Leonard Davis Institute of Health Economics; Robert Wood Johnson Foundation Health and Society Scholars Program; Robert Wood Johnson Foundation Clinical Scholars Program FX This study was funded by 2 intramural grants from the University of Pennsylvania: a health services research grant from the Leonard Davis Institute of Health Economics and a population health research grant from the Robert Wood Johnson Foundation Health and Society Scholars Program. D. C. Lee was also supported by the fellowship and faculty mentorship at the Robert Wood Johnson Foundation Clinical Scholars Program. NR 46 TC 4 Z9 4 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2015 VL 105 IS 9 BP E67 EP E74 DI 10.2105/AJPH.2015.302679 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV5PG UT WOS:000364322600017 PM 26180983 ER PT J AU Shields, RK Clancy, CJ Hao, BH Chen, L Press, EG Iovine, NM Kreiswirth, BN Nguyen, MH AF Shields, Ryan K. Clancy, Cornelius J. Hao, Binghua Chen, Liang Press, Ellen G. Iovine, Nicole M. Kreiswirth, Barry N. Nguyen, M. Hong TI Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum beta-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID US MEDICAL-CENTERS; SEQUENCE TYPE 258; DORIPENEM; COLISTIN; STRAINS; ENTEROBACTERIACEAE; COMBINATION; BACTEREMIA; RESPONSES; GENOTYPES AB Avibactam is a novel beta-lactamase inhibitor with affinity for Klebsiella pneumoniae carbapenemases (KPCs). In combination with ceftazidime, the agent demonstrates activity against KPC-producing K. pneumoniae (KPC-Kp). KPC-Kp strains are genetically diverse and harbor multiple resistance determinants, including defects in outer membrane proteins and extended-spectrum beta-lactamases (ESBLs). Mutations in porin gene ompK36 confer high-level carbapenem resistance to KPC-Kp strains. Whether specific mechanisms of antimicrobial resistance also influence the activity of ceftazidime-avibactam is unknown. We defined the effects of ceftazidime-avibactam against 72 KPC-Kp strains with diverse mechanisms of resistance, including various combinations of KPC subtypes and ESBL and ompK36 mutations. Ceftazidime MICs ranged from 64 to 4,096 mu g/ml and were lowered by a median of 512-fold with the addition of avibactam. All strains exhibited ceftazidime-avibactam MICs at or below the CLSI breakpoint for ceftazidime (<= 4 mu g/ml; range, 0.25 to 4). However, the MICs were within two 2-fold dilutions of the CLSI breakpoint against 24% of the strains, and those strains would be classified as nonsusceptible to ceftazidime by EUCAST criteria (MIC > 1 mu g/ml). Median ceftazidime-avibactam MICs were higher against KPC-3 than KPC-2 variants (P = 0.02). Among KPC-2-Kp strains, the presence of both ESBL and porin mutations was associated with higher drug MICs compared to those seen with either factor alone (P = 0.003 and P = 0.02, respectively). In conclusion, ceftazidime-avibactam displays activity against genetically diverse KPC-Kp strains. Strains with higher-level drug MICs provide a reason for caution. Judicious use of ceftazidime-avibactam alone or in combination with other agents will be important to prevent the emergence of resistance. C1 [Shields, Ryan K.; Clancy, Cornelius J.; Press, Ellen G.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Shields, Ryan K.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, Antibiot Management Program, Pittsburgh, PA USA. [Shields, Ryan K.; Clancy, Cornelius J.; Hao, Binghua; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Chen, Liang; Kreiswirth, Barry N.] Rutgers State Univ, New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ 07102 USA. [Iovine, Nicole M.] Univ Florida, Dept Med, Gainesville, FL USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. EM cjc76@pitt.edu FU University of Pittsburgh Medical Center; National Center for Advanced Translational Sciences of the National Institutes of Health (NIH) [KL2 RR024154] FX This project was supported by funding provided to the XDR Pathogen Laboratory by the University of Pittsburgh Medical Center and by the National Center for Advanced Translational Sciences of the National Institutes of Health (NIH) under award number KL2 RR024154 (awarded to R.K.S.). NR 17 TC 17 Z9 18 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2015 VL 59 IS 9 BP 5793 EP 5797 DI 10.1128/AAC.00548-15 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CV5XD UT WOS:000364343900085 PM 26169413 ER PT J AU Radulovic, M Bauman, WA Wecht, JM LaFountaine, M Kahn, N Hobson, J Singh, K Renzi, C Yen, C Schilero, GJ AF Radulovic, Miroslav Bauman, William A. Wecht, Jill M. LaFountaine, Michael Kahn, Nighat Hobson, Joshua Singh, Kamaldeep Renzi, Christopher Yen, Christina Schilero, Gregory J. TI Biomarkers of inflammation in persons with chronic tetraplegia SO JOURNAL OF BREATH RESEARCH LA English DT Article DE spinal cord injury; tetraplegia; oxidative stress; asthma ID EXHALED BREATH CONDENSATE; SPINAL-CORD-INJURY; OBSTRUCTIVE PULMONARY-DISEASE; NITRIC-OXIDE MEASUREMENTS; AIR-FLOW OBSTRUCTION; OXIDATIVE STRESS; ASTHMA CONTROL; BRONCHIAL HYPERRESPONSIVENESS; INDUCED BRONCHOCONSTRICTION; INCREASED 8-ISOPROSTANE AB In addition to lung volume restriction, individuals with chronic tetraplegia exhibit reduced airway caliber and bronchodilator responsiveness similar to persons with asthma. In asthma, airflow obstruction is closely linked to airway inflammation. Conversely, little is known regarding the airway inflammatory response in tetraplegia. To compare levels of biomarkers of inflammation in exhaled breath condensate (EBC) and serum in subjects with chronic tetraplegia, mild asthma, and able-bodied controls. Prospective, observational pilot study. Thirty-four subjects participated: tetraplegia (n = 12), asthma (n = 12), controls (n = 10). Biomarkers in EBC [8-isoprostane (8-IP), leukotriene B4 (LT-B4), prostaglandin E2 (PG-E2), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6)] and serum (8-IP, LT-B4, TNF-a, IL-6) were determined using commercially available EIA kits (Cayman Chemical Company, Ann Arbor, MI). Separate, one-way ANOVA with Bonferroni's post-hoc analyses were performed to determine group differences in demographic and dependent variables [EBC and serum biomarkers, fractional exhaled nitric oxide (FeNO), pulmonary function parameters, and specific airway conductance (sGaw)]. The tetraplegia group had significantly elevated 8-IP levels in EBC compared to the asthma (68 +/- 38 versus 21 +/- 13 pg ml(-1); p < 0.001) and control groups (22 +/- 13 pg ml(-1); p < 0.01), respectively. FeNO levels were significantly elevated in the asthma compared to the control group (26 +/- 18 versus 11 +/- 4 ppb; p < 0.05), and trended higher than levels in the tetraplegia group (15 +/- 6; p = 0.08). Levels of serum biomarkers did not differ significantly among groups. Through analysis of EBC, levels of 8-IP were significantly elevated compared to levels found in individuals with mild asthma and healthy controls. Further studies are needed to extend upon these preliminary findings that suggest the presence of airway inflammation in subjects with chronic tetraplegia, and how this relates to pulmonary dysfunction in this population. C1 [Radulovic, Miroslav; Bauman, William A.; Wecht, Jill M.; LaFountaine, Michael; Kahn, Nighat; Hobson, Joshua; Singh, Kamaldeep; Renzi, Christopher; Yen, Christina; Schilero, Gregory J.] James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA. [Radulovic, Miroslav; Bauman, William A.; Wecht, Jill M.; Schilero, Gregory J.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Radulovic, Miroslav; Bauman, William A.; Wecht, Jill M.; Schilero, Gregory J.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauman, William A.; Wecht, Jill M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. RP Radulovic, M (reprint author), James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA. EM Miroslav.Radulovic@va.gov FU Veteran Affairs Rehabilitation Research and Development Service [B6623R, B4335V, B4162C]; James J Peters VA Medical Center FX This research was supported by the Veteran Affairs Rehabilitation Research and Development Service (#B6623R, #B4335V, #B4162C) and the James J Peters VA Medical Center. NR 69 TC 0 Z9 0 U1 2 U2 3 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1752-7155 EI 1752-7163 J9 J BREATH RES JI J. Breath Res. PD SEP PY 2015 VL 9 IS 3 AR 036001 DI 10.1088/1752-7155/9/3/036001 PG 9 WC Biochemical Research Methods; Respiratory System SC Biochemistry & Molecular Biology; Respiratory System GA CW1YY UT WOS:000364789300004 PM 25971935 ER PT J AU Swerdloff, RS Pak, Y Wang, C Liu, PY Bhasin, S Gill, TM Matsumoto, AM Pahor, M Surampudi, P Snyder, PJ AF Swerdloff, Ronald S. Pak, Youngju Wang, Christina Liu, Peter Y. Bhasin, Shalender Gill, Thomas M. Matsumoto, Alvin M. Pahor, Marco Surampudi, Prasanth Snyder, Peter J. TI Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID METABOLIC-CLEARANCE; MASS-SPECTROMETRY; BODY-COMPOSITION; ELDERLY-MEN; METAANALYSIS; THERAPY; EVENTS; TRIALS; PHARMACOKINETICS; MORTALITY AB Context: The optimal frequency for on-treatment serum T measurement used for dose adjustment aftertransdermal T gel application is unknown, especially in older men withthinner skin and slower metabolic clearance. Objectives: The objectives of the study was to determine the variability of postgel application serum T concentrations and assess whether single levels are reflective of average serum T concentrations over 24 hours (Cavg(0-24)). Design: This was a double-blinded, placebo-controlled randomized trial. Setting: The study was conducted at five academic centers. Participants: Forty-seven symptomatic men 65 years old or older with an average of two morning T concentration less than 275 ng/dL participated in the study. Intervention(s): Transdermal T or placebo gel was applied for 120 +/- 14 days. Monthly dose adjustments were made if necessary to target serum T between 400 and 500 to 800 ng/dL. Main Outcome Measures: Variability of serum 12 hours afterthe gel application on two outpatient visits and at multiple time points over 24 hours during the inpatient day was measured. Results: On-treatment T levels varied substantially on the 2 ambulatory days and over 24 hours during the inpatient day. Ambulatory 2-hour postapplication T levels did not correlate significantly with either 2-hour postapplication serum T or Cavg(0-24) measured during the inpatient day. Only 22.2% of men receiving T had a Cavg(0-24) within the target range of 500-800 ng/dL; 81.5% had a Cavg0_24 within the broader 300-1000 ng/dL range. Conclusion: Large within-individual variations in serum T after T gel application render ambulatory 2-hour postapplication T level a poor indicator of average serum Ton another day. Our data point out the limitations of dose adjustments based on a single postapplication serum T measurement. C1 [Swerdloff, Ronald S.; Pak, Youngju; Wang, Christina; Liu, Peter Y.; Surampudi, Prasanth] Harbor UCLA Med Ctr, Dept Med, Div Endocrinol, Torrance, CA 90509 USA. [Pak, Youngju; Wang, Christina] Harbor UCLA Med Ctr, Clin & Translat Sci Inst, Torrance, CA 90509 USA. Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Bhasin, Shalender] Harvard Univ, Sch Med, Brigham & Womens Hosp, Res Program Mens Hlth Aging & Metab, Boston, MA 02115 USA. [Gill, Thomas M.] Yale Univ, New Haven, CT 06510 USA. [Matsumoto, Alvin M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA. [Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Clin, Seattle, WA 98108 USA. [Pahor, Marco] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL 32611 USA. [Snyder, Peter J.] Univ Penn, Dept Med, Div Endocrinol, Philadelphia, PA 19104 USA. RP Swerdloff, RS (reprint author), Harbor UCLA Med Ctr, Dept Med, Div Endocrinol, Walter Martin Res Bldg,1000 Carson St, Torrance, CA 90509 USA. EM swerdloff@labiomed.org FU National Institute on Aging, National Institutes of Health [U01 AG030644]; National Heart, Lung, and Blood Institute, National Institute of Neurological Diseases and Stroke, and Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences through University of California, Los Angeles, Clinical and Translational Science Institute [UL1TR000124]; Diabetes and Endocrinology Training Grant [T32 DK007571]; Department of Veterans Affairs Puget Sound Health Care System; National Institute on Aging [K07AG3587]; Claude D. Pepper Older Americans Independence Center [P30-AG021342]; Clinical and Translational Science Institute [UL1TR000142]; Boston Claude D. Pepper Older Americans Independence Center Grant [5P30AG031679]; Clinical and Translational Science Institute from Boston University [1 UL1RR025771] FX The testosterone trials were supported by a grant the National Institute on Aging, National Institutes of Health (Grant U01 AG030644), supplemented by support from the National Heart, Lung, and Blood Institute, National Institute of Neurological Diseases and Stroke, and Eunice Kennedy Shriver National Institute of Child Health and Human Development. AbbVie (formerly Solvay and Abbott Laboratories) generously provided support and donated the AndroGel and placebo gel.; This work was supported by the National Center for Advancing Translational Sciences through the University of California, Los Angeles, Clinical and Translational Science Institute (Grant UL1TR000124) and Diabetes and Endocrinology Training Grant T32 DK007571 to the Los Angeles site). A.M.M. is supported by the Department of Veterans Affairs Puget Sound Health Care System. T.M.G. was the recipient of Academic Leadership Award K07AG3587 from the National Institute on Aging. the Yale Field Center was partially supported by the Claude D. Pepper Older Americans Independence Center (Grant P30-AG021342) and Clinical and Translational Science Institute Grant UL1TR000142. Additional support was provided by resources of the Boston Claude D. Pepper Older Americans Independence Center Grant 5P30AG031679 (to S.B.) and Clinical and Translational Science Institute Grant 1 UL1RR025771 from Boston University. NR 21 TC 7 Z9 7 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD SEP PY 2015 VL 100 IS 9 BP 3280 EP 3287 DI 10.1210/JC.2015-1542 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CW3BV UT WOS:000364867800032 PM 26120790 ER PT J AU Hubbard, CS Hong, J Jiang, Z Ebrat, B Suyenobu, B Smith, S Heendeniya, N Naliboff, BD Tillisch, K Mayer, EA Labus, JS AF Hubbard, C. S. Hong, J. Jiang, Z. Ebrat, B. Suyenobu, B. Smith, S. Heendeniya, N. Naliboff, B. D. Tillisch, K. Mayer, E. A. Labus, J. S. TI Increased attentional network functioning related to symptom severity measures in females with irritable bowel syndrome SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE attention network test; chronic pain; fMRI; irritable bowel syndrome ID COGNITIVE CONTROL; CINGULATE CORTEX; EXECUTIVE CONTROL; VISUAL-ATTENTION; BRAIN RESPONSES; PAIN PERCEPTION; SCALE; INHIBITION; DEFICITS; SYSTEM AB Background Increased attention to gastrointestinal (GI) symptoms and disease-specific contexts may play an important role in the enhanced perception of visceral stimuli frequently reported in patients with irritable bowel syndrome (IBS). In this study, we test the hypothesis that altered attentional mechanisms underlie central pain amplification in IBS. Methods To evaluate brain networks that support alerting, orienting, and executive attention, we employed the attention network test (ANT), a modified flanker task which measures the efficiency of functioning of core attentional networks, during functional magnetic resonance imaging in 15 IBS patients (mean age = 31 [11.96]) and 14 healthy controls (HCs; mean age = 31 [10.91]). Key Results Patients with IBS, compared to HCs, showed shorter reaction times during the alerting and orienting conditions which were associated with greater activation of anterior midcingulate and insular cortices, and decreased activity in the right inferior frontal junction and supplementary motor cortex. Patients also showed activation in the dorsal medial prefrontal cortex and concurrent thalamic deactivation during the executive control portion of the ANT relative to HCs, but no group difference in reaction times were found. The activity in brain regions showing group differences during the ANT were associated with measures of GI-specific anxiety, pain catastrophizing, and fear of uncertainty. In IBS, activity in the anterior midcingulate during alerting correlated with duration of GI-symptoms and overall symptom severity. Conclusions (sic) Inferences Together, these results suggest that IBS patients have specific abnormalities in attentional network functioning and these deficits may underlie symptom-related anxiety, hypervigilance, and visceral hypersensitivity. C1 [Hubbard, C. S.; Hong, J.; Jiang, Z.; Ebrat, B.; Suyenobu, B.; Smith, S.; Heendeniya, N.; Naliboff, B. D.; Tillisch, K.; Mayer, E. A.; Labus, J. S.] Univ Calif Los Angeles, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Los Angeles, CA USA. [Hubbard, C. S.; Hong, J.; Ebrat, B.; Suyenobu, B.; Smith, S.; Heendeniya, N.; Naliboff, B. D.; Tillisch, K.; Mayer, E. A.; Labus, J. S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Hubbard, C. S.] Univ Maryland, Sch Dent, Dept Neural & Pain Sci, Baltimore, MD 21201 USA. [Hubbard, C. S.] Boston Childrens Hosp, Ctr Pain & Brain, Boston, MA 02115 USA. [Hong, J.] Univ Calif Los Angeles, Biomed Engn, Los Angeles, CA USA. [Hong, J.; Naliboff, B. D.; Tillisch, K.; Mayer, E. A.; Labus, J. S.] PAIN, Los Angeles, CA USA. [Naliboff, B. D.; Mayer, E. A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mayer, E. A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. [Naliboff, B. D.; Mayer, E. A.; Labus, J. S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Hubbard, CS (reprint author), Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Pain & Brain, 300 Longwood Ave, Boston, MA 02115 USA. EM catherine.hubbard@childrens.harvard.edu OI Hubbard, Catherine/0000-0002-9139-2198 FU National Institutes of Health [K08 DK071626, R03 DK 084169, R01 DK48351]; CORE-Neuroimaging & Psychophysiology [P50 DK064539]; CORE-Administrative [R24 AT002681]; CORE-Administrative Core Enrichment [P30 DK041301, R01 AT007137, K23 DK073451, T32 DK007180] FX This research was supported by grants from the National Institutes of Health including K08 DK071626 (JSL), R03 DK 084169, R01 DK48351 (EAM), P50 DK064539 CORE-Neuroimaging & Psychophysiology (EAM), CORE-Administrative (EAM), R24 AT002681 (EAM), P30 DK041301 CORE-Administrative Core & Enrichment, R01 AT007137 (KT), K23 DK073451 (KT), and T32 DK007180 (DJ). NR 81 TC 5 Z9 6 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1350-1925 EI 1365-2982 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD SEP PY 2015 VL 27 IS 9 BP 1282 EP 1294 DI 10.1111/nmo.12622 PG 13 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA CW1KF UT WOS:000364747900011 PM 26087779 ER PT J AU Kawasaki, M Tanaka, R Ono, K Minatoguchi, S Watanabe, T Iwama, M Hirose, T Arai, M Noda, T Watanabe, S Zile, MR Minatoguchi, S AF Kawasaki, Masanori Tanaka, Ryuhei Ono, Koji Minatoguchi, Shingo Watanabe, Takatomo Iwama, Makoto Hirose, Takeshi Arai, Masazumi Noda, Toshiyuki Watanabe, Sachiro Zile, Michael R. Minatoguchi, Shinya TI A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study SO JOURNAL OF CARDIOLOGY LA English DT Article DE Atrial volume; Atrial function; Diastolic dysfunction; Speckle tracking echocardiography; Pulmonary capillary wedge pressure ID VENTRICULAR FILLING PRESSURES; PRESERVED EJECTION FRACTION; DOPPLER-ECHOCARDIOGRAPHY; DIASTOLIC DYSFUNCTION; HEART-FAILURE; MITRAL REGURGITATION; MECHANICAL FUNCTION; FIBRILLATION; CATHETERIZATION; DISTENSIBILITY AB Background: We hypothesized that a development of a novel index based on the combination of left atrial volume (LAV) and left atrial (LA) function evaluated by the time-LA volume curve using speckle tracking echocardiography (STE) would be accurate and useful to estimate pulmonary capillary wedge pressure (PCWP). Our goal was to develop a novel index of PCWP based on a combination of LAV and LA function using STE. Methods: A cross-validation study was performed with the patients divided into a training study to define the novel index (n = 50) and a testing study to validate the index (n = 196). PCWP was measured by right heart catheterization, and phasic LAV and emptying function (EF) were measured by STE. Results: Simple linear regression analysis in the training study revealed that the novel index that best estimated PCWP was the kinetics-tracking index [KT index = log(10) (active LAEF/minimum LAV index)]. Multiple regression analysis revealed that the KT index was the most reliable predictor of PCWP. It had the strongest correlation with PCWP (r = -0.86, p < 0.001) among all echocardiographic parameters. In the testing study, PCWP estimated by the KT index was also strongly correlated with measured PCWP (r = 0.92, p < 0.001). These correlations were also strong in the patients with reduced left ventricular ejection fraction (<50%), chronic heart failure, and chronic atrial fibrillation (r = 0.92, r = 0.91, r = 0.79, p < 0.001, respectively). Conclusions: A novel index (KT index) using a combination of LAV and LA function was a powerful and useful predictor of PCWP and may be valuable in routine clinical practice. (C) 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. C1 [Kawasaki, Masanori; Minatoguchi, Shingo; Watanabe, Takatomo; Minatoguchi, Shinya] Gifu Univ, Grad Sch Med, Dept Cardiol, Gifu 5011194, Japan. [Tanaka, Ryuhei; Ono, Koji; Iwama, Makoto; Hirose, Takeshi; Arai, Masazumi; Noda, Toshiyuki; Watanabe, Sachiro] Gifu Prefectural Gen Med Ctr, Dept Cardiol, Gifu, Japan. [Zile, Michael R.] Med Univ S Carolina, Med Cardiol, Charleston, SC 29425 USA. [Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Kawasaki, M (reprint author), Gifu Univ, Grad Sch Med, Dept Cardiol, 1-1 Yanagido, Gifu 5011194, Japan. EM masanori@ya2.so-net.ne.jp NR 31 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0914-5087 EI 1876-4738 J9 J CARDIOL JI J. Cardiol. PD SEP-OCT PY 2015 VL 66 IS 3-4 BP 253 EP 262 DI 10.1016/j.jjcc.2014.11.008 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CV1BS UT WOS:000363988800013 PM 25547741 ER PT J AU Lucas, MS Brawner, BM Hardie, TL Beacham, B Paidipati, C Diaz, M Lauer, A Hobbie, WL Deatrick, JA AF Lucas, Matthew S. Brawner, Bridgette M. Hardie, Thomas L. Beacham, Barbara Paidipati, Cynthia Diaz, Magdaline Lauer, Amy Hobbie, Wendy L. Deatrick, Janet A. TI Assessing Suicidal Ideation and Behaviors Among Survivors of Childhood Brain Tumors and Their Mothers During Sociobehavioral Research SO ONCOLOGY NURSING FORUM LA English DT Article DE suicidal ideation; suicide; brain neoplasms; survivors ID POSTTRAUMATIC STRESS SYMPTOMS; ANTIDEPRESSANT EFFICACY TRIALS; QUALITY-OF-LIFE; ADULT SURVIVORS; CANCER-PATIENTS; UNITED-STATES; RISK; ADOLESCENT; DISORDER; EVENTS AB Purpose/Objectives: To describe the development and feasibility of a protocol for nonpsychiatric subspecialty research staff members to screen research participants who endorse suicidal ideations or behaviors during data collection. Design: Descriptive protocol development. Setting: The Children's Hospital of Philadelphia and the University of Pennsylvania. Sample: 186 mother caregivers and 134 adolescent or young adult survivors of childhood brain tumors, with the protocol implemented for 5 caregivers and 11 survivors. Methods: During telephone-and home-based interviews, the interviewer assessed the participant using the Columbia-Suicide Severity Rating Scale (C-SSRS). Main Research Variables: Expressed suicidal ideation or behavior. Findings: Implementation of the C-SSRS by nonpsychiatric subspecialty staff members was feasible and valid. Interviewers' conclusions based on this instrument matched those of the mental health professional who followed up with participants. Process notes contained themes about the participants, including anger and sadness in survivors and the physical and emotional demands of the survivor in caregivers. Progress notes for the interviewer included a reiteration of events, whether the assessment was successful, and whether the recommendation of the interviewer was in agreement with that of the mental health professional. Conclusions: The protocol based on the C-SSRS was useful and feasible for nonpsychiatric subspecialty staff members to use in the collection of data from survivors of childhood brain tumors and their caregivers. Implications for Nursing: Survivors of childhood brain tumors and their caregivers may experience psychosocial distress. Nurses, as research assistants or in other roles, can use tools such as the C-SSRS to assist in front-line assessments. C1 [Lucas, Matthew S.] Temple Univ, Sch Med, Ctr Bioeth Urban Hlth & Policy, Philadelphia, PA 19122 USA. [Lucas, Matthew S.] Temple Univ, Dept Philosophy, Philadelphia, PA 19122 USA. [Brawner, Bridgette M.; Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Brawner, Bridgette M.] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Hardie, Thomas L.; Paidipati, Cynthia; Diaz, Magdaline] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Beacham, Barbara] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA. [Paidipati, Cynthia; Lauer, Amy] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Hobbie, Wendy L.] Childrens Hosp Philadelphia, Canc Survivorship Program, Philadelphia, PA USA. [Deatrick, Janet A.] Univ Penn, Sch Nursing, Hlth Community Practices, Philadelphia, PA 19104 USA. RP Lucas, MS (reprint author), Temple Univ, Sch Med, Ctr Bioeth Urban Hlth & Policy, Philadelphia, PA 19122 USA. EM matthew.lucas@temple.edu OI Hardie, Thomas/0000-0002-4547-7991; Lucas, Matthew/0000-0002-1646-4139 FU U.S. National Institutes of Health via the National Institute of Nursing Research [T32NR007100, F31NR013091, R01NR009651]; American Cancer Society [122552-DSCN-10-089]; ONS Foundation FX Matthew S. Lucas, PhD, MBE, RN, is a graduate programs coordinator in the Center for Bioethics, Urban Health, and Policy in the School of Medicine and an adjunct assistant professor in the Department of Philosophy, both at Temple University in Philadelphia, PA; Bridgette M. Brawner, PhD, APRN, is an assistant professor of nursing in the Center for Health Equity Research and Center for Global Women's Health in the School of Nursing and Thomas L. Hardie, EdD, PMHCNS-BC, is an adjunct professor, both in the School of Nursing at the University of Pennsylvania in Philadelphia; Barbara Beacham, PhD, RN, is a postdoctoral fellow/assistant research scientist in the School of Nursing at Indiana University in Indianapolis; Cynthia Paidipati, MSN, CRNP, is a doctoral student in the School of Nursing at the University of Pennsylvania and a psychiatric nurse practitioner at Children's Hospital of Philadelphia; Magdaline Diaz, RN, is a student in the School of Nursing at the University of Pennsylvania; Amy Lauer, MSN, CRNP, is a pediatric oncology nurse and Wendy L. Hobbie, MSN, CRNP, FAAN, is an associate director in the Cancer Survivorship Program, both at the Children's Hospital of Philadelphia; and Janet A. Deatrick, PhD, RN, FAAN, is a professor and director in the Center for Health Equity Research and the Shearer Endowed Term Chair in Healthy Community Practices in the School of Nursing at the University of Pennsylvania. This research was funded by grants from the U.S. National Institutes of Health via the National Institute of Nursing Research (T32NR007100, F31NR013091 [MSL]; R01NR009651 [JAD]), the American Cancer Society (122552-DSCN-10-089 [MSL]), and the ONS Foundation (Neuro-Oncology Nursing Grant [JAD]). Lucas can be reached at matthew.lucas@temple.edu, with copy to editor at ONFEditor@ons.org. (Submitted February 2015. Accepted for publication April 13, 2015.) NR 46 TC 0 Z9 0 U1 4 U2 11 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X EI 1538-0688 J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD SEP PY 2015 VL 42 IS 5 BP E319 EP E329 DI 10.1188/15.ONF.42-05AP PG 11 WC Oncology; Nursing SC Oncology; Nursing GA CU9VA UT WOS:000363892900001 PM 26302289 ER PT J AU Reddy, LF Horan, WP Barch, DM Buchanan, RW Dunayevich, E Gold, JM Lyons, N Marder, SR Treadway, MT Wynn, JK Young, JW Green, MF AF Reddy, L. Felice Horan, William P. Barch, Deanna M. Buchanan, Robert W. Dunayevich, Eduardo Gold, James M. Lyons, Naomi Marder, Stephen R. Treadway, Michael T. Wynn, Jonathan K. Young, Jared W. Green, Michael F. TI Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1-Psychometric Characteristics of 5 Paradigms SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; effort; motivation; psychometric ID NEGATIVE SYMPTOMS; PHYSICAL EFFORT; VALIDATION; ANHEDONIA; TASK AB Impairments in willingness to exert effort contribute to the motivational deficits characteristic of the negative symptoms of schizophrenia. The current study evaluated the psychometric properties of 5 new or adapted paradigms to determine their suitability for use in clinical trials of schizophrenia. This study included 94 clinically stable participants with schizophrenia and 40 healthy controls. The effort-based decision-making battery was administered twice to the schizophrenia group (baseline, 4-week retest) and once to the control group. The 5 paradigms included 1 that assesses cognitive effort, 1 perceptual effort, and 3 that assess physical effort. Each paradigm was evaluated on (1) patient vs healthy control group differences, (2) test-retest reliability, (3) utility as a repeated measure (ie, practice effects), and (4) tolerability. The 5 paradigms showed varying psychometric strengths and weaknesses. The Effort Expenditure for Rewards Task showed the best reliability and utility as a repeated measure, while the Grip Effort Task had significant patient-control group differences, and superior tolerability and administration duration. The other paradigms showed weaker psychometric characteristics in their current forms. These findings highlight challenges in adapting effort and motivation paradigms for use in clinical trials. C1 [Reddy, L. Felice; Horan, William P.; Lyons, Naomi; Marder, Stephen R.; Wynn, Jonathan K.; Green, Michael F.] VISN 22 Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Los Angeles, CA USA. [Reddy, L. Felice; Horan, William P.; Marder, Stephen R.; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Barch, Deanna M.] Washington Univ, Dept Psychol, Dept Psychiat, St Louis, MO 63130 USA. [Barch, Deanna M.] Washington Univ, Dept Radiol, St Louis, MO 63130 USA. [Buchanan, Robert W.; Gold, James M.] Univ Maryland, Sch Med, Dept Psychiat, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA. [Dunayevich, Eduardo] Amgen Inc, Thousand Oaks, CA 91320 USA. [Treadway, Michael T.] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA. [Young, Jared W.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Young, Jared W.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA. RP Reddy, LF (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM lenafelice@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU Amgen, Inc. FX This project was an investigator-initiated research collaboration funded by Amgen, Inc. NR 32 TC 12 Z9 12 U1 4 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD SEP PY 2015 VL 41 IS 5 BP 1045 EP 1054 DI 10.1093/schbul/sbv089 PG 10 WC Psychiatry SC Psychiatry GA CV0YM UT WOS:000363979800009 PM 26142081 ER PT J AU Horan, WP Reddy, LF Barch, DM Buchanan, RW Dunayevich, E Gold, JM Marder, SR Wynn, JK Young, JW Green, MF AF Horan, William P. Reddy, L. Felice Barch, Deanna M. Buchanan, Robert W. Dunayevich, Eduardo Gold, James M. Marder, Steven R. Wynn, Jonathan K. Young, Jared W. Green, Michael F. TI Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2-External Validity and Correlates SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; effort; decision making; functional outcome ID NEGATIVE SYMPTOMS; INCENTIVE MOTIVATION; EFFORT ALLOCATION; REWARD; IMPAIRMENT; ACTIVATION; NEUROCOGNITION; VALIDATION; ANHEDONIA; MEDIATOR AB Effort-based decision making has strong conceptual links to the motivational disturbances that define a key subdomain of negative symptoms. However, the extent to which effort-based decision-making performance relates to negative symptoms, and other clinical and functionally important variables has yet to be systematically investigated. In 94 clinically stable outpatients with schizophrenia, we examined the external validity of 5 effort-based paradigms, including the Effort Expenditure for Rewards, Balloon Effort, Grip Strength Effort, Deck Choice Effort, and Perceptual Effort tasks. These tasks covered 3 types of effort: physical, cognitive, and perceptual. Correlations between effort related performance and 6 classes of variables were examined, including: (1) negative symptoms, (2) clinically rated motivation and community role functioning, (3) self-reported motivational traits, (4) neurocognition, (5) other psychiatric symptoms and clinical/demographic characteristics, and (6) subjective valuation of monetary rewards. Effort paradigms showed small to medium relationships to clinical ratings of negative symptoms, motivation, and functioning, with the pattern more consistent for some measures than others. They also showed small to medium relations with neurocognitive functioning, but were generally unrelated to other psychiatric symptoms, self-reported traits, antipsychotic medications, side effects, and subjective valuation of money. There were relatively strong interrelationships among the effort measures. In conjunction with findings from a companion psychometric article, all the paradigms warrant further consideration and development, and 2 show the strongest potential for clinical trial use at this juncture. C1 [Horan, William P.; Reddy, L. Felice; Marder, Steven R.; Wynn, Jonathan K.; Green, Michael F.] VISN 22 Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Los Angeles, CA USA. [Horan, William P.; Reddy, L. Felice; Marder, Steven R.; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Horan, William P.; Reddy, L. Felice; Marder, Steven R.; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Barch, Deanna M.] Washington Univ, Dept Psychol, Dept Psychiat, St Louis, MO 63130 USA. [Barch, Deanna M.] Washington Univ, Dept Radiol, St Louis, MO 63130 USA. [Buchanan, Robert W.; Gold, James M.] Univ Maryland, Sch Med, Dept Psychiat, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA. [Dunayevich, Eduardo] Amgen Inc, Thousand Oaks, CA 91320 USA. [Young, Jared W.] Univ Calif San Diego, Dept Psychiat, San Deigo, CA USA. [Young, Jared W.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA. RP Horan, WP (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU Amgen, Inc. FX This project was an investigator-initiated research collaboration funded by Amgen, Inc. NR 40 TC 11 Z9 11 U1 4 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD SEP PY 2015 VL 41 IS 5 BP 1055 EP 1065 DI 10.1093/schbul/sbv090 PG 11 WC Psychiatry SC Psychiatry GA CV0YM UT WOS:000363979800010 PM 26209546 ER PT J AU He, S Craig, BA Xu, HP Covinsky, KE Stallard, E Thomas, J Hass, Z Sands, LP AF He, Shuang Craig, Bruce A. Xu, Huiping Covinsky, Kenneth E. Stallard, Eric Thomas, Joseph, III Hass, Zach Sands, Laura P. TI Unmet Need for ADL Assistance Is Associated With Mortality Among Older Adults With Mild Disability SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Activities of daily living; Mortality; Unmet need ID PERSONAL ASSISTANCE; FUNCTIONAL STATUS; ELDERLY-PEOPLE; CARE NEEDS; HOSPITALIZATION; CONSEQUENCES; RISK; HELP AB Background. Unmet need for assistance with activities of daily living (ADLs) disability is associated with increased risk for future hospitalization. To further explore the association between unmet ADL need and future health outcomes, we examined the association between unmet need for ADL assistance and 1-year mortality. Methods. A prospective study of 6,730 community-living Medicare recipients was conducted among respondents to the 1994, 1999, and/or 2004 National Long Term Care Survey. Only those who reported having one or more ADL disabilities were included. Time to death within 1 year after the community survey was determined from Centers for Medicare and Medicaid Services vital statistics records. The community interviews provided demographic, health, and ADL information. Results. Unadjusted 1-year death rates were 8.7%, 10.6%, 11.4%, 19.2%, and 27.3%, respectively, for respondents with disabilities in 1, 2, 3, 4, and 5 ADLs. Overall, 21.3% reported unmet need for assistance for one or more ADL disabilities. After controlling for demographic and health characteristics, we found a significant interaction between unmet ADL need and level of ADL disability (p =.018). Post hoc analyses revealed that unmet ADL need was associated with increased risk for mortality only for those with one (hazard ratio = 1.96; 95% CI = 1.29-2.87) or two ADL disabilities (hazard ratio = 1.37; 95% CI = 1.07-1.75), but not for those with three or more ADL disabilities. Conclusion. Future studies are needed to determine whether these findings are replicable and, if so, whether physiologic or process of care variables explain why ADL is associated with mortality only for those with mild disability. C1 [He, Shuang; Craig, Bruce A.; Hass, Zach] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA. [Xu, Huiping] Indiana Univ, Sch Med, Indianapolis, IN USA. [Covinsky, Kenneth E.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. [Stallard, Eric] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC USA. [Thomas, Joseph, III] Purdue Univ, Coll Pharm, Ctr Aging & Life Course, Regenstrief Ctr Healthcare Engn,Ctr Hlth Outcomes, W Lafayette, IN 47907 USA. [Sands, Laura P.] Purdue Univ, Sch Nursing, W Lafayette, IN 47907 USA. [Sands, Laura P.] Purdue Univ, Ctr Aging & Life Course, W Lafayette, IN 47907 USA. RP Sands, LP (reprint author), Virginia Tech, Ctr Gerontol, 237 Wallace Hall 0426, Blacksburg, VA 24061 USA. EM lsands@vt.edu RI Craig, Bruce/D-5797-2017; Sands, Laura/E-8919-2015 OI Craig, Bruce/0000-0001-9346-467X; Sands, Laura/0000-0003-2446-4486 FU National Institute on Aging at the National Institutes of Health [R01AG034160] FX This research was funded by a grant from the National Institute on Aging at the National Institutes of Health (R01AG034160 to L.P.S.). NR 16 TC 1 Z9 1 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD SEP PY 2015 VL 70 IS 9 BP 1128 EP 1132 DI 10.1093/gerona/glv028 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CU4FK UT WOS:000363482300011 PM 25834196 ER PT J AU Gros, DF Szafranski, DD Brady, KT Back, SE AF Gros, Daniel F. Szafranski, Derek D. Brady, Kathleen T. Back, Sudie E. TI Relations Between Pain, PTSD Symptoms, and Substance Use in Veterans SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; ADDICTION SEVERITY INDEX; COMORBID CHRONIC PAIN; MUTUAL MAINTENANCE; PSYCHOMETRIC PROPERTIES; SOMATIC SYMPTOMS; PRIMARY-CARE; PREVALENCE; DEPRESSION; RISK AB Objective: The frequent co-occurrence of posttraumatic stress disorder (PTSD) and chronic pain has received much attention in the literature. However, the extant literature is limited in that these investigations generally exclude patients with co-occurring substance use disorders (SUD). Thus, the present study investigated symptoms of PTSD and SUD in veterans with high and low pain symptoms. Method: Veterans (N = 136) seeking treatment for comorbid symptoms of PTSD and SUD were recruited as part of a larger study. All participants completed a baseline assessment, which included a series of diagnostic interviews and self-report questionnaires measuring symptoms of pain, PTSD and SUD. Results: Higher levels of self-reported pain were found to be associated with both self-reported and clinician-rated PTSD symptoms above and beyond the influence of the demographic variables. However, no reliable relations were demonstrated between substance use and pain. Conclusions: Although preliminary, the findings highlight the common occurrence of chronic pain among veterans with comorbid PTSD/SUD, and the potential impact of pain on clinical presentation. The findings may help inform special considerations for assessment and treatment practices for this high-risk population. C1 [Gros, Daniel F.; Szafranski, Derek D.; Brady, Kathleen T.; Back, Sudie E.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Gros, Daniel F.; Szafranski, Derek D.; Brady, Kathleen T.; Back, Sudie E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. RP Gros, DF (reprint author), Mental Hlth Serv, 116,Ralph H Johnson VAMC,109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU NIDA [DA021228]; Department of Veteran Affairs CSR&D Career Development Award [CX000845] FX This research was supported by NIDA grant DA021228 (PI: Back) and Department of Veteran Affairs CSR&D Career Development Award CX000845 (PI: Gros). NR 41 TC 1 Z9 1 U1 2 U2 5 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0033-2747 J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PD FAL PY 2015 VL 78 IS 3 BP 277 EP 287 DI 10.1080/00332747.2015.1069659 PG 11 WC Psychiatry SC Psychiatry GA CU5UG UT WOS:000363596900012 PM 26391835 ER PT J AU Morgan, TR Osann, K Bottiglieri, T Pimstone, N Hoefs, JC Hu, KQ Hassanein, T Boyer, TD Kong, L Chen, WP Richmond, E Gonzalez, R Rodriguez, LM Meyskens, FL AF Morgan, Timothy R. Osann, Kathryn Bottiglieri, Teodoro Pimstone, Neville Hoefs, John C. Hu, Ke-Qin Hassanein, Tarek Boyer, Thomas D. Kong, Lorene Chen, Wen-Pin Richmond, Ellen Gonzalez, Rachel Rodriguez, Luz M. Meyskens, Frank L. TI A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum alpha-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP SO CANCER PREVENTION RESEARCH LA English DT Article ID ADENOSYL-L-METHIONINE; RAT-LIVER CARCINOGENESIS; QUALITY-OF-LIFE; HEPATOCELLULAR-CARCINOMA; PRENEOPLASTIC LESIONS; PLASMA HOMOCYSTEINE; DNA METHYLATION; CLINICAL-TRIAL; RISK-FACTORS; DOUBLE-BLIND AB In animal models of hepatocellular carcinoma (HCC), deficiency of S-adenosylmethionine (SAMe) increased the risk of HCC whereas administration of SAMe reduced HCC. The aim of this trial was to determine whether oral SAMe administration to patients with hepatitis C cirrhosis would decrease serum alpha-fetoprotein (AFP) level, a biomarker of HCC risk in hepatitis C. This was a prospective, randomized, placebo-controlled, double-blind trial of SAMe, up to 2.4 g/d, for 24 weeks as compared with placebo among subjects with hepatitis C cirrhosis and a mildly elevated serum AFP. Primary outcome was change in AFP between baseline and week 24. Secondary outcomes included changes in routine tests of liver function and injury, other biomarkers of HCC risk, SAMe metabolites, markers of oxidative stress, and quality of life. One hundred ten subjects were randomized and 87 (44 SAMe and 43 placebo) completed treatment. There was no difference in the change in AFP during 24 weeks among subjects receiving SAMe as compared with placebo. Changes in markers of liver function, liver injury, and hepatitis C viral level were not significantly different between groups. Similarly, SAMe did not change markers of oxidative stress or serum glutathione level. SAMe blood level increased significantly among subjects receiving SAMe. Changes in quality of life did not differ between groups. Overall, this trial did not find that SAMe treatment improved serum AFP in subjects with advanced hepatitis C cirrhosis and a mildly elevated AFP. SAMe did not improve tests of liver function or injury or markers of oxidative stress or antioxidant potential. (C) 2015 AACR. C1 [Morgan, Timothy R.] VA Long Beach Healthcare Syst, Med Healthcare Grp, Long Beach, CA USA. [Morgan, Timothy R.; Hu, Ke-Qin] Univ Calif Irvine, Dept Med, Div Gastroenterol, Irvine, CA 92717 USA. [Osann, Kathryn] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92717 USA. [Bottiglieri, Teodoro] Baylor Res Inst, Inst Metab Dis, Dallas, TX USA. [Pimstone, Neville] VA Greater Los Angeles Healthcare Syst, Med Healthcare Grp, Los Angeles, CA USA. [Hoefs, John C.; Meyskens, Frank L.] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA. [Hassanein, Tarek] Univ Calif San Diego, Dept Med, Div Hepatol, San Diego, CA 92103 USA. [Boyer, Thomas D.] Univ Arizona, Liver Res Inst, Tucson, AZ USA. [Boyer, Thomas D.] Univ Arizona, Dept Med, Tucson, AZ USA. [Kong, Lorene] Univ Calif Irvine, Res Pharm, Irvine, CA USA. [Chen, Wen-Pin; Meyskens, Frank L.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA. [Richmond, Ellen; Rodriguez, Luz M.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. [Gonzalez, Rachel] VA Long Beach Healthcare Syst, Res Healthcare Grp, Long Beach, CA USA. [Rodriguez, Luz M.] Walter Reed Natl Mil Med Ctr, Dept Surg, Bethesda, MD USA. [Meyskens, Frank L.] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA. [Meyskens, Frank L.] Univ Calif Irvine, Dept Publ Hlth, Irvine, CA USA. [Meyskens, Frank L.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. RP Morgan, TR (reprint author), VA Long Beach Healthcare Syst GI 11, 5901 East Seventh St, Long Beach, CA 90822 USA. EM timothy.morgan@va.gov FU NCI [N01-CN-35160]; National Center for Research Resources, NIH; National Center for Advancing Translational Sciences, NIH [UL1 TR000153] FX The study was supported by contract N01-CN-35160 from the NCI to F.L. Meyskens. The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, through Grant UL1 TR000153 to D.M. Cooper. NR 41 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD SEP PY 2015 VL 8 IS 9 BP 864 EP 872 DI 10.1158/1940-6207.CAPR-15-0029 PG 9 WC Oncology SC Oncology GA CU3BL UT WOS:000363398400013 PM 26130251 ER PT J AU Mellati, M Eaton, KD Brooks-Worrell, BM Hagopian, WA Martins, R Palmer, JP Hirsch, IB AF Mellati, Mahnaz Eaton, Keith D. Brooks-Worrell, Barbara M. Hagopian, William A. Martins, Renato Palmer, Jerry P. Hirsch, Irl B. TI Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes SO DIABETES CARE LA English DT Letter C1 [Mellati, Mahnaz; Brooks-Worrell, Barbara M.; Hagopian, William A.; Palmer, Jerry P.; Hirsch, Irl B.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Eaton, Keith D.; Martins, Renato] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA. [Brooks-Worrell, Barbara M.; Palmer, Jerry P.] VA Puget Sound Hlth Care Syst, Div Endocrinol, Seattle, WA USA. [Hagopian, William A.] Pacific Northwest Diabet Res Inst, Seattle, WA USA. RP Hirsch, IB (reprint author), Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. EM ihirsch@uw.edu NR 5 TC 11 Z9 11 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2015 VL 38 IS 9 BP E137 EP E138 DI 10.2337/dc15-0889 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CU3HZ UT WOS:000363416500004 PM 26116720 ER PT J AU Muram, D Zhang, X Cui, ZL Matsumoto, AM AF Muram, David Zhang, Xiang Cui, Zhanglin Matsumoto, Alvin M. TI Use of Hormone Testing for the Diagnosis and Evaluation of Male Hypogonadism and Monitoring of Testosterone Therapy: Application of Hormone Testing Guideline Recommendations in Clinical Practice SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Hypogonadism; Testosterone; Hormone Testing; Retrospective Study ID SERUM TESTOSTERONE; MEN; DEFICIENCY AB Introduction. Clinical practice guidelines recommend that testosterone (T) levels be measured on >= 2 occasions to confirm a diagnosis of hypogonadism, gonadotropins be measured to determine whether hypogonadism is primary or secondary, and T levels be measured to monitor the adequacy of T therapy. However, it is not known whether hormone testing as recommended by guidelines is routinely performed in real-world clinical practice. Aim. The aim of this study was to assess the use of hormone testing for the diagnosis and evaluation of hypogonadism and monitoring of T therapy in clinical practice. Methods. In this retrospective cohort study of the Truven Health Marketscan (R) Commercial and Medicare Supplemental Insurance Databases during 2010-2012, 63,534 men over 18 years old who received T therapy and had continuous medical benefit enrollment for 1 year prior to and 6 months after T therapy initiation were included in this analysis. Main Outcome Measures. Proportion of patients who received >= 2, 1, or no T-level determinations prior to or following T therapy initiation. Results. Seventy-one percent of hypogonadal men had T measured at least once and 40% had >= 2 tests, but only 12% of men had luteinizing hormone and/or follicle-stimulating hormone levels measured prior to T therapy initiation. Following T therapy initiation, 46% had >= 1 follow-up T measurements. Conclusions. Appropriate use of T and gonadotropin levels in clinical practice as recommended by guidelines is suboptimal, increasing the possibility of overdiagnosis of male hypogonadism, underdiagnosis of secondary hypogonadism, and inappropriate T therapy use and management. Further investigation is needed into reasons for nonadherence to guidelines for appropriate hormone testing to inform future quality improvement efforts. C1 [Muram, David; Zhang, Xiang; Cui, Zhanglin] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Matsumoto, Alvin M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Muram, D (reprint author), Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. EM muram_david@lilly.com FU Eli Lilly and Company FX This work was sponsored by Eli Lilly and Company. DM, XZ, and ZC are employees and minor shareholders of Eli Lilly and Company. Dr. Matsumoto has served as a consultant for Eli Lilly and Company. NR 17 TC 6 Z9 6 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD SEP PY 2015 VL 12 IS 9 BP 1886 EP 1894 DI 10.1111/jsm.12968 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CU3WJ UT WOS:000363456400005 PM 26272690 ER PT J AU Karavan, M Olerud, J Bouldin, E Taylor, L Reiber, GE AF Karavan, Mahsa Olerud, John Bouldin, Erin Taylor, Leslie Reiber, Gayle E. TI Evidence-based chronic ulcer care and lower limb outcomes among Pacific Northwest veterans SO WOUND REPAIR AND REGENERATION LA English DT Article DE evidence-based care; ulcer; lower limb; veterans ID DIABETIC FOOT ULCERS; PERIPHERAL ARTERIAL-DISEASE; VENOUS ULCERS; WOUND CARE; GUIDELINES; DEBRIDEMENT AB Evidence-based ulcer care guidelines detail optimal components of care for treatment of ulcers of different etiologies. We investigated the impact of providing specific evidence-based ulcer treatment components on healing outcomes for lower limb ulcers (LLU) among veterans in the Pacific Northwest. Components of evidence-based ulcer care for venous, arterial, diabetic foot ulcers/neuropathic ulcers were abstracted from medical records. The outcome was ulcer healing. Our analysis assessed the relationship between evidence-based ulcer care by etiology, components of care provided, and healing, while accounting for veteran characteristics. A minority of veterans in all three ulcer-etiology groups received the recommended components of evidence-based care in at least 80% of visits. The likelihood of healing improved when assessment for edema and infection were performed on at least 80% of visits (hazard ratio [HR]=3.20, p=0.009 and HR=3.54, p=0.006, respectively) in patients with venous ulcers. There was no significant association between frequency of care components provided and healing among patients with arterial ulcers. Among patients with diabetic/neuropathic ulcers, the chance of healing increased 2.5-fold when debridement was performed at 80% of visits (p=0.03), and doubled when ischemia was assessed at the first visit (p=0.045). Veterans in the Pacific Northwest did not uniformly receive evidence-based ulcer care. Not all evidence-based ulcer care components were significantly associated with healing. At a minimum, clinicians need to address components of ulcer care associated with improved ulcer healing. C1 [Karavan, Mahsa; Bouldin, Erin; Taylor, Leslie; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Karavan, Mahsa; Olerud, John] Univ Washington, Sch Med, Seattle, WA USA. [Olerud, John] Univ Washington, Div Dermatol, Seattle, WA 98195 USA. [Bouldin, Erin; Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bouldin, Erin; Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Reiber, GE (reprint author), VA Puget Sound Hlth Care Syst, 152,Met Pk West 1400,1100 Olive Way, Seattle, WA 98101 USA. EM gayle.reiber@va.gov OI Bouldin, Erin/0000-0001-7550-309X NR 38 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1067-1927 EI 1524-475X J9 WOUND REPAIR REGEN JI Wound Repair Regen. PD SEP-OCT PY 2015 VL 23 IS 5 BP 745 EP 752 DI 10.1111/wrr.12341 PG 8 WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery GA CU2YW UT WOS:000363390900013 PM 26171654 ER PT J AU Akthar, S Patel, DF Beale, RC Peiro, T Xu, X Gaggar, A Jackson, PL Blalock, JE Lloyd, CM Snelgrove, RJ AF Akthar, Samia Patel, Dhiren F. Beale, Rebecca C. Peiro, Teresa Xu, Xin Gaggar, Amit Jackson, Patricia L. Blalock, J. Edwin Lloyd, Clare M. Snelgrove, Robert J. TI Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection SO NATURE COMMUNICATIONS LA English DT Article ID LEUKOTRIENE A(4) HYDROLASE; EXTRACELLULAR-MATRIX DEGRADATION; ALVEOLAR MACROPHAGE PHAGOCYTOSIS; SMOKE-INDUCED EMPHYSEMA; KLEBSIELLA-PNEUMONIAE; DEFICIENT MICE; NEUTROPHIL CHEMOATTRACTANT; TRYPANOSOMA-CRUZI; HOST-DEFENSE; B-4 AB Bioactive matrix fragments (matrikines) have been identified in a myriad of disorders, but their impact on the evolution of airway inflammation has not been demonstrated. We recently described a pathway where the matrikine and neutrophil chemoattractant proline-glycine-proline (PGP) could be degraded by the enzyme leukotriene A(4) hydrolase (LTA(4)H). LTA(4)H classically functions in the generation of pro-inflammatory leukotriene B-4, thus LTA(4)H exhibits opposing pro- and anti-inflammatory activities. The physiological significance of this secondary anti-inflammatory activity remains unknown. Here we show, using readily resolving pulmonary inflammation models, that loss of this secondary activity leads to more pronounced and sustained inflammation and illness owing to PGP accumulation. PGP elicits an exacerbated neutrophilic inflammation and protease imbalance that further degrades the extracellular matrix, generating fragments that perpetuate inflammation. This highlights a critical role for the secondary anti-inflammatory activity of LTA(4)H and thus has consequences for the generation of global LTA(4)H inhibitors currently being developed. C1 [Akthar, Samia; Patel, Dhiren F.; Beale, Rebecca C.; Peiro, Teresa; Lloyd, Clare M.; Snelgrove, Robert J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England. [Xu, Xin; Gaggar, Amit; Jackson, Patricia L.; Blalock, J. Edwin] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Xu, Xin; Gaggar, Amit; Jackson, Patricia L.; Blalock, J. Edwin] Univ Alabama Birmingham, Lung Hlth Ctr, Dept Med, Birmingham, AL USA. [Gaggar, Amit] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Ctr, Birmingham, AL 35294 USA. [Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, Birmingham, AL 35294 USA. [Gaggar, Amit; Blalock, J. Edwin] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Snelgrove, RJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England. EM robert.snelgrove@imperial.ac.uk OI Blalock, J. Edwin/0000-0001-5303-8123 FU National Heart, Lung and Blood Institute [HL07783, HL110950, HL114439, HL102371-A1]; NIH [RR19231, P30CA13148, P50AT00277, U54CA100949, P30AR050948, P30DK740380]; Marie Curie Intra European Fellowship within the 7th European Community Framework Programme (FP7-PEOPLE-IEF) [627374] FX R.J.S. is a Wellcome Trust Career Development Fellow (095707/Z/11/Z). C.M.L. is a Wellcome Trust Senior Fellow in Basic Biomedical Sciences (087618/Z/08/Z). T.P. is supported by a Marie Curie Intra European Fellowship within the 7th European Community Framework Programme (FP7-PEOPLE-2013-IEF No. 627374). The National Heart, Lung and Blood Institute funds J.E.B. (HL07783, HL110950 and HL114439) and A.G. (HL102371-A1). The UAB Lung Health Center Pulmonary Proteomics Laboratory is funded through the NIH (RR19231, P30CA13148, P50AT00277, U54CA100949, P30AR050948 and P30DK740380). We would like to thank Dr Anna Caldwell and the Centre of Excellence for Mass Spectrometry at King's College London for the use of equipment and technical assistance. NR 70 TC 5 Z9 5 U1 4 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD SEP PY 2015 VL 6 AR 8423 DI 10.1038/ncomms9423 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT9MC UT WOS:000363140200001 PM 26400771 ER PT J AU Fatemi, G Fang, MA Breuer, P Cherniak, PE Gentili, A Hanlon, JT Karp, JF Morone, NE Rodriguez, E Rossi, MI Schmader, K Weiner, DK AF Fatemi, Gita Fang, Meika A. Breuer, Paula Cherniak, Paul E. Gentili, Angela Hanlon, Joseph T. Karp, Jordan F. Morone, Natalia E. Rodriguez, Eric Rossi, Michelle I. Schmader, Kenneth Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment Part III: Fibromyalgia Syndrome SO PAIN MEDICINE LA English DT Review DE Fibromyalgia; Low Back Pain; Elderly; Chronic Pain; Back Pain ID OF-RHEUMATOLOGY 1990; AEROBIC EXERCISE; DOUBLE-BLIND; MULTICENTER TRIAL; RANDOMIZED-TRIAL; SELF-MANAGEMENT; TAI CHI; PREVALENCE; SLEEP; PLACEBO AB Objective. To present the third in a series of articles designed to deconstruct chronic low back pain (CLBP) in older adults. The series presents CLBP as a syndrome, a final common pathway for the expression of multiple contributors rather than a disease localized exclusively to the lumbosacral spine. Each article addresses one of 12 important contributors to pain and disability in older adults with CLBP. This article focuses on fibromyalgia syndrome (FMS). Methods. A modified Delphi approach was used to create the evaluation and treatment algorithm, the table discussing the rationale behind each of the algorithm components, and the stepped-care drug recommendations. The team involved in the creation of these materials consisted of a principal investigator, a 5-member content expert panel, and a 9-member primary care panel. The evaluation and treatment recommendations were based on availability of medications and other resources within the Veterans Health Administration (VHA) facilities. However, non-VHA panelists were also involved in the development of these materials, which can be applied to both VA and civilian settings. The illustrative clinical case was taken from the clinical practice of the principal investigator. Results. Following expert consultations and a review of the literature, we developed an evaluation and treatment algorithm with supporting materials to aid in the care of older adults with CLBP who have concomitant FMS. A case is presented that demonstrates the complexity of pain evaluation and management in older patients with CLBP and concomitant FMS. Conclusions. Recognition of FMS as a common contributor to CLBP in older adults and initiating treatment targeting both FMS and CLBP may lead to improved outcomes in pain and disability. C1 [Fatemi, Gita; Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fatemi, Gita; Fang, Meika A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Breuer, Paula] Univ Pittsburgh, Med Ctr, Ctr Rehab Serv, Pittsburgh, PA USA. [Cherniak, Paul E.] Univ Miami, Miller Sch Med, Div Geriatr & Palliat Med, Miami, FL 33136 USA. [Cherniak, Paul E.] Bruce W Carter Miami VA Med Ctr, Miami, FL USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Geriatr Med, Sch Med, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Sch Med, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Sch Med, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.; Morone, Natalia E.; Rossi, Michelle I.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. [Hanlon, Joseph T.] VA Pittsburgh Hlth Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Rodriguez, Eric] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Schmader, Kenneth] Durham VA Med Ctr, GRECC, Durham, NC USA. [Schmader, Kenneth] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU NIA NIH HHS [K07 AG033174, P30 AG024827, T32 AG021885] NR 53 TC 1 Z9 1 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD SEP PY 2015 VL 16 IS 9 BP 1709 EP 1719 DI 10.1111/pme.12863 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CT5YR UT WOS:000362887700007 PM 26272644 ER PT J AU Solow, EB Yu, F Thiele, GM Sokolove, J Robinson, WH Pruhs, ZM Michaud, KD Erickson, AR Sayles, H Kerr, GS Gaffo, AL Caplan, L Davis, LA Cannon, GW Reimold, AM Baker, J Schwab, P Anderson, DR Mikuls, TR AF Solow, E. Blair Yu, Fang Thiele, Geoffrey M. Sokolove, Jeremy Robinson, William H. Pruhs, Zachary M. Michaud, Kaleb D. Erickson, Alan R. Sayles, Harlan Kerr, Gail S. Gaffo, Angelo L. Caplan, Liron Davis, Lisa A. Cannon, Grant W. Reimold, Andreas M. Baker, Joshua Schwab, Pascale Anderson, Daniel R. Mikuls, Ted R. TI Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality SO RHEUMATOLOGY LA English DT Article DE rheumatoid arthritis; vascular calcifications; hand radiographs; anti-citrullinated protein autoantibodies; mortality ID SMOOTH-MUSCLE-CELLS; DISEASE-ACTIVITY; CORONARY ATHEROSCLEROSIS; ARTERIAL CALCIFICATION; MYOCARDIAL-INFARCTION; ALPHA THERAPY; BONE LOSS; OSTEOPOROSIS; MICE; INTERLEUKIN-4 AB Objective. To examine whether vascular calcifications on hand films in RA might aid in determining mortality risk. Methods. Hand radiographs from 906 RA patients were scored as positive or negative for vascular calcifications. Patient characteristics associated with vascular calcifications were assessed using multivariable logistic regression, and associations with mortality were examined using Cox proportional hazards regression. Cytokines and multiplex ACPA were measured in both groups. Results. A total of 99 patients (11%) demonstrated radiographic vascular calcifications. Factors independently associated with vascular calcifications included diabetes [odds ratio (OR) 2.85; 95% CI 1.43, 5.66], cardiovascular disease at enrolment (OR 2.48; 95% CI 1.01, 6.09), prednisone use (OR 1.90; 95% CI 1.25, 2.91), current smoking (OR 0.06; 95% CI 0.01, 0.23) and former smoking (OR 0.36; 95% CI 0.27, 0.48) vs never smoking. In cytokine and ACPA subtype analysis, IL-4 and anti-citrullinated apolipoprotein E were significantly increased in patients with vascular calcifications in fully adjusted multivariable models. After multivariable adjustment, vascular calcifications were associated with an increase in all-cause mortality (hazard ratio 1.41; 95% CI 1.12, 1.78; P = 0.004). Conclusion. Vascular calcifications on hand radiographs were independently associated with increased all-cause mortality in RA. Mechanisms underpinning the associations of IL-4 and select ACPA with vascular calcifications and their utility as biomarkers predictive of cardiovascular disease risk in RA merit further study. C1 [Solow, E. Blair; Reimold, Andreas M.] UT Southwestern, Div Rheumat Dis, Dallas, TX USA. [Yu, Fang] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE USA. [Thiele, Geoffrey M.; Pruhs, Zachary M.; Michaud, Kaleb D.; Erickson, Alan R.; Sayles, Harlan; Mikuls, Ted R.] Omaha Vet Affairs Med Ctr, Div Rheumatol & Immunol, Omaha, NE 68198 USA. [Sokolove, Jeremy; Robinson, William H.] VA Palo Alto Hlth Care Syst, Div Rheumatol, Palo Alto, CA USA. [Michaud, Kaleb D.] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Kerr, Gail S.] Vet Affairs Med Ctr, Dept Med, Washington, DC 20422 USA. [Gaffo, Angelo L.] Birmingham Vet Affairs Med Ctr, Dept Med, Birmingham, AL USA. [Caplan, Liron; Davis, Lisa A.] Denver Vet Affairs Med Ctr, Div Rheumatol, Denver, CO USA. [Cannon, Grant W.] George Wahlen Vet Affairs Med Ctr, Div Rheumatol, Salt Lake City, UT USA. [Reimold, Andreas M.] Dallas Vet Affairs Med Ctr, Div Rheumatol, Dallas, TX USA. [Baker, Joshua] Philadelphia Vet Affairs Med Ctr, Div Rheumatol, Philadelphia, PA USA. [Schwab, Pascale] Portland VA Med Ctr, Div Rheumatol, Portland, OR USA. [Anderson, Daniel R.] Univ Nebraska Med Ctr, Div Cardiol, Omaha, NE USA. RP Mikuls, TR (reprint author), Omaha Vet Affairs Med Ctr, Div Rheumatol & Immunol, 986270 Nebraska Med Ctr, Omaha, NE 68198 USA. EM tmikuls@unmc.edu FU Nebraska Arthritis Outcomes Research Centre at the University of Nebraska Medical Centre FX This work was supported by the Nebraska Arthritis Outcomes Research Centre at the University of Nebraska Medical Centre. NR 45 TC 2 Z9 2 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD SEP PY 2015 VL 54 IS 9 BP 1587 EP 1595 DI 10.1093/rheumatology/kev027 PG 9 WC Rheumatology SC Rheumatology GA CT5KL UT WOS:000362848500009 PM 25854268 ER PT J AU Connor, DM Dhaliwal, G AF Connor, Denise M. Dhaliwal, Gurpreet TI When less is more for the struggling clinical reasoner SO DIAGNOSIS LA English DT Article DE clinical reasoning; deliberate practice; feedback; medical students; remediation ID MEDICAL-EDUCATION; DIFFICULTIES; REMEDIATION; OUTCOMES AB Busy clinician-educators are often tasked with remediating medical students who have deficits in clinical reasoning. In this essay, we share our early experience with providing less feedback and more practice to these trainees. We suggest that front line teachers can streamline their feedback to struggling reasoners by focusing solely on the problem representation and prioritized differential diagnosis of the main problem in their oral presentations and then engaging in repeated loops of feedback until the student achieves competency in real time. By receiving feedback targeted to the assessment alone and employing deliberate practice, struggling students have the opportunity to make concrete improvement during short-term clinical assignments. This remediation approach is feasible for busy clinician-educators and warrants formal study. C1 [Connor, Denise M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Connor, Denise M.; Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA 94121 USA. [Connor, Denise M.; Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Connor, DM (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM denise.connor@ucsf.edu NR 11 TC 0 Z9 0 U1 0 U2 1 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-8011 EI 2194-802X J9 DIAGNOSIS JI Diagnosis PD SEP PY 2015 VL 2 IS 3 BP 159 EP 162 DI 10.1515/dx-2015-0014 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CT8HV UT WOS:000363056900002 ER PT J AU Sheffrin, M AF Sheffrin, Meera TI Cholinesterase inhibitors cause significant weight loss in patients with dementia SO BRITISH JOURNAL OF HOSPITAL MEDICINE LA English DT News Item C1 Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. RP Sheffrin, M (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU MA HEALTHCARE LTD PI LONDON PA ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND SN 1750-8460 EI 1759-7390 J9 BRIT J HOSP MED JI Br. J. Hosp. Med. PD SEP PY 2015 VL 76 IS 9 BP 501 EP 501 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CS9AL UT WOS:000362381400005 ER PT J AU Roy, A Al-Qusairi, L Donnelly, BF Ronzaud, C Marciszyn, AL Gong, F Chang, YPC Butterworth, MB Pastor-Soler, NM Hallows, KR Staub, O Subramanya, AR AF Roy, Ankita Al-Qusairi, Lama Donnelly, Bridget F. Ronzaud, Caroline Marciszyn, Allison L. Gong, Fan Chang, Y. P. Christy Butterworth, Michael B. Pastor-Soler, Nuria M. Hallows, Kenneth R. Staub, Olivier Subramanya, Arohan R. TI Alternatively spliced praline-rich cassettes link WNK1 to aldosterone action SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID NA+-CL-COTRANSPORTER; SODIUM-CHLORIDE COTRANSPORTER; DISTAL CONVOLUTED TUBULE; KINASE-DEFECTIVE ISOFORM; PROTEIN-KINASE; BLOOD-PRESSURE; PHOSPHORYLATION SITES; SIGNALING PATHWAY; LIDDLES-SYNDROME; SALT TRANSPORT AB The thiazide-sensitive NaCl cotransporter (NCC) is important for renal salt handling and blood-pressure homeostasis. The canonical NCC-activating pathway consists of With-No-Lysine (WNK) kinases and their downstream effector kinases SPAK and OSR1, which phosphorylate NCC directly. The upstream mechanisms that connect physiological stimuli to this system remain obscure. Here, we have shown that aldosterone activates SPAK/OSR1 via WNk1. We identified 2 alternatively spliced exons embedded within a proline-rich region of WNK1 that contain PV motifs, which bind the E3 ubiquitin ligase NEDD4-2. PV motif-containing WNK1 isoforms were expressed in human kidney, and these isoforms were efficiently degraded by the ubiquitin proteasome system, an effect reversed by the aldosterone-induced kinase SGK1. In gene-edited cells, WNK1 deficiency negated regulatory effects of NEDD4-2 and SGK1 on NCC, suggesting that WNK1 mediates aldosterone-dependent activity of the WNK/SPAK/OSR1 pathway. Aldosterone infusion increased proline-rich WNK1 isoforrn abundance in WT mice but did not alter WNK1 abundance in hypertensive Nedd4-2 KO mice, which exhibit high baseline WNK1 and SPAK/OSR1 activity toward NCC. Conversely, hypotensive Sgk1 KO mice exhibited low WNK1 expression and activity. Together, our findings indicate that the proline-rich exons are modular cassettes that convert WNK1 into a NEDD4-2 substrate, thereby linking aldosterone and other NEDD4-2-suppressing antinatriuretic hormones to NCC phosphorylation status. C1 [Roy, Ankita; Donnelly, Bridget F.; Marciszyn, Allison L.; Gong, Fan; Pastor-Soler, Nuria M.; Hallows, Kenneth R.; Subramanya, Arohan R.] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15261 USA. [Al-Qusairi, Lama; Ronzaud, Caroline; Staub, Olivier] Univ Lausanne, Dept Pharmacol & Toxicol, Lausanne, Switzerland. [Chang, Y. P. Christy] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Butterworth, Michael B.; Pastor-Soler, Nuria M.; Hallows, Kenneth R.; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15261 USA. [Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Subramanya, AR (reprint author), Univ Pittsburgh, Dept Med, Sch Med, Renal Electrolyte Div, S828A Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM ars129@pitt.edu FU NIH [R01DK098145, R01DK84184, R01DK75048, R00DK78917, R01HL88120, P30DK79307]; American Society of Nephrology Gottschalk Scholar grant; Swiss National Science Foundation [310030_0141013]; Swiss National Centre of Competence in Research Kidney Control of Homeostasis (NCCR Kidney.CH); U.S. Department of Veterans Affairs; VA VISN4 Competitive Pilot Project Funds; James A. Shaver Fund of the American Heart Association [10BGIA3890010] FX This work was supported, in whole or in part, by NIH grants R01DK098145 (to A.R. Subramanya), R01DK84184 (to N.M. Pastor-Soler), R01DK75048 (to K.R. Hallows), R00DK78917 (to M.B. Butterworth), R01HL88120 (to Y.P.C. Chang), and P30DK79307 (to the Pittsburgh Center for Kidney Research), as well as an American Society of Nephrology Gottschalk Scholar grant (to M.B. Butterworth), Swiss National Science Foundation grant 310030_0141013 (to O. Staub), the Swiss National Centre of Competence in Research Kidney Control of Homeostasis (NCCR Kidney.CH) grant (to O. Staub), a Mid-Level Career Development Award from the U.S. Department of Veterans Affairs (to A.R. Subramanya), VA VISN4 Competitive Pilot Project Funds (to A.R. Subramanya), and grant 10BGIA3890010 from the James A. Shaver Fund of the American Heart Association (to A.R. Subramanya). We thank David Ellison and Jim Wade for NCC antibodies; Alan Pao for constructs; Alexandra Socovich, Sean Khadem, Avin C. Snyder, and Xiaoning Liu for technical assistance; and Vivek Bhalla and Rodrigo Alzamora for helpful discussions. NR 67 TC 12 Z9 12 U1 2 U2 5 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD SEP PY 2015 VL 125 IS 9 BP 3433 EP 3448 DI 10.1172/JCI75245 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CS7YT UT WOS:000362303600021 PM 26241057 ER PT J AU Piel, J AF Piel, Jennifer TI The Defense of Involuntary Intoxication by Prescribed Medications: An Appellate Case Review SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Review AB The defense of involuntary intoxication has long been an exception to the general notion that intoxication is not a defense to criminal liability. The consumption of medications prescribed by a physician can form the basis of an involuntary-intoxication defense. In this article, I review cases where defendants relied on the use of prescribed medications for an involuntary-intoxication defense. The medications most frequently implicated by defendants are listed by name and by class. From the case law, I provide a summary of the defense and a review of the pitfalls of the defense to serve as practice pointers for forensic evaluators. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Piel, J (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jennifer.piel@va.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 EI 1943-3662 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PD SEP 1 PY 2015 VL 43 IS 3 BP 321 EP 328 PG 8 WC Law; Psychiatry SC Government & Law; Psychiatry GA CS9VX UT WOS:000362442100010 PM 26438810 ER PT J AU Piel, J AF Piel, Jennifer TI Expanding Slayer Statutes to Elder Abuse SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Editorial Material AB Common law has a dictum that people must not benefit from their crimes. In years past, states have enacted slayer rules to prevent killers from inheriting from their victims. The specific criteria and applicability of slayer rules vary by jurisdiction. Recently, several states, including Washington, have expanded their slayer rules to disqualify persons from inheriting if they have been involved in abuse or financial exploitation of the deceased. Reviewed herein are the abuse disinheritance laws, the relationship of the laws to concepts of testamentary capacity and undue influence, and the relevance to forensic psychiatric evaluations. C1 [Piel, Jennifer] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Piel, Jennifer] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Piel, J (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way,MS 116 MHC, Seattle, WA 98108 USA. EM jennifer.piel@va.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 EI 1943-3662 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PD SEP 1 PY 2015 VL 43 IS 3 BP 369 EP 376 PG 8 WC Law; Psychiatry SC Government & Law; Psychiatry GA CS9VX UT WOS:000362442100015 PM 26438815 ER PT J AU Ramanathan, DS Gulati, T Ganguly, K AF Ramanathan, Dhakshin S. Gulati, Tanuj Ganguly, Karunesh TI Sleep-Dependent Reactivation of Ensembles in Motor Cortex Promotes Skill Consolidation SO PLOS BIOLOGY LA English DT Article ID SLOW-WAVE SLEEP; FOREBRAIN CHOLINERGIC SYSTEM; MEMORY CONSOLIDATION; PREFRONTAL CORTEX; CORTICOSTRIATAL PLASTICITY; CORTICAL PLASTICITY; DENDRITIC SPINES; BRAIN PLASTICITY; TIME-COURSE; IN-VIVO AB Despite many prior studies demonstrating offline behavioral gains in motor skills after sleep, the underlying neural mechanisms remain poorly understood. To investigate the neurophysiological basis for offline gains, we performed single-unit recordings in motor cortex as rats learned a skilled upper-limb task. We found that sleep improved movement speed with preservation of accuracy. These offline improvements were linked to both replay of task-related ensembles during non-rapid eye movement (NREM) sleep and temporal shifts that more tightly bound motor cortical ensembles to movements; such offline gains and temporal shifts were not evident with sleep restriction. Interestingly, replay was linked to the coincidence of slow-wave events and bursts of spindle activity. Neurons that experienced the most consistent replay also underwent the most significant temporal shift and binding to the motor task. Significantly, replay and the associated performance gains after sleep only occurred when animals first learned the skill; continued practice during later stages of learning (i.e., after motor kinematics had stabilized) did not show evidence of replay. Our results highlight how replay of synchronous neural activity during sleep mediates large-scale neural plasticity and stabilizes kinematics during early motor learning. C1 [Ramanathan, Dhakshin S.; Gulati, Tanuj; Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94121 USA. [Ramanathan, Dhakshin S.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA USA. [Ramanathan, Dhakshin S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Gulati, Tanuj; Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Ganguly, K (reprint author), San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94121 USA. EM karunesh.ganguly@ucsf.edu FU Department of Veterans Affairs, Veterans Health Administration [CDA B6674W]; American Heart Association; Northern California Institute for Research and Education (NCIRE); start-up funds from UCSF Department of Neurology; Burroughs Wellcome Fund FX This work was supported by fellowship awards from the Department of Veterans Affairs, Veterans Health Administration (http://www.va.gov/) to DSR and from the American Heart Association (http://www.heart.org/HEARTORG/) to TG. This work was also supported by awards to KG from the Department of Veterans Affairs, Veterans Health Administration (http://www.va.gov/, CDA B6674W); from the Northern California Institute for Research and Education (NCIRE, www.ncire.org) and start-up funds from the UCSF Department of Neurology (http://neurology.ucsf.edu). KG also holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund (http://www.bwfund.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 79 TC 11 Z9 11 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1545-7885 J9 PLOS BIOL JI PLoS. Biol. PD SEP PY 2015 VL 13 IS 9 AR e1002263 DI 10.1371/journal.pbio.1002263 PG 25 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA CS7LW UT WOS:000362266100025 PM 26382320 ER PT J AU Ona, K Oh, DH AF Ona, K. Oh, D. H. TI Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; LUNG-TRANSPLANT RECIPIENTS; NUCLEOTIDE EXCISION-REPAIR; LONG-TERM VORICONAZOLE; CYTOCHROME-P450 ENZYMES; SKIN-CANCER; DNA; PHOTOSENSITIVITY; PHOTOTOXICITY; THERAPY AB Background The antifungal agent, voriconazole, is associated with phototoxicity and photocarcinogenicity. Prior work has indicated that voriconazole and its hepatic N-oxide metabolite do not sensitize keratinocytes to ultraviolet B (UVB). Clinical observations have suggested that ultraviolet A (UVA) may be involved. Objectives To determine the photochemistry and photobiology of voriconazole and its major hepatic metabolite, voriconazole N-oxide. Materials and methods Voriconazole and voriconazole N-oxide were spectrophotometrically monitored following various doses of UVB. Cultured human keratinocytes were treated with parental drugs or with their UVB photoproducts, and survival following UVA irradiation was measured by thiazolyl blue metabolism. Reactive oxygen species (ROS) and 8-oxoguanine were monitored by fluorescence microscopy. Results Voriconazole and voriconazole N-oxide have varying UVB absorption but do not acutely sensitize cultured human keratinocytes following UVB exposure. However, sustained UVB exposures produced notable dose- and solvent-dependent changes in the absorption spectra of voriconazole N-oxide, which in aqueous solution acquires a prominent UVA absorption band, suggesting formation of a discrete photoproduct. Neither the parental drugs nor their photoproducts sensitized cells to UVB although all but voriconazole N-oxide were moderately toxic to cells in the dark. Notably, both voriconazole N-oxide and its UVB photoproduct, but not voriconazole or its photoproduct, additionally sensitized cells to UVA by greater than three-fold relative to controls in association with UVA-induced ROS and 8-oxoguanine levels. Conclusions Voriconazole N-oxide and its UVB-photoproduct act as UVA-sensitizers that generate ROS and that produce oxidative DNA damage. These results suggest a mechanism for the phototoxicity and photocarcinogenicity observed with voriconazole treatment. C1 [Ona, K.; Oh, D. H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Ona, K.; Oh, D. H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA 94121 USA. RP Oh, DH (reprint author), San Francisco VA Med Ctr, Dermatol Res Unit, 4150 Clement St, San Francisco, CA 94121 USA. EM ohd@derm.ucsf.edu FU VA Merit Award; NIH Grant [AR064958] FX VA Merit Award and NIH Grant AR064958. NR 35 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD SEP PY 2015 VL 173 IS 3 BP 751 EP 759 DI 10.1111/bjd.13862 PG 9 WC Dermatology SC Dermatology GA CS6GQ UT WOS:000362176800019 PM 25919127 ER PT J AU Banks, WA AF Banks, William A. TI A Vagina Monologue: Mom's Stress, Bugs, and Baby's Brain SO ENDOCRINOLOGY LA English DT Editorial Material C1 [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.] Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98108 USA. RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. FU NIA NIH HHS [R01 AG046619] NR 14 TC 3 Z9 3 U1 2 U2 6 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD SEP PY 2015 VL 156 IS 9 BP 3066 EP 3068 DI 10.1210/EN.2015-1590 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CS6ZV UT WOS:000362234100003 PM 26295492 ER PT J AU Upah, R Jacob, T Price, RK AF Upah, Roxanne Jacob, Theodore Price, Rumi Kato TI Trajectories of Lifetime Comorbid Alcohol and Other Drug Use Disorders Through Midlife SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; DSM-IV ALCOHOL; DEVELOPMENTAL TRAJECTORIES; DRINKING TRAJECTORIES; EPIDEMIOLOGIC SURVEY; VIETNAM VETERANS; MIXTURE MODEL; DEPENDENT MEN; SUBSTANCE USE; ABUSE AB Objective: Very few studies have examined the developmental nature of comorbid alcohol use disorders and drug use disorders (AUD-DUD). The current study sought to extend our understanding of the nature of AUD-DUD comorbidity by characterizing the developmental course of AUD-DUD comorbidity, determining the degree to which the two disorders occur during the same period, and eliciting differences in AUD-DUD trajectories over the life course. Method: Vietnam-era male veterans and matched civilians provided retrospective accounts of alcohol- and other drug related experiences spanning 25 years. Concurrent growth mixture modeling was used to describe the course of AUD-DUD lifetime comorbidity. Results: Five trajectories were identified based on the probabilities of diagnosing with AUD-DUD: substance switching (increasing AUD, decreasing DUD); young adult (both AUD and DUD decreasing rapidly after young adulthood); severe nonchronic (both ADD and DUD decreasing slowly in the third decade of life); severe chronic alcohol severe nonchronic drug (AUD remains high and DUD decreases in the fourth decade); and young adult alcohol severe chronic drug (decreasing ADD in the second decade and DUD remains high). Conclusions: For the majority of this sample, substance use disorders continued or worsened through adulthood, indicating a problem that extends far beyond young adulthood. Demographic characteristics differed among the trajectories; however, psychiatric diagnoses did not differ except for the number of years with diagnoses of antisocial personality disorder. Subthreshold symptoms in adulthood may be present for a significant period before diagnosis, making this period important for intervention and prevention. Integration of efforts into healthcare, employment, and public policy will help target those at highest risk. C1 [Upah, Roxanne; Jacob, Theodore] Vet Affairs Palo Alto Healthcare Syst, Family Res Ctr, Menlo Pk, CA USA. [Price, Rumi Kato] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. RP Upah, R (reprint author), Oxnard Community Based Outpatient Clin, Vet Affairs Greater Los Angeles Healthcare Syst, 1690 Universe Circle, Oxnard, CA 93033 USA. EM roxanne.upah@va.gov FU Veterans Affairs Merit Award FX This research was supported by a Veterans Affairs Merit Award to Theodore Jacob. The opinions expressed here are the authors' and do not necessarily represent the views of the Department of Veterans Affairs. NR 49 TC 1 Z9 1 U1 2 U2 2 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD SEP PY 2015 VL 76 IS 5 BP 721 EP 732 PG 12 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA CS4OQ UT WOS:000362055800007 PM 26402352 ER PT J AU Desai, JV Cheng, SJ Ying, T Nguyen, MH Clancy, CJ Lanni, F Mitchell, AP AF Desai, Jigar V. Cheng, Shaoji Ying, Tammy Nguyen, M. Hong Clancy, Cornelius J. Lanni, Frederick Mitchell, Aaron P. TI Coordination of Candida albicans Invasion and Infection Functions by Phosphoglycerol Phosphatase Rhr2 SO PATHOGENS LA English DT Article DE Candida albicans; adherence; invasion; biofilm; intra-abdominal candidiasis; glycerol; turgor; infection; adhesin ID BIOFILM FORMATION; EPITHELIAL-CELLS; HOST; PENETRATION; ATTACHMENT; RESPONSES; CONTACT; PATHWAY; STRESS; GROWTH AB The Candida albicans RHR2 gene, which specifies a glycerol biosynthetic enzyme, is required for biofilm formation in vitro and in vivo. Prior studies indicate that RHR2 is ultimately required for expression of adhesin genes, such as ALS1. In fact, RHR2 is unnecessary for biofilm formation when ALS1 is overexpressed from an RHR2-independent promoter. Here, we describe two additional biological processes that depend upon RHR2: invasion into an abiotic substrate and pathogenicity in an abdominal infection model. We report here that abiotic substrate invasion occurs concomitantly with biofilm formation, and a screen of transcription factor mutants indicates that biofilm and hyphal formation ability correlates with invasion ability. However, analysis presented here of the rhr2/ mutant separates biofilm formation and invasion. We found that an rhr2/ mutant forms a biofilm upon overexpression of the adhesin gene ALS1 or the transcription factor genes BRG1 or UME6. However, the biofilm-forming strains do not invade the substrate. These results indicate that RHR2 has an adhesin-independent role in substrate invasion, and mathematical modeling argues that RHR2 is required to generate turgor. Previous studies have shown that abdominal infection by C. albicans has two aspects: infection of abdominal organs and persistence in abscesses. We report here that an rhr2/ mutant is defective in both of these infection phenotypes. We find here that overexpression of ALS1 in the mutant restores infection of organs, but does not improve persistence in abscesses. Therefore, RHR2 has an adhesin-independent role in abdominal infection, just as it does in substrate invasion. This report suggests that RHR2, through glycerol synthesis, coordinates adherence with host- or substrate-interaction activities that enable proliferation of the C. albicans population. C1 [Desai, Jigar V.; Lanni, Frederick; Mitchell, Aaron P.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA. [Cheng, Shaoji; Ying, Tammy] Univ Pittsburgh, Div Infect Dis, Dept Med, Pittsburgh, PA 15261 USA. [Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15261 USA. RP Mitchell, AP (reprint author), Carnegie Mellon Univ, Dept Biol Sci, 4400 Fifth Ave MI-200B, Pittsburgh, PA 15213 USA. EM jigarkumar.desai@nih.gov; sjc43@pitt.edu; tammythinks@gmail.com; mhn5@pitt.edu; cjc76@pitt.edu; lanni@andrew.cmu.edu; apm1@cmu.edu FU NIH [R01 AI067703]; Stupakoff Graduate Fellowship FX We thank Carol Woolford, Wenjie Xu, Katie Lagree and Saranna Fanning for helpful advice and comments on the manuscript, and Tatyana Aleynikova for technical support. This study was supported by NIH research grant R01 AI067703 (A.P.M.) and a Stupakoff Graduate Fellowship (J.V.D.). NR 45 TC 2 Z9 2 U1 0 U2 1 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2076-0817 J9 PATHOGENS JI Pathogens PD SEP PY 2015 VL 4 IS 3 BP 573 EP 589 DI 10.3390/pathogens4030573 PG 17 WC Microbiology SC Microbiology GA CS7MB UT WOS:000362266600009 PM 26213976 ER PT J AU Wilde, EA Bouix, S Tate, DF Lin, AP Newsome, MR Taylor, BA Stone, JR Montier, J Gandy, SE Biekman, B Shenton, ME York, G AF Wilde, Elisabeth A. Bouix, Sylvain Tate, David F. Lin, Alexander P. Newsome, Mary R. Taylor, Brian A. Stone, James R. Montier, James Gandy, Samuel E. Biekman, Brian Shenton, Martha E. York, Gerald TI Advanced neuroimaging applied to veterans and service personnel with traumatic brain injury: state of the art and potential benefits SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Traumatic brain injury; Magnetic resonance imaging; Diffusion tensor imaging; fMRI; Positron emission tomography; Magnetic resonance spectroscopy; Veteran ID MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; POSTTRAUMATIC-STRESS-DISORDER; CEREBRAL-BLOOD-FLOW; DIFFUSE AXONAL INJURY; SPORTS-RELATED CONCUSSION; WHITE-MATTER ABNORMALITIES; AFGHANISTAN WAR VETERANS; MEDIAL TEMPORAL-LOBES; PITTSBURGH COMPOUND-B AB Traumatic brain injury (TBI) remains one of the most prevalent forms of morbidity among Veterans and Service Members, particularly for those engaged in the conflicts in Iraq and Afghanistan. Neuroimaging has been considered a potentially useful diagnostic and prognostic tool across the spectrum of TBI generally, but may have particular importance in military populations where the diagnosis of mild TBI is particularly challenging, given the frequent lack of documentation on the nature of the injuries and mixed etiologies, and highly comorbid with other disorders such as post-traumatic stress disorder, depression, and substance misuse. Imaging has also been employed in attempts to understand better the potential late effects of trauma and to evaluate the effects of promising therapeutic interventions. This review surveys the use of structural and functional neuroimaging techniques utilized in military studies published to date, including the utilization of quantitative fluid attenuated inversion recovery (FLAIR), susceptibility weighted imaging (SWI), volumetric analysis, diffusion tensor imaging (DTI), magnetization transfer imaging (MTI), positron emission tomography (PET), magnetoencephalography (MEG), task-based and resting state functional MRI (fMRI), arterial spin labeling (ASL), and magnetic resonance spectroscopy (MRS). The importance of quality assurance testing in current and future research is also highlighted. Current challenges and limitations of each technique are outlined, and future directions are discussed. C1 [Wilde, Elisabeth A.; Newsome, Mary R.; Taylor, Brian A.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA. [Wilde, Elisabeth A.; Newsome, Mary R.; Biekman, Brian] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Dept Psychiat, Sch Med, Boston, MA 02115 USA. [Tate, David F.] Univ Missouri St Louis, Missouri Inst Mental Hlth, Berkeley, MO USA. [Lin, Alexander P.] Harvard Univ, Brigham & Womens Hosp, Ctr Clin Spect, Sch Med, Boston, MA 02115 USA. [Lin, Alexander P.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA. [Montier, James] Univ Virginia Hlth Syst, Dept Radiol & Med Imaging, Dept Neurol Surg, Charlottesville, VA USA. [Gandy, Samuel E.] Icahn Sch Med, Ctr Cognit Hlth, New York, NY USA. [Gandy, Samuel E.] Icahn Sch Med, NFL Neurol Ctr, New York, NY USA. [Gandy, Samuel E.] James J Peters VA Med Ctr, Div Neurol, New York, NY USA. [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Dept Psychiat, Brockton Div, Brockton, MA USA. [York, Gerald] San Antonio Mil Med Ctr, Def Vet Brain Injury Ctr, Ft Sam Houston, TX USA. RP Wilde, EA (reprint author), Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. EM ewilde@bcm.edu RI Tate, David/I-3963-2013 OI Tate, David/0000-0003-0213-1920 FU US Department of Veterans Affairs; VA MERIT review grant program [1I01RX000684-01A2, 1I01RX001062-01A1, 1 I01 RX000928:]; VA SPIRE program [VA 1 I21RX001565, VA 1 I21RX001608]; Department of Defense Office of the Congressionally Directed Medical Research Programs (CDMRP) [W81XWH-10-1-0835, X81XWH-07-CC-CSDoD]; National Institutes of Health [R01-NS078337]; Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Material Command (USAMRMC) [W81XWH-13-2-0025]; United States Army Medical Research Acquisition Activity (USAMRAA) [W81XWH-09-2-0160]; Chronic Effects Neurotrauma Consortium (CENC) [PT108802-SC106187, 1W81XWH-13-2-0095]; Alzheimer's Drug Discovery Foundation FX The authors recognize the support of the US Department of Veterans Affairs (EAW, BAT, SG, MRN, MES, SG), the VA MERIT review grant program (1I01RX000684-01A2: SG, 1I01RX001062-01A1: EAW, MRN, and 1 I01 RX000928: MES, SB), and VA SPIRE program (VA 1 I21RX001565 BAT, and VA 1 I21RX001608 MRN); the Department of Defense Office of the Congressionally Directed Medical Research Programs (CDMRP) (W81XWH-10-1-0835: APL; X81XWH-07-CC-CSDoD: MES, SB), the National Institutes of Health (R01-NS078337: APL, MES, SB), Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Material Command (USAMRMC; W81XWH-13-2-0025: DFT), United States Army Medical Research Acquisition Activity (USAMRAA; W81XWH-09-2-0160: JRS, SG), the Chronic Effects Neurotrauma Consortium (CENC; PT108802-SC106187 and 1W81XWH-13-2-0095), and the Alzheimer's Drug Discovery Foundation (SG). We also wish to thank Rhonda O'Donovan for her assistance in manuscript preparation. NR 192 TC 9 Z9 9 U1 5 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD SEP PY 2015 VL 9 IS 3 BP 367 EP 402 DI 10.1007/s11682-015-9444-y PG 36 WC Neuroimaging SC Neurosciences & Neurology GA CR8LQ UT WOS:000361604300003 PM 26350144 ER PT J AU Cooper, DB Bunner, AE Kennedy, JE Balldin, V Tate, DF Eapen, BC Jaramillo, CA AF Cooper, Douglas B. Bunner, Anne E. Kennedy, Jan E. Balldin, Valerie Tate, David F. Eapen, Blessen C. Jaramillo, Carlos A. TI Treatment of persistent post-concussive symptoms after mild traumatic brain injury: a systematic review of cognitive rehabilitation and behavioral health interventions in military service members and veterans SO BRAIN IMAGING AND BEHAVIOR LA English DT Review DE Mild traumatic brain injury; Post-concussive syndrome; Cognitive rehabilitation; Posttraumatic stress disorder; Blast Injuries; Post-deployment; OEF/OIF; Psychoeducation; Psychotherapy ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; MULTIFAMILY GROUP TREATMENT; POSTCONCUSSIVE SYMPTOMS; RESIDENTIAL-TREATMENT; TREATMENT ADHERENCE; PROLONGED EXPOSURE; GOAL MANAGEMENT; HEAD-INJURY; PILOT AB Increased prevalence of traumatic brain injury (TBI) has been associated with service members and veterans who completed combat deployments in support of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF). Management of persistent post-concussive symptoms (PCS) has been a challenge to healthcare providers throughout the Military and Veterans Healthcare Systems, as well as civilian healthcare providers, due in part to the chronic nature of symptoms, co-occurrence of behavioral health disorders such as depression, Posttraumatic Stress Disorder (PTSD), and substance use disorders, and fear of a potential stigma associated with psychiatric diagnoses and behavioral health treatment(s). This systematic review examined non-pharmacologic behavioral health interventions and cognitive rehabilitation interventions for PCS in military service members and veterans with a history of mild TBI (mTBI). Six electronic databases were searched with specific term limitations, identifying 121 citations. Ultimately, 19 articles met criteria for inclusion in this systematic review. Studies were broadly categorized into four subtypes: psychoeducational interventions, cognitive rehabilitation, psychotherapeutic approaches, and integrated behavioral health interventions for PCS and PTSD. The review provides an update of the empirical evidence for these four types of interventions for PCS in active duty service members and veterans. Recommendations for future research are discussed, including the need to expand and improve the limited evidence basis on how to manage persistent post-concussive symptoms in this population. C1 [Cooper, Douglas B.; Kennedy, Jan E.] San Antonio Mil Med Ctr MCHE MDU DVBIC, Def & Vet Brain Injury Ctr, Ft Sam Houston, TX 78234 USA. [Cooper, Douglas B.; Kennedy, Jan E.] San Antonio Mil Med Ctr, Dept Neurol, Ft Sam Houston, TX USA. [Bunner, Anne E.] Def & Vet Brain Injury Ctr, Bethesda, MD USA. [Balldin, Valerie] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Tate, David F.] Univ Missouri, Missouri Inst Mental Hlth, St Louis, MO 63121 USA. [Eapen, Blessen C.; Jaramillo, Carlos A.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA. RP Cooper, DB (reprint author), San Antonio Mil Med Ctr MCHE MDU DVBIC, Def & Vet Brain Injury Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM douglas.b.cooper.ctr@mail.mil RI Tate, David/I-3963-2013 OI Tate, David/0000-0003-0213-1920 NR 71 TC 6 Z9 6 U1 8 U2 25 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD SEP PY 2015 VL 9 IS 3 BP 403 EP 420 DI 10.1007/s11682-015-9440-2 PG 18 WC Neuroimaging SC Neurosciences & Neurology GA CR8LQ UT WOS:000361604300004 PM 26330376 ER PT J AU Jaramillo, CA Cooper, DB Wang, CP Tate, DF Eapen, BC York, GE Pugh, MJ AF Jaramillo, Carlos A. Cooper, Douglas B. Wang, Chen-Pin Tate, David F. Eapen, Blessen C. York, Gerald E. Pugh, Mary Jo TI Subgroups of US IRAQ and Afghanistan veterans: associations with traumatic brain injury and mental health conditions SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Veterans; Iraq; Afghanistan; TBI; PTSD; Latent class analysis ID POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; ENDURING FREEDOM VETERANS; POLYTRAUMA-CLINICAL-TRIAD; SUBSTANCE USE DISORDERS; PTSD SYMPTOMS; WAR VETERANS; CHRONIC PAIN; OEF/OIF VETERANS; MILITARY SERVICE AB U. S. veterans of Iraq and Afghanistan are known to have a high prevalence of traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and depression, which are often comorbid and share many symptoms. Attempts to describe this cohort by single diagnoses have limited our understanding of the complex nature of this population. The objective of this study was to identify subgroups of Iraq and Afghanistan veterans (IAVs) with distinct compositions of symptoms associated with TBI, PTSD, and depression. Our cross-sectional, observational study included 303,716 IAVs who received care in the Veterans Health Administration in 2010-2011. Symptoms and conditions were defined using International Classification of Diseases, Ninth Revision codes and symptom-clusters were identified using latent class analysis. We identified seven classes with distinct symptom compositions. One class had low probability of any condition and low health care utilization (HCU) (48 %). Other classes were characterized by high probabilities of mental health comorbidities (14 %); chronic pain and sleep disturbance (20 %); headaches and memory problems (6 %); and auditory problems (2.5 %). Another class had mental health comorbidities and chronic pain (7 %), and the last had high probabilities of most symptoms examined (3 %). These last two classes had the highest likelihood of TBI, PTSD, and depression and were identified as high healthcare utilizers. There are subgroups of IAVs with distinct clusters of symptom that are meaningfully associated with TBI, PTSD, depression, and HCU. Additional studies examining these veteran subgroups could improve our understanding of this complex comorbid patient population. C1 [Jaramillo, Carlos A.; Eapen, Blessen C.] South Texas Vet Healthcare Syst ALMD, Polytrauma Rehabil Ctr, San Antonio, TX 78229 USA. [Cooper, Douglas B.; Tate, David F.; York, Gerald E.] San Antonio Mil Med Ctr, Def & Vet Brain Injury Ctr, San Antonio, TX USA. [Wang, Chen-Pin; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, Res & Dev, San Antonio, TX 78229 USA. [Wang, Chen-Pin; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. RP Jaramillo, CA (reprint author), South Texas Vet Healthcare Syst ALMD, Polytrauma Rehabil Ctr, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA. EM jaramilloc3@uthscsa.edu; douglas.b.cooper.ctr@mail.mil; wangc3@uthscsa.edu; dftatephd@mac.com; Blessen.Eapen2@va.gov; gerald.e.york4.mil@mail.mil; maryjo.pugh2@va.gov RI Tate, David/I-3963-2013 OI Tate, David/0000-0003-0213-1920; Pugh, Mary Jo/0000-0003-4196-7763 FU VA Health Services Research and Development [DHI 09-237] FX The study was funded by VA Health Services Research and Development (DHI 09-237). NR 53 TC 2 Z9 2 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD SEP PY 2015 VL 9 IS 3 BP 445 EP 455 DI 10.1007/s11682-015-9402-8 PG 11 WC Neuroimaging SC Neurosciences & Neurology GA CR8LQ UT WOS:000361604300006 PM 25963862 ER PT J AU Boots, EA Schultz, SA Oh, JM Larson, J Edwards, D Cook, D Koscik, RL Dowling, MN Gallagher, CL Carlsson, CM Rowley, HA Bendlin, BB LaRue, A Asthana, S Hermann, BP Sager, MA Johnson, SC Okonkwo, OC AF Boots, Elizabeth A. Schultz, Stephanie A. Oh, Jennifer M. Larson, Jordan Edwards, Dorothy Cook, Dane Koscik, Rebecca L. Dowling, Maritza N. Gallagher, Catherine L. Carlsson, Cynthia M. Rowley, Howard A. Bendlin, Barbara B. LaRue, Asenath Asthana, Sanjay Hermann, Bruce P. Sager, Mark A. Johnson, Sterling C. Okonkwo, Ozioma C. TI Cardiorespiratory fitness is associated with brain structure, cognition, and mood in a middle-aged cohort at risk for Alzheimer's disease SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Cardiorespiratory fitness; Preclinical Alzheimer's disease; MRI; White matter hyperintensities; Cognition; Mood ID WHITE-MATTER HYPERINTENSITIES; SURFACE-BASED ANALYSIS; OLDER-ADULTS; PHYSICAL-ACTIVITY; WISCONSIN-REGISTRY; IMPAIRMENT; PREVENTION; PREDICTION; INTEGRITY; DEMENTIA AB Cardiorespiratory fitness (CRF) is an objective measure of habitual physical activity (PA), and has been linked to increased brain structure and cognition. The gold standard method for measuring CRF is graded exercise testing (GXT), but GXT is not feasible in many settings. The objective of this study was to examine whether a non-exercise estimate of CRF is related to gray matter (GM) volumes, white matter hyperintensities (WMH), cognition, objective and subjective memory function, and mood in a middle-aged cohort at risk for Alzheimer's disease (AD). Three hundred and fifteen cognitively healthy adults (mean age =58.58 years) enrolled in the Wisconsin Registry for Alzheimer's Prevention underwent structural MRI scanning, cognitive testing, anthropometric assessment, venipuncture for laboratory tests, and completed a self-reported PA questionnaire. A subset (n = 85) underwent maximal GXT. CRF was estimated using a previously validated equation incorporating sex, age, body-mass index, resting heart rate, and self-reported PA. Results indicated that the CRF estimate was significantly associated with GXT-derived peak oxygen consumption, validating its use as a non-exercise CRF measure in our sample. Support for this finding was seen in significant associations between the CRF estimate and several cardiovascular risk factors. Higher CRF was associated with greater GM volumes in several AD-relevant brain regions including the hippocampus, amygdala, precuneus, supramarginal gyrus, and rostral middle frontal gyrus. Increased CRF was also associated with lower WMH and better cognitive performance in Verbal Learning & Memory, Speed & Flexibility, and Visuospatial Ability. Lastly, CRF was negatively correlated with self- and informant-reported memory complaints, and depressive symptoms. Together, these findings suggest that habitual participation in physical activity may provide protection for brain structure and cognitive function, thereby decreasing future risk for AD. C1 [Boots, Elizabeth A.; Schultz, Stephanie A.; Oh, Jennifer M.; Larson, Jordan; Gallagher, Catherine L.; Carlsson, Cynthia M.; Bendlin, Barbara B.; Asthana, Sanjay; Johnson, Sterling C.; Okonkwo, Ozioma C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Boots, Elizabeth A.; Schultz, Stephanie A.; Oh, Jennifer M.; Larson, Jordan; Edwards, Dorothy; Dowling, Maritza N.; Gallagher, Catherine L.; Carlsson, Cynthia M.; Rowley, Howard A.; Bendlin, Barbara B.; Asthana, Sanjay; Hermann, Bruce P.; Sager, Mark A.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. [Boots, Elizabeth A.; Schultz, Stephanie A.; Oh, Jennifer M.; Larson, Jordan; Edwards, Dorothy; Dowling, Maritza N.; Gallagher, Catherine L.; Carlsson, Cynthia M.; Rowley, Howard A.; Bendlin, Barbara B.; Asthana, Sanjay; Hermann, Bruce P.; Sager, Mark A.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Alzheimers Dis Res Ctr, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Edwards, Dorothy; Cook, Dane] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA. [Edwards, Dorothy; Koscik, Rebecca L.; Bendlin, Barbara B.; LaRue, Asenath; Asthana, Sanjay; Hermann, Bruce P.; Sager, Mark A.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Wisconsin Alzheimers Inst, Sch Med & Publ Hlth, Madison, WI 53705 USA. [Dowling, Maritza N.] Univ Wisconsin, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Gallagher, Catherine L.; Hermann, Bruce P.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53705 USA. [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53792 USA. RP Okonkwo, OC (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. EM ozioma@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875; Schultz, Stephanie/0000-0001-8460-4415 FU National Institute on Aging [K23 AG045957, R01 AG027161, R01 AG021155, P50 AG033514, P50 AG033514-S1]; Veterans Administration Merit Review Grant [I01CX000165]; Clinical and Translational Science Award [UL1RR025011]; Wisconsin Alumni Research Foundation; Helen Bader Foundation; Northwestern Mutual Foundation; Extendicare Foundation; Veterans Administration FX This work was supported by National Institute on Aging grants K23 AG045957 (OCO), R01 AG027161 (MAS), R01 AG021155 (SCJ), P50 AG033514 (SA), and P50 AG033514-S1 (OCO); by a Veterans Administration Merit Review Grant I01CX000165 (SCJ); and by a Clinical and Translational Science Award (UL1RR025011) to the University of Wisconsin, Madison. Portions of this research were supported by the Wisconsin Alumni Research Foundation, the Helen Bader Foundation, Northwestern Mutual Foundation, Extendicare Foundation, and from the Veterans Administration including facilities and resources at the Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison, WI. NR 53 TC 9 Z9 9 U1 2 U2 26 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD SEP PY 2015 VL 9 IS 3 BP 639 EP 649 DI 10.1007/s11682-014-9325-9 PG 11 WC Neuroimaging SC Neurosciences & Neurology GA CR8LQ UT WOS:000361604300022 PM 25319359 ER PT J AU Willette, AA Bendlin, BB Starks, EJ Birdsill, AC Johnson, SC Christian, BT Okonkwo, OC La Rue, A Hermann, BP Koscik, RL Jonaitis, EM Sager, MA Asthana, S AF Willette, Auriel A. Bendlin, Barbara B. Starks, Erika J. Birdsill, Alex C. Johnson, Sterling C. Christian, Bradley T. Okonkwo, Ozioma C. La Rue, Asenath Hermann, Bruce P. Koscik, Rebecca L. Jonaitis, Erin M. Sager, Mark A. Asthana, Sanjay TI Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease SO JAMA NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; FDG-PET; METABOLIC SYNDROME; DIFFERENTIAL-DIAGNOSIS; IMPROVES COGNITION; WISCONSIN-REGISTRY; NORMAL INDIVIDUALS; APOLIPOPROTEIN-E; RAT-BRAIN; LATE-LIFE AB IMPORTANCE Converging evidence suggests that Alzheimer disease (AD) involves insulin signaling impairment. Patients with AD and individuals at risk for AD show reduced glucose metabolism, as indexed by fludeoxyglucose F 18-labeled positron emission tomography (FDG-PET). OBJECTIVES To determine whether insulin resistance predicts AD-like global and regional glucose metabolism deficits in late middle-aged participants at risk for AD and to examine whether insulin resistance-predicted variation in regional glucose metabolism is associated with worse cognitive performance. DESIGN, SETTING, AND PARTICIPANTS This population-based, cross-sectional study included 150 cognitively normal, late middle-aged (mean [SD] age, 60.7 [5.8] years) adults from the Wisconsin Registry for Alzheimer's Prevention (WRAP) study, a general community sample enriched for AD parental history. Participants underwent cognitive testing, fasting blood draw, and FDG-PET at baseline. We used the homeostatic model assessment of peripheral insulin resistance (HOMA-IR). Regression analysis tested the statistical effect of HOMA-IR on global glucose metabolism. We used a voxelwise analysis to determine whether HOMA-IR predicted regional glucose metabolism. Finally, predicted variation in regional glucose metabolism was regressed against cognitive factors. Covariates included age, sex, body mass index, apolipoprotein E epsilon 4 genotype, AD parental history status, and a reference region used to normalize regional uptake. MAIN OUTCOMES AND MEASURES Regional glucose uptake determined using FDG-PET and neuropsychological factors. RESULTS Higher HOMA-IR was associated with lower global glucose metabolism (beta = -0.29; P < .01) and lower regional glucose metabolism across large portions of the frontal, lateral parietal, lateral temporal, and medial temporal lobes (P < .05, familywise error corrected). The association was especially robust in the left medial temporal lobe (R-2 = 0.178). Lower glucose metabolism in the left medial temporal lobe predicted by HOMA-IR was significantly related to worse performance on the immediate memory (beta = 0.317; t(148) = 4.08; P < .001) and delayed memory (beta = 0.305; t(148) = 3.895; P < .001) factor scores. CONCLUSIONS AND RELEVANCE Our results show that insulin resistance, a prevalent and increasingly common condition in developed countries, is associated with significantly lower regional cerebral glucose metabolism, which in turn may predict worse memory performance. Midlife may be a critical period for initiating treatments to lower peripheral insulin resistance to maintain neural metabolism and cognitive function. C1 [Willette, Auriel A.] Iowa State Univ, Dept Food Sci & Human Nutr, Ames, IA USA. [Willette, Auriel A.] Iowa State Univ, Neurosci Interdept Program, Ames, IA USA. [Bendlin, Barbara B.; Starks, Erika J.; Birdsill, Alex C.; Johnson, Sterling C.; Okonkwo, Ozioma C.; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Clin Sci, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53792 USA. [Bendlin, Barbara B.; Johnson, Sterling C.; Okonkwo, Ozioma C.; La Rue, Asenath; Hermann, Bruce P.; Koscik, Rebecca L.; Jonaitis, Erin M.; Sager, Mark A.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53792 USA. [Johnson, Sterling C.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Christian, Bradley T.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Clin Sci, Wisconsin Alzheimers Dis Res Ctr, Sect J5-1M,600 Highland Ave, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu FU National Institute on Aging [R01 AG037639, R01 AG027161, P50 AG033514, R01 AG021155]; Alzheimer's Disease Research Center from University of Wisconsin Institute for Clinical and Translational Research [5977]; National Center for Research Resources/National Institutes of Health [1UL1RR025011]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [P30 HD03352]; Department of Food Science and Human Nutrition, Iowa State University FX This study was supported by grants R01 AG037639 (Dr Bendlin), R01 AG027161 (Dr Johnson), P50 AG033514 (Dr Asthana), and R01 AG021155 (Dr Johnson), National Institute on Aging; by Alzheimer's Disease Research Center subproject 5977 (Dr Bendlin) from the University of Wisconsin Institute for Clinical and Translational Research, funded through Clinical and Translational Science Award 1UL1RR025011 from the National Center for Research Resources/National Institutes of Health; by grant P30 HD03352 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development; by funding from the Department of Food Science and Human Nutrition, Iowa State University; and by the facilities and resources at the Geriatric Research, Education, and Clinical Center of the William S. Middleton Memorial Veterans Hospital. NR 70 TC 34 Z9 34 U1 2 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD SEP PY 2015 VL 72 IS 9 BP 1013 EP 1020 DI 10.1001/jamaneurol.2015.0613 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CS0MU UT WOS:000361755400010 PM 26214150 ER PT J AU Shay, SG Chang, E Lewis, MS Wang, MB AF Shay, Sophie Grace Chang, Elena Lewis, Michael S. Wang, Marilene B. TI Characteristics of Human Papillomavirus-Associated Head and Neck Cancers in a Veteran Population SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; QUALITY-OF-LIFE; PHASE-III TRIAL; OROPHARYNGEAL CANCER; UNITED-STATES; ORAL-CANCER; AFRICAN-AMERICANS; TOBACCO SMOKING; INCREASED RISK; HEALTH-STATUS AB IMPORTANCE The US veteran population represents a unique cohort of patients in whom human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) has yet to be investigated. OBJECTIVE To investigate the incidence and characteristics of HPV-positive HNSCC within the veteran population. DESIGN, SETTING, AND PARTICIPANTS Retrospective medical record review including patients with HNSCC diagnosed between January 1, 2010, and November 15, 2013, from the VA Greater Los Angeles Healthcare System. Data were collected between November 16, 2013, and June 19, 2014, and analyzed between June 20, 2014, and March 26, 2015. EXPOSURES Chemoradiation therapy, radiation therapy, surgery, or no treatment. MAIN OUTCOMES AND MEASURES We determined HPV positivity by p16 testing. Demographic and clinicopathologic information and overall survival were extracted from medical records. RESULTS We identified 150 patients with the diagnosis of HNSCC. Sixty-nine patients had HPV-positive tumors (46%), and 65 (43%) had HPV-negative tumors (16 did not have HPV testing). Age at diagnosis ranged from 44 to 94 years (mean, 64.6 [SD, 8.0] years), and median (interquartile range) follow-up was 16.7 (8.7-27.3) years. Tumor location differed significantly between the 2 groups, with an HPV-positive predominance in the oropharynx (43 of 57 [75%]; P <.001). The HPV-positive patients were more likely to be treated primarily with combined chemoradiation therapy than radiation therapy or surgery (P <.001). T4 tumors had a nearly 9 times greater rate of mortality compared with T1 tumors (HR, 8.52 [95% CI, 2.60-18.40; P <.001); N3 disease was associated with 7.18 times greater mortality (HR, 7.18 [95% CI, 1.99-12.26]; P <.001) compared with N1 disease; and M1 disease was associated with 6.0 times greater mortality (HR, 5.99 [95% CI, 2.59-13.81]; P <.001). There were 42 total deaths during follow-up, 25 in the HPV-negative group and 17 in the HPV-positive group, with a nonsignificantly higher overall survival among HPV-positive patients independent of alcohol or tobacco use history (P =.09). CONCLUSIONS AND RELEVANCE Previous studies have found that the proportion of HPV-positive HNSCC in the general population ranges between 20% and 75%. Although the incidence of HPV-positive HNSCC in the Veterans Affairs population is comparable, these patients have unique risk factors and demographic characteristics that may suggest different prognostic factors for HPV-positive HNSCC in this population. Nonetheless, HPV-positive tumors still seem to portend a better overall prognosis regardless of alcohol or tobacco history among the Veterans Affairs population. C1 [Shay, Sophie Grace; Wang, Marilene B.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Shay, Sophie Grace; Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Chang, Elena; Lewis, Michael S.] VA Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. RP Wang, MB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, 200 UCLA Med Plaza Ste 550, Los Angeles, CA 90095 USA. EM mbwang@ucla.edu NR 46 TC 2 Z9 2 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD SEP PY 2015 VL 141 IS 9 BP 790 EP 796 DI 10.1001/jamaoto.2015.1447 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CS0NQ UT WOS:000361758200002 PM 26270931 ER PT J AU McCauley, HL Blosnich, JR Dichter, ME AF McCauley, Heather L. Blosnich, John R. Dichter, Melissa E. TI Adverse Childhood Experiences and Adult Health Outcomes Among Veteran and Non-Veteran Women SO JOURNAL OF WOMENS HEALTH LA English DT Article ID MILITARY SEXUAL TRAUMA; MENTAL-HEALTH; HOUSEHOLD DYSFUNCTION; US ADULTS; LIFE-SPAN; ABUSE; RISK; MORTALITY; VIOLENCE; SERVICE AB Background: Women veterans represent a vulnerable population with unique health needs and disparities in access to care. One constellation of exposures related to subsequent poor health includes adverse childhood experiences (ACEs; e.g., physical and sexual child abuse), though research on impacts of ACEs among women veterans is limited. Methods: Data were drawn from the 2010 Behavioral Risk Factor Surveillance System for the 11 states that included the ACE module (n=36,485). Weighted chi-squared tests and multivariable logistic regression were used to assess the prevalence of ACEs among women veterans compared with women non-veterans and differences in the following outcomes, controlling for ACEs: social support, inadequate sleep, life satisfaction, mental distress, smoking, heavy alcohol use, obesity, diabetes, cardiovascular disease symptoms, asthma, and disability. Results: Women veterans (1.6% of the total sample) reported a higher prevalence of 7 out of 11 childhood adversities and higher mean ACE score than women non-veterans. Women veterans were more likely to be current smokers and report a disability, associations which were attenuated when controlling for ACE. Conclusions: Despite women veterans' higher prevalence of ACE, their health outcomes did not differ substantially from non-veterans. Further research is needed to understand the intersections of traumatic experiences and sources of resilience over the lifecourse among women veterans. C1 [McCauley, Heather L.] Univ Pittsburgh, Div Adolescent & Young Adult Med, Childrens Hosp Pittsburgh UPMC, Dept Pediat,Sch Med, Pittsburgh, PA 15213 USA. [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Dichter, Melissa E.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP McCauley, HL (reprint author), Univ Pittsburgh, Sch Med, Dept Pediat, 3414 Fifth Ave,CHOB Room 109, Pittsburgh, PA 15213 USA. EM heather.mccauley@chp.edu FU National Institutes of Health/Office of Research on Women's Health Building Interdisciplinary Research Careers in Women's Health [K12HD043441]; Office of Academic Affiliations in the Department of Veterans Affairs; Department of Veterans Affairs, Veterans Health Administration, Health Service Research and Development Service (CDA) [10-202] FX This work was supported by National Institutes of Health/Office of Research on Women's Health Building Interdisciplinary Research Careers in Women's Health K12HD043441 scholar funds to HLM; a postdoctoral fellowship to JRB from the Office of Academic Affiliations in the Department of Veterans Affairs; and a career development award from the Department of Veterans Affairs, Veterans Health Administration, Health Service Research and Development Service to MED (CDA No. 10-202). NR 43 TC 1 Z9 1 U1 7 U2 18 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD SEP 1 PY 2015 VL 24 IS 9 BP 723 EP 729 DI 10.1089/jwh.2014.4997 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CR6RT UT WOS:000361475700005 PM 26390379 ER PT J AU Berger, D Bradley, KA AF Berger, Douglas Bradley, Katharine A. TI Primary Care Management of Alcohol Misuse SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Alcohol misuse; Unhealthy alcohol use; Alcohol use disorder; Alcohol abuse; Alcohol dependence; Alcohol screening; Brief intervention; Alcohol treatment ID NATIONAL EPIDEMIOLOGIC SURVEY; SERVICES TASK-FORCE; SUBSTANCE USE DISORDERS; CHRONIC NONCANCER PAIN; PREVENTIVE SERVICES; UNITED-STATES; RISK DRINKING; CONTROLLED-TRIAL; DSM-IV; RECOMMENDATION STATEMENT AB More than one in four American adults consume alcohol in quantities exceeding recommended limits. One in 12 have an alcohol use disorder marked by harmful consequences. Both types of alcohol misuse contribute to acute injury and chronic disease, making alcohol the third largest cause of preventable death in the United States. Alcohol misuse alters the management of common conditions from insomnia to anemia. Primary care providers should screen adult patients to identify the full spectrum of alcohol misuse. A range of effective treatments are available from brief counselling interventions and mutual help groups to medications and behavioral therapies. C1 [Berger, Douglas] VA Puget Sound, Gen Med Serv, Seattle, WA 98108 USA. [Berger, Douglas; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98101 USA. [Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Bradley, Katharine A.] VA Hlth Serv Res & Dev HSR&D, Seattle, WA USA. [Bradley, Katharine A.] CESATE, Seattle, WA USA. RP Berger, D (reprint author), S-123 PCC,1660 S Columbian Way, Seattle, WA 98108 USA. EM douglas.berger@va.gov NR 144 TC 3 Z9 3 U1 3 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD SEP PY 2015 VL 99 IS 5 BP 989 EP + DI 10.1016/j.mcna.2015.05.004 PG 29 WC Medicine, General & Internal SC General & Internal Medicine GA CS0TW UT WOS:000361776100007 PM 26320043 ER PT J AU Klein, JW Reddy, S AF Klein, Jared Wilson Reddy, Simha TI Care of the Homeless Patient SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Homelessness; Harm reduction; Housing first; Respite ID SERIOUS MENTAL-ILLNESS; HEALTH-CARE; ADULTS; PEOPLE; BARRIERS; DISEASE; PERCEPTIONS; MANAGEMENT; PROGRAMS; SAMPLE AB This article discusses the unique considerations when caring for patients who lack housing, one of the most essential human needs. Special attention is provided to diseases and conditions that are affected by homelessness as well as to particularly vulnerable populations of homeless patients. C1 [Klein, Jared Wilson] Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, Seattle, WA 98104 USA. [Reddy, Simha] Univ Washington, Dept Med, Div Gen Internal Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Klein, JW (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, 325 Ninth Ave,Box 359780, Seattle, WA 98104 USA. EM jaredwk@uw.edu NR 57 TC 0 Z9 0 U1 2 U2 13 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD SEP PY 2015 VL 99 IS 5 BP 1017 EP + DI 10.1016/j.mcna.2015.05.011 PG 23 WC Medicine, General & Internal SC General & Internal Medicine GA CS0TW UT WOS:000361776100008 PM 26320044 ER PT J AU Halpern, SD French, B Small, DS Saulsgiver, K Harhay, MO Audrain-McGovern, J Loewenstein, G Brennan, TA Asch, DA Volpp, KG AF Halpern, Scott D. French, Benjamin Small, Dylan S. Saulsgiver, Kathryn Harhay, Michael O. Audrain-McGovern, Janet Loewenstein, George Brennan, Troyen A. Asch, David A. Volpp, Kevin G. TI Randomized Trial of Four Financial-Incentive Programs for Smoking Cessation SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB In the 50 years since the release of the first Surgeon General's report on the harmful effects of smoking, national policies and behavioral programs as well as pharmacologic approaches have helped reduce smoking rates in the United States. Despite these interventions, the need for new approaches is clear because smoking is still the leading cause of preventable illness and death. Previous studies have demonstrated that financial incentives can promote a variety of health behaviors. However, effective ways to deliver health incentives are uncertain. A number of online and employer-based behavioral-change programs have been used. One of these programs involves use of deposit (commitment) contracts, whereby participants put some of their own money at risk and recover it if they are successful in changing their behavior. Deposit contracts should be more successful than reward programs because people are usually more motivated to avoid losses than to seek gains. The need to make deposits, however, may deter people from participating in such programs. No studies have directly compared the overall effectiveness of deposit and reward programs. This randomized controlled trial compared 4 financial-incentive programs for smoking cessation. Participants were CVS Caremark employees and their relatives and friends. The incentive programs were compared with usual care (which included informational resources and free smoking-cessation aids). Two of the incentive programs (reward based and deposit based) targeted individuals, whereas the other 2 targeted groups of 6 participants. One individual-oriented program and 1 group-oriented program provided rewards of approximately $800 for smoking cessation; the other 2 entailed refundable deposits of $150 plus $650 for successful participants. Levels of acceptance, overall effectiveness, and efficacy were assessed. The primary efficacy outcome was sustained abstinence for 6 months after the target quit date. A total of 2538 participants were randomized to 1 of the 4 incentive programs or to usual care. Participants in the 2 reward-based incentive programs were much more likely to accept the assignment (combined acceptance rate, 90.0%) than those in the 2 deposit-based programs (combined acceptance rate, 13.7%; P < 0.001). Intention-to-treat analyses using logistic regression showed that rates of sustained abstinence from smoking through 6 months were higher for each of the 4 incentive programs (range, 9.4%-16.0%) than usual care (6.0%) (P < 0.05 for all comparisons). Moreover, the superiority of reward-based programs was sustained through 12 months. The proportion of participants with sustained abstinence was similar at 6 months for participants assigned to group-oriented and individual-oriented programs (13.7% and 12.1%, respectively; P = 0.29). At 6 months, the proportion of participants with sustained abstinence was greater with reward-based incentives than with deposit-based incentives (15.7% vs 10.2%, P < 0.001). However, the rate of abstinence at 6 months in instrumental-variable analyses (accounting for differential acceptance) was 13.2 percentage points higher (95% confidence interval, 3.1-22.8) in the deposit-based programs than in the reward-based programs among the 13.7% of smokers who would accept participation in either type of program. These findings show that, among several financial-incentive programs for smoking cessation, rewards for smoking cessation achieve higher rates of sustained abstinence from smoking than deposit-based contracts owing to much higher rates of acceptance. Group-oriented programs are no more effective than the programs for individuals. C1 [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Halpern, Scott D.; French, Benjamin; Saulsgiver, Kathryn; Harhay, Michael O.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Halpern, Scott D.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Audrain-McGovern, Janet] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Halpern, Scott D.; French, Benjamin; Small, Dylan S.; Saulsgiver, Kathryn; Audrain-McGovern, Janet; Loewenstein, George; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Wharton Sch, Ctr Hlth Equ Res & Promot, Dept Stat, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Ctr Hlth Equ Res & Promot, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Ctr Hlth Care Innovat, Philadelphia, PA USA. [Loewenstein, George] Carnegie Mellon Univ, Ctr Behav Decis Res, Pittsburgh, PA 15213 USA. [Brennan, Troyen A.] CVS Caremark, Woonsocket, RI USA. RP Halpern, SD (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. OI Harhay, Michael/0000-0002-0553-674X NR 0 TC 0 Z9 0 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD SEP PY 2015 VL 70 IS 9 BP 566 EP 567 DI 10.1097/01.ogx.0000470840.40563.9a PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CS0LE UT WOS:000361749900012 ER PT J AU Grady, CD Dehlendorf, C Cohen, ED Schwarz, EB Borrero, S AF Grady, Cynthia D. Dehlendorf, Christine Cohen, Elan D. Schwarz, E. Bimla Borrero, Sonya TI Racial and Ethnic Differences in Contraceptive use Among Women Who Desire No Future Children, 2006-2010 National Survey of Family Growth SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB Uynintended pregnancies are either mistimed pregnancies occurring sooner than desired or unwanted pregnancies occurring when no children (or no more children) are desired. Unwanted pregnancies appear to be associated with poor pregnancy outcomes, specifically higher risk of preterm delivery and premature rupture of membranes. Women from racial and ethnic minority groups are more likely than white women to experience an unwanted pregnancy. Racial/ethnic differences in contraceptive use patterns among black and Hispanic women are the most likely proximal cause of observed disparities in unintended pregnancy. Several studies have reported that black women are more likely than white women to not use contraceptives or use contraception inconsistently, to have more contraceptive failures, and to less frequently use some prescription methods. Little is known about disparities in contraceptive use among the specific subset of women who do not want any (more) children and who may be at particularly high risk for having an unwanted pregnancy. This study evaluated racial/ethnic differences in contraceptive use among women who do not desire future pregnancy. Nationally representative data were obtained from the 2006-2010 National Survey of Family Growth (NSFG) to examine the relationships between race/ethnicity and contraceptive use among a sample of sexually active, reproductive-age women who stated that they do not desire any (more) children. The primary study outcome measures were (1) use of any contraceptive method and (2) the effectiveness of contraceptive methods used by women using any method at last heterosexual intercourse. Multivariable logistic regression models were used to assess the independent effect of race/ethnicity on contraceptive use patterns, adjusting for sociodemographic factors, reproductive characteristics, and indicators of health care access and utilization. The study sample comprised 2900 sexually active women, aged 15 to 44 years, who were at risk of an unwanted pregnancy. The vast majority (91.2%) used contraception at last sex, although use varied significantly by race/ethnicity; 93.2% of white women reported use of any method, compared with 84.7% of black and 90.5% of Hispanic women; P < 0.01. In the fully adjusted model, black women were significantly less likely than whites to use any contraception at last sex (odds ratio [OR], 0.43; 95% confidence interval, 0.27-0.73); in contrast, there was no significant difference among Hispanic women (OR, 0.95; 95% confidence interval, 0.52-1.72). In bivariate analysis, the type of contraceptive method used at last sex among women who used a method at last sex varied significantly by race/ethnicity (P < 0.01), although most women (59%) used a highly effective method. In the fully adjusted model, however, racial/ethnic differences were no longer significant: There were no significant differences between white women and black or Hispanic women with regard to use of highly/moderately effective contraception. Among the subset of women who report that they do not want (more) children, black women are significantly less likely than white women to use any contraception at last intercourse; this disparity does not appear to be due to differences in sociodemographic characteristics, reproductive factors, or utilization of health care. C1 [Grady, Cynthia D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cohen, Elan D.] Univ Pittsburgh, Ctr Res Hlth, Care Data Ctr, Pittsburgh, PA USA. [Schwarz, E. Bimla] Univ Calif Davis, Sch Med, Div Gen Internal Med, Sacramento, CA 95817 USA. [Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Grady, CD (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD SEP PY 2015 VL 70 IS 9 BP 574 EP 576 DI 10.1097/01.ogx.0000470841.16800.60 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CS0LE UT WOS:000361749900017 ER PT J AU Costa-Mallen, P Zabetian, CP Agarwal, P Hu, SC Yearout, D Samii, A Leverenz, JB Roberts, JW Checkoway, H AF Costa-Mallen, Paola Zabetian, Cyrus P. Agarwal, Pinky Hu, Shu-Ching Yearout, Dora Samii, Ali Leverenz, James B. Roberts, John W. Checkoway, Harvey TI Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Idiopathic Parkinson disease; Tobacco smoking; Serum iron; Serum ferritin; Haptoglobin phenotype ID NEURODEGENERATIVE DISEASES; SUBSTANTIA-NIGRA; FERRITIN; SUSCEPTIBILITY; POLYMORPHISM; ASSOCIATION; METABOLISM AB Introduction: Haptoglobin is a hemoglobin-binding protein that exists in three functionally different phenotypes, and haptoglobin phenotype 2-1 has previously been associated with Parkinson disease (PD) risk, with mechanisms not elucidated. Some evidence is emerging that low levels of serum iron may increase PD risk. In this study we investigated whether PD patients have lower serum iron and ferritin than controls, and whether this is dependent on haptoglobin phenotype. We also investigated the effect of Hp phenotype as a modifier of the effect of smoking on PD risk. Methods: The study population consisted of 128 PD patients and 226 controls. Serum iron, ferritin, and haptoglobin phenotype were determined, and compared between PD cases and controls. Stratified analysis by haptoglobin phenotype was performed to determine effect of haptoglobin phenotype on serum iron parameter differences between PD cases and controls and to investigate its role in the protective effect of smoking on PD risk. Results: PD cases had lower serum iron than controls (83.28 ug/100 ml vs 94.00 ug/100 ml, p 0.006), and in particular among subjects with phenotype 2-1. The protective effect of smoking on PD risk resulted stronger in subjects with phenotype 1-1 and 2-2, and weakest among subjects with phenotype 2-1. Ferritin levels were higher in PD cases than controls among subjects of White ethnicity. Conclusions: Our results report for the first time that the haptoglobin phenotype may be a contributor of iron levels abnormalities in PD patients. The mechanisms for these haptoglobin-phenotype specific effects will have to be further elucidated. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Costa-Mallen, Paola] Bastyr Univ, Res Inst, Kenmore, WA 98028 USA. [Zabetian, Cyrus P.; Yearout, Dora; Samii, Ali] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching; Samii, Ali] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Agarwal, Pinky] Evergreen Hlth, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Leverenz, James B.] Cleveland Clin, Neurol Inst, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Checkoway, Harvey] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. RP Costa-Mallen, P (reprint author), Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA 98028 USA. EM pcostamallen@bastyr.edu FU NIH [R21 NS070202-01A1, P50 NS062684, R01 NS065070]; Department of Veterans Affairs [1I01BX000531]; Bastyr University [3, 4] FX This study was funded by grants from the NIH (R21 NS070202-01A1, P50 NS062684, R01 NS065070), Department of Veterans Affairs (1I01BX000531), and Bastyr University (Faculty Seed Grants #3 and #4 2009-2011). NR 29 TC 7 Z9 7 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD SEP PY 2015 VL 21 IS 9 BP 1087 EP 1092 DI 10.1016/j.parkreldis.2015.07.006 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CR8BR UT WOS:000361576600013 PM 26228081 ER PT J AU Seltzer, EK Jean, NS Kramer-Golinkoff, E Asch, DA Merchant, RM AF Seltzer, E. K. Jean, N. S. Kramer-Golinkoff, E. Asch, D. A. Merchant, R. M. TI The content of social media's shared images about Ebola: a retrospective study SO PUBLIC HEALTH LA English DT Article DE Ebola; Social media; Public opinion; Public health; Communication ID EMERGENCY; EPIDEMIC; HEALTH AB Objective: Social media have strongly influenced awareness and perceptions of public health emergencies, but a considerable amount of social media content is now carried through images, rather than just text. This study's objective is to explore how image-sharing platforms are used for information dissemination in public health emergencies. Study design: Retrospective review of images posted on two popular image-sharing platforms to characterize public discourse about Ebola. Methods: Using the keyword '#ebola' we identified a 1% sample of images posted on Instagram and Flickr across two sequential weeks in November 2014. Images from both platforms were independently coded by two reviewers and characterized by themes. We reviewed 1217 images posted on Instagram and Flickr and identified themes. Results: Nine distinct themes were identified. These included: images of health care workers and professionals [308 (25%)], West Africa [75 (6%)], the Ebola virus [59 (5%)], and artistic renderings of Ebola [64 (5%)]. Also identified were images with accompanying embedded text related to Ebola and associated: facts [68 (6%)], fears [40 (3%)], politics [46 (4%)], and jokes [284 (23%)]. Several [273 (22%)] images were unrelated to Ebola or its sequelae. Instagram images were primarily coded as jokes [255 (42%)] or unrelated [219 (36%)], while Flickr images primarily depicted health care workers and other professionals [281 (46%)] providing care or other services for prevention or treatment. Conclusion: Image sharing platforms are being used for information exchange about public health crises, like Ebola. Use differs by platform and discerning these differences can help inform future uses for health care professionals and researchers seeking to assess public fears and misinformation or provide targeted education/awareness interventions. (C) 2015 The Royal Institute of Public Health. All rights reserved. C1 [Seltzer, E. K.; Jean, N. S.; Kramer-Golinkoff, E.; Asch, D. A.; Merchant, R. M.] Univ Penn, Penn Med Social Media & Hlth Innovat Lab, Philadelphia, PA 19104 USA. [Asch, D. A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Seltzer, EK (reprint author), 423 Blockley Hall, Philadelphia, PA 19104 USA. EM seltzer@uphs.upenn.edu FU NIH, NHLBI [K23: 10714038, R01: HL122457-01A1] FX Seltzer, Saint Jean, Kramer-Golinkoff: No conflicts to disclose; Asch: US Government employee, no conflicts to disclose; Merchant: Grant/Research support: NIH, NHLBI K23: 10714038, NIH, NHLBI, R01: HL122457-01A1. NR 23 TC 9 Z9 9 U1 6 U2 21 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0033-3506 EI 1476-5616 J9 PUBLIC HEALTH JI Public Health PD SEP PY 2015 VL 129 IS 9 BP 1273 EP 1277 DI 10.1016/j.puhe.2015.07.025 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR8VI UT WOS:000361631800019 PM 26285825 ER PT J AU Sripada, RK Bohnert, ASB Teo, AR Levine, DS Pfeiffer, PN Bowersox, NW Mizruchi, MS Chermack, ST Ganoczy, D Walters, H Valenstein, M AF Sripada, Rebecca K. Bohnert, Amy S. B. Teo, Alan R. Levine, Debra S. Pfeiffer, Paul N. Bowersox, Nicholas W. Mizruchi, Mark S. Chermack, Stephen T. Ganoczy, Dara Walters, Heather Valenstein, Marcia TI Social networks, mental health problems, and mental health service utilization in OEF/OIF National Guard veterans SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Social support; Social network; PTSD; Depression; Veteran; National Guard ID POSTTRAUMATIC-STRESS-DISORDER; OPERATIONS ENDURING FREEDOM; VIETNAM VETERANS; PTSD SYMPTOMS; TREATMENT-SEEKING; CARE UTILIZATION; SUPPORT NETWORKS; PHYSICAL HEALTH; SEXUAL ASSAULT; DEPRESSED MOOD AB Low social support and small social network size have been associated with a variety of negative mental health outcomes, while their impact on mental health services use is less clear. To date, few studies have examined these associations in National Guard service members, where frequency of mental health problems is high, social support may come from military as well as other sources, and services use may be suboptimal. Surveys were administered to 1448 recently returned National Guard members. Multivariable regression models assessed the associations between social support characteristics, probable mental health conditions, and service utilization. In bivariate analyses, large social network size, high social network diversity, high perceived social support, and high military unit support were each associated with lower likelihood of having a probable mental health condition (p < .001). In adjusted analyses, high perceived social support (OR .90, CI .88-.92) and high unit support (OR .96, CI .94-.97) continued to be significantly associated with lower likelihood of mental health conditions. Two social support measures were associated with lower likelihood of receiving mental health services in bivariate analyses, but were not significant in adjusted models. General social support and military-specific support were robustly associated with reduced mental health symptoms in National Guard members. Policy makers, military leaders, and clinicians should attend to service members' level of support from both the community and their units and continue efforts to bolster these supports. Other strategies, such as focused outreach, may be needed to bring National Guard members with need into mental health care. C1 [Sripada, Rebecca K.; Bohnert, Amy S. B.; Levine, Debra S.; Pfeiffer, Paul N.; Bowersox, Nicholas W.; Chermack, Stephen T.; Ganoczy, Dara; Walters, Heather; Valenstein, Marcia] VA Serious Mental Illness Treatment Resource & Ev, Ann Arbor, MI 48105 USA. [Sripada, Rebecca K.; Bohnert, Amy S. B.; Levine, Debra S.; Pfeiffer, Paul N.; Bowersox, Nicholas W.; Chermack, Stephen T.; Walters, Heather; Valenstein, Marcia] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [Sripada, Rebecca K.; Bohnert, Amy S. B.; Levine, Debra S.; Pfeiffer, Paul N.; Bowersox, Nicholas W.; Chermack, Stephen T.; Walters, Heather; Valenstein, Marcia] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Teo, Alan R.] Portland VA Med Ctr, Portland, OR USA. [Teo, Alan R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Mizruchi, Mark S.] Univ Michigan, Dept Sociol, Ann Arbor, MI 48109 USA. RP Sripada, RK (reprint author), VA Serious Mental Illness Treatment Resource & Ev, 2800 Plymouth Rd Bldg 16, Ann Arbor, MI 48105 USA. EM rekaufma@umich.edu OI Sripada, Rebecca/0000-0002-2844-3458 FU Department of Veterans Affairs Health Services Research and Development Service [RRP 09-420, SDP 10-047]; Welcome Back Veterans Initiative; McCormick Foundation; Families and Communities Together Coalition of Michigan State University FX This work was supported by the Department of Veterans Affairs Health Services Research and Development Service, RRP 09-420 and SDP 10-047; the Welcome Back Veterans Initiative, the McCormick Foundation, and Families and Communities Together Coalition of Michigan State University. Writing of this manuscript was supported by the Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, the Veterans Affairs Serious Mental Illness Treatment Resource and Evaluation Center (SMITREC) and the Mental Health Service of the VA Ann Arbor Healthcare System. NR 104 TC 1 Z9 1 U1 4 U2 14 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 EI 1433-9285 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD SEP PY 2015 VL 50 IS 9 BP 1367 EP 1378 DI 10.1007/s00127-015-1078-2 PG 12 WC Psychiatry SC Psychiatry GA CS1KA UT WOS:000361821700006 PM 26032182 ER PT J AU Jochum, JR Begley, AE Dew, MA Weiner, DK Karp, JF AF Jochum, John R. Begley, Amy E. Dew, Mary Amanda Weiner, Debra K. Karp, Jordan F. TI Advancing the screening of fibromyalgia in late-life depression: practical implications for psychiatric settings SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE fibromyalgia; screening; aging; pain; depression ID COGNITIVE IMPAIRMENT; PAIN; MANAGEMENT; DISORDERS; CRITERIA; CARE; POPULATION; DIAGNOSIS; SEVERITY AB Background: Fibromyalgia (FM) is common in older adults suffering from mood disorders. However, clinical diagnosis of FM is challenging, particularly in psychiatric settings. We examined the prevalence of FM and the sensitivity of three simple screeners for FM. Methods: Using cross-sectional data, we evaluated three tests against the American College of Rheumatology (ACR) 1990 Criteria for the Classification of FM: a "Do you often feel like you hurt all over?" question, a pain map score, and the Pope and Hudson (PH) interview for FM. Participants were 185 community-dwelling adults >= 60 years old with comorbid depression and chronic low back pain evaluated at a late-life mental health clinic. Results: Fifty three of 185 participants (29%) met the ACR 1990 FM criteria. Compared to those without FM, the FM group had more "yes" answers to the "hurt all over?" question and higher pain map scores. To reach a sensitivity of at least 0.90, the cut-off score for the pain map was 8. The sensitivity of the pain map, "hurt all over?" question, and PH criteria were 0.92 [95% CI 0.82-0.98], 0.91 [95% CI 0.79-0.97], and 0.94 [95% CI 0.843-0.99] respectively. Conclusions: Nearly one in three older adults suffering from depression and chronic low back pain met ACR 1990 FM criteria. Three short screening tests showed high sensitivity when compared to the ACR 1990 FM criteria. Implementation of one of the simple screeners for FM in geriatric psychiatry settings may guide the need for further diagnostic evaluation. C1 [Jochum, John R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Begley, Amy E.; Dew, Mary Amanda; Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Sch Med, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Sch Med, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Sch Med, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda; Weiner, Debra K.; Karp, Jordan F.] Clin & Translat Sci Inst, Pittsburgh, PA USA. [Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Karp, JF (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM karpjf@upmc.edu FU M-STREAM program: Medical Student Training and Research Experience in Aging and Mental Health [AG033575, R25 MH071544]; [P30 MH090333]; [UL1 RR024153]; [UL1TR000005] FX Supported in part by AG033575 (Karp) and R25 MH071544 through the M-STREAM program: Medical Student Training and Research Experience in Aging and Mental Health (Jochum). The project also received support by P30 MH090333, UL1 RR024153, and UL1TR000005. The content is solely the responsibility of the authors. NR 36 TC 2 Z9 2 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD SEP PY 2015 VL 27 IS 9 BP 1513 EP 1521 DI 10.1017/S1041610215000666 PG 9 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CR5LS UT WOS:000361384600011 PM 25907254 ER PT J AU Pomerantz, H Hogan, D Eilers, D Swetter, SM Chen, SC Jacob, SE Warshaw, EM Stricklin, G Dellavalle, RP Sidhu-Malik, N Konnikov, N Werth, VP Keri, J Lew, R Weinstock, MA AF Pomerantz, Hyemin Hogan, Daniel Eilers, David Swetter, Susan M. Chen, Suephy C. Jacob, Sharon E. Warshaw, Erin M. Stricklin, George Dellavalle, Robert P. Sidhu-Malik, Navjeet Konnikov, Nellie Werth, Victoria P. Keri, Jonette Lew, Robert Weinstock, Martin A. CA Vet Affairs Keratinocyte Carcinoma TI Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis A Randomized Clinical Trial SO JAMA DERMATOLOGY LA English DT Article ID TRETINOIN CHEMOPREVENTION TRIAL; 0.5-PERCENT FLUOROURACIL; 1-WEEK AB IMPORTANCE Topical fluorouracil was demonstrated to be effective in reducing the number of actinic keratoses (AKs) for up to 6 months, but no randomized trials studied its long-term efficacy. OBJECTIVE To evaluate the long-term efficacy of a single course of fluorouracil cream, 5%, for AK treatment. DESIGN, SETTING, AND PARTICIPANTS The Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) trial was a randomized, double-blinded, placebo-controlled trial with patients from dermatology clinics at 12 VA medical centers recruited from 2009 to 2011 and followed up until 2013. Our study population comprised 932 veterans with 2 or more keratinocyte carcinomas in the 5 years prior to enrollment. The mean follow-up duration was 2.6 years in both treatment and control groups. INTERVENTIONS Participants applied either topical fluorouracil cream, 5%(n = 468), or vehicle control cream (n = 464) to the face and ears twice daily for up to 4 weeks. MAIN OUTCOMES AND MEASURES This study reports on AK counts and treatments, which were secondary outcomes of the VAKCC trial. Actinic keratoses on the face and ears were counted by study dermatologists at enrollment and at study visits every 6 months. The number of spot treatments for AKs on the face and ears at semiannual study visits and in between study visits was recorded. RESULTS The number of AKs on the face and ears per participant was not different between the fluorouracil and control groups at randomization (11.1 vs 10.6, rho > .10). After randomization, the fluorouracil group had fewer AKs compared with the control group at 6 months (3.0 vs 8.1, rho < .001) and for the overall study duration (rho < .001). The fluorouracil group also had higher complete AK clearance rates (38% vs 17% at 6 months) and fewer spot treatments at 6-month intervals, at study visits, and in between study visits during the trial (rho < .01 for all). The fluorouracil group took longer to require the first spot AK treatment (6.2 months) compared with the control group (6.0 months) (hazard ratio, 0.69; 95% CI, 0.60-0.79). The number of hypertrophic AKs was not different between the 2 groups overall (rho = .60), although there were fewer hypertrophic AKs in the fluorouracil group at 6 months (0.23 vs 0.41) (rho = .05). CONCLUSIONS AND RELEVANCE Our results indicate that a single course of fluorouracil cream, 5%, effectively reduces AK counts and the need for spot treatments for longer than 2 years. C1 [Pomerantz, Hyemin; Weinstock, Martin A.] Vet Affairs VA Med Ctr, Ctr Dermatoepidemiol, Providence, RI USA. [Pomerantz, Hyemin; Weinstock, Martin A.] Brown Univ, Dept Dermatol, Providence, RI 02912 USA. [Hogan, Daniel] Bay Pines VA Healthcare Syst, Dermatol, Bay Pines, FL USA. [Hogan, Daniel] Nova SE Univ, Coll Osteopath Med, Dept Internal Med Dermatol, Davie, FL USA. [Eilers, David] Edward Hines Jr VA Hosp, Dermatol, Hines, IL USA. [Swetter, Susan M.] VA Palo Alto Hlth Care Syst, Dermatol, Palo Alto, CA USA. [Swetter, Susan M.] Stanford Univ, Med Ctr, Dept Dermatol, Palo Alto, CA 94304 USA. [Chen, Suephy C.] Atlanta VA Med Ctr, Dermatol, Atlanta, GA USA. [Chen, Suephy C.] Emory Univ, Dept Dermatol, Atlanta, GA 30322 USA. [Jacob, Sharon E.] VA San Diego Healthcare Syst, Dermatol, San Diego, CA USA. [Warshaw, Erin M.] Minneapolis VA Hlth Care Syst, Dermatol, Minneapolis, MN USA. [Warshaw, Erin M.] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA. [Stricklin, George] Tennessee Valley Healthcare Syst, Dermatol, Nashville, TN USA. [Stricklin, George] Vanderbilt Univ, Div Dermatol, Nashville, TN 37235 USA. [Dellavalle, Robert P.] VA Med Ctr, Dermatol, Denver, CO USA. [Sidhu-Malik, Navjeet] Durham VA Med Ctr, Dermatol, Durham, NC USA. [Sidhu-Malik, Navjeet] Duke Univ, Dept Dermatol, Durham, NC USA. [Konnikov, Nellie] Boston VA Med Ctr, Dermatol, Boston, MA USA. [Werth, Victoria P.] Philadelphia VA Med Ctr, Dermatol, Philadelphia, PA USA. [Keri, Jonette] Miami VA Hosp, Dermatol, Miami, FL USA. [Keri, Jonette] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA. [Lew, Robert] VA Cooperat Studies Coordinating Ctr, Boston, MA USA. [Weinstock, Martin A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI USA. [Weinstock, Martin A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. RP Pomerantz, H (reprint author), Providence VA Med Ctr, Ctr Dermatoepidemiol, 830 Chalkstone Ave, Providence, RI 02908 USA. EM hyemin.pomerantz@gmail.com OI Swan, James/0000-0002-9438-6391 FU Office of Research and Development Cooperative Studies Program, US Department of Veterans Affairs FX The study was supported by the Office of Research and Development Cooperative Studies Program, US Department of Veterans Affairs. NR 18 TC 9 Z9 9 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD SEP PY 2015 VL 151 IS 9 BP 952 EP 960 DI 10.1001/jamadermatol.2015.0502 PG 9 WC Dermatology SC Dermatology GA CR5HG UT WOS:000361371100007 PM 25950503 ER PT J AU Sonnenberg, A Genta, RM AF Sonnenberg, Amnon Genta, Robert M. TI Epithelial Dysplasia and Cancer in IBD Strictures SO JOURNAL OF CROHNS & COLITIS LA English DT Article DE Colon cancer; dysplasia; epidemiology; histopathology of inflammatory bowel disease; intestinal strictures ID INFLAMMATORY-BOWEL-DISEASE; MALIGNANT COLORECTAL STRICTURES; HELICOBACTER-PYLORI; CROHNS-DISEASE; ESOPHAGEAL EOSINOPHILIA; VIENNA CLASSIFICATION; PATHOLOGY DATABASE; ULCERATIVE-COLITIS; RISK-FACTOR; NEOPLASIA AB Colonic strictures and epithelial dysplasia are both known risk factors for the occurrence of colorectal cancer in inflammatory bowel disease (IBD) patients. The aim of the present work was to study colonic stricture as a risk factor for the occurrence of epithelial dysplasia and colonic adenocarcinoma. In a case-control study among 53568 IBD patients undergoing colonoscopy, we compared the prevalence of strictures among cases with dysplasia or adenocarcinoma and controls without such complications by calculating odds ratios (ORs) and their 95% confidence intervals (CIs). Multivariate logistic regressions were used to assess the joint influence of multiple predictor variables (age, sex, IBD type and stricture) on the occurrence of colonic dysplasia or adenocarcinoma. The prevalence of strictures was 1.06% in ulcerative colitis (UC) and 8.71% in Crohn's disease (CD, OR 11.09, 95% CI 9.72-12.70). The prevalence of dysplasia was 3.22% in UC and 2.08% in CD (OR 0.75, 95% CI 0.65-0.86). The prevalence of dysplasia was similar in IBD patients with and without stricture: 2.82 and 2.41%, respectively. The prevalence of cancer was higher in IBD patients with than without stricture: 0.78 and 0.11%, respectively (OR 6.87, 95% CI 3.30-12.89). In the multivariate analysis, old age, male sex and UC, but not stricture, were all significantly and independently associated with dysplasia. Old age, dysplasia and stricture were significantly and independently associated with cancer. The prevalence of epithelial dysplasia is not generally increased in IBD patients with strictures. C1 [Sonnenberg, Amnon; Genta, Robert M.] Miraca Life Sci, Irving, TX USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 22 TC 2 Z9 2 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1873-9946 EI 1876-4479 J9 J CROHNS COLITIS JI J. Crohns Colitis PD SEP 1 PY 2015 VL 9 IS 9 BP 769 EP 775 DI 10.1093/ecco-jcc/jjv108 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CR6PY UT WOS:000361470800011 PM 26079724 ER PT J AU Jeong, D Kim, J Nam, J Sun, H Lee, YH Lee, TJ Aguiar, RCT Kim, SW AF Jeong, D. Kim, J. Nam, J. Sun, H. Lee, Y-H Lee, T-J Aguiar, R. C. T. Kim, S-W TI MicroRNA-124 links p53 to the NF-kappa B pathway in B-cell lymphomas SO LEUKEMIA LA English DT Article ID RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PHOSPHODIESTERASE 4B; CANCER; MYC; EXPRESSION; NETWORK; PATHOGENESIS; VINCRISTINE; DOXORUBICIN; PREDNISONE AB The contribution of microRNAs to lymphoma biology is not fully understood. In particular, it remains untested whether microRNA dysregulation could contribute to the emergence of the aggressive subset of B-cell lymphomas that coexpress MYC and BCL2. Here, we identify microRNA-124 (miR-124) as a negative regulator of MYC and BCL2 expression in B-cell lymphomas. Concordantly, stable or transient ectopic expression of miR-124 suppressed cell proliferation and survival, whereas genetic inhibition of this miRNA enhanced the fitness of these tumors. Mechanistically, the activities of miR-124 towards MYC and BCL2 intersect with both oncogenic and tumor-suppressive pathways. In respect to the former, we show that miR-124 directly targets nuclear factor-kappa B (NF-kappa B) p65, and using genetic approaches, we demonstrate that this interaction accounts for the miR-124-mediated suppression of MYC and BCL2. We also characterized miR-124 promoter region and identified a functional p53 binding site. In agreement with this finding, endogenous or ectopic expression of wild-type, but not mutant, p53 increased miR-124 levels and suppressed p65, MYC and BCL2. Our data unveil an miRNA-dependent regulatory circuitry that links p53 to the NF-kappa B pathway, which when disrupted in B-cell lymphoma may be associated with aberrant coexpression of MYC and BCL2 and poor prognosis. C1 [Jeong, D.; Kim, J.; Nam, J.; Kim, S-W] Pusan Natl Univ, Dept Biol Sci, Pusan 609735, South Korea. [Sun, H.] Pusan Natl Univ, Dept Stat, Pusan 609735, South Korea. [Lee, Y-H] Yonsei Univ, Dept Radiat Oncol, Seoul 120749, South Korea. [Lee, T-J] Yeungnam Univ, Dept Anat, Daegu, South Korea. [Aguiar, R. C. T.] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, San Antonio, TX 78229 USA. [Aguiar, R. C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kim, SW (reprint author), Pusan Natl Univ, Dept Biol Sci, 63 Beon Gil 2, Pusan 609735, South Korea. EM kimsw@pusan.ac.kr FU Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2013R1A1A2008838]; NCI/NIH [R01-CA138747]; Veterans Administration Merit Award [I01-BX001882] FX We thank Dr Kyung Lib Jang (Pusan National University) for the WT and MUT (R248Q) p53 constructs. This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2013R1A1A2008838) to S-WK and RCTA was funded by NCI/NIH R01-CA138747 and Veterans Administration Merit Award (I01-BX001882). NR 28 TC 5 Z9 7 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD SEP PY 2015 VL 29 IS 9 BP 1868 EP 1874 DI 10.1038/leu.2015.101 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA CQ9MA UT WOS:000360937800008 PM 25915824 ER PT J AU Stein, BD Pacula, RL Gordon, AJ Burns, RM Leslie, DL Sorbero, MJ Bauhoff, S Mandell, TW Dick, AW AF Stein, Bradley D. Pacula, Rosalie Liccardo Gordon, Adam J. Burns, Rachel M. Leslie, Douglas L. Sorbero, Mark J. Bauhoff, Sebastian Mandell, Todd W. Dick, Andrew W. TI Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties SO MILBANK QUARTERLY LA English DT Article DE opioid-related disorders; health policy; substance abuse treatment; buprenorphine ID CLINICAL-TRIALS NETWORK; 1ST 3 YEARS; MAINTENANCE THERAPY; METHADONE-MAINTENANCE; DEPENDENT PATIENTS; AGONIST TREATMENT; OPIATE ADDICTION; UNITED-STATES; NALOXONE; PHYSICIANS AB Context: Opioid use disorders are a significant public health problem. In 2002, the FDA approved buprenorphine as an opioid use disorder treatment when prescribed by waivered physicians who were limited to treating 30 patients at a time. In 2006, federal legislation raised this number to 100 patients. Although federal legislators are considering increasing these limits further and expanding prescribing privileges to nonphysicians, little information is available regarding the impact of such changes on buprenorphine use. We therefore examined the impact of the 2006 legislation- as well as the association between urban and rural waivered physicians, opioid treatment programs, and substance abuse treatment facilities- on buprenorphine distributed per capita over the past decade. Methods: Using 2004- 2011 state- level data on buprenorphine dispensed and county- level data on the number of buprenorphine- waivered physicians and substance abuse treatment facilities using buprenorphine, we estimated a multivariate ordinary least squares regression model with state fixed effects of a state's annual total buprenorphine dispensed per capita as a function of the state's number of buprenorphine providers. Findings: The amount of buprenorphine dispensed has been increasing at a greater rate than the number of buprenorphine providers. The number of physicians waivered to treat 100 patients with buprenorphine in both rural and urban settings was significantly associated with increased amounts of buprenorphine dispensed per capita. There was no significant association in the growth of buprenorphine distributed and the number of physicians with 30- patient waivers. Conclusions: The greater amounts of buprenorphine dispensed are consistent with the potentially greater use of opioid agonists for opioid use disorder treatment, though they also make their misuse more likely. The changes after the 2006 legislation suggest that policies focused on increasing the number of patients that a single waivered physician could safely and effectively treat could bemore effective in increasing buprenorphine use than would alternatives such as opening new substance abuse treatment facilities or raising the overall number of waivered physicians. C1 [Stein, Bradley D.; Pacula, Rosalie Liccardo; Burns, Rachel M.; Sorbero, Mark J.; Bauhoff, Sebastian; Dick, Andrew W.] RAND Corp, Pittsburgh, PA 15213 USA. [Stein, Bradley D.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Leslie, Douglas L.] Penn State Coll Med, Hershey, PA USA. [Mandell, Todd W.] Community Substance Abuse Ctr, Chicopee, MA USA. RP Stein, BD (reprint author), RAND Corp, 4570 Fifth Ave, Pittsburgh, PA 15213 USA. EM stein@rand.org FU National Institute on Drug Abuse of the National Institutes of Health (NIH) [1R01DA032881-01A1] FX The National Institute on Drug Abuse of the National Institutes of Health (NIH) provided support (award 1R01DA032881-01A1) for this study. NR 67 TC 6 Z9 6 U1 7 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0887-378X EI 1468-0009 J9 MILBANK Q JI Milbank Q. PD SEP PY 2015 VL 93 IS 3 BP 561 EP 583 DI 10.1111/1468-0009.12137 PG 23 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CR3FQ UT WOS:000361216700011 PM 26350930 ER PT J AU Kabekkodu, SP Chakrabarty, S Shukla, V Varghese, VK Singh, KK Thangaraj, K Satyamoorthy, K AF Kabekkodu, Shama Prasada Chakrabarty, Sanjiban Shukla, Vaibhav Varghese, Vinay Koshy Singh, Keshav K. Thangaraj, Kumarasamy Satyamoorthy, Kapaettu TI Mitochondrial biology: From molecules to diseases SO MITOCHONDRION LA English DT Article DE Mitochondria; Clinical perspective; Mitochondrial biomarker; Mitochondrial database; Signaling and metabolism; Mitochondrial genetics ID TYPE-2 DIABETIC-RETINOPATHY; KEARNS-SAYRE SYNDROME; SODIUM-BUTYRATE; OXIDATIVE-PHOSPHORYLATION; POPULATION-GENETICS; COLORECTAL-CANCER; CERVICAL-CANCER; GENOME DATABASE; CELLS; APOPTOSIS AB As an integral part of the cell, mitochondria play a pivotal role in the regulation of energy metabolism, signaling pathways, cell differentiation, cell proliferation and cell death. Mitochondrion with its own genetic material has characteristics distinct from those of the nuclear counterpart and its dysregulation is associated with a myriad of diseases. The discovery of interplay between the nuclear and mitochondrial genes, and various post-transcriptional modifications associated with their products has added excitement in the field. This has led to a better understanding of the basic mitochondrial function in normal and disease states, and is important for diagnosis and prognosis of a large number of disorders. The Fourth Annual Conference of Society for Mitochondrial Research and Medicine - India (SMRM) was titled "Mitochondrial Biology: from Molecules to Disease". The conference was organized by K. Satyamoorthy and K. Thangaraj at School of Life Sciences, Manipal University, Manipal, India, during 8-9 December, 2014. The aim of the conference was to bring researchers and clinicians to a common platform; create an opportunity for networking between laboratories; and to discuss about the recent development in mitochondrial biology, diagnosis, and therapy. This review summarizes the key outcomes of the conference. (C) 2015 Elsevier B.V. and Mitochondria Research Society. All rights reserved. C1 [Kabekkodu, Shama Prasada; Chakrabarty, Sanjiban; Shukla, Vaibhav; Varghese, Vinay Koshy; Satyamoorthy, Kapaettu] Manipal Univ, Sch Life Sci, Dept Biotechnol, Manipal 576104, Karnataka, India. [Singh, Keshav K.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA. [Singh, Keshav K.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Singh, Keshav K.] Univ Alabama Birmingham, Dept Environm Hlth, Birmingham, AL USA. [Singh, Keshav K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Thangaraj, Kumarasamy] Ctr Cellular & Mol Biol, CSIR, Hyderabad 500007, Andhra Pradesh, India. RP Satyamoorthy, K (reprint author), Manipal Univ, Sch Life Sci, Manipal 576104, Karnataka, India. EM ksatyamoorthy@manipal.edu OI shukla, Vaibhav/0000-0003-4881-9894; Thangaraj, Kumarasamy/0000-0002-0075-0106 NR 50 TC 3 Z9 4 U1 4 U2 22 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD SEP PY 2015 VL 24 BP 93 EP 98 DI 10.1016/j.mito.2015.07.008 PG 6 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA CR5YD UT WOS:000361419400010 PM 26210788 ER PT J AU Sanchez, JR Reddick, TL Perez, M Centonze, VE Mitra, S Izumi, T McMahan, CA Walter, CA AF Sanchez, Jamila R. Reddick, Traci L. Perez, Marissa Centonze, Victoria E. Mitra, Sankar Izumi, Tadahide McMahan, C. Alex Walter, Christi A. TI Increased human AP endonuclease 1 level confers protection against the paternal age effect in mice SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS LA English DT Article DE Paternal Age; DNA repair; APEX1; Mutagenesis; LacI; Spermatogenesis ID BASE EXCISION-REPAIR; DE-NOVO MUTATIONS; APURINIC APYRIMIDINIC SITES; PROGRAMMED CELL-DEATH; DNA-POLYMERASE-BETA; HETEROZYGOUS MICE; SPERMATOGENIC CELLS; ALTERED EXPRESSION; NUCLEAR EXTRACTS; ABASIC SITES AB Increased paternal age is associated with a greater risk of producing children with genetic disorders originating from de novo germline mutations. Mice mimic the human condition by displaying an age-associated increase in spontaneous mutant frequency in spermatogenic cells. The observed increase in mutant frequency appears to be associated with a decrease in the DNA repair protein, AP endonuclease 1 (APEX1) and Apex1 heterozygous mice display an accelerated paternal age effect as young adults. In this study, we directly tested if APEX1 over-expression in cell lines and transgenic mice could prevent increases in mutagenesis. Cell lines with ectopic expression of APEX1 had increased APEX1 activity and lower spontaneous and induced mutations in the lad reporter gene relative to the control. Spermatogenic cells obtained from mice transgenic for human APEX1 displayed increased APEX1 activity, were protected from the age-dependent increase in spontaneous germline mutagenesis, and exhibited increased apoptosis in the spermatogonial cell population. These results directly indicate that increases in APEXI level confer protection against the murine paternal age effect, thus highlighting the role of APEX1 in preserving reproductive health with increasing age and in protection against genotoxin-induced mutagenesis in somatic cells. (C) 2015 Elsevier B.V. All rights reserved. C1 [Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Sanchez, Jamila R.; Perez, Marissa; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Reddick, Traci L.] Duke Univ, Duke Canc Inst, Durham, NC 27710 USA. [Centonze, Victoria E.] St Jude Childrens Res Hosp, Cell & Tissue Imaging Ctr, Memphis, TN 38105 USA. [Mitra, Sankar] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA. [Izumi, Tadahide] Grad Ctr Toxicol, Lexington, KY 40536 USA. [McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, MC 7762 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU National Institutes of Health [AG024364, AG021163] FX National Institutes of Health grants [AG024364 and AG021163]. NR 55 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0027-5107 EI 1873-135X J9 MUTAT RES-FUND MOL M JI Mutat. Res.-Fundam. Mol. Mech. Mutagen. PD SEP PY 2015 VL 779 BP 124 EP 133 DI 10.1016/j.mrfmmm.2015.06.008 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology GA CR3RT UT WOS:000361251500013 PM 26201249 ER PT J AU Geng, TY Xia, LL Russo, S Kamara, D Cawart, LA AF Geng, Tuoyu Xia, Lili Russo, Sarah Kamara, Davida Cawart, Lauren Ashley TI Prosteatotic genes are associated with unsaturated fat suppression of saturated fat-induced hepatic steatosis in C57BL/6 mice SO NUTRITION RESEARCH LA English DT Article DE Saturated fatty acid; Unsaturated fatty acid; Obese mice; Hepatic steatosis; Hepatic cells ID SKELETAL-MUSCLE CELLS; COA DESATURASE-1 GENE; BILE-ACID METABOLISM; PREGNANE-X-RECEPTOR; INSULIN-RESISTANCE; MEDIATED INDUCTION; NUCLEAR RECEPTORS; PPAR-GAMMA; LXR-ALPHA; LIVER AB Both high sugar and fat diets can induce prosteatotic genes, leading to obesity and obesity-associated diseases, including hepatic steatosis. Unsaturated fat/fatty acid (USFA) reduces high sugar-induced hepatic steatosis by inhibiting the induced prosteatotic genes. In contrast, it is still unclear how USFA ameliorates saturated fat/fatty acid (SFA)-induced hepatic steatosis. As sugar and fat have different transport and metabolic pathways, we hypothesized that USFA suppressed SFA-induced hepatic steatosis via a different set of prosteatotic genes. To test this, we implemented high SFA vs USFA diets and a control diet in C57BL/6 mice for 16 weeks. Severe hepatic steatosis was induced in mice fed the SPA diet. Among a nearly complete set of prosteatotic genes, only the stearoyl-coenzyme a desaturase 1 (Scd1), cluster of differentiation 36 (Cd36), and peroxisome proliferator-activated receptor gamma (Ppar gamma) genes that were differentially expressed in the liver could contribute to SPA-induced steatosis or the alleviative effect of USFA. That is, the SPA diet induced the expression of Cd36 and Ppar gamma but not Scd1, and the USFA diet suppressed Scd1 expression and the induction of Cd36 and Ppar gamma. These findings were mainly recapitulated in cultured hepatocytes. The essential roles of SCD1 and CD36 were confirmed by the observation that the suppression of SCD1 and CD36 with small interfering RNA or drug treatment ameliorated SPA-induced lipid accumulation in hepatocytes. We thus concluded that SCD1, CD36, and PPAR gamma were essential to the suppression of SFA-induced hepatic steatosis by main dietary USFA, which may provide different therapeutic targets for reducing high-fat vs sugar-induced hepatic steatosis. (C) 2015 Elsevier Inc. All rights reserved. C1 [Geng, Tuoyu] Yangzhou Univ, Inst Epigenet & Epigen, Yangzhou 225009, Jiangsu, Peoples R China. [Geng, Tuoyu; Xia, Lili] Yangzhou Univ, Coll Anim Sci & Technol, Yangzhou 225009, Jiangsu, Peoples R China. [Geng, Tuoyu; Russo, Sarah; Cawart, Lauren Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Cawart, Lauren Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Kamara, Davida] Union Hosp Cecil Cty, Elkton, MD 21921 USA. RP Geng, TY (reprint author), Yangzhou Univ, Inst Epigenet & Epigen, 48 Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China. EM tygeng@yzu.edu.cn FU Natural Sciences Foundation of China [31472086]; Priority Academic Program Development of Jiangsu Higher Education Institutions; VA Merit Award [1R01HL117233] FX This work was financially supported by the Natural Sciences Foundation of China (31472086) and the Priority Academic Program Development of Jiangsu Higher Education Institutions through awards to TG as well as by a VA Merit Award and 1R01HL117233 awarded to LAC. TG and LAC designed the research and wrote the article; TG, LX, and SBR conducted the research and analyzed the data. DK contributed to writing and editing of the article. NR 52 TC 4 Z9 4 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0271-5317 J9 NUTR RES JI Nutr. Res. PD SEP PY 2015 VL 35 IS 9 BP 812 EP 822 DI 10.1016/j.nutres.2015.06.012 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CR5XE UT WOS:000361416900008 PM 26277244 ER PT J AU Asch, DA Rader, DJ Merchant, RM AF Asch, David A. Rader, Daniel J. Merchant, Raina M. TI Mining the social mediome SO TRENDS IN MOLECULAR MEDICINE LA English DT Editorial Material DE communication; health information technology; health services research; social media ID FACEBOOK; HEALTH; DEPRESSION; SCALE; USERS AB The experiences and behaviors revealed in our everyday lives provide as much insight into health and disease as any analysis of our genome could ever produce. These characteristics are not found in the genome, but may be revealed in our online activities, which make up our social mediome. C1 [Asch, David A.; Merchant, Raina M.] Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Asch, David A.; Rader, Daniel J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Rader, Daniel J.] Univ Penn, Dept Med Genet, Philadelphia, PA 19104 USA. [Merchant, Raina M.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Merchant, RM (reprint author), Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu FU NHLBI NIH HHS [K23 HL109083, R01 HL122457, R01 HL122457-01A1]; PHS HHS [NHLBI K23 109083-01] NR 15 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4914 EI 1471-499X J9 TRENDS MOL MED JI Trends Mol. Med PD SEP PY 2015 VL 21 IS 9 BP 528 EP 529 DI 10.1016/j.molmed.2015.06.004 PG 2 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA CR5TP UT WOS:000361407500002 PM 26341614 ER PT J AU Rasmussen, DD Kincaid, CL Froehlich, JC AF Rasmussen, Dennis D. Kincaid, Carrie L. Froehlich, Janice C. TI Prazosin plus Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Prazosin; Naltrexone; Alcohol; Alcoholism Treatment; Noradrenergic; Opioid ID ALPHA(1)-ADRENERGIC RECEPTOR ANTAGONIST; RANDOMIZED CONTROLLED-TRIAL; ETHANOL-CONSUMPTION; NOREPINEPHRINE; STRESS; BRAIN; INHIBITION; PREFERENCE; ADDICTION; BEHAVIORS AB BackgroundPrazosin (PRZ; an (1)-adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or P), and the combination of PRZ+NTX decreases alcohol drinking more effectively than does either drug alone. As drug responsiveness can depend on history of alcohol drinking and dependence, we investigated whether various schedules of PRZ and NTX administration, alone or in combination, are effective in decreasing alcohol drinking in male P rats with a history of protracted voluntary alcohol drinking, dependence, and repeated withdrawals closely resembling human alcoholism. MethodsMale P rats became alcohol-dependent during 1year of adlibitum 24h/d access to food, water, and 20% alcohol with repetitive temporary alcohol withdrawals. Four sequential studies then addressed effects of oral PRZ (2mg/kg) and NTX (10mg/kg), alone or together, on alcohol drinking during: (i) daily alcohol access with daily drug treatment, (ii) intermittent alcohol access with daily drug treatment, (iii) intermittent alcohol access with occasional drug treatment, and (iv) postdeprivation reinstatement of alcohol access. ResultsThe combination of PRZ+NTX consistently suppressed alcohol drinking during daily or intermittent alcohol access conditions and when drug treatment was either daily or occasional. PRZ+NTX was consistently more effective than either drug alone. The reduction in alcohol drinking was not due to sedation, motor effects, or malaise. ConclusionsBoth daily and as-needed treatment with PRZ+NTX are highly effective in suppressing daily, intermittent, and postdeprivation alcohol drinking in male P rats with a protracted history of alcohol dependence and repeated withdrawals. This drug combination may be especially effective for treating individuals with long histories of heavy alcohol abuse, dependence, and repeated relapse, as commonly encountered in clinical practice. C1 [Rasmussen, Dennis D.] VISN 20 Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Rasmussen, Dennis D.; Kincaid, Carrie L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Rasmussen, Dennis D.; Kincaid, Carrie L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Froehlich, Janice C.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. RP Rasmussen, DD (reprint author), VA Puget Sound Hlth Care Syst Med Ctr, 116 MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM drasmuss@u.washington.edu FU VA Puget Sound Health Care System; VA VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC); NIH [R01 AA018604, P20 AA017839, P60 AA007611, R24 AA015512] FX This material is based on work supported in part by resources from the VA Puget Sound Health Care System, the VA VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), and NIH grants R01 AA018604, P20 AA017839, and P60 AA007611. P rats provided by the Indiana Alcohol Research Resource Center supported by NIH grant R24 AA015512. NR 53 TC 5 Z9 5 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD SEP PY 2015 VL 39 IS 9 BP 1832 EP 1841 DI 10.1111/acer.12828 PG 10 WC Substance Abuse SC Substance Abuse GA CQ7ZB UT WOS:000360824300030 PM 26260061 ER PT J AU Wortzel, HS AF Wortzel, Hal S. TI Psychiatric Expert Testimony: Emerging Applications SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Book Review C1 [Wortzel, Hal S.] Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Care Ctr, Neuropsychiat Consultat Serv, Denver, CO 80220 USA. [Wortzel, Hal S.] Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Care Ctr, Psychiat Fellowship Program, Denver, CO USA. RP Wortzel, HS (reprint author), Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Care Ctr, Neuropsychiat Consultat Serv, Denver, CO 80220 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD SEP PY 2015 VL 172 IS 9 BP 915 EP 916 DI 10.1176/appi.ajp.2015.15040480 PG 3 WC Psychiatry SC Psychiatry GA CR1SA UT WOS:000361103900022 PM 26324312 ER PT J AU Karabanov, A Ziemann, U Hamada, M George, MS Quartarone, A Classen, J Massimini, M Rothwell, J Siebner, HR AF Karabanov, Anke Ziemann, Ulf Hamada, Masashi George, Mark S. Quartarone, Angelo Classen, Joseph Massimini, Marcello Rothwell, John Siebner, Hartwig Roman TI Consensus Paper: Probing Homeostatic Plasticity of Human Cortex With Non-invasive Transcranial Brain Stimulation (vol 8, pg 442, 2015) SO BRAIN STIMULATION LA English DT Correction C1 [Karabanov, Anke; Siebner, Hartwig Roman] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark. [Ziemann, Ulf] Univ Tubingen, Dept Neurol & Stroke, Tubingen, Germany. [Ziemann, Ulf] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany. [Hamada, Masashi] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England. [George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Quartarone, Angelo] Univ Messina, Dept Neurosci, I-98100 Messina, Italy. [Classen, Joseph] Univ Hosp Leipzig, Dept Neurol, Leipzig, Germany. [Massimini, Marcello] Univ Milan, Dept Clin Sci, I-20122 Milan, Italy. [Rothwell, John] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England. [Siebner, Hartwig Roman] Univ Copenhagen, Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark. RP Karabanov, A (reprint author), Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark. EM ankenk@drcmr.dk NR 1 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD SEP-OCT PY 2015 VL 8 IS 5 BP 92 EP 92 DI 10.1016/j.brs.2015.06.016 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CR0ME UT WOS:000361012000028 ER PT J AU Karabanov, A Ziemann, U Hamada, M George, MS Quartarone, A Classen, J Massimini, M Rothwell, J Siebner, HR AF Karabanov, Anke Ziemann, Ulf Hamada, Masashi George, Mark S. Quartarone, Angelo Classen, Joseph Massimini, Marcello Rothwell, John Siebner, Hartwig Roman TI Consensus Paper: Probing Homeostatic Plasticity of Human Cortex With Non-invasive Transcranial Brain Stimulation SO BRAIN STIMULATION LA English DT Article ID HUMAN MOTOR CORTEX; LONG-TERM POTENTIATION; THETA-BURST STIMULATION; PAIRED ASSOCIATIVE STIMULATION; BIDIRECTIONAL SYNAPTIC PLASTICITY; PARKINSONS-DISEASE PATIENTS; DEPRESSION-LIKE PLASTICITY; LOW-FREQUENCY STIMULATION; FOCAL HAND DYSTONIA; LTP-LIKE PLASTICITY AB Homeostatic plasticity is thought to stabilize neural activity around a set point within a physiologically reasonable dynamic range. Over the last ten years, a wide range of non-invasive transcranial brain stimulation (NTBS) techniques have been used to probe homeostatic control of cortical plasticity in the intact human brain. Here, we review different NTBS approaches to study homeostatic plasticity on a systems level and relate the findings to both, physiological evidence from in vitro studies and to a theoretical framework of homeostatic function. We highlight differences between homeostatic and other non-homeostatic forms of plasticity and we examine the contribution of sleep in restoring synaptic homeostasis. Finally, we discuss the growing number of studies showing that abnormal homeostatic plasticity may be associated to a range of neuropsychiatric diseases. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Karabanov, Anke; Siebner, Hartwig Roman] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark. [Ziemann, Ulf] Univ Tubingen, Dept Neurol & Stroke, Hertie Inst Clin Brain Res, Tubingen, Germany. [Hamada, Masashi] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England. [George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Quartarone, Angelo] Univ Messina, Dept Neurosci, I-98100 Messina, Italy. [Classen, Joseph] Univ Hosp Leipzig, Dept Neurol, Leipzig, Germany. [Massimini, Marcello] Univ Milan, Dept Clin Sci, I-20122 Milan, Italy. [Rothwell, John] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England. [Siebner, Hartwig Roman] Univ Copenhagen, Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark. RP Karabanov, A (reprint author), Kettegaard Alle 30, DK-2650 Hvidovre, Denmark. EM ankenk@drcmr.dk OI QUARTARONE, Angelo/0000-0003-1485-6590; Massimini, Marcello/0000-0003-2271-957X; Rothwell, John/0000-0003-1367-6467 FU Swedish Research Council [2011-38769-82837-71] FX AK was supported by the Swedish Research Council (2011-38769-82837-71). NR 162 TC 7 Z9 7 U1 6 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD SEP-OCT PY 2015 VL 8 IS 5 BP 993 EP 1006 DI 10.1016/j.brs.2015.06.017 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CR0ME UT WOS:000361012000029 PM 26598772 ER PT J AU Hirsch, J DePalma, G Tsai, TT Sands, LP Leung, JM AF Hirsch, J. DePalma, G. Tsai, T. T. Sands, L. P. Leung, J. M. TI Impact of intraoperative hypotension and blood pressure fluctuations on early postoperative delirium after non-cardiac surgery SO BRITISH JOURNAL OF ANAESTHESIA LA English DT Article DE arterial blood pressure; delirium; hypotension ID IMPAIRED CEREBRAL AUTOREGULATION; OBSTRUCTIVE SLEEP-APNEA; RISK-FACTORS; ELDERLY-PATIENTS; HIP FRACTURE; HALOPERIDOL PROPHYLAXIS; PROGNOSTIC-SIGNIFICANCE; COGNITIVE DYSFUNCTION; PREDISPOSING FACTORS; SURGICAL-PATIENTS AB Introduction: Postoperative delirium is common in older patients. Despite its prognostic significance, the pathophysiology is incompletely understood. Although many risk factors have been identified, no reversible factors, particularly ones potentially modifiable by anaesthetic management, have been identified. The goal of this prospective cohort study was to investigate whether intraoperative hypotension was associated with postoperative delirium in older patients undergoing major non-cardiac surgery. Methods: Study subjects were patients >65 years of age, undergoing major non-cardiac surgery, who were enrolled in an ongoing prospective observational study of the pathophysiology of postoperative delirium. Intraoperative blood pressure was measured and predefined criteria were used to define hypotension. Delirium was measured by the Confusion Assessment Method on the first two postoperative days. Data were analysed using t-tests, two-sample proportion tests and ordered logistic regression multivariable models, including correction for multiple comparisons. Results: Data from 594 patients with a mean age of 73.6 years (SD 6.2) were studied. Of these 178 (30%) developed delirium on day 1 and 176 (30%) on day 2. Patients developing delirium were older, more often female, had lower preoperative cognitive scores, and underwent longer operations. Relative hypotension (decreases by 20, 30, or 40%) or absolute hypotension [mean arterial pressure (MAP)<50 mm Hg] were not significantly associated with postoperative delirium, nor was the duration of hypotension (MAP<50 mm Hg). Conversely, intraoperative blood pressure variance was significantly associated with postoperative delirium. Discussion: These results showed that increased blood pressure fluctuation, not absolute or relative hypotension, was predictive of postoperative delirium. C1 [Hirsch, J.; Tsai, T. T.; Leung, J. M.] Univ Calif San Francisco, Dept Anaesthesia & Perioperat Care, San Francisco, CA 94143 USA. [DePalma, G.; Sands, L. P.] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA. RP Hirsch, J (reprint author), Univ Calif San Francisco, San Francisco VAMC, San Francisco Anesthesiol Serv, Dept Anaesthesia & Perioperat Care, 4150 Clement St,Mail 129, San Francisco, CA 94121 USA. EM jan.hirsch@ucsf.edu RI Sands, Laura/E-8919-2015 OI Sands, Laura/0000-0003-2446-4486 FU Anesthesia Patient Safety Foundation (Indianapolis, IN, USA); National Institutes of Health of the United States (NIH) [1RO1AG031795-05] FX This work was supported by funding from the Anesthesia Patient Safety Foundation (Indianapolis, IN, USA), and the National Institutes of Health of the United States (NIH 1RO1AG031795-05) (to J.M.L.). NR 71 TC 19 Z9 21 U1 5 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0007-0912 EI 1471-6771 J9 BRIT J ANAESTH JI Br. J. Anaesth. PD SEP PY 2015 VL 115 IS 3 BP 418 EP 426 DI 10.1093/bja/aeu458 PG 9 WC Anesthesiology SC Anesthesiology GA CR2WL UT WOS:000361191400015 PM 25616677 ER PT J AU Willard-Grace, R Dube, K Hessler, D O'Brien, B Earnest, G Gupta, R Shunk, R Grumbach, K AF Willard-Grace, Rachel Dube, Kate Hessler, Danielle O'Brien, Bridget Earnest, Gillian Gupta, Reena Shunk, Rebecca Grumbach, Kevin TI Panel Management, Team Culture, and Worklife Experience SO FAMILIES SYSTEMS & HEALTH LA English DT Article DE burnout; panel management; patient care team; primary health care; team culture ID CENTERED MEDICAL HOME; RANDOMIZED-CONTROLLED-TRIAL; PRIMARY-CARE; INTERNAL-MEDICINE; LOWER BURNOUT; PATIENT-CARE; LOW-INCOME; PHYSICIANS; SATISFACTION; PROGRAM AB Burnout and professional dissatisfaction are threats to the primary care workforce. We investigated the relationship between panel management capability, team culture, cynicism, and perceived "do-ability" of primary care among primary care providers (PCPs) and staff in primary care practices. We surveyed 326 PCPs and 142 staff members in 10 county-administered, 6 university-run, and 3 Veterans Affairs primary care clinics in a large urban area in 2013. Predictor variables included capability for performing panel management and perception of team culture. Outcome variables included 2 work experience measures-the Maslach Burnout Inventory cynicism scale and a 1-item measure of the "do-ability" of primary care this year compared with last year. Generalized Estimation Equation (GEE) models were used to account for clustering at the clinic level. Greater panel management capability and higher team culture were associated with lower cynicism among PCPs and staff and higher reported "do-ability" of primary care among PCPs. Panel management capability and team culture interacted to predict the 2 work experience outcomes. Among PCPs and staff reporting high team culture, there was little association between panel management capability and the outcomes, which were uniformly positive. However, there was a strong relationship between greater panel management capability and improved work experience outcomes for PCPs and staff reporting low team culture. Team-based processes of care such as panel management may be an important strategy to protect against cynicism and dissatisfaction in primary care, particularly in settings that are still working to improve their team culture. C1 [Willard-Grace, Rachel; Dube, Kate; Hessler, Danielle; Grumbach, Kevin] Univ Calif San Francisco, Dept Family & Community Med, Ctr Excellence Primary Care, San Francisco, CA 94114 USA. [O'Brien, Bridget; Earnest, Gillian; Shunk, Rebecca] San Francisco VA Med Ctr, Ctr Excellence Primary Care Educ, San Francisco, CA USA. [O'Brien, Bridget; Gupta, Reena] Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94114 USA. [Gupta, Reena] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, Ctr Excellence Primary Care, San Francisco, CA 94114 USA. RP Willard-Grace, R (reprint author), Univ Calif San Francisco, Dept Family & Community Med, Ctr Excellence Primary Care, 995 Potrero Ave,Ward 83, San Francisco, CA 94114 USA. EM willardr@fcm.ucsf.edu RI Grumbach, Kevin/L-9222-2016 OI Willard-Grace, Rachel/0000-0002-1876-555X FU California Medicaid Waiver Delivery System Reform Incentive Program; University of California, San Francisco Medical Center; San Francisco Department of Public Health; UCSF Medical Center FX This research was supported by funding from the California Medicaid Waiver Delivery System Reform Incentive Program to San Francisco General Hospital and the University of California, San Francisco Medical Center. This research is the result of close partnership with the leadership and staff of 19 primary care clinics across San Francisco. Without the wisdom, expertise, and candid feedback of their clinic leadership, clinicians, and frontline staff, this survey would not have been possible. The study team thanks the San Francisco Department of Public Health and the UCSF Medical Center for their support of this project in conjunction with primary care reforms undertaken for the Centers for Medicare and Medicaid Services Incentive Program for these health systems under the Section 1115 California Medicaid Waiver. We acknowledge the UCSF Clinical & Translational Science Institute and Dr. Christy Boscardin's consultations on preliminary statistical analysis. NR 40 TC 2 Z9 2 U1 0 U2 5 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1091-7527 EI 1939-0602 J9 FAM SYST HEALTH JI Fam. Syst. Health PD SEP PY 2015 VL 33 IS 3 BP 231 EP 241 DI 10.1037/fsh0000113 PG 11 WC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health GA CR0FA UT WOS:000360992600007 PM 25730504 ER PT J AU Morshed, SA Davies, TF AF Morshed, S. A. Davies, T. F. TI Graves' Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies SO HORMONE AND METABOLIC RESEARCH LA English DT Article DE Graves' disease; thyroid; TSH-receptor antibodies; TSH; signaling ID HUMAN THYROTROPIN RECEPTOR; SIGNALING CASCADES; CRYSTAL-STRUCTURE; MURINE MODEL; T-CELLS; AUTOIMMUNITY; AUTOANTIBODY; ACTIVATION; EXPRESSION; IMMUNE AB The immunologic processes involved in Graves' disease (GD) have one unique characteristic - the autoantibodies to the TSH receptor (TSHR) which have both linear and conformational epitopes. Three types of TSHR antibodies (stimulating, blocking, and cleavage) with different functional capabilities have been described in GD patients, which induce different signaling effects varying from thyroid cell proliferation to thyroid cell death. The establishment of animal models of GD by TSHR antibody transfer or by immunization with TSHR antigen has confirmed its pathogenic role and, therefore, GD is the result of a breakdown in TSHR tolerance. Here we review some of the characteristics of TSHR antibodies with a special emphasis on new developments in our understanding of what were previously called "neutral" antibodies and which we now characterize as autoantibodies to the "cleavage" region of the TSHR ectodomain. C1 [Morshed, S. A.; Davies, T. F.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY 10029 USA. RP Morshed, SA (reprint author), Room 2F-26 VA Med Ctr,130 West Kingsbridge Rd, New York, NY 10468 USA. EM syed.morshed@mssm.edu FU NIH [DK069713, DK052464]; VA Merit Award Program FX This work was supported in part by NIH grants DK069713, DK052464 and the VA Merit Award Program. NR 49 TC 9 Z9 9 U1 1 U2 7 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0018-5043 EI 1439-4286 J9 HORM METAB RES JI Horm. Metab. Res. PD SEP PY 2015 VL 47 IS 10 BP 727 EP 734 DI 10.1055/s-0035-1559633 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CR2GV UT WOS:000361145500006 PM 26361259 ER PT J AU Young-Xu, Y Kuntz, JL Gerding, DN Neily, J Mills, P Dubberke, ER Olsen, MA Kelly, CP Mahe, C AF Young-Xu, Yinong Kuntz, Jennifer L. Gerding, Dale N. Neily, Julia Mills, Peter Dubberke, Erik R. Olsen, Margaret A. Kelly, Ciaran P. Mahe, Cedric TI Clostridium difficile Infection Among Veterans Health Administration Patients SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID TERM-CARE FACILITY; ASYMPTOMATIC CARRIERS; EPIDEMIOLOGY; DISEASE; SURVEILLANCE; RESIDENTS; BURDEN; SYSTEM AB OBJECTIVE. To report on the prevalence and incidence of Clostridium difficile infection (CDI) from 2009 to 2013 among Veterans Healthcare Administration patients DESIGN. A retrospective descriptive analysis of data extracted from a large electronic medical record (EMR) database SETTING. Data were acquired from VHA healthcare records from 2009 to 2013 that included outpatient clinical visits, long-term care, and hospitalized care as well as pharmacy and laboratory information. RESULTS. In 2009, there were 10,207 CDI episodes, and in 2013, there were 12,143 CDI episodes, an increase of 19.0%. The overall CDI rate increased by 8.4% from 193 episodes per 100,000 patient years in 2009 to 209 episodes per 100,000 patient years in 2013. Of the CDI episodes identified in 2009, 58% were identified during a hospitalization, and 42% were identified in an outpatient setting. In 2013, 44% of the CDI episodes were identified in an outpatient setting. CONCLUSION. This is one of the largest studies that has utilized timely EMR data to describe the current CDI epidemiology at the VHA. Despite an aging population with greater burden of comorbidity than the general US population, our data show that VHACDI rates stabilized between 2011 and 2013 following increases likely attributable to the introduction of the more sensitive nucleic acid amplification tests (NAATs). The findings in this report will help establish an accurate benchmark against which both current and future VA CDI prevention initiatives can be measured. C1 [Young-Xu, Yinong; Neily, Julia; Mills, Peter] Natl Ctr Patient Safety, Dept Vet Affairs, White River Jct, VT USA. [Young-Xu, Yinong; Mills, Peter] Geisel Sch Med Dartmouth, Hanover, NH USA. [Kuntz, Jennifer L.] Kaiser Permanente Northwest Ctr Hlth Res, Portland, OR USA. [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. [Dubberke, Erik R.; Olsen, Margaret A.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Olsen, Margaret A.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Kelly, Ciaran P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Sch Med, Boston, MA 02215 USA. [Mahe, Cedric] Sanofi Pasteur, Lyon, France. RP Young-Xu, Y (reprint author), VAMC, 10A4E,215 North Main St, White River Jct, VT 05009 USA. EM Yinong.Young-Xu@va.gov FU Sanofi-Pasteur, Lyon, France FX This research was supported by an unrestricted research grant from Sanofi-Pasteur, Lyon, France. NR 24 TC 2 Z9 2 U1 1 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2015 VL 36 IS 9 BP 1038 EP 1045 DI 10.1017/ice.2015.138 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CQ9FD UT WOS:000360917200007 PM 26047207 ER PT J AU Hwang, YC Hayashi, T Fujimoto, WY Kahn, SE Leonetti, DL McNeely, MJ Boyko, EJ AF Hwang, Y-C Hayashi, T. Fujimoto, W. Y. Kahn, S. E. Leonetti, D. L. McNeely, M. J. Boyko, E. J. TI Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article ID JAPANESE-AMERICAN MEN; IMPAIRED GLUCOSE-TOLERANCE; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; RISK-FACTORS; ALL-CAUSE; PREVALENCE; ASSOCIATION; METAANALYSIS; DEFINITION AB BACKGROUND: A proportion of obese subjects appear metabolically healthy (MHO) but little is known about the natural history of MHO and factors predicting its future conversion to metabolically unhealthy obese (MUO). OBJECTIVES: The aim was to determine prospectively the frequency of conversion of MHO to MUO and the clinical variables that independently predicted this conversion, with a particular focus on the role of body composition. METHODS: We identified 85 Japanese Americans with MHO (56 men, 29 women), aged 34-73 years (mean age 49.8 years) who were followed at 2.5, 5 and 10 years after enrollment with measurements of metabolic characteristics, lifestyle and abdominal and thigh fat areas measured by computed tomography. Obesity was defined using the Asian body mass index criterion of >= 25 kg m(-2). Metabolically healthy was defined as the presence of <= 2 of 5 metabolic syndrome components proposed by the National Cholesterol Education Program Adult Treatment Panel III, while metabolically unhealthy was defined as >= 3 components. RESULTS: Over 10 years of follow-up, 55 MHO individuals (64.7%) converted to MUO. Statistically significant univariate predictors of conversion included dyslipidemia, greater insulin resistance and greater visceral abdominal (VAT) and subcutaneous abdominal fat area (SAT). In multivariate analysis, VAT (odds ratio per 1-s.d. increment (95% confidence interval) 2.04 (1.11-3.72), P = 0.021), high-density lipoprotein (HDL) cholesterol (0.24 (0.11-0.53), P<0.001), fasting plasma insulin (2.45 (1.07-5.62), P = 0.034) and female sex (5.37 (1.14-25.27), P = 0.033) were significantly associated with future conversion to MUO. However, SAT was not an independent predictor for future conversion to MUO. CONCLUSIONS: In this population, MHO was a transient state, with nearly two-thirds developing MUO over 10 years, with higher conversion to MUO independently associated with VAT, female sex, higher fasting insulin level and lower baseline HDL cholesterol level. C1 [Hwang, Y-C; Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98101 USA. [Hwang, Y-C] Kyung Hee Univ, Sch Med, Kyung Hee Univ Hosp Gangdong, Div Endocrinol & Metab,Dept Med, Seoul, South Korea. [Hayashi, T.] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan. [Fujimoto, W. Y.; Kahn, S. E.; McNeely, M. J.; Boyko, E. J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Kahn, S. E.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA 98101 USA. [Leonetti, D. L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eboyko@uw.edu RI Hayashi, Tomoshige/N-8508-2015 OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU Diabetes Research Center [DK-17047]; Clinical Nutrition Research Unit [DK-35816]; General Clinical Research Center at the University of Washington [RR-00037]; VA Puget Sound Health Care System; King County Japanese American community; National Institutes of Health [DK-31170, HL-49293, DK-017047] FX This work was supported by facilities and services provided by the Diabetes Research Center (DK-17047), Clinical Nutrition Research Unit (DK-35816), and the General Clinical Research Center (RR-00037) at the University of Washington. VA Puget Sound Health Care System provided support for Drs Boyko and Kahn's involvement in this research. We are grateful to the King County Japanese American community for support and cooperation. Funding was through National Institutes of Health grants DK-31170, HL-49293 and DK-017047. The funding entities had no role in the conduct of this study or interpretation of its results. NR 32 TC 16 Z9 16 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD SEP PY 2015 VL 39 IS 9 BP 1365 EP 1370 DI 10.1038/ijo.2015.75 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CR0BY UT WOS:000360984400005 PM 25920773 ER PT J AU Newman, JC AF Newman, John C. TI Copyright and Bedside Cognitive Testing Why We Need Alternatives to the Mini-Mental State Examination SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. RP Newman, JC (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, 4150 Clement St, San Francisco, CA 94121 USA. EM newman@ucsf.edu RI Newman, John/L-8112-2013 FU NIA NIH HHS [K08AG048354] NR 8 TC 6 Z9 6 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP PY 2015 VL 175 IS 9 BP 1459 EP 1460 DI 10.1001/jamainternmed.2015.2159 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CR1CH UT WOS:000361059900010 PM 26053392 ER PT J AU Ong, MK AF Ong, Michael K. TI Tobacco Cessation-We Can Do Better SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID SMOKING-CESSATION C1 [Ong, Michael K.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. [Ong, Michael K.] Vet Affairs Greater Los Angeles HealthCare Syst, Los Angeles, CA USA. RP Ong, MK (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, 10940 Wilshire Blvd,Ste 700, Los Angeles, CA 90024 USA. EM michael.ong@ucla.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP PY 2015 VL 175 IS 9 BP 1516 EP 1517 DI 10.1001/jamainternmed.2015.2402 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CR1CH UT WOS:000361059900022 PM 26075733 ER PT J AU Zeliadt, SB Heffner, JL Sayre, G Klein, DE Simons, C Williams, J Reinke, LF Au, DH AF Zeliadt, Steven B. Heffner, Jaimee L. Sayre, George Klein, Deborah E. Simons, Carol Williams, Jennifer Reinke, Lynn F. Au, David H. TI Attitudes and Perceptions About Smoking Cessation in the Context of Lung Cancer Screening SO JAMA INTERNAL MEDICINE LA English DT Article ID SERVICES TASK-FORCE; COMPUTED-TOMOGRAPHY; PULMONARY NODULES; QUALITATIVE RESEARCH; RISK PERCEPTIONS; COGNITIVE-DISSONANCE; TRIAL PARTICIPANTS; FOLLOW-UP; DISCUSSIONS; DEPENDENCE AB IMPORTANCE Broad adoption of lung cancer screeningmay inadvertently lead to negative population health outcomes if it is perceived as a substitute for smoking cessation. OBJECTIVE To understand views on smoking cessation from current smokers in the context of being offered lung cancer screening as a routine service in primary care. DESIGN, SETTING, AND PARTICIPANTS As an ancillary study to the launch of a lung cancer screening program at 7 sites in the Veterans Health Administration, 45 in-depth semi-structured qualitative interviews about health beliefs related to smoking and lung cancer screening were administered from May 29 to September 22, 2014, by telephone to 37 current smokers offered lung cancer screening by their primary care physician. Analysis was conducted from June 15, 2014, to March 29, 2015. MAIN OUTCOMES AND MEASURES Attitudes and perceptions about the importance of smoking cessation in the context of lung cancer screening. RESULTS Lung cancer screening prompted most current smokers to reflect for the first time on what smoking means for their current and future health. However, 17 of 35 (49%) participants described mechanisms whereby screening lowered their motivation for cessation, including the perception that undergoing an imaging test yields the same health benefits as smoking cessation. Other misperceptions include the belief that everyone who participates in screening will benefit; the belief that screening and being able to return for additional screening offers protection from lung cancer; the perception by some individuals that findings from screenings have saved their lives by catching their cancer early when indeterminate findings are identified that can be monitored rather than immediately treated; and a reinforced belief in some individuals that a cancer-free screening test result indicates that they are among the lucky ones who will avoid the harms of smoking. CONCLUSIONS AND RELEVANCE In this qualitative, lung cancer screening prompted many current smokers to reflect on their health and may serve as a potential opportunity to engage patients in discussions about smoking cessation. However, several concerning pathways were identified in which screening, when offered as part of routine care and described as having proven efficacy, may negatively influence smoking cessation. Health care professionals should be aware that the opportunity for early detection of lung cancer may be interpreted as a way of avoiding the harms of smoking. To promote cessation, discussions should focus on the emotional response to screening rather than clinical details (eg, nodule size) and address misperceptions about the value of early detection so that screening does not lower motivation to quit smoking. C1 [Zeliadt, Steven B.; Sayre, George; Simons, Carol; Williams, Jennifer; Reinke, Lynn F.; Au, David H.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA 98108 USA. [Zeliadt, Steven B.; Sayre, George] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Heffner, Jaimee L.] Fred Hutchinson Canc Res Ctr, Tobacco & Hlth Behav Sci Res Grp, Seattle, WA 98104 USA. [Klein, Deborah E.] Swedish Med Ctr, Swedish Med Grp, Seattle, WA USA. [Reinke, Lynn F.; Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Zeliadt, SB (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, 1660 S Columbian Way, Seattle, WA 98108 USA. EM steven.zeliadt@va.gov FU Centers for Disease Control and Prevention's Health Promotion and Disease Prevention Research Centers Program through a Special Interest Project (Low Dose CT Lung Cancer Screening: Informed Decision Making and Smoking Cessation) [DP9001911-05S2, SIP13-038] FX This study was supported by grant DP9001911-05S2 from the Centers for Disease Control and Prevention's Health Promotion and Disease Prevention Research Centers Program through a Special Interest Project (SIP13-038: Low Dose CT Lung Cancer Screening: Informed Decision Making and Smoking Cessation). This material is the result of work supported by resources from VA Puget Sound Health Care System. NR 39 TC 16 Z9 16 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP PY 2015 VL 175 IS 9 BP 1530 EP 1537 DI 10.1001/jamainternmed.2015.3558 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CR1CH UT WOS:000361059900025 PM 26214612 ER PT J AU He, WJ Jimenez, F Martinez, H Harper, NL Manoharan, MS Carrillo, A Ingale, P Liu, YG Ahuja, SS Clark, RA Rather, CG Ramirez, DA Andrews, CP Jacobs, RL Ahuja, SK AF He, Weijing Jimenez, Fabio Martinez, Hernan Harper, Nathan L. Manoharan, Muthu Saravanan Carrillo, Andrew Ingale, Puraskar Liu, Ya-Guang Ahuja, Seema S. Clark, Robert A. Rather, Cynthia G. Ramirez, Daniel A. Andrews, Charles P. Jacobs, Robert L. Ahuja, Sunil K. TI Cockroach sensitization mitigates allergic rhinoconjunctivitis symptom severity in patients allergic to house dust mites and pollen SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Cockroach sensitization; allergen challenge chamber; allergic rhinoconjunctivitis; T-cell activation; aeroallergens; house dust mite; skin prick test; pollen ID INNATE LYMPHOID-CELLS; CHALLENGE CHAMBER; CD4/CD8 RATIO; HYGIENE HYPOTHESIS; IMMUNE; ACTIVATION; EXPOSURE; RESPONSES; ASTHMA; DISEASE AB Background: Modifiers of symptom severity in patients with allergic rhinoconjunctivitis (AR) are imprecisely characterized. The hygiene hypothesis implicates childhood microbial exposure as a protective factor. Cockroach sensitization (C+) might be a proxy for microbial exposure. Objective: We sought to determine whether C+ assayed by means of skin prick tests influenced AR symptom severity in controlled and natural settings. Methods: Total symptom scores (TSSs) were recorded by 21 participants with house dust mite allergy (M+) in the natural setting and during repeated exposures of 3 hours per day to house dust mite allergen in an allergen challenge chamber (ACC). In M+ participants the peripheral blood and nasal cells were assayed for T-cell activation and transcriptomic profiles (by using RNA sequencing), respectively. Participants allergic to mountain cedar (n = 21), oak (n = 34), and ragweed (n = 23) recorded TSSs during separate out-of-season exposures to these pollens (any pollen sensitization [P+]) in the ACC; a subset recorded TSSs in the pollination seasons. Results: The hierarchy of TSSs (highest to lowest) among M+ participants tracked the following skin prick test sensitization statuses: M+P+C- > M+P+C+ > M+P-C- > M+P-C+. In nasal cells and peripheral blood the immune/inflammatory responses were rapidly resolved in M+P+C+ compared with M+P+C- participants. Among those allergic to pollen, C+ was associated with a lower TSS during pollen challenges and the pollination season. After aggregated analysis of all 4 ACC studies, C+ status was associated with a 2.8-fold greater likelihood of a lower TSS compared with C- status (odds ratio, 2.78; 95% CI, 1.18-6.67; P = .02). Conclusions: C+ status is associated with mitigation of AR symptom severity in adults with AR. C1 [He, Weijing; Jimenez, Fabio; Martinez, Hernan; Harper, Nathan L.; Manoharan, Muthu Saravanan; Carrillo, Andrew; Ingale, Puraskar; Liu, Ya-Guang; Ahuja, Seema S.; Clark, Robert A.; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA. [He, Weijing; Jimenez, Fabio; Martinez, Hernan; Harper, Nathan L.; Manoharan, Muthu Saravanan; Carrillo, Andrew; Ingale, Puraskar; Liu, Ya-Guang; Ahuja, Seema S.; Clark, Robert A.; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Jimenez, Fabio; Martinez, Hernan; Harper, Nathan L.] Biomed Res Fdn South Texas, San Antonio, TX USA. [Rather, Cynthia G.; Ramirez, Daniel A.; Andrews, Charles P.; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA. RP Ahuja, SK (reprint author), 7400 Merton Minter Blvd,Room W200, San Antonio, TX 78229 USA. EM ahujas@uthscsa.edu OI Ingale, Puraskar/0000-0003-2769-878X FU Doris Duke Distinguished Clinical Scientist Award; Burroughs Wellcome Clinical Scientist in Transitional Research Award; Max and Minnie Tomerlin Voelcker Award; Center for Personalized Medicine at the South Texas Veterans Health Care System [CX00875-01AI] FX S.K.A. received support from the following grants: the Doris Duke Distinguished Clinical Scientist Award, the Burroughs Wellcome Clinical Scientist in Transitional Research Award, the Max and Minnie Tomerlin Voelcker Award, and the Center for Personalized Medicine (CX00875-01AI) at the South Texas Veterans Health Care System. R.L.J., C.P.A., and D.A.R., are co-owners of Biogenics Research Chamber and have not received financial support. C.G.R. is the Executive Director of Chamber Operations. NR 40 TC 5 Z9 5 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD SEP PY 2015 VL 136 IS 3 BP 658 EP 666 DI 10.1016/j.jaci.2015.02.041 PG 9 WC Allergy; Immunology SC Allergy; Immunology GA CQ9EA UT WOS:000360913300018 PM 26026342 ER PT J AU Singh, JA Qu, HY Yazdany, J Chatham, W Dall'era, M Shewchuk, RM AF Singh, Jasvinder A. Qu, Haiyan Yazdany, Jinoos Chatham, Winn Dall'era, Maria Shewchuk, Richard M. TI Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE SYSTEMIC LUPUS ERYTHEMATOSUS; MEDICATION DECISION MAKING; MINORITIES; RACE; BARRIERS; CHALLENGES ID ERYTHEMATOSUS PATIENTS; PATIENT PREFERENCES; TREATMENT ADHERENCE; RHEUMATIC-DISEASE; HEALTH-CARE; DISABILITIES; AMERICAN; IDENTIFY; QUALITY; COHORT AB Objective. To assess the perspectives of women with lupus nephritis on barriers to medication decision making. Methods. We used the nominal group technique (NGT), a structured process to elicit ideas from participants, for a formative assessment. Eight NGT meetings were conducted in English and moderated by an expert NGT researcher at 2 medical centers. Participants responded to the question: "What sorts of things make it hard for people to decide to take the medicines that doctors prescribe for treating their lupus kidney disease?" Patients nominated, discussed, and prioritized barriers to decisional processes involving medications for treating lupus nephritis. Results. Fifty-one women with lupus nephritis with a mean age of 40.6 +/- 13.3 years and disease duration of 11.8 +/- 8.3 years participated in 8 NGT meetings: 26 African Americans (4 panels), 13 Hispanics (2 panels), and 12 whites (2 panels). Of the participants, 36.5% had obtained at least a college degree and 55.8% needed some help in reading health materials. Of the 248 responses generated (range 19-37 responses/panel), 100 responses (40%) were perceived by patients as having relatively greater importance than other barriers in their own decision-making processes. The most salient perceived barriers, as indicated by percent-weighted votes assigned, were known/anticipated side effects (15.6%), medication expense/ability to afford medications (8.2%), and the fear that the medication could cause other diseases (7.8%). Conclusion. Women with lupus nephritis identified specific barriers to decisions related to medications. Information relevant to known/anticipated medication side effects and medication cost will form the basis of a patient guide for women with systemic lupus erythematosus, currently under development. C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Med Serv, Birmingham Vet Affairs VA Med Ctr, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Qu, Haiyan; Shewchuk, Richard M.] Univ Alabama Birmingham, Dept Hlth Serv Adm, Sch Hlth Profess, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Yazdany, Jinoos; Dall'era, Maria] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Patient-Centered Outcomes Research Institute [CE-1304-6631]; Agency for Health Quality and Research Center for Education and Research on Therapeutics [U19 HS021110]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [P50 AR060772, U34 AR062891]; National Institute on Aging [U01 AG018947]; National Cancer Institute [U10 CA149950]; US National Institutes of Health [K23 AR060259]; Rosalind Russell Medical Research Center for Arthritis FX This material is the result of work supported by the research contract CE-1304-6631 from the Patient-Centered Outcomes Research Institute. J.A. Singh is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA, and research grants from these US agencies: Agency for Health Quality and Research Center for Education and Research on Therapeutics U19 HS021110, National Institute of Arthritis and Musculoskeletal and Skin Diseases P50 AR060772 and U34 AR062891, National Institute on Aging U01 AG018947, and the National Cancer Institute U10 CA149950. J.Yazdany is also supported by the US National Institutes of Health K23 AR060259 and the Rosalind Russell Medical Research Center for Arthritis. NR 33 TC 4 Z9 4 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD SEP PY 2015 VL 42 IS 9 BP 1616 EP 1623 DI 10.3899/jrheum.150168 PG 8 WC Rheumatology SC Rheumatology GA CQ6SF UT WOS:000360733600014 PM 26178276 ER PT J AU Seay, K Khajoueinejad, N Zheng, JH Kiser, P Ochsenbauer, C Kappes, JC Herold, B Goldstein, H AF Seay, Kieran Khajoueinejad, Nazanin Zheng, Jian Hua Kiser, Patrick Ochsenbauer, Christina Kappes, John C. Herold, Betsy Goldstein, Harris TI The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR DISOPROXIL FUMARATE; FEMALE GENITAL-TRACT; SUB-SAHARAN AFRICA; HUMANIZED BLT MICE; TYPE-2 INFECTION; DENDRITIC CELLS; NEUTRALIZING ANTIBODIES; PREEXPOSURE PROPHYLAXIS; MUCOSAL TRANSMISSION AB Epidemiological studies have demonstrated that herpes simplex virus 2 (HSV-2) infection significantly increases the risk of HIV-1 acquisition, thereby contributing to the expanding HIV-1 epidemic. To investigate whether HSV-2 infection directly facilitates mucosal HIV-1 acquisition, we used our transgenic hCD4/R5/cT1 mouse model which circumvents major entry and transcription blocks preventing murine HIV-1 infection by targeting transgenic expression of human CD4, CCR5, and cyclin T1 genes to CD4(+) T cells and myeloid-committed cells. Productive infection of mucosal leukocytes, predominantly CD4(+) T cells, was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molecular clone, HIV-Du151.2(env)-NLuc, which expresses an env gene (C.Du151.2) cloned from an acute heterosexually infected woman and a NanoLuc luciferase reporter gene. Lower genital tract HIV-1 infection after HIV-Du151.2(env)-NLuc intravaginal challenge was increased similar to 4-fold in hCD4/R5/cT1 mice coinfected with HSV-2. Furthermore, HIV-1 dissemination to draining lymph nodes was detected only in HSV-2-coinfected mice. HSV-2 infection stimulated local infiltration and activation of CD4(+) T cells and dendritic cells, likely contributing to the enhanced HIV-1 infection and dissemination in HSV-2-coinfected mice. We then used this model to demonstrate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of tenofovir (TFV), but not the TFV microbicide gel utilized in the recent CAPRISA 004, VOICE (Vaginal and Oral Interventions to Control the Epidemic), and FACTS 001 clinical trials, was effective as preexposure prophylaxis (PrEP) to completely prevent vaginal HIV-1 infection in almost half of HSV-2-coinfected mice. These results also support utilization of hCD4/R5/cT1 mice as a highly reproducible immunocompetent preclinical model to evaluate HIV-1 acquisition across the female genital tract. IMPORTANCE Multiple epidemiological studies have reported that genital herpes simplex virus 2 (HSV-2) infection increases the risk of HIV-1 sexual acquisition by severalfold. Understanding the underlying mechanisms by which HSV-2 facilitates HIV-1 infection and optimizing the efficacy of therapies to inhibit HIV-1 infection during HSV-2 coinfection should contribute to reducing HIV-1 transmission. Using our novel transgenic hCD4/R5/cT1 mouse model infectible with HIV-1, we demonstrated that HSV-2 infection enhances vaginal transmission and dissemination of HIV-1 infection while stimulating recruitment and activation of CD4(+) T cells and dendritic cells in the lower genital tract. HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials. The hCD4/R5/cT1 mice represent a new preclinical mouse model to evaluate vaginal HIV-1 acquisition. C1 [Seay, Kieran; Khajoueinejad, Nazanin; Herold, Betsy; Goldstein, Harris] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. [Khajoueinejad, Nazanin; Zheng, Jian Hua; Herold, Betsy; Goldstein, Harris] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA. [Kiser, Patrick] Northwestern Univ, Dept Biomed Engn, McCormick Sch Engn, Evanston, IL 60208 USA. [Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. RP Goldstein, H (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. EM harris.goldstein@einstein.yu.edu RI Kiser, Patrick/C-2843-2014 OI Kiser, Patrick/0000-0002-3868-7122 FU National Institute of Drug Abuse at the National Institutes of Health [DA033788]; Einstein-Montefiore Center for AIDS Research [P30-AI51519]; University of Alabama at Birmingham Center for AIDS Research [P30-AI277670]; National Institute of Allergy and Infectious Diseases at the National Institutes of Health [AI065309, T32-AI007501]; NIH Center for HIV-1/AIDS Vaccine Immunology (CHAVI) [UO1-AI067854]; Charles Michael Chair in Autoimmune Diseases; VHA Merit Review Award FX This work was supported by the National Institute of Drug Abuse at the National Institutes of Health (DA033788), the Einstein-Montefiore Center for AIDS Research (P30-AI51519), the University of Alabama at Birmingham Center for AIDS Research (P30-AI277670), the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (AI065309 and T32-AI007501 to K.S.), NIH Center for HIV-1/AIDS Vaccine Immunology (CHAVI) (UO1-AI067854 to J.C.K. and C.O.), the Charles Michael Chair in Autoimmune Diseases (to H.G.), and a VHA Merit Review Award (to J.C.K.). NR 63 TC 5 Z9 5 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD SEP PY 2015 VL 89 IS 18 BP 9559 EP 9570 DI 10.1128/JVI.01326-15 PG 12 WC Virology SC Virology GA CQ6HE UT WOS:000360704400036 PM 26157126 ER PT J AU Panzer, SE Laskowski, J Renner, B Kulik, L Ljubanovic, D Huber, KM Zhong, WX Pickering, MC Holers, VM Thurman, JM AF Panzer, Sarah E. Laskowski, Jennifer Renner, Brandon Kulik, Liudmila Ljubanovic, Danica Huber, Kendra M. Zhong, Weixiong Pickering, Matthew C. Holers, V. Michael Thurman, Joshua M. TI IgM exacerbates glomerular disease progression in complement-induced glomerulopathy SO KIDNEY INTERNATIONAL LA English DT Article DE complement; glomerulonephritis; immunology ID NEPHROTIC SYNDROME; MESANGIAL HYPERCELLULARITY; REPERFUSION INJURY; NATURAL ANTIBODY; CELL; MICE; DEFICIENT; GLOMERULONEPHRITIS; ACTIVATION; DEPOSITION AB Although glomerular immunoglobulin M (IgM) deposition occurs in a variety of glomerular diseases, the mechanism of deposition and its clinical significance remain controversial. Some have theorized IgM becomes passively trapped in areas of glomerulosclerosis. However, recent studies found that IgM specifically binds damaged glomeruli. Therefore, we tested whether natural IgM binds to neo-epitopes exposed after insults to the glomerulus and exacerbates disease in mice deficient in the complement regulatory protein factor H; a model of non-sclerotic and nonimmune-complex glomerular disease. Immunofluorescence microscopy demonstrated mesangial and capillary loop deposition of IgM, whereas ultrastructural analysis found IgM deposition on endothelial cells and subendothelial areas. Factor H-deficient mice lacking B cells were protected from renal damage, as evidenced by milder histologic lesions on light and electron microscopy. IgM, but not IgG, from wild-type mice bound to cultured murine mesangial cells. Furthermore, injection of purified IgM into mice lacking B cells bound within the glomeruli and induced proteinuria. A monoclonal natural IgM-recognizing phospholipids also bound to glomeruli in vivo and induced albuminuria. Thus, our results indicate specific IgM antibodies bind to glomerular epitopes and that IgM contributes to the progression of glomerular damage in this mouse model of non-sclerotic glomerular disease. C1 [Panzer, Sarah E.] Univ Wisconsin, Div Nephrol, Dept Med, Madison, WI 53705 USA. [Laskowski, Jennifer; Renner, Brandon; Kulik, Liudmila; Huber, Kendra M.; Holers, V. Michael; Thurman, Joshua M.] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Ljubanovic, Danica] Univ Hosp Dubrava, Dept Pathol, Zagreb, Croatia. [Zhong, Weixiong] Univ Wisconsin, Dept Pathol, Madison, WI 53705 USA. [Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Serv, Madison, WI USA. [Pickering, Matthew C.] Univ London Imperial Coll Sci Technol & Med, Ctr Complement & Inflammat Res, London, England. RP Panzer, SE (reprint author), Univ Wisconsin, Div Nephrol, Dept Med, 1685 Highland Ave,Suite 5000, Madison, WI 53705 USA. EM sepanzer@medicine.wisc.edu FU KIDNEEDS Foundation; National Institutes of Health [F32DK096711-01, R01 DK076690] FX ZThis work was supported in part by the KIDNEEDS Foundation (JMT) and National Institutes of Health grants F32DK096711-01 (SEP) and R01 DK076690 (JMT). NR 34 TC 11 Z9 11 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD SEP PY 2015 VL 88 IS 3 BP 528 EP 537 DI 10.1038/ki.2015.120 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA CR1JA UT WOS:000361079800017 PM 25945405 ER PT J AU Beach, MC Roter, DL Saha, S Korthuis, PT Eggly, S Cohn, J Sharp, V Moore, RD Wilson, IB AF Beach, Mary Catherine Roter, Debra L. Saha, Somnath Korthuis, P. Todd Eggly, Susan Cohn, Jonathan Sharp, Victoria Moore, Richard D. Wilson, Ira B. TI Impact of a brief patient and provider intervention to improve the quality of communication about medication adherence among HIV patients SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Communication skills training; HIV/AIDS; Medication adherence ID ANTIRETROVIRAL THERAPY; CARE; SATISFACTION; PHYSICIANS; OUTCOMES; INFECTION; HIV/AIDS; DIALOGUE; RECALL AB Introduction: Medication adherence is essential in HIV care, yet provider communication about adherence is often suboptimal. We designed this study to improve patient-provider communication about HIV medication adherence. Methods: We randomized 26 providers at three HIV care sites to receive or not receive a one-hour communication skills training based on motivational interviewing principles applied to medication adherence. Prior to routine office visits, non-adherent patients of providers who received the training were coached to discuss adherence with their providers. Patients of providers who did not receive the training providers were not coached. We audio-recorded and coded patient-provider interactions using the roter interaction analysis system (RIAS). Results: There was more dialogue about therapeutic regimen in visits with intervention patients and providers (167 vs 128, respectively, p=.004), with the majority of statements coming from providers. These visits also included more brainstorming solutions to nonadherence (41% vs. 22%, p=0.026). Intervention compared with control visit providers engaged in more positive talk (44 vs. 38 statements, p=0.039), emotional talk (26 vs. 18 statements, p<0.001), and probing of patient opinion (3 vs. 2 statements, p=0.009). Conclusion: A brief provider training combined with patient coaching sessions, improved provider communication behaviors and increased dialogue regarding medication adherence. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Beach, Mary Catherine] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21287 USA. [Beach, Mary Catherine; Roter, Debra L.; Moore, Richard D.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Beach, Mary Catherine; Roter, Debra L.; Moore, Richard D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21287 USA. [Beach, Mary Catherine] Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. [Eggly, Susan; Cohn, Jonathan] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. [Wilson, Ira B.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA. RP Beach, MC (reprint author), Johns Hopkins Univ, Gen Internal Med, 2024 East Monument St, Baltimore, MD 21287 USA. EM mcbeach@jhmi.edu RI Wilson, Ira/F-9190-2016 OI Wilson, Ira/0000-0002-0246-738X; Eggly, Susan/0000-0002-8137-6098 FU Health Resources Service Administration; Agency for Healthcare Research and Quality [AHRQ 290-01-0012, K08HS013903-05]; National Institute of Drug Abuse [K23 DA019809]; Department of Veterans Affairs; Robert Wood Johnson Generalist Physician Faculty Scholars Awards FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis. was supported by the National Institute of Drug Abuse (K23 DA019809), Dr. Saha was supported by the Department of Veterans Affairs, Dr. Beach was supported by the Agency for Healthcare Research and Quality (K08HS013903-05) and both Drs. Beach and Saha were supported by Robert Wood Johnson Generalist Physician Faculty Scholars Awards. None of the funders had a role in the design and conduct of this analysis, nor was it subject to their final approval. None of the authors have any relevant financial conflicts of interest. NR 33 TC 7 Z9 7 U1 2 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD SEP PY 2015 VL 98 IS 9 BP 1078 EP 1083 DI 10.1016/j.pec.2015.05.011 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA CQ8PH UT WOS:000360870200006 PM 26021185 ER PT J AU Han, LJ Cai, W Mao, LL Liu, J Li, PY Leak, RK Xu, Y Hu, XM Chen, J AF Han, Lijuan Cai, Wei Mao, Leilei Liu, Jia Li, Peiying Leak, Rehana K. Xu, Yun Hu, Xiaoming Chen, Jun TI Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia SO STROKE LA English DT Article DE bromodeoxyuridine; inflammation; polarization; stroke; white matter ID ACTIVATED-RECEPTOR-GAMMA; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; TRAUMATIC BRAIN-INJURY; PPAR-GAMMA; OLIGODENDROCYTE DIFFERENTIATION; INTRACEREBRAL HEMORRHAGE; AGONIST ROSIGLITAZONE; NEUROPROTECTION; CELLS; PROGENITORS AB Background and Purpose-Oligodendrogenesis is essential for white matter repair after stroke. Although agonists of peroxisome proliferator-activated receptors. confer neuroprotection in models of cerebral ischemia, it is not known whether this effect extends to white matter protection. This study tested the hypothesis that the peroxisome proliferator-activated receptors. agonist rosiglitazone enhances oligodendrogenesis and improves long-term white matter integrity after ischemia/reperfusion. Methods-Male adult C57/BL6 mice (25-30 g) were subjected to 60-minute middle cerebral artery occlusion and reperfusion. Rosiglitazone (3 mg/kg) was injected intraperitoneally once daily for 14 days beginning 2 hours after reperfusion. Sensorimotor and cognitive functions were evaluated <= 21 days after middle cerebral artery occlusion. Immunostaining was used to assess infarct volume, myelin loss, and microglial activation. Bromodeoxyuridine (BrdU) was injected for measurements of proliferating NG2(+) oligodendrocyte precursor cells (OPCs) and newly generated adenomatous polyposis coli(+) oligodendrocytes. Mixed glial cultures were used to confirm the effect of rosiglitazone on oligodendrocyte differentiation and microglial polarization. Results-Rosiglitazone significantly reduced brain tissue loss, ameliorated white matter injury, and improved sensorimotor and cognitive functions for at least 21 days after middle cerebral artery occlusion. Rosiglitazone enhanced OPC proliferation and increased the numbers of newly generated mature oligodendrocytes after middle cerebral artery occlusion. Rosiglitazone treatment also reduced the numbers of Iba1(+)/CD16(+) M1 microglia and increased the numbers of Iba1(+)/CD206(+) M2 microglia after stroke. Glial culture experiments confirmed that rosiglitazone promoted oligodendrocyte differentiation, perhaps by promoting microglial M2 polarization. Conclusions-Rosiglitazone treatment improves long-term white matter integrity after cerebral ischemia, at least, in part, by promoting oligodendrogenesis and facilitating microglial polarization toward the beneficial M2 phenotype. C1 [Han, Lijuan; Xu, Yun] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurol, Nanjing 21008, Jiangsu, Peoples R China. [Han, Lijuan; Cai, Wei; Mao, Leilei; Hu, Xiaoming; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Liu, Jia; Li, Peiying; Hu, Xiaoming; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Liu, Jia; Li, Peiying; Hu, Xiaoming; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Cai, Wei] Sun Yat Sen Univ, Affiliated Hosp 3, Multiple Sclerosis Ctr, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. EM xuyun20042001@aliyun.com; chenj2@upmc.edu OI Leak, Rehana/0000-0003-2817-7417 FU National institutes of Health/National Institute of neurological disorders and stroke [NS095671, NS045048, NS036736, NS089534, NS092618]; US Department of Veterans Affairs Research Career Scientist Award and RRD Merit Review [I01RX000420]; American Heart Association [13SDG14570025]; Chinese Scholarship Council; China Natural Science Foundation [81230026, 81171085]; Science and Technology Commission of Shanghai Municipality [13ZR1452200]; National Natural Science Foundation [81400956] FX This work was supported by the National institutes of Health/National Institute of neurological disorders and stroke grants NS095671, NS045048, NS036736, and NS089534 (to Dr Chen) and NS092618 (to Dr Hu), US Department of Veterans Affairs Research Career Scientist Award and RR&D Merit Review I01RX000420 (to Dr Chen), and grant 13SDG14570025 from the American Heart Association (to Dr Hu). Dr Han was supported by predoctoral fellowship from the Chinese Scholarship Council. Dr Xu was supported by China Natural Science Foundation grants (No. 81230026 and No. 81171085). Dr Li was supported by the Science and Technology Commission of Shanghai Municipality (13ZR1452200) and National Natural Science Foundation grant (No. 81400956). NR 36 TC 11 Z9 11 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD SEP PY 2015 VL 46 IS 9 BP 2628 EP 2636 DI 10.1161/STROKEAHA.115.010091 PG 9 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA CQ9FZ UT WOS:000360919700046 PM 26243225 ER PT J AU Mishra, R Roux, BM Posukonis, M Bodamer, E Brey, EM Fisher, JP Dean, D AF Mishra, R. Roux, B. M. Posukonis, M. Bodamer, E. Brey, E. M. Fisher, J. P. Dean, D. TI Effect of HUVEC/hMSC Pre-culture on Vascularization of Fibrin-Loaded Poly(propylene Fumarate) Scaffolds In Vitro and In Vivo SO TISSUE ENGINEERING PART A LA English DT Meeting Abstract CT 4th TERMIS World Congress CY SEP 08-11, 2015 CL Boston, MA SP TERMIS C1 [Mishra, R.; Posukonis, M.; Bodamer, E.; Dean, D.] Ohio State Univ, Plast Surg, Columbus, OH 43210 USA. [Roux, B. M.; Brey, E. M.] IIT, Biomed Engn, Chicago, IL 60616 USA. [Roux, B. M.; Brey, E. M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Fisher, J. P.] Univ Maryland, Bioengn, College Pk, MD 20742 USA. NR 0 TC 0 Z9 0 U1 5 U2 9 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD SEP 1 PY 2015 VL 21 SU 1 BP S361 EP S361 PG 1 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA CP9HR UT WOS:000360205202506 ER PT J AU Roux, BM Gandhi, JK Brey, EM AF Roux, B. M. Gandhi, J. K. Brey, E. M. TI Evaluation of MSC Source on Angiogenesis in 3D Co-Culture SO TISSUE ENGINEERING PART A LA English DT Meeting Abstract CT 4th TERMIS World Congress CY SEP 08-11, 2015 CL Boston, MA SP TERMIS C1 [Roux, B. M.; Gandhi, J. K.; Brey, E. M.] IIT, Biomed Engn, Chicago, IL 60616 USA. [Roux, B. M.; Gandhi, J. K.; Brey, E. M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 3 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD SEP 1 PY 2015 VL 21 SU 1 BP S156 EP S157 PG 2 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA CP9HR UT WOS:000360205201212 ER PT J AU Lehavot, K O'Hara, R Washington, DL Yano, EM Simpson, TL AF Lehavot, Keren O'Hara, Ruth Washington, Donna L. Yano, Elizabeth M. Simpson, Tracy L. TI Posttraumatic Stress Disorder Symptom Severity and Socioeconomic Factors Associated with Veterans Health Administration Use among Women Veterans SO WOMENS HEALTH ISSUES LA English DT Article ID FEMALE VETERANS; PTSD RISK; CARE; VALIDITY; SAMPLE; RELIABILITY; DEPRESSION; PROJECT; NEED AB Background: The Veterans Health Administration (VA) has historically focused on treating men. Although women veterans' VA use is increasing, they remain more likely than male veterans to receive their care in non-VA settings. To date, there is limited research on factors associated with VA use among women. We examined the relationship between demographic, civilian, military, and health-related variables with past-year VA use among women veterans. Methods: Women veterans were recruited over the internet to participate in an anonymous national survey (n = 617) in 2013. An empirically derived decision tree was computed using signal detection software for iterative receiver operator characteristics (ROC) to identify variables with the best sensitivity/specificity balance associated with past-year VA use. Results: ROC analysis indicated that 85% of participants with high posttraumatic stress disorder (PTSD) and depressive symptoms and who were younger than 54 years of age used VA in the past year. Of those who were 54 years of age or older and had very high PTSD symptoms, 94% used the VA in the last year. By contrast, only 40% of participants with relatively lower PTSD symptoms had VA past-year use, although among these individuals, VA past-year use increased to 65% for those with a relatively lower income. Conclusions: Findings suggest that greater PTSD symptoms, depressive symptoms, and low income correlate with VA use, with very high PTSD symptoms in older groups, high PTSD symptoms coupled with high depressive symptoms in younger groups, and low income in those with lower PTSD symptoms each associated with greater past-year VA use. Ensuring PTSD assessment and treatment, and addressing socioeconomic factors, may be key strategies for health care delivered directly or through contract with VA facilities. Published by Elsevier Inc. C1 [Lehavot, Keren] VA Puget Sound Hlth Care Syst, HSR&D, Ctr Innovat COIN, Seattle, WA 98108 USA. [Lehavot, Keren; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA 98108 USA. [Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [O'Hara, Ruth] Palo Alto VA Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA. [O'Hara, Ruth] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Washington, Donna L.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Sepulveda, CA USA. [Washington, Donna L.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA 98108 USA. RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, 116-POC,1660 S Columbian Way, Seattle, WA 98108 USA. EM klehavot@uw.edu FU VISN-20 Mental Illness Research, Education, and Clinical Center (MIRECC); VA CSR&D Career Development Award [IK2 CX000867]; VA HSR&D Service Senior Research Career Scientist award [RCS 05-195] FX This research was supported by a research grant to Drs. Lehavot and Simpson from the VISN-20 Mental Illness Research, Education, and Clinical Center (MIRECC). Dr. Lehavot's effort was supported by a VA CSR&D Career Development Award (IK2 CX000867) and Dr. Yano's effort was supported by a VA HSR&D Service Senior Research Career Scientist award (Project # RCS 05-195). NR 40 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD SEP-OCT PY 2015 VL 25 IS 5 BP 535 EP 541 DI 10.1016/j.whi.2015.05.003 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA CR1CM UT WOS:000361060400016 PM 26123641 ER PT J AU Callegari, LS Borrero, S Reiber, GE Nelson, KM Zephyrin, L Sayre, GG Katon, JG AF Callegari, Lisa S. Borrero, Sonya Reiber, Gayle E. Nelson, Karin M. Zephyrin, Laurie Sayre, George G. Katon, Jodie G. TI Reproductive Life Planning in Primary Care: A Qualitative Study of Women Veterans' Perceptions SO WOMENS HEALTH ISSUES LA English DT Article ID SHARED DECISION-MAKING; VA HEALTH-CARE; UNITED-STATES; PRECONCEPTION HEALTH; PREFERENCES; RECOMMENDATIONS; CONTRACEPTION; EXPERIENCES; PREGNANCY; MILITARY AB Background: Women veterans using Veterans Administration (VA) health care have high rates of medical and mental health comorbidities, placing them at increased risk of poor outcomes from unplanned pregnancy. Reproductive life planning is a strategy recommended by the U.S. Centers of Disease Control and Prevention that could promote healthy pregnancies and reduce unplanned pregnancy in the VA. However, no data exist on women veterans' perceptions of reproductive life planning discussions. Methods: We trained six VA primary care physicians at two VA Women's Health Clinics to conduct reproductive life planning discussions with veterans aged 18 to 44 during primary care visits. After the visit, we performed semi-structured telephone interviews with consenting veterans to explore perceptions of 1) reproductive life planning content and 2) provider-patient communication in reproductive life planning discussions. Interviews were audio-recorded, transcribed, and analyzed using content analysis. Results: We interviewed 27 veterans with a mean age of 31 years (range, 22-42). Women veterans perceived generally reproductive life planning discussions as important opportunities to discuss reproductive goals with providers and to obtain new and relevant information about contraception, planning healthy pregnancies, and available VA reproductive health services. Perceptions of reproductive life planning content were influenced by women's pregnancy intentions. Perceptions related to provider-patient communication included preferences for provider-initiated discussions and nonjudgmental counseling that incorporates patients' values and preferences. Conclusions: Women veterans perceived reproductive life planning as valuable and important to their health. Reproductive life planning has the potential to enhance patient-centered delivery of reproductive health services in VA primary care. Published by Elsevier Inc. C1 [Callegari, Lisa S.; Reiber, Gayle E.; Nelson, Karin M.; Sayre, George G.; Katon, Jodie G.] Dept Vet Affairs VA Puget Sound Hlth Care Syst Hl, Seattle, WA USA. [Callegari, Lisa S.] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Borrero, Sonya] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Borrero, Sonya] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA. [Reiber, Gayle E.; Nelson, Karin M.; Sayre, George G.; Katon, Jodie G.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA. [Nelson, Karin M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Zephyrin, Laurie] Womens Hlth Serv, VA Off Patient Care Serv, Washington, DC USA. [Zephyrin, Laurie] NYU, Dept Obstet & Gynecol, Langone Sch Med, New York, NY 10016 USA. RP Callegari, LS (reprint author), VA Puget Sound Hlth Care Syst, Seattle HSR&D Ctr, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM lisa.callegari@va.gov FU Department of Veterans Affairs (VA) National Office of Patient Care Services, Office of Women's Health and Office of Public Health; VA Health Services Research and Development Postdoctoral Fellowship [TPM 61-041] FX The authors acknowledge Marie Lutton for her assistance with patient recruitment, interviewing, and data management. The authors also acknowledge the generous VA clinicians and veterans who donated their time to participate in the project. This study was supported by a quality improvement grant from the Department of Veterans Affairs (VA) National Office of Patient Care Services, Office of Women's Health and Office of Public Health. L.S.C. was supported by a VA Health Services Research and Development Postdoctoral Fellowship (TPM 61-041). NR 36 TC 3 Z9 3 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD SEP-OCT PY 2015 VL 25 IS 5 BP 548 EP 554 DI 10.1016/j.whi.2015.05.002 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA CR1CM UT WOS:000361060400018 PM 26123640 ER PT J AU Maezawa, Y Paltser, G Tsui, H Cheung, R Wu, P Nicholas, AP Dosch, HM AF Maezawa, Y. Paltser, G. Tsui, H. Cheung, R. Wu, P. Nicholas, A. P. Dosch, H. -M. TI 2-Chloroacetamidine, a novel immunomodulator, suppresses antigen-induced mouse airway inflammation SO ALLERGY LA English DT Article DE animal model; asthma; protein citrullination; T cell ID PEPTIDYLARGININE-DEIMINASE; CITRULLINATED PROTEINS; T-CELLS; ASTHMA; PATHOGENESIS; INVOLVEMENT; EXPRESSION; APOPTOSIS; RESPONSES; FEATURES AB BackgroundCitrullination is a presently under-recognized posttranslational protein modification catalyzed by PAD enzymes. Immune responses to citrullinated neo-epitopes are identified in a growing number of inflammatory and autoimmune diseases. However, the involvement of hypercitrullination in the pathogenesis of bronchial asthma is still unknown. MethodsAs main experimental tool, we examined the effect of 2-chloroacetamidine (2CA), a PAD enzyme inhibitor, on OVA-immunized and airway-challenged BALB/c mice; a commonly used model of allergic airway inflammation. We also measured the effect of 2CA on exvivo lymphocytes and cell lines. ResultsIn vivo, 2CA dramatically suppressed lung tissue hypercitrullination, inflammatory cell recruitment, and airway-Th2 cytokine secretion. 2CA also suppressed systemic OVA-specific and total IgE production dramatically, effectively preventing de novo and diminishing established disease without measurably impacting general immunocompetence. In vitro, 2CA markedly inhibited the proliferation of mouse and human T cells with cell cycle block and apoptosis during a limited, postactivation phase. Conclusions2CA acts as narrow-spectrum immunosuppressant that selectively targets lymphocyte populations involved in active inflammatory tissue lesions. If hypercitrullination is generated in patients with asthma, 2CA may represent a novel disease modulator for human asthmatics/allergic diseases. C1 [Maezawa, Y.; Paltser, G.; Tsui, H.; Cheung, R.; Wu, P.; Dosch, H. -M.] Univ Toronto, Hosp Sick Children, Res Inst, Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada. [Nicholas, A. P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Nicholas, A. P.] Univ Alabama Birmingham, Ctr Neuroimmunol, Birmingham, AL USA. [Nicholas, A. P.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Dosch, HM (reprint author), Univ Toronto, Hosp Sick Children, NMH Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM michael.dosch@me.com NR 25 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-4538 EI 1398-9995 J9 ALLERGY JI Allergy PD SEP PY 2015 VL 70 IS 9 BP 1130 EP 1138 DI 10.1111/all.12651 PG 9 WC Allergy; Immunology SC Allergy; Immunology GA CQ2QW UT WOS:000360447200011 PM 25969859 ER PT J AU Zhao, JY An, Q Goldberg, J Quyyumi, AA Vaccarino, V AF Zhao, Jinying An, Qiang Goldberg, Jack Quyyumi, Arshed A. Vaccarino, Viola TI Promoter methylation of glucocorticoid receptor gene is associated with subclinical atherosclerosis: A monozygotic twin study SO ATHEROSCLEROSIS LA English DT Article DE DNA methylation; NR3C1; Subclinical atherosclerosis; Monozygotic twins ID SEROTONIN TRANSPORTER GENE; PITUITARY-ADRENAL AXIS; FLOW-MEDIATED DILATION; DNA METHYLATION; EPIGENETIC INHERITANCE; CARDIOVASCULAR-DISEASE; ENDOTHELIAL FUNCTION; BRACHIAL-ARTERY; HEART-DISEASE; RISK AB Objective: Endothelial dysfunction assessed by brachial artery flow-mediated dilation (FMD) is a marker of early atherosclerosis. Glucocorticoid receptor gene (NR3C1) regulates many biological processes, including stress response, behavioral, cardiometabolic and immunologic functions. Genetic variants in NR3C1 have been associated with atherosclerosis and related risk factors. This study investigated the association of NR3C1 promoter methylation with FMD, independent of genetic and family-level environmental factors. Methods: We studied 84 middle-aged, male-male monozygotic twin pairs recruited from the Vietnam Era Twin Registry. Brachial artery FMD was measured by ultrasound. DNA methylation levels at 22 CpG residues in the NR3C1 exon 1F promoter region were quantified by bisulfite pyrosequencing in genomic DNA isolated from peripheral blood leukocytes. Co-twin control analyses were conducted to examine the association of methylation variation with FMD, adjusting for smoking, physical activity, body mass index, lipids, blood pressure, fasting glucose, and depressive symptoms. Multiple testing was corrected using the false discovery rate. Results: Mean methylation level across the 22 studied CpG sites was 2.02%. Methylation alterations at 12 out of the 22 CpG residues were significantly associated with FMD. On average, a 1% increase in the intra-pair difference in mean DNA methylation was associated with 2.83% increase in the intra-pair difference in FMD (95% CI: 1.46-4.20; P < 0.0001) after adjusting for risk factors and multiple testing. Conclusion: Methylation variation in NR3C1 exon 1F promoter significantly influences subclinical atherosclerosis, independent of genetic, early family environmental and other risk factors. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Zhao, Jinying; An, Qiang] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA. [Goldberg, Jack] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Goldberg, Jack] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Quyyumi, Arshed A.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Vaccarino, Viola] Emory Univ, Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA. RP Zhao, JY (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1440 Canal St,Suite 2000-SL18, New Orleans, LA 70112 USA. EM jzhao5@tulane.edu FU NIH [R01MH097018, R21HL092363, K01AG034259, K24HL077506, R01HL68630, R01AG026255]; United States Department of Veterans Affairs FX This study was supported by NIH grants R01MH097018, R21HL092363, and K01AG034259 (Dr. Zhao), and grants K24HL077506, R01HL68630 and R01AG026255 (Dr. Vaccarino).; The United States Department of Veterans Affairs has provided financial support for the development and maintenance of the Vietnam Era Twin (VET) Registry. Numerous organizations have provided invaluable assistance in the conduct of this study, including: Department of Defense; National Personnel Records Center, National Archives and Records Administration; the Internal Revenue Service; National Institutes of Health; National Opinion Research Center; National Research Council, National Academy of Sciences; the Institute for Survey Research, Temple University. Most importantly, the authors gratefully acknowledge the continued cooperation and participation of the members of the VET Registry and their families. Without their contribution this research would not have been possible. NR 48 TC 2 Z9 2 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD SEP PY 2015 VL 242 IS 1 BP 71 EP 76 DI 10.1016/j.atherosclerosis.2015.07.007 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CP7WU UT WOS:000360100900012 PM 26186654 ER PT J AU Quispe, R Manalac, RJ Faridi, KF Blaha, MJ Toth, PP Kulkarni, KR Nasir, K Virani, SS Banach, M Blumenthal, RS Martin, SS Jones, SR AF Quispe, Renato Manalac, Raoul J. Faridi, Kamil F. Blaha, Michael J. Toth, Peter P. Kulkarni, Krishnaji R. Nasir, Khurram Virani, Salim S. Banach, Maciej Blumenthal, Roger S. Martin, Seth S. Jones, Steven R. TI Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study SO ATHEROSCLEROSIS LA English DT Article DE Triglycerides; High-density lipoprotein cholesterol; TG/HDL-C ratio; Lipids; Cut-off points; Remnant lipoprotein particle cholesterol ID CORONARY-ARTERY-DISEASE; ISCHEMIC-HEART-DISEASE; LOW-GRADE INFLAMMATION; HDL-CHOLESTEROL; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; POSTMENOPAUSAL WOMEN; REMNANT CHOLESTEROL; LDL-CHOLESTEROL; MYOCARDIAL-INFARCTION AB Background: High levels of the triglycerides to high-density lipoprotein cholesterol (TG/HDL-C) ratio are associated with obesity, metabolic syndrome, and insulin resistance. Objectives: We evaluated variability in the remaining lipid profile, especially remnant lipoprotein particle cholesterol (RLP-C) and its components (very low-density lipoprotein cholesterol subfraction 3 and intermediate-density lipoprotein cholesterol), with variability in the TG/HDL-C ratio in a very large study cohort representative of the general U.S. population. Methods: We examined data from 1,350,908 US individuals who were clinically referred for lipoprotein cholesterol ultracentrifugation (Atherotech, Birmingham, AL) from 2009 to 2011. Demographic information other than age and sex was not available. Changes to the remaining lipid profile across percentiles of the TG/HDL-C ratio were quantified, as well as by three TG/HDL-C cut-off points previously proposed in the literature: 2.5 (male) and 2 (female), 3.75 (male) and 3 (female), and 3.5 (male and female). Results: The mean age of our study population was 58.7 years, and 48% were men. The median TG/HDL-C ratio was 2.2. Across increasing TG/HDL-C ratios, we found steadily increasing levels of RLP-C, non-HDL-C and LDL density. Among the lipid parameters studied, RLP-C and LDL density had the highest relative increase when comparing individuals with elevated TG/HDL-C levels to those with lower TG/HDL-C levels using established cut-off points. Approximately 47% of TG/HDL-C ratio variance was attributable to RLP-C. Conclusions: In the present analysis, a higher TG/HDL-C ratio was associated with an increasingly atherogenic lipid phenotype, characterized by higher RLP-C along with higher non-HDL-C and LDL density. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Quispe, Renato; Manalac, Raoul J.; Faridi, Kamil F.; Blaha, Michael J.; Toth, Peter P.; Nasir, Khurram; Blumenthal, Roger S.; Martin, Seth S.; Jones, Steven R.] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD 21287 USA. [Toth, Peter P.] CGH Med Ctr, Dept Prevent Cardiol, Sterling, IL USA. [Toth, Peter P.] Univ Illinois, Coll Med, Peoria, IL 61656 USA. [Kulkarni, Krishnaji R.] Atherotech Diagnost Lab, Birmingham, AL USA. [Nasir, Khurram] Univ Miami, South Beach Prevent Cardiol Ctr, Miami, FL USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA. [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Lodz, Poland. RP Quispe, R (reprint author), Johns Hopkins Ciccarone Ctr Prevent Heart Dis, 600 N Wolfe St,Blalock 524-C, Baltimore, MD 21287 USA. EM jquispe1@jhmi.edu RI Banach, Maciej/A-1271-2009 OI Banach, Maciej/0000-0001-6690-6874; Virani, Salim/0000-0001-9541-6954 FU Atherotech FX Dr. Blaha served on an Advisory Board for Pfizer. Dr. Toth reports consulting for Amgen, AstraZeneca, Atherotech, GlaxoSmithKline, Kowa, Liposcience, and Merck; serving on the speakers bureau for Amarin, AstraZeneca, Genzyme, Kowa, Merck. Dr. Kulkarni is a research director at Atherotech Diagnostics Lab; owns uncashable stocks for Atherotech Diagnostics Labs; and receives modest royalties from the University of Alabama at Birmingham. Dr. Nasir served on an Advisory Board for Quest Diagnostic. Dr Jones reports serving on the medical advisory board for, and receiving grant funding from, Atherotech. Drs. Quispe, Manalac, Faridi, Virani, Banach, Blumenthal, and Martin have nothing to disclose. NR 60 TC 8 Z9 9 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD SEP PY 2015 VL 242 IS 1 BP 243 EP 250 DI 10.1016/j.atherosclerosis.2015.06.057 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CP7WU UT WOS:000360100900039 PM 26232164 ER PT J AU Kim, E Zeng, DL Zhou, XH AF Kim, Eunhee Zeng, Donglin Zhou, Xiao-Hua TI Semiparametric transformation models for multiple continuous biomarkers in ROC analysis SO BIOMETRICAL JOURNAL LA English DT Article DE Biomarkers; ROC analysis; Nonparametric maximum likelihood estimation; Semiparametric efficiency; Transformation models ID OPERATING CHARACTERISTIC CURVE; MAXIMUM-LIKELIHOOD-ESTIMATION; CENSORED-DATA; EM ALGORITHM; INFERENCE; SUBJECT; MARKERS; CLASSIFICATION; DISEASE; LIMITS AB Recent technological advances continue to provide noninvasive and more accurate biomarkers for evaluating disease status. One standard tool for assessing the accuracy of diagnostic tests is the receiver operating characteristic (ROC) curve. Few statistical methods exist to accommodate multiple continuous-scale biomarkers in the framework of ROC analysis. In this paper, we propose a method to integrate continuous-scale biomarkers to optimize classification accuracy. Specifically, we develop semiparametric transformation models formultiple biomarkers. We assume that unknown and marker-specific transformations of biomarkers follow a multivariate normal distribution. Our models accommodate biomarkers subject to limits of detection and account for the dependence among biomarkers by including a subject-specific random effect. We also propose a diagnostic measure using an optimal linear combination of the transformed biomarkers. Our diagnostic rule does not depend on any monotone transformation of biomarkers and is not sensitive to extreme biomarker values. Nonparametric maximum likelihood estimation (NPMLE) is used for inference. We show that the parameter estimators are asymptotically normal and efficient. We illustrate our semiparametric approach using data from the Endometriosis, Natural History, Diagnosis, and Outcomes (ENDO) study. C1 [Kim, Eunhee] Brown Univ, Dept Biostat, Providence, RI 02912 USA. [Kim, Eunhee] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA. [Zeng, Donglin] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA. [Zhou, Xiao-Hua] Univ Washington, VA Puget Sound Hlth Care Syst, HSRD Ctr Excellence, Seattle, WA 98198 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98198 USA. RP Kim, E (reprint author), Brown Univ, Dept Biostat, Providence, RI 02912 USA. EM ekim@stat.brown.edu FU Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child and Human Development, National Institute of Heath [NO1-DK-6-3428, NO1-DK-6-3427, 10001406-02] FX The authors thank Zhen Chen for his valuable comments and suggestions and Youdan Wang for providing programming support. This research was supported in part by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child and Human Development, National Institute of Heath (contracts #NO1-DK-6-3428; NO1-DK-6-3427; 10001406-02; 10001406-02). NR 37 TC 0 Z9 0 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0323-3847 EI 1521-4036 J9 BIOMETRICAL J JI Biom. J. PD SEP PY 2015 VL 57 IS 5 BP 808 EP 833 DI 10.1002/bimj.201400043 PG 26 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA CQ7CA UT WOS:000360759200006 PM 26138227 ER PT J AU Zhu, X Waldron, R Lugea, A Li, L AF Zhu, X. Waldron, R. Lugea, A. Li, L. TI Insulin and IGF-1 promote pancreatic stellate cells activation and galectin-3 expression: potential role in promotion of pancreatic cancer SO DIABETOLOGIA LA English DT Meeting Abstract CT 51st Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) CY SEP 14-18, 2015 CL Stockholm, SWEDEN SP European Assoc Study Diabet C1 [Zhu, X.; Li, L.] Southeast Univ, Dept Endocrinol, Affiliated ZhongDa Hosp, Nanjing, Jiangsu, Peoples R China. [Waldron, R.; Lugea, A.; Li, L.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Waldron, R.; Lugea, A.; Li, L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 3 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2015 VL 58 SU 1 MA 699 BP S334 EP S334 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CP3ZE UT WOS:000359820901388 ER PT J AU Ambrecht, LA Perlman, JI McDonnell, JF Zhai, YG Qiao, L Bu, P AF Ambrecht, Lindsay A. Perlman, Jay I. McDonnell, James F. Zhai, Yougang Qiao, Liang Bu, Ping TI Protection of retinal function by sulforaphane following retinal ischemic injury SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE Sulforaphane; Retinal ischemic reperfusion injury; Electroretinography; Neuroprotection; Retinal morphology ID NRF2-DEPENDENT PHASE-2 ENZYME; REPERFUSION INJURY; INDUCTION; NEURONS; ELEMENT; DAMAGE; NRF2; MICE AB Sulforaphane, a precursor of glucosinolate in cruciferous vegetables such as broccoli and cauliflower, has been shown to protect brain ischemic injury. In this study, we examined the effect of systemic administration of sulforaphane on retinal ischemic reperfusion injury. Intraocular pressure was elevated in two groups of C57BL/6 mice (n = 8 per group) for 45 min to induce retinal ischemic reperfusion injury. Following retinal ischemic reperfusion injury, vehicle (I% DMSO saline) or sulforaphane (25 mg/kg/day) was administered intraperitoneally daily for 5 days. Scotopic electroretinography (ERG) was used to quantify retinal function prior to and one-week after retinal ischemic insult. Retinal morphology was examined one week after ischemic insult. Following ischemic reperfusion injury, ERG a- and b-wave amplitudes were significantly reduced in the control mice. Sulforaphane treatment significantly attenuated ischemic-induced loss of retinal function as compared to vehicle treated mice. In vehicle treated mice, ischemic reperfusion injury produced marked thinning of the inner retinal layers, but the thinning of the inner retinal layers appeared significantly less with sulforaphane treatment. Thus, sulforaphane may be beneficial in the treatment of retinal disorders with ischemic reperfusion injury. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Ambrecht, Lindsay A.; Perlman, Jay I.; McDonnell, James F.; Bu, Ping] Loyola Univ Chicago, Dept Ophthalmol, Maywood, IL 60153 USA. [Perlman, Jay I.] Loyola Univ Chicago, Dept Pathol, Maywood, IL 60153 USA. [Zhai, Yougang; Qiao, Liang] Loyola Univ Chicago, Dept Microbiol & Immunol, Maywood, IL 60153 USA. [Bu, Ping] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Perlman, Jay I.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv, Hines, IL 60141 USA. RP Bu, P (reprint author), Loyola Univ Chicago, Dept Ophthalmol, 2160 S First Ave, Maywood, IL 60153 USA. EM pbu@luc.edu FU Richard A. Perritt Charitable Foundation; Illinois Society for the Prevention of Blindness; American Society of Cataract and Refractive Surgery FX The authors thank Dr. Xiaorong Liu for her suggestions. This work was supported by The Richard A. Perritt Charitable Foundation, Illinois Society for the Prevention of Blindness, and American Society of Cataract and Refractive Surgery. NR 21 TC 3 Z9 4 U1 2 U2 3 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 EI 1096-0007 J9 EXP EYE RES JI Exp. Eye Res. PD SEP PY 2015 VL 138 BP 66 EP 69 DI 10.1016/j.exer.2015.06.030 PG 4 WC Ophthalmology SC Ophthalmology GA CQ7IV UT WOS:000360777100008 PM 26142954 ER PT J AU Osborn-Heaford, HL Murthy, S Gu, LL Larson-Casey, JL Ryan, AJ Shi, L Glogauer, M Neighbors, JD Hohl, R Carter, AB AF Osborn-Heaford, Heather L. Murthy, Shubha Gu, Linlin Larson-Casey, Jennifer L. Ryan, Alan J. Shi, Lei Glogauer, Michael Neighbors, Jeffrey D. Hohl, Raymond Carter, A. Brent TI Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Macrophage; Reactive oxygen species; Mitochondria; Pulmonary fibrosis; Rac1; Isoprenoid; Pathway ID COA REDUCTASE INHIBITOR; OXIDATIVE STRESS; EXTRACELLULAR-MATRIX; IN-VIVO; MACROPHAGES; RAC1; FIBROBLASTS; ACTIVATION; APOPTOSIS; SURVIVAL AB Fibrotic remodeling in lung injury is a major cause of morbidity. The mechanism that mediates the ongoing fibrosis is unclear, and there is no available treatment to abate the aberrant repair. Reactive oxygen species (ROS) have a critical role in inducing fibrosis by modulating extracellular matrix deposition. Specifically, mitochondrial hydrogen peroxide (H2O2) production by alveolar macrophages is directly linked to pulmonary fibrosis as inhibition of mitochondrial H2O2 attenuates the fibrotic response in mice. Prior studies indicate that the small GTP-binding protein, Rac1, directly mediates H2O2 generation in the mitochondrial intermembrane space. Geranylgeranylation of the C-terminal cysteine residue (Cys(189)) is required for Rac1 activation and mitochondria! import. We hypothesized that impairment of geranylgeranylation would limit mitochondrial oxidative stress and, thus, abrogate progression of pulmonary fibrosis. By targeting the isoprenoid pathway with a novel agent, digeranyl bisphosphonate (DGBP), which impairs geranylgeranylation, we demonstrate that Rac1 mitochondrial import, mitochondrial oxidative stress, and progression of the fibrotic response to lung injury are significantly attenuated. These observations reveal that targeting the isoprenoid pathway to alter Rac1 geranylgeranylation halts the progression of pulmonary fibrosis after lung injury. (C) 2015 Elsevier Inc. All rights reserved. C1 [Osborn-Heaford, Heather L.; Murthy, Shubha; Ryan, Alan J.; Hohl, Raymond; Carter, A. Brent] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. [Gu, Linlin; Larson-Casey, Jennifer L.; Carter, A. Brent] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Larson-Casey, Jennifer L.; Carter, A. Brent] Univ Iowa, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA. [Shi, Lei; Carter, A. Brent] Univ Iowa, Human Toxicol Program, Iowa City, IA 52242 USA. [Glogauer, Michael] Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON, Canada. [Neighbors, Jeffrey D.] Univ Iowa, Dept Chem, Iowa City, IA 52242 USA. [Hohl, Raymond] Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA. [Carter, A. Brent] Iowa City VA Healthcare Syst, Iowa City, IA USA. [Carter, A. Brent] Birmingham VAMC, Birmingham, AL USA. RP Carter, AB (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham VAMC, 1918 Univ Blvd,404 MCLM, Birmingham, AL 35294 USA. EM bcarter1@uab.edu OI Larson-Casey, Jennifer L./0000-0001-7238-7986 FU National Institutes of Health [2R01ES015981-07, R01ES014871]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development [1BX001135-01] FX This work was supported, in whole or in part, by National Institutes of Health Grants 2R01ES015981-07 and R01ES014871. This work was also supported by a Merit Review from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Grant 1BX001135-01. NR 58 TC 2 Z9 2 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD SEP PY 2015 VL 86 BP 47 EP 56 DI 10.1016/j.freeradbiomed.2015.04.031 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA CQ4JA UT WOS:000360569700005 PM 25958207 ER PT J AU Sadowska, GB Chen, XD Zhang, JY Lim, YP Cummings, EE Makeyev, O Besio, WG Gaitanis, J Padbury, JF Banks, WA Stonestreet, BS AF Sadowska, Grazyna B. Chen, Xiaodi Zhang, Jiyong Lim, Yow-Pin Cummings, Erin E. Makeyev, Oleksandr Besio, Walter G. Gaitanis, John Padbury, James F. Banks, William A. Stonestreet, Barbara S. TI Interleukin-1 beta transfer across the blood-brain barrier in the ovine fetus SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE blood-brain barrier; brain; cytokines; fetus; hypoxia-ischemia; sheep ID NECROSIS-FACTOR-ALPHA; PROTEIN EXPRESSION; WHITE-MATTER; NEONATAL-RAT; TRANSPORT; CYTOKINES; ISCHEMIA; INJURY; MECHANISM; MOUSE AB Pro-inflammatory cytokines contribute to hypoxic-ischemic brain injury. Blood-brain barrier (BBB) dysfunction represents an important component of hypoxic-ischemic brain injury in the fetus. Hypoxic-ischemic injury could accentuate systemic cytokine transfer across the fetal BBB. There has been considerable conjecture suggesting that systemic cytokines could cross the BBB during the perinatal period. Nonetheless, evidence to support this contention is sparse. We hypothesized that ischemia-reperfusion increases the transfer of systemic interleukin-1 beta (IL-1 beta) across the BBB in the fetus. Ovine fetuses at 127 days of gestation were studied 4 hours after 30 minutes of bilateral carotid artery occlusion and compared with a nonischemic group. Recombinant ovine IL-1 beta protein was expressed from an IL-1 beta pGEX-2 T vector in E. coli BL-21 cells and purified. The BBB function was quantified in 12 brain regions using a blood-to-brain transfer constant with intravenous I-125-radiolabeled IL-1 beta (I-125-IL-1 beta). Interleukin-1 beta crossed the intact BBB in nonischemic fetuses. Blood-to-brain transport of I-125-IL-1 beta was higher (P < 0.05) across brain regions in fetuses exposed to ischemia-reperfusion than nonischemic fetuses. We conclude that systemic IL-1 beta crosses the intact fetal BBB, and that ischemia-reperfusion increases transfer of this cytokine across the fetal BBB. Therefore, altered BBB function after hypoxia-ischemia facilitates entry of systemic cytokines into the brain of the fetus. C1 [Sadowska, Grazyna B.; Chen, Xiaodi; Zhang, Jiyong; Cummings, Erin E.; Padbury, James F.; Stonestreet, Barbara S.] Brown Univ, Alpert Med Sch, Women & Infants Hosp Rhode Isl, Dept Pediat, Providence, RI 02905 USA. [Lim, Yow-Pin] ProThera Biol Inc, Providence, RI USA. [Makeyev, Oleksandr; Besio, Walter G.] Univ Rhode Isl, Dept Elect Comp & Biomed Engn, Kingston, RI 02881 USA. [Gaitanis, John] Brown Univ, Alpert Med Sch, Rhode Isl Hosp, Dept Neurol, Providence, RI 02905 USA. [Banks, William A.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Div Gerontol & Geriatr Med,Geriatr Res Educ & Cli, Seattle, WA USA. RP Stonestreet, BS (reprint author), Brown Univ, Alpert Med Sch, Women & Infants Hosp Rhode Isl, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA. EM bstonestreet@wihri.org FU National Institute of General Medical Sciences of the National Institutes of Health [1R01-HD-057100, P20 RR018728, P20GM103537]; American Heart Association [13POST16860015] FX Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 1R01-HD-057100, by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20 RR018728 and P20GM103537, and by a postdoctoral fellowship award (JZ) from the American Heart Association under grant number 13POST16860015. NR 46 TC 3 Z9 3 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD SEP PY 2015 VL 35 IS 9 BP 1388 EP 1395 DI 10.1038/jcbfm.2015.134 PG 8 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA CQ6BN UT WOS:000360689500002 PM 26082012 ER PT J AU Wang, SY Aldridge, MD Gross, CP Canavan, M Cherlin, E Johnson-Hurzeler, R Bradley, E AF Wang, Shi-Yi Aldridge, Melissa D. Gross, Cary P. Canavan, Maureen Cherlin, Emily Johnson-Hurzeler, Rosemary Bradley, Elizabeth TI Geographic Variation of Hospice Use Patterns at the End of Life SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID CARE; CANCER; DEATH; QUALITY; INDICATORS; DEPRESSION; ENROLLMENT; CAREGIVERS; BENEFIT; LENGTH AB Background: Little is known about state-level variation in patterns of hospice use, an important indicator of quality of care at the end of life. Findings may identify states where targeted efforts for improving end-of-life care may be warranted. Objective: Our aim was to characterize the state-level variation in patterns of hospice use among decedents and to examine state, county, and individual factors associated with these patterns. Methods: We conducted a retrospective analysis of Medicare fee-for-service decedents. The primary outcome measures were state-level hospice use during the last 6 months of life and the state's proportion of hospice users with very short hospice enrollment (7 days), very long hospice enrollment (180 days), and hospice disenrollment prior to death. Results: In 2011, the percentage of decedents who used hospice in the last 6 months of life nationally was 47.1%, and varied across states from 20.3% in Alaska to 60.8% in Utah. Hospice utilization patterns also varied by state, with the percentage of hospice users with very short hospice enrollment ranging from 23.0% in the District of Columbia to 39.9% in Connecticut. The percentage of very long hospice use varied from 5.7% in Connecticut to 15.9% in Delaware. The percentage of hospice disenrollment ranged from 6.2% in Hawaii to 19.0% in the District of Columbia. Nationally, state-level hospice use among decedents was positively correlated with the percentage of potentially concerning patterns (including very short hospice enrollment, very long hospice enrollment, and hospice disenrollment) among hospice users (the Pearson correlation coefficient=0.52, p value<0.001). Oregon was the only state in the highest quartile of hospice use and the lowest quartiles of both very short and very long hospice enrollment. Conclusions: The percentage of decedents who use hospice may mask important state-level variation in these patterns, including the timing of hospice enrollment, a potentially important component of the quality of end-of-life care. C1 [Wang, Shi-Yi] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT 06520 USA. [Canavan, Maureen; Cherlin, Emily; Bradley, Elizabeth] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06520 USA. [Wang, Shi-Yi; Gross, Cary P.] Yale Canc Ctr, Canc Outcomes Publ Policy & Effectiveness Res COP, New Haven, CT USA. [Wang, Shi-Yi; Gross, Cary P.] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Aldridge, Melissa D.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Aldridge, Melissa D.] James J Peters VA Med Ctr, Bronx, NY USA. [Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06520 USA. [Johnson-Hurzeler, Rosemary] John D Thompson Hospice Inst Educ Training & Res, Branford, CT USA. RP Wang, SY (reprint author), Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St,POB 208034, New Haven, CT 06520 USA. EM shiyi.wang@yale.edu FU National Cancer Institute [1R01CA116398-01A2]; John D. Thompson Foundation; National Institute of Nursing Research [5R01NR013499] FX This study was supported by grant 1R01CA116398-01A2 from the National Cancer Institute (Drs. Aldridge and Bradley), the John D. Thompson Foundation (Dr. Bradley), and grant 5R01NR013499 from the National Institute of Nursing Research (Dr. Aldridge). NR 23 TC 7 Z9 7 U1 2 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD SEP 1 PY 2015 VL 18 IS 9 BP 771 EP 780 DI 10.1089/jpm.2014.0425 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CQ1LE UT WOS:000360358400010 PM 26172615 ER PT J AU Rinne, ST Wong, ES Hebert, PL Au, DH Lindenauer, PK Neely, EL Sulc, CA Liu, CF AF Rinne, Seppo T. Wong, Edwin S. Hebert, Paul L. Au, David H. Lindenauer, Peter K. Neely, Emily L. Sulc, Christine A. Liu, Chuan-Fen TI Weekend Discharges and Length of Stay Among Veterans Admitted for Chronic Obstructive Pulmonary Disease SO MEDICAL CARE LA English DT Article DE weekend; COPD; length of stay; efficiency; readmission ID MYOCARDIAL-INFARCTION; HEART-FAILURE; HOSPITALS; MORTALITY; OUTCOMES; SERVICE; DELAYS; RATES AB Background:Discharge rates are substantially lower on weekends, though the impact on hospital length of stay (LOS) is not fully understood.Objectives:The primary objective was to examine the association of weekend discharges with hospital LOS. We also examined the association of weekend discharges with readmission, mortality, and postdischarge follow-up.Research Design and Methods:A cohort study of 25,301 patients who were admitted to Veterans Affairs hospitals for chronic obstructive pulmonary disease during October 01, 2008-September 30, 2010, including 3845 patients discharged on the weekend (Saturday or Sunday) and 21,456 discharged on weekdays (Monday through Friday).Results:There were significantly fewer discharges on the weekend (1922 per weekend day vs. 4279 per weekday, P<0.01). Inpatient status during the weekend at any point in hospitalization was associated with an increased LOS of 0.59 day [95% confidence interval (CI), 0.54-0.63 d]. Discharge on the weekend was not associated with increased odds of 30-day hospital readmission [odds ratio (OR)=1.00; 95% CI, 0.90-1.10] or lack of primary care follow-up visit within 14 days of discharge (OR=0.94; 95% CI, 0.85-1.03). However, weekend discharges were significantly associated with lower odds of mortality within 30 days after discharge (OR=0.80; 95% CI, 0.65-0.99).Conclusions:The presence of fewer weekend discharges was associated with significantly longer hospital lengths of stay. Weekend discharges were not associated with higher readmission rates and had lower rates of mortality compared with weekdays discharges. Identifying methods to increase weekend discharges may create an opportunity to improve hospital efficiency. C1 [Rinne, Seppo T.] VA Connecticut Hlth Care Syst, West Haven, CT USA. [Rinne, Seppo T.] Yale Univ, Dept Med, Div Pulm & Crit Care, New Haven, CT 06520 USA. [Wong, Edwin S.; Hebert, Paul L.; Au, David H.; Neely, Emily L.; Sulc, Christine A.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA. [Wong, Edwin S.; Hebert, Paul L.; Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Au, David H.] Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA USA. [Lindenauer, Peter K.] Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA. RP Rinne, ST (reprint author), 950 Campbell Ave,Bldg 35a,Room 2-234, West Haven, CT 06516 USA. EM seppo.rinne@va.gov FU Veterans Affairs clinical research grant [IIR-09-354] FX Supported by Veterans Affairs clinical research grant: IIR-09-354. NR 24 TC 2 Z9 2 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD SEP PY 2015 VL 53 IS 9 BP 753 EP 757 DI 10.1097/MLR.0000000000000395 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CQ4QM UT WOS:000360589700003 PM 26147865 ER PT J AU Toth, M Holmes, M Van Houtven, C Toles, M Weinberger, M Silberman, P AF Toth, Matthew Holmes, Mark Van Houtven, Courtney Toles, Mark Weinberger, Morris Silberman, Pam TI Rural Medicare Beneficiaries Have Fewer Follow-up Visits and Greater Emergency Department Use Postdischarge SO MEDICAL CARE LA English DT Article DE Medicare; rural health; postacute care; readmission ID QUALITY-OF-CARE; HEART-FAILURE; TRANSITIONAL CARE; HEALTH-CARE; HOSPITAL READMISSIONS; 30-DAY READMISSION; ACCESS; RATES; DISCHARGE; OPPORTUNITIES AB Background:Hospitals are focused on improving postdischarge services for older adults, such as early follow-up care after hospitalization to reduce readmissions and unnecessary emergency department (ED) use. Rural Medicare beneficiaries face many barriers to receiving quality care, but little is known about their postdischarge care and outcomes. We hypothesize that rural Medicare beneficiaries compared with urban beneficiaries, will have fewer follow-up visits, and a greater likelihood of readmission and ED use.Methods:We conducted a retrospective analysis of elderly Medicare beneficiaries discharged home using the Medicare Current Beneficiary Survey, Cost and Use files, 2000-2010. Multivariate Cox proportional hazard models were used to assess the risk of rural residency on readmission, ED use, and follow-up care up to 30 days' postdischarge. Covariates include demographic, health, and hospital-level characteristics.Results:Compared with urban beneficiaries, Medicare beneficiaries living in isolated rural settings had a lower rate of follow-up care [hazard ratio (HR)=0.81, P<0.001]. Beneficiaries in large and small rural settings had a greater risk of an ED visit compared with urban beneficiaries (HR=1.44, P<0.001; HR=1.52, P<0.01). Rural beneficiaries did not have a greater risk of readmission, though risk of readmission was higher for beneficiaries discharged from hospitals in large and small rural settings (HR=1.33, P<0.05; HR=1.42, P<0.05).Conclusions:This study provides evidence of lower quality postdischarge care for Medicare beneficiaries in rural settings. As readmission penalties expand, hospitals serving rural beneficiaries may be disproportionately affected. This suggests a need for policies that increase follow-up care in rural settings. C1 [Toth, Matthew; Holmes, Mark; Weinberger, Morris; Silberman, Pam] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA. [Van Houtven, Courtney] Durham VA Med Ctr, US Dept Vet Affairs, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Van Houtven, Courtney] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27706 USA. [Toles, Mark] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA. RP Toth, M (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Sheps Ctr Hlth Serv Res, 135 Dauer Dr,1101 McGavran Greeberg Hall,CB 7411, Chapel Hill, NC 27599 USA. EM tbmatthe@live.unc.edu FU T-32 National Research Service Award, Sheps Center for Health Services Research [2T32HS000032-25]; North Carolina Rural Health Research Program [UL1-TR000083, F30-HL110483, T32-GM008719]; UNC Institute on Aging FX Supported by a T-32 National Research Service Award, Sheps Center for Health Services Research, Grant #: 2T32HS000032-25. Support was also provided by the North Carolina Rural Health Research Program. UL1-TR000083, F30-HL110483, T32-GM008719, and UNC Institute on Aging pilot grant supported the purchase of the Medicare Current Beneficiary Survey. NR 47 TC 4 Z9 4 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD SEP PY 2015 VL 53 IS 9 BP 800 EP 808 DI 10.1097/MLR.0000000000000401 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CQ4QM UT WOS:000360589700009 PM 26270827 ER PT J AU Nelson, RE Samore, MH Jones, M Greene, T Stevens, VW Liu, CF Graves, N Evans, MF Rubin, MA AF Nelson, Richard E. Samore, Matthew H. Jones, Makoto Greene, Tom Stevens, Vanessa W. Liu, Chuan-Fen Graves, Nicholas Evans, Martin F. Rubin, Michael A. TI Reducing Time-dependent Bias in Estimates of the Attributable Cost of Health Care-associated Methicillin-resistant Staphylococcus aureus Infections A Comparison of Three Estimation Strategies SO MEDICAL CARE LA English DT Article DE costs; MRSA; health care-associated infection ID LENGTH-OF-STAY; BURDEN; IMPACT AB Background:Previous estimates of the excess costs due to health care-associated infection (HAI) have scarcely addressed the issue of time-dependent bias.Objective:We examined time-dependent bias by estimating the health care costs attributable to an HAI due to methicillin-resistant Staphylococcus aureus (MRSA) using a unique dataset in the Department of Veterans Affairs (VA) that makes it possible to distinguish between costs that occurred before and after an HAI. In addition, we compare our results to those from 2 other estimation strategies.Methods:Using a historical cohort study design to estimate the excess predischarge costs attributable to MRSA HAIs, we conducted 3 analyses: (1) conventional, in which costs for the entire inpatient stay were compared between patients with and without MRSA HAIs; (2) post-HAI, which included only costs that occurred after an infection; and (3) matched, in which costs for the entire inpatient stay were compared between patients with an MRSA HAI and subset of patients without an MRSA HAI who were matched based on the time to infection.Results:In our post-HAI analysis, estimates of the increase in inpatient costs due to MRSA HAI were $12,559 (P<0.0001) and $24,015 (P<0.0001) for variable and total costs, respectively. The excess variable and total cost estimates were 33.7% and 31.5% higher, respectively, when using the conventional methods and 14.6% and 11.8% higher, respectively, when using matched methods.Conclusions:This is the first study to account for time-dependent bias in the estimation of incremental per-patient health care costs attributable to HAI using a unique dataset in the VA. We found that failure to account for this bias can lead to overestimation of these costs. Matching on the timing of infection can reduce this bias substantially. C1 [Nelson, Richard E.; Samore, Matthew H.; Jones, Makoto; Stevens, Vanessa W.; Rubin, Michael A.] Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Nelson, Richard E.; Samore, Matthew H.; Jones, Makoto; Greene, Tom; Rubin, Michael A.] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA. [Stevens, Vanessa W.] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA. [Liu, Chuan-Fen] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Graves, Nicholas] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia. [Evans, Martin F.] Lexington Vet Affairs Med Ctr, Lexington, KY USA. [Evans, Martin F.] Univ Kentucky, Dept Internal Med, Lexington, KY USA. RP Nelson, RE (reprint author), 500 Foothill Blvd, Salt Lake City, UT 84148 USA. EM richard.nelson@utah.edu OI Graves, Nicholas/0000-0002-5559-3267; Stevens, Vanessa/0000-0001-8933-5453 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service [CDA 11-210]; Centers for Disease Control and Prevention, Safety and Healthcare Epidemiology Prevention Research Development Program [200-2011-42039] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (CDA 11-210) with R.E.N. as the principal investigator and the Centers for Disease Control and Prevention, Safety and Healthcare Epidemiology Prevention Research Development Program (contract number 200-2011-42039) with M.H.S. as the principal investigator. NR 28 TC 4 Z9 4 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD SEP PY 2015 VL 53 IS 9 BP 827 EP 834 DI 10.1097/MLR.0000000000000403 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CQ4QM UT WOS:000360589700012 PM 26225444 ER PT J AU Gassman, AA Lewis, MS Bradley, JP Lee, JC AF Gassman, Andrew A. Lewis, Michael S. Bradley, James P. Lee, Justine C. TI Remote Ischemic Preconditioning Improves the Viability of Donor Lipoaspirate during Murine Fat Transfer SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID REPERFUSION INJURY; RAT MODEL; SURVIVAL; BREAST; CELLS; TRANSPLANTATION; RECONSTRUCTION; LIPOSUCTION; HARVEST; HEART AB Background: Variable results associated with fat grafting have been attributed to local trauma, inconsistencies in transfer, and ischemia before the development of recipient circulation. Remote ischemic preconditioning is an inexpensive noninvasive technique that has been used in animal models and multicenter clinical trials to protect organ systems. In this work, the authors describe a novel animal model for analyzing the efficacy of fat grafting, and investigate the effect of remote ischemic preconditioning on volume retention. Methods: Subcutaneous adipose tissue samples from green fluorescent protein/luciferase-expressing FVB mice were obtained with or without pretreatment with a temporary hind-limb tourniquet. The samples were injected into the dorsal skin folds of wild-type FVB mice. The viability of the transferred tissue was examined over a 28-day period with quantitative bioluminescence after luciferin injection. Transferred tissue was also explanted for histologic analysis. Results: The remote ischemic preconditioning group had significantly increased bioluminescence at days 0, 1, and 28. Histologic analysis at day 28 confirmed the presence of vascularized adipose in both groups. However, significant amounts of interstitial fibrosis were found in the control group, whereas substantially less was found in the remote ischemic preconditioning group. The remote ischemic preconditioning group retained a substantially greater amount of green fluorescent protein, suggesting increased survival of donor adipocytes. Conclusions: In this work, the authors describe a novel animal model for quantitative evaluation of fat grafting using in vivo bioluminescence of adipocytes from luciferase-expressing mice. The authors also demonstrate that remote ischemic preconditioning increases the viability of fat transfer and decreases interstitial fibrosis. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, Dept Surg, Los Angeles, CA 90024 USA. Greater Los Angeles VA Healthcare Syst, Dept Pathol, Los Angeles, CA USA. Temple Univ Hosp & Sch Med, Dept Surg, Div Plast & Reconstruct Surg, Philadelphia, PA USA. RP Gassman, AA (reprint author), Univ Texas SW Med Ctr Dallas, Dept Plast Surg, 1801 Inwood Rd, Dallas, TX 75390 USA. EM Andrew.Gassman@UTsouthwestern.edu FU Plastic Surgery Foundation [274376]; Jean Perkins Foundation FX This work was supported by the Plastic Surgery Foundation (Pilot Research Grant 274376) (to A.A.G.) and the Jean Perkins Foundation (to J.C.L.). NR 26 TC 3 Z9 3 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0032-1052 EI 1529-4242 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD SEP PY 2015 VL 136 IS 3 BP 495 EP 502 DI 10.1097/PRS.0000000000001488 PG 8 WC Surgery SC Surgery GA CQ5YO UT WOS:000360681800005 PM 25989298 ER PT J AU Suri, P Pashova, H Heagerty, PJ Jarvik, JG Turner, JA Comstock, BA Bauer, Z Annaswamy, TM Nedeljkovic, SS Wasan, AD Friedly, JL AF Suri, Pradeep Pashova, Hristina Heagerty, Patrick J. Jarvik, Jeffrey G. Turner, Judith A. Comstock, Bryan A. Bauer, Zoya Annaswamy, Thiru M. Nedeljkovic, Srdjan S. Wasan, Ajay D. Friedly, Janna L. TI Short-term Improvements in Disability Mediate Patient Satisfaction After Epidural Corticosteroid Injections for Symptomatic Lumbar Spinal Stenosis SO SPINE LA English DT Article DE glucocorticoid; transforaminal; interlaminar; neurogenic; claudication; radiculopathy; randomized controlled trial; low back pain; outcomes ID LOW-BACK-PAIN; SICKNESS IMPACT PROFILE; STEROID INJECTIONS; VALIDITY; TRIAL; SCALE AB Study Design. Secondary analysis of data from a double-blind randomized controlled trial. Objective. To identify mediators of the effect of lumbar epidural injections of corticosteroid plus lidocaine on patient satisfaction at 6 weeks postinjection in patients with lumbar spinal stenosis. We hypothesized that short-term (3 wk) change in leg pain would be a significant mediator of satisfaction. Summary of Background Data. No prior studies have identified mediators of effects of epidural injections on patient satisfaction with treatment of lumbar spinal stenosis. Methods. We used mediation analysis methods to examine selected intermediate variables (adverse events and change in leg pain, back pain, disability, depression, and fatigue at 3 wk) as potential mediators of the effect of lumbar epidural injections of corticosteroid plus lidocaine on patient satisfaction with treatment. We used the overall satisfaction item from the Swiss Spinal Stenosis Questionnaire as our primary outcome to measure patient satisfaction with the injection procedure at 6 weeks. Results. Among 400 patients randomized to receive epidural injections with corticosteroid plus lidocaine or with lidocaine alone, 369 had complete data for the satisfaction outcome and potential mediators and served as the analysis sample. Contrary to our expectations, 3-week change in leg pain intensity did not have significant mediation effects on patient satisfaction. Three-week change in disability as measured by the Roland-Morris Disability Questionnaire was a significant mediator of the effects of lumbar epidural corticosteroid injections on patient satisfaction at 6 weeks, explaining 48% to 60% of the treatment effect on satisfaction. Changes in pain intensity in the leg and back together explained very little of the treatment effect on satisfaction beyond the information contributed by disability change alone. We did not find other intermediate variables to be mediators of patient satisfaction. Conclusion. These findings support the current approach of examining disability as a primary patient-reported outcome in comparative effectiveness studies of lumbar spinal stenosis. Level of Evidence: 2 C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Div Rehabil Care Serv, Seattle, WA 98108 USA. [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr ERIC, Seattle, WA 98108 USA. [Suri, Pradeep; Turner, Judith A.; Friedly, Janna L.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Pashova, Hristina; Heagerty, Patrick J.; Comstock, Bryan A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Heagerty, Patrick J.; Jarvik, Jeffrey G.; Turner, Judith A.; Comstock, Bryan A.; Bauer, Zoya; Friedly, Janna L.] Univ Washington, Comparat Effectiveness Cost & Outcomes Res Ctr, Seattle, WA 98195 USA. [Jarvik, Jeffrey G.; Bauer, Zoya] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Jarvik, Jeffrey G.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Turner, Judith A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Annaswamy, Thiru M.] VA North Texas Hlth Care Syst, Dept Phys Med & Rehabil, Dallas, TX USA. [Annaswamy, Thiru M.] UT Southwestern Med Ctr, Dallas, TX USA. [Nedeljkovic, Srdjan S.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA. [Nedeljkovic, Srdjan S.] Harvard Vanguard Med Associates, Spine Unit, Boston, MA USA. [Wasan, Ajay D.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Wasan, Ajay D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Div Rehabil Care Serv, S-152-ERIC,1660 S Columbian Way, Seattle, WA 98108 USA. EM pradeep.suri@va.gov FU Agency for Healthcare Research and Quality (AHRQ) [1R01HS019222-01, 1R01HS022972-01]; Patient-Centered Outcomes Research Institute (PCORI) Program Award [CE-12-11-4469]; VA Puget Sound Health Care System FX Agency for Healthcare Research and Quality (AHRQ), award numbers 1R01HS019222-01 and1R01HS022972-01, funds were received to support this work. Also partially supported through a Patient-Centered Outcomes Research Institute (PCORI) Program Award (CE-12-11-4469). Dr. Suri's participation is this study was funded by VA Puget Sound Health Care System. NR 23 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD SEP 1 PY 2015 VL 40 IS 17 BP 1363 EP 1370 DI 10.1097/BRS.0000000000001000 PG 8 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA CQ5QW UT WOS:000360661500007 PM 26010037 ER PT J AU Blosnich, JR Gordon, AJ Fine, MJ AF Blosnich, John R. Gordon, Adam J. Fine, Michael J. TI Associations of sexual and gender minority status with health indicators, health risk factors, and social stressors in a national sample of young adults with military experience SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Veterans health; Sexuality; Transgendered persons; Health surveys; Minority health; Mental health; Military personnel ID UNITED-STATES; BISEXUAL POPULATIONS; TRANSGENDER VETERANS; WOMEN VETERANS; SAME-SEX; ORIENTATION DISPARITIES; PROBABILITY SAMPLE; SUICIDAL IDEATION; CARE UTILIZATION; MENTAL-HEALTH AB Purpose: To assess the associations of self-identified lesbian, gay, bisexual, and questioning sexual orientation or transgender status (LGBTQ) and military experience with health indicators. Methods: We used data from the Fall 2012 National College Health Assessment. The survey included self-identified sociodemographic characteristics, mental (e.g., depression) and physical (e.g., human immunodeficiency virus) conditions, health risk behaviors (e.g., smoking), and social stressors (e.g., victimization). We used modified Poisson regression models, stratified by self-reported military service, to examine LGBTQ-related differences in health indicators, whereas adjusting for sociodemographic characteristics. Results: Of 27,176 in the sample, among the military-experienced group, LGBTQ individuals had increased adjusted risks of reporting a past-year suicide attempt (adjusted risk ratio [aRR] = 4.37; 95% confidence interval [CI] = 1.39-13.67), human immunodeficiency virus (aRR = 9.90; 95% CI = 1.04-79.67), and discrimination (aRR = 4.67; 95% CI = 2.05-10.66) than their non-LGBTQ peers. Among LGBTQ individuals, military experience was associated with a nearly four-fold increased risk of reporting a past-year suicide attempt (aRR = 3.61; 95% CI = 1.46-8.91) adjusting for age, sex, race and ethnicity, marital status, depression, and other psychiatric diagnoses. Conclusions: Military experience may moderate health indicators among LGBTQ populations, and likewise, LGBTQ status likely modifies health conditions among military-experienced populations. Results suggest that agencies serving military populations should assess how and if the health needs of LGBTQ individuals are met. Published by Elsevier Inc. C1 [Blosnich, John R.; Gordon, Adam J.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Blosnich, John R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Gordon, Adam J.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Ctr Hlth Equity Res & Promot, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov FU Department of Veterans Affairs Office of Academic Affiliations; Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System FX The authors thank the American College Health Association for use of the Fall 2012 survey data set. This work was partially supported by a postdoctoral fellowship to J.R. Blosnich through the Department of Veterans Affairs Office of Academic Affiliations and the Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System. The opinions expressed in this work are those of the authors and do not represent the funders, institutions, the Department of Veterans Affairs, or the U.S. government. NR 63 TC 5 Z9 5 U1 7 U2 35 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD SEP PY 2015 VL 25 IS 9 BP 661 EP 667 DI 10.1016/j.annepidem.2015.06.001 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP9AV UT WOS:000360187000005 PM 26184439 ER PT J AU Bird, TD Swanson, PD AF Bird, Thomas D. Swanson, Phillip D. TI Congenital insensitivity to pain with anhidrosis SO ANNALS OF NEUROLOGY LA English DT Letter C1 [Bird, Thomas D.] Univ Washington, Seattle, WA 98195 USA. [Bird, Thomas D.; Swanson, Phillip D.] VA Puget Sound Hlth Care, GRECC, Seattle, WA USA. RP Bird, TD (reprint author), Univ Washington, Seattle, WA 98195 USA. FU CSRD VA [I01 CX001006] NR 4 TC 0 Z9 1 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD SEP PY 2015 VL 78 IS 3 BP 500 EP 500 DI 10.1002/ana.24450 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CP9MQ UT WOS:000360218800017 PM 26032179 ER PT J AU Chang, HH Dwivedi, N Nicholas, AP Ho, IC AF Chang, Hui-Hsin Dwivedi, Nishant Nicholas, Anthony P. Ho, I-Cheng TI The W620 Polymorphism in PTPN22 Disrupts Its Interaction With Peptidylarginine Deiminase Type 4 and Enhances Citrullination and NETosis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID PROTEIN-TYROSINE-PHOSPHATASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; CELL ACTIVATION; GENETIC-VARIATION; ALLELIC VARIANT; AUTOIMMUNITY; EXPRESSION; NEUTROPHILS; DISEASE AB Objective. A C-to-T single-nucleotide polymorphism (SNP) located at position 1858 of human protein tyrosine phosphatase PTPN22 complementary DNA carries the highest risk of rheumatoid arthritis (RA) among all non-HLA genetic variants. This C1858T SNP converts an arginine (R620) to a tryptophan (W620), but it is unclear why it has such a strong impact on RA, a disease characterized by anti-citrullinated protein antibodies. The aim of this study was to test the hypothesis that PTPN22 regulates protein citrullination. Methods. The level of citrullinated proteins in immune cells was quantified by Western blotting. The physical interaction between PTPN22 and peptidyl arginine deiminase type 4 (PAD-4), which is one of the enzymes that catalyzes protein citrullination, was examined by coimmunoprecipitation. Neutrophils were collected from healthy donors carrying the C1858T SNP and healthy donors not carrying this SNP. The formation of neutrophil extracellular traps (NETs) was examined by immunocytochemistry. Results. PTPN22 physically interacted with PAD-4, and a deficiency in PTPN22 enhanced protein citrullination. This abnormality was reversed by exogenous wild-type PTPN22 or catalytically dead mutant PTPN22. The R-to-W conversion rendered PTPN22 unable to interact with PAD-4 and suppress citrullination. The C1858T SNP was associated with hypercitrullination in peripheral blood mononuclear cells and a heightened propensity for spontaneous formation of NETs, which is a PAD-4-dependent process. Conclusion. PTPN22 is an inhibitor of PAD-4 and protein citrullination. This function of PTPN22 is independent of its phosphatase activity but requires R620. Our data not only establish a molecular link between PTPN22 and PAD-4, but also suggest that the C1858T SNP increases the risk of RA by enhancing protein citrullination and spontaneous formation of NETs. C1 [Chang, Hui-Hsin; Dwivedi, Nishant; Ho, I-Cheng] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chang, Hui-Hsin; Dwivedi, Nishant; Ho, I-Cheng] Harvard Univ, Sch Med, Boston, MA USA. [Nicholas, Anthony P.] Univ Alabama Birmingham, Birmingham, AL USA. [Nicholas, Anthony P.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Ho, IC (reprint author), Brigham & Womens Hosp, One Jimmy Fund Way, Boston, MA 02115 USA. EM iho@partners.org OI Dwivedi, Nishant/0000-0003-3812-4917 FU US Department of Defense [W81XWH-11-1-0492] FX Supported by the US Department of Defense (grant W81XWH-11-1-0492 to Dr. Ho). NR 48 TC 16 Z9 16 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD SEP PY 2015 VL 67 IS 9 BP 2323 EP 2334 DI 10.1002/art.39215 PG 12 WC Rheumatology SC Rheumatology GA CQ1SP UT WOS:000360379500005 PM 26019128 ER PT J AU Rice, T Hoffman, L Sher, L AF Rice, Timothy Hoffman, Leon Sher, Leo TI Portrayal of violent male psychiatric patients by entertainment media and the stigma of psychiatric illness SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter C1 [Rice, Timothy; Hoffman, Leon; Sher, Leo] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Hoffman, Leon] New York Psychoanalyt Soc & Inst, New York, NY USA. [Sher, Leo] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA. RP Rice, T (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM Timothy.rice@mssm.edu NR 3 TC 2 Z9 2 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 EI 1440-1614 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD SEP PY 2015 VL 49 IS 9 BP 849 EP 849 DI 10.1177/0004867415579465 PG 1 WC Psychiatry SC Psychiatry GA CQ2FE UT WOS:000360414000018 PM 25829483 ER PT J AU Shah, NN Kucharczuk, CR Mitra, N Hirsh, R Svoboda, J Porter, D Loren, A Frey, N Schapira, MM AF Shah, Nirav N. Kucharczuk, Colleen R. Mitra, Nandita Hirsh, Rebecca Svoboda, Jakub Porter, David Loren, Alison Frey, Noelle Schapira, Marilyn M. TI Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Allogeneic transplant; Outcomes; APPs ID PRACTITIONERS; CANCER AB Allogeneic stem cell transplantation (ASCT) is a complex medical procedure for some patients with hematologic malignancies. Most ASCTs occur at academic centers where either medical residents (house staff [HS]) or advanced practice providers (APPs) provide daily care. As a result of increasing work-hour regulations, APPs have assumed greater responsibilities, including those traditionally held by HS. In this study we evaluate ASCT patient outcomes by inpatient provider service. A retrospective, single-center chart review of ASCT patients was performed. ASCT patients admitted to an HS service from May 2011 to May 2012 (N = 86) were compared with ASCT patients admitted to a newly formed APP service from October 2012 to October 2013 (N = 81). As part of a secondary sensitivity analysis, we compared ASCT patients on the APP service to a subset of ASCT patients admitted to the HS service also from October 2012 to October 2013 (n = 27). Our primary outcomes were 100-day survival and relapse-free survival rates. Additional outcomes included length of stay (LOS), inpatient complications, and ordering behavior. Our primary pre- and post-analyses found no differences in 100-day overall survival and 100-day relapse-free survival rate between the services. The rate of pneumonia was lower on the APP service (15% versus 28%, P = .04), with no significant differences in other infectious complications. HS ordered more blood cultures (6.7 versus 4.2, P = .03) per patient than the APP service. There was no difference in LOS, readmission rates, or inpatient mortality. With regards to our secondary sensitivity analysis, no differences were found in 100-day overall survival and 100-day relapse-free survival rates between the services. There was a decreased LOS on the APP service (29.4 versus 37.2 days, P = .01). HS ordered more blood cultures (9.3 versus 4.2, P < .01) and more radiological films (8.1 versus 5.2, P = .05) per patient than the APP service. This increased ordering and LOS was associated with an increase in mean hospital charges on the HS service (P = .04). ASCT patients on an APP service had similar 100-day outcomes as those on the HS service. In the setting of limited resources, APPs are potential alternative providers for complex transplant inpatients. (C) 2015 American Society for Blood and Marrow Transplantation. C1 [Shah, Nirav N.; Kucharczuk, Colleen R.; Hirsh, Rebecca; Svoboda, Jakub; Porter, David; Loren, Alison; Frey, Noelle] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19103 USA. [Shah, Nirav N.; Kucharczuk, Colleen R.; Hirsh, Rebecca; Svoboda, Jakub; Porter, David; Loren, Alison; Frey, Noelle] Hosp Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA. [Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19103 USA. [Schapira, Marilyn M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19103 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Div Gen Internal Med, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Shah, NN (reprint author), Univ Penn, Div Hematol Oncol, 1930 Chestnut Apt,9B, Philadelphia, PA 19103 USA. EM nirav.shah@uphs.upenn.edu FU Cancer Center Research Training Program [NCI 5-T32 CA09615-25] FX Financial disclosure: Fellowship funding support was provided by the Cancer Center Research Training Program (NCI 5-T32 CA09615-25) as salary support via a T32 training grant to N.N.S. NR 24 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD SEP PY 2015 VL 21 IS 9 BP 1692 EP 1698 DI 10.1016/j.bbmt.2015.05.021 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CQ0AB UT WOS:000360255900022 PM 26028503 ER PT J AU Shiota, S Reddy, R Alsarraj, A El-Serag, HB Graham, DY AF Shiota, Seiji Reddy, Rita Alsarraj, Abeer El-Serag, Hashem B. Graham, David Y. TI Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Gastritis; Bacterial Resistance; Drug; Eradication Therapy ID ANTIMICROBIAL RESISTANCE; RISK-FACTORS; STREPTOCOCCUS-PNEUMONIAE; PRESCRIPTION RATES; TRIPLE-THERAPY; METRONIDAZOLE; INFECTIONS; CLARITHROMYCIN; ERADICATION; PREVALENCE AB BACKGROUND & AIMS: The most recent information published on resistance of Helicobacter pylori to antibiotics in a large population in the United States is more than 10 years old. We assessed the susceptibility of H pylori to antibiotics among patients in a large metropolitan hospital, as well as demographic, clinical, and lifestyle factors associated with antimicrobial resistance. METHODS: We performed a cross-sectional study of a random sample of 656 patients (90.2% men) from a cohort of 1559 undergoing esophagogastroduodenoscopy with collection of gastric biopsies from 2009 through 2013 at the Houston Veterans Affairs Medical Center. We performed culture analyses of gastric tissues to detect H pylori. The minimum inhibitory concentrations of amoxicillin, clarithromycin, metronidazole, levofloxacin, and tetracycline were determined by the Epsilometer test. Logistic regression analysis was performed to estimate the association between risk factors and antimicrobial resistance. RESULTS: Biopsies from 135 subjects (20.6%) tested positive for H pylori; 128 of these were from men (94.8%). Only 65 strains were susceptible to all 5 antibiotics. The prevalence of resistance to levofloxacin was 31.3% (95% confidence interval [CI], 23.1%-39.4%), to metronidazole it was 20.3% (95% CI, 13.2%-27.4%), to clarithromycin it was 16.4% (95% CI, 9.9%-22.9%), and to tetracycline it was 0.8% (95% CI, 0.0%-2.3%). No isolate was resistant to amoxicillin. Clarithromycin resistance increased from 9.1% in 2009-2010 to 24.2% in 2011-2013. In multivariate analysis, prior treatment of H pylori infection and use of fluoroquinolones were significantly associated with clarithromycin and levofloxacin resistance, respectively. CONCLUSIONS: H pylori resistance to clarithromycin increased between 2009 and 2013; resistance to metronidazole remains high in infected men in the United States. The high frequency of resistance to levofloxacin is a new and concerning finding. C1 [Shiota, Seiji; Reddy, Rita; Alsarraj, Abeer; El-Serag, Hashem B.; Graham, David Y.] Michael E DeBakey VA Med Ctr, Sect Gastroenterol & Hepatol, Dept Med, Houston, TX USA. [Shiota, Seiji; Alsarraj, Abeer; El-Serag, Hashem B.; Graham, David Y.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [Shiota, Seiji; Alsarraj, Abeer; El-Serag, Hashem B.; Graham, David Y.] Baylor Coll Med, Dept Med, Sect Hepatol, Houston, TX 77030 USA. [Alsarraj, Abeer; El-Serag, Hashem B.] Houston VA HSR&D Ctr Innovat Qual Effectiveness &, Houston, TX USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.edu FU NIDDK NIH HHS [DK58338]; PHS HHS [NCI R01 116845, NIDDK K24-04-107] NR 43 TC 17 Z9 17 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD SEP PY 2015 VL 13 IS 9 BP 1616 EP 1624 DI 10.1016/j.cgh.2015.02.005 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP7TG UT WOS:000360090400016 PM 25681693 ER PT J AU Greenstein, RJ Cameron, DW Brown, ST AF Greenstein, Robert J. Cameron, D. William Brown, Sheldon T. TI Yet Another Flawed "Placebo Controlled" Study in Crohn's Disease? SO FOODBORNE PATHOGENS AND DISEASE LA English DT Letter ID SUBSPECIES PARATUBERCULOSIS C1 [Greenstein, Robert J.] James J Peters Vet Affairs Med Ctr, Dept Surg, Bronx, NY 10468 USA. [Cameron, D. William] Ottawa Hosp Res Inst, Dept Med, Ottawa, ON, Canada. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Div Infect Dis, Bronx, NY 10468 USA. [Brown, Sheldon T.] Inchan Sch Med Mt Sinai, New York, NY USA. RP Greenstein, RJ (reprint author), James J Peters Vet Affairs Med Ctr, Lab Mol Surg Res, Res Block 4F 05,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Greenstein.Robert@gmail.com NR 5 TC 0 Z9 0 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD SEP 1 PY 2015 VL 12 IS 9 BP 812 EP 812 DI 10.1089/fpd.2015.1999 PG 1 WC Food Science & Technology SC Food Science & Technology GA CP9KX UT WOS:000360214100012 PM 26110358 ER PT J AU Berry, K Ioannou, GN AF Berry, Kristin Ioannou, George N. TI Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States SO GASTROENTEROLOGY LA English DT Article DE Liver Cancer; UNOS; Priority; Exception Points ID ALLOCATION SYSTEM; WAITING-LIST; MORTALITY; POLICY; MODEL; CANDIDATES; OUTCOMES AB BACKGROUND & AIMS: Patients with T2 hepatocellular carcinoma (HCC) can obtain an exception that allows them to undergo liver transplantation with much lower actual Model for End-Stage Liver Disease (MELD) scores than patients without HCC. We compared patients who received liver transplants, with and without HCC, with regard to transplantation-related survival benefit. METHODS: We modeled the post-transplantation survival of adult, first-time liver transplant recipients with HCC (n = 9135) or without (n = 25,890) from 2002 through 2013 using Cox proportional hazards regression. We modeled waitlist survival of patients listed for transplantation with HCC (n = 15,605) or without (n = 85,229) using competing risks analysis and combined outcomes of death or liver failure (defined as MELD score >= 30). We used these survival models to calculate monthly transition probabilities and 5-year life expectancies. Survival benefit was calculated as the difference between post-transplantation and waitlist life expectancy. RESULTS: The 5-year survival benefit increased with actual MELD score for patients with and without HCC, ranging from just a few months in patients with low MELD scores (ie, 6 - 8) to 4 years in patients with the highest MELD scores (ie, 36 - 40). The survival benefit of patients with HCC was similar to that of patients without HCC who had the same actual MELD score, irrespective of tumor burden or serum level of a-fetoprotein. However, because patients with HCC received liver transplants when they had a lower mean MELD score (13.3 +/- 6.2) than patients without HCC (21.8 +/- 8.0), a much lower mean 5-year survival benefit was achieved by providing liver transplants to patients with HCC (0.12 years/patient) than patients without HCC (1.47 years/patient). CONCLUSIONS: The HCC MELD exception policy has unintentionally resulted in a large reduction in transplantation-related survival benefit. C1 [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA. [Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu NR 22 TC 15 Z9 15 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD SEP PY 2015 VL 149 IS 3 BP 669 EP 680 DI 10.1053/j.gastro.2015.05.025 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CQ0FE UT WOS:000360269800036 PM 26021233 ER PT J AU Muriel, A Penuelas, O Frutos-Vivar, F Arroliga, AC Abraira, V Thille, AW Brochard, L Nin, N Davies, AR Amin, P Du, B Raymondos, K Rios, F Violi, DA Maggiore, SM Soares, MA Gonzalez, M Abroug, F Bulow, HH Hurtado, J Kuiper, MA Moreno, RP Zeggwagh, AA Villagomez, AJ Jibaja, M Soto, L D'Empaire, G Matamis, D Koh, Y Anzueto, A Ferguson, ND Esteban, A AF Muriel, Alfonso Penuelas, Oscar Frutos-Vivar, Fernando Arroliga, Alejandro C. Abraira, Victor Thille, Arnaud W. Brochard, Laurent Nin, Nicolas Davies, Andrew R. Amin, Pravin Du, Bin Raymondos, Konstantinos Rios, Fernando Violi, Damian A. Maggiore, Salvatore M. Soares, Marco Antonio Gonzalez, Marco Abroug, Fekri Buelow, Hans-Henrik Hurtado, Javier Kuiper, Michael A. Moreno, Rui P. Zeggwagh, Amine Ali Villagomez, Asisclo J. Jibaja, Manuel Soto, Luis D'Empaire, Gabriel Matamis, Dimitrios Koh, Younsuck Anzueto, Antonio Ferguson, Niall D. Esteban, Andres TI Impact of sedation and analgesia during noninvasive positive pressure ventilation on outcome: a marginal structural model causal analysis SO INTENSIVE CARE MEDICINE LA English DT Article DE Noninvasive positive pressure ventilation; Acute respiratory failure Sedation; Analgesia; Mortality ID ACUTE RESPIRATORY-FAILURE; MECHANICAL VENTILATION; SUPPORT VENTILATION; RISK-FACTORS; DEXMEDETOMIDINE; MIDAZOLAM; EFFICACY AB There are limited data available about the role of sedation and analgesia during noninvasive positive pressure ventilation (NPPV). The objective of study was to estimate the effect of analgesic or sedative drugs on the failure of NPPV. We studied patients who received at least 2 h of NPPV as first-line therapy in a prospective observational study carried out in 322 intensive care units from 30 countries. A marginal structural model (MSM) was used to analyze the association between the use of analgesic or sedative drugs and NPPV failure (defined as need for invasive mechanical ventilation). 842 patients were included in the analysis. Of these, 165 patients (19.6 %) received analgesic or sedative drugs at some time during NPPV; 33 of them received both. In the adjusted analysis, the use of analgesics (odds ratio 1.8, 95 % confidence interval 0.6-5.4) or sedatives (odds ratio 2.8, 95 % CI 0.85-9.4) alone was not associated with NPPV failure, but their combined use was associated with failure (odds ratio 5.7, 95 % CI 1.8-18.4). Slightly less than 20 % of patients received analgesic or sedative drugs during NPPV, with no apparent effect on outcome when used alone. However, the simultaneous use of analgesics and sedatives may be associated with failure of NPPV. C1 [Muriel, Alfonso; Abraira, Victor] Hosp Ramon & Cajal, Unidad Bioestadist Clin, Inst Ramon & Cajal Invest Sanitarias, E-28034 Madrid, Spain. [Muriel, Alfonso; Abraira, Victor] Ctr Invest Red Epidemiol & Salud Publ CIBERESP, Madrid, Spain. [Penuelas, Oscar] Hosp Infanta Cristina, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Parla, Spain. [Frutos-Vivar, Fernando; Esteban, Andres] Hosp Univ Getafe, Intens Care Unit, Getafe 28905, Spain. [Frutos-Vivar, Fernando; Esteban, Andres] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Getafe 28905, Spain. [Arroliga, Alejandro C.] Scott & White Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. [Thille, Arnaud W.] Univ Hosp Poitiers, Poitiers, France. [Brochard, Laurent] St Michaels Hosp, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada. [Brochard, Laurent] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada. [Nin, Nicolas] Hosp Espanol Montevideo, Montevideo, Uruguay. [Nin, Nicolas] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Montevideo, Uruguay. [Davies, Andrew R.] Monash Univ, Melbourne, Vic 3004, Australia. [Amin, Pravin] Bombay Hosp Inst Med Sci, Bombay, Maharashtra, India. [Du, Bin] Beijing Union Med Coll Hosp, Beijing, Peoples R China. [Raymondos, Konstantinos] Hannover Med Sch, Hannover, NH, Germany. [Rios, Fernando] Hosp Nacl Alejandro Posadas, Buenos Aires, DF, Argentina. [Violi, Damian A.] Hosp HIGA Guemes, Haedo, Argentina. [Maggiore, Salvatore M.] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy. [Soares, Marco Antonio] Hosp Univ Sao Jose, Belo Horizonte, MG, Brazil. [Gonzalez, Marco] Clin Medellin, Medellin, Colombia. [Gonzalez, Marco] Univ Pontificia Bolivariana, Medellin, Colombia. [Abroug, Fekri] Hosp Fattouma Bourguina, Monastir, Tunisia. [Buelow, Hans-Henrik] Reg Zealand Univ Copenhagen, Holbaek Hosp, Copenhagen, Denmark. [Hurtado, Javier] Hosp Clin Montevideo, Montevideo, Uruguay. [Kuiper, Michael A.] Med Ctr Leeuwarden, Leeuwarden, Netherlands. [Moreno, Rui P.] Hosp Sao Jose, Ctr Hosp Lisboa Cent, Lisbon, Portugal. [Zeggwagh, Amine Ali] Hop Ibn Sina, Rabat, Morocco. [Villagomez, Asisclo J.] Hosp Reg Octubre, Inst Seguridad & Serv Social Trabajadores Estado, Mexico City, DF, Mexico. [Jibaja, Manuel] Hosp Eugenio Espejo, Quito, Ecuador. [Soto, Luis] Inst Nacl Torax Santiago, Santiago, Chile. [D'Empaire, Gabriel] Hosp Clin Caracas, Caracas, Venezuela. [Matamis, Dimitrios] Papageorgiou Hosp, Thessaloniki, Greece. [Koh, Younsuck] Univ Ulsan, Asan Med Ctr, Seoul, South Korea. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ferguson, Niall D.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada. [Ferguson, Niall D.] Univ Toronto, Dept Med, Toronto, ON, Canada. [Ferguson, Niall D.] Univ Toronto, Dept Physiol, Toronto, ON, Canada. RP Frutos-Vivar, F (reprint author), Hosp Univ Getafe, Intens Care Unit, Carretera Toledo, Km 12-5, Getafe 28905, Spain. EM ffrutos@ucigetafe.com RI Soares, Marcio/B-3083-2013 OI Soares, Marcio/0000-0003-2503-6088; MAGGIORE, Salvatore Maurizio/0000-0002-1828-9143; Frutos-Vivar, Fernando/0000-0002-4648-9636; Ferguson, Niall/0000-0002-6213-5264; Muriel, Alfonso /0000-0002-4805-4011 NR 22 TC 7 Z9 7 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD SEP PY 2015 VL 41 IS 9 BP 1586 EP 1600 DI 10.1007/s00134-015-3854-6 PG 15 WC Critical Care Medicine SC General & Internal Medicine GA CQ0VD UT WOS:000360314900007 PM 25971392 ER PT J AU Sharma, A Shi, QH Hoover, DR Anastos, K Tien, PC Young, MA Cohen, MH Golub, ET Gustafson, D Yin, MT AF Sharma, Anjali Shi, Qiuhu Hoover, Donald R. Anastos, Kathryn Tien, Phyllis C. Young, Mary A. Cohen, Mardge H. Golub, Elizabeth T. Gustafson, Deborah Yin, Michael T. TI Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article ID BONE-MINERAL DENSITY; POPULATION-BASED COHORT; ANTIRETROVIRAL THERAPY; RISK-FACTORS; OSTEOPOROSIS; PREVALENCE; INITIATION; MEN AB Background: We previously reported that fracture incidence rates did not differ by HIV status among predominantly premenopausal Women's Interagency HIV Study participants. We now conduct a follow-up study with 5 additional observation years to further characterize fracture risk associated with HIV infection in women as they age. Methods: We measured time to first new fracture at any site in 2375 (1713 HIV-infected and 662 HIV-uninfected) Women's Interagency HIV Study participants, with median 10-year follow-up. Fractures were self-reported semiannually. Proportional hazards models assessed predictors of incident fracture. Results: At index visit, HIV-infected women were older [median age of 40 years (IQR: 34-46) vs. 35 (27-43), P < 0.0001] and more likely to be postmenopausal, hepatitis C virus infected, and weigh less than HIV-uninfected women. Among HIV-infected women, mean CD4(+) count was 480 cells per microliter and 63% were taking highly active antiretroviral therapy. Unadjusted incidence rates of any fracture were higher in HIV-infected than in HIV-uninfected women [2.19/100 person-years (py) vs. 1.54/100 py, P = 0.002]. In multivariate models, HIV status, older age, white (vs. black) race, prior fracture, history of cocaine use, and history of injection drug use were significant predictors of incident fracture. Among HIV-infected women, age, white race, prior fracture, smoking, and prior AIDS were predictors of new fracture. Conclusions: Middle-aged HIV-infected women had a higher adjusted fracture rate than HIV-uninfected women. Cocaine use and injection drug use were also associated with a greater risk of incident fracture. Further research is needed to understand whether the risk of fracture associated with cocaine use relates to increased rate of falls or direct effects on bone metabolism. C1 [Sharma, Anjali; Anastos, Kathryn] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA. [Shi, Qiuhu] New York Med Coll, Dept Epidemiol & Community Hlth, Valhalla, NY 10595 USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Tien, Phyllis C.] Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Young, Mary A.] Georgetown Univ, Sch Med, Dept Med, Washington, DC USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA. [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Gustafson, Deborah] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA. [Yin, Michael T.] Columbia Univ, Med Ctr, Div Infect Dis, New York, NY USA. RP Sharma, A (reprint author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave,Block Bldg 305, Bronx, NY 10461 USA. EM anjali.sharma@einstein.yu.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131]; National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute on Deafness and other Communication Disorders (NIDCD); NIH Office of Research on Women's Health; National Institutes of Health [AI095089, K23AR06199301] FX Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (K.A.); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Chicago Consortium (M.H.C.); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources (UCSF-CTSI Grant No. UL1 RR024131). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD), and the NIH Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA) and UL1-TR000454 (Atlanta CTSA). This research was also supported by National Institutes of Health AI095089 (M.T.Y.) and K23AR06199301 (A.S.). NR 31 TC 16 Z9 16 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2015 VL 70 IS 1 BP 54 EP 61 DI 10.1097/QAI.0000000000000674 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CQ1HM UT WOS:000360347900007 PM 26322667 ER PT J AU Gellad, WF Flynn, KE Alexander, GC AF Gellad, Walid F. Flynn, Kathryn E. Alexander, G. Caleb TI Evaluation of Flibanserin Science and Advocacy at the FDA SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Gellad, Walid F.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Flynn, Kathryn E.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Flynn, Kathryn E.] Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, Milwaukee, WI 53226 USA. [Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA. [Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Alexander, G. Caleb] Johns Hopkins Med, Dept Med, Gen Internal Med Sect, Baltimore, MD USA. RP Gellad, WF (reprint author), Div Gen Internal Med, Univ Dr 151C, Pittsburgh, PA 15240 USA. EM walid.gellad@pitt.edu NR 6 TC 12 Z9 12 U1 2 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 1 PY 2015 VL 314 IS 9 BP 869 EP 870 DI 10.1001/jama.2015.8405 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CQ1WX UT WOS:000360392100008 PM 26148201 ER PT J AU Calleo, JS Amspoker, AB Sarwar, AI Kunik, ME Jankovic, J Marsh, L York, M Stanley, MA AF Calleo, Jessica S. Amspoker, Amber B. Sarwar, Aliya I. Kunik, Mark E. Jankovic, Joseph Marsh, Laura York, Michele Stanley, Melinda A. TI A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE anxiety; depression; cognitive-behavioral therapy; Parkinson disease ID STRUCTURED INTERVIEW GUIDE; QUALITY-OF-LIFE; CONTROLLED-TRIAL; OLDER-ADULTS; RANDOMIZED-TRIAL; RATING-SCALE; PRIMARY-CARE; THERAPY; DISORDER; PREVALENCE AB Anxiety and depression often remain unrecognized or inadequately treated in patients with Parkinson disease (PD). Cognitive-behavioral therapy (CBT) is effective, but limited evidence supports its use for anxiety and depression in patients with PD. Sixteen patients with PD having significant anxiety and/or depressive symptoms were assigned to CBT or enhanced usual care. Assessments occurred at baseline, posttreatment, and 1-month follow-up. The CBT intervention included tools for anxiety, depression, and healthy living with PD symptoms. Individual sessions were delivered by telephone or in person, based on patient preference. Treatment was feasible with participants choosing 67% of sessions by telephone and 80% completed treatment. The between-group effect sizes for change scores from baseline to posttreatment and baseline to 1-month follow-up were large (posttreatment: d = 1.49 for depression and 1.44 for anxiety; 1-month follow-up: d = .73 for depression and 1.24 for anxiety), although only the posttreatment effect size for depression was significant. This pilot CBT program is feasible for treatment of anxiety and depression in patients with PD. C1 [Calleo, Jessica S.; Amspoker, Amber B.; Kunik, Mark E.; Stanley, Melinda A.] Ctr Innovat Qual Effectiveness & Safety, Houston VA Hlth Serv Res & Dev HSR&D, Houston, TX USA. [Calleo, Jessica S.; Sarwar, Aliya I.; Kunik, Mark E.; Marsh, Laura; York, Michele; Stanley, Melinda A.] Michael E DeBakey Vet Affairs Med Ctr 152, Houston, TX 77030 USA. [Calleo, Jessica S.; Amspoker, Amber B.; Sarwar, Aliya I.; Kunik, Mark E.; Jankovic, Joseph; Marsh, Laura; York, Michele; Stanley, Melinda A.] Baylor Coll Med, Houston, TX 77030 USA. [Kunik, Mark E.; Stanley, Melinda A.] VA South Cent Mental Illness Res Educ & Clin Ctr, North Little Rock, AR USA. RP Calleo, JS (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM jcalleo@bcm.edu FU Parkinson Study Group; Parkinson's Disease Foundation's Advancing Parkinson Treatments Innovations Grant; Veteran Affairs South Central Mental Illness Research Education and Clinical Center; Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety [CIN-13-413] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Parkinson Study Group and the Parkinson's Disease Foundation's Advancing Parkinson Treatments Innovations Grant; a grant from the Veteran Affairs South Central Mental Illness Research Education and Clinical Center; and the Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (CIN-13-413). The views expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, US Government or Baylor College of Medicine. NR 30 TC 2 Z9 2 U1 4 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 EI 1552-5708 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD SEP PY 2015 VL 28 IS 3 BP 210 EP 217 DI 10.1177/0891988715588831 PG 8 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA CQ0JA UT WOS:000360280100007 PM 26047635 ER PT J AU Ruggiero, KJ Price, M Adams, Z Stauffacher, K McCauley, J Danielson, CK Knapp, R Hanson, RF Davidson, TM Amstadter, AB Carpenter, MJ Saunders, BE Kilpatrick, G Resnick, HS AF Ruggiero, Kenneth J. Price, Matthew Adams, Zachary Stauffacher, Kirstin McCauley, Jenna Danielson, Carla Kmett Knapp, Rebecca Hanson, Rochelle F. Davidson, Tatiana M. Amstadter, Ananda B. Carpenter, Matthew J. Saunders, Benjamin E. Kilpatrick, G. Resnick, Heidi S. TI Web Intervention for Adolescents Affected by Disaster: Population-Based Randomized Controlled Trial SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE disaster mental health; technology; posttraumatic stress; depression ID INTERNET-BASED INTERVENTION; POSTTRAUMATIC-STRESS; SUBSTANCE-ABUSE; CHILDREN; DEPRESSION; YOUTH; RISK AB Objective: To assess the efficacy of Bounce Back Now (BBN), a modular, Web-based intervention for disaster-affected adolescents and their parents. Method: A population-based randomized controlled trial used address-based sampling to enroll 2,000 adolescents and parents from communities affected by tornadoes in Joplin, MO, and several areas in Alabama. Data collection via baseline and follow-up semi-structured telephone interviews was completed between September 2011 and August 2013. All families were invited to access the BBN study Web portal irrespective of mental health status at baseline. Families who accessed the Web portal were assigned randomly to 1 of 3 groups: BBN, which featured modules for adolescents and parents targeting adolescents' mental health symptoms; BBN plus additional modules targeting parents' mental health symptoms; or assessment only. The primary outcomes were adolescent symptoms of posttraumatic stress disorder (PTSD) and depression. Results: Nearly 50% of families accessed the Web portal. Intent-to-treat analyses revealed time x condition interactions for PTSD symptoms (B = -0.24, SE = 0.08, p < .01) and depressive symptoms (B = -0.23, SE = 0.09, p < .01). Post hoc comparisons revealed fewer PTSD and depressive symptoms for adolescents in the experimental versus control conditions at 12-month follow-up (PTSD: B = -0.36, SE = 0.19, p = .06; depressive symptoms: B = -0.42, SE = 0.19, p = 0.03). A time x condition interaction also was found that favored the BBN versus BBN + parent self-help condition for PTSD symptoms (B = 0.30, SE = 0.12, p = .02) but not depressive symptoms (B = 0.12, SE = 0.12, p = .33). Conclusion: Results supported the feasibility and initial efficacy of BBN as a scalable disaster mental health intervention for adolescents. Technology-based solutions have tremendous potential value if found to reduce the mental health burden of disasters. C1 [Ruggiero, Kenneth J.; Adams, Zachary; McCauley, Jenna; Danielson, Carla Kmett; Knapp, Rebecca; Hanson, Rochelle F.; Davidson, Tatiana M.; Carpenter, Matthew J.; Saunders, Benjamin E.; Kilpatrick, G.; Resnick, Heidi S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.; Stauffacher, Kirstin; Davidson, Tatiana M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Price, Matthew] Univ Vermont, Burlington, VT 05405 USA. [Amstadter, Ananda B.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, 99 Jonathan Lucas St, Charleston, SC 29425 USA. EM ruggierk@musc.edu FU National Institute of Mental Health (NIMH) [R01 MH081056]; NIDA [K12DA031794]; NIAAA [K02AA023239]; [R21 MH086313] FX This research was supported by National Institute of Mental Health (NIMH) Grant R01 MH081056 (PI: Ruggiero). This includes a Diversity supplement awarded to T.M.D. Grant R21 MH086313 (PI .Danielson) also supported some elements of this work The preparation of this manuscript was supported by NIDA Grant K12DA031794 (PI: Brady; support to J.M., Z.A.) and NIAAA K02AA023239 (PI: Amstadter). All views and opinions expressed herein are those of the authors and do not necessarily reflect those of the funding agency or respective institutions. NR 30 TC 6 Z9 6 U1 0 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 EI 1527-5418 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD SEP PY 2015 VL 54 IS 9 BP 709 EP 717 DI 10.1016/j.jaac.2015.07.001 PG 9 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA CQ0BL UT WOS:000360259500005 PM 26299292 ER PT J AU Hagstrom, EL Patel, S Karimkhani, C Boyers, LN Williams, HC Hay, RJ Weinstock, MA Armstrong, AW Dunnick, CA Margolis, DJ Dellavalle, RP AF Hagstrom, Erika L. Patel, Shivani Karimkhani, Chante Boyers, Lindsay N. Williams, Hywel C. Hay, Roderick J. Weinstock, Martin A. Armstrong, April W. Dunnick, Cory A. Margolis, David J. Dellavalle, Robert P. TI Comparing cutaneous research funded by the US National Institutes of Health (NIH) with the US skin disease burden SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE dermatitis; disability-adjusted life years; disease burden; leprosy; melanoma; National Institutes of Health; priority setting; skin conditions ID GLOBAL BURDEN; ATOPIC-DERMATITIS; CONTINUING CHALLENGES; BIOMEDICAL-RESEARCH; SYSTEMATIC ANALYSIS; ANIMAL RESEARCH; INJURIES; LIFE; PRIORITIES; MELANOMA AB Background: Disease burden should be an important component for guiding research funding. Objective: We sought to examine the relationship between dermatologic research funded from 2012 to 2013 by the National Institutes of Health (NIH) and US skin disease burden as measured by disabilityadjusted life years in the Global Burden of Disease 2010 study. Methods: A cross-sectional analysis was independently performed by 2 researchers who matched projects from the 2012 to 2013 NIH Research Portfolio Online Reporting Tools with 15 skin conditions and their respective disability-adjusted life years from Global Burden of Disease 2010. Results: The NIH funded 1108 projects spanning the 15 skin conditions. Melanoma received almost half of the total skin condition budget (49.5%). Melanoma, nonmelanoma skin cancer, and leprosy were funded above what would be suggested by their disease burden, whereas dermatitis, acne vulgaris, pruritus, urticaria, decubitus ulcer, fungal skin diseases, alopecia areata, cellulitis, and scabies appeared underfunded. Bacterial skin diseases, viral skin diseases, and psoriasis were well matched with disease burden. Limitations: Disease burden is one of many factors that may be used to guide priority-setting decisions. Conclusion: Skin disease burden measured by disability-adjusted life year metrics partially correlates with NIH funding prioritization. Comparing US disease burden with NIH funding suggests possible underfunded and overfunded skin diseases. C1 [Hagstrom, Erika L.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. [Patel, Shivani] Med Univ S Carolina, Charleston, SC USA. [Karimkhani, Chante] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Boyers, Lindsay N.] Georgetown Univ, Sch Med, Washington, DC USA. [Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England. [Hay, Roderick J.] Kings Coll Hosp Natl Hlth Serv Trust, Dept Dermatol, London, England. [Weinstock, Martin A.] Vet Affairs Med Ctr, Dermatoepidemiol Unit, Providence, RI USA. [Weinstock, Martin A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI 02903 USA. [Weinstock, Martin A.] Brown Univ, Dept Dermatol, Providence, RI 02912 USA. [Weinstock, Martin A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. [Armstrong, April W.; Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Aurora, CO USA. [Armstrong, April W.; Dunnick, Cory A.; Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, Denver, CO USA. [Dunnick, Cory A.] Univ Penn, Dept Biostat & Epidemiol & Dermatol, Philadelphia, PA 19104 USA. [Margolis, David J.; Dellavalle, Robert P.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. RP Dellavalle, RP (reprint author), US Dept Vet Affairs, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu FU Bill and Melinda Gates Foundation; US Department of Veterans Affairs; Centers for Disease Control and Prevention [3U48DP001938-04S1]; National Institutes of Health (NIH) [NCI R21 CA173654]; NIH FX The Global Burden of Disease Study 2010 was supported in part by the Bill and Melinda Gates Foundation. Drs Dellavalle, Weinstock, Dunnick, and Armstrong receive a salary from the US Department of Veterans Affairs. Dr Dellavalle is also supported by grants from the Centers for Disease Control and Prevention (Grant 3U48DP001938-04S1) and National Institutes of Health (NIH) (Grant NCI R21 CA173654). Drs Dellavalle, Weinstock, and Margolis previously received NIH funding for research grants. All other authors have no relevant funding/support. NR 42 TC 3 Z9 3 U1 5 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD SEP PY 2015 VL 73 IS 3 BP 383 EP + DI 10.1016/j.jaad.2015.04.039 PG 10 WC Dermatology SC Dermatology GA CP7KO UT WOS:000360066500020 PM 26051697 ER PT J AU Hwang, E Dehesa, LA Kowalewski, CL AF Hwang, Elisha Dehesa, Luis A. Kowalewski, Catherine L. TI Brown hyperpigmentation of the hands and chest in a patient with lung cancer and muscle weakness SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Editorial Material C1 [Hwang, Elisha; Dehesa, Luis A.] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA. [Kowalewski, Catherine L.] Audie L Murphy Mem Vet Affairs Hosp, San Antonio, TX USA. RP Hwang, E (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, 7979 Wurzbach Dr,Grossman Bldg,3rd Fl, San Antonio, TX 78229 USA. EM elishahwang@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD SEP PY 2015 VL 73 IS 3 BP E89 EP E90 DI 10.1016/j.jaad.2015.03.032 PG 2 WC Dermatology SC Dermatology GA CP7KO UT WOS:000360066500003 PM 26282820 ER PT J AU Levy, C AF Levy, Cari TI Expectation Conversations About the Very Predictable Events in Advanced Dementia SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Editorial Material ID NURSING-HOME RESIDENTS; FEEDING-TUBE INSERTION; ADVANCED COGNITIVE IMPAIRMENT; OF-LIFE ISSUES; DECISION-MAKING; HOSPICE CARE; END; PNEUMONIA; MANAGEMENT; SURVIVAL C1 [Levy, Cari] Univ Colorado Denver, Dept Med, Denver, CO 80220 USA. [Levy, Cari] Denver Vet Affairs Med Ctr, Div Hlth Care Policy & Res, Denver, CO 80220 USA. RP Levy, C (reprint author), Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM cari.levy@va.gov NR 36 TC 1 Z9 1 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD SEP 1 PY 2015 VL 16 IS 9 BP 724 EP 727 DI 10.1016/j.jamda.2015.05.003 PG 4 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA CQ0XC UT WOS:000360320100004 PM 26115816 ER PT J AU Luttrell, LM Maudsley, S Bohn, LM AF Luttrell, Louis M. Maudsley, Stuart Bohn, Laura M. TI Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism SO MOLECULAR PHARMACOLOGY LA English DT Review ID MU-OPIOID RECEPTOR; ARRESTIN-MEDIATED ACTIVATION; SEROTONIN 2A RECEPTOR; BETA-ARRESTIN; IN-VIVO; FUNCTIONAL SELECTIVITY; PARATHYROID-HORMONE; BETA(2)-ADRENERGIC RECEPTOR; PHARMACOLOGICAL AGONISM; SIGNALING PATHWAYS AB The fact that over 30% of current pharmaceuticals target heptahelical G protein-coupled receptors (GPCRs) attests to their tractability as drug targets. Although GPCR drug development has traditionally focused on conventional agonists and antagonists, the growing appreciation that GPCRs mediate physiologically relevant effects via both G protein and non-G protein effectors has prompted the search for ligands that can " bias" downstream signaling in favor of one or the other process. Biased ligands are novel entities with distinct signaling profiles dictated by ligand structure, and the potential prospect of biased ligands as better drugs has been pleonastically proclaimed. Indeed, preclinical proof-of-concept studies have demonstrated that both G protein and arrestin pathwayselective ligands can promote beneficial effects in vivo while simultaneously antagonizing deleterious ones. But along with opportunity comes added complexity and new challenges for drug discovery. If ligands can be biased, then ligand classification becomes assay dependent, and more nuanced screening approaches are needed to capture ligand efficacy across several dimensions of signaling. Moreover, because the signaling repertoire of biased ligands differs from that of the native agonist, unpredicted responses may arise in vivo as these unbalanced signals propagate. For any given GPCR target, establishing a framework relating in vitro efficacy to in vivo biologic response is crucial to biased drug discovery. This review discusses approaches to describing ligand efficacy in vitro, translating ligand bias into biologic response, and developing a systemslevel understanding of biased agonism in vivo, with the overall goal of overcoming current barriers to developing biased GPCR therapeutics. C1 [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Maudsley, Stuart] Univ Antwerp, Translat Neurobiol Grp, VIB Dept Mol Genet, Lab Neurogenet Inst Born Bunge, Antwerp, Belgium. [Bohn, Laura M.] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL USA. [Bohn, Laura M.] Scripps Res Inst, Dept Neurosci, Jupiter, FL USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,Suite 816CSB,MSC624, Charleston, SC 29425 USA. EM luttrell@musc.edu FU National Institutes of Health National Institute of General Medical Sciences [R01-GM095497]; National Institute of Diabetes, Digestive, and Kidney Diseases [R01-DK055524]; Intramural Research Program of the National Institute on Aging; National Institute on Drug Abuse [R01-DA031927, R01-DA033073, P01-DA009158, R01-DA038964]; Research Service of the Charleston, SC Veterans Affairs Medical Center FX This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant R01-GM095497], the National Institute of Diabetes, Digestive, and Kidney Diseases [Grant R01-DK055524], the Intramural Research Program of the National Institute on Aging, the National Institute on Drug Abuse [Grants R01-DA031927, R01-DA033073, P01-DA009158, and R01-DA038964], and the Research Service of the Charleston, SC Veterans Affairs Medical Center. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 118 TC 35 Z9 35 U1 5 U2 35 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X EI 1521-0111 J9 MOL PHARMACOL JI Mol. Pharmacol. PD SEP PY 2015 VL 88 IS 3 BP 579 EP 588 DI 10.1124/mol.115.099630 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CP8JI UT WOS:000360139400006 PM 26134495 ER PT J AU Voytek, B Kayser, AS Badre, D Fegen, D Chang, EF Crone, NE Parvizi, J Knight, RT D'Esposito, M AF Voytek, Bradley Kayser, Andrew S. Badre, David Fegen, David Chang, Edward F. Crone, Nathan E. Parvizi, Josef Knight, Robert T. D'Esposito, Mark TI Oscillatory dynamics coordinating human frontal networks in support of goal maintenance SO NATURE NEUROSCIENCE LA English DT Article ID HUMAN PREFRONTAL CORTEX; SHORT-TERM-MEMORY; COGNITIVE CONTROL; THETA RHYTHM; PHASE; FREQUENCY; COMMUNICATION; MECHANISM; BEHAVIOR; POWER AB Humans have a capacity for hierarchical cognitive control-the ability to simultaneously control immediate actions while holding more abstract goals in mind. Neuropsychological and neuroimaging evidence suggests that hierarchical cognitive control emerges from a frontal architecture whereby prefrontal cortex coordinates neural activity in the motor cortices when abstract rules are needed to govern motor outcomes. We utilized the improved temporal resolution of human intracranial electrocorticography to investigate the mechanisms by which frontal cortical oscillatory networks communicate in support of hierarchical cognitive control. Responding according to progressively more abstract rules resulted in greater frontal network theta phase encoding (4-8 Hz) and increased prefrontal local neuronal population activity (high gamma amplitude, 80-150 Hz), which predicts trial-by-trial response times. Theta phase encoding coupled with high gamma amplitude during inter-regional information encoding, suggesting that inter-regional phase encoding is a mechanism for the dynamic instantiation of complex cognitive functions by frontal cortical subnetworks. C1 [Voytek, Bradley; Fegen, David; Knight, Robert T.; D'Esposito, Mark] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Kayser, Andrew S.; D'Esposito, Mark] US Dept Vet Affairs, Div Neurol, Martinez, CA USA. [Kayser, Andrew S.] Univ Calif San Francisco, Ctr Integrat Neurosci, Dept Neurol, San Francisco, CA 94143 USA. [Badre, David] Brown Univ, Dept Cognit Linguist & Psychol Sci, Providence, RI 02912 USA. [Badre, David] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA. [Chang, Edward F.] Univ Calif San Francisco, Dept Neurol Surg, Ctr Integrat Neurosci, San Francisco, CA USA. [Chang, Edward F.] Univ Calif San Francisco, Dept Physiol, Ctr Integrat Neurosci, San Francisco, CA USA. [Crone, Nathan E.] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21205 USA. [Parvizi, Josef] Stanford Univ, SHICEP, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Knight, Robert T.; D'Esposito, Mark] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. RP Voytek, B (reprint author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. EM bradley.voytek@gmail.com RI Voytek, Bradley/K-3305-2016 OI Voytek, Bradley/0000-0003-1640-2525 FU US National Institutes of Health (NIH) Institutional Research and Academic Career Development Award; Society for Neuroscience Scholars Program; US National Institutes of Health Institutional Research and Academic Career Development Award [GM081266]; Department of Veterans Affairs; National Eye Institute; National Institute of Neurological Disorders and Stroke [NS065046, NS065120, NS40596, NS07839601, NS21135]; Nielsen Corporation; National Institute of Mental Health [MH063901] FX We thank A. Flinker, J. Hoffman and A. Shestyuk for assistance with data collection, and C. Hamame, T. Lee and B. Postle for useful comments and suggestions. B.V. is funded by a US National Institutes of Health (NIH) Institutional Research and Academic Career Development Award and the Society for Neuroscience Scholars Program. B.V. is funded by a US National Institutes of Health Institutional Research and Academic Career Development Award (GM081266) and the Society for Neuroscience Scholars Program. A.S.K. is funded by the Department of Veterans Affairs and the National Eye Institute. D.B., E.F.C., N.E.C., J.P. and R.T.K. are funded by the National Institute of Neurological Disorders and Stroke (NS065046, NS065120, NS40596, NS07839601, NS21135). R.T.K. is funded by the Nielsen Corporation. M.D. is funded by the Department of Veterans Affairs and the National Institute of Mental Health (MH063901). NR 55 TC 18 Z9 18 U1 4 U2 16 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1097-6256 EI 1546-1726 J9 NAT NEUROSCI JI Nat. Neurosci. PD SEP PY 2015 VL 18 IS 9 BP 1318 EP + DI 10.1038/nn.4071 PG 10 WC Neurosciences SC Neurosciences & Neurology GA CQ0NI UT WOS:000360292600022 PM 26214371 ER PT J AU Javitt, DC Sweet, RA AF Javitt, Daniel C. Sweet, Robert A. TI Auditory dysfunction in schizophrenia: integrating clinical and basic features SO NATURE REVIEWS NEUROSCIENCE LA English DT Review ID SUPERIOR TEMPORAL GYRUS; TRANSCRANIAL MAGNETIC STIMULATION; MISMATCH NEGATIVITY GENERATION; NMDA-RECEPTOR ANTAGONIST; VOXEL-BASED MORPHOMETRY; STEADY-STATE RESPONSES; GRAY-MATTER VOLUME; VERBAL HALLUCINATIONS; PLANUM TEMPORALE; CORTICAL DYSFUNCTION AB Schizophrenia is a complex neuropsychiatric disorder that is associated with persistent psychosocial disability in affected individuals. Although studies of schizophrenia have traditionally focused on deficits in higher-order processes such as working memory and executive function, there is an increasing realization that, in this disorder, deficits can be found throughout the cortex and are manifest even at the level of early sensory processing. These deficits are highly amenable to translational investigation and represent potential novel targets for clinical intervention. Deficits, moreover, have been linked to specific structural abnormalities in post-mortem auditory cortex tissue from individuals with schizophrenia, providing unique insights into underlying pathophysiological mechanisms. C1 [Javitt, Daniel C.] Columbia Univ Coll Phys & Surg, Dept Psychiat & Neurosci, Div Expt Therapeut, New York, NY 10032 USA. [Javitt, Daniel C.] Nathan S Kline Inst, Program Cognit Neurosci & Schizophrenia, Orangeburg, NY 10962 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Res Off, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15240 USA. RP Javitt, DC (reprint author), Columbia Univ Coll Phys & Surg, Dept Psychiat & Neurosci, Div Expt Therapeut, 1051 Riverside Dr,Unit 21, New York, NY 10032 USA. EM dcj2113@cumc.columbia.edu FU NIMH NIH HHS [P50 MH103204, R01 MH049334, R01 MH071533] NR 167 TC 21 Z9 21 U1 4 U2 20 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-003X EI 1471-0048 J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD SEP PY 2015 VL 16 IS 9 BP 535 EP 550 DI 10.1038/nrn4002 PG 16 WC Neurosciences SC Neurosciences & Neurology GA CP9CU UT WOS:000360192100008 PM 26289573 ER PT J AU Cirnigliaro, CM LaFountaine, MF Dengel, DR Bosch, TA Emmons, RR Kirshblum, SC Sauer, S Asselin, P Spungen, AM Bauman, WA AF Cirnigliaro, Christopher M. LaFountaine, Michael F. Dengel, Donald R. Bosch, Tyler A. Emmons, Racine R. Kirshblum, Steven C. Sauer, Sue Asselin, Pierre Spungen, Ann M. Bauman, William A. TI Visceral adiposity in persons with chronic spinal cord injury determined by dual energy X-Ray absorptiometry SO OBESITY LA English DT Article ID BODY-FAT DISTRIBUTION; WAIST CIRCUMFERENCE; INSULIN SENSITIVITY; ABDOMINAL ADIPOSITY; COMPUTED-TOMOGRAPHY; WEIGHT-LOSS; OBESITY; MEN; INDIVIDUALS; TISSUE AB ObjectiveTo determine visceral adipose tissue (VAT) volume (VAT(vol)) by dual energy X-ray absorptiometry (DXA) in spinal cord injured (SCI) and able-bodied (AB) participants and to explore the relationships between VAT(vol) and routine anthropometric measures. MethodsSixty-three subjects with SCI and 126 healthy male AB controls were stratified as low risk [LR: waist circumference (WC)<102 cm] and moderate to high risk (MHR: WC102 cm) for identification of risk for cardiometabolic disease: AB-LR, SCI-LR, AB-MHR, and SCI-MHR. Anthropometrics and standard body composition measurements by DXA with analysis to derive VAT(vol) were performed. ResultsComparison of the four subgroups demonstrated the highest subcutaneous adipose tissue volume (SAT(vol)) in the AB-MHR group (P<0.01), and the highest VAT(vol) in the SCI-MHR group (P<0.01). Furthermore, when compared to the AB group, participants with SCI had a 27% increase in VAT(vol) for every centimeter increase in WC and a 20% increase in VAT(vol) for every unit increase in BMI. ConclusionsBecause cutoff values for the routine surrogate measures of adiposity underestimate visceral adiposity in persons with SCI, the risk of adverse metabolic consequences would also be underestimated, which necessitates adjustment of the these cutoff values or, preferably, to perform its direct measurement. C1 [Cirnigliaro, Christopher M.; LaFountaine, Michael F.; Asselin, Pierre; Spungen, Ann M.; Bauman, William A.] Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs Rehabil Res & Dev Serv, James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [LaFountaine, Michael F.] Seton Hall Univ, Inst Adv Study Rehabil & Sports Sci, Sch Hlth & Med Sci, S Orange, NJ 07079 USA. [LaFountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, Dept Phys Therapy, S Orange, NJ 07079 USA. [Dengel, Donald R.; Bosch, Tyler A.] Univ Minnesota, Sch Kinesiol, Minneapolis, MN USA. [Emmons, Racine R.] William Patterson Univ, Dept Kinesiol, Wayne, NJ USA. [Kirshblum, Steven C.; Sauer, Sue] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Rutgers State Univ, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07102 USA. [Spungen, Ann M.; Bauman, William A.] James J Peters Vet Affairs Med Ctr, Med Serv, Bronx, NY USA. [Spungen, Ann M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med & Rehabil Med, New York, NY 10029 USA. RP Cirnigliaro, CM (reprint author), Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs Rehabil Res & Dev Serv, James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. EM christopher.cirnigliaro@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B4162C]; James J. Peters Veterans Affairs Medical Center FX Veterans Affairs Rehabilitation Research and Development Service (#B4162C) and the James J. Peters Veterans Affairs Medical Center. NR 37 TC 2 Z9 2 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD SEP PY 2015 VL 23 IS 9 BP 1811 EP 1817 DI 10.1002/oby.21194 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CQ1VK UT WOS:000360388100014 PM 26239944 ER PT J AU Moore, TM Scott, JC Reise, SP Port, AM Jackson, CT Ruparel, K Savitt, AP Gur, RE Gur, RC AF Moore, Tyler M. Scott, J. Cobb Reise, Steven P. Port, Allison M. Jackson, Chad T. Ruparel, Kosha Savitt, Adam P. Gur, Raquel E. Gur, Ruben C. TI Development of an Abbreviated Form of the Penn Line Orientation Test Using Large Samples and Computerized Adaptive Test Simulation SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE psychometrics; Penn Computerized Neurocognitive Battery; item response theory; computerized adaptive testing; line orientation test ID ITEM RESPONSE THEORY; CEREBRAL BLOOD-FLOW; NEUROCOGNITIVE BATTERY; SEX-DIFFERENCES; SCHIZOPHRENIA; JUDGMENT; PERFORMANCE; ENDOPHENOTYPES; INTERNET; QUESTIONNAIRES AB Visuospatial processing is a commonly assessed neurocognitive domain with deficits linked to dysfunction in right posterior regions of the brain. With the growth of large-scale clinical research studies, there is an increased need for efficient and scalable assessments of neurocognition, including visuospatial processing. The purpose of the current study was to use a novel method that combines item response theory (IRT) and computerized adaptive testing (CAT) approaches to create an abbreviated form of the computerized Penn Line Orientation Test (PLOT). The 24-item PLOT was administered to 8,498 youths (aged 8-21 years) as part of the Philadelphia Neurodevelopmental Cohort study and, by Web-based data collection, in an independent sample of 4,593 adults from Great Britain as part of a TV documentary. IRT-based CAT simulations were used to select the best PLOT items for an abbreviated form by performing separate simulations in each group and choosing only items that were selected as useful (i.e., high item discrimination and in the appropriate difficulty range) in at least 1 of the simulations. Fifteen items were chosen for the final, short form of the PLOT, indicating substantial agreement among the models in how they evaluated each item's usefulness. Moreover, this abbreviated version performed comparably to the full version in tests of sensitivity to age and sex effects. This abbreviated version of the PLOT cuts administration time by 50% without detectable loss of information, which points to its feasibility for large-scale clinical and genomic studies. C1 [Moore, Tyler M.; Scott, J. Cobb; Port, Allison M.; Jackson, Chad T.; Ruparel, Kosha; Savitt, Adam P.; Gur, Raquel E.; Gur, Ruben C.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Scott, J. Cobb; Gur, Ruben C.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA. [Reise, Steven P.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Gur, RC (reprint author), Univ Penn, Brain Behav Lab, Perelman Sch Med, 3400 Spruce St,10th Floor Gates Pavil, Philadelphia, PA 19104 USA. EM gur@upenn.edu FU National Institute of Mental Health [MH089983, MH019112, MH096891]; Department of Veterans Affairs [1IK2CX000772] FX This work was supported by National Institute of Mental Health grants MH089983, MH019112, and MH096891. J. Cobb Scott's contribution was supported by Department of Veterans Affairs Career Development Award 1IK2CX000772. NR 46 TC 2 Z9 2 U1 2 U2 6 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 EI 1939-134X J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD SEP PY 2015 VL 27 IS 3 BP 955 EP 964 DI 10.1037/pas0000102 PG 10 WC Psychology, Clinical SC Psychology GA CQ1UX UT WOS:000360386700023 PM 25822834 ER PT J AU Hazlett, EA Blair, NJ Fernandez, NG New, AS Goodman, M AF Hazlett, Erin A. Blair, Nicholas J. Fernandez, Nicolas G. New, Antonia S. Goodman, Marianne TI GENDER DIFFERENCES IN AFFECTIVE STARTLE MODULATION AND EMOTION REGULATION IN BORDERLINE PERSONALITY DISORDER SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the Society-for-Psychophysiological-Research CY SEP 30-OCT 04, 2015 CL Seattle, WA SP Soc Psychophysiol Res DE startle; borderline personality disorder; emotion regulation C1 Icahn Sch Med Mt Sinai, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD SEP PY 2015 VL 52 SU 1 SI SI MA 3-82 BP S94 EP S94 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA CQ2PS UT WOS:000360444100404 ER PT J AU Sheerin, CM Konig, A Eonta, AM Vrana, SR AF Sheerin, Christina M. Konig, Andrea Eonta, Alison M. Vrana, Scott R. TI CHANGE IN RESPIRATORY SINUS ARRHYTHMIA OVER TIME DURING AN EXPRESSIVE WRITING TASK SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the Society-for-Psychophysiological-Research CY SEP 30-OCT 04, 2015 CL Seattle, WA SP Soc Psychophysiol Res DE heart rate variability; expressive writing C1 [Sheerin, Christina M.] Richmond VAMC, Richmond, VA USA. [Sheerin, Christina M.; Vrana, Scott R.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Konig, Andrea] Bon Secours St Marys Hosp Richmond Hlth Syst, Richmond, VA USA. [Eonta, Alison M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD SEP PY 2015 VL 52 SU 1 SI SI MA 4-13 BP S104 EP S104 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA CQ2PS UT WOS:000360444100445 ER PT J AU Rosenfeld, EA Marx, J Terry, MA Stall, R Pallatino, C Miller, E AF Rosenfeld, Elian A. Marx, John Terry, Martha A. Stall, Ron Pallatino, Chelsea Miller, Elizabeth TI Healthcare providers' perspectives on expedited partner therapy for chlamydia: a qualitative study SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; US PHYSICIANS; NOTIFICATION; GONORRHEA; PRACTITIONERS; ATTITUDES; TRIAL; STD; UK AB Objectives Expedited partner therapy (EPT) effectively reduces rates of reinfection with chlamydia and increases the number of partners treated for the infection. Healthcare provider (HCP) provision of EPT is low. The objective of this qualitative study was to understand HCP views and opinions regarding the use of EPT in a state where EPT is permissible but underused. Methods Using a purposive sampling strategy to include diverse HCPs who treat young women at risk for chlamydia, 23 semistructured, in-depth interviews were conducted between October and December 2013. The interviews included questions about knowledge, attitudes, experiences with, and barriers and facilitators regarding the use of EPT. Results Many respondents report using EPT and believe the practice is beneficial for their patients. Most providers were unaware of their colleagues' practices and had limited knowledge regarding institutional policies around EPT. HCPs noted a variety of barriers, such as fear of liability, confusion around the legal status of EPT and not being able to counsel patients' partners that make routine use of this practice a challenge. Facilitators of EPT include speaking on the phone with patients' partners and establishing legislation enabling EPT. Conclusions This is the first study to qualitatively examine HCPs' perspectives on EPT in the USA. Barriers to EPT, including concerns about counselling patients' partners and the legal status of EPT, can be overcome. EPT recommendations could include the use of phone calls as part of their guidelines. Changing EPT legislation at the state level in the USA is an important factor to facilitate EPT use. C1 [Rosenfeld, Elian A.] VA Pittsburgh Healthcare Syst, VA Womens Hlth, Pittsburgh, PA 15240 USA. [Marx, John; Terry, Martha A.; Stall, Ron; Pallatino, Chelsea] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Miller, Elizabeth] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Div Adolescent Med, Pittsburgh, PA USA. RP Rosenfeld, EA (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C 151C Bldg 30, Pittsburgh, PA 15240 USA. EM elian.rosenfeld@va.gov FU University of Pittsburgh FX The Myrna Silverman Award and William Green Award from the University of Pittsburgh. NR 25 TC 3 Z9 3 U1 6 U2 11 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 EI 1472-3263 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD SEP PY 2015 VL 91 IS 6 BP 407 EP 411 DI 10.1136/sextrans-2014-051873 PG 5 WC Infectious Diseases SC Infectious Diseases GA CP9BZ UT WOS:000360190000008 PM 25792537 ER PT J AU Keddem, S Barg, FK Glanz, K Jackson, T Green, S George, M AF Keddem, Shimrit Barg, Frances K. Glanz, Karen Jackson, Tara Green, Sarah George, Maureen TI Mapping the urban asthma experience: Using qualitative GIS to understand contextual factors affecting asthma control SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Asthma control; Disparities; Geographic information systems; Semi-structured interviews ID NEW-YORK-CITY; GEOGRAPHIC INFORMATION-SYSTEMS; PHYSICAL-ACTIVITY; CHILDHOOD ASTHMA; AIR-POLLUTION; MIXED METHODS; HEALTH; OBESITY; DISPARITIES; COMMUNITY AB Asthma is complex and connected to a number of factors including access to healthcare, crime and violence, and environmental triggers. A mixed method approach was used to examine the experiences of urban people with asthma in controlling their asthma symptoms. The study started with an initial phase of qualitative interviews in West Philadelphia, a primarily poor African American community. Data from qualitative, semi-structured interviews indicated that stress, environmental irritants, and environmental allergens were the most salient triggers of asthma. Based on the interviews, the team identified six neighborhood factors to map including crime, housing vacancy, illegal dumping, tree canopy and parks. These map layers were combined into a final composite map. These combined methodologies contextualized respondents' perceptions in the framework of the actual community and built environment which tells a more complete story about their experience with asthma. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Keddem, Shimrit] Univ Penn, Perelman Sch Med, Dept Gen Internal Med, Philadelphia, PA 19104 USA. [Keddem, Shimrit] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Barg, Frances K.] Univ Penn, Perelman Sch Med, Mixed Methods Res Lab, Philadelphia, PA 19104 USA. [Barg, Frances K.] Univ Penn, Perelman Sch Med, Dept Family Med, Philadelphia, PA 19104 USA. [Glanz, Karen; George, Maureen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Glanz, Karen; Green, Sarah] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Jackson, Tara] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Cartog Modeling Lab, Philadelphia, PA 19104 USA. RP Keddem, S (reprint author), Philadelphia VA Med Ctr, CEPACT, 4100 Chester Ave,Ste 203, Philadelphia, PA 19104 USA. EM Shimrit.keddem@uphs.upenn.edu NR 52 TC 3 Z9 3 U1 9 U2 45 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD SEP PY 2015 VL 140 BP 9 EP 17 DI 10.1016/j.socscimed.2015.06.039 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CP9ZE UT WOS:000360253600002 PM 26184704 ER PT J AU Tran, NH Cavalcante, LL Lubner, SJ Mulkerin, DL LoConte, NK Clipson, L Matkowskyj, KA Deming, DA AF Tran, Nguyen H. Cavalcante, Ludmila L. Lubner, Sam J. Mulkerin, Daniel L. LoConte, Noelle K. Clipson, Linda Matkowskyj, Kristina A. Deming, Dustin A. TI Precision medicine in colorectal cancer: the molecular profile alters treatment strategies SO THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY LA English DT Review DE BRAF; cetuximab; KRAS; NRAS; panitumumab; PIK3CA ID KRAS WILD-TYPE; 1ST-LINE TREATMENT; ANTIBODY THERAPY; RANDOMIZED-TRIAL; RAS MUTATIONS; COLON CANCERS; POOR SURVIVAL; PIK3CA GENE; CETUXIMAB; FLUOROURACIL AB When considering treatment options for patients with metastatic colorectal cancer (mCRC), molecular profiling has become a pivotal component in guiding clinical decisions. FOLFOX and FOLFIRI (fluorouracuil, leucovorin plus oxaliplatin or ininotecan, respectively) are the standard base regimens used for the treatment of mCRC. Biologic agents, such as the epidermal growth factor receptor (EGFR) targeted therapies, cetuximab and panitumumab and the vascular endothelial growth factor monoclonal antibody, bevacizumab, are safe and effective in the first-line setting. The most efficacious use of these agents in terms of timing and selection of the right patient population continues to be debated. Here we review multiple investigations into the effectiveness of treatment options as a function of the mutations present in colon cancers. Early studies have reported that KRAS mutations at exon 2 predict resistance to EGFR targeted therapies. More recently the data have expanded to include KRAS mutations at exons 3 and 4 and NRAS mutations at exons 2, 3 and 4 as well as other biomarkers including BRAF and PIK3CA, leading to the evolution of the treatment of mCRC to a more precision-based approach. As our understanding of relevant biomarkers increases, and data from both molecular profiling and treatment response become more readily available, treatment options will become more precise and their outcomes more effective. C1 [Tran, Nguyen H.; Cavalcante, Ludmila L.; Lubner, Sam J.; Mulkerin, Daniel L.; LoConte, Noelle K.; Deming, Dustin A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hematol & Oncol, Madison, WI 53792 USA. [Cavalcante, Ludmila L.; Lubner, Sam J.; Mulkerin, Daniel L.; LoConte, Noelle K.; Matkowskyj, Kristina A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53792 USA. [Clipson, Linda] Univ Wisconsin, Dept Oncol, Madison, WI 53792 USA. [Matkowskyj, Kristina A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA. [Matkowskyj, Kristina A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Deming, DA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hematol & Oncol, 600 Highland Ave,K6-544, Madison, WI 53792 USA. EM ddeming@medicine.wisc.edu FU National Institutes of Health (Core Grant, University of Wisconsin Carbone Cancer Center) [P30 CA014520] FX This work was supported by the National Institutes of Health (P30 CA014520, Core Grant, University of Wisconsin Carbone Cancer Center). NR 43 TC 15 Z9 15 U1 0 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1758-8340 EI 1758-8359 J9 THER ADV MED ONCOL JI Ther. Adv. Med. Oncol. PD SEP PY 2015 VL 7 IS 5 BP 252 EP 262 DI 10.1177/1758834015591952 PG 11 WC Oncology SC Oncology GA CQ0KK UT WOS:000360283800002 PM 26327923 ER PT J AU Williams, RM Turner, AP Green, M Norvell, DC Henderson, AW Hakimi, KN Blake, DJ Czerniecki, JM AF Williams, Rhonda M. Turner, Aaron P. Green, Monica Norvell, Daniel C. Henderson, Alison W. Hakimi, Kevin N. Blake, Donna Jo Czerniecki, Joseph M. TI Relationship Between Cognition and Functional Outcomes After Dysvascular Lower Extremity Amputation A Prospective Study SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article ID LOWER-LIMB AMPUTATION; FOLLOW-UP; DISABILITY; AMPUTEES; QUESTIONNAIRE; PREDICT; PROSTHESIS; ADJUSTMENT; HANDICAP; VALIDITY AB Objective The aim of this study was to examine associations between a cognitive screen and four neuropsychologic tests administered at both 6 wks and 4 mos after amputation and five functional outcomes measured 12 mos after lower extremity amputation. Design This study includes a prospective cohort from four medical centers. Participants were primarily male Veterans experiencing their first lower extremity amputation as a result of complications of diabetes mellitus or peripheral arterial disease. Of those eligible, 87 (64%) enrolled; 75 (86%) were retained at 12 mos. Measures included demographic/health information, four neuropsychologic measures, the Locomotor Capability Index-5, the Gronigen Activity Restriction Scale, prosthetic use, community participation, and social integration. Results Better performance on the Short Portable Mental Status Questionnaire at 4 mos was associated with greater 12-mo mobility and social integration. Better attention and working memory abilities 6 wks after amputation were associated with increased 12-mo prosthetic wear; and at 4 mos after amputation, with greater 12-mo mobility. Better verbal memory at 6 wks was associated with greater 12-mo social integration and community participation as well as increased prosthetic wear. Conclusions These findings highlight the potential value in including a brief, formal cognitive assessment in addition to a general mental status screen. Specific domains of cognitive function are differentially associated with functional outcomes and may inform amputation rehabilitation decisions. C1 [Williams, Rhonda M.; Turner, Aaron P.; Green, Monica; Henderson, Alison W.; Hakimi, Kevin N.; Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Williams, Rhonda M.; Turner, Aaron P.; Hakimi, Kevin N.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Norvell, Daniel C.] Spectrum Res Inc, Tacoma, WA USA. [Blake, Donna Jo] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Blake, Donna Jo] Univ Colorado, Denver, CO 80202 USA. RP Williams, RM (reprint author), VA Puget Sound Hlth Care Syst, RCS 117,1660 S Columbian Way, Seattle, WA 98108 USA. OI Turner, Aaron/0000-0001-6897-8003 FU United States Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development [A41241, B4927W] FX Supported by the United States Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development (Merit Review A41241 Joseph Czerniecki, principal investigator, and Career Development Award B4927W Aaron P. Turner, principal investigator). Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article. NR 38 TC 1 Z9 1 U1 0 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD SEP PY 2015 VL 94 IS 9 BP 707 EP 717 DI 10.1097/PHM.0000000000000235 PG 11 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CP5PI UT WOS:000359935400005 PM 25357146 ER PT J AU Thorpe, JM Thorpe, CT Schulz, R Van Houtven, CH Schleiden, L AF Thorpe, Joshua M. Thorpe, Carolyn T. Schulz, Richard Van Houtven, Courtney H. Schleiden, Loren TI Informal Caregiver Disability and Access to Preventive Care in Care Recipients SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID EXPENDITURE PANEL SURVEY; HEALTH-CARE; FAMILY CAREGIVERS; OLDER-ADULTS; PSYCHOLOGICAL DISTRESS; MEDICATION ADHERENCE; ELDERLY PATIENTS; RISK-FACTOR; SERVICES; DEMENTIA AB Introduction: Many informal caregivers of dependent midlife and older adults suffer from their own functional limitations. The impact of caregiver functional limitations on care recipient receipt of preventive services is unknown. The purpose of this study is to examine the association between caregiver functional limitations and decreased access to recommended preventive services in dependent care recipients. Methods: Dependent adults (those receiving assistance with activities of daily living or instrumental activities of daily living) and their primary informal caregiver were identified from pooled alternate years (2000-2008) of the nationally representative Medical Expenditure Panel Survey (data analyzed February-October 2014). The impact of caregiver limitations (cognitive, mobility, sensory, emotional health) on care recipient's receipt of up to seven different preventive services was assessed via survey-weighted linear and logistic regression. Results: Of the 5-year weighted estimate of 14.2 million caregiver-care recipient dyads, 38.0% of caregivers reported at least one functional limitation. The percentage of recommended preventive services received by care recipients was significantly lower if the caregiver had cognitive, mobility, or emotional health limitations. Each type of caregiver functional limitation was negatively associated with at least four different preventive services. Conclusions: Informal caregivers burdened by their own functional impairments may face challenges in facilitating access to preventive care in dependent midlife and older adults. Policies and interventions designed to prevent or mitigate the impact of caregiver functional impairments are critical to the success of community-based models of care for dependent adults. (C) 2015 American Journal of Preventive Medicine C1 [Thorpe, Joshua M.; Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.; Schleiden, Loren] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Schulz, Richard] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA. [Schulz, Richard] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15261 USA. [Van Houtven, Courtney H.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Van Houtven, Courtney H.] Duke Univ, Med Ctr, Sch Med, Div Gen Internal Med, Durham, NC 27710 USA. RP Thorpe, JM (reprint author), Univ Pittsburgh, Sch Pharm, 916 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA. EM jmthorpe@pitt.edu FU National Institute of Nursing Research (NINR) [1R01 NR014434] FX R. Schulz received funding support from a National Institute of Nursing Research (NINR) R01 on tailored technology interventions among caregivers of Alzheimer disease patients (1R01 NR014434). The NINR had no role in the study design, analysis, interpretation of data, writing of the manuscript, or the decision to submit for publication. NR 47 TC 0 Z9 0 U1 5 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 370 EP 379 DI 10.1016/j.amepre.2015.02.003 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200005 PM 26091932 ER PT J AU Karimkhani, C Boyers, LN Schilling, LM Dellavalle, RP AF Karimkhani, Chante Boyers, Lindsay N. Schilling, Lisa M. Dellavalle, Robert P. TI The Surgeon General Should Say That Indoor Ultraviolet Radiation Tanning Causes Skin Cancer SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID METAANALYSIS; ASSOCIATION C1 [Karimkhani, Chante] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Boyers, Lindsay N.] Georgetown Univ, Sch Med, Washington, DC USA. [Schilling, Lisa M.] Univ Colorado, Dept Med, Aurora, CO USA. [Dellavalle, Robert P.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Aurora, CO USA. [Dellavalle, Robert P.] US Dept Vet Affairs, Dermatol Serv, Eastern Colorado Hlth Care Syst, Denver, CO USA. RP Dellavalle, RP (reprint author), Dept Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu NR 10 TC 2 Z9 2 U1 0 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2015 VL 49 IS 3 BP 437 EP 440 DI 10.1016/j.amepre.2015.02.006 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CP5VX UT WOS:000359954200015 PM 25863587 ER PT J AU Eschenauer, GA Nguyen, MH Clancy, CJ AF Eschenauer, Gregory A. Nguyen, Minh-Hong Clancy, Cornelius J. TI Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia SO ANNALS OF PHARMACOTHERAPY LA English DT Review DE fluconazole; echinocandin; candidemia; Candida; candidiasis ID CRITICALLY-ILL PATIENTS; BLOOD-STREAM INFECTION; INVASIVE CANDIDIASIS; ANTIFUNGAL AGENTS; RISK-FACTORS; ANIDULAFUNGIN; MORTALITY; GLABRATA; OUTCOMES; THERAPY AB Objective: Candidemia is among the most common nosocomial bloodstream infections and is associated with high mortality, increased length of hospital stay, and significant economic burden. The introduction of the echinocandins in the 2000s has expanded the armamentarium against Candida spp and provides therapeutic options that are effective, safe, and tolerable. Although the Infectious Diseases Society of America favors echinocandins as treatment for candidemia in selected settings (at least as initial therapy), there remain divergent opinions about whether an echinocandin or fluconazole is the preferred agent for candidemia, and clinical practice guidelines are in flux. In this review, the currently available laboratory and clinical data are summarized and critically evaluated. Data Sources: A MEDLINE search of the English language literature was performed using the search terms echinocandin, fluconazole, and candidemia. References of review articles and guidelines were also screened for inclusion. Study Selection and Data Extraction: Studies whose primary goal was to compare echinocandins with fluconazole were evaluated as well as studies that differentiated pharmacological and pharmacokinetic properties between agents. Data Synthesis: It is clear that echinocandins and fluconazole each have roles in the management of candidemia. Specific recommendations are provided that will hopefully optimize outcomes in candidemia while incorporating stewardship concepts of cost-effectiveness and limiting the emergence of resistance. Conclusions: Despite the advantages brought by the echinocandins and fluconazole, outcomes among patients with candidemia remain suboptimal. Improved treatment of candidennia may ultimately be achieved by optimizing the use of antifungal agents rather than the development of new drugs. C1 [Eschenauer, Gregory A.] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA. [Nguyen, Minh-Hong; Clancy, Cornelius J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Eschenauer, GA (reprint author), Univ Michigan, Coll Pharm, Dept Clin Social & Adm Sci, Dept Pharm, 1500 East Med Ctr, Ann Arbor, MI 48109 USA. EM gregorye@med.umich.edu NR 45 TC 3 Z9 4 U1 0 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD SEP PY 2015 VL 49 IS 9 BP 1068 EP 1074 DI 10.1177/1060028015590838 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CP6XN UT WOS:000360031600013 PM 26104051 ER PT J AU Cordoba-Chacon, J Majumdar, N List, EO Diaz-Ruiz, A Frank, SJ Manzano, A Bartrons, R Puchowicz, M Kopchick, JJ Kineman, RD AF Cordoba-Chacon, Jose Majumdar, Neena List, Edward O. Diaz-Ruiz, Alberto Frank, Stuart J. Manzano, Anna Bartrons, Ramon Puchowicz, Michelle Kopchick, John J. Kineman, Rhonda D. TI Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice SO DIABETES LA English DT Article ID NONALCOHOLIC FATTY LIVER; BODY-COMPOSITION; GH DEFICIENCY; TRIGLYCERIDE SYNTHESIS; RECEPTOR ANTAGONIST; ENDOGENOUS GH; IGF-I; INSULIN; DISEASE; STEATOSIS AB Patients with nonalcoholic fatty liver disease (NAFLD) are reported to have low growth hormone (GH) production and/or hepatic GH resistance. GH replacement can resolve the fatty liver condition in diet-induced obese rodents and in GH-deficient patients. However, it remains to be determined whether this inhibitory action of GH is due to direct regulation of hepatic lipid metabolism. Therefore, an adult-onset, hepatocyte-specific, GH receptor (GHR) knockdown (aLivGHRkd) mouse was developed to model hepatic GH resistance in humans that may occur after sexual maturation. Just 7 days after aLivGHRkd, hepatic de novo lipogenesis (DNL) was increased in male and female chow-fed mice, compared with GHR-intact littermate controls. However, hepatosteatosis developed only in male and ovariectomized female aLivGHRkd mice. The increase in DNL observed in aLivGHRkd mice was not associated with hyperactivation of the pathway by which insulin is classically considered to regulate DNL. However, glucokinase mRNA and protein levels as well as fructose-2,6-bisphosphate levels were increased in aLivGHRkd mice, suggesting that enhanced glycolysis drives DNL in the GH-resistant liver. These results demonstrate that hepatic GH actions normally serve to inhibit DNL, where loss of this inhibitory signal may explain, in part, the inappropriate increase in hepatic DNL observed in NAFLD patients. C1 [Cordoba-Chacon, Jose; Majumdar, Neena; Kineman, Rhonda D.] Jesse Brown VA Med Ctr, Div Res & Dev, Chicago, IL 60612 USA. [Cordoba-Chacon, Jose; Majumdar, Neena; Kineman, Rhonda D.] Univ Illinois, Coll Med, Div Endocrinol Diabet & Metab, Dept Med, Chicago, IL USA. [List, Edward O.; Kopchick, John J.] Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA. [List, Edward O.] Ohio Univ, Heritage Coll Osteopath Med, Dept Special Med, Athens, OH 45701 USA. [Diaz-Ruiz, Alberto] NIA, NIH, Translat Gerontol Branch, Expt Gerontol Sect, Baltimore, MD 21224 USA. [Frank, Stuart J.] Univ Alabama Birmingham, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL USA. [Frank, Stuart J.] Birmingham VA Med Ctr, Endocrinol Sect Med Serv, Birmingham, AL USA. [Manzano, Anna; Bartrons, Ramon] Univ Barcelona, Dept Physiol Sci, Barcelona, Spain. [Puchowicz, Michelle] Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH USA. [Kopchick, John J.] Ohio Univ, Heritage Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA. RP Kineman, RD (reprint author), Jesse Brown VA Med Ctr, Div Res & Dev, Chicago, IL 60612 USA. EM kineman@uic.edu RI Kineman, Rhonda/H-2221-2011 OI Kineman, Rhonda/0000-0001-7322-1152; Cordoba-Chacon, Jose/0000-0001-8787-2706 FU Endocrine Society/Genentech, Inc.; Endocrine Scholars Award in Growth Hormone Research; Intramural Research Program of the National Institutes of Health; National Institute on Aging; Institute de Salud Carlos III (Madrid, Spain) [PI13-00096]; Mouse Metabolic Phenotyping Center of Case Western Reserve University grant [U24 DK76174]; State of Ohio's Eminent Scholar Program; National Institutes of Health [P01AG031736, R01DK088133]; U.S. Department of Veterans Affairs, Office of Research and Development Merit Award [BX001114] FX This work was supported by an Endocrine Society/Genentech, Inc. Endocrine Scholars Award in Growth Hormone Research (to J.C.-C.); Intramural Research Program of the National Institutes of Health, National Institute on Aging (to A.D.-R.); Institute de Salud Carlos III (Madrid, Spain) grant PI13-00096 (to R.B.); Mouse Metabolic Phenotyping Center of Case Western Reserve University grant U24 DK76174 (to M.P.); State of Ohio's Eminent Scholar Program, which includes a gift by Milton and Lawrence Goll, and National Institutes of Health grant P01AG031736 (to J.J.K.); U.S. Department of Veterans Affairs, Office of Research and Development Merit Award BX001114; and National Institutes of Health grant R01DK088133 (to R.D.K.). NR 61 TC 6 Z9 6 U1 1 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD SEP PY 2015 VL 64 IS 9 BP 3093 EP 3103 DI 10.2337/db15-0370 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CP9AE UT WOS:000360185300008 PM 26015548 ER PT J AU Akiba, Y Kaji, I Kaunitz, JD AF Akiba, Yasutada Kaji, Izumi Kaunitz, Jonathan D. TI Short-Chain Fatty Acid Chemosensing and Transport in the Duodenal Epithelium SO DIGESTIVE DISEASES AND SCIENCES LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Brentwood Biomed Res Inst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD SEP PY 2015 VL 60 IS 9 BP 2552 EP 2553 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP6LC UT WOS:000359997700022 ER PT J AU Kaji, I Akiba, Y Kaunitz, JD AF Kaji, Izumi Akiba, Yasutada Kaunitz, Jonathan D. TI Luminal 5-HT Induces Colonic Anion Secretion in Rats: Segmental Differences and an Inhibitory Effect of Submucosal Nitric Oxide SO DIGESTIVE DISEASES AND SCIENCES LA English DT Meeting Abstract C1 Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Brentwood Biomed Res Inst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD SEP PY 2015 VL 60 IS 9 BP 2552 EP 2552 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP6LC UT WOS:000359997700020 ER PT J AU Beste, LA Harp, BK Blais, RK Evans, GA Zickmund, SL AF Beste, Lauren A. Harp, Bonnie K. Blais, Rebecca K. Evans, Ginger A. Zickmund, Susan L. TI Primary Care Providers Report Challenges to Cirrhosis Management and Specialty Care Coordination SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Primary care health; Specialty care; Chronic liver disease; Attitudes ID QUALITY-OF-CARE; HEPATITIS-C; HEPATOCELLULAR-CARCINOMA; COMMUNICATION; SURVEILLANCE; PHYSICIANS; SERVICES; OUTCOMES; DISEASE AB Two-thirds of patients with cirrhosis do not receive guideline-concordant liver care. Cirrhosis patients are less likely to receive recommended care when followed exclusively by primary care providers (PCPs), as opposed to specialty co-management. Little is known about how to optimize cirrhosis care delivered by PCPs. We conducted a qualitative analysis to explore PCPs' attitudes and self-reported roles in caring for patients with cirrhosis. We recruited PCPs from seven Veterans Affairs facilities in the Pacific Northwest via in-service trainings and direct email from March to October 2012 (n = 24). Trained staff administered structured telephone interviews covering: (1) general attitudes; (2) roles and practices; and (3) barriers and facilitators to cirrhosis management. Two trained, independent coders reviewed each interview transcript and thematically coded responses. Three overarching themes emerged in PCPs' perceptions of cirrhosis patients: the often overwhelming complexity of comorbid medical, psychiatric, and substance issues; the importance of patient self-management; and challenges surrounding specialty care involvement and co-management of cirrhosis. While PCPs felt they brought important skills to bear, such as empathy and care coordination, they strongly preferred to defer major cirrhosis management decisions to specialists. The most commonly reported barriers to care included patient behaviors, access issues, and conflicts with specialists. PCPs perceive Veterans with cirrhosis as having significant medical and psychosocial challenges. PCPs tend not to see their role as directing cirrhosis-related management decisions. Educational efforts directed at PCPs must foster PCP empowerment and improve comfort with managing cirrhosis. C1 [Beste, Lauren A.; Evans, Ginger A.] VA Puget Sound Hlth Care Syst, Primary Care Serv, Seattle, WA 98108 USA. [Beste, Lauren A.; Harp, Bonnie K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Beste, Lauren A.; Evans, Ginger A.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Blais, Rebecca K.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA 98108 USA. [Blais, Rebecca K.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Zickmund, Susan L.] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Zickmund, Susan L.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Zickmund, Susan L.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. RP Beste, LA (reprint author), VA Puget Sound Hlth Care Syst, Primary Care Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Lauren.Beste@va.gov FU VA National Hepatitis C Resource Centers program, through the Office of HIV, Hepatitis C, and Public Health Pathogens FX The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. Portions of this work were presented at The Liver Meeting (November 5, 2013), the annual meeting of the American Association for the Study of Liver Disease. This material is the result of work supported by resources from the VA Puget Sound Health Care System (Seattle, Washington). Funding was provided by the VA National Hepatitis C Resource Centers program, through the Office of HIV, Hepatitis C, and Public Health Pathogens. NR 25 TC 3 Z9 3 U1 2 U2 9 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD SEP PY 2015 VL 60 IS 9 BP 2628 EP 2635 DI 10.1007/s10620-015-3592-1 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP6LC UT WOS:000359997700070 PM 25732712 ER PT J AU Barclay, L Yeargin, T Langley, C Kanwar, N Selvarangan, R Bryant, PW Beenhouwer, D Matthews-Greer, J Vinje, J AF Barclay, L. Yeargin, T. Langley, C. Kanwar, N. Selvarangan, R. Bryant, P. W. Beenhouwer, D. Matthews-Greer, J. Vinje, J. TI Multicenter evaluation of RIDA Gene Norovirus GI/GII assay for the detection of norovirus from stool specimens SO JOURNAL OF CLINICAL VIROLOGY LA English DT Meeting Abstract C1 [Barclay, L.; Yeargin, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Langley, C.; Vinje, J.] CDC, Div Viral Dis, Atlanta, GA 30333 USA. [Kanwar, N.; Selvarangan, R.] Childrens Mercy Hosp, Kansas City, MO 64108 USA. [Bryant, P. W.] Wadsworth Ctr, Albany, NY USA. [Beenhouwer, D.] VA Greater LA Healthcare Syst, Los Angeles, CA USA. [Matthews-Greer, J.] Michigan Dept Community Hlth, Bur Labs, Lansing, MI USA. NR 0 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2015 VL 70 SU 1 MA 1692 BP S60 EP S61 DI 10.1016/j.jcv.2015.07.143 PG 2 WC Virology SC Virology GA CP7QI UT WOS:000360082500134 ER PT J AU Ryskina, KL Dine, CJ Kim, EJ Bishop, TF Epstein, AJ AF Ryskina, Kira L. Dine, C. Jessica Kim, Esther J. Bishop, Tara F. Epstein, Andrew J. TI Effect of Attending Practice Style on Generic Medication Prescribing by Residents in the Clinic Setting: An Observational Study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Medical education; Graduate; Practice variation; Health care costs; Drugs; Medical culture ID TOP 5 LISTS; CARE; RESPONSIBILITY; ATORVASTATIN; SIMVASTATIN; PRAVASTATIN; COMPETENCE; PHYSICIANS AB Despite increased emphasis on cost-consciousness in graduate medical training, there is little empirical evidence of the role of attending physician supervision on resident practice in this area. To study whether the prescribing practices of attendings influence residents' prescribing of brand-name statin medications in the ambulatory clinic setting. A retrospective study of statin prescriptions by residents at two internal medicine residency programs, using electronic medical record data from July 2007 through November 2011. We estimated multivariable hierarchical logistic regression models to assess the independent effect of the supervising attending's rate of brand-name prescribing in the preceding quarter on the likelihood of a resident prescribing a brand-name statin. The sample included 342 residents and 58 attendings, accounting for 10,151 initial statin prescriptions, including 3,942 by residents. Brand-name statins were prescribed in about one-fourth of encounters. After adjusting for patient-, physician-, and practice-level factors, the supervising attendings' brand-name prescribing rate in the quarter preceding the encounter was positively associated with a postgraduate year (PGY)-1 resident's prescribing a brand-name statin, but not for PGY-2 or PGY-3 residents. For PGY-1 residents, the adjusted probability of a resident prescribing a brand-name statin ranged from 22.6 % (95 % CI 17.3-28.0 %, p < 0.001) for residents supervised by an attending who prescribed < 20 % brand-name statins in the previous quarter to 41.6 % (95 % CI 24.6-58.5 %, p < 0.001) for residents supervised by an attending who prescribed at least 80 % brand-name statins in the previous quarter. A higher PGY level was associated with brand-name prescribing (aOR 2.07, 95 % CI 1.28-3.35, p = 0.003 for PGY-2; aOR 2.15, 95 % CI 1.31-3.55, p = 0.003 for PGY-3, vs. PGY-1). Supervising attendings' prescribing of brand-name medications may have a significant influence on PGY-1 residents' prescribing of brand-name medications, but not on prescribing by more senior residents. C1 [Ryskina, Kira L.; Kim, Esther J.; Epstein, Andrew J.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ryskina, Kira L.; Dine, C. Jessica; Epstein, Andrew J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Dine, C. Jessica] Univ Penn, Div Pulm & Crit Care, Philadelphia, PA 19104 USA. [Bishop, Tara F.] Weill Cornell Med Coll, Div Hlth Outcomes & Effectiveness, Dept Publ Hlth, New York, NY USA. [Bishop, Tara F.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Epstein, Andrew J.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA. RP Ryskina, KL (reprint author), Univ Penn, Div Gen Internal Med, Perelman Sch Med, 13-30B4 13th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM ryskina@mail.med.upenn.edu FU Ruth L. Kirschstein National Research Service Award (NRSA) [T32-HP10026] FX Dr. Ryskina is supported by the Ruth L. Kirschstein National Research Service Award (NRSA) T32-HP10026. This study received no external funding. NR 20 TC 4 Z9 4 U1 1 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2015 VL 30 IS 9 BP 1286 EP 1293 DI 10.1007/s11606-015-3323-5 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CP5PC UT WOS:000359934600013 PM 26173522 ER PT J AU Patel, MS Reed, DA Smith, C Arora, VM AF Patel, Mitesh S. Reed, Darcy A. Smith, Cynthia Arora, Vineet M. TI Role-Modeling Cost-Conscious Care-A National Evaluation of Perceptions of Faculty at Teaching Hospitals in the United States SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE cost-conscious care; high-value; role-modeling; resident; program director; residency program; teaching hospitals; faculty; medical education ID MEDICAL-EDUCATION; PHYSICIANS; RESIDENTS; IMPACT AB Little is known about how well faculty at teaching hospitals role-model behaviors consistent with cost-conscious care. We aimed to evaluate whether residents and program directors report that faculty at their program consistently role-model cost-conscious care, and whether the presence of a formal residency curriculum in cost-conscious care impacted responses. Cost-conscious care surveys were administered to internal medicine residents during the 2012 Internal Medicine In-Training Examination and to program directors during the 2012 Association of Program Directors in Internal Medicine Annual Survey. Respondents stated whether or not they agreed that faculty in their program consistently role-model cost-conscious care. To evaluate a more comprehensive assessment of faculty behaviors, resident responses were matched with those of the director of their residency program. A multivariate logistic regression model was fit to the outcome variable, to identify predictors of responses that faculty do consistently role-model cost-conscious care from residency program, resident, and program director characteristics. Responses from 12,623 residents (58.4 % of total sample) and 253 program directors (68.4 %) from internal medicine residency programs in the United States were included. The primary outcome measure was responses to questionnaires on faculty role-modeling cost-conscious care. Among all responses in the final sample, 6,816 (54.0 %) residents and 121 (47.8 %) program directors reported that faculty in their program consistently role-model cost-conscious care. Among paired responses of residents and their program director, the proportion that both reported that faculty do consistently role-modeled cost-conscious care was 23.0 % for programs with a formal residency curriculum in cost-conscious care, 26.3 % for programs working on a curriculum, and 23.7 % for programs without a curriculum. In the adjusted model, the presence of a formal curriculum in cost-conscious care did not have a significant impact on survey responses (odds ratio [OR], 1.04; 95 % Confidence Interval [CI], 0.52-2.06; p value [p] = 0.91). Responses from residents and program directors indicate that faculty at US teaching hospitals were not consistently role-modeling cost-conscious care. The presence of a formal residency curriculum in cost-conscious care did not impact responses. Future efforts should focus on placing more emphasis on faculty development and on combining curricular improvements with institutional interventions to adapt the training environment. C1 [Patel, Mitesh S.] Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Patel, Mitesh S.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Patel, Mitesh S.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Reed, Darcy A.] Mayo Clin, Div Primary Care Internal Med, Rochester, MN USA. [Smith, Cynthia] Amer Coll Physicians, Philadelphia, PA USA. [Arora, Vineet M.] Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA. RP Patel, MS (reprint author), Univ Penn, Med & Hlth Care Management, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu OI Arora, Vineet/0000-0002-4745-7599 FU Department of Veteran Affairs; Robert Wood Johnson Foundation FX Dr. Patel was supported in part by the Department of Veteran Affairs and the Robert Wood Johnson Foundation. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. NR 32 TC 6 Z9 6 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2015 VL 30 IS 9 BP 1294 EP 1298 DI 10.1007/s11606-015-3242-5 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CP5PC UT WOS:000359934600014 PM 26173514 ER PT J AU Friedlander, AH Chang, TI Hazboun, RC Garrett, NR AF Friedlander, Arthur H. Chang, Tina I. Hazboun, Renna C. Garrett, Neal R. TI High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID OSTEOPOROSIS; CTX; PREVENTION; POSITION; THERAPY; WOMEN; SERUM AB Purpose: The clinical significance of bone turnover marker C-terminal cross-linking telopeptide (CTX) levels less than 150 pg/mL among recipients of oral bisphosphonate (OBP) medications who develop osteonecrosis of the jaws (MRONJ) after exodontia is unclear. We searched the published data to determine the prevalence of such levels and the association, if any, with development of MRONJ. Materials and Methods: A systematic review of published studies in the PubMed database was undertaken to ascertain the prevalence of preoperative, fasting CTX levels less than 150 pg/mL among recipients of OBP scheduled for exodontia and to determine whether such levels are associated with the development of postoperative MRONJ. The data were aggregated and analyzed to provide the sensitivity, specificity, and positive and negative predictive values of the association between low CTX levels and the development of MRONJ. Results: Two studies were chosen for review. The first, with an enrollment of 21 patients, reported that 10 (48%) patients had a preoperative CTX level less than 150 pg/mL and that after exodontia, none developed MRONJ. The second study, with an enrollment of 950 patients, reported that approximately 282 (30%) had a preoperative CTX level less than 150 pg/mL. All the patients with depressed CTX levels were offered a "drug holiday''; however, only 101 accepted the offer. Of the remaining 181 patients, 4 developed MRONJ. The aggregated study data have demonstrated that 30% of patients evidence CTX levels less than 150 pg/mL and that the sensitivity and specificity of these levels in association with the development of MRONJ was 100% and 80.7%, respectively. The positive predictive value was 2.09% and the negative predictive value was 100%. Conclusion: The published data suggest that approximately one third of patients exposed to OBP will evidence depressed CTX levels and that only a very small minority (similar to 2%) will develop postexodontia MRONJ. Prudence would suggest that patients scheduled for exodontia and receiving OBPs should be informed about the strengths and weaknesses of the CTX test and that it should be offered during the consent process. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons C1 [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Ronald Reagan Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA. Ronald Reagan Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA. [Friedlander, Arthur H.; Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Inpatient Oral & Maxillofacial Surg, Los Angeles, CA 90073 USA. [Hazboun, Renna C.] Vet Affairs Greater Los Angeles Healthcare Syst, Dent Serv, Oral & Maxillofacial Surg Sect, Los Angeles, CA 90073 USA. [Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Educ, Los Angeles, CA 90024 USA. [Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Adv Prosthodont, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 25 TC 3 Z9 3 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD SEP PY 2015 VL 73 IS 9 BP 1735 EP 1740 DI 10.1016/j.joms.2015.03.015 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CP6SG UT WOS:000360017800018 PM 25863230 ER PT J AU Jacobson, IG Donoho, CJ Crum-Cianflone, NF Maguen, S AF Jacobson, Isabel G. Donoho, Carrie J. Crum-Cianflone, Nancy F. Maguen, Shira TI Longitudinal assessment of gender differences in the development of PTSD among US military personnel deployed in support of the operations in Iraq and Afghanistan SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE PTSD; Gender; Military; Combat; Sexual assault ID POSTTRAUMATIC-STRESS-DISORDER; MILLENNIUM COHORT; COMBAT DEPLOYMENT; MENTAL-HEALTH; FUNCTIONAL HEALTH; PRIMARY-CARE; PRIME-MD; PREVALENCE; VALIDATION; EXPOSURES AB Divergent findings from previous research examining gender differences in the development of post-traumatic stress disorder (PTSD) among US military members deployed to the operations in Iraq or Afghanistan (recent operations) prompted this study utilizing a matching approach to examine whether risk for new-onset PTSD and PTSD severity scores differed by gender. US military members from the Millennium Cohort Study deployed in support of the recent operations were followed for approximately 7 years from baseline through 2 follow-up periods between 2001 and 2008. Propensity score matching was used to match 1 male to each female using demographic, military, and behavioral factors including baseline sexual assault. Analyses were stratified by combat experience defined as reporting at least one of five exposures during follow-up. Outcome measures included a positive screen for PTSD and severity scores measured by the PTSD Patient Checklist Civilian Version. Discrete-time survival analysis quantified the association between gender and incident PTSD. Among 4684 matched subjects (2342 women and men), 6.7% of women and 6.1% of men developed PTSD during follow-up. Results showed no significant gender differences for the likelihood of developing PTSD or for PTSD severity scores among women and men who reported combat experience and among those who did not. This study is the first of its kind to match a large population of male and female service members on important baseline characteristics including sexual assault. Findings suggest that while combat deployed personnel develop PTSD, women do not have a significantly different risk for developing PTSD than men after experiencing combat. Published by Elsevier Ltd. C1 [Jacobson, Isabel G.; Donoho, Carrie J.; Crum-Cianflone, Nancy F.] Naval Hlth Res Ctr, Deployment Hlth Res Dept, San Diego, CA 92106 USA. [Donoho, Carrie J.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA. [Crum-Cianflone, Nancy F.] Naval Med Ctr San Diego, San Diego, CA USA. [Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA. [Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Donoho, CJ (reprint author), Naval Hlth Res Ctr, Deployment Hlth Res Dept, 140 Sylvester Rd, San Diego, CA 92106 USA. EM carrie.j.donoho.mil@mail.mil FU Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command, Fort Detrick, Maryland FX Funding/support: The Millennium Cohort Study is funded through the Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command, Fort Detrick, Maryland. The funding organization had no role in the design and conduct of the study; collection, analysis, or preparation of data; or preparation, review or approval of the manuscript. NR 36 TC 5 Z9 5 U1 3 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD SEP PY 2015 VL 68 BP 30 EP 36 DI 10.1016/j.jpsychires.2015.05.015 PG 7 WC Psychiatry SC Psychiatry GA CP5WM UT WOS:000359956100005 PM 26228397 ER PT J AU Maguen, S Madden, E Cohen, BE Bertenthal, D Neylan, TC Seal, KH AF Maguen, Shira Madden, Erin Cohen, Beth E. Bertenthal, Daniel Neylan, Thomas C. Seal, Karen H. TI Suicide risk in Iraq and Afghanistan veterans with mental health problems in VA care SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Suicide; Suicidal ideation; Mental health; Veteran; Veterans health ID POSTTRAUMATIC-STRESS-DISORDER; SERVICEMEMBERS ARMY STARRS; VIETNAM VETERANS; WARNING SIGNS; IDEATION; MILITARY; PREVALENCE; PTSD; RESILIENCE; DEPRESSION AB Suicide rates among U.S. military personnel and veterans are a public health concern, and those with mental health conditions are at particular risk. We examined demographic, military, temporal, and diagnostic associations with suicidality in veterans. We conducted a population-based, retrospective cohort study of all Iraq and Afghanistan war veterans who screened positive for posttraumatic stress disorder (PTSD) and/or depression, received a suicide risk assessment, and endorsed hopelessness about the present or future after their last deployment and between January 1, 2010 and June 29, 2014 (N = 45,741). We used bivariate and multivariate logistic regression analyses to examine variables associated with having endorsed suicidal thoughts and a plan. Multiple factors were associated with suicidality outcomes, including longer time from last deployment to screening (proxy for time to seeking VA care), an alcohol use disorder diagnosis, further distance from VA (rurality), and being active duty during military service. Hispanic veterans were at decreased risk of having suicidal ideation and a plan, compared to their white counterparts. In high-risk veterans, some of the strongest associations with suicidality were with modifiable risk factors, including time to VA care and alcohol use disorder diagnoses. Promising avenues for suicide prevention efforts can include early engagement/intervention strategies with a focus on amelioration of high-risk drinking. Published by Elsevier Ltd. C1 [Maguen, Shira; Madden, Erin; Cohen, Beth E.; Bertenthal, Daniel; Neylan, Thomas C.; Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Maguen, Shira; Cohen, Beth E.; Neylan, Thomas C.; Seal, Karen H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Bertenthal, Daniel; Neylan, Thomas C.] Mental Illness Res Educ & Clin Ctr, San Francisco, CA 94121 USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov; Erin.Madden@va.gov; Beth.Cohen@va.gov; Daniel.Bertenthal@va.gov; Thomas.Neylan@va.gov; Karen.Seal@va.gov FU Department of Defense [W81XWH-11-2-0189]; Sierra Pacific Mental Illness Research, Education and Clinical Center (MIRECC) FX This research was supported by Department of Defense Award Grant (W81XWH-11-2-0189) and the Sierra Pacific Mental Illness Research, Education and Clinical Center (MIRECC). The authors would like to thank Julie Dinh for her assistance with this manuscript. NR 37 TC 2 Z9 2 U1 8 U2 32 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD SEP PY 2015 VL 68 BP 120 EP 124 DI 10.1016/j.jpsychires.2015.06.013 PG 5 WC Psychiatry SC Psychiatry GA CP5WM UT WOS:000359956100019 PM 26228410 ER PT J AU Rajaram, R Chung, JW Cohen, ME Dahlke, AR Yang, AD Meeks, JJ Ko, CY Tarpley, JL Hoyt, DB Bilimoria, KY AF Rajaram, Ravi Chung, Jeanette W. Cohen, Mark E. Dahlke, Allison R. Yang, Anthony D. Meeks, Joshua J. Ko, Clifford Y. Tarpley, John L. Hoyt, David B. Bilimoria, Karl Y. TI Association of the 2011 ACGME Resident Duty Hour Reform with Postoperative Patient Outcomes in Surgical Specialties SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID INSTITUTE-OF-MEDICINE; HOURS ENHANCING SLEEP; ACCREDITATION COUNCIL; WORKING HOURS; SURGERY; QUALITY; SAFETY; MORTALITY; RESTRICTIONS; EDUCATION AB BACKGROUND: The 2011 ACGME resident duty hour reform implemented additional restrictions to existing duty hour policies. Our objective was to determine the association between this reform and patient outcomes among several surgical specialties. STUDY DESIGN: Patients from 5 surgical specialties (neurosurgery, obstetrics/gynecology, orthopaedic surgery, urology, and vascular surgery) were identified from the American College of Surgeons NSQIP. Data from 1 year before and 2 years after the reform was implemented were obtained for teaching and nonteaching hospitals. Hospital teaching status was defined based on the percentage of operations with a resident present intraoperatively. Difference-in-differences models were developed separately for each specialty and adjusted for patient demographics, comorbidities, procedural case-mix, and time trends. The association between duty hour reform and a composite measure of death or serious morbidity within 30 days of surgery was estimated for each specialty. RESULTS: The unadjusted rate of death or serious morbidity decreased during the study period in both teaching and nonteaching hospitals for all surgical specialties. In multivariable analyses, there were no significant associations between duty hour reform and the composite outcomes of death or serious morbidity in the 2 years post-reform for any surgical specialty evaluated (neurosurgery: odds ratio [OR] = 0.90; 95% CI, 0.75-1.08; p = 0.26; obstetrics/gynecology: OR = 0.96; 95% CI, 0.71-1.30; p = 0.80; orthopaedic surgery: OR = 0.95; 95% CI, 0.74-1.22; p = 0.70; urology: OR = 1.16; 95% CI, 0.89-1.51; p = 0.26; vascular surgery: OR = 1.07; 95% CI, 0.93-1.22; p = 0.35). CONCLUSIONS: Implementation of the 2011 ACGME resident duty hour reform was not associated with a significant change in patient outcomes for several surgical specialties in the 2 years after reform. (C) 2015 by the American College of Surgeons C1 [Rajaram, Ravi; Cohen, Mark E.; Ko, Clifford Y.; Hoyt, David B.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Rajaram, Ravi; Chung, Jeanette W.; Dahlke, Allison R.; Yang, Anthony D.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, SOQIC, Dept Surg, Chicago, IL 60611 USA. [Rajaram, Ravi; Chung, Jeanette W.; Dahlke, Allison R.; Yang, Anthony D.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Inst Publ Hlth & Med, Chicago, IL 60611 USA. [Meeks, Joshua J.] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tarpley, John L.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN USA. RP Rajaram, R (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM rrajaram@facs.org FU Agency for Healthcare Research and Quality [T32HS000078]; American College of Surgeons Clinical Scholars in Residence Program; Merck FX Dr Rajaram is supported by the Agency for Healthcare Research and Quality #T32HS000078, the American College of Surgeons Clinical Scholars in Residence Program, and an unrestricted educational grant from Merck. The sponsors had no part in the design and conduct of the study; analysis and interpretation of the data; and preparation or approval of the manuscript. The sponsors had no access to the data and did not perform any of the analyses. NR 38 TC 8 Z9 8 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2015 VL 221 IS 3 BP 748 EP 757 DI 10.1016/j.jamcollsurg.2015.06.010 PG 10 WC Surgery SC Surgery GA CP7UK UT WOS:000360093800014 PM 26228013 ER PT J AU Singh, JA Ramachandran, R AF Singh, Jasvinder A. Ramachandran, Rekha TI Are there racial disparities in utilization and outcomes after total elbow arthroplasty? SO RHEUMATOLOGY INTERNATIONAL LA English DT Article DE Racial disparities; Total elbow arthroplasty; Race; Utilization; Outcomes; Mortality; Discharge; Hospital stay ID UNITED-STATES; HIP-REPLACEMENT; TOTAL SHOULDER; VOLUME; TRENDS AB The aim of the study was to assess racial disparities in utilization rates and outcomes after primary total elbow arthroplasty (TEA). We used the National Inpatient Sample from 1998 to 2010, a US national database. Patient characteristics, comorbidity and outcomes after TEA were assessed over time and differences by race studied over the study period. Cochran-Armitage test was used for time trends and logistic regression for the comparison of outcomes by race. In 1998, TEA utilization rate was 0.38/100,000 in Whites and 0.24/100,000 in Blacks (p = 0.002); in 2010, it was 0.91 and 0.59/100,000, respectively (p < 0.0001). White-Black disparity in TEA utilization was significant across 13 years (p = 0.03). Compared with White patients, Black patients undergoing TEA were younger (61.9 vs. 52 years; p < 0.0001), less likely to be female (70.6 vs. 61.4 %; p = 0.0007) and more likely to have rheumatoid arthritis as the underlying diagnosis (13.0 vs. 17.2 %; p = 0.036). Mortality was rare, 0.26 % in Blacks and 0.32 % in Whites (p = 0.83). Discharge to an inpatient facility was higher in White versus Black patients in unadjusted analyses (16.8 vs. 10.4 %; p = 0.003), but in analyses adjusted for age, sex, Deyo-Charlson index and the underlying diagnosis, the differences were no longer significant (p = 0.79). The length of hospital stay greater than the median stay was noted in 29.8 % Whites versus 31.2 % Blacks, respectively (p = 0.61). There was no evidence of White-Black disparity in hospital length of stay in 1998-2000 (p = 0.66) or 2009-2010 (p = 0.59) periods. In this study, we found persisting racial disparities in TEA utilization rates. No White-Black disparities were noted in TEA outcomes, except slight differences in discharge disposition. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. EM Jasvinder.md@gmail.com FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging (NIA); National Cancer Institute (NCI) FX This material is the result of work supported by the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. J.A.S. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute of Aging (NIA) and National Cancer Institute (NCI). NR 13 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0172-8172 EI 1437-160X J9 RHEUMATOL INT JI Rheumatol. Int. PD SEP PY 2015 VL 35 IS 9 BP 1479 EP 1487 DI 10.1007/s00296-015-3252-y PG 9 WC Rheumatology SC Rheumatology GA CP4EG UT WOS:000359834200004 PM 25812536 ER PT J AU Quinzanos, I Hirsh, JM Bright, C Caplan, L AF Quinzanos, Itziar Hirsh, Joel M. Bright, Christina Caplan, Liron TI Cross-sectional correlation of single-item health literacy screening questions with established measures of health literacy in patients with rheumatoid arthritis SO RHEUMATOLOGY INTERNATIONAL LA English DT Article DE Rheumatoid arthritis; Health literacy; Patient outcome assessment; Vulnerable populations ID ASSOCIATION; HOSPITALS; OUTCOMES; ADULTS; SKILLS AB Research suggests that health literacy (HL) is associated with rheumatoid arthritis (RA) patients' functional status. Single-item health literacy screening (SILS) questionnaires may establish patients' HL; however, the wording of SILS may be misinterpreted by RA patients as a query regarding physical limitations. Despite this threat to validity, multiple publications have employed the SILSs as a measure of health literacy. We assessed the construct validity of two SILS's versions by correlating scores with standardized HL measures. English-speaking adult RA patients at a hospital serving low-income patients were enrolled in a cross-sectional study. Subjects completed two SILS versions, as well as two longer HL measurement tools [short test of functional health literacy in adults (s-TOFHLA) and the rapid estimate of adult literacy in medicine (REALM)]. Spearman correlation was used to compare these tools. The study enrolled 110 subjects. There was a good correlation between the two SILS versions (r = 0.705). The correlation of SILS2 and REALM or s-TOFHLA was less robust. The distribution of scores within each SILS2 category demonstrated substantial variation. The SILS2 has construct validity in the assessment of HL in patients with RA, though its correlation with traditional methods of assessing HL is weak. C1 [Quinzanos, Itziar; Caplan, Liron] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA. [Quinzanos, Itziar; Hirsh, Joel M.; Bright, Christina; Caplan, Liron] Univ Colorado, Sch Med, Dept Med, Div Rheumatol, Aurora, CO 80045 USA. [Hirsh, Joel M.] Denver Hlth Med Ctr, Dept Internal Med, Div Rheumatol, Denver, CO 80204 USA. RP Quinzanos, I (reprint author), Denver Vet Affairs Med Ctr, Dept Med, 1055 Clermont St,Res A151, Denver, CO 80220 USA. EM itziar.quinzanos@ucdenver.edu; Joel.Hirsh@dhha.org; Christina.m.bright@gmail.com; Liron.Caplan@ucdenver.edu FU VA HSR&D Career Development Award [07-221, 09-388] FX Dr. Caplan is supported by a VA HSR&D Career Development Award (07-221 and 09-388). The funding sources had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 22 TC 1 Z9 1 U1 2 U2 5 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0172-8172 EI 1437-160X J9 RHEUMATOL INT JI Rheumatol. Int. PD SEP PY 2015 VL 35 IS 9 BP 1497 EP 1502 DI 10.1007/s00296-015-3238-9 PG 6 WC Rheumatology SC Rheumatology GA CP4EG UT WOS:000359834200006 PM 25744280 ER PT J AU Durazzo, TC Mon, A Gazdzinski, S Yeh, PH Meyerhoff, DJ AF Durazzo, Timothy C. Mon, Anderson Gazdzinski, Stefan Yeh, Ping-Hong Meyerhoff, Dieter J. TI Serial longitudinal magnetic resonance imaging data indicate non-linear regional gray matter volume recovery in abstinent alcohol-dependent individuals SO ADDICTION BIOLOGY LA English DT Article DE Alcohol use disorders; brain volume; cigarette smoking; cognition; recovery ID CHRONIC CIGARETTE-SMOKING; NATIONAL EPIDEMIOLOGIC SURVEY; USE DISORDERS; TREATMENT-SEEKING; BRAIN VOLUMES; NEUROCOGNITION; PREVALENCE; MECHANISMS; DRINKERS; RELAPSE AB The trajectory of regional volume changes during the first year of sustained abstinence in those recovering from an alcohol use disorder is unclear because previous research typically employed only two assessment points. To better understand the trajectory of regional brain volume recovery in treatment-seeking alcohol-dependent individuals (ALC), regional brain volumes were measured after 1 week, 1 month and 7.5 months of sustained abstinence via magnetic resonance imaging at 1.5T. ALC showed significant volume increases in frontal, parietal and occipital gray matter (GM) and white matter (WM), total cortical GM and total lobar WM, thalamus and cerebellum, and decreased ventricular volume over 7.5 months of abstinence. Volume increases in regional GM were significantly greater over 1 week to 1 month than from 1 month to 7.5 months of abstinence, indicating a non-linear rate of change in regional GM over 7.5 months. Overall, regional lobar WM showed linear volume increases over 7.5 months. With increasing age, smoking ALC showed lower frontal and total cortical GM volume recovery than non-smoking ALC. Despite significant volume increases, ALC showed smaller GM volumes in all regions, except the frontal cortex, than controls after 7.5 months of abstinence. ALC and controls showed no regional WM volume differences at any assessment point. In non-smoking ALC only, increasing regional GM and WM volumes were related to improving processing speed. Findings may indicate a differential rate of recovery of cell types/cellular components contributing to GM and WM volume during early abstinence, and that GM volume deficits persist after 7.5 months of sustained sobriety in this ALC cohort. C1 [Durazzo, Timothy C.; Mon, Anderson; Gazdzinski, Stefan; Yeh, Ping-Hong; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Durazzo, Timothy C.; Mon, Anderson; Gazdzinski, Stefan; Yeh, Ping-Hong; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu FU National Institutes of Health [DA24136, AA10788] FX This work was supported by grants from the National Institutes of Health (DA24136 to T.C.D and AA10788 to D.J.M.) administered by the Northern California Institute for Research and Education, and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. We thank Mary Rebecca Young, Bill Clift, Ricky Chen, and Drs. Ellen Herbst, Peter Banys and Steven Batki of the San Francisco VA Medical Center Substance Abuse Day Hospital, and Dr. David Pating, Karen Moise and their colleagues at the Kaiser Permanente Chemical Dependency Recovery Program in San Francisco for their valuable assistance in participant recruitment. We also thank Mary Vertinski and Molly Estrin for their assistance in the neurocognitive and clinical assessment of participants. Finally, we thank the study participants who made this research possible. NR 48 TC 7 Z9 7 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 EI 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD SEP PY 2015 VL 20 IS 5 BP 956 EP 967 DI 10.1111/adb.12180 PG 12 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA CP1XF UT WOS:000359670200009 PM 25170881 ER PT J AU Childers, RE Williams, JL Sonnenberg, A AF Childers, Ryan E. Williams, J. Lucas Sonnenberg, Amnon TI Practice patterns of sedation for colonoscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID UPPER GASTROINTESTINAL ENDOSCOPY; COLORECTAL-CANCER; UNITED-STATES; RACIAL/ETHNIC DISPARITIES; MEDICARE BENEFICIARIES; CONSCIOUS SEDATION; RACIAL-DIFFERENCES; DIAGNOSTIC YIELD; AFRICAN-AMERICAN; WEB SURVEY AB Background: Sedative and analgesic medications have been used routinely for decades to provide patient comfort, reduce procedure time, and improve examination quality during colonoscopy. Objective: To evaluate trends of sedation during colonoscopy in the United States. Setting: Endoscopic data repository of U.S. gastroenterology practices (Clinical Outcomes Research Initiative, CORI database from 2000 until 2013). Patients: The study population was made up of patients undergoing a total of 1,385,436 colonoscopies. Interventions: Colonoscopy without any intervention or with mucosal biopsy, polypectomy, various means of hemostasis, luminal dilation, stent placement, or ablation. Main Outcome Measurements: Dose of midazolam, diazepam, fentanyl, meperidine, diphenhydramine, promethazine, and propofol used for sedation during colonoscopy. Results: During the past 14 years, midazolam, fentanyl, and propofol have become the most commonly used sedatives for colonoscopy. Except for benzodiazepines, which were dosed higher in women than men, equal doses of sedation were given to female and male patients. White patients were given higher doses than other ethnic groups undergoing sedation for colonoscopy. Except for histamine-1 receptor antagonists, all sedative medications were given at lower doses to patients with increasing age. The dose of sedatives was higher in colonoscopies associated with procedural interventions or of long duration. Limitations: Potential for incomplete or incorrect documentation in the database. Conclusion: The findings reflect on colonoscopy practice in the United States during the last 14 years and provide an incentive for future research on how sex and ethnicity influence sedation practices. C1 Portland VA Med Ctr, Div Gastroenterol & Hepatol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. FU NIDDK [UO1 CA 89389-01, U01 DK057132, R33-DK61778-01] FX This project was supported with funding from NIDDK UO1 CA 89389-01, NIDDK U01 DK057132, and R33-DK61778-01. In addition, the practice network (Clinical Outcomes Research Initiative) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Novartis, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. All authors disclosed no financial relationships relevant to this article. NR 52 TC 2 Z9 2 U1 2 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD SEP PY 2015 VL 82 IS 3 BP 503 EP 511 DI 10.1016/j.gie.2015.01.041 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP0XX UT WOS:000359601300013 PM 25851159 ER PT J AU Shergill, AK Conners, EE McQuaid, KR Epstein, S Ryan, JC Shah, JN Inadomi, J Somsouk, M AF Shergill, Amandeep K. Conners, Erin E. McQuaid, Kenneth R. Epstein, Sara Ryan, James C. Shah, Janak N. Inadomi, John Somsouk, Ma TI Protective association of colonoscopy against proximal and distal colon cancer and patterns in interval cancer SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID COLORECTAL-CANCER; SCREENING SIGMOIDOSCOPY; LOWER ENDOSCOPY; MORTALITY; POLYP; RISK; PREVENTION; VETERANS; DEATH; SURVEILLANCE AB Background: The protective effect of colonoscopy against proximal colorectal cancer is variable and depends on the detection and complete removal of precancerous polyps. Objective: To estimate the efficacy of colonoscopy in a medical center with open-access screening colonoscopy since 1998. Design: Nested case-control study with incidence density sampling. Setting: University-affiliated Veterans Affairs Medical Center. Patients: Colorectal cancer (CRC) cases and control subjects selected from screening age patients matched by age, gender, and date of first primary care visit. Main Outcome Measurement: Colonoscopy preceding the CRC diagnosis date. Results: A total of 20.2% of CRC cases had a colonoscopy in the preceding 10 years compared with 49.0% of control subjects (adjusted odds ratio [aOR], 0.20; 95% confidence interval [CI], 0.11-0.34). Colonoscopy was strongly associated with decreased odds of both distal CRC (aOR, 0.16; 95% CI, 0.07-0.34) and proximal CRC (aOR, 0.26; 95% CI, 0.11-0.58). The fraction of cases attributed to interval cancers was 10.5%. Missed lesions predominantly localized to the cecum and rectum, and recurrent lesions clustered in the hepatic flexure. Cecal intubation rate was 93% (98% in adequately prepped patients), and the adenoma detection rate was 45.2% in the control group. Limitations: Single-center, retrospective case-control design. Conclusion: In an open access colonoscopy program characterized by a high cecal intubation rate and adenoma detection rate, colonoscopy was strongly associated with reduced odds of both distal and proximal CRC. Among interval cancers, missed lesions clustered in the cecum and rectum and recurrent lesions in the hepatic flexure. C1 [Shergill, Amandeep K.; Conners, Erin E.; McQuaid, Kenneth R.; Ryan, James C.; Shah, Janak N.] San Francisco VA Med Ctr, Div Gastroenterol, Dept Med, San Francisco, CA USA. [Shergill, Amandeep K.; Conners, Erin E.; McQuaid, Kenneth R.; Ryan, James C.; Shah, Janak N.; Somsouk, Ma] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Conners, Erin E.] Univ Calif San Diego, Joint Doctoral Program Publ Hlth, San Diego, CA 92103 USA. [Conners, Erin E.] San Diego State Univ, San Diego, CA 92182 USA. [Epstein, Sara] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Inadomi, John] Univ Washington, Dept Med, Div Gastroenterol & Hepatol, Seattle, WA USA. [Somsouk, Ma] San Francisco Gen Hosp, Dept Med, Div Gastroenterol, San Francisco, CA 94110 USA. RP Shergill, AK (reprint author), 4150 Clement St, San Francisco, CA 94121 USA. FU National Institutes of Health [K23 CA157929] FX The following author received research support for this study from the National Institutes of Health (K23 CA157929): M. Somsouk. All authors disclosed no financial relationships relevant to this publication. NR 46 TC 6 Z9 6 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD SEP PY 2015 VL 82 IS 3 BP 529 EP + DI 10.1016/j.gie.2015.01.053 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP0XX UT WOS:000359601300017 PM 25936449 ER PT J AU Farrand, AJ Haley, KP Lareau, NM Heilbronner, S McLean, JA Foster, T Skaar, EP AF Farrand, Allison J. Haley, Kathryn P. Lareau, Nichole M. Heilbronner, Simon McLean, John A. Foster, Timothy Skaar, Eric P. TI An Iron-Regulated Autolysin Remodels the Cell Wall To Facilitate Heme Acquisition in Staphylococcus lugdunensis SO INFECTION AND IMMUNITY LA English DT Article ID SURFACE-PROTEINS; LYTIC TRANSGLYCOSYLASES; N-ACETYLGLUCOSAMINIDASE; HEMOGLOBIN BINDING; ANCHOR STRUCTURE; AUREUS HEME; SORTASE; BACTERIAL; ISDC; PATHOGENESIS AB Bacteria alter their cell surface in response to changing environments, including those encountered upon invasion of a host during infection. One alteration that occurs in several Gram-positive pathogens is the presentation of cell wall-anchored components of the iron-regulated surface determinant (Isd) system, which extracts heme from host hemoglobin to fulfill the bacterial requirement for iron. Staphylococcus lugdunensis, an opportunistic pathogen that causes infective endocarditis, encodes an Isd system. Unique among the known Isd systems, S. lugdunensis contains a gene encoding a putative autolysin located adjacent to the Isd operon. To elucidate the function of this putative autolysin, here named IsdP, we investigated its contribution to Isd protein localization and hemoglobin-dependent iron acquisition. S. lugdunensis IsdP was found to be iron regulated and cotranscribed with the Isd operon. IsdP is a specialized peptidoglycan hydrolase that cleaves the stem peptide and pentaglycine cross-bridge of the cell wall and alters processing and anchoring of a major Isd system component, IsdC. Perturbation of IsdC localization due to isdP inactivation results in a hemoglobin utilization growth defect. These studies establish IsdP as an autolysin that functions in heme acquisition and describe a role for IsdP in cell wall reorganization to accommodate nutrient uptake systems during infection. C1 [Farrand, Allison J.; Haley, Kathryn P.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Lareau, Nichole M.; McLean, John A.] Vanderbilt Univ, Dept Chem, Ctr Innovat Technol, Inst Chem Biol, Nashville, TN USA. [Lareau, Nichole M.; McLean, John A.] Vanderbilt Univ, Inst Integrat Biosyst Res & Educ, Nashville, TN 37235 USA. [Heilbronner, Simon; Foster, Timothy] Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin, Ireland. [Skaar, Eric P.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. EM eric.skaar@vanderbilt.edu FU NIH [RO1 AI069233, RO1 AI101171]; NIAID; Department of Veterans Affairs Merit Award [INFB-024-13F]; National Institutes of Health [R01GM092218]; Vanderbilt Chemical Biology Interface training program [5RT32GM065086] FX This research was supported by NIH RO1 AI069233, funded by the NIAID ( E.P.S.). The Skaar laboratory is also supported by Department of Veterans Affairs Merit Award INFB-024-13F and NIH RO1 AI101171. Funding for J.A.M. and N.M.L. was provided by the National Institutes of Health (R01GM092218). Additional funding for N.M.L. was provided by the Vanderbilt Chemical Biology Interface training program (5RT32GM065086) supported by the NIH. NR 49 TC 4 Z9 4 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD SEP PY 2015 VL 83 IS 9 BP 3578 EP 3589 DI 10.1128/IAI.00397-15 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CO8QP UT WOS:000359435600023 PM 26123800 ER PT J AU Bril, F Ortiz-Lopez, C Lomonaco, R Orsak, B Freckleton, M Chintapalli, K Hardies, J Lai, S Solano, F Tio, F Cusi, K AF Bril, Fernando Ortiz-Lopez, Carolina Lomonaco, Romina Orsak, Beverly Freckleton, Michael Chintapalli, Kedar Hardies, Jean Lai, Song Solano, Felipe Tio, Fermin Cusi, Kenneth TI Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients SO LIVER INTERNATIONAL LA English DT Article DE hepatic steatosis; NAFLD; NASH; Obesity; steatohepatitis ID MAGNETIC-RESONANCE-SPECTROSCOPY; HEPATIC STEATOSIS; METABOLIC PARAMETERS; INSULIN-RESISTANCE; STEATOHEPATITIS; PREVALENCE; NAFLD; ULTRASONOGRAPHY; HISTOLOGY; ACCURACY AB Background & AimsLiver ultrasound (US) is usually used in the clinical setting for the diagnosis and follow-up of patients with nonalcoholic fatty liver disease (NAFLD). However, no large study has carefully assessed its performance using a semiquantitative ultrasonographic scoring system in overweight/obese patients, in comparison to magnetic resonance spectroscopy (H-1-MRS) and histology. MethodsWe recruited 146 patients and performed: a liver US using a 5-parameter scoring system, a liver H-1-MRS to quantify liver fat content, and a liver biopsy to assess histology. All measurements were repeated in a subgroup of patients (n=62) after 18months of follow-up. ResultsThe performance of liver US (parenchymal echo alone) was rather modest, and significantly worse than H-1-MRS (AUROC: 0.82 [0.69-0.94] vs. 0.96 [0.90-1.00]; P=0.04). However, the AUROC improved when different echographic parameters were taken into account (AUROC: 0.89 [0.83-0.96], P=0.15 against H-1-MRS). Optimum sensitivity for liver US was achieved at a liver fat content 12.5%, suggesting that below this threshold, liver US is less sensitive. Liver H-1-MRS showed a high accuracy for the diagnosis of NAFLD, and correlated strongly with histological steatosis (r=0.73, P<0.0001). None of the imaging tests was adequate enough to predict changes over time in histology. ConclusionsDespite its widespread use, liver US has several important limitations that healthcare providers should recognize, particularly because of its low sensitivity. Using a combination of echographic parameters, liver US showed a significant improvement in its diagnostic performance, but still was of limited value for monitoring treatment over time. C1 [Bril, Fernando; Lomonaco, Romina; Cusi, Kenneth] Univ Florida, Div Endocrinol Diabet & Metab, Gainesville, FL 32610 USA. [Bril, Fernando; Lomonaco, Romina; Cusi, Kenneth] Malcom Randall Vet Adm Med Ctr, Gainesville, FL USA. [Ortiz-Lopez, Carolina; Orsak, Beverly; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA. [Freckleton, Michael; Chintapalli, Kedar; Hardies, Jean] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Lai, Song] Univ Florida, McKnight Brain Inst, Clin Translat Sci Inst, Human Imaging Core, Gainesville, FL 32610 USA. [Solano, Felipe; Tio, Fermin] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Cusi, Kenneth] Audie L Murphy Vet Adm Med Ctr, San Antonio, TX USA. RP Cusi, K (reprint author), Univ Florida, Div Endocrinol Diabet & Metab, 1600 SW Archer Rd,Room H-2, Gainesville, FL 32610 USA. EM Kenneth.Cusi@medicine.ufl.edu FU Burroughs Wellcome Fund; American Diabetes Association [1-08-CR-08]; VA Merit Award [1 I01 CX000167-01] FX Financial support: Supported by the Burroughs Wellcome Fund (K. C.), the American Diabetes Association (1-08-CR-08 [K. C.]) and a VA Merit Award (1 I01 CX000167-01 [K. C.]). NR 33 TC 19 Z9 19 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1478-3223 EI 1478-3231 J9 LIVER INT JI Liver Int. PD SEP PY 2015 VL 35 IS 9 BP 2139 EP 2146 DI 10.1111/liv.12840 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP2KI UT WOS:000359705500011 PM 25847730 ER PT J AU Gensheimer, MF Hummel-Kramer, SM Cain, D Quang, TS AF Gensheimer, Michael F. Hummel-Kramer, Sharon M. Cain, David Quang, Tony S. TI Simple tool for prediction of parotid gland sparing in intensity-Modulated radiation therapy SO MEDICAL DOSIMETRY LA English DT Article DE IMRT; Parotid gland; Head and neck cancer; Process improvement ID VOLUME; IMRT; HEAD AB Sparing one or both parotid glands is a key goal when planning head and neck cancer radiation treatment. If the planning target volume (PTV) overlaps one or both parotid glands substantially, it may not be possible to achieve adequate gland sparing. This finding results in physicians revising their PTV contours after an intensity-modulated radiation therapy (IMRT) plan has been run and reduces workflow efficiency. We devised a simple formula for predicting mean parotid gland dose from the overlap of the parotid gland and isotropically expanded PTV contours. We tested the tool using 44 patients from 2 institutions and found agreement between predicted and actual parotid gland doses (mean absolute error = 5.3 Gy). This simple method could increase treatment planning efficiency by improving the chance that the first plan presented to the physician will have optimal parotid gland sparing. Published by Elsevier Inc. on behalf of American Association of Medical Dosimetrists C1 [Gensheimer, Michael F.] Univ Washington, Med Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA. [Hummel-Kramer, Sharon M.; Cain, David; Quang, Tony S.] VA Puget Sound Hlth Care Syst, Dept Radiat Oncol, Seattle, WA 98108 USA. RP Hummel-Kramer, SM (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mail Stop S-111 RadOnc, Seattle, WA 98108 USA. EM sharonhummel@comcast.net FU Department of Veterans Affairs FX We thank Drs. Upendra Parvathaneni and Jay Liao at the University of Washington for allowing us to include their patients in this study. This research was conducted with support from the Department of Veterans Affairs. NR 6 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0958-3947 EI 1873-4022 J9 MED DOSIM JI Med. Dosim. PD FAL PY 2015 VL 40 IS 3 BP 232 EP 234 DI 10.1016/j.meddos.2015.01.002 PG 3 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA CO8VD UT WOS:000359449400012 PM 25704638 ER PT J AU Wu, JX Dawes, AJ Sacks, GD Brunicardi, FC Keeler, EB AF Wu, James X. Dawes, Aaron J. Sacks, Greg D. Brunicardi, F. Charles Keeler, Emmett B. TI Cost effectiveness of nonoperative management versus laparoscopic appendectomy for acute uncomplicated appendicitis SO SURGERY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; PERFORATED APPENDICITIS; ANTIBIOTIC-TREATMENT; CLAVULANIC-ACID; METAANALYSIS; THERAPY; SURGERY; OUTCOMES; DIVERTICULITIS AB Background. Appendectomy remains the gold standard in the treatment of acute, uncomplicated appendicitis in the United States. Nonetheless, there is growing evidence that nonoperative management is safe and efficacious. Methods. We constructed a decision tree to compare nonoperative management of appendicitis with laparoscopic appendectomy in otherwise healthy adults. Model variables were abstracted from a literature review, data from the Healthcare Cost and Utilization Project data, the Medicare Physician Fee schedule, and the American College of Surgeons Surgical Risk Calculator. Uncertainty surrounding parameters of the model was assessed via 1-way and probabilistic sensitivity analyses. Results. Operative management cost $12,213 per patient. Nonoperative management without interval appendectomy (IA) was the dominant strategy, costing $1,865 less and producing 0.03 more quality-adjusted life-years (QALYs). Nonoperative management with IA cost $4,271 more than operative management, but yielded only 0.01 additional QALY. One-way sensitivity analysis suggested operative management would become the preferred strategy if the recurrence rate was >40.5% or the total cost of appendectomy was decreased to <$5,468. Probabilistic sensitivity analysis confirmed nonoperative management without IA was the preferred strategy in 95.6% of cases. Conclusion. Nonoperative management without IA is the least costly, most effective treatment for acute, uncomplicated appendicitis and warrants further evaluation in a disease thought to be definitively surgical. C1 [Wu, James X.; Dawes, Aaron J.; Sacks, Greg D.; Brunicardi, F. Charles] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Dawes, Aaron J.; Sacks, Greg D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dawes, Aaron J.; Sacks, Greg D.; Keeler, Emmett B.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Keeler, Emmett B.] RAND Corp, Santa Monica, CA USA. RP Wu, JX (reprint author), 757 Westwood Blvd,Mail Room B711, Los Angeles, CA 90095 USA. EM JamesWu@mednet.ucla.edu OI Dawes, Aaron/0000-0003-4574-6765 FU Robert Wood Johnson Foundation; VA Office of Academic Affiliations; H. H. Lee Research Award FX This work was supported by the Robert Wood Johnson Foundation Clinical Scholars Program (Dr Dawes, Dr Sacks), VA Office of Academic Affiliations (Dr Dawes), and H. H. Lee Research Award (Dr James Wu). NR 39 TC 3 Z9 3 U1 1 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD SEP PY 2015 VL 158 IS 3 BP 712 EP 721 DI 10.1016/j.surg.2015.06.021 PG 10 WC Surgery SC Surgery GA CP3CS UT WOS:000359755000017 PM 26195106 ER PT J AU Young, MRI Levingston, C Johnson, SD AF Young, M. Rita I. Levingston, Corinne Johnson, Sara D. TI Cytokine and Adipokine Levels in Patients with Premalignant Oral Lesions or in Patients with Oral Cancer Who Did or Did Not Receive 1 alpha,25-Dihydroxyvitamin D-3 Treatment upon Cancer Diagnosis SO CANCERS LA English DT Article DE adipokines; cytokines; HNSCC; inflammation; oral cancer; premalignant lesions AB Differences in levels of inflammation-modulating cytokines and adipokines in patients with premalignant oral lesions versus in patients that develop squamous cell carcinoma of the head and neck (HNSCC) were assessed. Also assessed was the impact of treating HNSCC patients with the immune regulatory mediator, 1 alpha,25-dihydroxyvitamin D3 [1,25(OH)(2)D-3], on modulators of inflammation. Compared to healthy controls, patients with premalignant oral lesions had increases in their systemic levels of the inflammatory cytokines IL-6 and IL-17, and increases in the adipokine, leptin. However, levels of these pro-inflammatory cytokines and adipokine were reduced in patients with HNSCC. Treatment of HNSCC patients with 1,25(OH)(2)D-3 increased levels of each of the measured immune mediators. Levels of the anti-inflammatory adipokine, adiponectin, were shifted inversely with the levels of the pro-inflammatory cytokines and with leptin. These studies demonstrate heightened immune reactivity in patients with premalignant lesions, which wanes in patients with HNSCC, but which is restored by treatment with 1,25(OH)(2)D-3. C1 [Young, M. Rita I.; Levingston, Corinne] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. [Young, M. Rita I.; Johnson, Sara D.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@va.gov; cos25@musc.edu; johsad@musc.edu FU Department of Veterans Affairs [I01-CX000100, I01-CX000851]; National Institutes of Health [R01-CA128837, R01-DE018268] FX This work was supported by Clinical Sciences Research awards I01-CX000100 and I01-CX000851 from the Department of Veterans Affairs and by grants R01-CA128837 and R01-DE018268 from the National Institutes of Health (M.R.I. Young). NR 58 TC 3 Z9 3 U1 0 U2 0 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2072-6694 J9 CANCERS JI Cancers PD SEP PY 2015 VL 7 IS 3 BP 1109 EP 1124 DI 10.3390/cancers7030827 PG 16 WC Oncology SC Oncology GA V47KR UT WOS:000209951200001 PM 26120967 ER PT J AU McCarthy, FH Groeneveld, PW Kobrin, D McDermott, KM Wirtalla, C Desai, ND AF McCarthy, Fenton H. Groeneveld, Peter W. Kobrin, Dale McDermott, Katherine M. Wirtalla, Christopher Desai, Nimesh D. TI Effect of Clinical Trial Experience on Transcatheter Aortic Valve Replacement Outcomes SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE aortic valve stenosis; clinical trial; comorbidity; medicare; transcatheter aortic valve replacement AB Background-Transcatheter aortic valve replacement (TAVR) was approved by the Food and Drug Administration (FDA) in November 2011 after a collaborative technology development process involving professional medical societies, the medical device industry, and the FDA. After FDA approval, TAVR was adopted by numerous hospitals that had not participated in TAVR clinical trials. It is uncertain if outcomes at these hospitals were comparable with those at clinical trial hospitals. Methods and Results-All patients with Medicare physician claims for TAVR between January 1, 2011, and November 30, 2012, were identified, and postoperative mortality was assessed using Medicare enrollment data. Risk-adjusted mortality was calculated via a multivariable model that adjusted for demographics and comorbidities. We identified 5009 patients who underwent TAVR, with 3617 TAVRs performed at 68 hospitals that had participated in clinical trials and 1392 TAVRs performed at 140 nontrial hospitals. The preoperative characteristics of patients at trial versus nontrial hospitals were similar. There were no significant differences in risk-adjusted 30-day mortality (5.9% versus 5.6%, odds ratio, 0.88; 95% confidence interval, 0.66-1.15; P=0.34) or 180-day mortality (16.5% versus 15.8%, odds ratio, 0.99; 95% confidence interval, 0.75-1.3; P=0.94). Conclusions-Patients undergoing TAVR at nontrial hospitals had comparable clinical outcomes to patients undergoing TAVR at clinical trial hospitals. This finding contrasts with several other cardiovascular devices and procedures for which higher mortality was observed at hospitals that did not participate in clinical trials. The unique policy and regulatory environment governing TAVR adoption by hospitals may have contributed to better outcomes during the technology diffusion process. C1 [McCarthy, Fenton H.; Groeneveld, Peter W.; Desai, Nimesh D.] Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. [McCarthy, Fenton H.; Kobrin, Dale; McDermott, Katherine M.; Desai, Nimesh D.] Univ Penn, Perelman Sch Med, Div Cardiovasc Surg, 3400 Spruce St,6 Silverstein, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.; Wirtalla, Christopher] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA. [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Desai, ND (reprint author), Univ Penn, Perelman Sch Med, Div Cardiovasc Surg, 3400 Spruce St,6 Silverstein, Philadelphia, PA 19104 USA. EM Nimesh.Desai@uphs.upenn.edu NR 19 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7640 EI 1941-7632 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD SEP PY 2015 VL 8 IS 9 AR e002234 DI 10.1161/CIRCINTERVENTIONS.114.002234 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V47VK UT WOS:000209979100002 PM 26286740 ER PT J AU Prigerson, HG Bao, YH Shah, MA Paulk, ME LeBlanc, TW Schneider, BJ Garrido, MM Reid, MC Berlin, DA Adelson, KB Neugut, AI Maciejewski, PK AF Prigerson, Holly G. Bao, Yuhua Shah, Manish A. Paulk, M. Elizabeth LeBlanc, Thomas W. Schneider, Bryan J. Garrido, Melissa M. Reid, M. Carrington Berlin, David A. Adelson, Kerin B. Neugut, Alfred I. Maciejewski, Paul K. TI Chemotherapy Use, Performance Status, and Quality of Life at the End of Life SO JAMA ONCOLOGY LA English DT Article ID METASTATIC BREAST-CANCER; CELL LUNG-CANCER; MEDICARE BENEFICIARIES; PROGNOSTIC FACTORS; CARE; SURVIVAL; MONOTHERAPY; DOCETAXEL; ONCOLOGY; DESIGN AB IMPORTANCE Although many patients with end-stage cancer are offered chemotherapy to improve quality of life (QOL), the association between chemotherapy and QOL amid progressive metastatic disease has not been well-studied. American Society for Clinical Oncology guidelines recommend palliative chemotherapy only for solid tumor patients with good performance status. OBJECTIVE To evaluate the association between chemotherapy use and QOL near death (QOD) as a function of patients' performance status. DESIGN, SETTING, AND PARTICIPANTS A multi-institutional, longitudinal cohort study of patients with end-stage cancer recruited between September 2002 and February 2008. Chemotherapy use (n = 158 [50.6%]) and Eastern Cooperative Oncology Group (ECOG) performance status were assessed at baseline (median = 3.8 months before death) and patients with progressive metastatic cancer (N = 312) following at least 1 chemotherapy regimen were followed prospectively until death at 6 outpatient oncology clinics in the United States. MAIN OUTCOMES AND MEASURES Patient QOD was determined using validated caregiver ratings of patients' physical and mental distress in their final week. RESULTS Chemotherapy use was not associated with patient survival controlling for clinical setting and patients' performance status. Among patients with good (ECOG score = 1) baseline performance status, chemotherapy use compared with nonuse was associated with worse QOD (odds ratio [OR], 0.35; 95% CI, 0.17-0.75; P =.01). Baseline chemotherapy use was not associated with QOD among patients with moderate (ECOG score = 2) baseline performance status (OR, 1.06; 95% CI, 0.51-2.21; P =.87) or poor (ECOG score = 3) baseline performance status (OR, 1.34; 95% CI, 0.46-3.89; P =.59). CONCLUSIONS AND RELEVANCE Although palliative chemotherapy is used to improve QOL for patients with end-stage cancer, its use did not improve QOD for patients with moderate or poor performance status and worsened QOD for patients with good performance status. The QOD in patients with end-stage cancer is not improved, and can be harmed, by chemotherapy use near death, even in patients with good performance status. C1 [Prigerson, Holly G.; Maciejewski, Paul K.] Weill Cornell Med Coll, Ctr Res End Of Life Care, New York, NY USA. [Prigerson, Holly G.; Reid, M. Carrington] Weill Cornell Med Coll, Dept Med, Div Geriatr & Palliat Med, New York, NY USA. [Bao, Yuhua] Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY USA. [Shah, Manish A.] Weill Cornell Med Coll, Meyer Canc Ctr, Med Oncol Solid Tumor Program, New York, NY USA. [LeBlanc, Thomas W.] Duke Univ, Sch Med, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27706 USA. [Paulk, M. Elizabeth] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Schneider, Bryan J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Garrido, Melissa M.] James J Peters VA Med Ctr, Bronx, NY USA. [Garrido, Melissa M.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Berlin, David A.] New York Presbyterian Hosp, Weill Cornell Ctr, Dept Med, Med Intens Care Unit, New York, NY USA. [Neugut, Alfred I.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Neugut, Alfred I.] Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA. [Neugut, Alfred I.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Adelson, Kerin B.] Yale Univ, Sch Med, Smilow Canc Hosp Yale New Haven, New Haven, CT USA. [Maciejewski, Paul K.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA. RP Prigerson, HG (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Ctr Res End Of Life Care, 525 E 68th St,Box 39,1404 Baker Pavil, New York, NY 10065 USA. EM hgp2001@med.cornell.edu FU National Institute of Mental Health [MH63892]; National Cancer Institute [CA106370]; National Institute of Minority Heath and Health Disparities [MD007652]; Weill Cornell Medical College grant; Health Services Research and Development Service Career Development Award from the Department of Veterans Affairs [11-201/CDP 12-255] FX This research was supported in part by the following grants: MH63892 from the National Institute of Mental Health and CA106370 from the National Cancer Institute (Dr Prigerson); MD007652 from the National Institute of Minority Heath and Health Disparities (Drs Prigerson and Maciejewski); Weill Cornell Medical College grant (Drs Prigerson and Bao); and Health Services Research and Development Service Career Development Award 11-201/CDP 12-255 from the Department of Veterans Affairs (Dr Garrido). NR 31 TC 52 Z9 54 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD SEP PY 2015 VL 1 IS 6 BP 778 EP 784 DI 10.1001/jamaoncol.2015.2378 PG 7 WC Oncology SC Oncology GA DW5HO UT WOS:000383674800013 PM 26203912 ER PT J AU Chen, LJ Na, R Boldt, E Ran, QT AF Chen, Liuji Na, Ren Boldt, Erin Ran, Qitao TI NLRP3 inflammasome activation by mitochondrial reactive oxygen species plays a key role in long-term cognitive impairment induced by paraquat exposure SO NEUROBIOLOGY OF AGING LA English DT Article DE Toxin exposure; Alzheimer's disease; Inflammation; NLRP3 inflammasome; Paraquat; Mitochondria; Oxidative stress; A beta ID ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; MICROGLIAL CELLS; NITRIC-OXIDE; MOUSE-BRAIN; TNF-ALPHA; IN-VIVO; BETA; NEUROTOXICITY; EXPRESSION AB Exposure to environmental toxins such as pesticides is implicated in increasing Alzheimer's disease risk. In this study, we investigated the long-term effects of paraquat exposure on cognition of Alzheimer's disease animal model APP/PS1 mice and wild-type (WT) mice. Our results showed that APP/PS1 mice had exacerbated cognition impairment and elevated A beta levels at 5 months after paraquat exposure, and that WT mice had cognition impairment at 5 and 16 months after paraquat exposure. In addition, increased mitochondrial oxidative stress and augmented brain inflammation were observed in both paraquat-exposed APP/PS1 mice and WT mice. Interestingly, activation of NLRP3 inflammasome, which triggers inflammation in response to mitochondrial stress, was enhanced in paraquat-exposed mice. Moreover, transgenic mice overexpressing Prdx3, a key enzyme in detoxifying mitochondrial H2O2, had suppressed NLRP3 inflammasome activation, reduced brain inflammation, and attenuated cognition impairment after paraquat exposure. Together, our results indicate that NLRP3 inflammasome activation induced by mitochondrial reactive oxygen species plays a key role in mediating paraquat-induced long-term cognition decline by elevating brain inflammation. Published by Elsevier Inc. C1 [Chen, Liuji; Na, Ren; Boldt, Erin; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ran, Qitao] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. RP Ran, QT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ran@uthscsa.edu FU Department of Veteran Affairs [5I10BX001382] FX The study was supported by a Merit Award (5I10BX001382 to Ran Q.) from the Department of Veteran Affairs. All procedures for handling the mice in this study were reviewed and approved by the Institutional Animal Care and Use Committees of the University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System. NR 44 TC 7 Z9 7 U1 6 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD SEP PY 2015 VL 36 IS 9 BP 2533 EP 2543 DI 10.1016/j.neurobiolaging.2015.05.018 PG 11 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA CN9XI UT WOS:000358803400009 PM 26119225 ER PT J AU Butt, AA Yan, P Shaikh, OS Freiberg, MS Lo Re, V Justice, AC Sherman, KE AF Butt, A. A. Yan, P. Shaikh, O. S. Freiberg, M. S. Lo Re, V., III Justice, A. C. Sherman, K. E. CA ERCHIVES Elect Retrieved Cohort TI Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE boceprevir; directly acting antiviral agents; ERCHIVES; haematologic toxicity; sustained virologic response; telaprevir ID HEPATITIS-C VIRUS; TREATMENT-NAIVE PATIENTS; PHASE-2 TRIAL; INFECTION; RIBAVIRIN; SURVIVAL; PEGINTERFERON; SIMEPREVIR; SOFOSBUVIR; ALPHA-2A AB Effectiveness, safety and tolerability of boceprevir (BOC) and telaprevir (TPV) in actual clinical settings remain unknown. We determined rates of sustained virologic response (SVR) and haematologic adverse effects among persons treated with BOC- or TPV-containing regimens, compared with pegylated interferon/ribavirin (PEG/RBV). Using an established cohort of hepatitis C virus (HCV)-infected persons, Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), we identified those treated with a BOC- or TPV-containing regimen and HCV genotype 1-infected controls treated with PEG/RBV. We excluded those with HIV co-infection and missing HCV RNA values to determine SVR. Primary endpoints were SVR (undetectable HCV RNA >= 12 weeks after treatment completion) and haematologic toxicity (grade 3/4 anaemia, neutropenia and thrombocytopenia). We evaluated 2288 persons on BOC-, 409 on TPV-containing regimen and 6308 on PEG/RBV. Among these groups, respectively, 31%, 43% and 9% were treatment-experienced; 17%, 37% and 14% had baseline cirrhosis; 63%, 54% and 48% were genotype 1a. SVR rates among noncirrhotics were as follows: treatment naive: 65% (BOC), 67% (TPV) and 31% (PEG/RBV); treatment experienced: 57% (BOC), 54% (TPV) and 13% (PEG/RBV); (P-value not significant for BOC vs TPV; P < 0.0001 for BOC or TPV vs PEG/RBV). Haematologic toxicities among BOC-, TPV- and PEG/RBV-treated groups were as follows: grade 3/4 anaemia 7%, 11% and 3%; grade 4 thrombocytopenia 2.2%, 5.4% and 1.7%; grade 4 neutropenia 8.2%, 5.6% and 3.4%. SVR rates are higher and closer to those reported in pivotal clinical trials among BOC- and TPV-treated persons compared with PEG/RBV-treated persons. Haematologic adverse events are frequent, but severe toxicity is uncommon. C1 [Butt, A. A.; Yan, P.; Shaikh, O. S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Butt, A. A.; Shaikh, O. S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, A. A.] Hamad Med Corp, Doha, Qatar. [Freiberg, M. S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Lo Re, V., III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Justice, A. C.] Vet Affairs Healthcare Syst, West Haven, CT USA. [Justice, A. C.] Yale Univ, Sch Med, New Haven, CT USA. [Sherman, K. E.] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA. RP Butt, AA (reprint author), 3601 Fifth Ave,Suite 3A, Pittsburgh, PA 15213 USA. EM aabutt@pitt.edu RI Lo Re, Vincent/N-7817-2015 OI Butt, Adeel/0000-0002-1118-1826; Justice, Amy/0000-0003-0139-5502 FU National Institutes of Health: NIAAA [1U24AA020794, 1U01AA020790, U24AA022001]; NIMH [2P30MII062294]; NIAID [2 U01-A1069918]; NIDA [R01DA035616]; AHRQ [R01HS018372]; NCI [R01 CA173754] FX This work was supported by an investigator initiated grant by Merck Sharp and Dohme, Whitehouse Station, NJ. Study questions, data acquisition, data analysis and reporting were under the sole discretion of study investigators. Dr. Butt assumes all responsibility for the data presented in this paper. ACJ's time is supported by: National Institutes of Health: NIAAA (1U24AA020794, 1U01AA020790, U24AA022001), NIMH (2P30MII062294), NIAID (2 U01-A1069918), NIDA (R01DA035616), AHRQ (R01HS018372), NCI (R01 CA173754). NR 21 TC 6 Z9 6 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 EI 1365-2893 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD SEP PY 2015 VL 22 IS 9 BP 691 EP 700 DI 10.1111/jvh.12375 PG 10 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA CM6RI UT WOS:000357816800002 PM 25524834 ER PT J AU Berg, KM Piper, ME Smith, SS Fiore, MC Jorenby, DE AF Berg, Kristin M. Piper, Megan E. Smith, Stevens S. Fiore, Michael C. Jorenby, Douglas E. TI Defining and predicting short-term alcohol use changes during a smoking cessation attempt SO ADDICTIVE BEHAVIORS LA English DT Article DE Tobacco use; Smoking cessation; Alcohol use ID NICOTINE DEPENDENCE; TOBACCO DEPENDENCE; DISTRESS TOLERANCE; UNITED-STATES; CONSUMPTION; ADDICTION; HEALTH; DRINKING; WITHDRAWAL; DISORDERS AB Introduction: Alcohol and nicotine are commonly used substances in the U.S., with significant impacts on health. Using both substances concurrently impacts quit attempts. While studies have sought to examine changes in alcohol use co-occurring with tobacco cessation, results have not been consistent. Understanding these changes has clinical implications. The objective of this study is to identify changes in alcohol consumption that occur following tobacco cessation, as well as predictors of alcohol use patterns following a smoking cessation attempt. Methods: A secondary analysis of a randomized, placebo-controlled trial evaluating the efficacy of five tobacco cessation pharmacotherapies. Participants (N = 1301) reported their smoking and alcohol consumption daily for two weeks prior to, and two weeks after, the target quit date (TQD). Results: Generally, alcohol use decreased post-TQD. Smokers who reported less pre-quit alcohol use, as well as smokers who were female, non-white, and had a history of alcohol dependence tended to use less alcohol post-quit. Pre- and post-quit alcohol use were more strongly related among men and among those without a history of alcohol dependence. Conclusions: For most smokers alcohol use decreased following smoking cessation. These results suggest that the expectation should be of decreased alcohol use post cessation. However, attention may be warranted for those who drink higher amounts of alcohol pre-cessation because they may be more likely to drink more in the post-quit period which may influence smoking cessation success. Published by Elsevier Ltd. C1 [Berg, Kristin M.; Piper, Megan E.; Smith, Stevens S.; Fiore, Michael C.; Jorenby, Douglas E.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Dept Med, Madison, WI 53711 USA. [Berg, Kristin M.] William S Middleton Mem Vet Adm Med Ctr, Adv Fellowship Womens Hlth, Madison, WI 53705 USA. RP Berg, KM (reprint author), Ctr Tobacco Res & Intervent, 1930 Monroe St, Madison, WI 53711 USA. EM kberg@medicine.wisc.edu; mep@ctri.wisc.edu; Sss@ctri.wisc.edu; mcf@ctri.wisc.edu; dej@ctri.wisc.edu FU Training Tobacco Scientists Mini-Grant through the University of Wisconsin Center for Tobacco Research and Intervention - National Cancer Institute [9P50CA143188-11] FX This research was supported by the Training Tobacco Scientists Mini-Grant through the University of Wisconsin Center for Tobacco Research and Intervention, which is funded from grant 9P50CA143188-11 from the National Cancer Institute. The funding source did not have impact on the planning, design, analysis or interpretation of this secondary analysis. NR 46 TC 3 Z9 3 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD SEP PY 2015 VL 48 BP 52 EP 57 DI 10.1016/j.addbeh.2015.04.004 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CL1WZ UT WOS:000356736900009 PM 25997014 ER PT J AU Crysel, LC Cook, CL Schember, TO Webster, GD AF Crysel, Laura C. Cook, Corey L. Schember, Tatiana Orozco Webster, Gregory D. TI Harry Potter and the measures of personality: Extraverted Gryffindors, agreeable Hufflepuffs, clever Ravenclaws, and manipulative Slytherins SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Dark Triad; Harry Potter; Psychopathy; Narcissism; Machiavellianism; Need for cognition; Need to belong; Big Five ID DARK TRIAD; DIRTY DOZEN; NEED; SELF; MACHIAVELLIANISM; TRANSPORTATION; PSYCHOPATHY; MOTIVATION; NARCISSISM; COGNITION AB People use fiction and storytelling to learn about themselves and their social world. Fans of J.K. Rowling's popular Harry Potter book series often identify with one of the four Hogwarts school communities or "houses"-Gryffindor, Hufflepuff, Ravenclaw, and Slytherin-that correspond to characters' specific traits. Fans use a feature on Rowling's "Pottermore" website that tests their personality and sorts them into the Hogwarts. house that best fits them. But what does Pottermore's sorting quiz measure? We asked fans from online Harry Potter groups into which Hogwarts house they had been sorted on Pottermore. Fans then completed personality measures, including the Big Five traits, need to belong, need for cognition, and the Dark Triad traits narcissism, Machiavellianism, and psychopathy. Planned contrasts found positive associations between need for cognition and placement in Ravenclaw (known for wit and learning), and between the Dark Triad traits and placement in Slytherin (known for using any means to achieve their ends). We expected but did not find that those in Gryffindor (known for bravery) would be higher in extraversion and openness, and that Hufflepuffs (known for loyalty) would be higher on need to belong. Our findings suggest that fiction can reflect real underlying personality dimensions. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Crysel, Laura C.] Stetson Univ, Deland, FL 32723 USA. [Cook, Corey L.] Univ Washington Tacoma, Tacoma, WA USA. [Schember, Tatiana Orozco] US Dept Vet Affairs, Tulsa, OK USA. [Webster, Gregory D.] Univ Florida, Gainesville, FL 32611 USA. RP Crysel, LC (reprint author), Stetson Univ, Deland, FL 32723 USA. EM lcrysel@stetson.edu NR 27 TC 1 Z9 1 U1 14 U2 78 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD SEP PY 2015 VL 83 BP 174 EP 179 DI 10.1016/j.paid.2015.04.016 PG 6 WC Psychology, Social SC Psychology GA CL0OQ UT WOS:000356642400031 ER PT J AU Cheraghi-Sohi, S Singh, H Reeves, D Stocks, J Rebecca, M Esmail, A Campbell, S de Wet, C AF Cheraghi-Sohi, Sudeh Singh, Hardeep Reeves, David Stocks, Jill Rebecca, Morris Esmail, Aneez Campbell, Stephen de Wet, Carl TI Missed diagnostic opportunities and English general practice: a study to determine their incidence, confounding and contributing factors and potential impact on patients through retrospective review of electronic medical records (vol 10, 105, 2015) SO IMPLEMENTATION SCIENCE LA English DT Correction C1 [Cheraghi-Sohi, Sudeh; Stocks, Jill; Rebecca, Morris; Esmail, Aneez; Campbell, Stephen] Univ Manchester, NIHR Greater Manchester Primary Care Patient Safe, Manchester M13 9PL, Lancs, England. [Cheraghi-Sohi, Sudeh; Reeves, David; Rebecca, Morris; Esmail, Aneez; Campbell, Stephen] Univ Manchester, Inst Populat Hlth, Ctr Primary Care, Manchester M13 9PL, Lancs, England. [Singh, Hardeep] Houston Vet Affairs Ctr Innovat Qual Effectivenes, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Houston, TX 77030 USA. [Campbell, Stephen] Univ Canberra, Ctr Res & Act Publ Hlth CeRAPH, Bruce, ACT 2617, Australia. [de Wet, Carl] Griffith Univ, Sch Med, Nathan, Qld 4111, Australia. RP Campbell, S (reprint author), Univ Manchester, NIHR Greater Manchester Primary Care Patient Safe, 7th Floor,Williamson Bldg, Manchester M13 9PL, Lancs, England. EM stephen.campbell@manchester.ac.uk FU NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre; Houston VA Health Services Research and Development Service Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX The authors acknowledge the contribution of Dr Rahul Alam and Angela Swallow. The research was funded by the NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Dr. Singh is partially supported by the Houston VA Health Services Research and Development Service Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). NR 2 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD AUG 29 PY 2015 VL 10 AR 124 DI 10.1186/s13012-015-0314-1 PG 1 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CQ0BU UT WOS:000360260900001 PM 26319233 ER PT J AU Singh, T Gupta, NA Xu, S Prasad, R Velu, SE Katiyar, SK AF Singh, Tripti Gupta, Nirzari A. Xu, Su Prasad, Ram Velu, Sadanandan E. Katiyar, Santosh K. TI Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor SO ONCOTARGET LA English DT Article DE oncology; carcinogenesis; chemotherapy; targeted therapy; signal transduction; prevention; animal model ID IN-VIVO; BCL-2 FAMILY; CANCER; APOPTOSIS; PROTEIN; DEATH; REGULATORS; SURVIVAL; THERAPY; CYCLINS AB Here, we report the chemotherapeutic effect of honokiol, a phytochemical from Magnolia plant, on human head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC cell lines from different sub-sites, SCC-1 (oral cavity), SCC-5 (larynx), OSC-19 (tongue) and FaDu (pharynx) with honokiol inhibited their cell viability, which was associated with the: (i) induction of apoptosis, (ii) correction of dysregulatory cell cycle proteins of G0/G1 phase. Honokiol decreased the expression levels of epidermal growth factor receptor (EGFR), mTOR and their downstream signaling molecules. Treatment of FaDu and SCC-1 cell lines with rapamycin, an inhibitor of mTOR pathway, also reduced cell viability of HNSCC cells. Administration of honokiol by oral gavage (100 mg/kg body weight) significantly (P < 0.01-0.001) inhibited the growth of SCC-1 and FaDu xenografts in athymic nude mice, which was associated with: (i) inhibition of tumor cell proliferation, (ii) induction of apoptosis, (iii) reduced expressions of cyclins and Cdks, and (iv) inhibition of EGFR signaling pathway. Molecular docking analysis of honokiol in EGFR binding site indicated that the chemotherapeutic effect of honokiol against HNSCC is mediated through its firm binding with EGFR, which is better than that of gefitinib, a commonly used drug for HNSCC treatment. C1 [Singh, Tripti; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Gupta, Nirzari A.; Xu, Su; Velu, Sadanandan E.] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA. [Velu, Sadanandan E.; Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. EM skatiyar@uab.edu RI Xu, Su/S-3631-2016 OI Xu, Su/0000-0002-3695-5605 FU Veterans Administration Merit Review Award [1I01BX001410-01] FX This work was financially supported by the funds from the Veterans Administration Merit Review Award (1I01BX001410-01, S.K.K.). The content of this manuscript does not necessarily reflect the views or policies of the funding agency. NR 32 TC 12 Z9 13 U1 3 U2 6 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD AUG 28 PY 2015 VL 6 IS 25 BP 21268 EP 21282 PG 15 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CQ9XO UT WOS:000360969200045 PM 26020804 ER PT J AU Gantz, SC Robinson, BG Buck, DC Bunzow, JR Neve, RL Williams, JT Neve, KA AF Gantz, Stephanie C. Robinson, Brooks G. Buck, David C. Bunzow, James R. Neve, Rachael L. Williams, John T. Neve, Kim A. TI Distinct regulation of dopamine D2S and D2L autoreceptor signaling by calcium SO ELIFE LA English DT Article ID VENTRAL TEGMENTAL AREA; PROTEIN-COUPLED RECEPTOR; HAMSTER OVARY CELLS; UP-REGULATION; IMPULSE ACTIVITY; MESSENGER-RNA; LONG RECEPTOR; MICE LACKING; 2 ISOFORMS; KINASE-C AB D2 autoreceptors regulate dopamine release throughout the brain. Two isoforms of the D2 receptor, D2S and D2L, are expressed in midbrain dopamine neurons. Differential roles of these isoforms as autoreceptors are poorly understood. By virally expressing the isoforms in dopamine neurons of D2 receptor knockout mice, this study assessed the calcium-dependence and drug-induced plasticity of D2S and D2L receptor-dependent G protein-coupled inwardly rectifying potassium (GIRK) currents. The results reveal that D2S, but not D2L receptors, exhibited calciumdependent desensitization similar to that exhibited by endogenous autoreceptors. Two pathways of calcium signaling that regulated D2 autoreceptor-dependent GIRK signaling were identified, which distinctly affected desensitization and the magnitude of D2S and D2L receptor-dependent GIRK currents. Previous in vivo cocaine exposure removed calcium-dependent D2 autoreceptor desensitization in wild type, but not D2S-only mice. Thus, expression of D2S as the exclusive autoreceptor was insufficient for cocaine-induced plasticity, implying a functional role for the co-expression of D2S and D2L autoreceptors. C1 [Gantz, Stephanie C.; Robinson, Brooks G.; Bunzow, James R.; Williams, John T.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA. [Buck, David C.; Neve, Kim A.] US Dept Vet Affairs, Res Serv, VA Portland Hlth Care Syst, Portland, OR 97204 USA. [Buck, David C.; Neve, Kim A.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Neve, Rachael L.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. RP Neve, KA (reprint author), US Dept Vet Affairs, Res Serv, VA Portland Hlth Care Syst, Portland, OR 97204 USA. EM nevek@ohsu.edu FU National Institutes of Health [P50 DA018165, R01 DA004523, R01 DA034388, F32 DA038456]; U.S. Department of Veterans Affairs [BX000810] FX National Institutes of Health P50 DA018165 Kim A Neve; U.S. Department of Veterans Affairs BX000810 Kim A Neve; National Institutes of Health R01 DA004523 John T Williams; National Institutes of Health R01 DA034388 John T Williams; National Institutes of Health F32 DA038456 Brooks G Robinson NR 60 TC 5 Z9 5 U1 2 U2 3 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD AUG 26 PY 2015 VL 4 AR e09358 DI 10.7554/eLife.09358.001 PG 19 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DI9JK UT WOS:000373818700001 ER PT J AU McFarland, LV AF McFarland, Lynne V. TI Application of meta-analysis to specific research fields: Lessons learned SO WORLD JOURNAL OF META-ANALYSIS LA English DT Editorial Material DE Meta-analysis; Study designs; Probiotics; Sensitivity analysis; Meta-regression ID ANTIBIOTIC-ASSOCIATED DIARRHEA; RANDOMIZED CONTROLLED-TRIALS; PROBIOTICS; PREVENTION; CHILDREN; DISEASE; THERAPY; LIPIDS; RISK AB Scientific research is challenged to translate findings from multiple, often conflicting, clinical trials into a simple answer of whether a treatment works or not. The public and healthcare providers alike frequently voice their frustrations when the media reports a treatment working on one day, but seemingly the next day reports a study refuting the previous one. Meta-analyses are being used more commonly by researchers to convey an understandable summary of scientific studies to the general public and healthcare providers. As time goes by, we have learned how to improve meta-analytic techniques to reflect more valid results and when it is appropriate to pool or not to pool results from different studies. Retrospective reviews often don't acknowledge this learning curve and may fail to recommend the most current valid guidelines. This editorial presents an example of how the current use of meta-analysis has shifted in one field (the therapeutic effects of probiotics) and recommendations on how to correctly interpret the results of such an analysis. C1 [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98108 USA. [McFarland, Lynne V.] VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. RP McFarland, LV (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM lynne.mcfarland@va.gov NR 30 TC 2 Z9 2 U1 0 U2 0 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 2308-3840 J9 WORLD J META-ANAL JI World J. Meta-Anal. PD AUG 26 PY 2015 VL 3 IS 4 BP 188 EP 192 DI 10.13105/wjma.v3.i4.188 PG 5 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA CR0GG UT WOS:000360995900001 ER PT J AU Gornalusse, GG Mummidi, S Gaitan, AA Jimenez, F Ramsuran, V Picton, A Rogers, K Manoharan, MS Avadhanam, N Murthy, KK Martinez, H Murillo, AM Chykarenko, ZA Hutt, R Daskalakis, D Shostakovich-Koretskaya, L Karim, SA Martin, JN Deeks, SG Hecht, F Sinclair, E Clark, RA Okulicz, J Valentine, FT Martinson, N Tiemessen, CT Ndung'u, T Hunt, PW He, WJ Ahuja, SK AF Gornalusse, German G. Mummidi, Srinivas Gaitan, Alvaro A. Jimenez, Fabio Ramsuran, Veron Picton, Anabela Rogers, Kristen Manoharan, Muthu Saravanan Avadhanam, Nymisha Murthy, Krishna K. Martinez, Hernan Murillo, Angela Molano Chykarenko, Zoya A. Hutt, Richard Daskalakis, Demetre Shostakovich-Koretskaya, Ludmila Karim, Salim Abdool Martin, Jeffrey N. Deeks, Steven G. Hecht, Frederick Sinclair, Elizabeth Clark, Robert A. Okulicz, Jason Valentine, Fred T. Martinson, Neil Tiemessen, Caroline Tanya Ndung'u, Thumbi Hunt, Peter W. He, Weijing Ahuja, Sunil K. TI Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE HIV; CCR5; methylation; T-cell activation; polymorphism ID IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSCRIPTION FACTOR; DNA METHYLATION; UNINFECTED INDIVIDUALS; ANTIRETROVIRAL THERAPY; DISEASE PROGRESSION; MESSENGER-RNA; IN-VITRO; INFECTION; PROMOTER AB T-cell expression levels of CC chemokine receptor 5 (CCR5) are a critical determinant of HIV/AIDS susceptibility, and manifest wide variations (i) between T-cell subsets and among individuals and (ii) in T-cell activation-induced increases in expression levels. We demonstrate that a unifying mechanism for this variation is differences in constitutive and T-cell activation-induced DNA methylation status of CCR5 cis-regulatory regions (cis-regions). Commencing at an evolutionarily conserved CpG (CpG-41), CCR5 cis-regions manifest lower vs. higher methylation in T cells with higher vs. lower CCR5 levels (memory vs. naive T cells) and in memory T cells with higher vs. lower CCR5 levels. HIV-related and in vitro induced T-cell activation is associated with demethylation of these cis-regions. CCR5 haplotypes associated with increased vs. decreased gene/surface expression levels and HIV/AIDS susceptibility magnify vs. dampen T-cell activation-associated demethylation. Methylation status of CCR5 intron 2 explains a larger proportion of the variation in CCR5 levels than genotype or T-cell activation. The ancestral, protective CCR5-HHA haplotype bears a polymorphism at CpG-41 that is (i) specific to southern Africa, (ii) abrogates binding of the transcription factor CREB1 to this cis-region, and (iii) exhibits a trend for overrepresentation in persons with reduced susceptibility to HIV and disease progression. Genotypes lacking the CCR5-Delta 32 mutation but with hypermethylated cis-regions have CCR5 levels similar to genotypes heterozygous for CCR5-.32. In HIV-infected individuals, CCR5 cis-regions remain demethylated, despite restoration of CD4+ counts (>= 800 cells per mm(3)) with antiretroviral therapy. Thus, methylation content of CCR5 cis-regions is a central epigenetic determinant of T-cell CCR5 levels, and possibly HIV-related outcomes. C1 [Gornalusse, German G.; Mummidi, Srinivas; Gaitan, Alvaro A.; Jimenez, Fabio; Rogers, Kristen; Manoharan, Muthu Saravanan; Avadhanam, Nymisha; Martinez, Hernan; Murillo, Angela Molano; Clark, Robert A.; He, Weijing; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA. [Gornalusse, German G.; Mummidi, Srinivas; Gaitan, Alvaro A.; Jimenez, Fabio; Rogers, Kristen; Manoharan, Muthu Saravanan; Avadhanam, Nymisha; Martinez, Hernan; Murillo, Angela Molano; Clark, Robert A.; He, Weijing; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX 78229 USA. [Gornalusse, German G.; Mummidi, Srinivas; Gaitan, Alvaro A.; Jimenez, Fabio; Rogers, Kristen; Manoharan, Muthu Saravanan; Avadhanam, Nymisha; Martinez, Hernan; Murillo, Angela Molano; Clark, Robert A.; He, Weijing; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Gornalusse, German G.; Rogers, Kristen; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol, San Antonio, TX 78229 USA. [Ramsuran, Veron; Ndung'u, Thumbi] Univ KwaZulu Natal, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, ZA-4013 Durban, South Africa. [Ramsuran, Veron; Karim, Salim Abdool; Ndung'u, Thumbi] Univ KwaZulu Natal, Ctr AIDS Program Res South Africa CAPRISA, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, ZA-4013 Durban, South Africa. [Picton, Anabela; Tiemessen, Caroline Tanya] Natl Inst Communicable Dis, Ctr HIV & Sexually Transmitted Infect, ZA-2131 Johannesburg, South Africa. [Picton, Anabela; Martinson, Neil; Tiemessen, Caroline Tanya] Univ Witwatersrand, Fac Hlth Sci, ZA-2193 Johannesburg, South Africa. [Murthy, Krishna K.] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX 78245 USA. [Chykarenko, Zoya A.; Shostakovich-Koretskaya, Ludmila] Dnepropetrovsk State Med Acad, Dept Gen Pediat & Pediat Infect Dis, UA-49044 Dnepropetrovsk, Ukraine. [Hutt, Richard; Daskalakis, Demetre; Valentine, Fred T.] NYU, Sch Med, Dept Med, New York, NY 10016 USA. [Martin, Jeffrey N.; Deeks, Steven G.; Hecht, Frederick; Sinclair, Elizabeth; Hunt, Peter W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA. [Martin, Jeffrey N.; Deeks, Steven G.; Hecht, Frederick; Sinclair, Elizabeth; Hunt, Peter W.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA. [Martin, Jeffrey N.; Deeks, Steven G.; Hecht, Frederick; Sinclair, Elizabeth; Hunt, Peter W.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Okulicz, Jason] San Antonio Mil Med Ctr, San Antonio, TX 78234 USA. [Martinson, Neil] Univ Witwatersrand, Perinatal HIV Res Unit, ZA-2193 Johannesburg, South Africa. [Martinson, Neil; Tiemessen, Caroline Tanya] MRC, Soweto Matlosana Ctr HIV AIDS & TB, ZA-2193 Johannesburg, South Africa. [Martinson, Neil] Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD 21205 USA. RP Ahuja, SK (reprint author), South Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA. EM ahujas@uthscsa.edu OI Ndung'u, Thumbi/0000-0003-2962-3992; Valentine, Fred/0000-0002-6046-5913; Abdool Karim, Salim/0000-0002-4986-2133 FU BLRD VA [I01 BX000975]; CSRD VA [IP1 CX000875]; NCATS NIH HHS [UL1 TR001120]; NCI NIH HHS [NIH-NCI P30CA54174]; NCRR NIH HHS [UL1 RR024131, UL1RR025767]; NHLBI NIH HHS [R01HL090312]; NIAID NIH HHS [R37-AI046326, NIH P01AI057127, P30 AI027763, P30AI027742, R01 AI043279, R01-AI043279, R24 AI067039, U19 AI 51794]; NIH HHS [P51 OD011133]; NIMH NIH HHS [P30 MH62246] NR 44 TC 7 Z9 7 U1 4 U2 12 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD AUG 25 PY 2015 VL 112 IS 34 BP E4762 EP E4771 DI 10.1073/pnas.1423228112 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CP6NZ UT WOS:000360005600018 PM 26307764 ER PT J AU Jenkins, CR Postma, DS Anzueto, AR Make, BJ Peterson, S Eriksson, G Calverley, PM AF Jenkins, Christine R. Postma, Dirkje S. Anzueto, Antonio R. Make, Barry J. Peterson, Stefan Eriksson, Goran Calverley, Peter M. TI Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease SO BMC PULMONARY MEDICINE LA English DT Article DE COPD; Budesonide/formoterol; Exacerbation; Reliever medication; Predictor ID METERED-DOSE INHALER; SEVERE COPD; CLINICAL-TRIAL; ASTHMA CONTROL; HEALTH-STATUS; EFFICACY; BUDESONIDE/FORMOTEROL; TIOTROPIUM; MODERATE; THERAPY AB Background: Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting beta(2)-agonist (SABA) reliever use would predict short-and long-term exacerbation risk in COPD patients. Methods: We performed a retrospective analysis of data from a study (ClinicalTrials.govregistration: NCT00419744) comparing budesonide/formoterol 320/9 mu g with formoterol 9 mu g (both twice daily) in patients with moderate-to-very-severe COPD; reliever salbutamol 90 mu g was provided. First occurrence of reliever use >4 (low), >10 (medium), and >20 (high) inhalations/day was assessed as a predictor of short-term (3-week) exacerbation risk. Mean daily reliever use in the week preceding the 2-month visit was investigated as a predictor of the long-term (10-month) exacerbation risk, using intervals of 2-5, 6-9, and = 10 inhalations/day. Results: Overall, 810 patients were included (61 % male; mean age 63.2 years; post-bronchodilator forced expiratory volume in 1 s 37.7 % of predicted). First occurrence of low, medium, or high reliever use was predictive of an exacerbation within the following 3 weeks; exacerbation risk increased significantly with increasing reliever use. Mean reliever use over 1 week was predictive of long-term exacerbation risk. Patients with mean use of 2-5, 6-9, and = 10 inhalations/day exhibited 21 %, 67 %, and 135 % higher exacerbation rates, respectively, in the following 10 months, compared with <2 inhalations/day. Budesonide/formoterol was associated with lower short-and long-term exacerbation risk than formoterol in all reliever-use groups. Conclusions: SABA reliever use is a predictor of short-and long-term exacerbation risk in moderate-to-very-severe COPD patients with a history of exacerbations receiving budesonide/formoterol or formoterol. C1 [Jenkins, Christine R.] Univ Sydney, Concord Hosp, Dept Thorac Med, Sydney, NSW 2139, Australia. [Jenkins, Christine R.] George Inst Global Hlth, Sydney, NSW 2139, Australia. [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Med & TB, NL-9700 RB Groningen, Netherlands. [Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Pulm Sect, San Antonio, TX 78229 USA. [Anzueto, Antonio R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Make, Barry J.] Univ Colorado, Denver Sch Med, Natl Jewish Hlth, Div Pulm Sci & Crit Care Med, Denver, CO 80206 USA. [Peterson, Stefan] Medicon Village AB, StatMind, S-22363 Lund, Sweden. [Eriksson, Goran] Univ Lund Hosp, Dept Resp Med & Allergol, S-22187 Lund, Sweden. [Calverley, Peter M.] Aintree Univ Hosp NHS Fdn Trust, Inst Ageing & Chron Dis, Clin Sci Dept, Liverpool L9 7AL, Merseyside, England. RP Jenkins, CR (reprint author), Univ Sydney, Concord Hosp, Dept Thorac Med, Hosp Rd, Sydney, NSW 2139, Australia. EM christine.jenkins@sydney.edu.au FU AstraZeneca FX AstraZeneca funded the analysis and were responsible for data collection and analysis of this post-hoc analysis. The authors thank Malin Fageras and Magnus Lindberg of AstraZeneca R&D, Molndal, Sweden, and Thomas Similowski of Service de Pneumologie et Reanimation Medicale, Paris, France, for their assistance with the development of this manuscript. Anna Mett and Shaun Foley of inScience Communications, Springer Healthcare, provided medical writing assistance, funded by AstraZeneca. NR 29 TC 2 Z9 2 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2466 J9 BMC PULM MED JI BMC Pulm. Med. PD AUG 21 PY 2015 VL 15 AR 97 DI 10.1186/s12890-015-0077-0 PG 9 WC Respiratory System SC Respiratory System GA CP7BP UT WOS:000360042500001 PM 26293575 ER PT J AU Hubbuch, JE Bennett, BW Dean, JC AF Hubbuch, Jill E. Bennett, Blake W. Dean, Jesse C. TI Proprioceptive feedback contributes to the adaptation toward an economical gait pattern SO JOURNAL OF BIOMECHANICS LA English DT Article; Proceedings Paper CT 7th World Congress of Biomechanics CY JUL 06-11, 2014 CL Boston, MA DE Gait adaptation; Metabolic cost; Muscle activity; Tendon vibration ID HUMAN WALKING; TENDON VIBRATION; ENERGY-EXPENDITURE; MUSCLE AFFERENTS; MECHANICAL POWER; ACHILLES-TENDON; STEP FREQUENCY; METABOLIC COST; LEVEL WALKING; SPEED AB Humans generally prefer gait patterns with a low metabolic cost, but it is unclear how such patterns are chosen. We have previously proposed that humans may use proprioceptive feedback to identify economical movement patterns. The purpose of the present experiments was to investigate the role of plantarflexor proprioception in the adaptation toward an economical gait pattern. To disrupt proprioception in some trials, we applied noisy vibration (randomly varying between 40-120 Hz) over the bilateral Achilles tendons while participants stood quietly or walked on a treadmill. For all 10 min walking trials, the treadmill surface was initially level before slowly increasing to a 2.5% incline midway through the trial without participant knowledge. During standing posture, noisy vibration increased sway, indicating decreased proprioception accuracy. While walking on a level surface, vibration did not significantly influence stride period or metabolic rate. However, vibration had clear effects for the first 23 min after the incline increase; vibration caused participants to walk with shorter stride periods, reduced medial gastrocnemius (MG) activity during mid-stance (30-65% stance), and increased MG activity during late-stance (65-100% stance). Over time, these metrics gradually converged toward the gait pattern without vibration. Likely as a result of this delayed adaptation to the new mechanical context, the metabolic rate when walking uphill was significantly higher in the presence of noisy vibration. These results may be explained by the disruption of proprioception preventing rapid identification of muscle activation patterns which allow the muscles to operate under favorable mechanical conditions with low metabolic demand. Published by Elsevier Ltd. C1 [Hubbuch, Jill E.; Bennett, Blake W.; Dean, Jesse C.] Med Univ S Carolina, Coll Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA. [Dean, Jesse C.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Dean, JC (reprint author), 77 President St,MSC 700, Charleston, SC 29425 USA. EM deaje@musc.edu OI Dean, Jesse/0000-0003-2034-4217 FU United States Department of Veterans Affairs Rehabilitation Research and Development Service [1 IK2 RX000750] FX This work was supported in part by a Career Development Award (1 IK2 RX000750) from the United States Department of Veterans Affairs Rehabilitation Research and Development Service. Study sponsors had no role in the study design, data collection, analysis and interpretation of data, writing of the manuscript, or the decision to submit the manuscript for publication. NR 47 TC 0 Z9 0 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD AUG 20 PY 2015 VL 48 IS 11 SI SI BP 2925 EP 2931 DI 10.1016/j.jbiomech.2015.04.024 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA CV1DO UT WOS:000363993800014 PM 25935689 ER PT J AU Naggie, S Cooper, C Saag, M Workowski, K Ruane, P Towner, WJ Marks, K Luetkemeyer, A Baden, RP Sax, PE Gane, E Santana-Bagur, J Stamm, LM Yang, JC German, P Dvory-Sobol, H Ni, LY Pang, PS McHutchison, JG Stedman, CAM Morales-Ramirez, JO Brau, N Jayaweera, D Colson, AE Tebas, P Wong, DK Dieterich, D Sulkowski, M AF Naggie, Susanna Cooper, Curtis Saag, Michael Workowski, Kimberly Ruane, Peter Towner, William J. Marks, Kristen Luetkemeyer, Anne Baden, Rachel P. Sax, Paul E. Gane, Edward Santana-Bagur, Jorge Stamm, Luisa M. Yang, Jenny C. German, Polina Dvory-Sobol, Hadas Ni, Liyun Pang, Phillip S. McHutchison, John G. Stedman, Catherine A. M. Morales-Ramirez, Javier O. Braeu, Norbert Jayaweera, Dushyantha Colson, Amy E. Tebas, Pablo Wong, David K. Dieterich, Douglas Sulkowski, Mark CA ION-4 Investigators TI Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID HEPATITIS-C VIRUS; GENOTYPE 1 INFECTION; ALPHA-2A PLUS RIBAVIRIN; HEPATOCELLULAR-CARCINOMA; LIVER-DISEASE; INTERFERON; CIRRHOSIS; THERAPY; COHORT; VETERANS AB BACKGROUND Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains an unmet medical need. METHODS We conducted a multicenter, single-group, open-label study involving patients coinfected with HIV-1 and genotype 1 or 4 HCV receiving an antiretroviral regimen of tenofovir and emtricitabine with efavirenz, rilpivirine, or raltegravir. All patients received ledipasvir, an NS5A inhibitor, and sofosbuvir, a nucleotide polymerase inhibitor, as a single fixed-dose combination for 12 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS Of the 335 patients enrolled, 34% were black, 55% had been previously treated for HCV, and 20% had cirrhosis. Overall, 322 patients (96%) had a sustained virologic response at 12 weeks after the end of therapy (95% confidence interval [CI], 93 to 98), including rates of 96% (95% CI, 93 to 98) in patients with HCV genotype 1a, 96% (95% CI, 89 to 99) in those with HCV genotype 1b, and 100% (95% CI, 63 to 100) in those with HCV genotype 4. Rates of sustained virologic response were similar regardless of previous treatment or the presence of cirrhosis. Of the 13 patients who did not have a sustained virologic response, 10 had a relapse after the end of treatment. No patient had confirmed HIV-1 virologic rebound. The most common adverse events were headache (25%), fatigue (21%), and diarrhea (11%). No patient discontinued treatment because of adverse events. CONCLUSIONS Ledipasvir and sofosbuvir for 12 weeks provided high rates of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4. (Funded by Gilead Sciences; C1 [Naggie, Susanna] Duke Clin Res Inst, Durham, NC 27705 USA. [Cooper, Curtis] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada. [Wong, David K.] Univ Toronto, Toronto Gen Hosp, Dept Hepatol, Immunodeficiency Clin, Toronto, ON M5G 1L7, Canada. [Saag, Michael] Univ Alabama Birmingham, Birmingham, AL USA. [Workowski, Kimberly] Emory Univ, Emory Healthcare, Atlanta, GA 30322 USA. [Ruane, Peter] Ruane Med & Liver Hlth Inst, Los Angeles, CA USA. [Towner, William J.] Kaiser Permanente, Los Angeles Med Ctr, Los Angeles, CA USA. [Luetkemeyer, Anne] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA. [Stamm, Luisa M.; Yang, Jenny C.; German, Polina; Dvory-Sobol, Hadas; Ni, Liyun; Pang, Phillip S.; McHutchison, John G.] Gilead Sci, Foster City, CA USA. [Marks, Kristen] Weill Cornell Med Coll, New York, NY USA. [Braeu, Norbert; Dieterich, Douglas] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Braeu, Norbert] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Baden, Rachel P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Sax, Paul E.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Sax, Paul E.] Harvard Univ, Sch Med, Boston, MA USA. [Colson, Amy E.] Community Res Initiat New England, Boston, MA USA. [Gane, Edward] Univ Auckland, Auckland City Hosp, Auckland 1, New Zealand. [Stedman, Catherine A. M.] Christchurch Hosp, Christchurch, New Zealand. [Stedman, Catherine A. M.] Univ Otago, Christchurch, New Zealand. [Santana-Bagur, Jorge] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA. [Morales-Ramirez, Javier O.] Clin Res Puerto Rico, San Juan, PR USA. [Jayaweera, Dushyantha] Univ Miami, Miami, FL USA. [Tebas, Pablo] Univ Penn, Philadelphia, PA 19104 USA. [Sulkowski, Mark] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Naggie, S (reprint author), Duke Clin Res Inst, Infect Dis Sect, 2400 Pratt St, Durham, NC 27705 USA. EM susanna.naggie@duke.edu OI Wong, David/0000-0002-3310-3538 FU Gilead Sciences FX Funded by Gilead Sciences; ION-4 ClinicalTrials.gov number, NCT02073656. NR 26 TC 110 Z9 110 U1 4 U2 20 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 20 PY 2015 VL 373 IS 8 BP 705 EP 713 DI 10.1056/NEJMoa1501315 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CP2LU UT WOS:000359709400007 PM 26196665 ER PT J AU Kelley, AS Morrison, RS AF Kelley, Amy S. Morrison, R. Sean TI Palliative Care for the Seriously Ill SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; ADVANCED CANCER-PATIENTS; QUALITY-OF-LIFE; SPIRITUAL CARE; NEAR-DEATH; ADVANCED ILLNESS; MEDICAL-CARE; LAST WEEK; END; COMMUNICATION C1 [Kelley, Amy S.; Morrison, R. Sean] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Kelley, Amy S.; Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Kelley, AS (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM amy.kelley@mssm.edu FU NIA NIH HHS [K23 AG040774, K24 AG022345, P30 AG028741, R24 AG044300] NR 56 TC 48 Z9 49 U1 5 U2 12 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 20 PY 2015 VL 373 IS 8 BP 747 EP 755 DI 10.1056/NEJMra1404684 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CP2LU UT WOS:000359709400011 PM 26287850 ER PT J AU Scremin, OU Roch, M Norman, KM Djazayeri, S Liu, YY AF Scremin, O. U. Roch, M. Norman, K. M. Djazayeri, S. Liu, Y. -Y. TI BRAIN ACETYLCHOLINE AND CHOLINE CONCENTRATIONS AND DYNAMICS IN A MURINE MODEL OF THE FRAGILE X SYNDROME: AGE, SEX AND REGION-SPECIFIC CHANGES SO NEUROSCIENCE LA English DT Article DE acetylcholine turnover; mice; cholinergic function; GCMS; fmr1-KO mice ID FMR1 KNOCKOUT MICE; MAGNETIC-RESONANCE-SPECTROSCOPY; GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; WORKING MEMORY; CGG REPEAT; LONG-TERM; NEURONS; EXPRESSION; SYSTEMS AB Fragile X syndrome is a learning disability caused by excess of CGG repeats in the 50 untranslated region of the Fragile X gene (FMR1) silencing its transcription and translation. We used a murine model of this condition, Fmr1 knock-out mice (KO) to study acetylcholine (ACh) metabolism and compared it to that of wild-type control mice (WT). Brain endogenous ACh (D0ACh), free choline (D0Ch), their deuterated variants D4ACh and D4Ch and mole ratios (AChMR and ChMR) were measured by gas chromatography- mass spectrometry in the cerebral hemisphere, cerebral cortex, hippocampus and cerebellum, following D4Ch administration. Regression analysis indicated a significant decrease with age (negative slope) of D4ACh, AChMR, D4Ch and ChMR in WT mice. Age dependence was only present for D4ACh and AChMR in KO mice. Analysis of variance with age as covariate indicated a significant greater D4Ch in the cerebral cortex of KO females when compared to WT females. Contrasts between sexes within genotypes indicated lower D0Ch in cortex and cerebellum of female KO mice but not in WT and lower D4Ch in hippocampus of female KO and WT mice. In conclusion, after adjusting for age, D0ACh concentrations and synthesis from deuterium-labeled Ch were similar in KO and control WT mice in all brain regions. In contrast, significant changes in Ch dynamics were found in hippocampus and cerebral cortex of KO mice that might contribute to the pathogenesis of FXS. Published by Elsevier Ltd. C1 [Scremin, O. U.; Roch, M.; Norman, K. M.; Djazayeri, S.; Liu, Y. -Y.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. [Scremin, O. U.] Univ Calif Los Angeles, Dept Physiol, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Liu, Y. -Y.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Scremin, OU (reprint author), Greater Los Angeles VA Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM oscremin@ucla.edu FU VA RR&D Senior Research Career Scientist Award FX This work was supported by a VA RR&D Senior Research Career Scientist Award to O.U. Scremin. NR 62 TC 1 Z9 1 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD AUG 20 PY 2015 VL 301 BP 520 EP 528 DI 10.1016/j.neuroscience.2015.06.036 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CM7MO UT WOS:000357877800045 PM 26117713 ER PT J AU Habib, SL Mohan, S Liang, ST Li, BJ Yadav, M AF Habib, Samy L. Mohan, Sumathy Liang, Sitai Li, Baojie Yadav, Mukesh TI Novel mechanism of transcriptional regulation of cell matrix protein through CREB SO CELL CYCLE LA English DT Article DE AMPK; cell matrix; CREB; fibronectin; renal cells; transcription ID HUMAN TUBULOINTERSTITIAL CELLS; OXIDATIVE DNA-DAMAGE; COLLAGEN-SYNTHESIS; MAMMALIAN TARGET; PROXIMAL TUBULE; GROWTH; RAPAMYCIN; MTOR; FIBRONECTIN; EXPRESSION AB The transcription mechanism(s) of renal cell matrix accumulation in diabetes does not explored. Phosphorylation of the transcription factor cAMP-responsive element binding protein (CREB) significantly increased in cells treated with high glucose (HG) compared to cell grown in normal glucose (NG). Cells pretreated with rapamycin before exposure to HG showed significant decrease phosphorylation of CREB, increase in AMPK activity and decrease protein/mRNA and promoter activity of fibronectin. In addition, cells transfected with siRNA against CREB showed significant increase in AMPK activity, decrease in protein/mRNA and promoter activity of fibronectin. Cells treated with HG showed nuclear localization of p-CREB while pretreated cells with rapamycin reversed HG effect. Moreover, gel shift analysis shows increase binding of CREB to fibronectin promoter in cells treated with HG while cells pretreated with rapamycin reversed the effect of HG. Furthermore, db/db mice treated with rapamycin showed significant increase in AMPK activity, decrease in expression of p-CREB and protein/mRNA of fibronectin. Strong staining of fibronectin and p-CREB was detected in kidney cortex of db/db mice while treated mice with rapamycin reversed hyperglycemia effect. In summary, our data provide a novel mechanism of transcriptional regulation of fibronectin through CREB that may be used as therapeutic approach to prevent diabetes complications. C1 [Habib, Samy L.] South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. [Li, Baojie] Shanghai Jiao Tong Univ, Minist Educ, Bio X Inst, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China. [Habib, Samy L.; Liang, Sitai; Yadav, Mukesh] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Mohan, Sumathy] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. RP Habib, SL (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. EM habib@uthscsa.edu FU American Heart Association; South Texas Veterans Healthcare System FX This work was supported in part by grants from the American Heart Association and Merit Review Award from South Texas Veterans Healthcare System (to SLH). NR 28 TC 0 Z9 0 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PD AUG 18 PY 2015 VL 14 IS 16 BP 2598 EP 2608 DI 10.1080/15384101.2015.1064204 PG 11 WC Cell Biology SC Cell Biology GA CQ0OG UT WOS:000360295400019 PM 26115221 ER PT J AU Downs, JR O'Malley, PG AF Downs, John R. O'Malley, Patrick G. TI Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID INTENSIVE STATIN THERAPY; CORONARY-HEART-DISEASE; 14 RANDOMIZED-TRIALS; C-REACTIVE PROTEIN; PRIMARY PREVENTION; CHOLESTEROL LEVELS; METAANALYSIS; EFFICACY; EVENTS; SAFETY AB Description: In December 2014, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of dyslipidemia for cardiovascular disease risk reduction in adults. This synopsis summarizes the major recommendations. Methods: On 30 September 2013, the VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included clinical stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions, systematically searched and evaluated the literature, developed a simple 1-page algorithm, and rated each of 26 recommendations by using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations: This synopsis summarizes key features of the guideline in 5 areas: elimination of treatment targets, additional tests for risk prediction, primary and secondary prevention, and laboratory testing. C1 [Downs, John R.] South Texas Vet Hlth Care Syst, Med Serv 111, San Antonio, TX 78229 USA. [O'Malley, Patrick G.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA. RP Downs, JR (reprint author), South Texas Vet Hlth Care Syst, Med Serv 111, 7400 Merton Minter, San Antonio, TX 78229 USA. EM john.downs@va.gov NR 40 TC 17 Z9 18 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 18 PY 2015 VL 163 IS 4 BP 291 EP + DI 10.7326/M15-0840 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CQ0LC UT WOS:000360286400007 PM 26099117 ER PT J AU Haghighi, F Ge, YC Chen, S Xin, YR Umali, MU De Gasperi, R Sosa, MAG Ahlers, ST Elder, GA AF Haghighi, Fatemeh Ge, Yongchao Chen, Sean Xin, Yurong Umali, Michelle U. De Gasperi, Rita Sosa, Miguel A. Gama Ahlers, Stephen T. Elder, Gregory A. TI Neuronal DNA Methylation Profiling of Blast-Related Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE blast overpressure; DNA methylation; epigenetic; sleep disturbance; traumatic brain injury ID SLEEP DISTURBANCE; INTRACRANIAL-PRESSURE; N-ACETYLTRANSFERASE; INDUCED NEUROTRAUMA; NITRIC-OXIDE; MOUSE MODEL; RAT MODEL; EXPOSURE; EXPRESSION; MICE AB Long-term molecular changes in the brain resulting from blast exposure may be mediated by epigenetic changes, such as deoxyribonucleic acid (DNA) methylation, that regulate gene expression. Aberrant regulation of gene expression is associated with behavioral abnormalities, where DNA methylation bridges environmental signals to sustained changes in gene expression. We assessed DNA methylation changes in the brains of rats exposed to three 74.5kPa blast overpressure events, conditions that have been associated with long-term anxiogenic manifestations weeks or months following the initial exposures. Rat frontal cortex eight months post-exposure was used for cell sorting of whole brain tissue into neurons and glia. We interrogated DNA methylation profiles in these cells using Expanded Reduced Representation Bisulfite Sequencing. We obtained data for millions of cytosines, showing distinct methylation profiles for neurons and glia and an increase in global methylation in neuronal versus glial cells (p<10(-7)). We detected DNA methylation perturbations in blast overpressure-exposed animals, compared with sham blast controls, within 458 and 379 genes in neurons and glia, respectively. Differentially methylated neuronal genes showed enrichment in cell death and survival and nervous system development and function, including genes involved in transforming growth factor and nitric oxide signaling. Functional validation via gene expression analysis of 30 differentially methylated neuronal and glial genes showed a 1.2 fold change in gene expression of the serotonin N-acetyltransferase gene (Aanat) in blast animals (p<0.05). These data provide the first genome-based evidence for changes in DNA methylation induced in response to multiple blast overpressure exposures. In particular, increased methylation and decreased gene expression were observed in the Aanat gene, which is involved in converting serotonin to the circadian hormone melatonin and is implicated in sleep disturbance and depression associated with traumatic brain injury. C1 [Haghighi, Fatemeh] James J Peters Dept Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [De Gasperi, Rita; Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA. [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA. [Haghighi, Fatemeh; Chen, Sean; Xin, Yurong; Umali, Michelle U.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. [Haghighi, Fatemeh; De Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Ge, Yongchao; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [De Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Dept Neurotrauma, Silver Spring, MD USA. RP Haghighi, F (reprint author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,Floor 10,Room 10-70D, New York, NY 10029 USA. EM fatemeh.haghighi@mssm.edu FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award [1I01RX000996-01]; [MH094774] FX This work was supported by MH094774 and the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award 1I01RX000996-01. The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. The study protocol was reviewed and approved by the Walter Reed Army Institute of Research/Naval Medical Research Center Institutional Animal Care and Use Committee in compliance with all applicable Federal regulations governing the protection of animals in research. NR 74 TC 9 Z9 9 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD AUG 15 PY 2015 VL 32 IS 16 BP 1200 EP 1209 DI 10.1089/neu.2014.3640 PG 10 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CU9RU UT WOS:000363883400003 PM 25594545 ER PT J AU Camp, ER Ellis, LM AF Camp, E. Ramsay Ellis, Lee M. TI CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR-Targeted Therapy for Colorectal Cancer-From Concept to Practice SO CLINICAL CANCER RESEARCH LA English DT Editorial Material ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; MUTATIONS; CETUXIMAB; ANTIBODY; KRAS; RESISTANCE; GEFITINIB; ERLOTINIB; BENEFIT AB Clinical data support the use of EGFR mAbs in patients with metastatic colorectal cancer (mCRC) with wild-type RAS status. This notion, hypothesized in the review article by Camp, Ellis, and colleagues in the January 1, 2005, issue of Clinical Cancer Research, serves as an example of the successful application of basic science principles to clinical practice. The exclusion of patients with mCRC with Ras-mutated tumors from therapy with EGFR mAbs has led to improved outcomes while sparing patients unnecessary and potentially harmful therapy. (C)2015 AACR. C1 [Camp, E. Ramsay] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Camp, E. Ramsay] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Camp, E. Ramsay] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Ellis, Lee M.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA. [Ellis, Lee M.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA. RP Ellis, LM (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Unit 1484, POB 301402,1515 Holcombe Blvd, Houston, TX 77230 USA. EM lellis@mdanderson.org FU NCI NIH HHS [K08 CA142904, CA100879, K08CA142904, R01 CA157880, R01CA157880] NR 14 TC 2 Z9 2 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD AUG 15 PY 2015 VL 21 IS 16 BP 3578 EP 3580 DI 10.1158/1078-0432.CCR-14-2900 PG 3 WC Oncology SC Oncology GA CS2NX UT WOS:000361909100002 PM 26275951 ER PT J AU Spinler, SA Cziraky, MJ Willey, VJ Tang, FM Maddox, TM Thomas, T Duenas, GG Virani, SS AF Spinler, Sarah A. Cziraky, Mark J. Willey, Vincent J. Tang, Fengming Maddox, Thomas M. Thomas, Tyan Duenas, Gladys G. Virani, Salim S. CA NCDR TI Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID PANEL-III GUIDELINES; DYSLIPIDEMIA; STATIN; ADULTS; RISK; RECOMMENDATIONS; ACHIEVEMENT; MANAGEMENT AB Studies have found that non-high-density lipoprotein cholesterol (non-HDL-C) is a superior marker for coronary heart disease compared to low-density lipoprotein cholesterol (LDL-C). Little is known about achievement of non-HDL-C goals outside clinical trials. Within a population of 146,064 patients with dyslipidemia in the PINNACLE Registry and a subgroup of 36,188 patients with diabetes mellitus (DM), we examined the proportion of patients and patient characteristics associated with having LDL-C, non-HDL-C, and both LDL-C and non-HDL-C levels at National Cholesterol Education Program goals. LDL-C, non-HDL-C, and both LDL-C and non-HDL-C goals in the overall cohort were achieved by 73%, 73.4%, and 68.9% patients, respectively. Significant predictors of meeting all 3 goals were age, male gender, statin, nonstatin, and combined statin plus nonstatin use. Patients with co-morbidities of hypertension, previous stroke or transient ischemic attack, peripheral arterial disease, myocardial infarction, and smoking were less likely to have LDL-C, non-HDL-C, and both LDL-C and non-HDL-C levels at National Cholesterol Education Program goal. In the overall cohort, patients with DM were less likely to meet non-HDL-C and both LDL-C and non-HDL-C goals. In the subgroup of patients with DM, predictors of meeting lipid goals were similar to the overall cohort. In conclusion, these data suggest contemporary treatment patterns by cardiologists successfully achieve lipid goals in most patients. Younger, female patients and those with atherosclerotic cardiovascular disease and risk factors, such as hypertension and DM, are less likely to achieve goals and may require more careful follow-up after statin initiation. Both LDL-C and non-HDL-C goals are achieved in <70% of patients, suggesting room for improvement if a goal-targeted individualized strategy is adopted. (C) 2015 Elsevier Inc. All rights reserved. C1 [Spinler, Sarah A.; Cziraky, Mark J.; Willey, Vincent J.; Thomas, Tyan; Duenas, Gladys G.] Univ Sci, Philadelphia Coll Pharm, Dept Pharm Practice & Pharm Adm, Philadelphia, PA 19104 USA. [Cziraky, Mark J.; Willey, Vincent J.] HealthCore Inc, Wilmington, DE USA. [Tang, Fengming] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Maddox, Thomas M.] Univ Colorado, Sch Med, Eastern Colorado Healthcare Syst, Denver, CO USA. [Maddox, Thomas M.] CCOR Consortium, Denver, CO USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Virani, Salim S.] Baylor Coll Med, Sect Cardiovasc Res, Dept Med, Houston, TX USA. RP Spinler, SA (reprint author), Univ Sci, Philadelphia Coll Pharm, Dept Pharm Practice & Pharm Adm, Philadelphia, PA 19104 USA. EM s.spinle@usciences.edu OI Virani, Salim/0000-0001-9541-6954; Spinler, Sarah/0000-0003-4552-0053 FU Bristol-Myers Squibb; Pfizer Inc. FX PINNACLE Registry is an initiative of the American College of Cardiology Foundation. Bristol-Myers Squibb and Pfizer Inc. are Founding Sponsors of the PINNACLE Registry. NR 17 TC 3 Z9 3 U1 0 U2 5 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD AUG 15 PY 2015 VL 116 IS 4 BP 547 EP 553 DI 10.1016/j.amjcard.2015.05.011 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CP9ZG UT WOS:000360253800010 PM 26089010 ER PT J AU Goetz, MB Hoang, T Kan, VL Rimland, D Rodriguez-Barradas, MC Asch, SM AF Goetz, Matthew Bidwell Hoang, Tuyen Kan, Virginia L. Rimland, David Rodriguez-Barradas, Maria C. Asch, Steven M. TI Rates and Predictors of Newly Diagnosed HIV Infection Among Veterans Receiving Routine Once-Per-Lifetime HIV Testing in the Veterans Health Administration SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; COST-EFFECTIVENESS; CARE SETTINGS; PERSONS AWARE; POPULATION; AFFAIRS; OLDER; RISK AB Objective: To determine predictors and variations in the rate of newly diagnosed HIV infection among persons who underwent routine (ie, non-risk based) rather than risk-based HIV testing in Veterans Health Administration (VHA) facilities. Methods: Retrospective observational study of the HIV infection new rates during the period when VHA policy called for routine (2009-2012) versus risk-based (2006-2009) HIV testing. Source data for testing results at 18 VHA facilities were obtained from the VHA National Corporate Data Warehouse. Results: New HIV diagnoses were established in 0.14% (95% confidence interval (CI): 0.12 to 0.46) of the 210,957 patients tested in the routine testing period versus 0.46% (95% CI: 0.42 to 1.29) of the 89,652 patients tested in the risk-based testing period. Among persons aged 65-74 years and 75 years or older, the new diagnosis rates were 0.07% (95% CI: 0.04 to 0.09) and 0.02% (95% CI: 0.00 to 0.03), respectively, and thus less than the generally accepted cost-effective threshold of 0.10%. Among African Americans, the upper bound of the 95% CI of the crude rate of new diagnoses during the routine-testing period was greater than 0.1% across all age strata. When assessed by year of testing, the adjusted rates of new diagnoses fell from 0.20% in 2010 to 0.10% in 2012. Conclusions: Routine HIV testing is cost-effective among persons younger than 65 years. Among older patients, risk-based testing may be a more efficient and cost-effective approach. This will be increasingly relevant if rates of new HIV diagnoses in persons undergoing routine testing continue to decrease. C1 [Goetz, Matthew Bidwell; Hoang, Tuyen] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Goetz, Matthew Bidwell; Hoang, Tuyen] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kan, Virginia L.] Washington DC VA Med Ctr, Washington, DC USA. [Kan, Virginia L.] George Washington Univ, Sch Med, Washington, DC USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Asch, Steven M.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM matthew.goetz@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU Veterans Health Administration, Health Services Research & Development Service [RRP 12-220] FX Supported by Veterans Health Administration, Health Services Research & Development Service (RRP 12-220). NR 46 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 15 PY 2015 VL 69 IS 5 BP 544 EP 550 DI 10.1097/QAI.0000000000000653 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN1VP UT WOS:000358208800005 PM 25886931 ER PT J AU Riedel, MC Ray, KL Dick, AS Sutherland, MT Hernandez, Z Fox, PM Eickhoff, SB Fox, PT Laird, AR AF Riedel, Michael C. Ray, Kimberly L. Dick, Anthony S. Sutherland, Matthew T. Hernandez, Zachary Fox, P. Mickle Eickhoff, Simon B. Fox, Peter T. Laird, Angela R. TI Meta-analytic connectivity and behavioral parcellation of the human cerebellum SO NEUROIMAGE LA English DT Article DE Cerebellum; Meta-analysis; Co-activations; BrainMap; Meta-analytic connectivity modeling; MACM; Functional connectivity; Neuroinformatics ID INTRINSIC FUNCTIONAL CONNECTIVITY; COGNITIVE-AFFECTIVE SYNDROME; VERBAL WORKING-MEMORY; BASAL GANGLIA; NEUROIMAGING DATA; INTERNAL-MODELS; MOTOR CORTEX; CORTICAL NETWORKS; ACTIVATION; AREAS AB The cerebellum historically has been thought to mediate motor and sensory signals between the body and cerebral cortex, yet cerebellar lesions are also associated with altered cognitive behavioral performance. Neuroimaging evidence indicates that the cerebellum contributes to a wide range of cognitive, perceptual, and motor functions. Here, we used the BrainMap database to investigate whole-brainco-activation patterns between cerebellar structures and regions of the cerebral cortex, as well as associations with behavioral tasks. Hierarchical clustering was performed to meta-analytically identify cerebellar structures with similar cortical co-activation, and independently, with similar correlations to specific behavioral tasks. Strong correspondences were observed in these separate but parallel analyses of meta-analytic connectivity and behavioral metadata. We recovered differential zones of cerebellar co-activation that are reflected across the literature. Furthermore, the behaviors and tasks associated with the different cerebellar zones provide insight into the specialized function of the cerebellum, relating to high-order cognition, emotion, perception, interoception, and action. Taken together, these task-basedmeta-analytic results implicate distinct zones of the cerebellum as critically involved in the monitoring and mediation of psychological responses to internal and external stimuli. Published by Elsevier Inc. C1 [Riedel, Michael C.; Fox, P. Mickle] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Ray, Kimberly L.] Univ Calif Davis, Imaging Res Ctr, Sacramento, CA 95817 USA. [Dick, Anthony S.; Sutherland, Matthew T.] Florida Int Univ, Dept Psychol, Miami, FL 33199 USA. [Hernandez, Zachary] Univ Houston, Dept Elect & Comp Engn, Houston, TX USA. [Eickhoff, Simon B.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Eickhoff, Simon B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China. [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. RP Laird, AR (reprint author), Florida Int Univ, Dept Phys, Modesto Maidique Campus,AHC 4 310,11200 SW 8th St, Miami, FL 33199 USA. EM alaird@fiu.edu RI Eickhoff, Simon/K-2061-2013 OI Eickhoff, Simon/0000-0001-6363-2759; Ray, Kimberly/0000-0003-1302-2834 FU National Institute of Mental Health [R01MH084812, R01-MH074457, R56-MH097870]; National Institute of Drug Abuse [K01-DA037819] FX This study was supported by awards from the National Institute of Mental Health(R01MH084812, R01-MH074457, R56-MH097870) and the National Institute of Drug Abuse(K01-DA037819). NR 117 TC 10 Z9 11 U1 0 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD AUG 15 PY 2015 VL 117 BP 327 EP 342 DI 10.1016/j.neuroimage.2015.05.008 PG 16 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CM9QX UT WOS:000358045100031 PM 25998956 ER PT J AU Vargas-Santos, AB Castelar-Pinheiro, GD Coutinho, ESF Schumacher, HR Singh, JA Schlesinger, N AF Vargas-Santos, Ana Beatriz Castelar-Pinheiro, Geraldo da Rocha Freire Coutinho, Evandro Silva Schumacher, H. Ralph, Jr. Singh, Jasvinder A. Schlesinger, Naomi TI Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists SO PLOS ONE LA English DT Article ID CURRENT PRESCRIBING PRACTICES; EVIDENCE-BASED RECOMMENDATIONS; URATE-LOWERING DRUGS; PHYSICIAN QUESTIONNAIRE; TASK-FORCE; ARTHRITIS; DIAGNOSIS; CARE; HYPERURICEMIA; COLCHICINE AB Objective To describe the current pharmacological approach to gout treatment reported by rheumatologists in Brazil. Methods We performed a cross-sectional survey study using an online questionnaire e-mailed to 395 rheumatologists, randomly selected, from among the members of the Brazilian Society of Rheumatology. Results Three hundred and nine rheumatologists (78.2%) responded to the survey. For acute gout attacks, combination therapy (NSAIDs or steroid + colchicine) was often used, even in monoarticular involvement, and colchicine was commonly started as monotherapy after 36 hours or more from onset of attack. During an acute attack, urate-lowering therapy (ULT) was withdrawn by approximately a third of rheumatologists. Anti-inflammatory prophylaxis (98% colchicine) was initiated when ULT was started in most cases (92.4%), but its duration was varied. Most (70%) respondents considered the target serum uric acid level to be less than 6 mg/dl. Approximately 50% of rheumatologists reported starting allopurinol at doses of 100 mg daily or less and 42% reported the initial dose to be 300 mg daily in patients with normal renal function. ULT was maintained indefinitely in 76% of gout patients with tophi whereas in gout patients without tophi its use was kept indefinitely in 39.6%. Conclusion This is the first study evaluating gout treatment in a representative, random sample of Brazilian rheumatologists describing common treatment practices among these specialists. We identified several gaps in reported gout management, mainly concerning the use of colchicine and ULT and the duration of anti-inflammatory prophylaxis and ULT. Since rheumatologists are considered as opinion leaders in this disease, a program for improving quality of care for gout patients should focus on increasing their knowledge in this common disease. C1 [Vargas-Santos, Ana Beatriz; Castelar-Pinheiro, Geraldo da Rocha] Univ Estado Rio de Janeiro, Dept Internal Med, Div Rheumatol, BR-20550011 Rio De Janeiro, RJ, Brazil. [Freire Coutinho, Evandro Silva] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Dept Epidemiol, Rio De Janeiro, RJ, Brazil. [Schumacher, H. Ralph, Jr.] Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Schumacher, H. Ralph, Jr.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Schlesinger, Naomi] Rutgers State Univ, Robert Wood Johnson Med Sch, Div Rheumatol, Dept Med, New Brunswick, NJ 08903 USA. RP Vargas-Santos, AB (reprint author), Univ Estado Rio de Janeiro, Dept Internal Med, Div Rheumatol, BR-20550011 Rio De Janeiro, RJ, Brazil. EM anabvargas@gmail.com OI Vargas dos Santos, Ana Beatriz/0000-0001-5307-0254; Pinheiro, Geraldo/0000-0002-7778-569X FU Astrazeneca; Abbvie; Takeda; Ardea; Merck; Metabolex; Novartis Pharmaceutical Corporation; Regeneron; Savient; Allergan; Sobi; BMS; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging (NIA); National Cancer Institute (NCI) FX Ana Beatriz Vargas-Santos has received consultant fee from Astrazeneca; H. Ralph Schumacher Jr. has received research grants from Abbvie and Takeda, and consultant fees from Abbvie, Ardea, AstraZeneca, Merck, Metabolex, Novartis Pharmaceutical Corporation, Regeneron and Takeda; Jasvinder A. Singh has received research and travel grants from Takeda and Savient, and consultant fees from Savient, Takeda, Allergan and Regeneron; Naomi Schlesinger has received grants from Novartis Pharmaceutical Corporation, consultant fees from Novartis Pharmaceutical Corporation, Sobi, BMS, is on the Speakers' Bureau of Novartis Pharmaceutical Corporation and Takeda, and serves on the advisory boards of Novartis Pharmaceutical Corporation, Takeda and Sobi. Jasvinder A. Singh is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute of Aging (NIA) and National Cancer Institute (NCI). Geraldo da Rocha Castelar-Pinheiro and Evandro Silva Freire Coutinho have declared that no competing interests exist. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials. NR 51 TC 1 Z9 1 U1 4 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 14 PY 2015 VL 10 IS 8 AR e0135805 DI 10.1371/journal.pone.0135805 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO9KD UT WOS:000359493600115 PM 26274585 ER PT J AU Liu, XH Bauma, WA Cardozo, C AF Liu, Xin-Hua Bauma, William A. Cardozo, Christopher TI ANKRD1 modulates inflammatory responses in C2C12 myoblasts through feedback inhibition of NF-kappa B signaling activity SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Inflammation; NF-kB signaling; AnkrD1; Myoblasts ID ANKYRIN-REPEAT PROTEIN; SPINAL MUSCULAR-ATROPHY; SKELETAL-MUSCLE; CONGENITAL MYOPATHY; I-BAND; EXPRESSION; ACTIVATION; CARP; IDENTIFICATION; TRANSCRIPTION AB Transcription factors of the nuclear factor-kappa B (NF-kappa B) family play a pivotal role in inflammation, immunity and cell survival responses. Recent studies revealed that NF-kappa B also regulates the processes of muscle atrophy. NF-kappa B activity is regulated by various factors, including ankyrin repeat domain 2 (AnkrD2), which belongs to the muscle ankyrin repeat protein family. Another member of this family, AnkrD1 is also a transcriptional effector. The expression levels of AnkrD1 are highly upregulated in denervated skeletal muscle, suggesting an involvement of AnkrD1 in NF-kappa B mediated cellular responses to paralysis. However, the molecular mechanism underlying the interactive role of AnkrD1 in NF-kappa B mediated cellular responses is not well understood. In the current study, we examined the effect of AnkrD1 on NF-kappa B activity and determined the interactions between AnkrD1 expression and NF-kappa B signaling induced by TNF alpha in differentiating C2C12 myoblasts. TNF alpha upregulated AnkrD1 mRNA and protein levels. AnkrD1-siRNA significantly increased TNF alpha-induced transcriptional activation of NF-kappa B, whereas overexpression of AnkrD1 inhibited TNF alpha-induced NF-kappa B activity. Co-immunoprecipitation studies demonstrated that AnkrD1 was able to bind p50 subunit of NF-kappa B and vice versa. Finally, CHIP assays revealed that AnkrD1 bound chromatin at a NF-kappa B binding site in the AnrkD2 promoter and required NF-kappa B to do so. These results provide evidence of signaling integration between AnkrD1 and NF-kappa B pathways, and suggest a novel anti-inflammatory role of AnkrD1 through feedback inhibition of NF-kappa B transcriptional activity by which AnkrD1 modulates the balance between physiological and pathological inflammatory responses in skeletal muscle. Published by Elsevier Inc. C1 [Liu, Xin-Hua; Bauma, William A.; Cardozo, Christopher] James J Peter VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY 10468 USA. [Liu, Xin-Hua; Bauma, William A.; Cardozo, Christopher] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauma, William A.; Cardozo, Christopher] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Cardozo, Christopher] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. RP Cardozo, C (reprint author), James J Peter VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM chris.cardozo@va.gov FU Veterans Health Administration, Rehabilitation Research and Development Service [B9212C, F7756R] FX This work was supported by the Veterans Health Administration, Rehabilitation Research and Development Service (Grants B9212C, F7756R). NR 34 TC 2 Z9 3 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD AUG 14 PY 2015 VL 464 IS 1 BP 208 EP 213 DI 10.1016/j.bbrc.2015.06.118 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CO5AY UT WOS:000359173200033 PM 26102030 ER PT J AU Gunasekera, D Ettinger, RA Fletcher, SN James, EA Liu, MC Barrett, JC Withycombe, J Matthews, DC Epstein, MS Hughes, RJ Pratt, KP AF Gunasekera, Devi Ettinger, Ruth A. Fletcher, Shelley Nakaya James, Eddie A. Liu, Maochang Barrett, John C. Withycombe, Janice Matthews, Dana C. Epstein, Melinda S. Hughes, Richard J. Pratt, Kathleen P. CA Personalized Approaches Therapies TI Factor VIII gene variants and inhibitor risk in African American hemophilia A patients SO BLOOD LA English DT Article ID T-CELL RESPONSES; HIGS COMBINED COHORT; IMMUNE-RESPONSES; EPITOPE IDENTIFICATION; F8; MUTATION; SUBSTITUTION; RECOGNITION; TOLERANCE; CHILDREN AB African American hemophilia A (HA) patients experience a higher incidence of neutralizing anti-factor VIII (FVIII) antibodies ("inhibitors") vis-a-vis white patients. Nonsynonymous single-nucleotide polymorphisms (ns-SNPs) in the F8 gene encoding FVIII-H484, FVIII-E1241, and FVIII-V2238 are more prevalent in African Americans. This study tested the hypothesis that immune responses to these sites provoke inhibitors. Blood samples were obtained from 174 African American and 198 white HA subjects and their F8 gene sequences determined. Major histocompatibility complex class II binding and T-cell recognition of polymorphic sequences were evaluated using quantitative binding assays and HLA-DRB1 tetramers. Peptides corresponding to 4 common ns-SNPs showed limited binding to 11 HLA-DRB1 proteins. CD4 T cells from 22 subjects treated with FVIII products having sequences at residues FVIII-484, 1241, and 2238 differing from those of putative proteins encoded by their F8 genes did not show high-avidity tetramer binding, whereas positive-control staining of tetanus-specific CD4 T cells was routinely successful. African Americans with an intron-22 inversion mutation showed a 2-3 times-higher inhibitor incidence than whites with the same mutation(odds ratio = 2.3 [1.1-5.0, P = .04]), but this did not correlate with any of the ns-SNPs. We conclude that immune responses to "sequence-mismatched" FVIII products are unlikely to contribute appreciably to the inhibitor incidence in African Americans. C1 [Gunasekera, Devi; Pratt, Kathleen P.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Gunasekera, Devi; Ettinger, Ruth A.; Liu, Maochang; Pratt, Kathleen P.] Puget Sound Blood Ctr Res Inst, Seattle, WA USA. [Fletcher, Shelley Nakaya] Puget Sound Blood Ctr, Genom Lab, Seattle, WA 98104 USA. [James, Eddie A.] Benaroya Res Inst, Seattle, WA USA. [Barrett, John C.] Virginia Commonwealth Univ, Cent Virginia Ctr Coagulat Disorders, Richmond, VA USA. [Withycombe, Janice] Palmetto Hlth, Columbia, SC USA. [Matthews, Dana C.] Seattle Childrens Hosp, Pediat Canc & Blood Disorders Ctr, Seattle, WA USA. [Epstein, Melinda S.; Hughes, Richard J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Pratt, KP (reprint author), Uniformed Serv Univ Hlth Sci, Dept Med MED A3075, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM kathleen.pratt@usuhs.edu FU National Institutes of Health National Heart, Lung, and Blood Institute [1RC2-HL101851]; CSL Behring and Bayer FX This work was supported by National Institutes of Health National Heart, Lung, and Blood Institute grant 1RC2-HL101851, and unrestricted hemophilia research grants from CSL Behring and Bayer (K.P.P.). NR 47 TC 8 Z9 8 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD AUG 13 PY 2015 VL 126 IS 7 BP 895 EP 904 DI 10.1182/blood-2014-09-599365 PG 10 WC Hematology SC Hematology GA CQ3VC UT WOS:000360530800013 PM 25617427 ER PT J AU Zhang, YN Zhao, KT Fox, SG Kim, J Kirsch, DR Ferrante, RJ Morirnoto, RI Silverman, RB AF Zhang, Yinan Zhao, Kevin Tianmeng Fox, Susan G. Kim, Jinho Kirsch, Donald R. Ferrante, Robert J. Morimoto, Richard I. Silverman, Richard B. TI Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID POTENTIAL APPLICATION; BRAIN EXPOSURE; DESIGN; ALS; DERIVATIVES; TOXICITY; DRUGS; MOUSE AB Pyrazolone derivatives have previously been found to be inhibitors of Cu/Zn superoxide dismutase 1 (S OD 1) - dep en dent protein aggregation, which extended survival of an amyotrophic lateral sclerosis (ALS) mouse model. On the basis of ADME analysis, we describe herein a new series of tertiary amine-containing pyrazolones and their structure activity relationships. Further conversion to the conjugate salts greatly improved their solubility. Phosphate compound 17 exhibited numerous benefits both to cellular activity and to CNS-related drug-like properties in vitro and in vivo, including microsomal stability, tolerated toxicity, and blood brain barrier permeation. These results indicate that tertiary amine pyrazolones comprise a valuable class of ALS drug candidates. C1 [Zhang, Yinan; Zhao, Kevin Tianmeng; Silverman, Richard B.] Northwestern Univ, Dept Chem, Ctr Mol Innovat & Drug Discovery, Dept Mol Biosci,Chem Life Proc Inst, Evanston, IL 60208 USA. [Fox, Susan G.; Morimoto, Richard I.] Northwestern Univ, Rice Inst Biomed Res, Dept Mol Biosci, Evanston, IL 60208 USA. [Kim, Jinho; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA. [Kim, Jinho; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Kim, Jinho; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA. [Kim, Jinho; Ferrante, Robert J.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, Pittsburgh, PA 15206 USA. [Kirsch, Donald R.] Cambria Pharmaceut, Cambridge, MA 02142 USA. RP Silverman, RB (reprint author), Northwestern Univ, Dept Chem, Ctr Mol Innovat & Drug Discovery, Dept Mol Biosci,Chem Life Proc Inst, 2145 Sheridan Rd, Evanston, IL 60208 USA. EM Agman@chem.northwestern.edu RI Zhang, Yinan/D-5769-2016 OI Zhang, Yinan/0000-0002-0362-1473 FU National Institutes of Health [1R43 NS057849]; ALS Association (TREAT program); Department of Defense [AL093052] FX We thank Prof. Meiyu Wang, College of Pharmacy, Soochew University, China, for her generous help with pharmacokinetic analysis and constructive discussions. We thank the National Institutes of Health (grant no. 1R43 NS057849), the ALS Association (TREAT program), and the Department of Defense (AL093052), for their generous support of this research. NR 32 TC 1 Z9 1 U1 4 U2 9 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 EI 1520-4804 J9 J MED CHEM JI J. Med. Chem. PD AUG 13 PY 2015 VL 58 IS 15 BP 5942 EP 5949 DI 10.1021/acs.jmedchem.5b00561 PG 8 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA CP2BY UT WOS:000359683700018 PM 26186011 ER PT J AU Asch, DA Rosin, R AF Asch, David A. Rosin, Roy TI Innovation as Discipline, Not Fad SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Asch, David A.; Rosin, Roy] Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Asch, DA (reprint author), Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. NR 4 TC 5 Z9 5 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 13 PY 2015 VL 373 IS 7 BP 592 EP 594 DI 10.1056/NEJMp1506311 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CP2LE UT WOS:000359707700003 PM 26267619 ER PT J AU Alawieh, A Elvington, A Tomlinson, S AF Alawieh, Ali Elvington, Andrew Tomlinson, Stephen TI Complement in the homeostatic and ischemic brain SO FRONTIERS IN IMMUNOLOGY LA English DT Review DE complement; stroke; innate immunity; neuroprotection; brain ischemia; reperfusion injury ID MANNOSE-BINDING LECTIN; CENTRAL-NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; C-REACTIVE PROTEIN; ANAPHYLATOXIN C5A NEUROPROTECTS; TISSUE-PLASMINOGEN ACTIVATOR; MEMBRANE ATTACK COMPLEX; NONHUMAN PRIMATE MODEL; APOPTOTIC CELL-DEATH; REPERFUSION INJURY AB The complement system is a component of the immune system involved in both recognition and response to pathogens, and it is implicated in an increasing number of homeostatic and disease processes. It is well documented that reperfusion of ischemic tissue results in complement activation and an inflammatory response that causes post-reperfusion injury. This occurs following cerebral ischemia and reperfusion and triggers secondary damage that extends beyond the initial infarcted area, an outcome that has rationalized the use of complement inhibitors as candidate therapeutics after stroke. In the central nervous system, however, recent studies have revealed that complement also has essential roles in synaptic pruning, neurogenesis, and neuronal migration. In the context of recovery after stroke, these apparent divergent functions of complement may account for findings that the protective effect of complement inhibition in the acute phase after stroke is not always maintained in the subacute and chronic phases. The development of effective stroke therapies based on modulation of the complement system will require a detailed understanding of complement-dependent processes in both early neurodegenerative events and delayed neuro-reparatory processes. Here, we review the role of complement in normal brain physiology, the events initiating complement activation after cerebral ischemia-reperfusion injury, and the contribution of complement to both injury and recovery. We also discuss how the design of future experiments may better characterize the dual role of complement in recovery after ischemic stroke. C1 [Alawieh, Ali] Med Univ S Carolina, Neurosci Inst, Dept Neurosci, Charleston, SC 29425 USA. [Elvington, Andrew] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA. [Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave,BSB 203,MSC 504, Charleston, SC 29425 USA. EM tomlinss@musc.edu OI Alawieh, Ali/0000-0003-2601-8850 FU Veterans Affairs [RX001141, BX001201]; NIH [P20GM109040] FX ST is supported by grants from Veterans Affairs (RX001141 and BX001201) and the NIH (P20GM109040). NR 130 TC 9 Z9 11 U1 0 U2 7 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PD AUG 12 PY 2015 VL 6 BP 1 EP 18 AR 417 DI 10.3389/fimmu.2015.00417 PG 18 WC Immunology SC Immunology GA CO9DM UT WOS:000359472900001 PM 26322048 ER PT J AU Salam, MT Avoundjian, T Knight, WM Gilliland, FD AF Salam, Muhammad T. Avoundjian, Tigran Knight, Wendy M. Gilliland, Frank D. TI Genetic Ancestry and Asthma and Rhinitis Occurrence in Hispanic Children: Findings from the Southern California Children's Health Study SO PLOS ONE LA English DT Article ID MEXICAN-AMERICAN CHILDREN; MULTILOCUS GENOTYPE DATA; CHILDHOOD ASTHMA; ACCULTURATION SCALE; AFRICAN ANCESTRY; UNITED-STATES; RISK-FACTOR; ASSOCIATIONS; BIRTH; SUSCEPTIBILITY AB Background Asthma and rhinitis are common childhood health conditions. Being an understudied and rapidly growing population in the US, Hispanic children have a varying risk for these conditions that may result from sociocultural (including acculturative factors), exposure and genetic diversities. Hispanic populations have varying contributions from European, Amerindian and African ancestries. While previous literature separately reported associations between genetic ancestry and acculturation factors with asthma, whether Amerindian ancestry and acculturative factors have independent associations with development of early-life asthma and rhinitis in Hispanic children remains unknown. We hypothesized that genetic ancestry is an important determinant of early-life asthma and rhinitis occurrence in Hispanic children independent of sociodemographic, acculturation and environmental factors. Methods Subjects were Hispanic children (5-7 years) who participated in the southern California Children's Health Study. Data from birth certificates and questionnaire provided information on acculturation, sociodemographic and environmental factors. Genetic ancestries (Amerindian, European, African and Asian) were estimated based on 233 ancestry informative markers. Asthma was defined by parental report of doctor-diagnosed asthma. Rhinitis was defined by parental report of a history of chronic sneezing or runny or blocked nose without a cold or flu. Sample sizes were 1,719 and 1,788 for investigating the role of genetic ancestry on asthma and rhinitis, respectively. Results Children had major contributions from Amerindian and European ancestries. After accounting for potential confounders, per 25% increase in Amerindian ancestry was associated with 17.6% (95% confidence interval [CI]: 0.74-0.99) and 13.6% (95% CI: 0.79-0.98) lower odds of asthma and rhinitis, respectively. Acculturation was not associated with either outcome. Conclusions Earlier work documented that Hispanic children with significant contribution from African ancestry are at increased asthma risk; however, in Hispanic children who have little contribution from African ancestry, Amerindian ancestry was independently associated with lower odds for development of early-childhood asthma and rhinitis. C1 [Salam, Muhammad T.; Gilliland, Frank D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Salam, Muhammad T.] Kern Med Ctr, Dept Psychiat, Bakersfield, CA USA. [Avoundjian, Tigran] US Dept Vet Affairs, Ctr Hlth Care Evaluat, Palo Alto, CA USA. [Knight, Wendy M.] Los Angeles Cty Dept Publ Hlth, Acute Communicable Dis Control Program, Los Angeles, CA USA. RP Salam, MT (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. EM msalam@usc.edu FU National Heart, Lung and Blood Institute [5R01HL61768, 5R01HL76647]; Southern California Environmental Health Sciences Center - National Institute of Environmental Health Sciences [5P30ES007048]; Children's Environmental Health Center - National Institute of Environmental Health Sciences [5P01ES009581, R826708-01, RD831861-01]; U.S. Environmental Protection Agency; National Institute of Environmental Health Sciences [5P01ES011627]; Hastings Foundation FX This work was supported by the National Heart, Lung and Blood Institute (grants 5R01HL61768 and 5R01HL76647; URL http://www.nhlbi.nih.gov/); the Southern California Environmental Health Sciences Center (grant 5P30ES007048) funded by the National Institute of Environmental Health Sciences; the Children's Environmental Health Center (grants 5P01ES009581, R826708-01, and RD831861-01) funded by the National Institute of Environmental Health Sciences (URL: http://www.niehs.nih.gov/) and the U.S. Environmental Protection Agency (URL: http://www.epa.gov/); the National Institute of Environmental Health Sciences (grants 5P01ES011627; URL: http://www.niehs.nih.gov); and the Hastings Foundation. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. NR 36 TC 2 Z9 2 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 11 PY 2015 VL 10 IS 8 AR e0135384 DI 10.1371/journal.pone.0135384 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO7PP UT WOS:000359353300078 PM 26263549 ER PT J AU Achtman, JC Werth, VP AF Achtman, Jordan C. Werth, Victoria P. TI Pathophysiology of cutaneous lupus erythematosus SO ARTHRITIS RESEARCH & THERAPY LA English DT Review ID FAMILIAL CHILBLAIN LUPUS; HUMAN KERATINOCYTES; ULTRAVIOLET-LIGHT; SKIN-LESIONS; T-CELLS; APOPTOTIC KERATINOCYTES; EXPRESSION; ALPHA; ASSOCIATION; IRRADIATION AB The pathophysiology of cutaneous lupus erythematosus (CLE) encompasses the complex interactions between genetics, the environment, and cells and their products. Recent data have provided enhanced understanding of these interactions and the mechanism by which they cause disease. A number of candidate genes have been identified which increase the risk of developing CLE. Ultraviolet radiation, the predominant environmental exposure associated with CLE, appears to initiate CLE lesion formation by inducing apoptosis, precipitating autoantigen presentation, and promoting cellular production of specific cytokines. Autoantibodies are a well-known entity in CLE, but their exact role remains unclear. Finally, cells ranging from native skin cells to innate and adaptive immune cells produce cytokines and other molecules and play specific roles in lesion formation and perpetuation. Native skin cells implicated in CLE include keratinocytes and endothelial cells. Innate immune cells crucial to CLE pathophysiology include dendritic cells and neutrophils. The primary adaptive immune cells thought to be involved include Th1 cells, Th17 cells, cytotoxic T cells, and invariant natural killer T cells. Though the pathophysiology of CLE has yet to be fully characterized, current research provides direction for future research and therapies. C1 [Achtman, Jordan C.; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Achtman, Jordan C.; Werth, Victoria P.] Perelman Ctr Adv Med, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX This material is supported by the Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. NR 65 TC 8 Z9 8 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD AUG 10 PY 2015 VL 17 AR 182 DI 10.1186/s13075-015-0706-2 PG 10 WC Rheumatology SC Rheumatology GA CO6QL UT WOS:000359281100001 PM 26257198 ER PT J AU Hsu, JJ AF Hsu, Jung-Jiin TI Flip-angle profile of slice-selective excitation and the measurement of the MR longitudinal relaxation time with steady-state magnetization SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article DE flip angle profile; longitudinal relaxation time; T-1 measurement; steady-state magnetization; slice profile; DESPOT ID RF PULSE-SHAPE; RADIOFREQUENCY FIELD; SPOILED FLASH; T-1; RESONANCE; ACCURATE; T1; T2; ACQUISITION; NMR AB In MRI, the flip angle (FA) of slice-selective excitation is not uniform across the slice-thickness dimension. This work investigates the effect of the non-uniform FA profile on the accuracy of a commonly-used method for the measurement, in which the T-1 value, i.e., the longitudinal relaxation time, is determined from the steady-state signals of an equally-spaced RF pulse train. By using the numerical solutions of the Bloch equation, it is shown that, because of the non-uniform FA profile, the outcome of the T-1 measurement depends significantly on T-1 of the specimen and on the FA and the inter-pulse spacing tau of the pulse train. A new method to restore the accuracy of the T-1 measurement is described. Different from the existing approaches, the new method also removes the FA profile effect for the measurement of the FA, which is normally a part of the T-1 measurement. In addition, the new method does not involve theoretical modeling, approximation, or modification to the underlying principle of the T-1 measurement. An imaging experiment is performed, which shows that the new method can remove the FA-, the tau-, and the T-1-dependence and produce T-1 measurements in excellent agreement with the ones obtained from a gold standard method (the inversion-recovery method). C1 [Hsu, Jung-Jiin] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Hsu, Jung-Jiin] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA. RP Hsu, JJ (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St Bldg 13 114M, San Francisco, CA 94121 USA. EM jj.jason.hsu@outlook.com FU US Department of Defense [W81XWH-10-2-0078] FX This work is supported in part by a grant from the US Department of Defense (W81XWH-10-2-0078; PI: Michael Weiner). The Author thanks Gerald Matson and Norbert Schuff for helpful discussion during manuscript preparation. NR 25 TC 0 Z9 0 U1 0 U2 6 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 EI 1361-6560 J9 PHYS MED BIOL JI Phys. Med. Biol. PD AUG 7 PY 2015 VL 60 IS 15 BP 5785 EP 5801 DI 10.1088/0031-9155/60/15/5785 PG 17 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA CR0VH UT WOS:000361040900006 PM 26159799 ER PT J AU Artinian, N Cloninger, C Holmes, B Benavides-Serrato, A Bashir, T Gera, J AF Artinian, Nicholas Cloninger, Cheri Holmes, Brent Benavides-Serrato, Angelica Bashir, Tariq Gera, Joseph TI Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID YES-ASSOCIATED PROTEIN-1; TUMOR-SUPPRESSOR; MOLECULAR PATHOLOGY; COMPLEX; GLIOMAS; ONCOPROTEIN; INHIBITION; RESISTANCE; REGULATOR; CANCER AB The mechanistic target of rapamycin (mTOR) and Hippo signaling pathways are two major signaling cascades that coordinately regulate cell growth and proliferation. Dysregulation of these pathways plays a critical role in gliomagenesis. Recent reports have provided evidence of cross-talk between the mTOR and Hippo pathways; however, a complete description of the signaling relationships between these pathways remains to be elucidated. Utilizing a gene-trapping strategy in a mouse glioma model, we report the identification of AMOTL2 as a candidate substrate for mTORC2. AMOTL2 is phosphorylated at serine 760 by mTORC2. Mutation of AMOTL2 mimicking constitutive Ser(760) phosphorylation blocks its ability to bind and repress YAP leading to increased relative expression of known YAP gene targets. Moreover, overexpression of AMOTL2 or a non-phosphorylatable AMOTL2-S760A mutant inhibited YAP-induced transcription, foci formation, growth, and metastatic properties, whereas overexpression of a phosphomimetic AMOTL2-S760E mutant negated these repressive effects of AMOTL2 in glioblastoma (GBM) cells in vitro. Similar effects on xenograft growth were observed in GBM cells expressing these AMOTL2 Ser(760) mutants. YAP was also shown to be required for Rictor-mediated GBM growth and survival. Finally, an analysis of mTORC2/AMOTL2/YAP activities in primary GBM samples supported the clinical relevance of this signaling cascade, and we propose that pharmacological agents cotargeting these regulatory circuits may hold therapeutic potential. C1 [Artinian, Nicholas; Bashir, Tariq; Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Gera, Joseph] Univ Calif Los Angeles, Jonnson Comprehens Canc Ctr, Los Angeles, CA 90048 USA. [Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90048 USA. [Artinian, Nicholas; Cloninger, Cheri; Holmes, Brent; Benavides-Serrato, Angelica; Bashir, Tariq; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. RP Gera, J (reprint author), 16111 Plummer St 151 Bldg 1,Rm C111A, Los Angeles, CA 91343 USA. EM jgera@mednet.ucla.edu RI Regan, Clinton/E-6250-2012 FU National Institutes of Health [R01CA168700]; Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grant R01CA168700. This work was also supported by the Department of Veterans Affairs. The authors declare that they have no conflicts of interest with the contents of this article. NR 46 TC 6 Z9 6 U1 1 U2 11 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 7 PY 2015 VL 290 IS 32 BP 19387 EP 19401 DI 10.1074/jbc.M115.656587 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CO7TL UT WOS:000359364600001 PM 25998128 ER PT J AU Lee, C Jones, A Kainz, D Khan, F Carrithers, MD AF Lee, Cara Jones, Alexis Kainz, Danielle Khan, Faatima Carrithers, Michael D. TI A sodium channel variant in Aedes aegypti as a candidate pathogen sensor for viral-associated molecular patterns SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Para; Yellow fever mosquito; Imidazolquinilone; RelA; ssRNA ID NAV1.5; SEQUENCE AB Recent work demonstrated that a splice variant of a human macrophage voltage-gated sodium channel expressed on endosomes acts as an intracellular sensor for dsRNA, a viral-associated molecular pattern. Here our goal was to identify a candidate gene in a clinically relevant invertebrate model with related cellular and pattern recognition properties. The para gene in drosophila and other insects encodes voltage-gated sodium channels with similar electrophysiological properties to those found in vertebrate excitable membranes. A database search revealed that the AAEL006019 gene in Aedes aegypti, the yellow fever mosquito, encodes a voltage-gated sodium channel that is distinct from genes that encode para-like sodium channels. As compared to para-like channels, the protein products from this gene have deletions in the N-terminus and in the DII-DIII linker region. When over-expressed in an Aedes aegypti cell line, CCL-125, the AAEL006019 channel demonstrated cytoplasmic expression on vesicular-like organelles. Electrophysiologic analysis revealed that the channel mediates small inward currents that are enhanced by synthetic mimics of viral-derived ssRNA, R848 and ORNO2, but not the dsRNA mimic, poly I:C. R848 treatment of CCL-125 cells that express high levels of the channels led to increased expression of RelA and Ago2, two mediators of insect innate immunity. These results suggest that the AAEL006019 channel acts as an intracellular pathogen sensor for ssRNA molecular patterns. Published by Elsevier Inc. C1 [Lee, Cara; Jones, Alexis; Kainz, Danielle; Khan, Faatima; Carrithers, Michael D.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Lee, Cara; Jones, Alexis; Kainz, Danielle; Khan, Faatima; Carrithers, Michael D.] Univ Wisconsin, Dept Pathol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Lee, Cara; Jones, Alexis; Kainz, Danielle; Khan, Faatima; Carrithers, Michael D.] Univ Wisconsin, Program Cellular & Mol Pathol, Sch Med & Publ Hlth, Madison, WI USA. [Carrithers, Michael D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Carrithers, MD (reprint author), Univ Illinois, Coll Med, Dept Neurol, 912 South Wood, Chicago, IL 60612 USA. EM mcar1@uic.edu OI Lee, Cara/0000-0003-0614-9060 FU U.S. Department of Veterans Affairs [2 I01 BX000467-05] FX This work was supported by a Merit Award (BLR&D, 2 I01 BX000467-05) from the U.S. Department of Veterans Affairs. NR 16 TC 0 Z9 0 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD AUG 7 PY 2015 VL 463 IS 4 BP 1203 EP 1209 DI 10.1016/j.bbrc.2015.06.085 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CN5FN UT WOS:000358455300116 PM 26086103 ER PT J AU Moyer, CE Shelton, MA Sweet, RA AF Moyer, Caitlin E. Shelton, Micah A. Sweet, Robert A. TI Dendritic spine alterations in schizophrenia SO NEUROSCIENCE LETTERS LA English DT Review DE Schizophrenia; Dendritic spine; Postmortem; Adolescence; MAP2; Kalirin ID MICROTUBULE-ASSOCIATED PROTEINS; LIGHT-CHAIN PHOSPHORYLATION; CORTICAL PYRAMIDAL NEURONS; PRIMATE CEREBRAL-CORTEX; PREFRONTAL CORTEX; PSYCHIATRIC-DISORDERS; SYNAPTIC PLASTICITY; MASS-SPECTROMETRY; MAP2 EXPRESSION; EARLY ADULTHOOD AB Schizophrenia is a chronic illness affecting approximately 0.5-1% of the world's population. The etiology of schizophrenia is complex, including multiple genes, and contributing environmental effects that adversely impact neurodevelopment. Nevertheless, a final common result, present in many subjects with schizophrenia, is impairment of pyramidal neuron dendritic morphology in multiple regions of the cerebral cortex. In this review, we summarize the evidence of reduced dendritic spine density and other dendritic abnormalities in schizophrenia, evaluate current data that informs the neurodevelopment timing of these impairments, and discuss what is known about possible upstream sources of dendritic spine loss in this illness. Published by Elsevier Ireland Ltd. C1 [Moyer, Caitlin E.; Shelton, Micah A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15206 USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645 3811 OHara St, Pittsburgh, PA 15240 USA. EM sweetra@upmc.edu FU National Institutes of Health [MH071533, MH103204, 5T32NS007433] FX This work was supported in part by National Institutes of Health grants MH071533, MH103204, and 5T32NS007433. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 94 TC 13 Z9 14 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 EI 1872-7972 J9 NEUROSCI LETT JI Neurosci. Lett. PD AUG 5 PY 2015 VL 601 BP 46 EP 53 DI 10.1016/j.neulet.2014.11.042 PG 8 WC Neurosciences SC Neurosciences & Neurology GA CN5HR UT WOS:000358460900007 PM 25478958 ER PT J AU Yudina, Z Roa, A Johnson, R Biris, N Vieira, DADA Tsiperson, V Reszka, N Taylor, AB Hart, PJ Demeler, B Diaz-Griffero, F Ivanov, DN AF Yudina, Zinaida Roa, Amanda Johnson, Rory Biris, Nikolaos Vieira, Daniel A. de Souza Aranha Tsiperson, Vladislav Reszka, Natalia Taylor, Alexander B. Hart, P. John Demeler, Borries Diaz-Griffero, Felipe Ivanov, Dmitri N. TI RING Dimerization Links Higher-Order Assembly of TRIM5 alpha to Synthesis of K63-Linked Polyubiquitin SO CELL REPORTS LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; E3 UBIQUITIN LIGASE; RETROVIRAL RESTRICTION; REVERSE TRANSCRIPTION; CAPSID LATTICE; DOMAIN; REVEALS; HIV-1; PROTEIN; COMPLEX AB Members of the tripartite motif (TRIM) protein family of RING E3 ubiquitin (Ub) ligases promote innate immune responses by catalyzing synthesis of polyubiquitin chains linked through lysine 63 (K63). Here, we investigate the mechanism by which the TRIM5 alpha retroviral restriction factor activates Ubc13, the K63-linkage-specific E2. Structural, biochemical, and functional characterization of the TRIM5 alpha: Ubc13-Ub interactions reveals that activation of the Ubc13-Ub conjugate requires dimerization of the TRIM5 alpha RING domain. Our data explain how higher-order oligomerization of TRIM5 alpha, which is promoted by the interaction with the retroviral capsid, enhances the E3 Ub ligase activity of TRIM5 alpha and contributes to its antiretroviral function. This E3 mechanism, in which RING dimerization is transient and depends on the interaction of the TRIM protein with the ligand, is likely to be conserved in many members of the TRIM family and may have evolved to facilitate recognition of repetitive epitope patterns associated with infection. C1 [Yudina, Zinaida; Johnson, Rory; Biris, Nikolaos; Taylor, Alexander B.; Hart, P. John; Demeler, Borries; Ivanov, Dmitri N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Roa, Amanda; Vieira, Daniel A. de Souza Aranha; Tsiperson, Vladislav; Reszka, Natalia; Diaz-Griffero, Felipe] Albert Einstein Coll Med, Microbiol & Immunol, Bronx, NY 10461 USA. RP Diaz-Griffero, F (reprint author), Albert Einstein Coll Med, Microbiol & Immunol, Bronx, NY 10461 USA. EM felipe.diaz-griffero@einstein.yu.edu; ivanov@uthscsa.edu FU Center for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH) [NIH P50 GM082545]; Robert A. Welch Foundation [AQ-1399]; NIH [R01 AI087390, R21 AI102824, R56 AI108432, R01 AI104476, P30 CA054174]; Cancer Prevention and Research Institute of Texas (CPRIT); NIH-NIGMS [P41 GM103403]; NIH-ORIP HEI at Argonne National Laboratory under DOE Office of Science [S10 RR029205, DE-AC02-06CH11357] FX This research was supported in part by the Collaborative Development Award to D.N.I. from the Center for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH; NIH P50 GM082545); R01 AI087390, R21 AI102824, and R56 AI108432 to F.D.-G; Robert A. Welch Foundation grant AQ-1399 to P.J.H; NIH R01 AI104476 to D.N.I.; and Scholar Award from the Cancer Prevention and Research Institute of Texas (CPRIT) to D.N.I. A.R., D.A.d.S.A.V., V.T., N.R., and F.D.-G. were supported by NIH grants R01 AI087390, R21 AI102824, and R56 AI108432 to F.D.-G. The NMR, X-ray, and Analytical Ultracentrifugation core facilities at the UT Health Science Center at San Antonio (UTHSCSA) are supported in part by the NIH P30 CA054174 to the Cancer Therapy and Research Center. B.D. acknowledges support from NSF for the development of the UltraScan Science Gateway used in the analysis of AUC data (ACI-1339649 and TG-MCB070039). X-ray diffraction data were collected at the Advanced Photon Source beamline 24-IDC NE-CAT funded by NIH-NIGMS P41 GM103403 and NIH-ORIP HEI S10 RR029205 at Argonne National Laboratory under DOE Office of Science contract no. DE-AC02-06CH11357. NR 50 TC 10 Z9 10 U1 0 U2 6 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD AUG 4 PY 2015 VL 12 IS 5 BP 788 EP 797 DI 10.1016/j.celrep.2015.06.072 PG 10 WC Cell Biology SC Cell Biology GA CO2PT UT WOS:000358999800008 PM 26212332 ER PT J AU Kearney, DJ Simpson, TL AF Kearney, David J. Simpson, Tracy L. TI Broadening the Approach to Posttraumatic Stress Disorder and the Consequences of Trauma SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID QUALITY-OF-LIFE; PTSD TREATMENT; THERAPY; TRIAL; VETERANS; EXPOSURE C1 [Kearney, David J.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Kearney, David J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Kearney, DJ (reprint author), Seattle VAMC 111GI, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM david.kearney@va.gov NR 20 TC 0 Z9 0 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 4 PY 2015 VL 314 IS 5 BP 453 EP 455 DI 10.1001/jama.2015.7522 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CO1OI UT WOS:000358924500009 PM 26241596 ER PT J AU Rhodes, KV Rodgers, M Sommers, M Hanlon, A Chittams, J Doyle, A Datner, E Crits-Christoph, P AF Rhodes, Karin V. Rodgers, Melissa Sommers, Marilyn Hanlon, Alexandra Chittams, Jesse Doyle, Andrea Datner, Elizabeth Crits-Christoph, Paul TI Brief Motivational Intervention for Intimate Partner Violence and Heavy Drinking in the Emergency Department A Randomized Clinical Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ALCOHOL-USE; DOMESTIC VIOLENCE; AGGRESSION; SYMPTOMS; INJURY; AUDIT; RISK AB IMPORTANCE Intimate partner violence (IPV) and heavy drinking are co-occurring public health problems, but integrated brief interventions for these conditions have not been tested. OBJECTIVE To determine whether a brief motivational intervention provided at the time of an emergency department (ED) visit reduces IPV and heavy drinking. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial conducted at 2 US academic urban EDs between January 2011 and December 2014 to assess the effectiveness of a motivational intervention for IPV-involved female ED patients (ages: 18-64 years; N = 600) who exceeded sex-specific safe drinking limits. All received social service referrals; 2: 2: 1 to brief intervention (n = 242), assessed control (n = 237), or no-contact control (n = 121). INTERVENTIONS A 20- to 30-minute manual-guided motivational intervention (recorded and monitored for fidelity) delivered by master's-level therapists with a follow-up telephone booster. The assessed control group received the same number of assessments as the brief intervention group; the no-contact control group was assessed only once at 3 months. MAIN OUTCOMES AND MEASURES Incidents of heavy drinking and experiencing IPV measured over prespecified, 12 weekly assessments using an interactive voice response system. RESULTS Of 600 participants, 80% were black women with a mean age of 32 years. Retention was 89% for 2 or more interactive voice response system calls. Seventy-eight percent of women completed the 3-month interview, 79% at 6 months, and 71% at 12 months. During the 12-week period following the brief motivational intervention, there were no significant differences between the intervention group and the assessed control group on weekly assessments for experiencing IPV (odds ratio [OR], 1.02; 95% CI, 0.98-1.06) or heavy drinking (OR, 0.99; 95% CI, 0.96-1.03). From baseline to 12 weeks, the number of women with any IPV in the past week decreased from 57%(134 of 237) in the intervention group to 43%(83 of 194) and from 63%(145 of 231) in the assessed control group to 41%(77 of 187) (absolute difference of 8%). From baseline to 12 weeks, the number of women with past week heavy drinking decreased from 51%(120 of 236) in the intervention group to 43%(83 of 194) and from 46%(107 of 231) in the assessed control group to 41%(77 of 187) (absolute difference of 3%). At 12 months, 43%(71 of 165) of the intervention group and 47%(78 of 165) of the assessed control group reported no IPV during the previous 3 months and 19% (29 of 152) of the intervention group and 24%(37 of 153) of the control group had reduced their alcohol consumption to sex-specific National Institute on Alcohol Abuse and Alcoholism safe drinking levels. CONCLUSIONS AND RELEVANCE For women experiencing IPV and heavy drinking, the use of a brief motivational intervention in the ED compared with assessed and no-contact controls did not significantly reduce the days of heavy drinking or incidents of IPV. These findings do not support a brief motivational intervention in this setting. C1 [Rhodes, Karin V.; Rodgers, Melissa; Datner, Elizabeth; Crits-Christoph, Paul] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Rhodes, Karin V.; Doyle, Andrea] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Sommers, Marilyn; Hanlon, Alexandra; Chittams, Jesse] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Datner, Elizabeth] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Rhodes, KV (reprint author), Univ Penn, Ctr Emergency Care Policy & Res, Dept Emergency Med, Perelman Sch Med,HUP, 34th & Spruce St,First Floor Ravidin, Philadelphia, PA 19104 USA. EM karin.rhodes@uphs.upenn.edu FU National Institute on Alcohol Abuse and Alcoholism [R01-AA018705] FX This project was funded by award R01-AA018705 from the National Institute on Alcohol Abuse and Alcoholism. NR 40 TC 5 Z9 5 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 4 PY 2015 VL 314 IS 5 BP 466 EP 477 DI 10.1001/jama.2015.8369 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA CO1OI UT WOS:000358924500011 PM 26241598 ER PT J AU Spoont, MR Williams, JW Kehle-Forbes, S Nieuwsma, JA Mann-Wrobel, MC Gross, R AF Spoont, Michele R. Williams, John W., Jr. Kehle-Forbes, Shannon Nieuwsma, Jason A. Mann-Wrobel, Monica C. Gross, Raz TI Does This Patient Have Posttraumatic Stress Disorder? Rational Clinical Examination Systematic Review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID NATIONAL COMORBIDITY SURVEY; PRIMARY-CARE PATIENTS; DSM-IV DISORDERS; PTSD CHECKLIST; MENTAL-HEALTH; SCREENING INSTRUMENT; PROLONGED EXPOSURE; PERFORMANCE-CHARACTERISTICS; OPERATING CHARACTERISTICS; DIAGNOSTIC-ACCURACY AB IMPORTANCE Posttraumatic stress disorder (PTSD) is a relatively common mental health condition frequently seen, though often unrecognized, in primary care settings. Identifying and treating PTSD can greatly improve patient health and well-being. OBJECTIVE To systematically review the utility of self-report screening instruments for PTSD among primary care and high-risk populations. EVIDENCE REVIEW We searched MEDLINE and the National Center for PTSD's Published International Literature on Traumatic Stress (PILOTS) databases for articles published on screening instruments for PTSD published from January 1981 through March 2015. Study quality was rated using Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria. STUDY SELECTION Studies of screening instruments for PTSD evaluated using gold standard structured clinical diagnostic interviews that had interview samples of at least 50 individuals. FINDINGS We identified 2522 citations, retrieved 318 for further review, and retained 23 cohort studies that evaluated 15 screening instruments for PTSD. Of the 23 studies, 15 were conducted in primary care settings in the United States (n = 14 707 were screened, n = 5374 given diagnostic interview, n = 814 had PTSD) and 8 were conducted in community settings following probable trauma exposure (ie, natural disaster, terrorism, and military deployment; n = 5302 were screened, n = 4263 given diagnostic interview, n = 393 were known to have PTSD with an additional 50 inferred by rates reported by authors). Two screens, the Primary Care PTSD Screen (PC-PTSD) and the PTSD Checklist were the best performing instruments. The 4-item PC-PTSD has a positive likelihood ratio of 6.9 (95% CI, 5.5-8.8) and a negative likelihood ratio of 0.30 (95% CI, 0.21-0.44) using the same score indicating a positive screen as used by the Department of Veterans Affairs in all of its primary care clinics. The 17-item PTSD Checklist has a positive likelihood ratio of 5.2 (95% CI, 3.6-7.5) and a negative likelihood ratio of 0.33 (95% CI, 0.29-0.37) using scores of around 40 as indicating a positive screen. Using the same score employed by primary care clinics in the Department of Veterans Affairs to indicate a positive screen, the 4-item PC-PTSD has a sensitivity of 0.69 (95% CI, 0.55-0.81), a specificity of 0.92 (95% CI, 0.86-0.95), a positive likelihood ratio of 8.49 (95% CI, 5.56-12.96) and a negative likelihood ratio of 0.34 (95% CI, 0.22-0.48). For the 17-item PTSD Checklist, scores around 40 as indicating a positive screen, have a sensitivity of 0.70 (95% CI, 0.64-0.77), a specificity of 0.90 (95% CI, 0.84-0.93), a positive likelihood ratio of 6.8 (95% CI, 4.7-9.9) and a negative likelihood ratio of 0.33 (95% CI, 0.27-0.40). CONCLUSIONS AND RELEVANCE Two screening instruments, the PC-PTSD and the PTSD Checklist, show reasonable performance characteristics for use in primary care clinics or in community settings with high-risk populations. Both are easy to administer and interpret and can readily be incorporated into a busy practice setting. C1 [Spoont, Michele R.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Minneapolis Vet Affairs Healthcare Syst, Minneapolis, MN USA. [Spoont, Michele R.; Kehle-Forbes, Shannon] Minneapolis Vet Affairs Healthcare Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA. [Spoont, Michele R.; Kehle-Forbes, Shannon] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Williams, John W., Jr.] Durham Vet Affairs Med Ctr, US Dept Vet Affairs Evidence Based Synth Ctr, Durham, NC USA. [Williams, John W., Jr.] Duke Univ, Sch Med, Div Gen Internal Med, Durham, NC USA. [Nieuwsma, Jason A.] Durham Vet Affairs Med Ctr, Midatlantic Mental Illness Res Educ & Clin Ctr, Durham, NC USA. [Nieuwsma, Jason A.; Mann-Wrobel, Monica C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Mann-Wrobel, Monica C.] Durham Vet Affairs Med Ctr, Dept Mental Hlth, Durham, NC USA. [Gross, Raz] Tel Aviv Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth, Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Gross, Raz] Chaim Sheba Med Ctr, Gertner Inst Hlth Policy & Epidemiol, IL-52621 Tel Hashomer, Israel. RP Spoont, MR (reprint author), Minneapolis Vet Affairs Healthcare Syst, Ctr Chron Dis Outcomes Res, 152,Bldg 9,1 Vet Dr, Minneapolis, MN 55417 USA. EM michele.spoont@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative (VA-ESP) [09-009, 09-010] FX This report is based on research conducted by the Evidence-based Synthesis Program (ESP) Center located at the Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, and expanded on by the ESP Center located at the Durham Veterans Affairs Medical Center, Durham, North Carolina. Both centers are funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative (VA-ESP Project #09-009 and VA-ESP Project #09-010, respectively). The initial evidence report is available at http://www.hsrd.research.va.gov/publications/esp/ptsd-screening.cfm. NR 85 TC 10 Z9 10 U1 4 U2 17 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 4 PY 2015 VL 314 IS 5 BP 501 EP 510 DI 10.1001/jama.2015.7877 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CO1OI UT WOS:000358924500014 PM 26241601 ER PT J AU Alawieh, A Sabra, M Sabra, Z Tomlinson, S Zaraket, FA AF Alawieh, Ali Sabra, Mohammed Sabra, Zahraa Tomlinson, Stephen Zaraket, Fadi A. TI Molecular Architecture of Spinal Cord Injury Protein Interaction Network SO PLOS ONE LA English DT Article ID FUNCTIONAL RECOVERY; PROTEOMIC ANALYSIS; DATABASE; ORGANIZATION; INFLAMMATION; PERMEABILITY; MECHANISMS; NEUROTROPHIN-3; DEGENERATION; APOPTOSIS AB Spinal cord injury (SCI) is associated with complex pathophysiological processes that follow the primary traumatic event and determine the extent of secondary damage and functional recovery. Numerous reports have used global and hypothesis-driven approaches to identify protein changes that contribute to the overall pathology of SCI in an effort to identify potential therapeutic interventions. In this study, we use a semi-automatic annotation approach to detect terms referring to genes or proteins dysregulated in the SCI literature and develop a curated SCI interactome. Network analysis of the SCI interactome revealed the presence of a rich-club organization corresponding to a "powerhouse" of highly interacting hub-proteins. Studying the modular organization of the network have shown that rich-club proteins cluster into modules that are specifically enriched for biological processes that fall under the categories of cell death, inflammation, injury recognition and systems development. Pathway analysis of the interactome and the rich-club revealed high similarity indicating the role of the rich-club proteins as hubs of the most prominent pathways in disease pathophysiology and illustrating the centrality of pro-and anti-survival signal competition in the pathology of SCI. In addition, evaluation of centrality measures of single nodes within the rich-club have revealed that neuronal growth factor (NGF), caspase 3, and H-Ras are the most central nodes and potentially an interesting targets for therapy. Our integrative approach uncovers the molecular architecture of SCI interactome, and provide an essential resource for evaluating significant therapeutic candidates. C1 [Alawieh, Ali; Sabra, Zahraa; Tomlinson, Stephen] Med Univ S Carolina, Dept Neurosci, Inst Neurosci, Charleston, SC 29425 USA. [Alawieh, Ali; Sabra, Mohammed; Sabra, Zahraa; Zaraket, Fadi A.] Amer Univ Beirut, Dept Elect & Comp Engn, Beirut, Lebanon. [Tomlinson, Stephen] Med Univ S Carolina, Childrens Res Inst, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Neurosci, Inst Neurosci, Charleston, SC 29425 USA. EM tomlinss@musc.edu; fz11@aub.edu.lb OI Alawieh, Ali/0000-0003-2601-8850 FU Veterans Affairs merit awards [BX001218, RX001141]; Farouk Jabre Award [2013/14] FX This work was supported by Veterans Affairs merit awards [BX001218 and RX001141] to S.T. and the Farouk Jabre Award [2013/14] to F.Z. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 0 Z9 0 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 4 PY 2015 VL 10 IS 8 AR e0135024 DI 10.1371/journal.pone.0135024 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO1VB UT WOS:000358942700090 PM 26241741 ER PT J AU Duvvuri, U AF Duvvuri, Umamaheswar TI ANO1 plays a critical role in prostatic hyperplasia SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Editorial Material ID CANCER PROGRESSION; CHANNEL ANO1; TMEM16A; PROTEIN; EXPRESSION; 11Q13; GENE; HEAD; EGFR C1 [Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA 15240 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu NR 17 TC 0 Z9 0 U1 0 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD AUG 4 PY 2015 VL 112 IS 31 BP 9506 EP 9507 DI 10.1073/pnas.1512075112 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO1QQ UT WOS:000358930600035 PM 26216998 ER PT J AU Wilczynski, C Shah, L Emanuele, MA Emanuele, N Mazhari, A AF Wilczynski, Cory Shah, Lisa Emanuele, Mary Ann Emanuele, Nicholas Mazhari, Alaleh TI SELECTIVE HYPOALDOSTERONISM: A REVIEW SO ENDOCRINE PRACTICE LA English DT Review ID RENAL TUBULAR-ACIDOSIS; CRITICALLY-ILL PATIENT; HYPERRENINEMIC HYPOALDOSTERONISM; HYPORENINEMIC HYPOALDOSTERONISM; ALDOSTERONE DEFICIENCY; ANGIOTENSIN-II; UNILATERAL ADRENALECTOMY; PROLONGED HYPERKALEMIA; POTASSIUM HOMEOSTASIS; METABOLIC-ACIDOSIS AB Objective: Selective hypoaldosteronism (SH) is a condition manifested by hyperkalemia due to low aldosterone secretion with normal cortisol. One of the obstacles in diagnosis is the awareness of the condition itself. The objective of this review is to highlight what is known about the epidemiology, pathophysiology, etiology, presentation, diagnosis, and treatment of SH. Methods: Literature search was performed on PubMed and Ovid Medline for articles which contained hypoaldosteronism as a major topic. Results: The recent literature on this topic is surprisingly limited. Few recent review articles were found, none of which were in English and less than 5 years old. Case reports and genetic literature were also included in this review, as they contain the most recent reports of SH in the literature. Conclusion: Awareness about SH will hopefully help physicians to identify patients at risk as well as decide on treatment if any therapy is required. C1 [Wilczynski, Cory; Shah, Lisa; Emanuele, Mary Ann; Emanuele, Nicholas; Mazhari, Alaleh] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Wilczynski, Cory; Shah, Lisa; Emanuele, Mary Ann; Emanuele, Nicholas] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Wilczynski, C (reprint author), 2160 South First Ave, Maywood, IL 60153 USA. EM cwilczynski@gmail.com NR 77 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD AUG PY 2015 VL 21 IS 8 BP 957 EP 965 DI 10.4158/EP14551.RA PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO7LT UT WOS:000377964800012 PM 26121445 ER PT J AU Luciano, JA Kautza, B Darwiche, S Martinez, S Stratimirovic, S Waltz, P Sperry, J Rosengart, M Shiva, S Zuckerbraun, BS AF Luciano, Jason A. Kautza, Benjamin Darwiche, Sophie Martinez, Silvia Stratimirovic, Sladjana Waltz, Paul Sperry, Jason Rosengart, Matthew Shiva, Sruti Zuckerbraun, Brian S. TI SIRTUIN 1 AGONIST MINIMIZES INJURY AND IMPROVES THE IMMUNE RESPONSE FOLLOWING TRAUMATIC SHOCK SO SHOCK LA English DT Article DE Innate immune response; mitochondrial biogenesis; PGC1 alpha; trauma-hemorrhage ID NF-KAPPA-B; MITOCHONDRIAL BIOGENESIS; HEMORRHAGIC-SHOCK; ISCHEMIA-REPERFUSION; NITRIC-OXIDE; CELL-DEATH; ACTIVATION; DYSFUNCTION; RESUSCITATION; EXPRESSION AB Survival from traumatic injury requires a coordinated and controlled inflammatory and immune response. Mitochondrial and metabolic responses to stress have been shown to play a role in these inflammatory and immune responses. We hypothesized that increases in mitochondrial biogenesis via a sirtuin 1 agonist would decrease tissue injury and partially ameliorate the immunosuppression seen following trauma. C57Bl/6 mice were subjected to a multiple trauma model. Mice were pretreated with either 100 mg/kg per day of the sirtuin 1 agonist, Srt1720, via oral gavage for 2 days prior to trauma and extended until the day the animals were killed, or they were pretreated with peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1 alpha) siRNA via hydrodynamic tail vein injection 48 h prior to trauma. Markers for mitochondrial function and biogenesis were measured in addition to splenocyte proliferative capacity and bacterial clearance. Srt1720 was noted to improve mitochondrial biogenesis, mitochondrial function, and complex IV activity following traumatic injury (P < 0.05), whereas knockdown of PGC1 alpha resulted in exacerbation of mitochondrial dysfunction (P < 0.05). These changes in mitochondrial function were associated with altered severity of hepatic injury with significant reductions in serum alanine aminotransferase levels seen in mice treated with srt1720. Splenocyte proliferative capacity and intraperitoneal bacterial clearance were evaluated as markers for overall immune function following trauma-hemorrhage. Treatment with Srt1720 minimized the trauma-induced decreases in splenocyte proliferation (P < 0.05), whereas treatment with PGC1 alpha siRNA led to diminished bacterial clearance. The PGC1 alpha signaling pathway is an important regulator of mitochondrial function and biogenesis, which can potentially be harnessed to protect against hepatic injury and minimize the immunosuppression that is seen following trauma-hemorrhage. C1 [Luciano, Jason A.; Kautza, Benjamin; Darwiche, Sophie; Martinez, Silvia; Stratimirovic, Sladjana; Waltz, Paul; Sperry, Jason; Rosengart, Matthew; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Stratimirovic, Sladjana; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sperry, Jason; Rosengart, Matthew] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. [Shiva, Sruti] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA. [Shiva, Sruti; Zuckerbraun, Brian S.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA USA. [Zuckerbraun, Brian S.] Univ Pittsburgh, Ctr Crit Care Nephrol, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), F1267 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu FU National Institutes of Health [R01GM082830]; Veterans Affairs Merit Award [1I01BX000566]; Department of Defense [DM102439] FX This work is supported by National Institutes of Health (grant R01GM082830 to B.S.Z.), Veterans Affairs Merit Award (grant 1I01BX000566 to B.S.Z.), and the Department of Defense (grant DM102439 to B.S.Z.) NR 34 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1073-2322 EI 1540-0514 J9 SHOCK JI Shock PD AUG PY 2015 VL 44 SU 1 BP 149 EP 155 DI 10.1097/SHK.0000000000000412 PG 7 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA DO3NA UT WOS:000377687100021 PM 26009827 ER PT J AU Mitsui, Y Hirata, H Arichi, N Hiraki, M Yasumono, H Chang, I Fukuhara, S Yamamura, S Shahryari, V Deng, GR Saini, S Majid, S Tanaka, Y Dahiya, R Shiina, H AF Mitsui, Yozo Hirata, Hiroshi Arichi, Naoko Hiraki, Miho Yasumono, Hiroaki Chang, Inik Fukuhara, Shinichiro Yamamura, Soichiro Shahryari, Varahram Deng, Guoren Saini, Sharanjot Majid, Shahana Tanaka, Yuichiro Dahiya, Rajvir Shiina, Hiroaki TI Dysregulation of bone morphogenetic protein 2 serves as a candidate molecular marker in human renal cell carcinoma SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Mitsui, Yozo; Hirata, Hiroshi; Yamamura, Soichiro; Shahryari, Varahram; Deng, Guoren; Saini, Sharanjot; Majid, Shahana; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Mitsui, Yozo; Hirata, Hiroshi; Yamamura, Soichiro; Shahryari, Varahram; Deng, Guoren; Saini, Sharanjot; Majid, Shahana; Tanaka, Yuichiro; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Arichi, Naoko; Hiraki, Miho; Yasumono, Hiroaki; Shiina, Hiroaki] Shimane Univ, Fac Med, Dept Urol, Izumo, Shimane, Japan. [Chang, Inik] Yonsei Univ, Dept Oral Biol, Coll Densitry, Seoul 120749, South Korea. [Fukuhara, Shinichiro] Osaka Univ, Grad Sch Med, Dept Urol, Suita, Osaka, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 3823 DI 10.1158/1538-7445.AM2015-3823 PG 2 WC Oncology SC Oncology GA DF8HA UT WOS:000371597102351 ER PT J AU Patel, JM Noble, PW Chan, G Weisbart, RH Hansen, JE AF Patel, Jaymin M. Noble, Phil W. Chan, Grace Weisbart, Richard H. Hansen, James E. TI Engineering a trivalent lupus anti-DNA autoantibody fragment for cancer therapy SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Patel, Jaymin M.; Noble, Phil W.; Hansen, James E.] Yale Univ, Sch Med, New Haven, CT USA. [Chan, Grace; Weisbart, Richard H.] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 4276 DI 10.1158/1538-7445.AM2015-4276 PG 3 WC Oncology SC Oncology GA DF8HA UT WOS:000371597103360 ER PT J AU Suswam, EA Putcha, BDK Tiwari, AK Jadhav, T Walker, KD Harkins, L Amer, S Eltoum, IE Bae, S Manne, U AF Suswam, Esther A. Putcha, Balananda-Dhurjati K. Tiwari, Amit K. Jadhav, Trafina Walker, Kiera D. Harkins, Lualhati Amer, Samir Eltoum, Isam-Eldin Bae, Sejong Manne, Upender TI Molecular and cellular localization profiles of tristetraprolin in colorectal cancer: Implications for tumor progression in diverse patient populations SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Suswam, Esther A.; Putcha, Balananda-Dhurjati K.; Jadhav, Trafina; Walker, Kiera D.; Eltoum, Isam-Eldin; Bae, Sejong; Manne, Upender] Univ Alabama Birmingham, Birmingham, AL USA. [Tiwari, Amit K.] Tuskegee Univ, Tuskegee, AL 36088 USA. [Harkins, Lualhati] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Amer, Samir] Natl Canc Inst, Cairo, Egypt. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 4953 DI 10.1158/1538-7445.AM2015-4953 PG 2 WC Oncology SC Oncology GA DF8HA UT WOS:000371597105134 ER PT J AU Gary, JM Xu, JF Simmons, J Zhang, SL Gamache, B Zhang, K Kovalchuk, A Michalowski, A Chen, JQ Herrmann, M Dubois, W Testa, J Mock, BA AF Gary, Joy M. Xu, Jinfei Simmons, John Zhang, Shuling Gamache, Benjamin Zhang, Ke Kovalchuk, Alexander Michalowski, Aleksandra Chen, Jin-Qiu Herrmann, Michelle Dubois, Wendy Testa, Joseph Mock, Beverly A. TI Murine model of dual mTORC kinase inhibition identifies CDK6 as a synergistic target in T-ALL SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Gary, Joy M.; Simmons, John; Zhang, Shuling; Gamache, Benjamin; Zhang, Ke; Michalowski, Aleksandra; Chen, Jin-Qiu; Herrmann, Michelle; Dubois, Wendy; Mock, Beverly A.] NCI, Bethesda, MD 20892 USA. [Xu, Jinfei] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Kovalchuk, Alexander] NIAID, Rockville, MD USA. [Testa, Joseph] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 2309 DI 10.1158/1538-7445.AM2015-2309 PG 1 WC Oncology SC Oncology GA DF8AH UT WOS:000371578504411 ER PT J AU Goicochea, NL Garnovskaya, M Blanton, M Chan, G Weisbart, R Lilly, M AF Goicochea, Nancy L. Garnovskaya, Maria Blanton, Mary Chan, Grace Weisbart, Richard Lilly, Michael TI Cell-penetrating bispecific antibodies for targeting androgen receptor signaling in advanced prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Goicochea, Nancy L.; Garnovskaya, Maria; Blanton, Mary; Lilly, Michael] Med Univ S Carolina, Charleston, SC 29425 USA. [Chan, Grace; Weisbart, Richard] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 642 DI 10.1158/1538-7445.AM2015-642 PG 3 WC Oncology SC Oncology GA DF8AH UT WOS:000371578501098 ER PT J AU Rodriguez, CI Setaluri, V AF Rodriguez, Carlos I. Setaluri, Vijayasaradhi TI Cyclic AMP signaling in melanoma: Paradoxical downregulation of pCREB upon activation of adenylate cyclase confers resistance to MAPK inhibition SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Rodriguez, Carlos I.] Univ Wisconsin Madison, Dept Dermatol, Grad Program Mol & Environm Toxicol, Madison, WI USA. [Setaluri, Vijayasaradhi] Univ Wisconsin Madison, Dept Dermatol, William S Middleton Mem Vet Hosp, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 2680 DI 10.1158/1538-7445.AM2015-2680 PG 1 WC Oncology SC Oncology GA DF8AH UT WOS:000371578505268 ER PT J AU Yamamura, S Mitsui, Y Bucay, N Saini, S Majid, S Deng, GR Shahryary, V Dahiya, R Tanaka, Y AF Yamamura, Soichiro Mitsui, Yozo Bucay, Nathan Saini, Sharanjot Majid, Shahana Deng, Guoren Shahryary, Varahram Dahiya, Rajvir Tanaka, Yuichiro TI RNA-Seq profiling of silibinin effects on bladder cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract CT 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 18-22, 2015 CL Philadelphia, PA SP Amer Assoc Canc Res C1 [Yamamura, Soichiro; Mitsui, Yozo; Bucay, Nathan; Saini, Sharanjot; Majid, Shahana; Deng, Guoren; Shahryary, Varahram; Dahiya, Rajvir; Tanaka, Yuichiro] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2015 VL 75 SU 15 MA 902 DI 10.1158/1538-7445.AM2015-902 PG 2 WC Oncology SC Oncology GA DF8AH UT WOS:000371578501353 ER PT J AU Volpp, KG Troxel, AB Long, JA Ibrahim, SA Appleby, D Smith, JO Jaskowiak, J Helweg-Larsen, M Doshi, JA Kimmel, SE AF Volpp, Kevin G. Troxel, Andrea B. Long, Judith A. Ibrahim, Said A. Appleby, Dina Smith, J. Otis Jaskowiak, Jane Helweg-Larsen, Marie Doshi, Jalpa A. Kimmel, Stephen E. TI A Randomized Controlled Trial of Co-Payment Elimination: The CHORD Trial SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID INSURANCE DESIGN PROGRAM; CORONARY-HEART-DISEASE; MEDICATION ADHERENCE; BLOOD-PRESSURE; LONG-TERM; STATIN THERAPY; MYOCARDIAL-INFARCTION; COPAYMENT INCREASE; PRESCRIPTION DRUGS; ELDERLY PATIENTS AB Objectives: Efforts to improve adherence by reducing co-payments through value-based insurance design are become more prevalent despite limited evidence of improved health outcomes. The objective of this study was to determine whether eliminating patient co-payments for blood pressure medications improves blood pressure control. Study Design: Randomized controlled trial. Methods: The Collaboration to Reduce Disparities in Hypertension (CHORD) was a randomized controlled trial with 12 months' follow-up conducted among patients from the Philadelphia and Pittsburgh Veterans Administration Medical Centers. We enrolled 479 patients with poorly controlled systolic blood pressure. Participants were randomly assigned to: a) receive reductions in co-payments from $8 to $0 per medication per month for each antihypertensive prescription filled, b) a computerized behavioral intervention (CBI), c) both co-pay reduction and CBI, or d) usual care. Our main outcome measure was change in systolic blood pressure from enrollment to 12 months post enrollment. We also measured adherence using the medication possession ratio in a subset of participants. Results: There were no significant interactions between the co-payment interventions and the CBI interventions. There was no relative difference in the change in medication possession ratio between baseline and 12 months (0.05% and 0.90% in control and incentive groups, respectively; P = .74) or in continuous medication gaps of 30, 60, or 90 days. Blood pressure decreased among all participants, but to a similar degree between the financial incentive and control groups. Systolic pressure within the incentive group dropped 13.2 mm Hg versus 15.2 mm Hg for the control group (difference = 2.0; 95% CI, -2.3 to 6.3; P = .36). The proportion of patients with blood pressure under control at 12 months was 29.5% in the incentive group versus 33.9 in the control group (odds ratio, 0.8; 95% CI, 0.5-1.3; P = .36). Conclusions: Among patients with poorly controlled blood pressure, financial incentives as implemented in this trial that reduced patient cost sharing for blood pressure medications did not improve medication adherence or blood pressure control. C1 [Volpp, Kevin G.; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.; Troxel, Andrea B.; Long, Judith A.; Kimmel, Stephen E.] Penn CMU Roybal P30 Ctr Behav Econ & Hlth, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA USA. [Volpp, Kevin G.; Long, Judith A.; Doshi, Jalpa A.; Kimmel, Stephen E.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.] Univ Penn, Ctr Therapeut Effectiveness Res, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Appleby, Dina; Jaskowiak, Jane; Kimmel, Stephen E.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Ibrahim, Said A.] Pittsburgh Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ibrahim, Said A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Smith, J. Otis] Cheyney Univ, Dept Psychol, Cheyney, PA USA. [Helweg-Larsen, Marie] Dickinson Coll, Dept Psychol, Carlisle, PA 17013 USA. RP Volpp, KG (reprint author), Univ Penn, Leonard Davis Inst Ctr Hlth Incent & Behav Econ, Perelman Sch Med, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.; Volpp, KG (reprint author), Univ Penn, Wharton Sch, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu NR 58 TC 2 Z9 2 U1 2 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD AUG PY 2015 VL 21 IS 8 BP E455 EP U16 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DD4AF UT WOS:000369864000002 PM 26618226 ER PT J AU Volpp, KG Troxel, AB Long, JA Ibrahim, SA Appleby, D Smith, JO Doshi, JA Jaskowiak, J Helweg-Larsen, M Kimmel, SE AF Volpp, Kevin G. Troxel, Andrea B. Long, Judith A. Ibrahim, Said A. Appleby, Dina Smith, J. Otis Doshi, Jalpa A. Jaskowiak, Jane Helweg-Larsen, Marie Kimmel, Stephen E. TI A Randomized Controlled Trial of Negative Co-Payments: The CHORD Trial SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CORONARY-HEART-DISEASE; MEDICATION ADHERENCE; INSURANCE DESIGN; BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; COPAYMENT INCREASE; PRESCRIPTION DRUGS; LONG-TERM; BENEFITS; HYPERTENSION AB Objectives: Value-based insurance designs are being widely used. We undertook this study to examine whether a financial incentive that lowered co-payments for blood pressure medications below $0 improved blood pressure control among patients with poorly controlled hypertension. Study Design: Randomized controlled trial. Methods: Participants from 3 Pennsylvania hospitals (n = 337) were randomly assigned to: a) be paid $8 per medication per month for filling blood pressure prescriptions, b) a computerized behavioral intervention (CBI), c) both payment and CBI, or d) usual care. The primary outcome was change in blood pressure between baseline and 12 months post enrollment. We also measured adherence using the medication possession ratio in a subset of participants. Results: There were no significant interactions between the incentive and the CBI interventions. There were no significant changes in medication possession ratio in the treatment group. Blood pressure decreased among all participants, but to a similar degree between the financial incentive and control groups. Systolic blood pressure (SBP) dropped 13.7 mm Hg for the incentive group versus 10.0 mm Hg for the control group (difference = -3.7; 95% CI, -9.0 to 1.6; P = .17). The proportion of patients with blood pressure under control 12 months post enrollment was 35.6% of the incentive group versus 27.7% of the control group (odds ratio, 1.4; 95% CI, 0.8-2.5; P = .19). Diabetics in the incentive group had an average drop in SBP of 12.7 mm Hg between baseline and 12 months compared with 4.0 mm Hg in the control group (P = .02). Patients in the incentive group without diabetes experienced average SBP reductions of 15.0 mm Hg, compared with 16.3 mm Hg for control group nondiabetics (P = .71). Conclusions: Among patients with poorly controlled blood pressure, financial incentives as implemented in this trial did not improve blood pressure control or adherence except among patients with diabetes. C1 [Volpp, Kevin G.; Long, Judith A.; Ibrahim, Said A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.; Troxel, Andrea B.; Doshi, Jalpa A.; Kimmel, Stephen E.] Penn CMU Roybal P30 Ctr Behav Econ & Hlth, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA USA. [Volpp, Kevin G.; Long, Judith A.; Ibrahim, Said A.; Doshi, Jalpa A.; Kimmel, Stephen E.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.] Univ Penn, Ctr Therapeut Effectiveness Res, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Appleby, Dina; Jaskowiak, Jane; Kimmel, Stephen E.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Appleby, Dina; Jaskowiak, Jane; Kimmel, Stephen E.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Ibrahim, Said A.] Pittsburgh Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ibrahim, Said A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Smith, J. Otis] Cheyney Univ, Dept Psychol, Cheyney, PA USA. [Helweg-Larsen, Marie] Dickinson Coll, Dept Psychol, Carlisle, PA 17013 USA. RP Volpp, KG (reprint author), Univ Penn, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.; Volpp, KG (reprint author), Univ Penn, Wharton Sch, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu NR 40 TC 0 Z9 0 U1 1 U2 1 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD AUG PY 2015 VL 21 IS 8 BP E465 EP U26 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DD4AF UT WOS:000369864000003 PM 26625506 ER PT J AU Lo-Ciganic, WH Donohue, JM Thorpe, JM Perera, S Thorpe, CT Marcum, ZA Gellad, WF AF Lo-Ciganic, Wei-Hsuan Donohue, Julie M. Thorpe, Joshua M. Perera, Subashan Thorpe, Carolyn T. Marcum, Zachary A. Gellad, Walid F. TI Using Machine Learning to Examine Medication Adherence Thresholds and Risk of Hospitalization SO MEDICAL CARE LA English DT Article DE medication adherence; diabetes; machine learning; survival tree; classification and regression tree ID RANDOM SURVIVAL FORESTS; HEALTH-CARE; DIABETES-MELLITUS; HEART-FAILURE; CLAIMS DATA; COSTS; NONADHERENCE; ASSOCIATION; MORTALITY; POPULATION AB Background: Quality improvement efforts are frequently tied to patients achieving >= 80% medication adherence. However, there is little empirical evidence that this threshold optimally predicts important health outcomes. Objective: To apply machine learning to examine how adherence to oral hypoglycemic medications is associated with avoidance of hospitalizations, and to identify adherence thresholds for optimal discrimination of hospitalization risk. Methods: A retrospective cohort study of 33,130 non-dual-eligible Medicaid enrollees with type 2 diabetes. We randomly selected 90% of the cohort (training sample) to develop the prediction algorithm and used the remaining (testing sample) for validation. We applied random survival forests to identify predictors for hospitalization and fit survival trees to empirically derive adherence thresholds that best discriminate hospitalization risk, using the proportion of days covered (PDC). Outcomes: Time to first all-cause and diabetes-related hospitalization. Results: The training and testing samples had similar characteristics (mean age, 48 y; 67% female; mean PDC = 0.65). We identified 8 important predictors of all-cause hospitalizations (rank in order): prior hospitalizations/emergency department visit, number of prescriptions, diabetes complications, insulin use, PDC, number of prescribers, Elixhauser index, and eligibility category. The adherence thresholds most discriminating for risk of all-cause hospitalization varied from 46% to 94% according to patient health and medication complexity. PDC was not predictive of hospitalizations in the healthiest or most complex patient subgroups. Conclusions: Adherence thresholds most discriminating of hospitalization risk were not uniformly 80%. Machine-learning approaches may be valuable to identify appropriate patient-specific adherence thresholds for measuring quality of care and targeting nonadherent patients for intervention. C1 [Lo-Ciganic, Wei-Hsuan; Donohue, Julie M.; Thorpe, Joshua M.; Thorpe, Carolyn T.; Marcum, Zachary A.; Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA. [Donohue, Julie M.] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Perera, Subashan] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Perera, Subashan; Marcum, Zachary A.; Gellad, Walid F.] Univ Pittsburgh, Dept Med, Sch Pharm, Pittsburgh, PA 15261 USA. [Marcum, Zachary A.] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA. RP Lo-Ciganic, WH (reprint author), Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, POB 210202,Drachman Hall Room 306K,1295N Martin A, Tucson, AZ 85719 USA. EM lociganic@pharmacy.arizona.edu OI Donohue, Julie/0000-0003-2418-6017 FU University of Pittsburgh Health Policy Institute, Center for Pharmaceutical Policy and Prescribing; VA HSR&D Career Development Award; Pittsburgh Claude D. Pepper Older Americans Independence Center (NIA) [P30 AGAG024827] FX W.-H.L.-C. was funded by a post-doctoral fellowship through the University of Pittsburgh Health Policy Institute, Center for Pharmaceutical Policy and Prescribing. W.F.G. is supported by a VA HSR&D Career Development Award. W.F.G. has previously served as a consultant to IMS health on the topic of medication adherence and serves as an unpaid member of the Board of Advisors for HealthPrize. S.P. is supported by the Pittsburgh Claude D. Pepper Older Americans Independence Center (NIA P30 AGAG024827). NR 49 TC 3 Z9 3 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD AUG PY 2015 VL 53 IS 8 BP 720 EP 728 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DD0UR UT WOS:000369636000011 PM 26147866 ER PT J AU Evans, LD Stock, EM Zeber, JE Morissette, SB MacCarthy, AA Sako, EY Lappin, J Lawrence, VA MacCarthy, DJ Copeland, LA AF Evans, Lianna D. Stock, Eileen M. Zeber, John E. Morissette, Sandra B. MacCarthy, Andrea A. Sako, Edward Y. Lappin, Jacqueline Lawrence, Valerie A. MacCarthy, Daniel J. Copeland, Laurel A. TI Posttransplantation Outcomes in Veterans With Serious Mental Illness SO TRANSPLANTATION LA English DT Article ID HEART-TRANSPLANTATION; ORGAN-TRANSPLANTATION; LIVER-TRANSPLANTATION; LUNG-TRANSPLANTATION; ADMINISTRATIVE DATA; CO-MORBIDITY; CANDIDATES; SCHIZOPHRENIA; DEPRESSION; DISORDERS AB Background. Anticipating poor recovery due to impaired self-management and appointment-keeping, clinicians may consider serious mental illness (SMI) a significant concern in organ transplantation. However, little empirical evidence exists regarding posttransplantation outcomes for patients with SMI. Methods. This study analyzed health services data to evaluate posttransplantation 3-year survival by SMI status in a nationwide cohort of patients in the Veterans Health Administration (VHA). Results. A total of 960 recipients of solid organ or bone marrow transplants were identified from Veterans Health Administration administrative data extracts for fiscal years 2006 to 2009. Of these, 164 (17%) had an SMI diagnosis before transplantation (schizophrenia, posttraumatic stress, major depressive, and bipolar disorders); 301 (31%) had some other mental illness diagnosis (such as anxiety, adjustment reactions, or substance abuse); and 495 (52%) had no mental health diagnosis. Twenty-two patients (2%) required retransplantation and 208 patients (22%) died during follow-up. Data on whether these were primary or repeat transplantations were unavailable. Rates of attendance at postoperative outpatient visits and number of months for which immunosuppressive drugs fills were recorded were similar among mental illness groups, as were rates of diagnosed immunological rejection. Three-year mortality was equivalent among mental health groups: no mental health (19%) versus other mental illness (23%) versus SMI (27%;X-2 = 5.11; df= 2; P =.08). In adjusted survival models, no effect of mental health status was observed. Conclusions. Serious mental illness diagnosis does not appear to be associated with adverse transplantation outcomes over the first 3 years; however, a potentially diverging survival curve may portend higher mortality at 5 years. C1 [Evans, Lianna D.; Stock, Eileen M.; Zeber, John E.; Morissette, Sandra B.; Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Dept Vet Affairs, Temple, TX USA. [Evans, Lianna D.; Stock, Eileen M.; Zeber, John E.; Morissette, Sandra B.; Lappin, Jacqueline; Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. [Stock, Eileen M.; Zeber, John E.; Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA. [Morissette, Sandra B.] VISN 17 Ctr Excellence Res Returning War Vet, Dept Vet Affairs, Waco, TX USA. [MacCarthy, Andrea A.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. [Sako, Edward Y.; Lawrence, Valerie A.; MacCarthy, Daniel J.] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Lappin, Jacqueline] Baylor Scott & White Hlth, Temple, TX USA. RP Evans, LD (reprint author), Cent Texas Vet Hlth Care Syst, 4800 Mem Dr Waco, Waco, TX 76711 USA. EM Lianna.Evans@va.gov OI Copeland, Laurel/0000-0002-9478-0209 NR 36 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD AUG PY 2015 VL 99 IS 8 BP E57 EP E65 DI 10.1097/TP.0000000000000616 PG 9 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DC2YD UT WOS:000369083800002 PM 25706275 ER PT J AU Goins, RT Schure, MB Noonan, C Buchwald, D AF Goins, R. Turner Schure, Marc B. Noonan, Carolyn Buchwald, Dedra TI Prostate Cancer Screening Among American Indians and Alaska Natives: The Health and Retirement Survey, 1996-2008 SO PREVENTING CHRONIC DISEASE LA English DT Article ID US; DISPARITIES; RECOMMENDATION; SURVEILLANCE; BEHAVIORS; URBAN; MEN AB Introduction Among US men, prostate cancer is the leading malignancy diagnosed and the second leading cause of cancer death. Disparities in cancer screening rates exist between American Indians/Alaska Natives and other racial/ethnic groups. Our study objectives were to examine prostate screening at 5 time points over a 12-year period among American Indian/Alaska Native men aged 50 to 75 years, and to compare their screening rates to African American men and white men in the same age group. Methods We analyzed Health and Retirement Study data for 1996, 1998, 2000, 2004, and 2008. Prostate screening was measured by self-report of receipt of a prostate examination within the previous 2 years. Age-adjusted prevalence was estimated for each year. We used regression with generalized estimating equations to compare prostate screening prevalence by year and race. Results Our analytic sample included 119 American Indian/Alaska Native men (n = 333 observations), 1,359 African American men (n = 3,704 observations), and 8,226 white men (n = 24,292 observations). From 1996 to 2008, prostate screening rates changed for each group: from 57.0% to 55.7% among American Indians/Alaska Natives, from 62.0% to 71.2% among African Americans, and from 68.6% to 71.3% among whites. Although the disparity between whites and African Americans shrank over time, it was virtually unchanged between whites and American Indians/Alaska Natives. Conclusion As of 2008, American Indians/Alaska Natives were less likely than African Americans and whites to report a prostate examination within the previous 2 years. Prevalence trends indicated a modest increase in prostate cancer screening among African Americans and whites, while rates remained substantially lower for American Indians/Alaska Natives. C1 [Goins, R. Turner] Western Carolina Univ, Dept Social Work, Coll Hlth & Human Sci, 4121 Little Savannah Rd, Cullowhee, NC 28723 USA. [Schure, Marc B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Noonan, Carolyn; Buchwald, Dedra] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. RP Goins, RT (reprint author), Western Carolina Univ, Dept Social Work, Coll Hlth & Human Sci, 4121 Little Savannah Rd, Cullowhee, NC 28723 USA. EM rtgoins@wcu.edu FU National Cancer Institute [P50 CA148110] FX This work was supported by grant no. P50 CA148110 from the National Cancer Institute. NR 32 TC 2 Z9 2 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2015 VL 12 AR E123 DI 10.5888/pcd12.150088 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZQ UT WOS:000368664600001 PM 26247423 ER PT J AU Baker, JF Tan, YK Conaghan, PG AF Baker, Joshua F. Tan, York Kiat Conaghan, Philip G. TI Monitoring in established RA: Role of imaging and soluble biomarkers SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY LA English DT Article DE Rheumatoid arthritis; Magnetic resonance imaging; Ultrasound; Soluble biomarkers ID EARLY RHEUMATOID-ARTHRITIS; LOW DISEASE-ACTIVITY; MRI SCORING SYSTEM; DOPPLER ULTRASONOGRAPHIC ASSESSMENT; RADIOGRAPHIC JOINT DAMAGE; ULTRASOUND TASK-FORCE; TREAT-TO-TARGET; CLINICAL REMISSION; BONE EROSIONS; MUSCULOSKELETAL ULTRASOUND AB Rheumatoid arthritis (RA) disease activity often remains difficult to define and to quantify. As a result, numerous techniques to estimate clinical activity have been developed and are in clinical use. Therefore, more objective biomarkers for early detection and accurate measurement and quantification of the disease burden are desired for clinical use and investigative studies. Several imaging and soluble biomarkers have been studied in the disease including conventional radiography, ultrasound, magnetic resonance imaging (MRI), and serum biomarker assays. While these tools are available to physicians in many settings, their role in routine clinical care remains unclear. The goals of this review are to outline the current state of the literature regarding each of these objective tools, assess their strengths and weaknesses, and clarify the knowledge gaps to be filled before these techniques may be more widely used. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Baker, Joshua F.] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Div Rheumatol,Perelman Sch Med, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Tan, York Kiat] Singapore Gen Hosp, Dept Rheumatol & Immunol, Singapore, Singapore. [Tan, York Kiat] Duke NUS Grad Med Sch, Singapore, Singapore. [Tan, York Kiat] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore. [Conaghan, Philip G.] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds LS7 4SA, W Yorkshire, England. [Conaghan, Philip G.] Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. RP Conaghan, PG (reprint author), Univ Leeds, Chapel Allerton Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds LS7 4SA, W Yorkshire, England. EM bakerjo@uphs.upenn.edu; tan.york.kiat@singhealth.com.sg; p.conaghan@leeds.ac.uk FU Veterans Affairs Clinical Science Research and Development Career Development Award [IK2 CX000955]; Arthritis Research, UK FX Dr. Baker is supported by a Veterans Affairs Clinical Science Research and Development Career Development Award (IK2 CX000955). The contents of this work do not represent the views of the Department of the Veterans Affairs or the United States Government. Professor Conaghan is supported in part by a grant from Arthritis Research, UK. NR 97 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-6942 EI 1521-1770 J9 BEST PRACT RES CL RH JI Best Pract. Res. Clin. Rheumatol. PD AUG-DEC PY 2015 VL 29 IS 4-5 BP 566 EP 579 DI 10.1016/j.berh.2015.09.002 PG 14 WC Rheumatology SC Rheumatology GA DA4IE UT WOS:000367762800005 PM 26697767 ER PT J AU Rojas, JM Matsen, ME Mundinger, TO Morton, GJ Stefanovski, D Bergman, RN Kaiyala, KJ Taborsky, GJ Schwartz, MW AF Rojas, Jennifer M. Matsen, Miles E. Mundinger, Thomas O. Morton, Gregory J. Stefanovski, Darko Bergman, Richard N. Kaiyala, Karl J. Taborsky, Gerald J., Jr. Schwartz, Michael W. TI Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response SO MOLECULAR METABOLISM LA English DT Article DE Central FGF receptors; FGF receptor inhibitor PD173074; Frequently sampled intravenous glucose tolerance test; Sympathoadrenal response; Minimal model; Glucose metabolism ID GROWTH-FACTOR; FOOD-INTAKE; INSULIN SENSITIVITY; INDIVIDUAL TISSUES; ENERGY-EXPENDITURE; RATS; TOLERANCE; METABOLISM; CATECHOLAMINES; EPINEPHRINE AB Objective: Central administration of ligands for fibroblast growth factor receptors (FGFRs) such as fibroblast growth factor-19 (FGF19) and FGF21 exert glucose-lowering effects in rodent models of obesity and type 2 diabetes (T2D). Conversely, intracerebroventricular (icv) administration of the non-selective FGFR inhibitor (FGFRi) PD173074 causes glucose intolerance, implying a physiological role for neuronal FGFR signaling in glucose homeostasis. The current studies were undertaken to identify neuroendocrine mechanisms underlying the glucose intolerance induced by pharmacological blockade of central FGFRs. Methods: Overnight fasted, lean, male, Long-Evans rats received icv injections of either PD173074 or vehicle (Veh) followed 30 min later by performance of a frequently sampled intravenous glucose tolerance test (FSIGT). Minimal model analysis of glucose and insulin data from the FSIGT was performed to estimate insulin-dependent and insulin-independent components of glucose disposal. Plasma levels of lactate, glucagon, corticosterone, non-esterified free fatty acids (NEFA) and catecholamines were measured before and after intravenous (iv) glucose injection. Results: Within 20 min of icv PD173074 injection (prior to the FSIGT), plasma levels of lactate, norepinephrine and epinephrine increased markedly, and each returned to baseline rapidly (within 8 min) following the iv glucose bolus. In contrast, plasma glucagon levels were not altered by icv FGFRi at either time point. Consistent with a previous report, glucose tolerance was impaired following icv PD173074 compared to Veh injection and, based on minimal model analysis of FSIGT data, this effect was attributable to reductions of both insulin secretion and the basal insulin effect (BIE), consistent with the inhibitory effect of catecholamines on pancreatic beta-cell secretion. By comparison, there were no changes in glucose effectiveness at zero insulin (GEZI) or the insulin sensitivity index (SI). To determine if iv glucose (given during the FSIGT) contributed to the rapid resolution of the sympathoadrenal response induced by icv FGFRi, we performed an additional study comparing groups that received iv saline or iv glucose 30 min after icv FGFRi. Our finding that elevated plasma catecholamine levels returned rapidly to baseline irrespective of whether rats subsequently received an iv bolus of saline or glucose indicates that the rapid reversal of sympathoadrenal activation following icv FGFRi was unrelated to the subsequent glucose bolus. Conclusions: The effect of acute inhibition of central FGFR signaling to impair glucose tolerance likely involves a stress response associated with pronounced, but transient, sympathoadrenal activation and an associated reduction of insulin secretion. Whether this effect is a true consequence of FGFR blockade or involves an off-target effect of the FGFR inhibitor requires additional study. (C) 2015 The Authors. Published by Elsevier GmbH. C1 [Rojas, Jennifer M.; Matsen, Miles E.; Mundinger, Thomas O.; Morton, Gregory J.; Taborsky, Gerald J., Jr.; Schwartz, Michael W.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Taborsky, Gerald J., Jr.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Stefanovski, Darko] Univ Penn, Sch Vet Med, New Bolton Ctr, Philadelphia, PA 19104 USA. [Bergman, Richard N.] Cedars Sinai Med Ctr, Diabet & Obes Res Inst, Los Angeles, CA 90048 USA. [Kaiyala, Karl J.] Univ Washington, Sch Dent, Dept Dent Publ Hlth Sci, Seattle, WA 98195 USA. RP Schwartz, MW (reprint author), Univ Washington, Dept Med, South Lake Union, 850 Republican St,N334,Box 358055, Seattle, WA 98195 USA. EM mschwart@u.washington.edu FU NIDDK NIH HHS [P30 DK035816, R01 DK101997, R01 DK090320, R01 DK027619, P30 DK017047, R01 DK029867, R37 DK027619, T32 DK007247, R01 DK083042, R01 DK089056] NR 35 TC 6 Z9 6 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2212-8778 J9 MOL METAB JI Mol. Metab. PD AUG PY 2015 VL 4 IS 8 BP 561 EP 568 DI 10.1016/j.molmet.2015.05.005 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CZ9VR UT WOS:000367445600002 PM 26266088 ER PT J AU Richman, JS Andreae, S Safford, MM AF Richman, Joshua S. Andreae, Susan Safford, Monika M. TI Challenges of Prolonged Follow-up and Temporal Imbalance in Pragmatic Trials: Analysis of the ENCOURAGE Trial SO ANNALS OF FAMILY MEDICINE LA English DT Article DE statistical data interpretation; nonlinear models; community-based trials AB PURPOSE Peer support intervention trials are typically conducted in community-based settings and provide generalizable results. The logistic challenges of community-based trials often result in unplanned temporal imbalances in recruitment and follow-up. When imbalances are present, as in the ENCOURAGE trial, appropriate statistical methods must be used to account for these imbalances. We present the design, conduct, and analysis of the ENCOURAGE trial as a case study of a cluster-randomized, community-based, peer-coaching intervention. METHODS Preliminary data analysis included examination of study data for imbalances in participant characteristics at baseline, the presence of both secular and seasonal trends in outcome measures, and imbalances in time from baseline to follow-up. Additional examination suggested the presence of nonlinear trends in the intervention effect. The final analyses adjusted for all identified imbalances with accounting for community clustering by supplementing linear mixed effect models with generalized additive mixed models (GAMM) to examine nonlinear trends. RESULTS Largely due to the location of participants across a considerable geographic area, temporal imbalances were discovered in recruitment, baseline, and follow-up data collection, along with evidence for both secular and seasonal trends in study outcome measures. Using the standard analytical approach, ENCOURAGE appeared to be a null trial. After incorporating adjustment for these temporal imbalances, linear regression analyses still showed no intervention effect. Upon further analyses using GAMM to consider nonlinear intervention trends, we observed intervention effects that were both significant (P < .05) and nonlinear. DISCUSSION In community-based trials, recruitment and follow-up may not occur as planned, and complex temporal imbalance may greatly influence the analysis. Real-world trials should use careful logistic planning and monitoring to avoid temporal imbalance. If imbalance is unavoidable, sophisticated statistical methods may nevertheless extract useful information, although the potential problem of residual confounding due to other unmeasured imbalances must be considered. C1 [Richman, Joshua S.] Birmingham VA Med Ctr, Birmingham, AL USA. [Richman, Joshua S.] Univ Alabama Birmingham, Sch Med, Dept Surg, Birmingham, AL 35294 USA. [Andreae, Susan; Safford, Monika M.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. RP Richman, JS (reprint author), 1720,2nd Ave South,KB428, Birmingham, AL 35294 USA. EM jrichman@uabmc.edu FU American Academy of Family Physicians Foundation; Eli Lilly and Company Foundation FX Funding for this research was provided by the American Academy of Family Physicians Foundation through the Peers for Progress program with support from the Eli Lilly and Company Foundation. NR 6 TC 2 Z9 2 U1 0 U2 1 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA SN 1544-1709 EI 1544-1717 J9 ANN FAM MED JI Ann. Fam. Med. PD AUG 1 PY 2015 VL 13 SU 1 BP S66 EP S72 DI 10.1370/afm.1790 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA CW2PI UT WOS:000364834300009 PM 26304974 ER PT J AU Safford, MM Andreae, S Cherrington, AL Martin, MY Halanych, J Lewis, M Patel, A Johnson, E Clark, D Gamboa, C Richman, JS AF Safford, Monika M. Andreae, Susan Cherrington, Andrea L. Martin, Michelle Y. Halanych, Jewell Lewis, Marquita Patel, Ashruta Johnson, Ethel Clark, Debra Gamboa, Christopher Richman, Joshua S. TI Peer Coaches to Improve Diabetes Outcomes in Rural Alabama: A Cluster Randomized Trial SO ANNALS OF FAMILY MEDICINE LA English DT Article DE Peer health coaching; self-management support; diabetes; primary care ID HEALTH WORKER INTERVENTION; PATIENT ACTIVATION MEASURE; SELF-MANAGEMENT; AFRICAN-AMERICAN; SUPPORT AB PURPOSE It is unclear whether peer coaching is effective in minority populations living with diabetes in hard-to-reach, under-resourced areas such as the rural South. We examined the effect of an innovative peer-coaching intervention plus brief education vs brief education alone on diabetes outcomes. METHODS This was a community-engaged, cluster-randomized, controlled trial with primary care practices and their surrounding communities serving as clusters. The trial enrolled 424 participants, with 360 completing baseline and follow-up data collection (84.9% retention). The primary outcomes were change in glycated hemoglobin (HbA(1c)), systolic blood pressure (BP), low density lipoprotein cholesterol (LDL-C), body mass index (BMI), and quality of life, with diabetes distress and patient activation as secondary outcomes. Peer coaches were trained for 2 days in community settings; the training emphasized motivational interviewing skills, diabetes basics, and goal setting. All participants received a 1-hour diabetes education class and a personalized diabetes report card at baseline. Intervention arm participants were also paired with peer coaches; the protocol called for telephone interactions weekly for the first 8 weeks, then monthly for a total of 10 months. RESULTS Due to real-world constraints, follow-up was protracted, and intervention effects varied over time. The analysis that included the 68% of participants followed up by 15 months showed only a significant increase in patient activation in the intervention group. The analysis that included all participants who eventually completed follow-up revealed that intervention arm participants had significant differences in changes in systolic BP (P = .047), BMI (P = .02), quality of life (P = .003), diabetes distress (P = .004), and patient activation (P = .03), but not in HbA(1c) (P = .14) or LDL-C (P = .97). CONCLUSION Telephone-delivered peer coaching holds promise to improve health for individuals with diabetes living in under-resourced areas. C1 [Safford, Monika M.; Andreae, Susan; Cherrington, Andrea L.; Martin, Michelle Y.; Halanych, Jewell; Lewis, Marquita; Patel, Ashruta; Johnson, Ethel; Clark, Debra; Gamboa, Christopher] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Johnson, Ethel] West Cent Alabama Community Hlth Improvement Leag, Camden, AL USA. [Clark, Debra] Sumter Cty Hlth & Wellness Educ Ctr, Livingston, AL USA. [Richman, Joshua S.] Birmingham VA Med Ctr, Birmingham, AL USA. [Richman, Joshua S.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Richman, Joshua S.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Safford, MM (reprint author), 1717 11th Ave South, Birmingham, AL 35294 USA. EM msafford@uab.edu FU American Academy of Family Physicians Foundation; Eli Lilly and Company Foundation FX Funding for this research was provided by the American Academy of Family Physicians Foundation through the Peers for Progress program with support from the Eli Lilly and Company Foundation. NR 26 TC 7 Z9 7 U1 3 U2 12 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA SN 1544-1709 EI 1544-1717 J9 ANN FAM MED JI Ann. Fam. Med. PD AUG 1 PY 2015 VL 13 SU 1 BP S18 EP S26 DI 10.1370/afm.1798 PG 9 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA CW2PI UT WOS:000364834300003 PM 26304967 ER PT J AU Waltz, P Escobar, D Botero, AM Zuckerbraun, BS AF Waltz, Paul Escobar, Daniel Botero, Ana Maria Zuckerbraun, Brian S. TI Nitrate/Nitrite as Critical Mediators to Limit Oxidative Injury and Inflammation SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review ID ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; ACUTE LUNG INJURY; RANDOMIZED CONTROLLED-TRIAL; PROTEIN-TYROSINE NITRATION; S-NITROSOTHIOL TRANSPORT; MITOCHONDRIAL COMPLEX-I; GASTRIC-MUCOSAL INJURY; REGIONAL BLOOD-FLOW; DIETARY NITRATE AB Significance: Nitric oxide (NO) is a critical signaling molecule marked by complex chemistry and varied biological responses depending on the context of the redox environment. In the setting of inflammation, NO can not only contribute to tissue injury and be causative of oxidative damage but can also signal as an adaptive molecule to limit inflammatory signaling in multiple cell types and tissues. Recent Advances: An advance in our understanding of NO biology was the recognition of the nitrate-nitrite-NO axis, whereby nitrate (predominantly from dietary sources) could be converted to nitrite and nitrite could be reduced to NO. Critical Issues: Intriguingly, the recognition of multiple enzymes that serve as nitrite reductases in the setting of hypoxia or ischemia established the concept of nitrite as a circulating endocrine reservoir of NO, with the selective release of NO at sites that were primed for this reaction. This review highlights the anti-inflammatory roles of nitrite in numerous clinical conditions, including ischemia/reperfusion, transplant, cardiac arrest, and vascular injury, and in gastrointestinal inflammation. Future Directions: These preclinical and clinical investigations set up further clinical trials and studies that elucidate the endogenous role this pathway plays in protection against inflammatory signaling. Antioxid. Redox Signal. 23, 328-339. C1 [Waltz, Paul; Escobar, Daniel; Botero, Ana Maria; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA. [Zuckerbraun, Brian S.] Univ Pittsburgh, Ctr Crit Care Nephrol, Pittsburgh, PA USA. [Zuckerbraun, Brian S.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA USA. [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Dept Surg, F1267 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu FU NIGMS NIH HHS [R01 GM082830] NR 111 TC 4 Z9 5 U1 4 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD AUG 1 PY 2015 VL 23 IS 4 BP 328 EP 339 DI 10.1089/ars.2015.6256 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA CU9VU UT WOS:000363895200004 PM 26140517 ER PT J AU Handrakis, JP Liu, SA Rosado-Rivera, D Krajewski, M Spungen, AM Bang, C Swonger, K Bauman, WA AF Handrakis, John P. Liu, Shou-An Rosado-Rivera, Dwindally Krajewski, Megan Spungen, Ann M. Bang, Charlene Swonger, Kirsten Bauman, William A. TI Effect of Mild Cold Exposure on Cognition in Persons with Tetraplegia SO JOURNAL OF NEUROTRAUMA LA English DT Article DE cognitive function; human studies; hypothermia; traumatic spinal cord injury ID SPINAL-CORD-INJURY; BODY-TEMPERATURE; PERFORMANCE; THERMOREGULATION; HYPOTHERMIA; EXERCISE; HUMANS; COMPLICATIONS; IMPAIRMENT; RESPONSES AB Persons with a cervical spinal cord injury (SCI) have impaired thermoregulatory mechanisms secondary to interrupted of motor, sensory, and sympathetic pathways. In this study, our primary aim was to determine the effect of cool temperature exposure on core body temperature (Tcore) and cognitive performance in persons with tetraplegia. Seven men with chronic tetraplegia (C3-C7, American Spinal Injury Association Impairment Scale [AIS] A-C) and seven able-bodied controls were exposed to 27 degrees C temperature at baseline (BL) before being exposed to 18 degrees C for 120min (Cool Challenge). Rectal temperature (Tcore), distal skin temperatures (Tsk(avg)), microvascular skin perfusion (LDFavg), and systolic blood pressure (SBP) were measured. Cognitive performance was assessed using Delayed Recall, Stroop Interference tests at the end of BL and Cool Challenge. After Cool Challenge, Tcore decreased -1.2 +/- 0.12 degrees C (p<0.0001) in tetraplegics after an average of 109 +/- 15.9min with no change in controls after 120min. Tsk(avg) declined in both groups, but decline was less in tetraplegics than in controls (-8.6 +/- 5.8% vs. -31.6 +/- 7.9%, respectively; p<0.0001). LDFavg declined only in controls (-72 +/- 17.9%; p<0.001). Plasma norepinephrine levels differed after Cool Challenge (tetraplegics vs. controls: 86 +/- 62pg/mL vs. 832 +/- 431pg/mL, respectively; p<0.01). SBP increased from BL to Cool Challenge only in controls (123 +/- 16mm Hg to 149 +/- 17mm Hg, respectively; p<0.01). Delayed Recall and Stroop Interference scores both declined in tetraplegics (-55 +/- 47.4%; p<0.05 and -3.9 +/- 3.8%; p<0.05, respectively), but not in controls. We conclude that persons with tetraplegia lack adequate thermoregulatory mechanisms to prevent downward drift in Tcore on exposure to cool temperatures. This decline in Tcore was associated with deterioration of working memory and executive function. C1 [Handrakis, John P.; Liu, Shou-An; Rosado-Rivera, Dwindally; Krajewski, Megan; Spungen, Ann M.; Swonger, Kirsten; Bauman, William A.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs Rehabil Res & Dev Serv, Bronx, NY 10468 USA. [Spungen, Ann M.; Bang, Charlene; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Spungen, Ann M.; Bang, Charlene; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Spungen, Ann M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Handrakis, John P.; Liu, Shou-An; Krajewski, Megan] New York Inst Technol, Sch Hlth Profess, Dept Phys Therapy, Old Westbury, NY 11568 USA. RP Handrakis, JP (reprint author), James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs Rehabil Res & Dev Serv, 130 West Kingsbridge Rd,7A-13, Bronx, NY 10468 USA. EM john.handrakis@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service National Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162-C]; James J. Peters Veterans Affairs Medical Center FX Support for this work was provided by the Department of Veterans Affairs Rehabilitation Research and Development Service National Center of Excellence for the Medical Consequences of Spinal Cord Injury (B4162-C) and the James J. Peters Veterans Affairs Medical Center. Clinical Trial Registration Number: NCT01822535. NR 54 TC 0 Z9 0 U1 2 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD AUG 1 PY 2015 VL 32 IS 15 BP 1168 EP 1175 DI 10.1089/neu.2014.3719 PG 8 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CV0JK UT WOS:000363936800004 PM 25531297 ER PT J AU Lee, SM Takemoto, S Wallace, AW AF Lee, Susan M. Takemoto, Steven Wallace, Arthur W. TI Association between Withholding Angiotensin Receptor Blockers in the Early Postoperative Period and 30-day Mortality A Cohort Study of the Veterans Affairs Healthcare System SO ANESTHESIOLOGY LA English DT Article ID CONVERTING ENZYME-INHIBITORS; ACUTE KIDNEY INJURY; VASCULAR-SURGERY; CARDIAC-SURGERY; RISK; ANTAGONISTS; DISCONTINUATION; MEDICATIONS; VARIABLES; BLOCKADE AB Background: Despite widespread use, there is limited information to guide perioperative management of angiotensin receptor blockers (ARBs). Methods: In this retrospective cohort study, the authors evaluated the patterns of postoperative ARB use in veterans regularly prescribed ARBs admitted for noncardiac surgery at the Veterans Affairs Healthcare system between 1999 and 2011. Multivariable and propensity score-matched Cox proportional hazards models were used to determine the independent effect of failure to resume ARB by postoperative day 2 on the primary outcome of all-cause 30-day mortality. Results: Out of 1,167,482 surgical admissions, 30,173 inpatient surgical admissions met inclusion criteria. Approximately 10,205 patients (33.8%) in the cohort did not resume ARB by day 2. Those that resumed ARB had a 30-day mortality rate of 1.3% (260 of 19,968), whereas 3.2% (323 of 10,205) died in the group that withheld ARB. The unadjusted hazard ratio (HR) for 30-day mortality was 2.45 (95% CI, 2.08 to 2.89; P < 0.001) for those that withheld ARB compared with those that resumed, whereas the multivariable adjusted HR was 1.74 (95% CI, 1.47 to 2.06; P < 0.001). When restricted to a propensity score-matched subset of 19,490, the HR was similar (1.47; 95% CI, 1.22 to 1.78; P < 0.001). Withholding ARB in younger patients increased mortality risk (HR = 2.52; 95% CI, 1.69 to 3.76; P < 0.001 for age <60 yr) compared with older patients (HR = 1.42; 95% CI, 1.09 to 1.85; P = 0.01 for age >75 yr). Conclusions: Postoperative delay in resuming ARB is common, particularly in patients who are frail after surgery. Withholding ARB is strongly associated with increased 30-day mortality, especially in younger patients, although residual confounding may be present. C1 [Lee, Susan M.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Lee, SM (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 521 Parnassus Ave Rm C-450, San Francisco, CA 94143 USA. EM susan.lee5@va.gov FU Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, California; San Francisco Veterans Affairs Medical Center Anesthesiology Service, San Francisco, California; Northern California Institute for Research and Education, San Francisco, California FX Research time for the authors was internally funded by the Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, California; the San Francisco Veterans Affairs Medical Center Anesthesiology Service, San Francisco, California; and the Northern California Institute for Research and Education, San Francisco, California. NR 36 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD AUG PY 2015 VL 123 IS 2 BP 288 EP 306 DI 10.1097/ALN.0000000000000739 PG 19 WC Anesthesiology SC Anesthesiology GA CU4YI UT WOS:000363537300008 PM 26200181 ER PT J AU Monk, TG Bronsert, MR Henderson, WG Mangione, MP Sum-Ping, STJ Bentt, DR Nguyen, JD Richman, JS Meguid, RA Hammermeister, KE AF Monk, Terri G. Bronsert, Michael R. Henderson, William G. Mangione, Michael P. Sum-Ping, S. T. John Bentt, Deyne R. Nguyen, Jennifer D. Richman, Joshua S. Meguid, Robert A. Hammermeister, Karl E. TI Association between Intraoperative Hypotension and Hypertension and 30-day Postoperative Mortality in Noncardiac Surgery SO ANESTHESIOLOGY LA English DT Article ID AFFAIRS SURGICAL RISK; CARDIAC RISK; QUALITY; ANESTHESIA; CARE; ADJUSTMENT; MANAGEMENT; COMPLICATIONS; DEFINITIONS; PRESSURE AB Background: Although deviations in intraoperative blood pressure are assumed to be associated with postoperative mortality, critical blood pressure thresholds remain undefined. Therefore, the authors estimated the intraoperative thresholds of systolic blood pressure (SBP), mean blood pressure (MAP), and diastolic blood pressure (DBP) associated with increased risk-adjusted 30-day mortality. Methods: This retrospective cohort study combined intraoperative blood pressure data from six Veterans Affairs medical centers with 30-day outcomes to determine the risk-adjusted associations between intraoperative blood pressure and 30-day mortality. Deviations in blood pressure were assessed using three methods: (1) population thresholds (individual patient sum of area under threshold [AUT] or area over threshold 2 SDs from the mean of the population intraoperative blood pressure values), (2). absolute thresholds, and (3) percent change from baseline blood pressure. Results: Thirty-day mortality was associated with (1) population threshold: systolic AUT (odds ratio, 3.3; 95% CI, 2.2 to 4.8), mean AUT (2.8; 1.9 to 4.3), and diastolic AUT (2.4; 1.6 to 3.8). Approximate conversions of AUT into its separate components of pressure and time were SBP < 67 mmHg for more than 8.2min, MAP < 49 mmHg for more than 3.9min, DBP < 33 mmHg for more than 4.4min. (2) Absolute threshold: SBP < 70 mmHg for more than or equal to 5min (odds ratio, 2.9; 95% CI, 1.7 to 4.9), MAP < 49 mmHg for more than or equal to 5min (2.4; 1.3 to 4.6), and DBP < 30 mmHg for more than or equal to 5min (3.2; 1.8 to 5.5). (3) Percent change: MAP decreases to more than 50% from baseline for more than or equal to 5min (2.7; 1.5 to 5.0). Intraoperative hypertension was not associated with 30-day mortality with any of these techniques. Conclusion: Intraoperative hypotension, but not hypertension, is associated with increased 30-day operative mortality. C1 [Monk, Terri G.] Durham VA Med Ctr, Emeritus Fac, Durham, NC USA. [Monk, Terri G.] Univ Missouri, Dept Anesthesiol & Perioperat Med, Columbia, MO USA. [Bronsert, Michael R.; Henderson, William G.] ACCORDS, Aurora, CO USA. [Henderson, William G.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Mangione, Michael P.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Sum-Ping, S. T. John] Univ Texas SW Med Ctr Dallas, VA North Texas Hlth Care Syst, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA. [Bentt, Deyne R.] George Washington Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Washington DC VA Med Ctr, Washington, DC USA. [Nguyen, Jennifer D.] Baylor Coll Med, Michael DeBakey Vet Affairs Med Ctr, Dept Anesthesiol, Houston, TX 77030 USA. [Richman, Joshua S.] Univ Alabama Birmingham, Dept Surg, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Meguid, Robert A.] Univ Colorado, Dept Surg, Sch Med, Aurora, CO USA. [Hammermeister, Karl E.] Univ Colorado, Dept Med Cardiol, Sch Med, Aurora, CO USA. RP Monk, TG (reprint author), Dept Anesthesiol & Perioperat Med, One Hosp Dr,3w-27F,DC005-00, Columbia, MO 65212 USA. EM monkt@health.missouri.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Washington, D.C. [IIR 05-229] FX This study is supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Grant Number IIR 05-229, Washington, D.C. NR 32 TC 30 Z9 30 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD AUG PY 2015 VL 123 IS 2 BP 307 EP 319 DI 10.1097/ALN.0000000000000756 PG 13 WC Anesthesiology SC Anesthesiology GA CU4YI UT WOS:000363537300009 PM 26083768 ER PT J AU Dismuke, CE Gebregziabher, M Yeager, D Egede, LE AF Dismuke, Clara E. Gebregziabher, Mulugeta Yeager, Derik Egede, Leonard E. TI Racial/Ethnic Differences in Combat- and Non-Combat-Associated Traumatic Brain Injury Severity in the Veterans Health Administration: 2004-2010 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID FUNCTIONAL OUTCOMES; ETHNIC DISPARITIES; MILITARY PERSONNEL; REHABILITATION; SERVICE; IRAQ; DISORDERS; RISK AB Objectives. We examined the association between traumatic brain injury (TBI) severity and combat exposure by race/ethnicity. Methods. We estimated logit models of the fully adjusted association of combat exposure with TBI severity in separate race/ethnicity models for a national cohort of 132 995 veterans with TBI between 2004 and 2010. Results. Of veterans with TBI, 25.8% had served in a combat zone. Mild TBI increased from 11.5% to 40.3%, whereas moderate or severe TBI decreased from 88.5% to 59.7%. Moderate or severe TBI was higher in non-Hispanic Blacks (80.0%) and Hispanics (89.4%) than in non-Hispanic Whites (71.9%). In the fully adjusted all-race/ethnicity model, non-Hispanic Blacks (1.44; 95% confidence interval [CI] = 1.37, 1.52) and Hispanics (1.47; 95% CI = 1.26, 1.72) had higher odds of moderate or severe TBI than did non-Hispanic Whites. However, combat exposure was associated with higher odds of mild TBI in non-Hispanic Blacks (2.48; 95% CI = 2.22, 2.76) and Hispanics (3.42; 95% CI = 1.84, 6.35) than in non-Hispanic Whites (2.17; 95% CI = 2.09, 2.26). Conclusions. Research is needed to understand racial differences in the effect of combat exposure on mild TBI and on interventions to prevent TBI across severity levels. C1 [Dismuke, Clara E.; Gebregziabher, Mulugeta; Yeager, Derik; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Dismuke, Clara E.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Dismuke, Clara E.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X NR 27 TC 1 Z9 1 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2015 VL 105 IS 8 BP 1696 EP 1702 DI 10.2105/AJPH.2014.302545 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6VL UT WOS:000362950400059 PM 26066928 ER PT J AU Simonetti, JA Rowhani-Rahbar, A Mills, B Young, B Rivara, FP AF Simonetti, Joseph A. Rowhani-Rahbar, Ali Mills, Brianna Young, Bessie Rivara, Frederick P. TI State Firearm Legislation and Nonfatal Firearm Injuries SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NATIONAL INPATIENT SAMPLE; ACCESS PREVENTION LAWS; TERM MARKED DEFICITS; QUALITY-OF-LIFE; UNITED-STATES; ADOLESCENT CHILDREN; MEDICAL COSTS; DEATH RATES; GUN LAWS; SUICIDE AB Objectives. We investigated whether stricter state-level firearm legislation was associated with lower hospital discharge rates for nonfatal firearm injuries. Methods. We estimated discharge rates for hospitalized and emergency department-treated nonfatal firearm injuries in 18 states in 2010 and used negative binomial regression to determine whether strength of state firearm legislation was independently associated with total nonfatal firearm injury discharge rates. Results. We identified 26 744 discharges for nonfatal firearm injuries. The overall age-adjusted discharge rate was 19.0 per 100 000 person-years (state range = 3.3-36.6), including 7.9 and 11.1 discharges per 100 000 for hospitalized and emergency department-treated injuries, respectively. In models adjusting for differences in state sociodemographic characteristics and economic conditions, states in the strictest tertile of legislative strength had lower discharge rates for total (incidence rate ratio [IRR] = 0.60; 95% confidence interval [CI] = 0.44, 0.82), assault-related (IRR = 0.58; 95% CI = 0.34, 0.99), self-inflicted (IRR = 0.18; 95% CI = 0.14, 0.24), and unintentional (IRR = 0.53; 95% CI = 0.34, 0.84) nonfatal firearm injuries. Conclusions. There is significant variation in state-level hospital discharge rates for nonfatal firearm injuries, and stricter state firearm legislation is associated with lower discharge rates for such injuries. C1 [Simonetti, Joseph A.; Rowhani-Rahbar, Ali; Mills, Brianna; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA USA. [Simonetti, Joseph A.; Young, Bessie] VA Puget Sound Healthcare Syst, Seattle Denver Ctr Innovat, Seattle, WA 98101 USA. [Rowhani-Rahbar, Ali; Mills, Brianna] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Young, Bessie] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. RP Simonetti, JA (reprint author), VA Puget Sound Healthcare Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM simonja@uw.edu FU Ruth L. Kirschstein National Research Service [T32HP10002]; Veterans Affairs Puget Sound Healthcare System, University of Washington; Harborview Injury Prevention and Research Center; Health Resources and Services Administration (HRSA) FX This study was supported by the Ruth L. Kirschstein National Research Service (award (T32HP10002 to J. A. S.); the Veterans Affairs Puget Sound Healthcare System, University of Washington; the Harborview Injury Prevention and Research Center; and the Health Resources and Services Administration (HRSA). NR 64 TC 3 Z9 3 U1 0 U2 7 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2015 VL 105 IS 8 BP 1703 EP 1709 DI 10.2105/AJPH.2015.302617 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6VL UT WOS:000362950400060 PM 26066935 ER PT J AU Kvale, EA Meneses, K Demark-Wahnefried, W Bakitas, M Ritchie, C AF Kvale, Elizabeth A. Meneses, Karen Demark-Wahnefried, Wendy Bakitas, Marie Ritchie, Christine TI Formative research in the development of a care transition intervention in breast cancer survivors SO EUROPEAN JOURNAL OF ONCOLOGY NURSING LA English DT Article DE Breast cancer; Survivorship; Transitional care; Self-management; Qualitative research ID QUALITY-OF-LIFE; SELF-MANAGEMENT; LONG-TERM; PHYSICAL-ACTIVITY; HEALTH BEHAVIORS; CHRONIC ILLNESS; CHRONIC DISEASE; PROJECT LEAD; OUTCOMES; SUPPORT AB Purpose: The purpose of this qualitative study was to evaluate breast cancer survivors' (BCS) responses to a self-management survivorship care transition intervention in the formative development of such an intervention. The experience of BCS is marked by uncertainty and anxiety about subsequent care, and a desire for more information about future care needs and late effects of treatment. Self-management strategies have demonstrated improved outcomes in chronic illness, and may address the unmet needs of breast cancer survivors. Methods and Sample: Five focus and discussion groups each were conducted at a single site in the Southeastern United States with a total of twenty breast cancer survivors. BCS were presented with a description of a survivorship transition intervention that encouraged self-management. Groups were led by a trained moderator using a semi-structured guide with 7 open-ended questions about their care transition experience and response to the proposed intervention. A theoretically-derived, concept-guided coding strategy was developed after review of transcripts. Iterative constant comparative methods were used to ensure that transcripts were reviewed exhaustively for emerging codes and relationships. Key results: Three dominant themes emerged around readiness for self-management: 1) the breast cancer experience as a catalyst for self-management; 2) fear of recurrence as a catalyst for self-management; and 3) the impact of the meaning of breast cancer on individual readiness for self-management. Conclusions: These findings contribute to further development of a conceptual model and interventions built on BCS self-management to improve the survivorship experience. Published by Elsevier Ltd. C1 [Kvale, Elizabeth A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Kvale, Elizabeth A.; Meneses, Karen; Demark-Wahnefried, Wendy; Bakitas, Marie] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Bakitas, Marie] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL 35294 USA. [Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Kvale, EA (reprint author), CH19 Room 219R, Birmingham, AL 35294 USA. EM ekvale@uabmc.edu OI Demark-Wahnefried, Wendy/0000-0001-5241-932X; Meneses, Karen/0000-0002-6094-2230; Bakitas, Marie/0000-0002-2913-2053 FU American Cancer Society [121093-CCCDA-11-191-01-CCCDA] FX Supported by Cancer Control Career Development Award for Primary Care Physicians (grant number 121093-CCCDA-11-191-01-CCCDA) from the American Cancer Society. The sponsor had no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. NR 40 TC 3 Z9 3 U1 1 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1462-3889 EI 1532-2122 J9 EUR J ONCOL NURS JI Eur. J. Oncol. Nurs. PD AUG PY 2015 VL 19 IS 4 BP 329 EP 335 DI 10.1016/j.ejon.2015.01.010 PG 7 WC Oncology; Nursing SC Oncology; Nursing GA CR5RV UT WOS:000361402500001 PM 25726359 ER PT J AU Maung, AA Toevs, CC Kayser, JB Kaplan, LJ AF Maung, Adrian A. Toevs, Christine C. Kayser, Joshua B. Kaplan, Lewis J. TI Conflict management teams in the intensive care unit: A concise definitive review SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Review ID OF-LIFE-CARE; PALLIATIVE CARE; ETHICS-CONSULTATION; END; ICU; COMMUNICATION; CHALLENGES; RESOLUTION; SOCIETY; QUALITY C1 [Maung, Adrian A.] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Toevs, Christine C.] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Kayser, Joshua B.; Kaplan, Lewis J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Maung, AA (reprint author), Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, 330 Cedar St,BB310, New Haven, CT 06520 USA. EM Adrian.Maung@yale.edu NR 37 TC 1 Z9 1 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD AUG PY 2015 VL 79 IS 2 BP 314 EP 320 DI 10.1097/TA.0000000000000728 PG 7 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA CS2II UT WOS:000361892800023 PM 26218703 ER PT J AU Chu, S Boxer, R Madison, P Kleinman, L Skolarus, T Altman, L Bennett, C Shelton, J AF Chu, Stephanie Boxer, Richard Madison, Pauline Kleinman, Leonard Skolarus, Ted Altman, Lisa Bennett, Carol Shelton, Jeremy TI Veterans Affairs Telemedicine: Bringing Urologic Care to Remote Clinics SO UROLOGY LA English DT Article ID PATIENT SATISFACTION; UNITED-STATES; SERVICES; ACCESS; TELECONSULTATION; COMMUNICATION; CONSULTATIONS; SURGERY; IMPACT; LEVEL AB OBJECTIVE To report the use of telemedicine to deliver general urologic care to remote locations within the Veterans Affairs Greater Los Angeles Healthcare System. We describe the diagnoses managed, patient satisfaction, safety, and benefit to patients in terms of saved travel time and expense. METHODS We conducted a retrospective chart review examining care delivered through urology telemedicine clinics over a 6-month period. We examined the urologic conditions, patient satisfaction, and emergency department visits within 30 days of the visit. We estimated patient benefit by calculating travel distance and time and the saved travel-associated costs using Google Maps and US Census income data. RESULTS Ninety-seven unique telemedicine visits were conducted and a total of 171 urologic diseases were assessed. The most common conditions were lower urinary tract symptoms (35%), elevated prostate-specific antigen level (15%), and prostate cancer (14%). One patient was seen in the emergency department within 30 days with an unpreventable urologic complaint. Patient satisfaction was "very good" to "excellent" in 95% of cases, and 97% would refer another veteran to the urology telemedicine clinic. Patients saved an average of 277 travel miles, 290 minutes of travel time, $67 in travel expenses, and $126 in lost opportunity cost. CONCLUSION Telemedicine was successfully and safely used to evaluate and treat a wide range of urologic conditions within the Veterans Affairs Greater Los Angeles Healthcare System, and saves patients nearly 5 hours and up to $193 per visit. Further investigation of the potential of telemedicine for the delivery of urologic care in a cost-effective manner is warranted. (C) 2015 Elsevier Inc. C1 [Chu, Stephanie] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles, Los Angeles, CA USA. Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. Vet Affairs Ann Arbor, HSR&D Ctr Hlth Commun Res, Ann Arbor, MI USA. RP Chu, S (reprint author), Univ Calif Los Angeles, Dept Urol, 405 Hilgard Ave, Los Angeles, CA 90024 USA. EM sdchu@mednet.ucla.edu NR 30 TC 8 Z9 8 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD AUG PY 2015 VL 86 IS 2 BP 255 EP 260 DI 10.1016/j.urology.2015.04.038 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA CS2MJ UT WOS:000361904800016 PM 26168998 ER PT J AU Chu, S Boxer, R Madison, P Kleinman, L Skolarus, T Altman, L Bennett, C Shelton, J AF Chu, Stephanie Boxer, Richard Madison, Pauline Kleinman, Leonard Skolarus, Ted Altman, Lisa Bennett, Carol Shelton, Jeremy TI Veterans Affairs Telemedicine: Bringing Urologic Care to Remote Clinics REPLY SO UROLOGY LA English DT Editorial Material C1 [Chu, Stephanie; Boxer, Richard; Bennett, Carol; Shelton, Jeremy] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. [Boxer, Richard; Madison, Pauline; Kleinman, Leonard; Altman, Lisa; Bennett, Carol; Shelton, Jeremy] Vet Affairs Greater Los Angeles, Los Angeles, CA USA. [Skolarus, Ted] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. [Skolarus, Ted] Vet Affairs Ann Arbor, HSR&D Ctr Hlth Commun Res, Ann Arbor, MI USA. RP Chu, S (reprint author), Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD AUG PY 2015 VL 86 IS 2 BP 260 EP 261 DI 10.1016/j.urology.2015.04.040 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA CS2MJ UT WOS:000361904800018 PM 26169002 ER PT J AU Oh, SY He, F Krans, A Frazer, M Taylor, JP Paulson, HL Todd, PK AF Oh, Seok Yoon He, Fang Krans, Amy Frazer, Michelle Taylor, J. Paul Paulson, Henry L. Todd, Peter K. TI RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome SO HUMAN MOLECULAR GENETICS LA English DT Article ID RNA-MEDIATED NEURODEGENERATION; C9ORF72 HEXANUCLEOTIDE REPEAT; AGGREGATE-PRONE PROTEINS; ALPHA-SYNUCLEIN TOXICITY; FMR1 MESSENGER-RNA; TREMOR/ATAXIA SYNDROME; DROSOPHILA MODEL; MYOTONIC-DYSTROPHY; ANTISENSE TRANSCRIPTS; PREMUTATION ALLELES AB Fragile X-associated tremor ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by a CGG trinucleotide repeat expansion in the 5'UTR of the Fragile X gene, FMR1. FXTAS is thought to arise primarily from an RNA gain-of-function toxicity mechanism. However, recent studies demonstrate that the repeat also elicits production of a toxic polyglycine protein, FMRpolyG, via repeat-associated non-AUG (RAN)-initiated translation. Pathologically, FXTAS is characterized by ubiquitin-positive intranuclear neuronal inclusions, raising the possibility that failure of protein quality control pathways could contribute to disease pathogenesis. To test this hypothesis, we used Drosophila-and cell-based models of CGG-repeat-associated toxicity. In Drosophila, ubiquitin proteasome system (UPS) impairment led to enhancement of CGG-repeat-induced degeneration, whereas overexpression of the chaperone protein HSP70 suppressed this toxicity. In transfected mammalian cells, CGG repeat expression triggered accumulation of a UPS reporter in a length-dependent fashion. To delineate the contributions from CGG repeats as RNA from RAN translation-associated toxicity, we enhanced or impaired the production of FMRpolyG in these models. Driving expression of FMRpolyG enhanced induction of UPS impairment in cell models, while prevention of RAN translation attenuated UPS impairment in cells and suppressed the genetic interaction with UPS manipulation in Drosophila. Taken together, these findings suggest that CGG repeats induce UPS impairment at least in part through activation of RAN translation. C1 [Oh, Seok Yoon; He, Fang; Krans, Amy; Frazer, Michelle; Paulson, Henry L.; Todd, Peter K.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA. [Taylor, J. Paul] St Jude Childrens Res Hosp, Dept Cell & Mol Biol, Memphis, TN 38105 USA. [Todd, Peter K.] US Dept Vet Affairs, Med Ctr, Neurol, Ann Arbor, MI USA. RP Todd, PK (reprint author), 4005 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA. EM petertod@umich.edu FU National Ataxia Foundation; AAN CRTF fellowship; NIH [R01NS08681001, K08NS069809]; Department of Veterans Affairs BLRD [1I21BX001841] FX Funding for this project was derived from a National Ataxia Foundation grant to F.H. and an AAN CRTF fellowship, NIH R01NS08681001, NIH K08NS069809 and the Department of Veterans Affairs BLRD 1I21BX001841 to P.K.T. NR 75 TC 13 Z9 13 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD AUG 1 PY 2015 VL 24 IS 15 BP 4317 EP 4326 DI 10.1093/hmg/ddv165 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA CR4OK UT WOS:000361314100012 PM 25954027 ER PT J AU Blakney, R Gudnadottir, U Warrack, S O'Horo, JC Anderson, M Sethi, A Schmitz, M Wang, J Duster, M Ide, E Safdar, N AF Blakney, Rebekah Gudnadottir, Unnur Warrack, Simone O'Horo, John C. Anderson, Michael Sethi, Ajay Schmitz, Michelle Wang, Jennifer Duster, Megan Ide, Emma Safdar, Nasia TI The relationship between patient functional status and environmental contamination by Clostridium difficile: a pilot study SO INFECTION LA English DT Article DE Healthcare-associated infections; Clostridium difficile; Environmental contamination; Infection control ID STRAIN AB Introduction Limited data exist on patient factors related to environmental contamination with Clostridium difficile. Methods We evaluated the association between the functional status of patients with C. difficile infection (CDI) and environmental contamination with C. difficile. Results Contamination of patient rooms was frequent and higher functional status was associated with contaminated surfaces remote from the bed. All but one environmental isolates matched the corresponding patient's stool isolate for the seven patients tested. Conclusion Functional status is a factor that influences environmental contamination with C. difficile. Future studies should evaluate strategies to reduce contamination in CDI patient rooms, taking into account the patient's functional status. C1 [Blakney, Rebekah; Gudnadottir, Unnur; Sethi, Ajay; Safdar, Nasia] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53705 USA. [Blakney, Rebekah; Warrack, Simone; Anderson, Michael; Wang, Jennifer; Duster, Megan; Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [O'Horo, John C.] Mayo Clin, Dept Med, Rochester, MN USA. [Schmitz, Michelle] Univ Wisconsin, Dept Nat Sci, Madison, WI 53705 USA. [Ide, Emma; Safdar, Nasia] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin, Dept Populat Hlth Sci, 5221 MFCB,1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu RI O'Horo, John/N-8681-2013 OI O'Horo, John/0000-0002-0880-4498 FU NIA NIH HHS [AG40669, R03 AG040669] NR 10 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8126 EI 1439-0973 J9 INFECTION JI Infection PD AUG PY 2015 VL 43 IS 4 BP 483 EP 487 DI 10.1007/s15010-015-0770-1 PG 5 WC Infectious Diseases SC Infectious Diseases GA CR4JU UT WOS:000361299000010 PM 25869819 ER PT J AU Fernandes, L Mateos, R Engedal, K von Gunten, A Stek, ML Ramakrishnan, A Ihl, R Wang, HL Mintzer, J Brodaty, H AF Fernandes, Lia Mateos, Raimundo Engedal, Knut von Gunten, Armin Stek, Max L. Ramakrishnan, Anand Ihl, Ralf Wang, Huali Mintzer, Jacobo Brodaty, Henry CA Int Psychogeriatric Association TI The state of psychogeriatrics in Europe: challenges and opportunities in six European countries SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Editorial Material ID PSYCHIATRY C1 [Fernandes, Lia] Univ Porto, Fac Med, UNIFAI CINTESIS, P-4100 Oporto, Portugal. [Mateos, Raimundo] Fac Med Santiago de Compostela, Dept Psiquiatria, Santiago De Compostela, Spain. [Engedal, Knut] Vestfold Hosp Trust, Norwegian Ctr Aging & Hlth, Tonsberg, Norway. [von Gunten, Armin] Univ Lausanne Hosp, Dept Psychiat, Serv Univ Psychiat Age Aavance, Prilly, Switzerland. [Stek, Max L.] Acad Werkplaats Ouderenpsychiat GGZ inGeest VUmc, Dept Old Age Psychiat, Amsterdam, Netherlands. [Ramakrishnan, Anand] Royal Coll Psychiatrists, Fac Old Age Psychiat, London SW1X 8PG, England. [Ihl, Ralf] Univ Dusseldorf, Dept Psychiat & Psychotherapy, Krefeld, Germany. [Ihl, Ralf] Alexian Res Ctr, Krefeld, Germany. [Wang, Huali] Peking Univ, Minist Hlth, Inst Mental Hlth, Key Lab Mental Hlth, Beijing 100871, Peoples R China. [Mintzer, Jacobo] Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC USA. [Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Brodaty, Henry] Univ New S Wales, Ctr Hlth Brain Ageing, Sydney, NSW, Australia. RP Fernandes, L (reprint author), Univ Porto, Fac Med, UNIFAI CINTESIS, Rua Campo Alegre 823, P-4100 Oporto, Portugal. EM lfernandes@med.up.pt RI FMUP, CINTESIS/C-6631-2014 OI FMUP, CINTESIS/0000-0001-7248-2086; Fernandes, Lia/0000-0002-3391-0647 NR 16 TC 1 Z9 1 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD AUG PY 2015 VL 27 IS 8 BP 1243 EP 1246 DI 10.1017/S1041610214002191 PG 4 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CR5LR UT WOS:000361384500001 PM 25355137 ER PT J AU Teuffel, P Wang, L Prinz, P Goebel-Stengel, M Scharner, S Kobelt, P Hofmann, T Rose, M Klapp, BF Reeve, JR Stengel, A AF Teuffel, P. Wang, L. Prinz, P. Goebel-Stengel, M. Scharner, S. Kobelt, P. Hofmann, T. Rose, M. Klapp, B. F. Reeve, J. R., Jr. Stengel, A. TI TREATMENT WITH THE GHRELIN-O-ACYLTRANSFERASE (GOAT) INHIBITOR GO-COA-TAT REDUCES FOOD INTAKE BY REDUCING MEAL FREQUENCY IN RATS SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY LA English DT Article DE automated food intake monitoring system; behavior; behavioral satiety sequence; food intake pattern; ghrelin ID BEHAVIORAL SATIETY SEQUENCE; BODY-MASS INDEX; PATTERN-ANALYSIS; MICROSTRUCTURE; PEPTIDE; MICE; INCREASES; RECEPTOR; HORMONE; OBESITY AB The ghrelin acylating enzyme ghrelin-O-acyltransferase (GOAT) was recently identified and implicated in several biological functions. However, the effects on food intake warrant further investigation. While several genetic GOAT mouse models showed normal food intake, acute blockade using a GOAT inhibitor resulted in reduced food intake. The underlying food intake microstructure remains to be established. In the present study we used an automated feeding monitoring system to assess food intake and the food intake microstructure. First, we validated the basal food intake and feeding behavior in rats using the automated monitoring system. Afterwards, we assessed the food intake microstructure following intraperitoneal injection of the GOAT inhibitor, GO-CoA-Tat (32, 96 and 288 mu g/kg) in freely fed male Sprague-Dawley rats. Rats showed a rapid habituation to the automated food intake monitoring system and food intake levels were similar compared to manual monitoring (P = 0.43). Rats housed under these conditions showed a physiological behavioral satiety sequence. Injection of the GOAT inhibitor resulted in a dose-dependent reduction of food intake with a maximum effect observed after 96 mu g/kg (-27%, P = 0.03) compared to vehicle. This effect was delayed in onset as the first meal was not altered and lasted for a period of 2 h. Analysis of the food intake microstructure showed that the anorexigenic effect was due to a reduction of meal frequency (-15%, P = 0.04), whereas meal size (P = 0.29) was not altered compared to vehicle. In summary, pharmacological blockade of GOAT reduces dark phase food intake by an increase of satiety while satiation is not affected. C1 [Teuffel, P.; Prinz, P.; Scharner, S.; Kobelt, P.; Hofmann, T.; Rose, M.; Klapp, B. F.; Stengel, A.] Charite, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, D-12200 Berlin, Germany. [Wang, L.; Reeve, J. R., Jr.] Univ Calif Los Angeles, Div Digest Dis, Dept Med, CURE Digest Dis Res Ctr,Ctr Neurobiol Stress, Los Angeles, CA 90024 USA. [Wang, L.; Reeve, J. R., Jr.] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Goebel-Stengel, M.] Martin Luther Krankenhaus, Dept Internal Med, Berlin, Germany. [Goebel-Stengel, M.] Martin Luther Krankenhaus, Inst Neurogastroenterol, Berlin, Germany. RP Stengel, A (reprint author), Charite, Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, 30 Hindenburgdamm St, D-12200 Berlin, Germany. EM andreas.stengel@charite.de FU German Research Foundation Grants [STE 1765/3-1, R01 NIH DK083449]; Sonnenfeld Foundation Berlin; Charite University Funding [UFF 89/441-176] FX This work was supported by German Research Foundation Grants STE 1765/3-1 (A.S.), R01 NIH DK083449 (J.R.R., Jr.), the Sonnenfeld Foundation Berlin (A.S.) and Charite University Funding UFF 89/441-176 (A.S.). NR 50 TC 4 Z9 4 U1 1 U2 2 PU POLISH PHYSIOLOGICAL SOC PI GRZEGORZECKA PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLAND SN 0867-5910 J9 J PHYSIOL PHARMACOL JI J. Physiol. Pharmacol. PD AUG PY 2015 VL 66 IS 4 BP 493 EP 503 PG 11 WC Physiology SC Physiology GA CR7AL UT WOS:000361499800003 PM 26348074 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI Treatment: special conditions Co-existing heart disease: coronary artery disease, myocardial infarction, heart failure SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article ID ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES; FOCUSED UPDATE; BLOOD-PRESSURE; PREVENTION; MANAGEMENT; HYPERTENSION AB There is a strong epidemiologic association between hypertension (HT) and coronary artery disease (CAD). In men older than the age of 65 years, HT increases the relative risk of CAD to 1.6, of stroke to 2.0, and heart failure (HF) to 1.9. The figures for women of the same age are even worse: 1.9, 2.6, and 1.9. Consequently, HT and CAD commonly occur together and raise some unique problems of management. These include the elusive definition of the blood pressure (BP) goal of therapy in these patients and the optimal choice of the treatment of HT, both for the prevention and management of CAD. C1 Icahn Sch Med Mt Sinai, Dept Med, James J Peters VA Med Ctr, Bronx, NY 10029 USA. RP Rosendorff, C (reprint author), Icahn Sch Med Mt Sinai, Dept Med, James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10029 USA. EM clive.rosendorff@va.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD AUG PY 2015 VL 9 IS 8 BP 651 EP 654 DI 10.1016/j.jash.2015.06.008 PG 4 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CR4XI UT WOS:000361343000014 PM 26183895 ER PT J AU Smith, BA Trujillo-Priego, IA Lane, CJ Finley, JM Horak, FB AF Smith, Beth A. Trujillo-Priego, Ivan A. Lane, Christianne J. Finley, James M. Horak, Fay B. TI Daily Quantity of Infant Leg Movement: Wearable Sensor Algorithm and Relationship to Walking Onset SO SENSORS LA English DT Article DE infant; movement; growth and development; wearable sensors ID FULL-TERM INFANTS; LOW-BIRTH-WEIGHT; PRETERM INFANTS; SPONTANEOUS KICKING; DOWN-SYNDROME; COORDINATION; ORGANIZATION; PATTERNS; AGE AB Background: Normative values are lacking for daily quantity of infant leg movements. This is critical for understanding the relationship between the quantity of leg movements and onset of independent walking, and will begin to inform early therapy intervention for infants at risk for developmental delay. Methods: We used wearable inertial movement sensors to record full-day leg movement activity from 12 infants with typical development, ages 1-12 months. Each infant was tested three times across 5 months, and followed until the onset of independent walking. We developed and validated an algorithm to identify infant-produced leg movements. Results: Infants moved their legs tens of thousands of times per day. There was a significant effect of leg movement quantity on walking onset. Infants who moved their legs more walked later than infants who moved their legs less, even when adjusting for age, developmental level or percentile length. We will need a much larger sample to adequately capture and describe the effect of movement experience on developmental rate. Our algorithm defines a leg movement in a specific way (each pause or change in direction is counted as a new movement), and further assessment of movement characteristics are necessary before we can fully understand and interpret our finding that infants who moved their legs more walked later than infants who moved their legs less. Conclusions: We have shown that typically-developing infants produce thousands of leg movements in a typical day, and that this can be accurately captured in the home environment using wearable sensors. In our small sample we can identify there is an effect of leg movement quantity on walking onset, however we cannot fully explain it. C1 [Smith, Beth A.; Trujillo-Priego, Ivan A.; Finley, James M.] Univ So Calif, Div Biokinesiol & Phys Therapy, Los Angeles, CA 90089 USA. [Lane, Christianne J.] Univ So Calif, Keck Sch Med, Div Biostat, Dept Preventat Med, Los Angeles, CA 90089 USA. [Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Horak, Fay B.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Smith, BA (reprint author), Univ So Calif, Div Biokinesiol & Phys Therapy, Los Angeles, CA 90089 USA. EM beth.smith@usc.edu; itrujill@usc.edu; christianne.lane@med.usc.edu; jmfinley@usc.edu; horakf@ohsu.edu RI Finley, James/I-5699-2016; Smith, Beth A./D-2914-2014 OI Finley, James/0000-0003-2679-2221; Smith, Beth A./0000-0003-2531-5394 FU American Physical Therapy Association Section on Pediatrics Research Grant 2 Award; Foundation for Physical Therapy (NIFTI); Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health [K12HD073945, 2R42HD071760]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000130]; [K12-HD055929] FX Thank you to the infants and their families. Funding sources: This work was funded in part by an American Physical Therapy Association Section on Pediatrics Research Grant 2 Award (BAS). Smith's salary was supported by the Foundation for Physical Therapy (NIFTI to BAS) and currently her salary and research are supported by K12-HD055929 (Ottenbacher). Finley's and Horak's efforts were supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Numbers K12HD073945 (Finley) and 2R42HD071760 (Horak). Study data were collected and managed using REDCap electronic data capture tools hosted at Oregon Health & Science University (OHSU) (1 UL1 RR024140 01). Research reported in this publication was partially supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000130 (formerly by the National Center for Research Resources, Award Number UL1RR031986). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 20 TC 2 Z9 2 U1 4 U2 11 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1424-8220 J9 SENSORS-BASEL JI Sensors PD AUG PY 2015 VL 15 IS 8 BP 19006 EP 19020 DI 10.3390/s150819006 PG 15 WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation SC Chemistry; Electrochemistry; Instruments & Instrumentation GA CQ9BS UT WOS:000360906500061 PM 26247951 ER PT J AU Sabri, O Sabbagh, MN Seibyl, J Barthel, H Akatsu, H Ouchi, Y Senda, K Murayama, S Ishii, K Takao, M Beach, TG Rowe, CC Leverenz, JB Ghetti, B Ironside, JW Catafau, AM Stephens, AW Mueller, A Koglin, N Hoffmann, A Roth, K Reininger, C Schulz-Schaeffer, WJ AF Sabri, Osama Sabbagh, Marwan N. Seibyl, John Barthel, Henryk Akatsu, Hiroyasu Ouchi, Yasuomi Senda, Kohei Murayama, Shigeo Ishii, Kenji Takao, Masaki Beach, Thomas G. Rowe, Christopher C. Leverenz, James B. Ghetti, Bernardino Ironside, James W. Catafau, Ana M. Stephens, Andrew W. Mueller, Andre Koglin, Norman Hoffmann, Anja Roth, Katrin Reininger, Cornelia Schulz-Schaeffer, Walter J. CA Florbetaben Phase 3 Study Grp TI Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study SO ALZHEIMERS & DEMENTIA LA English DT Article DE Amyloid; PET; Florbetaben; Histopathology ID NATIONAL INSTITUTE; F-18-FLORBETABEN; DIAGNOSIS AB Background: Evaluation of brain beta-amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Methods: Open-label, nonrandomized, multicenter, phase 3 study to validate the F-18-labeled beta-amyloid tracer florbetaben by comparing in vivo PET imaging with post-mortem histopathology. Results: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed. Forty-six of 47 neuritic beta-amyloid-positive cases were read as PET positive, and 24 of 27 neuritic beta-amyloid plaque-negative cases were read as PET negative (sensitivity 97.9% [95% confidence interval or CI 93.8-100%], specificity 88.9% [95% CI 77.0-100%]). In a subgroup, a regional tissue-scan matched analysis was performed. In areas known to strongly accumulate beta-amyloid plaques, sensitivity and specificity were 82% to 90%, and 86% to 95%, respectively. Conclusions: Florbetaben PET shows high sensitivity and specificity for the detection of histopathology-confirmed neuritic beta-amyloid plaques and may thus be a valuable adjunct to clinical diagnosis, particularly for the exclusion of AD. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer'sAssociation. C1 [Sabri, Osama; Barthel, Henryk] Univ Leipzig, Dept Nucl Med, D-04109 Leipzig, Germany. [Sabbagh, Marwan N.; Beach, Thomas G.] Banner Sun Hlth Res Inst, Sun City, AZ USA. [Seibyl, John] Mol Neuroimaging LLC, New Haven, CT USA. [Akatsu, Hiroyasu] Fukushimura Hosp, Toyohashi, Aichi, Japan. [Akatsu, Hiroyasu] Nagoya City Univ, Grad Sch Med Sci, Dept Community Based Med, Nagoya, Aichi, Japan. [Akatsu, Hiroyasu] Nagoya City Univ, Grad Sch Med Sci, Dept Neurol, Nagoya, Aichi, Japan. [Ouchi, Yasuomi] Hamamatsu Univ Sch Med, Med Photon Res Ctr, Dept Biofunct Imaging, Hamamatsu, Shizuoka 4313192, Japan. [Senda, Kohei] Koseikai Hosp, Toyohashi, Aichi, Japan. [Murayama, Shigeo] Tokyo Metropolitan Geriatr Hosp, Dept Neurol & Neuropathol, Tokyo 173, Japan. [Murayama, Shigeo] Inst Gerontol, Tokyo, Japan. [Murayama, Shigeo; Ishii, Kenji; Takao, Masaki] Tokyo Metropolitan Inst Gerontol, Tokyo, Japan. [Takao, Masaki] Mihara Mem Hosp, Isesaki, Japan. [Rowe, Christopher C.] Univ Melbourne, Dept Mol Imaging, Austin Hlth, Melbourne, Vic, Australia. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Seattle, WA 98195 USA. [Ghetti, Bernardino] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA. [Ironside, James W.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland. [Catafau, Ana M.; Stephens, Andrew W.; Mueller, Andre; Koglin, Norman] Piramal Imaging GmbH, Berlin, Germany. [Hoffmann, Anja; Roth, Katrin; Reininger, Cornelia] Bayer Pharma AG, Berlin, Germany. [Schulz-Schaeffer, Walter J.] Univ Med Ctr Gottingen, Dept Neuropathol, Gottingen, Germany. RP Sabri, O (reprint author), Univ Leipzig, Dept Nucl Med, D-04109 Leipzig, Germany. EM osama.sabri@medizin.uni-leipzig.de OI Ironside, James/0000-0001-5869-2108 FU Piramal Imaging S.A; Bayer Pharma AG, Berlin (Germany); Piramal Imaging S.A., Matran (Switzerland) FX Medical writing support was provided by Dan Booth (Bioscript Medical, London, UK) and funded by Piramal Imaging S.A. Additional statistical analysis was carried out by Santi Bullich (Piramal Imaging GmbH).; The trial was funded by Bayer Pharma AG, Berlin (Germany), and Piramal Imaging S.A., Matran (Switzerland). Bayer Pharma AG was involved in the design of the study; Bayer Pharma AG and Piramal Imaging SA were involved in the conduct of the study; collection, management, analysis, and interpretation of the data; and in the preparation, review, and approval of the manuscript. NR 31 TC 43 Z9 46 U1 1 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD AUG PY 2015 VL 11 IS 8 BP 964 EP 974 DI 10.1016/j.jalz.2015.02.004 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA CQ9DT UT WOS:000360912300008 PM 25824567 ER PT J AU Dodson, M Redmann, M Rajasekaran, NS Darley-Usmar, V Zhang, JH AF Dodson, Matthew Redmann, Matthew Rajasekaran, Namakkal S. Darley-Usmar, Victor Zhang, Jianhua TI KEAP1-NRF2 signalling and autophagy in protection against oxidative and reductive proteotoxicity SO BIOCHEMICAL JOURNAL LA English DT Review DE antioxidants; autophagy; KEAP1-NRF2; mitophagy; p62; redox signalling ID TRANSCRIPTION FACTOR NRF2; CUL3-BASED E3 LIGASE; ANTIOXIDANT RESPONSE; NEURODEGENERATIVE DISEASE; PROTEIN AGGREGATION; SELECTIVE AUTOPHAGY; OXIDIZED PROTEINS; REDOX REGULATION; NUCLEAR EXPORT; MOUSE MODEL AB Maintaining cellular redox status to allow cell signalling to occur requires modulation of both the controlled production of oxidants and the thiol-reducing networks to allow specific regulatory post-translational modification of protein thiols. The oxidative stress hypothesis captured the concept that overproduction of oxidants can be proteotoxic, but failed to predict the recent finding that hyperactivation of the KEAP1-NRF2 system also leads to proteotoxicity. Furthermore, sustained activation of thiol redox networks by KEAP1-NRF2 induces a reductive stress, by decreasing the lifetime of necessary oxidative post-translational modifications required for normal metabolism or cell signalling. In this context, it is now becoming clear why antioxidants or hyperactivation of antioxidant pathways with electrophilic therapeutics can be deleterious. Furthermore, it suggests that the autophagy-lysosomal pathway is particularly important in protecting the cell against redox-stress-induced proteotoxicity, since it can degrade redox-damaged proteins without causing aberrant changes to the redox network needed for metabolism or signalling. In this context, it is important to understand: (i) how NRF2-mediated redox signalling, or (ii) the autophagy-mediated antioxidant/reductant pathways sense cellular damage in the context of cellular pathogenesis. Recent studies indicate that the modification of protein thiols plays an important role in the regulation of both the KEAP1-NRF2 and autophagy pathways. In the present review, we discuss evidence demonstrating that the KEAP1-NRF2 pathway and autophagy act in concert to combat the deleterious effects of proteotoxicity. These findings are discussed with a special emphasis on their impact on cardiovascular disease and neurodegeneration. C1 [Dodson, Matthew; Redmann, Matthew; Rajasekaran, Namakkal S.; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Dodson, Matthew; Redmann, Matthew; Rajasekaran, Namakkal S.; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35233 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Ctr Free Rad Biol, 901 19th St South, Birmingham, AL 35294 USA. EM zhanja@uab.edu OI Zhang, Jianhua/0000-0002-2128-9574 FU National Institutes of Health [NIHR01-NS064090, NIHR01-HL118067, NIHR03-AG042860]; American Heart Association [0865015F] FX This work was supported by the National Institutes of Health [grant numbers NIHR01-NS064090 (to J.Z.), NIHR01-HL118067 (to N.S.R.), and NIHR03-AG042860 (to N.S.R.)] and the American Heart Association [grant number AHA-BGIA# 0865015F (to N.S.R.)]. NR 118 TC 21 Z9 24 U1 4 U2 26 PU PORTLAND PRESS LTD PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND SN 0264-6021 EI 1470-8728 J9 BIOCHEM J JI Biochem. J. PD AUG 1 PY 2015 VL 469 BP 347 EP 355 DI 10.1042/BJ20150568 PN 3 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CR0ZW UT WOS:000361053400002 PM 26205490 ER PT J AU Goyal, SD Zhang, MJ Wang, HL Akpek, G Copelan, EA Freytes, C Gale, RP Hamadani, M Inamoto, Y Kamble, RT Lazarus, HM Marks, DI Nishihori, T Olsson, RF Reshef, R Ritchie, DS Saber, W Savani, BN Seber, A Shea, TC Tallman, MS Wirk, B Bunjes, DW Devine, SM de Lima, M Weisdorf, DJ Uy, GL AF Goyal, S. D. Zhang, M-J Wang, H-L Akpek, G. Copelan, E. A. Freytes, C. Gale, R. P. Hamadani, M. Inamoto, Y. Kamble, R. T. Lazarus, H. M. Marks, D. I. Nishihori, T. Olsson, R. F. Reshef, R. Ritchie, D. S. Saber, W. Savani, B. N. Seber, A. Shea, T. C. Tallman, M. S. Wirk, B. Bunjes, D. W. Devine, S. M. de Lima, M. Weisdorf, D. J. Uy, G. L. CA Ctr Int Blood Marrow TI Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome SO BONE MARROW TRANSPLANTATION LA English DT Article ID ACUTE MYELOID-LEUKEMIA; LONG-TERM SURVIVAL; RISK-FACTORS; RELAPSE; REMISSION; SARCOMA; MARROW AB The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for International Blood and Marrow Transplant Research, we compared the outcomes of patients who had EMD of AML at any time before transplant, with a cohort of AML patients without EMD. We reviewed data from 9797 AML patients including 814 with EMD from 310 reporting centers and 44 different countries, who underwent alloHCT between and 1995 and 2010. The primary outcome was overall survival (OS) after alloHCT. Secondary outcomes included leukemia-free survival (LFS), relapse rate and treatment-related mortality (TRM). In a multivariate analysis, the presence of EMD did not affect either OS (hazard ratio 1.00, 95% confidence interval (Cl) 0.91-1.09), LFS (0.98, 0.89-1.09), TRM (relative risk 0.92, 95% CI 0.80-1.16, P=0.23) or relapse (relative risk= 1.03, 95% CI, 0.92-1.16; P=0.62). Furthermore, the outcome of patients with EMD was not influenced by the location, timing of EMD, or intensity of conditioning regimen. The presence of EMD in AML does not affect transplant outcomes and should not be viewed as an independent adverse prognostic feature. C1 [Goyal, S. D.] St Louis Univ, Med Ctr, St Louis, MO USA. [Zhang, M-J; Wang, H-L; Hamadani, M.; Saber, W.] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Zhang, M-J] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA. [Akpek, G.] Banner MD Anderson Canc Ctr, Hematol Oncol Sect, Gilbert, AZ USA. [Copelan, E. A.] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA. [Freytes, C.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Gale, R. P.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Hematol Res Ctr, Div Expt Med, London, England. [Inamoto, Y.] Natl Canc Ctr, Tokyo, Japan. [Kamble, R. T.] Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Lazarus, H. M.; de Lima, M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Marks, D. I.] Univ Hosp Bristol NHS Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England. [Nishihori, T.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA. [Olsson, R. F.] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden. [Olsson, R. F.] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Reshef, R.] Univ Penn, Med Ctr, Dept Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Ritchie, D. S.] Royal Melbourne Hosp, Melbourne, Vic, Australia. [Savani, B. N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Seber, A.] Hosp Samaritano, Sao Paulo, Brazil. [Shea, T. C.] Univ North Carolina Hlth Care, Dept Med, Div Hematol & Oncol, Chapel Hill, NC USA. [Tallman, M. S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA. [Wirk, B.] SUNY Stony Brook, Dept Internal Med, Med Ctr, Stony Brook, NY 11794 USA. [Bunjes, D. W.] Univ Ulm Klinikum, Dept Internal Med 3, Ulm, Germany. [Devine, S. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Columbus, OH 43210 USA. [Weisdorf, D. J.] Univ Minnesota, Dept Med, Med Ctr, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA. [Uy, G. L.] Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA. RP Uy, GL (reprint author), Washington Univ, Dept Med, Sch Med, 660 South Euclid Ave,Campus Box 8007, St Louis, MO 63110 USA. EM guy@dom.wustl.edu FU NCI NIH HHS [K23 CA140707, U24 CA076518, U24-CA076518]; NHLBI NIH HHS [5U10HL069294, U10 HL069294]; PHS HHS [HHSH250201200016C] NR 17 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD AUG PY 2015 VL 50 IS 8 BP 1057 EP 1062 DI 10.1038/bmt.2015.82 PG 6 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA CR2MM UT WOS:000361164200005 PM 25915806 ER PT J AU Friedberg, MW Rosenthal, MB Werner, RM Volpp, KG Schneider, EC AF Friedberg, Mark W. Rosenthal, Meredith B. Werner, Rachel M. Volpp, Kevin G. Schneider, Eric C. TI Effects of a Medical Home and Shared Savings Intervention on Quality and Utilization of Care SO JAMA INTERNAL MEDICINE LA English DT Article ID LONGITUDINAL DATA-ANALYSIS; PATIENT SATISFACTION; EFFICIENCY; PROVIDERS; FEATURES; BURNOUT; COSTS AB IMPORTANCE Published evaluations of medical home interventions have found limited effects on quality and utilization of care. OBJECTIVE To measure associations between participation in the Northeastern Pennsylvania Chronic Care Initiative and changes in quality and utilization of care. DESIGN, SETTING, AND PARTICIPANTS The northeast region of the Pennsylvania Chronic Care Initiative began in October 2009, included 2 commercial health plans and 27 volunteering small primary care practice sites, and was designed to run for 36 months. Both participating health plans provided medical claims and enrollment data spanning October 1, 2007, to September 30, 2012 (2 years prior to and 3 years after the pilot inception date). We analyzed medical claims for 17 363 patients attributed to 27 pilot and 29 comparison practices, using difference-in-difference methods to estimate changes in quality and utilization of care associated with pilot participation. EXPOSURES The intervention included learning collaboratives, disease registries, practice coaching, payments to support care manager salaries and practice transformation, and shared savings incentives (bonuses of up to 50% of any savings generated, contingent on meeting quality targets). As a condition of participation, pilot practices were required to attain recognition by the National Committee for Quality Assurance as medical homes. MAIN OUTCOMES AND MEASURES Performance on 6 quality measures for diabetes and preventive care; utilization of hospital, emergency department, and ambulatory care. RESULTS All pilot practices received recognition as medical homes during the intervention. By intervention year 3, relative to comparison practices, pilot practices had statistically significantly better performance on 4 process measures of diabetes care and breast cancer screening; lower rates of all-cause hospitalization (8.5 vs 10.2 per 1000 patients per month; difference, -1.7 [95% CI, -3.2 to -0.03]), lower rates of all-cause emergency department visits (29.5 vs 34.2 per 1000 patients per month; difference, -4.7 [95% CI, -8.7 to -0.9]), lower rates of ambulatory care-sensitive emergency department visits (16.2 vs 19.4 per 1000 patients per month; difference, -3.2 [95% CI, -5.7 to -0.9]), lower rates of ambulatory visits to specialists (104.9 vs 122.2 per 1000 patients per month; difference, -17.3 [95% CI, -26.6 to -8.0]); and higher rates of ambulatory primary care visits (349.0 vs 271.5 per 1000 patients per month; difference, 77.5 [95% CI, 37.3 to 120.5]). CONCLUSIONS AND RELEVANCE During a 3-year period, this medical home intervention, which included shared savings for participating practices, was associated with relative improvements in quality, increased primary care utilization, and lower use of emergency department, hospital, and specialty care. With further experimentation and evaluation, such interventions may continue to become more effective. C1 [Friedberg, Mark W.; Schneider, Eric C.] RAND Corp, Boston, MA USA. [Friedberg, Mark W.; Schneider, Eric C.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. [Friedberg, Mark W.; Schneider, Eric C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Rosenthal, Meredith B.; Schneider, Eric C.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Werner, Rachel M.; Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Werner, Rachel M.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Wharton Business Sch, Dept Hlth Care Management, Philadelphia, PA USA. [Volpp, Kevin G.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA. RP Friedberg, MW (reprint author), 20 Pk Plaza,Ste 920, Boston, MA 02116 USA. EM mfriedbe@rand.org OI Schneider, Eric/0000-0002-1132-5084 FU Commonwealth Fund FX This study was sponsored by the Commonwealth Fund. NR 26 TC 23 Z9 23 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD AUG PY 2015 VL 175 IS 8 BP 1362 EP 1368 DI 10.1001/jamainternmed.2015.2047 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CR1BL UT WOS:000361057700023 PM 26030123 ER PT J AU Tiet, QQ Leyva, YE Moos, RH Frayne, SM Osterberg, L Smith, B AF Tiet, Quyen Q. Leyva, Yani E. Moos, Rudolf H. Frayne, Susan M. Osterberg, Lars Smith, Brandy TI Screen of Drug Use Diagnostic Accuracy of a New Brief Tool for Primary Care SO JAMA INTERNAL MEDICINE LA English DT Article ID NEUROPSYCHIATRIC INTERVIEW MINI; RANDOMIZED CLINICAL-TRIAL; BRIEF INTERVENTION; USE DISORDERS; ALCOHOL; SETTINGS; INSTRUMENTS; RELIABILITY; VALIDATION; VALIDITY AB IMPORTANCE Illicit drug use is prevalent, and primary care provides an ideal setting in which to screen for drug use disorders (DUDs) and negative consequences of drug use (NCDU). Comprehensive reviews have concluded that existing drug use screening instruments are not appropriate for routine use in primary care. OBJECTIVE To develop and validate a screening instrument for drug use. DESIGN, SETTING, AND PARTICIPANTS We revised items drawn from existing screening instruments and conducted signal detection analyses to develop the new instrument. We approached 3173 patients at 2 primary care clinics in a US Department of Veterans Affairs health care system from February 1, 2012, through April 30, 2014. A total of 1300 (41.0%) patients consented to the study, of whom 1283 adults were eligible (mean [SD] age, 62.2 [12.6] years). In the last 12 months, 241 (18.8%) participants reported using illicit drugs or prescription medication for a nonmedical purpose, and 189 (14.7%) reported 1 or more NCDU. A total of 133 (10.4%) patients met DSM-IV criteria for a DUD. The sample was randomly divided first to develop the measure and then to validate it. MAIN OUTCOMES AND MEASURES The Mini-International Diagnostic Interview was used as the criterion for DUDs, and the Inventory of Drug Use Consequences was used as the criterion for NCDU. RESULTS The screening instrument has 2 questions. The first is, "How many days in the past 12 months have you used drugs other than alcohol?" Patients meet that criterion with a response of 7 or more days. The second question asks, "How many days in the past 12 months have you used drugs more than you meant to?" A response of 2 or more days meets that criterion. The screening instrument was 100% sensitive and 93.73% specific for DUDs (643 patients); when replicated in the second half of the sample (640 patients), it was 92.31% sensitive and 92.87% specific. The screening instrument was 93.18% sensitive and 96.03% specific for NCDU (643 patients); when replicated in the second half of the sample (640 patients), it was 83.17% sensitive and 96.85% specific. CONCLUSIONS AND RELEVANCE The 2-item screen of drug use has excellent statistical properties and is a brief screening instrument for DUDs and problems suitable for busy US Department of Veterans Affairs primary care clinics. C1 [Tiet, Quyen Q.; Leyva, Yani E.; Moos, Rudolf H.; Frayne, Susan M.; Smith, Brandy] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA. [Tiet, Quyen Q.; Leyva, Yani E.; Smith, Brandy] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA 94025 USA. [Tiet, Quyen Q.; Moos, Rudolf H.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Tiet, Quyen Q.] Alliant Int Univ, Calif Sch Profess Psychol, Clin Psychol PhD Program, San Francisco, CA USA. [Leyva, Yani E.] San Francisco VA Med Ctr, Div Res, San Francisco, CA USA. [Frayne, Susan M.; Osterberg, Lars] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Osterberg, Lars] VA Palo Alto Hlth Care Syst, Gen Internal Med, Palo Alto, CA USA. RP Tiet, QQ (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM quyen.tiet@va.gov FU Department of Veterans Affairs, Health Services Research and Development [IIR 10-347] FX Dr Tiet reported receiving grant IIR 10-347 from the Department of Veterans Affairs, Health Services Research and Development. NR 31 TC 5 Z9 5 U1 2 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD AUG PY 2015 VL 175 IS 8 BP 1371 EP 1377 DI 10.1001/jamainternmed.2015.2438 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CR1BL UT WOS:000361057700025 PM 26075352 ER PT J AU Subak, LL King, WC Belle, SH Chen, JY Courcoulas, AP Ebel, FE Flum, DR Khandelwal, S Pender, JR Pierson, SK Pories, WJ Steffen, KJ Strain, GW Wolfe, BM Huang, AJ AF Subak, Leslee L. King, Wendy C. Belle, Steven H. Chen, Jia-Yuh Courcoulas, Anita P. Ebel, Faith E. Flum, David R. Khandelwal, Saurabh Pender, John R. Pierson, Sheila K. Pories, Walter J. Steffen, Kristine J. Strain, Gladys W. Wolfe, Bruce M. Huang, Alison J. TI Urinary Incontinence Before and After Bariatric Surgery SO JAMA INTERNAL MEDICINE LA English DT Article ID PELVIC FLOOR DISORDERS; WEIGHT-LOSS SURGERY; MIDDLE-AGED WOMEN; QUALITY-OF-LIFE; OBESE WOMEN; OLDER WOMEN; UNITED-STATES; FECAL INCONTINENCE; PHYSICAL-ACTIVITY; RISK-FACTORS AB IMPORTANCE Among women and men with severe obesity, evidence for improvement in urinary incontinence beyond the first year after bariatric surgery-induced weight loss is lacking. OBJECTIVES To examine change in urinary incontinence before and after bariatric surgery and to identify factors associated with improvement and remission among women and men in the first 3 years after bariatric surgery. DESIGN, SETTING, AND PARTICIPANTS The Longitudinal Assessment of Bariatric Surgery 2 is an observational cohort study at 10 US hospitals in 6 geographically diverse clinical centers. Participants were recruited between February 21, 2005, and February 17, 2009. Adults undergoing first-time bariatric surgical procedures as part of clinical care by participating surgeons between March 14, 2006, and April 24, 2009, were followed up for 3 years (through October 24, 2012). INTERVENTION Participants undergoing bariatric surgery completed research assessments before the procedure and annually thereafter. MAIN OUTCOMES AND MEASURES The frequency and type of urinary incontinence episodes in the past 3 months were assessed using a validated questionnaire. Prevalent urinary incontinence was defined as at least weekly urinary incontinence episodes, and remission was defined as change from prevalent urinary incontinence at baseline to less than weekly urinary incontinence episodes at follow-up. RESULTS Of 2458 participants, 1987 (80.8%) completed baseline and follow-up assessments. At baseline, the median age was 47 years (age range, 18-78 years), the median body mass index was 46 kg/m(2) (range, 34-94 kg/m(2)), and 1565 of 1987 (78.8%) were women. Urinary incontinence was more prevalent among women (49.3%; 95% CI, 46.9%-51.9%) than men (21.8%; 95% CI, 18.2%-26.1%) (P <.001). After a mean 1-year weight loss of 29.5%(95% CI, 29.0%-30.1%) in women and 27.0%(95% CI, 25.9%-28.6%) in men, year 1 urinary incontinence prevalence was significantly lower among women (18.3%; 95% CI, 16.4%-20.4%) and men (9.8%; 95% CI, 7.2%-13.4%) (P <.001 for all). The 3-year prevalence was higher than the 1-year prevalence for both sexes (24.8%; 95% CI, 21.8%-26.5% among women and 12.2%; 95% CI, 9.0%-16.4% among men) but was substantially lower than baseline (P <.001 for all). Weight loss was independently related to urinary incontinence remission (relative risk, 1.08; 95% CI, 1.06-1.10 in women and 1.07; 95% CI, 1.02-1.13 in men) per 5% weight loss, as were younger age and the absence of a severe walking limitation. CONCLUSIONS AND RELEVANCE Among women and men with severe obesity, bariatric surgery was associated with substantially reduced urinary incontinence over 3 years. Improvement in urinary incontinence may be an important benefit of bariatric surgery. C1 [Subak, Leslee L.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Subak, Leslee L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Subak, Leslee L.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Subak, Leslee L.] San Francisco VA Med Ctr, San Francisco, CA USA. [King, Wendy C.; Belle, Steven H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Belle, Steven H.; Chen, Jia-Yuh] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Courcoulas, Anita P.; Pierson, Sheila K.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA. [Ebel, Faith E.; Strain, Gladys W.] Weill Cornell Med Coll, GI Metab & Bariatr Surg, New York, NY USA. [Flum, David R.; Khandelwal, Saurabh] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Pender, John R.; Pories, Walter J.] E Carolina Univ, Brody Sch Med, Dept Surg, Greenville, NC USA. [Steffen, Kristine J.] Univ N Dakota, Sch Med & Hlth Sci, Neuropsychiat Res Unit, Dept Neurosci, Grand Forks, ND 58201 USA. RP Subak, LL (reprint author), Univ Calif San Francisco, UCSF Womens Hlth Clin Res Ctr, Dept Obstet Gynecol & Reprod Sci, 550 16th St,Sixth Floor,Mailstop 1793, San Francisco, CA 94143 USA. EM leslee.subak@ucsf.edu OI King, Wendy/0000-0002-0740-0029 FU National Institute of Diabetes and Digestive and Kidney Diseases [U01 DK066557, U01-DK66667, UL1-RR024996, U01-DK66568, M01RR-00037, U01-DK66471, U01-DK66526, U01-DK66585, UL1-RR024153, U01-DK66555, K24 DK080775] FX The Longitudinal Assessment of Bariatric Surgery 2 represents a cooperative agreement funded by the National Institute of Diabetes and Digestive and Kidney Diseases, including the following grant numbers: grant U01 DK066557 (Data Coordinating Center), grant U01-DK66667 (Columbia University Medical Center) in collaboration with grant UL1-RR024996 (Cornell University Medical Center), grant U01-DK66568 (University of Washington) in collaboration with grant M01RR-00037 (Cornell University Medical Center), grant U01-DK66471 (Neuropsychiatric Research Institute), grant U01-DK66526 (East Carolina University), grant U01-DK66585 (University of Pittsburgh Medical Center) in collaboration with grant UL1-RR024153 (Cornell University Medical Center), and grant U01-DK66555 (Oregon Health & Science University). Dr Subak is the recipient of grant K24 DK080775 from the National Institute of Diabetes and Digestive and Kidney Diseases. NR 43 TC 12 Z9 12 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD AUG PY 2015 VL 175 IS 8 BP 1378 EP 1387 DI 10.1001/jamainternmed.2015.2609 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CR1BL UT WOS:000361057700027 PM 26098620 ER PT J AU Folmer, RL Theodoroff, SM Casiana, L Shi, YB Griest, S Vachhani, J AF Folmer, Robert L. Theodoroff, Sarah M. Casiana, Linda Shi, Yongbing Griest, Susan Vachhani, Jay TI Repetitive Transcranial Magnetic Stimulation Treatment for Chronic Tinnitus A Randomized Clinical Trial SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID QUALITY-OF-LIFE; TEMPOROPARIETAL JUNCTION; AUDITORY-CORTEX; DEPRESSION; MANAGEMENT; DISTRESS; INDEX; RTMS AB IMPORTANCE Chronic tinnitus negatively affects the quality of life for millions of people. This clinical trial assesses a potential treatment for tinnitus. OBJECTIVES To determine if repetitive transcranial magnetic stimulation (rTMS) can reduce the perception or severity of tinnitus and to test the hypothesis that rTMS will result in a statistically significantly greater percentage of responders to treatment in an active rTMS group compared with a placebo rTMS group. DESIGN, SETTING, AND PARTICIPANTS A randomized, participant and clinician or observer-blinded, placebo-controlled clinical trial of rTMS involving individuals who experience chronic tinnitus. Follow-up assessments were conducted at 1, 2, 4, 13, and 26 weeks after the last treatment session. The trial was conducted between April 2011 and December 2014 at Portland Veterans Affairs Medical Center among 348 individuals with chronic tinnitus who were initially screened for participation. Of those, 92 provided informed consent and underwent more detailed assessments. Seventy individuals met criteria for inclusion and were randomized to receive active or placebo rTMS. Sixty-four participants (51 men and 13 women, with a mean [SD] age of 60.6 [8.9] years) were included in the data analyses. No participants withdrew because of adverse effects of rTMS. INTERVENTIONS Participants received 2000 pulses per session of active or placebo rTMS at a rate of 1-Hz rTMS daily on 10 consecutive workdays. MAIN OUTCOMES AND MEASURES The Tinnitus Functional Index (TFI) was the main study outcome. Our hypothesis was tested by comparing baseline and posttreatment TFIs for each participant and group. RESULTS Overall, 18 of 32 participants (56%) in the active rTMS group and 7 of 32 participants (22%) in the placebo rTMS group were responders to rTMS treatment. The difference in the percentage of responders to treatment in each group was statistically significant (chi(2)(1) = 7.94, P < .005). CONCLUSIONS AND RELEVANCE Application of 1-Hz rTMS daily for 10 consecutive workdays resulted in a statistically significantly greater percentage of responders to treatment in the active rTMS group compared with the placebo rTMS group. Improvements in tinnitus severity experienced by responders were sustained during the 26-week follow-up period. Before this procedure can be implemented clinically, larger studies should be conducted to refine treatment protocols. C1 [Folmer, Robert L.; Theodoroff, Sarah M.; Casiana, Linda; Shi, Yongbing; Griest, Susan; Vachhani, Jay] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Folmer, Robert L.; Theodoroff, Sarah M.; Griest, Susan] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM robert.folmer@va.gov NR 51 TC 13 Z9 13 U1 2 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD AUG PY 2015 VL 141 IS 8 BP 716 EP 722 DI 10.1001/jamaoto.2015.1219 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CR1AW UT WOS:000361056100008 PM 26181507 ER PT J AU Hempel, S Maggard-Gibbons, M Nguyen, DK Dawes, AJ Miake-Lye, I Beroes, JM Booth, MJ Miles, JNV Shanman, R Shekelle, PG AF Hempel, Susanne Maggard-Gibbons, Melinda Nguyen, David K. Dawes, Aaron J. Miake-Lye, Isomi Beroes, Jessica M. Booth, Marika J. Miles, Jeremy N. V. Shanman, Roberta Shekelle, Paul G. TI Wrong-Site Surgery, Retained Surgical Items, and Surgical Fires A Systematic Review of Surgical Never Events SO JAMA SURGERY LA English DT Review ID WRONG INTRAOCULAR-LENS; PREVENTING WRONG SITE; OPERATING-ROOM FIRES; WRONG-LEVEL SURGERY; FOREIGN-BODY LEFT; SPINE SURGERY; RISK-FACTORS; UNIVERSAL PROTOCOL; TOOTH EXTRACTION; MEDICAL-CENTER AB IMPORTANCE Serious, preventable surgical events, termed never events, continue to occur despite considerable patient safety efforts. OBJECTIVE To examine the incidence and root causes of and interventions to prevent wrong-site surgery, retained surgical items, and surgical fires in the era after the implementation of the Universal Protocol in 2004. DATA SOURCES We searched 9 electronic databases for entries from 2004 through June 30, 2014, screened references, and consulted experts. STUDY SELECTION Two independent reviewers identified relevant publications in June 2014. DATA EXTRACTION AND SYNTHESIS One reviewer used a standardized form to extract data and a second reviewer checked the data. Strength of evidence was established by the review team. Data extraction was completed in January 2015. MAIN OUTCOMES AND MEASURES Incidence of wrong-site surgery, retained surgical items, and surgical fires. RESULTS We found 138 empirical studies that met our inclusion criteria. Incidence estimates for wrong-site surgery in US settings varied by data source and procedure (median estimate, 0.09 events per 10 000 surgical procedures). The median estimate for retained surgical items was 1.32 events per 10 000 procedures, but estimates varied by item and procedure. The per-procedure surgical fire incidence is unknown. A frequently reported root cause was inadequate communication. Methodologic challenges associated with investigating changes in rare events limit the conclusions of 78 intervention evaluations. Limited evidence supported the Universal Protocol (5 studies), education (4 studies), and team training (4 studies) interventions to prevent wrong-site surgery. Limited evidence exists to prevent retained surgical items by using data-matrix-coded sponge-counting systems (5 pertinent studies). Evidence for preventing surgical fires was insufficient, and intervention effects were not estimable. CONCLUSIONS AND RELEVANCE Current estimates for wrong-site surgery and retained surgical items are 1 event per 100 000 and 1 event per 10 000 procedures, respectively, but the precision is uncertain, and the per-procedure prevalence of surgical fires is not known. Root-cause analyses suggest the need for improved communication. Despite promising approaches and global Universal Protocol evaluations, empirical evidence for interventions is limited. C1 [Hempel, Susanne; Booth, Marika J.; Shanman, Roberta] RAND Corp, Southern Calif Evidence Based Practice Ctr, Santa Monica, CA 90401 USA. [Maggard-Gibbons, Melinda; Dawes, Aaron J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Maggard-Gibbons, Melinda; Nguyen, David K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Dawes, Aaron J.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Miake-Lye, Isomi; Beroes, Jessica M.; Shekelle, Paul G.] West Los Angeles Vet Affairs Med Ctr, Evidence Based Synth Program ESP Ctr, Los Angeles, CA USA. [Miles, Jeremy N. V.] RAND Corp, RAND Hlth, Santa Monica, CA 90401 USA. RP Hempel, S (reprint author), RAND Corp, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90401 USA. EM susanne_hempel@rand.org OI Dawes, Aaron/0000-0003-4574-6765 FU Department of Veterans Affairs (VA) FX The study is based on a systematic review conducted by the Evidence-Based Synthesis Program (ESP) funded by the Department of Veterans Affairs (VA). NR 83 TC 8 Z9 8 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD AUG PY 2015 VL 150 IS 8 BP 796 EP 805 DI 10.1001/jamasurg.2015.0301 PG 10 WC Surgery SC Surgery GA CR1BO UT WOS:000361058000023 PM 26061125 ER PT J AU Narayanavari, SA Lourdault, K Sritharan, M Haake, DA Matsunaga, J AF Narayanavari, Suneel A. Lourdault, Kristel Sritharan, Manjula Haake, David A. Matsunaga, James TI Role of sph2 Gene Regulation in Hemolytic and Sphingomyelinase Activities Produced by Leptospira interrogans SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID EXTRACELLULAR RELEASE; MOLECULAR-CLONING; BINDING PROTEINS; HEME OXYGENASE; SEROVAR LAI; EXPRESSION; PATHOGENESIS; DISEASE; IRON; IDENTIFICATION AB Pathogenic members of the genus Leptospira are the causative agents of leptospirosis, a neglected disease of public and veterinary health concern. Leptospirosis is a systemic disease that in its severest forms leads to renal insufficiency, hepatic dysfunction, and pulmonary failure. Many strains of Leptospira produce hemolytic and sphingomyelinase activities, and a number of candidate leptospiral hemolysins have been identified based on sequence similarity to well-characterized bacterial hemolysins. Five of the putative hemolysins are sphingomyelinase paralogs. Although recombinant forms of the sphingomyelinase Sph2 and other hemolysins lyse erythrocytes, none have been demonstrated to contribute to the hemolytic activity secreted by leptospiral cells. In this study, we examined the regulation of sph2 and its relationship to hemolytic and sphingomyelinase activities produced by several L. interrogans strains cultivated under the osmotic conditions found in the mammalian host. The sph2 gene was poorly expressed when the Fiocruz L1-130 (serovar Copenhageni), 56601 (sv. Lai), and L495 (sv. Manilae) strains were cultivated in the standard culture medium EMJH. Raising EMJH osmolarity to physiological levels with sodium chloride enhanced Sph2 production in all three strains. In addition, the Pomona subtype kennewicki strain LC82-25 produced substantially greater amounts of Sph2 during standard EMJH growth than the other strains, and sph2 expression increased further by addition of salt. When 10% rat serum was present in EMJH along with the sodium chloride supplement, Sph2 production increased further in all strains. Osmotic regulation and differences in basal Sph2 production in the Manilae L495 and Pomona strains correlated with the levels of secreted hemolysin and sphingomyelinase activities. Finally, a transposon insertion in sph2 dramatically reduced hemolytic and sphingomyelinase activities during incubation of L. interrogans at physiologic osmolarity. Complementation of the mutation with the sph2 gene partially restored production of hemolytic and sphingomyelinase activities. These results indicate that the sph2 gene product contributes to the hemolytic and sphingomyelinase activities secreted by L. interrogans and most likely dominates those functions under the culture condition tested. C1 [Narayanavari, Suneel A.; Sritharan, Manjula] Univ Hyderabad, Dept Anim Biol, Hyderabad 500134, Andhra Pradesh, India. [Lourdault, Kristel; Matsunaga, James] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Lourdault, Kristel; Haake, David A.; Matsunaga, James] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. RP Narayanavari, SA (reprint author), Max Delbruck Ctr Mol Med, Berlin, Germany. EM jamesm@ucla.edu FU Veterans Affairs Merit Award; United States India Educational Foundation (USIEF) [15111348]; National Institutes of Health [R01 AI 034431] FX This work was supported by a Veterans Affairs Merit Award to JM, a Fulbright-Nehru Doctoral and Professional Research Fellowship (Grantee ID: 15111348) from the United States India Educational Foundation (USIEF) to SAN, and National Institutes of Health grant R01 AI 034431 to DAH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 3 Z9 3 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD AUG PY 2015 VL 9 IS 8 AR e0003952 DI 10.1371/journal.pntd.0003952 PG 23 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CQ6IO UT WOS:000360708200038 PM 26274394 ER PT J AU Caroff, SN Hurford, I Bleier, HR Gorton, GE Campbell, EC AF Caroff, Stanley N. Hurford, Irene Bleier, Henry R. Gorton, Gregg E. Campbell, E. Cabrina TI Recurrent Idiopathic Catatonia: Implications beyond the Diagnostic and Statistical Manual of Mental Disorders 5th Edition SO CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE LA English DT Article DE Catatonia; Periodic catatonia; Schizophrenia; Cycloid psychosis; Antipsychotic agents; Neuroleptic malignant syndrome ID DRUGS AB We describe a case of recurrent, life threatening, catatonic stupor, without evidence of any associated medical, toxic or mental disorder. This case provides support for the inclusion of a separate category of "unspecified catatonia" in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) to be used to classify idiopathic cases, which appears to be consistent with Kahlbaum's concept of catatonia as a distinct disease state. But beyond the limited, cross sectional, syndromal approach adopted in DSM-5, this case more importantly illustrates the prognostic and therapeutic significance of the longitudinal course of illness in differentiating cases of catatonia, which is better defined in the Wernicke-Kleist-Leonhard classification system. The importance of differentiating cases of catatonia is further supported by the efficacy of antipsychotics in treatment of this case, contrary to conventional guidelines. C1 [Caroff, Stanley N.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Caroff, SN (reprint author), Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM stanley.caroff@va.gov NR 19 TC 2 Z9 2 U1 2 U2 11 PU KOREAN COLL NEUROPSYCHOPHARMACOLOGY PI SEOUL PA RN 1003 OFFICETEL 40, 63-RO YEONGDEUNGPO-GU, SEOUL, 150-731, SOUTH KOREA SN 1738-1088 EI 2093-4327 J9 CLIN PSYCHOPHARM NEU JI Clin. Psychopharmacol. Neurosci. PD AUG PY 2015 VL 13 IS 2 BP 218 EP 221 DI 10.9758/cpn.2015.13.2.218 PG 4 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA CQ4TM UT WOS:000360597500017 PM 26243853 ER PT J AU Lukasewicz, CL Mattox, EA AF Lukasewicz, Carol L. Mattox, Elizabeth Andersson TI Understanding Clinical Alarm Safety SO CRITICAL CARE NURSE LA English DT Article ID INTENSIVE-CARE-UNIT; MONITORING ALARMS; OPERATING-ROOM; FATIGUE; BEHAVIOR; EVENTS; ICU AB Patient safety organizations and health care accreditation agencies recognize the significance of clinical alarm hazards. The Association for the Advancement of Medical Instrumentation, a nonprofit organization focused on development and use of safe and effective medical equipment, identifies alarm management as a major issue for health care organizations. ECRI Institute, a nonprofit organization that researches approaches for improving patient safety and quality of care, identifies alarm hazards as the most significant of the "Top Ten Health Technology Hazards" for 2014. A new Joint Commission National Patient Safety Goal focusing on clinical alarm safety contains new requirements for accredited hospitals to be fully implemented by 2016. Through a fictional unfolding case study, this article reviews selected contributing factors to clinical alarm hazards present in inpatient, high-acuity settings. Understanding these factors improves contributions by nurses to clinical alarm safety practice. C1 [Lukasewicz, Carol L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Mattox, Elizabeth Andersson] VA Puget Sound Hlth Care Syst, Dept Pulm & Crit Care Med, Seattle, WA USA. RP Mattox, EA (reprint author), 344 NW 103rd St, Seattle, WA 98177 USA. EM emattox@gmail.com NR 65 TC 2 Z9 3 U1 1 U2 15 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 EI 1940-8250 J9 CRIT CARE NURSE JI Crit. Care Nurse PD AUG PY 2015 VL 35 IS 4 BP 45 EP 57 DI 10.4037/ccn2015113 PG 13 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA CQ4KR UT WOS:000360574100008 PM 26232801 ER PT J AU Fisher, V Lee, D McGrath, J Krejci-Manwaring, J AF Fisher, Valerie Lee, Deborah McGrath, John Krejci-Manwaring, Jennifer TI Veterans Speak Up: Current Warnings on Skin Cancer Miss the Target, Suggestions for Improvement SO MILITARY MEDICINE LA English DT Article ID UNITED-STATES; PREVENTION AB Background: Skin cancer is the most common cancer in the world and its incidence is increasing. Veterans may have increased exposure to risk factors, but data are lacking in terms of their perceptions of skin cancer and the types of prevention strategies that might resonate with this population. Objective: This study examines veterans' awareness of the risk factors for skin cancer and importance of sun protection and seeks to identify effective communication and educational strategies for this at-risk population. Methods: A telephone survey was conducted of 100 veterans, who have been diagnosed with skin cancer at the Audie Murphy Veteran's Hospital in San Antonio, Texas. Results: The majority of respondents' said that their skin cancer resulted from sun exposure and that the best way to prevent skin cancer was to use sunscreen. However, when asked if they believed they were at risk for being diagnosed with skin cancer, most veterans responded that they believed they were at little risk. In response to why veterans did not heed warnings about skin cancer, many replied that they believed skin cancer would not happen to them. A statistically significant increase in usage of sunscreen and sun protectant garments occurred after being diagnosed with skin cancer and education by their physicians. Doctors talking to patients was rated the most effective communication method to inform them about the risks of skin cancer, followed by education during basic training. Limitations: Recall bias is the major limitation with a retrospective survey design. Discussion: Our results reveal poor patient awareness of the risks of skin cancer and the benefits of sun protection before their diagnosis. The veterans agreed that the physician-patient interaction is the best and most effective means of communication, which is evident by the significant increase in sun protection and sunscreen usage after their diagnosis. Our survey revealed that other effective communication strategies included education in basic training, the use of a veteran spokes model with skin cancer, and the use of images to emphasize the severity of the disease. C1 [Fisher, Valerie; Lee, Deborah; Krejci-Manwaring, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, Canc Therapy Res Ctr, San Antonio, TX 78229 USA. [McGrath, John; Krejci-Manwaring, Jennifer] Audie L Murphy Vet Hosp, Dept Dermatol, San Antonio, TX 78229 USA. RP Fisher, V (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, Canc Therapy Res Ctr, 7979 Wurzbach Rd,Mail Code 7876, San Antonio, TX 78229 USA. NR 14 TC 0 Z9 0 U1 1 U2 3 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD AUG PY 2015 VL 180 IS 8 BP 892 EP 897 DI 10.7205/MILMED-D-14-00318 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CQ3TE UT WOS:000360524800016 PM 26226533 ER PT J AU Zhang, Y Wu, IW Buckley, S Coffey, CS Foster, E Mendick, S Seibyl, J Schuff, N AF Zhang, Yu Wu, I-Wei Buckley, Shannon Coffey, Christopher S. Foster, Eric Mendick, Susan Seibyl, John Schuff, Norbert TI Diffusion Tensor Imaging of the Nigrostriatal Fibers in Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; MRI; diffusion tensor imaging; diffusion tensor tractography; nigrostriatal pathway ID STRIATAL DOPAMINE TRANSPORTERS; SUBSTANTIA-NIGRA; BASAL GANGLIA; NEUROTROPHIC FACTOR; BRAIN; CONNECTIVITY; TRACTOGRAPHY; PROGRESSION; DISORDERS; INFUSION AB Background: Parkinson's disease (PD) is histopathologically characterized by the loss of dopamine neurons in the substantia nigra pars cornpacta. The depletion of these neurons is thought to reduce the dopaminergic function of the nigrostriatal pathway, as well as the neural fibers that link the substantia nigra to the striatum (putamen and caudate), causing a dysregulation in striatal activity that ultimately leads to lack of movement control. Based on diffusion tensor imaging, visualizing this pathway and measuring alterations of the fiber integrity remain challenging. The objectives were to 1) develop a diffusion tensor tractography protocol for reliably tracking the nigrostriatal fibers on multicenter data; 2) test whether the integrities measured by diffusion tensor imaging of the nigrostriatal fibers are abnormal in PD; and 3) test whether abnormal integrities of the nigrostriatal fibers in PD patients are associated with the severity of motor disability and putarninal dopamine binding ratios. Methods: Diffusion tensor tractography was performed on 50 drug-naive PD patients and 27 healthy control subjects from the international multicenter Parkinson's Progression Marker Initiative. Results: Tractography consistently detected the nigrostriatal fibers, yielding reliable diffusion measures. Fractional anisotropy, along with radial and axial diffusivity of the nigrostriatal tract, showed systematic abnormalities in patients. In addition, variations in fractional anisotropy and radial diffusivity of the nigrostriatal tract were associated with the degree of motor deficits in PD patients. Conclusion: Taken together, the findings imply that the diffusion tensor imaging characteristic of the nigrostriatal tract is potentially an index for detecting and staging of early PD. 2015 International Parkinson and Movement Disorder Society C1 [Zhang, Yu; Wu, I-Wei; Buckley, Shannon; Schuff, Norbert] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Zhang, Yu; Wu, I-Wei; Buckley, Shannon; Schuff, Norbert] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Coffey, Christopher S.; Foster, Eric] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA. [Mendick, Susan; Seibyl, John] IND, New Haven, CT USA. [Mendick, Susan; Seibyl, John] Mol NeuroImaging LLC MNI, New Haven, CT USA. RP Zhang, Y (reprint author), Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St,Mail Stop 114M, San Francisco, CA 94121 USA. EM Yu.Zhang@ucsf.edu FU Parkinson's Progression Marker Initiative (PPMI) group; Michael J. Fox Foundation for Parkinson's Research (MJFF); MJFF; Abbot; Avid Radiopharmaceuticals; Biogen Idec; Bristol-Myers Squibb; Covance; Elan Corporation; Eli Lilly Co.; F. Hoffman-La Roche, Ltd.; GE Healthcare; Genentech; GlaxoSmithKline; Lundbeck; Merck; MesoScale; Pfizer; UCB; NIH [P41 EB015904] FX The study was supported by the funding partners of the Parkinson's Progression Marker Initiative (PPMI) group. PPMI is sponsored by the Michael J. Fox Foundation for Parkinson's Research (MJFF) and is co-funded by MJFF, Abbot, Avid Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, Elan Corporation, Eli Lilly & Co., F. Hoffman-La Roche, Ltd., GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, MesoScale, Pfizer and UCB. The study was also supported by an NIH grant (P41 EB015904). NR 39 TC 11 Z9 11 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD AUG PY 2015 VL 30 IS 9 BP 1229 EP 1236 DI 10.1002/mds.26251 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CQ7BY UT WOS:000360759000012 PM 25920732 ER PT J AU Ali, SK Malakouti, M AF Ali, Sayed K. Malakouti, Mazyar TI The family meeting SO PALLIATIVE & SUPPORTIVE CARE LA English DT Editorial Material C1 [Ali, Sayed K.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Malakouti, Mazyar] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Ali, SK (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Sayed.ali@va.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 EI 1478-9523 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD AUG PY 2015 VL 13 IS 4 BP 1135 EP 1136 DI 10.1017/S1478951514000984 PG 2 WC Health Policy & Services SC Health Care Sciences & Services GA CQ5FQ UT WOS:000360629100037 PM 25159138 ER PT J AU Xu, SP Chheda, C Ouhaddi, Y Benhaddou, H Bourhim, M Grippo, PJ Principe, DR Mascarinas, E DeCant, B Tsukamoto, H Pandol, SJ Edderkaoui, M AF Xu, Shiping Chheda, Chintan Ouhaddi, Yassine Benhaddou, Hajar Bourhim, Mouloud Grippo, Paul J. Principe, Daniel R. Mascarinas, Emman DeCant, Brian Tsukamoto, Hidekazu Pandol, Stephen J. Edderkaoui, Mouad TI Characterization of Mouse Models of Early Pancreatic Lesions Induced by Alcohol and Chronic Pancreatitis SO PANCREAS LA English DT Article DE alcohol; chronic pancreatitis; pancreatic cancer ID EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; HISTONE DEACETYLASES; CARCINOMA CELLS; STELLATE CELLS; CANCER; INTERLEUKIN-6; INFLAMMATION; FIBROSIS; DIFFERENTIATION AB Objective We describe the first mouse model of pancreatic intraepithelial neoplasia (PanIN) lesions induced by alcohol in the presence and absence of chronic pancreatitis. Methods Pdx1-Cre;LSL-K-ras mice were exposed to Lieber-DeCarli alcohol diet for 6 weeks with cerulein injections. The PanIN lesions and markers of fibrosis, inflammation, histone deacetylation, epithelial-to-mesenchymal transition (EMT), and cancer stemness were measured by immunohistochemistry and Western. Results Exposure of Pdx1-Cre;LSL-K-ras mice to an alcohol diet significantly stimulated fibrosis and slightly but not significantly increased the level of PanIN lesions associated with an increase in tumor-promoting M2 macrophages. Importantly, the alcohol diet did not increase activation of stellate cells. Alcohol diet and cerulein injections resulted in synergistic and additive effects on PanIN lesion and M2 macrophage phenotype induction, respectively. Cerulein pancreatitis caused stellate cell activation, EMT, and cancer stemness in the pancreas. Pancreatitis caused histone deacetylation, which was promoted by the alcohol diet. Pancreatitis increased EMT and cancer stemness markers, which were not further affected by the alcohol diet. Conclusions The results suggest that alcohol has independent effects on promotion of PDAC associated with fibrosis formed through a stellate cell-independent mechanism and that it further promotes early PDAC and M2 macrophage induction in the context of chronic pancreatitis. C1 [Xu, Shiping; Pandol, Stephen J.; Edderkaoui, Mouad] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Xu, Shiping] Peoples Liberat Army Gen Hosp, Dept Gastroenterol, Nanlou Div, Beijing, Peoples R China. [Chheda, Chintan; Ouhaddi, Yassine; Benhaddou, Hajar; Pandol, Stephen J.; Edderkaoui, Mouad] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Chheda, Chintan; Ouhaddi, Yassine; Benhaddou, Hajar; Pandol, Stephen J.; Edderkaoui, Mouad] Cedars Sinai Med Ctr, Dept Biol Sci, Los Angeles, CA 90048 USA. [Ouhaddi, Yassine; Benhaddou, Hajar; Bourhim, Mouloud] Univ Mohamed Ben Abdellah, Fac Sci Dhar el Mehraz, Fes, Morocco. [Grippo, Paul J.; Principe, Daniel R.; Mascarinas, Emman; DeCant, Brian] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Grippo, Paul J.; Principe, Daniel R.; Mascarinas, Emman; DeCant, Brian] Univ Illinois, Dept Med, Chicago, IL USA. [Tsukamoto, Hidekazu] Univ So Calif, Keck Sch Med, Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA 90033 USA. RP Edderkaoui, M (reprint author), 8700 Beverly Blvd,Davis Bldg,Suite 3100, Los Angeles, CA 90048 USA. EM mouad.edderkaoui@cshs.org FU National Institute on Alcohol Abuse and Alcoholism [K01AA019996]; National Cancer Institute [P01CA163200]; Department of Veterans Affairs; [P50AA011999] FX This study was supported by the National Institute on Alcohol Abuse and Alcoholism grant K01AA019996 (M.E.), the P50AA011999 grant (H.T.), the National Cancer Institute grant P01CA163200 (S.J.P.), and Merit Review awards from the Department of Veterans Affairs (S.J.P., H.T.). NR 40 TC 2 Z9 2 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD AUG PY 2015 VL 44 IS 6 BP 882 EP 887 DI 10.1097/MPA.0000000000000380 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CQ5FL UT WOS:000360628600005 PM 26166469 ER PT J AU Khazanie, P Heizer, GM Hasselblad, V Armstrong, PW Califf, RM Ezekowitz, J Dickstein, K Levy, WC McMurray, JJV Metra, M Tang, WHW Teerlink, JR Voors, AA O'Connor, CM Hernandez, AF Starling, R AF Khazanie, Prateeti Heizer, Gretchen M. Hasselblad, Vic Armstrong, Paul W. Califf, Robert M. Ezekowitz, Justin Dickstein, Kenneth Levy, Wayne C. McMurray, John J. V. Metra, Marco Tang, W. H. Wilson Teerlink, John R. Voors, Adriaan A. O'Connor, Christopher M. Hernandez, Adrian F. Starling, Randall TI Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models SO AMERICAN HEART JOURNAL LA English DT Article ID NATIONAL REGISTRY ADHERE; WORSENING RENAL-FUNCTION; RISK STRATIFICATION; OPTIMIZE-HF; MORTALITY; IMPACT; TRIAL; HYPONATREMIA; ADMISSION; SURVIVAL AB Background Patients hospitalized for acute decompensated heart failure (ADHF) are at high risk for early mortality and rehospitalization. Risk stratification of ADHF using clinically available data on admission is increasingly important to integrate with clinical pathways. Our goal was to create a simple method of screening patients upon admission to identify those with increased risk of future adverse events. Methods Using ASCEND-HF, a pragmatic clinical trial conducted in 398 sites globally, we developed and validated logistic regression risk models for (a) 30-day mortality/HF rehospitalization, (b) 30-day mortality/all-cause rehospitalization, (c) 30-day all-cause mortality, and (d) 180-day all-cause mortality. Fifty-one candidate variables were evaluated based on prior publications and clinical review. Final models were selected based on stepwise selection with entry and a staying criterion of P < .01. The 30-day mortality model was externally validated, and coefficients were converted to an additive risk score. Results Among 7,141 patients, the median age was 67 years, 34% were female, and 80% had a left ventricular ejection fraction <40%. The models had between 5 and 12 risk factors with c-indices ranging from 0.68 to 0.75. A simplified score, including age, systolic blood pressure, sodium, blood urea nitrogen, and dyspnea at rest, discriminated 30-day mortality risk from 0.5% (score 0) to 53% (score 10). Conclusions Commonly available clinical variables provide simple risk stratification for clinical outcomes among patients with ADHF, and these models may be considered for integration into routine clinical care. C1 [Khazanie, Prateeti; Heizer, Gretchen M.; Hasselblad, Vic; Califf, Robert M.; O'Connor, Christopher M.; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC 27715 USA. [Khazanie, Prateeti; Califf, Robert M.; O'Connor, Christopher M.; Hernandez, Adrian F.] Duke Univ, Sch Med, Durham, NC USA. [Armstrong, Paul W.; Ezekowitz, Justin] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada. [Dickstein, Kenneth] Univ Bergen, Stavenger Univ Hosp, Bergen, Norway. [Levy, Wayne C.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [McMurray, John J. V.] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Metra, Marco] Univ Brescia, Inst Cardiol, Brescia, Italy. [Tang, W. H. Wilson; Starling, Randall] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. RP Khazanie, P (reprint author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA. EM prateeti.khazanie@duke.edu RI Hernandez, Adrian F./A-7818-2016 OI Hernandez, Adrian F./0000-0003-3387-9616; Metra, Marco/0000-0001-6691-8568; mcmurray, john/0000-0002-6317-3975 FU Scios FX ASCEND-HF was supported by Scios. NR 34 TC 10 Z9 10 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD AUG PY 2015 VL 170 IS 2 BP 290 EP U128 DI 10.1016/j.ahj.2015.04.006 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CQ1LV UT WOS:000360360100016 PM 26299226 ER PT J AU Corrales-Medina, VF Taljaard, M Yende, S Kronmal, R Dwivedi, G Newman, AB Elkind, MSV Lyles, MF Chirinos, JA AF Corrales-Medina, Vicente F. Taljaard, Monica Yende, Sachin Kronmal, Richard Dwivedi, Girish Newman, Anne B. Elkind, Mitchell S. V. Lyles, Mary F. Chirinos, Julio A. TI Intermediate and long-term risk of new-onset heart failure after hospitalization for pneumonia in elderly adults SO AMERICAN HEART JOURNAL LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; INFLAMMATORY MARKERS; EJECTION FRACTION; OLDER AMERICANS; MORTALITY; EPIDEMIOLOGY; FRACTURE; SEPSIS; ASSOCIATION; MORBIDITY AB Background Pneumonia is associated with high risk of heart failure (HF) in the short term (30 days) postinfection. Whether this association persists beyond this period is unknown. Methods We studied 5,613 elderly (>= 65 years) adults enrolled in the Cardiovascular Health Study between 1989 and 1994 at 4 US communities. Participants had no clinical diagnosis of HF at enrollment, and they were followed up through December 2010. Hospitalizations for pneumonia were identified using validated International Classification of Disease Ninth Revision codes. A centralized committee adjudicated new-onset HF events. Using Cox regression, we estimated adjusted hazard ratios (HRs) of new-onset HF at different time intervals after hospitalization for pneumonia. Results A total of 652 participants hospitalized for pneumonia during follow-up were still alive and free of clinical diagnosis of HF by day 30 posthospitalization. Relative to the time of their hospitalization, new-onset HF occurred in 22 cases between 31 and 90 days (HR 6.9, 95% CI 4.46-10.63, P < .001), 14 cases between 91 days and 6 months (HR 3.2, 95% CI 1.88-5.50, P < .001), 20 cases between 6 months and 1 year (HR 2.6, 95% CI 1.64-4.04, P < .001), 76 cases between 1 and 5 years (HR 1.7, 95% CI 1.30-2.12, P < .001), and 71 cases after 5 years (HR 2.0, 95% CI 1.56-2.58, P < .001). Results were robust to sensitivity analyses using stringent definitions of pneumonia and extreme assumptions for potential informative censoring. Conclusion Hospitalization for pneumonia is associated with increased risk of new-onset HF in the intermediate and long term. Studies should characterize the mechanisms of this association in order to prevent HF in elderly pneumonia survivors. C1 [Corrales-Medina, Vicente F.; Taljaard, Monica; Dwivedi, Girish] Ottawa Hosp Res Inst, Ottawa, ON, Canada. [Corrales-Medina, Vicente F.; Dwivedi, Girish] Univ Ottawa, Dept Med, Ottawa, ON K1Y 4E9, Canada. [Taljaard, Monica] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1Y 4E9, Canada. [Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. [Kronmal, Richard] Univ Washington, Dept Stat, Seattle, WA 98195 USA. [Dwivedi, Girish] Univ Ottawa, Inst Heart, Ottawa, ON K1Y 4E9, Canada. [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Elkind, Mitchell S. V.] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA. [Elkind, Mitchell S. V.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Lyles, Mary F.] Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA. [Chirinos, Julio A.] Univ Penn, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Corrales-Medina, VF (reprint author), Univ Ottawa, Dept Med, 1053 Carling Ave,CPC 470, Ottawa, ON K1Y 4E9, Canada. EM vcorrales@toh.on.ca RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Corrales-Medina, Vicente/0000-0002-9691-491X FU National Heart, Lung, and Blood Institute [HL080295, HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086]; National Institute of Neurological Disorders and Stroke; National Institute on Aging [AG023629]; Department of Medicine of The Ottawa Hospital; Ottawa Hospital Research Institute in Ottawa, Ontario, Canada; [K23GM083215] FX CHS was supported by contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and Grant HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by AG023629 from the National Institute on Aging. A full list of principal CHS investigators and institutions can be found at CHS-NHLB.org. Dr Corrales-Medina is supported by a Recruitment Award from the Department of Medicine of The Ottawa Hospital and the Ottawa Hospital Research Institute in Ottawa, Ontario, Canada. Dr Yende is supported by K23GM083215. NR 38 TC 8 Z9 8 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD AUG PY 2015 VL 170 IS 2 BP 306 EP U149 DI 10.1016/j.ahj.2015.04.028 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CQ1LV UT WOS:000360360100018 PM 26299228 ER PT J AU Jones, WS Patel, MR Tsai, TT Go, AS Gupta, R Hedayati, N Ho, PM Jazaeri, O Rehring, TF Rogers, RK Shetterly, SM Wagner, NM Magid, DJ AF Jones, W. Schuyler Patel, Manesh R. Tsai, Thomas T. Go, Alan S. Gupta, Rajan Hedayati, Nasim Ho, P. Michael Jazaeri, Omid Rehring, Thomas F. Rogers, R. Kevin Shetterly, Susan M. Wagner, Nicole M. Magid, David J. TI Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization SO AMERICAN HEART JOURNAL LA English DT Article ID ANKLE-BRACHIAL INDEX; CRITICAL LIMB ISCHEMIA; MYOCARDIAL-INFARCTION; SUPERVISED EXERCISE; VASCULAR-SURGERY; BYPASS-SURGERY; HIGH MORTALITY; ANGIOPLASTY; THERAPY; INTERVENTIONS AB Background Although the presence, extent, and severity of obstruction in patients with lower extremity peripheral artery disease (LE PAD) affect their functional status, quality of life, and treatment, it is not known if these factors are associated with future cardiovascular events. We empirically created an anatomic runoff score (ARS) to approximate the burden of LE PAD and determined its association with clinical outcomes. Methods We evaluated all patients with LE PAD and bilateral angiography undergoing revascularization in a community-based clinical study. Primary clinical outcomes of interest were (1) a composite of all-cause death, myocardial infarction (MI), and stroke and (2) amputation-free survival. Cox proportional hazards models were created to identify predictors of clinical outcomes. Results We evaluated 908 patients undergoing angiography, and a total of 260 (28.0%) patients reached the composite end point (45 MI, 63 stroke, and 152 death) during the study period. Anatomic runoff score ranged from 0 to 15 (mean 4.7; SD 2.5) with higher scores indicating a higher burden of disease, and an optimal cutpoint analysis classified patients into low ARS (<5) and high ARS (>= 5). The unadjusted rates of the primary composite end point and amputation-free survival were nearly 2-fold higher in patients with a high ARS when compared with patients with a low ARS. The most significant predictors of the composite end point (death/MI/stroke) were age (delta 10 years; hazard ratio [HR] 1.53; CI 1.32-1.78; P < .001), diabetes mellitus (HR 1.65; CI 1.26-2.18; P < .001), glomerular filtration rate <30 (HR 2.23; CI 1.44-3.44; P < .001), statin use (HR 0.66; CI 0.48-0.88; P < .001), and ARS (d 2 points; HR 1.21; CI 1.08-1.35; P < .001). Conclusions After adjustment for clinical factors, the LE PAD ARS was an independent predictor of future cardiovascular morbidity and mortality in a broadly representative patient population undergoing revascularization for symptomatic PAD. A clinically useful anatomic scoring system, if validated, may assist clinicians in risk stratification during the course of clinical decision making. C1 [Jones, W. Schuyler; Patel, Manesh R.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA. [Jones, W. Schuyler; Patel, Manesh R.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Tsai, Thomas T.; Ho, P. Michael; Rehring, Thomas F.] Kaiser Permanente Colorado, Div Cardiol, Denver, CO USA. [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Tsai, Thomas T.; Gupta, Rajan; Ho, P. Michael; Rogers, R. Kevin] Univ Colorado, Denver, CO 80202 USA. [Hedayati, Nasim] Univ Calif Davis, Med Ctr, Div Vasc & Endovasc Surg, Sacramento, CA 95817 USA. [Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA. [Jazaeri, Omid] Univ Colorado, Sect Vasc Surg, Denver, CO 80202 USA. [Magid, David J.] Colorado Permanente Med Grp, Dept Vasc Therapy, Denver, CO USA. [Tsai, Thomas T.; Shetterly, Susan M.; Wagner, Nicole M.; Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. RP Jones, WS (reprint author), Duke Univ, Med Ctr, Box 3126, Durham, NC 27710 USA. EM schuyler.jones@dm.duke.edu OI Jones, William/0000-0002-7288-9596 NR 34 TC 4 Z9 4 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD AUG PY 2015 VL 170 IS 2 BP 400 EP U273 DI 10.1016/j.ahj.2015.04.026 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CQ1LV UT WOS:000360360100029 PM 26299239 ER PT J AU Hunt, LJ Covinsky, KE Yaffe, K Stephens, CE Miao, YH Boscardin, WJ Smith, AK AF Hunt, Lauren J. Covinsky, Kenneth E. Yaffe, Kristine Stephens, Caroline E. Miao, Yinghui Boscardin, W. John Smith, Alex K. TI Pain in Community-Dwelling Older Adults with Dementia: Results from the National Health and Aging Trends Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE NHATS; community-dwelling; dementia; pain ID NURSING-HOME RESIDENTS; SELF-REPORTED PAIN; COGNITIVE IMPAIRMENT; UNITED-STATES; ALZHEIMERS-DISEASE; ASSESSMENT SCALES; CAREGIVER REPORT; PREVALENCE; PATIENT; DEPRESSION AB ObjectivesTo report prevalence, correlates, and medication management of pain in community-dwelling older adults with dementia. DesignCross-sectional. SettingIn-person interviews with self- or proxy respondents living in private residences or non-nursing home residential care settings. ParticipantsNationally representative sample of community-dwelling Medicare beneficiaries aged 65 and older enrolled in the National Health and Aging Trends Study 2011 wave. MeasurementsDementia status was determined using a modified previously validated algorithm. Participants were asked whether they had had bothersome and activity-limiting pain over the past month. A multivariable Poisson regression model was used to determine the relationship between bothersome pain and sociodemographic and clinical characteristics. ResultsOf the 7,609 participants with complete data on cognitive function, 802 had dementia (67.2% aged 80, 65.0% female, 67.9% white, 49.7% proxy response, 32.0% lived alone, 18.8% lived in residential care); 670 (63.5%) participants with dementia experienced bothersome pain, and 347 (43.3%) had pain that limited activities. These rates were significantly higher than in a propensity score-matched cohort without dementia (54.5% bothersome pain, P<.001, 27.2% pain that limited activity, P<.001). Proxies reported slightly higher rates of pain than self-respondents, but differences were statistically significant only for activity-limiting pain (46.6% proxy vs 40.1% self, P=.03). Correlates of bothersome pain included arthritis, heart and lung disease, less than high school education, activity of daily living disability, depressive and anxiety symptoms, and low energy. Of those reporting pain, 30.3% stated that they rarely or never took any medications for pain. ConclusionCommunity-living older adults with dementia are at high risk of having pain. Creative interventions and programs are needed to manage pain adequately in this vulnerable population. C1 [Hunt, Lauren J.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.; Yaffe, Kristine; Smith, Alex K.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Stephens, Caroline E.] Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA 94143 USA. [Miao, Yinghui; Boscardin, W. John; Smith, Alex K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hunt, LJ (reprint author), Univ Calif San Francisco, Dept Physiol Nursing, 2 Koret Way,N-319X,UCSF Box 0602, San Francisco, CA 94143 USA. EM Lauren.Hunt@ucsf.edu FU National Institute of Nursing Research [T32-NR07088]; National Institute on Aging (NIA) [1K23 AG040772]; NIA [1 K24 AG041180, 2 K24 AG031155]; Clinical and Translational Sciences Institute Career Development Award [8 KL2 TR000143-08]; National Institute on Aging [U01AG032947]; Johns Hopkins Bloomberg School of Public Health FX LJH is supported by Grant T32-NR07088 from the National Institute of Nursing Research. AKS is supported by Paul Beeson Career Development Award in Aging 1K23 AG040772 from the National Institute on Aging (NIA). KEC is supported by Mentoring Award 1 K24 AG041180 from the NIA. KY is supported by Mentoring Award 2 K24 AG031155 from the NIA. CES is supported by Clinical and Translational Sciences Institute Career Development Award 8 KL2 TR000143-08. NHATS is sponsored by National Institute on Aging Grant U01AG032947 through a cooperative agreement with the Johns Hopkins Bloomberg School of Public Health. NR 50 TC 6 Z9 6 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2015 VL 63 IS 8 BP 1503 EP 1511 DI 10.1111/jgs.13536 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CP9IG UT WOS:000360207000002 PM 26200445 ER PT J AU Sheffrin, M Miao, YH Boscardin, WJ Steinman, MA AF Sheffrin, Meera Miao, Yinghui Boscardin, W. John Steinman, Michael A. TI Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cholinesterase inhibitors; dementia; weight loss ID PROBABLE VASCULAR DEMENTIA; PLACEBO-CONTROLLED TRIAL; ALZHEIMERS-DISEASE; DOUBLE-BLIND; LEWY BODIES; PARKINSONS-DISEASE; RANDOMIZED-TRIAL; DONEPEZIL; EFFICACY; TOLERABILITY AB ObjectivesTo determine whether initiation of cholinesterase inhibitors is associated with significant weight loss in a real-word clinical setting. DesignRetrospective cohort study from 2007 to 2010 comparing weight loss in individuals with dementia newly prescribed cholinesterase inhibitors and those newly prescribed other chronic medications. SettingNational Veterans Affairs data. ParticipantsIndividuals aged 65 and older with a diagnosis of dementia who received a new prescription for a cholinesterase inhibitor or other new chronic medication. MeasurementsThe primary outcome was time to 10-pound weight loss over 12months. Propensity score matching was used to control for the likelihood of receiving a cholinesterase inhibitor based on baseline characteristics. Data were analyzed in a priori defined subgroups according to age, comorbid burden, and initial weight. ResultsOf 6,504 individuals that met study criteria, 1,188 started on cholinesterase inhibitors were matched to 2,189 started on other medications. The propensity-matched cohorts were well balanced on baseline covariates. Participants initiated on cholinesterase inhibitors had a higher risk of weight loss than matched controls at 12months (hazard ratio=1.23, 95% confidence interval (CI) =1.07-1.41). At 12months, 29.3% of participants taking cholinesterase inhibitors had experienced weight loss, compared with 22.8% of nonusers, corresponding to a number needed to harm of 21.2 (95% CI=12.5-71.4) over 1year. There were no significant differences in the risk of weight loss within subgroups. ConclusionThese results are consistent with the available data from randomized controlled trials. Clinicians should consider the risk of weight loss when prescribing cholinesterase inhibitors. C1 [Sheffrin, Meera; Miao, Yinghui; Boscardin, W. John; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Sheffrin, Meera; Miao, Yinghui; Boscardin, W. John; Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Sheffrin, M (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA. EM meera.sheffrin@ucsf.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center; Centers for Medicare and Medicaid Services data [SDR 02-237, 98-004] FX The Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center provide support for VA and Centers for Medicare and Medicaid Services data (Project Numbers SDR 02-237 and 98-004). NR 32 TC 5 Z9 5 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2015 VL 63 IS 8 BP 1512 EP 1518 DI 10.1111/jgs.13511 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CP9IG UT WOS:000360207000003 PM 26234945 ER PT J AU Lund, BC Carrel, M Gellad, WF Chrischilles, EA Kaboli, PJ AF Lund, Brian C. Carrel, Margaret Gellad, Walid F. Chrischilles, Elizabeth A. Kaboli, Peter J. TI Incidence- Versus Prevalence-Based Measures of Inappropriate Prescribing in the Veterans Health Administration SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE medication safety; quality of care; pharmacotherapy; pharmacoepidemiology ID BEERS CRITERIA; MEDICATION USE; QUALITY; CARE; IMPACT; ELDERS AB ObjectivesTo describe variations in potentially inappropriate prescribing (PIP) and characterize the extent to which switching to an incidence-based indicator would affect health system quality rankings. DesignObservational study. SettingVeterans Health Administration in 2011. ParticipantsOlder adults receiving outpatient primary care. MeasurementsPIP was defined according to the National Committee for Quality Assurance High-Risk Medications in the Elderly list. Ranks were separately assigned for prevalent and incident PIP at the regional, network, and healthcare system levels. ResultsNational PIP prevalence was 12.3% (167,766/1,360,251), and incidence was 5.8% (78,604/1,360,251). PIP prevalence ranged from 3.5% to 33.1% across healthcare systems (interquartile range (IQR)=9.2-15.5%). PIP incidence ranged from 1.2% to 14.9% (IQR=4.1-7.2%). Rank order in PIP prevalence and incidence was correlated (Spearman correlation; =0.934, P<.001), although substantial changes in ranks were seen for some healthcare systems, with seven of 139 (5.0%) systems shifting more than 30 rank positions and 21 (15.1%) systems shifting 16 to 30 positions. ConclusionPrevalence- and incidence-based indicators of prescribing quality were strongly correlated. Transitioning to incidence-based indicators would not produce an initial disruption in quality rankings for most healthcare systems and might yield more-salient measures for tracking healthcare quality. C1 [Lund, Brian C.; Carrel, Margaret] Iowa City Vet Affairs Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA. [Lund, Brian C.; Chrischilles, Elizabeth A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Carrel, Margaret] Univ Iowa, Coll Med, Dept Geog & Sustainabil Sci, Iowa City, IA USA. [Gellad, Walid F.] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Kaboli, Peter J.] Univ Iowa, Div Gen Internal Med, Coll Med, Iowa City, IA USA. RP Lund, BC (reprint author), VA Iowa City Hlth Care Syst, Mailstop 152,601 Hwy 6 West, Iowa City, IA 52246 USA. EM Brian.Lund@va.gov FU Health Services Research and Development Service, Department of Veterans Affairs [CDA 10-017, CIN 13-412, CDA 09-207] FX This study was supported by supported by the Health Services Research and Development Service, Department of Veterans Affairs (Dr. Lund, CDA 10-017 and CIN 13-412; Dr. Gellad, CDA 09-207). NR 28 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2015 VL 63 IS 8 BP 1601 EP 1607 DI 10.1111/jgs.13560 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CP9IG UT WOS:000360207000014 PM 26200069 ER PT J AU Song, Y Dzierzewski, JM Fung, CH Rodriguez, JC Jouldjian, S Mitchell, MN Josephson, KR Alessi, CA Martin, JL AF Song, Yeonsu Dzierzewski, Joseph M. Fung, Constance H. Rodriguez, Juan C. Jouldjian, Stella Mitchell, Michael N. Josephson, Karen R. Alessi, Cathy A. Martin, Jennifer L. TI Association Between Sleep and Physical Function in Older Veterans in an Adult Day Healthcare Program SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE adult day health care; elderly adults; physical function; sleep; veterans ID ASSISTED LIVING FACILITIES; QUALITY-OF-LIFE; POOR SLEEP; ACTIVATION; DEPRESSION; DEMENTIA; VALIDITY; DECLINE; WOMEN; INDEX AB ObjectivesTo examine whether sleep disturbance is associated with poor physical function in older veterans in an adult day healthcare (ADHC) program. DesignCross-sectional. SettingOne ADHC program in a Veterans Affairs Ambulatory Care Center. ParticipantsOlder veterans (N=50) enrolled in a randomized controlled trial of a sleep intervention program who had complete baseline data. MeasurementsInformation on participant characteristics (e.g., age, depression, relationship to caregiver, pain, comorbidity) was collected using appropriate questionnaires. Physical function was measured using activity of daily living (ADL) and instrumental ADL (IADL) total scores from the Older Americans Resources and Services Multidimensional Functional Assessment Questionnaire. Sleep was assessed subjectively (Pittsburgh Sleep Quality Index, Insomnia Severity Index) and objectively (wrist actigraphy). ResultsParticipants required substantial assistance with ADLs and IADLs. A regression model showed that participant characteristics (marital status, use of sleep medication, comorbidity, posttraumatic stress disorder) and living arrangement (living with a spouse or others) were significantly associated with poor physical function. Poorer objective sleep (total sleep time, total numbers of awakenings, total wake time) was significantly associated with poor physical function, accounting for a significant proportion of the variance other than participant characteristics. ConclusionObjective measures of nighttime sleep disturbance were associated with poor physical function in older veterans in an ADHC program. Further research is needed to determine whether interventions to improve sleep will delay functional decline in this vulnerable population. C1 [Song, Yeonsu; Dzierzewski, Joseph M.; Fung, Constance H.; Rodriguez, Juan C.; Jouldjian, Stella; Mitchell, Michael N.; Josephson, Karen R.; Alessi, Cathy A.; Martin, Jennifer L.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Dzierzewski, Joseph M.; Fung, Constance H.; Rodriguez, Juan C.; Alessi, Cathy A.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Rodriguez, Juan C.] Pontificia Univ Catolica Chile, Dept Med, Santiago, Chile. RP Martin, JL (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr 11E, 16111 Plummer St, North Hills, CA 91343 USA. EM Jennifer.Martin@va.gov FU VA Rehabilitation Research and Development Service Merit Review Project [1RX000135-01]; VA Advanced Geriatrics Fellowship Program; VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center; University of California at Los Angeles (UCLA) Claude Pepper Older Americans Independence Center [5P30AG028748]; National Center for Advancing Translational Sciences UCLA Clinical and Translational Science Institute [UL1TR000124]; National Institute on Aging, National Institutes of Health [K23AG045937] FX This study was supported by the VA Rehabilitation Research and Development Service Merit Review Project 1RX000135-01 (PI: Martin), VA Advanced Geriatrics Fellowship Program, and VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center. Research reported in this publication was also supported by the University of California at Los Angeles (UCLA) Claude Pepper Older Americans Independence Center (5P30AG028748, PI: Dzierzewski), National Center for Advancing Translational Sciences UCLA Clinical and Translational Science Institute (UL1TR000124, PI: Dzierzewski), and National Institute on Aging, National Institutes of Health (K23AG045937, PI: Fung). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs, National Institute of Health, or the U.S. government. NR 29 TC 4 Z9 4 U1 4 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2015 VL 63 IS 8 BP 1622 EP 1627 DI 10.1111/jgs.13527 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CP9IG UT WOS:000360207000017 PM 26200520 ER PT J AU Troen, BR Ouslander, JG Yoshikawa, T AF Troen, Bruce R. Ouslander, Joseph G. Yoshikawa, Thomas TI Statement of Principle SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material C1 [Troen, Bruce R.] SUNY Buffalo, Dept Med, Div Geriatr & Palliat Med, Buffalo, NY 14260 USA. [Troen, Bruce R.] Vet Affairs Western New York Healthcare Syst, Buffalo, NY USA. [Ouslander, Joseph G.] Florida Atlantic Univ, Christine E Lynn Coll Nursing, Charles E Schmidt Coll Biomed Sci, Clin Biomed Sci, Boca Raton, FL 33431 USA. [Yoshikawa, Thomas] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Yoshikawa, Thomas] Charles Drew Univ Med & Sci, Los Angeles, CA USA. RP Troen, BR (reprint author), SUNY Buffalo, Dept Med, Div Geriatr & Palliat Med, Buffalo, NY 14260 USA. NR 10 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2015 VL 63 IS 8 BP 1693 EP 1693 DI 10.1111/jgs.13589 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CP9IG UT WOS:000360207000028 PM 26289687 ER PT J AU Chai, XJ Guo, Y Jiang, MX Hu, BF Li, ZG Fan, J Deng, MH Billiar, TR Kucera, HR Gaikwad, NW Xu, MS Lu, PP Yan, J Fu, HY Liu, YH Yu, LS Huang, M Zeng, S Xie, W AF Chai, Xiaojuan Guo, Yan Jiang, Mengxi Hu, Bingfang Li, Zhigang Fan, Jie Deng, Meihong Billiar, Timothy R. Kucera, Heidi R. Gaikwad, Nilesh W. Xu, Meishu Lu, Peipei Yan, Jiong Fu, Haiyan Liu, Youhua Yu, Lushan Huang, Min Zeng, Su Xie, Wen TI Oestrogen sulfotransferase ablation sensitizes mice to sepsis SO NATURE COMMUNICATIONS LA English DT Article ID IN-VIVO; KUPFFER CELLS; X-RECEPTOR; ACTIVATION; INJURY; LIVER; INFLAMMATION; SHOCK; TLR4; GENE AB Sepsis is the host's deleterious systemic inflammatory response to microbial infections. Here we report an essential role for the oestrogen sulfotransferase (EST or SULT1E1), a conjugating enzyme that sulfonates and deactivates estrogens, in sepsis response. Both the caecal ligation and puncture (CLP) and lipopolysaccharide models of sepsis induce the expression of EST and compromise the activity of oestrogen, an anti-inflammatory hormone. Surprisingly, EST ablation sensitizes mice to sepsis-induced death. Mechanistically, EST ablation attenuates sepsis-induced inflammatory responses due to compromised oestrogen deactivation, leading to increased sepsis lethality. In contrast, transgenic overexpression of EST promotes oestrogen deactivation and sensitizes mice to CLP-induced inflammatory response. The induction of EST by sepsis is NF-kappa B dependent and EST is a NF-kappa B-target gene. The reciprocal regulation of inflammation and EST may represent a yet-to-be-explored mechanism of endocrine regulation of inflammation, which has an impact on the clinical outcome of sepsis. C1 [Chai, Xiaojuan; Guo, Yan; Jiang, Mengxi; Hu, Bingfang; Xu, Meishu; Lu, Peipei; Yan, Jiong; Yu, Lushan; Xie, Wen] Univ Pittsburgh, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA. [Chai, Xiaojuan; Guo, Yan; Jiang, Mengxi; Hu, Bingfang; Xu, Meishu; Lu, Peipei; Yan, Jiong; Yu, Lushan; Xie, Wen] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Chai, Xiaojuan; Yu, Lushan; Zeng, Su] Zhejiang Univ, Dept Pharmaceut Anal & Drug Metab, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Zhejiang, Peoples R China. [Guo, Yan] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai 200025, Peoples R China. [Hu, Bingfang; Huang, Min] Sun Yat Sen Univ, Inst Clin Pharmacol, Guangzhou 510006, Guangdong, Peoples R China. [Li, Zhigang; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA 15240 USA. [Fan, Jie; Deng, Meihong; Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA. [Kucera, Heidi R.; Gaikwad, Nilesh W.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. [Kucera, Heidi R.; Gaikwad, Nilesh W.] Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA. [Fu, Haiyan; Liu, Youhua] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA. [Xie, Wen] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA. RP Zeng, S (reprint author), Zhejiang Univ, Dept Pharmaceut Anal & Drug Metab, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Zhejiang, Peoples R China. EM zengsu@zju.edu.cn; wex6@pitt.edu RI Xie, Wen/M-1768-2016 FU NIH [ES023438, DK099232, HD073070, HL079669, GM50441, GM53789]; VA Merit Award; Government of China's China Scholarship Council [2010632117] FX We thank Dr Gutian Xiao for the NF-kappa B reporter gene. This work was supported in part by the NIH grants ES023438, DK099232 and HD073070 (to W.X.), HL079669 (to J.F.), GM50441 (to T.R.B.), GM53789 (to T.R.B. and J.F.), and a VA Merit Award (to J.F.). X.C. is supported by a Scholarship from Government of China's China Scholarship Council (No. 2010632117). NR 36 TC 2 Z9 3 U1 3 U2 15 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD AUG PY 2015 VL 6 AR 7979 DI 10.1038/ncomms8979 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CQ1HC UT WOS:000360346900020 PM 26259151 ER PT J AU Janzen, DM Tiourin, E Salehi, JA Paik, DY Lu, J Pellegrini, M Memarzadeh, S AF Janzen, D. M. Tiourin, E. Salehi, J. A. Paik, D. Y. Lu, J. Pellegrini, M. Memarzadeh, S. TI An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer SO NATURE COMMUNICATIONS LA English DT Article ID NF-KAPPA-B; STEM-CELLS; FALLOPIAN-TUBE; IAP PROTEINS; CHEMOTHERAPY; ACTIVATION; THERAPY; TARGETS; CISPLATIN; DEATH AB High-grade serous ovarian cancers (HGSCs) are deadly malignancies that relapse despite carboplatin chemotherapy. Here we show that 16 independent primary HGSC samples contain a CA125-negative population enriched for carboplatin-resistant cancer initiating cells. Transcriptome analysis reveals upregulation of homologous recombination DNA repair and anti-apoptotic signals in this population. While treatment with carboplatin enriches for CA125-negative cells, co-treatment with carboplatin and birinapant eliminates these cells in HGSCs expressing high levels of the inhibitor of apoptosis protein cIAP in the CA125-negative population. Birinapant sensitizes CA125-negative cells to carboplatin by mediating degradation of cIAP causing cleavage of caspase 8 and restoration of apoptosis. This co-therapy significantly improves disease-free survival in vivo compared with either therapy alone in tumour-bearing mice. These findings suggest that therapeutic strategies that target CA125-negative cells may be useful in the treatment of HGSC. C1 [Janzen, D. M.; Tiourin, E.; Salehi, J. A.; Paik, D. Y.; Memarzadeh, S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Lu, J.; Pellegrini, M.] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA. [Pellegrini, M.; Memarzadeh, S.] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA. [Memarzadeh, S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Memarzadeh, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. EM smemarzadeh@mednet.ucla.edu OI Pellegrini, Matteo/0000-0001-9355-9564 FU NIH/NCI [R01CA183877]; American Cancer Society [VA CDA-2, RSG-14-217-01-TBG]; NIH/National Center for Advancing Translational Science UCLA CTSI [UL1TR000124]; Ovarian Cancer Circle Inspired by Robin Babbini; Leath L. and Marcia L. Millen Family Fund; Jonsson Cancer Center Foundation/UCLA; Lynne Cohen Foundation; Phase One Foundation; Gynecologic Oncology Discovery Lab Foundation FX We thank Drs Jeffery Gornbein, Jianyu Rao, Xinmin Li and Donghui Cheng for technical advice and support. We also thank the UCLA Eli and Edythe Broad Center of regenerative medicine and stem cell research FACS and microarray core facilities and the UCLA Translational Pathology Core Laboratory. Work in this manuscript was funded partly by an NIH/NCI R01CA183877 grant and a VA CDA-2 Award and largely by a Research Scholar Grant RSG-14-217-01-TBG from the American Cancer Society, an NIH/National Center for Advancing Translational Science UCLA CTSI Grant Number UL1TR000124, the Ovarian Cancer Circle Inspired by Robin Babbini, the Leath L. and Marcia L. Millen Family Fund, and funds from the Jonsson Cancer Center Foundation/UCLA, the Lynne Cohen Foundation, Phase One Foundation and the Gynecologic Oncology Discovery Lab Foundation. NR 60 TC 15 Z9 15 U1 0 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD AUG PY 2015 VL 6 AR 7956 DI 10.1038/ncomms8956 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CQ1HA UT WOS:000360346700011 PM 26234182 ER PT J AU Wells, DM Lehavot, K Isaac, ML AF Wells, Deva M. Lehavot, Keren Isaac, Margaret L. TI Sounding Off on Social Media: The Ethics of Patient Storytelling in the Modern Era SO ACADEMIC MEDICINE LA English DT Article ID ONLINE PROFESSIONALISM; HEALTH-PROFESSIONALS; NETWORKING; STUDENTS; CARE; PERCEPTIONS; REFLECTION; PHYSICIANS AB Use of social networking programs like Facebook and Twitter, which enable the public sharing of diverse content over the Internet, has risen dramatically in recent years. Although health professionals have faced consequences for clearly unethical online behavior, a relatively unexamined practice among medical students is the disclosure of patient care stories on social media in a manner that is technically compliant with the Health Insurance Portability and Accountability Act, yet is ethically questionable. In this Perspective, the authors review three such cases in which students do not specifically reveal a patient's identity but share details of a personal nature, motivated by a variety of intentions (e.g., a desire to reflect on a meaningful experience, reaching out for social support in the event of a patient's death). Using ethical principles and professional policy recommendations, they discuss aspects of these postings that are potentially problematic. Consequences include the possibility of undermining public trust in the profession, inadvertently identifying patients, and violating expectations of privacy. The authors recommend that medical schools explicitly address these issues across the preclinical and clinical curricula and emphasize that patient-related postings on social media may carry inherent risks both to patients and to the profession. C1 [Wells, Deva M.] Univ Washington, Sch Med, Seattle, WA USA. [Lehavot, Keren] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Lehavot, Keren] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Isaac, Margaret L.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Wells, DM (reprint author), 1959 NE Pacific St, Seattle, WA 98195 USA. EM devaw@uw.edu NR 36 TC 12 Z9 12 U1 4 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD AUG PY 2015 VL 90 IS 8 BP 1015 EP 1019 DI 10.1097/ACM.0000000000000668 PG 5 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CP3EU UT WOS:000359761100011 PM 25692559 ER PT J AU Moayyedi, P Quigley, EMM Lacy, BE Lembo, AJ Saito, YA Schiller, LR Soffer, EE Spiegel, BMR Ford, AC AF Moayyedi, Paul Quigley, Eamonn M. M. Lacy, Brian E. Lembo, Anthony J. Saito, Yuri A. Schiller, Lawrence R. Soffer, Edy E. Spiegel, Brennan M. R. Ford, Alexander C. TI The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review SO CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY LA English DT Review ID FUNCTIONAL GASTROINTESTINAL DISORDERS; RANDOMIZED CONTROLLED-TRIAL; CELIAC WHEAT SENSITIVITY; GLUTEN-FREE DIET; FOOD HYPERSENSITIVITY; GAS-PRODUCTION; SYMPTOMS; METAANALYSIS; INTOLERANCE; MANAGEMENT AB OBJECTIVES: Elimination diets have been used for many years to treat irritable bowel syndrome (IBS). These approaches had fallen out of favor until a recent resurgence, which was based on new randomized controlled trial (RCT) data that suggested it might be effective. The evidence for the efficacy of dietary therapies has not been evaluated systematically. We have therefore conducted a systematic review to examine this issue. METHODS: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched up to December 2013. Trials recruiting adults with IBS, which compared any form of dietary restriction or addition of an offending food group in patients already on a restricted diet vs. placebo, control therapy, or "usual management", were eligible. Dichotomous symptom data were pooled to obtain a relative risk of remaining symptomatic after therapy as well as the number needed to treat with a 95% confidence interval. RESULTS: We identified 17 RCTs involving 1,568 IBS patients that assessed elimination diets. Only three RCTs involving 230 patients met our eligibility criteria, all of which evaluated different approaches, and thus a meta-analysis could not be conducted. CONCLUSIONS: More evidence is needed before generally recommending elimination diets for IBS patients. C1 [Moayyedi, Paul] McMaster Univ, Hlth Sci Ctr, Farncombe Family Digest Hlth Res Inst, Hamilton, ON L8N 3Z5, Canada. [Quigley, Eamonn M. M.] Houston Methodist Hosp, Dept Med, Div Gastroenterol & Hepatol, Houston, TX USA. [Lacy, Brian E.] Dartmouth Hitchcock Med Ctr, Div Gastroenterol & Hepatol, Lebanon, NH 03766 USA. [Lembo, Anthony J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Saito, Yuri A.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. [Schiller, Lawrence R.] Baylor Univ, Med Ctr, Digest Hlth Associates Texas, Dallas, TX USA. [Soffer, Edy E.] Univ So Calif, Div Gastroenterol Cedars Sinai, Los Angeles, CA USA. [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Ford, Alexander C.] St James Univ Hosp, Leeds Gastroenterol Inst, Leeds, W Yorkshire, England. [Ford, Alexander C.] Univ Leeds, Leeds Inst Biomed & Clin Sci, Leeds, W Yorkshire, England. RP Moayyedi, P (reprint author), McMaster Univ, Hlth Sci Ctr, Farncombe Family Digest Hlth Res Inst, Hamilton, ON L8N 3Z5, Canada. EM moayyep@mcmaster.ca RI Ford, Alexander/K-5491-2012 OI Ford, Alexander/0000-0001-6371-4359 FU American College of Gastroenterology FX American College of Gastroenterology. NR 36 TC 10 Z9 10 U1 2 U2 14 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2155-384X J9 CLIN TRANSL GASTROEN JI Clin. Transl. Gastroenterol. PD AUG PY 2015 VL 6 AR e107 DI 10.1038/ctg.2015.21 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP8FM UT WOS:000360127700002 PM 26291435 ER PT J AU Kraut, JA AF Kraut, Jeffrey A. TI Diagnosis of toxic alcohols: limitations of present methods SO CLINICAL TOXICOLOGY LA English DT Review DE Toxic alcohols; Serum osmolal gap; Serum anion gap; Fomepizole; Methanol; Ethylene glycol; Propylene glycol ID HYPEROSMOLAR METABOLIC-ACIDOSIS; PROPYLENE-GLYCOL TOXICITY; ETHYLENE-GLYCOL; DIETHYLENE GLYCOL; OSMOLAL GAP; ANION-GAP; INTRAVENOUS LORAZEPAM; PRACTICE GUIDELINES; URINE FLUORESCENCE; AMERICAN-ACADEMY AB Context. Methanol, ethylene glycol, diethylene glycol, and propylene glycol intoxications are associated with cellular dysfunction and an increased risk of death. Adverse effects can develop quickly; thus, there is a need for methods for rapidly detecting their presence. Objective. To examine the value and limitations of present methods to diagnose patients with possible toxic alcohol exposure. Methods. I searched MEDLINE for articles published between 1969 and 2014 using the terms: toxic alcohols, serum osmolality, serum osmol gap, serum anion gap, metabolic acidosis, methanol, ethylene glycol, diethylene glycol, propylene glycol, and fomepizole. Each article was reviewed for additional references. Results. The diagnosis of toxic alcohol exposure is often made on the basis of this history and physical findings along with an increase in the serum osmol and anion gaps. However, an increase in the osmol and/or anion gaps is not always present. Definitive detection in blood requires gas or liquid chromatography, laborious and expensive procedures which are not always available. Newer methods including a qualitative colorimetric test for detection of all alcohols or enzymatic tests for a specific alcohol might allow for more rapid diagnosis. Conclusions. Exposure to toxic alcohols is associated with cellular dysfunction and increased risk of death. Treatment, if initiated early, can markedly improve outcome, but present methods of diagnosis including changes in serum osmol and anion gap, and use of gas or liquid chromatography have important limitations. Development of more rapid and effective tests for detection of these intoxications is essential for optimal care of patients. C1 [Kraut, Jeffrey A.] Univ Calif Los Angeles, Membrane Biol Lab, Med & Res Serv Vet Adm Greater Los Angeles Health, Los Angeles, CA USA. [Kraut, Jeffrey A.] Vet Adm Greater Los Angeles Healthcare Syst, Div Nephrol, Los Angeles, CA USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Kraut, JA (reprint author), VHAGLA Healthcare Syst, Div Nephrol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkraut@ucla.edu NR 62 TC 6 Z9 6 U1 3 U2 14 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1556-3650 EI 1556-9519 J9 CLIN TOXICOL JI Clin. Toxicol. PD AUG PY 2015 VL 53 IS 7 BP 589 EP 595 DI 10.3109/15563650.2015.1056880 PG 7 WC Toxicology SC Toxicology GA CP4WN UT WOS:000359883400001 PM 26114345 ER PT J AU Kaunitz, JD AF Kaunitz, Jonathan D. TI The Discovery of PCR: ProCuRement of Divine Power SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material C1 [Kaunitz, Jonathan D.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK054221, P30 DK041301] NR 5 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD AUG PY 2015 VL 60 IS 8 BP 2230 EP 2231 DI 10.1007/s10620-015-3747-0 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP6LF UT WOS:000359998000007 PM 26077976 ER PT J AU Joly, JM Lloyd, SG AF Joly, Joanna M. Lloyd, Steven G. TI Imaging in patients with advanced therapies for heart failure SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID CARDIAC ALLOGRAFT VASCULOPATHY; TRANSPLANT; TOMOGRAPHY C1 [Joly, Joanna M.; Lloyd, Steven G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Lloyd, Steven G.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Lloyd, SG (reprint author), Cardiovasc MRI, D-101,1808 7th Ave South, Birmingham, AL 35294 USA. EM sglloyd@uab.edu NR 14 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD AUG PY 2015 VL 22 IS 4 BP 639 EP 642 DI 10.1007/s12350-015-0111-x PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CP5QE UT WOS:000359937800006 PM 25824016 ER PT J AU Hage, FG AlJaroudi, WA AF Hage, Fadi G. AlJaroudi, Wael A. TI Review of cardiovascular imaging in The Journal of Nuclear Cardiology in 2014: Part 2 of 2: Myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Review DE Myocardial perfusion imaging; SPECT; phase analysis; dyssynchrony; appropriateness; safety; regadenoson ID VENTRICULAR MECHANICAL DYSSYNCHRONY; CORONARY-ARTERY-DISEASE; PROGNOSTIC VALUE; GATED SPECT; COMPUTED-TOMOGRAPHY; DIABETIC-PATIENTS; PHASE-ANALYSIS; HEART-FAILURE; REGADENOSON; STRESS AB In this new feature of The Journal of Nuclear Cardiology we will summarize key articles that were published in the Journal in the previous year. In the first article of this 2-part series we concentrated on publications dealing with cardiac positron emission tomography, computed tomography, and neuronal imaging. This review will focus on myocardial perfusion imaging summarizing advances in the field including in diagnosis, prognosis, appropriateness, and safety of testing. C1 [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [AlJaroudi, Wael A.] Amer Univ Beirut, Div Cardiovasc Med Cardiovasc Imaging, Med Ctr, Beirut, Lebanon. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. EM fadihage@uab.edu; wa53@aub.edu.lb OI Hage, Fadi/0000-0002-1397-4942 FU Astellas Pharma US FX Dr. Hage has received grant support from Astellas Pharma US. NR 32 TC 3 Z9 3 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD AUG PY 2015 VL 22 IS 4 BP 714 EP 719 DI 10.1007/s12350-015-0144-1 PG 6 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CP5QE UT WOS:000359937800016 PM 25920482 ER PT J AU Farag, AA Hage, FG AF Farag, Ayman A. Hage, Fadi G. TI Incidentally found giant thymomas by SPECT myocardial perfusion imaging (vol 22, pg 385, 2015) SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Correction C1 [Farag, Ayman A.; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Farag, AA (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, THT 311,1900 Univ Blvd, Birmingham, AL 35294 USA. EM afarag@uab.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD AUG PY 2015 VL 22 IS 4 BP 786 EP 786 DI 10.1007/s12350-015-0189-1 PG 1 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CP5QE UT WOS:000359937800023 PM 26058351 ER PT J AU Monteith, LL Menefee, DS Forster, JE Wanner, JL Bahraini, NH AF Monteith, Lindsey L. Menefee, Deleene S. Forster, Jeri E. Wanner, Jill L. Bahraini, Nazanin H. TI Sexual Trauma and Combat During Deployment: Associations With Suicidal Ideation Among OEF/OIF/OND Veterans SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID MENTAL-HEALTH; GENDER-DIFFERENCES; RESILIENCE INVENTORY; MILITARY PERSONNEL; AFGHANISTAN; RISK; IRAQ; ASSAULT; SAMPLE; EXPERIENCES AB Compelling evidence has emerged on the association between military sexual trauma and suicide attempt; however, research investigating how sexual trauma during deployment relates to suicidal ideation has received considerably less attention and has yielded mixed findings. Furthermore, such research has not accounted for other types of trauma that may occur during deployment. Our objectives were to examine whether sexual trauma during deployment was associated with recent suicidal ideation, adjusting for exposure to combat. Our sample included 199 Operation Enduring Freedom/Iraqi Freedom/New Dawn (OEF/OIF/OND) veterans entering inpatient trauma-focused treatment who completed the Beck Scale for Suicide Ideation (Beck & Steer, ) and the Deployment Risk and Resilience Inventory Sexual Harassment and Combat Experiences Scales (King, King, Vogt, Knight, & Samper, ). Deployment-related sexual trauma was significantly associated with recent suicidal ideation, adjusting for age and gender ( = .18, (2)(p) = .03) and additionally for combat ( = .17, (2)(p) = .02). These findings underscore the importance of assessing for deployment-related sexual trauma when assessing suicide risk in OEF/OIF/OND veterans in inpatient settings. Resumen Trauma Sexual, Combate e Ideacion Suicida Evidencia convincente ha surgido sobre la asociacion entre trauma sexual militar e intento suicida; sin embargo, la investigacion de como el trauma sexual durante el despliegue se relaciona con la ideacion suicida ha recibido considerablemente menos atencion y ha arrojado resultados mixtos. Ademas, tal investigacion no ha dado cuenta de otros tipos de trauma que pueden ocurrir durante el despliegue. Nuestros objetivos fueron investigar si el trauma sexual durante el despliegue estaba asociado a ideacion suicida reciente, ajustando por exposicion a combate. Nuestra mezcla incluyo 199 veteranos OEF/OIF/OND hospitalizados para tratamiento focalizado en el trauma, que completaron la Escala de Beck para Ideacion Suicida, el Inventario de Riesgo de Despliegue y Resiliencia, y las escalas de Acoso Sexual y de Experiencias de Combate. El trauma asociado a despliegue se asocio en forma significativa a ideacion suicida reciente, ajustando por edad y genero ( = .18, p 2 = .03) y adicionalmente por combate ( = .17, p 2 = .02). Estos hallazgos subrayan la importancia de considerar el trauma asociado a despliegue al evaluar riesgo suicida en veteranos OEF/OIF/OND en contexto de hospitalizacion. Traditional and Simplified Chinese Abstracts by AsianSTSS ?? : OEF/OIF/OND????,???????????????????? ??: ?????????????????????,?????????????????????????,?????????;?????????????????????????????????????,??????????????????????????199?????????????OEF/OIF/OND????,????????????????????????????????????????????( = .18, p(2) = .03),???????????( = .17, p(2) = .02)?,?????????????????????????????,????OEF/OIF/OND??????????,????????????????? ?? : OEF/OIF/OND????,??????????????????? ??: ?????????????????????,?????????????????????????,?????????;????????????????????????????????????,??????????????????????????199?????????????OEF/OIF/OND????,???????????????????????????????????????????( = .18, p(2) = .03),??????????( = .17, p(2) = .02)?,?????????????????????????????,????OEF/OIF/OND??????????,????????????????? C1 [Monteith, Lindsey L.; Forster, Jeri E.; Bahraini, Nazanin H.] Denver VA Med Ctr, VISN MIRECC 19, Denver, CO 80220 USA. [Monteith, Lindsey L.; Bahraini, Nazanin H.] Univ Colorado, Dept Psychiat, Aurora, CO USA. [Menefee, Deleene S.; Wanner, Jill L.] Michael E DeBakey VA Med Ctr, VISN MIRECC 19, Houston, CO USA. [Menefee, Deleene S.; Wanner, Jill L.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Forster, Jeri E.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Bahraini, Nazanin H.] Univ Colorado, Dept Phys Med & Rehabil, Aurora, CO USA. RP Monteith, LL (reprint author), Denver VA Med Ctr, VISN MIRECC 19, 1055 Clermont St, Denver, CO 80220 USA. EM lindsey.monteith@va.gov NR 28 TC 2 Z9 2 U1 1 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD AUG PY 2015 VL 28 IS 4 BP 283 EP 288 DI 10.1002/jts.22018 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CP5HR UT WOS:000359912400003 PM 26190530 ER PT J AU Yu, F Duong, T Tantiwongkosi, B AF Yu, Fang Duong, Timothy Tantiwongkosi, Bundhit TI Advanced MR Imaging of the Visual Pathway SO NEUROIMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Visual pathway; Retina; Lateral geniculate nucleus; MR imaging; Diffusion tensor imaging; Diffusion-weighted imaging; Magnetization transfer ratio; Functional imaging; Retinotopic mapping ID LATERAL GENICULATE-NUCLEUS; ISCHEMIC OPTIC NEUROPATHY; MAGNETIZATION-TRANSFER; HIGH-RESOLUTION; BLOOD-FLOW; RETINOTOPIC ORGANIZATION; INITIAL-EXPERIENCE; SINGLE-SHOT; GLAUCOMA; RETINA AB Vision is one of our most vital senses, deriving from the eyes as well as structures deep within the intracranial compartment. MR imaging, through its wide selection of sequences, offers an array of structural and functional imaging tools to interrogate this intricate system. This review describes several advanced MR imaging sequences and explores their potential clinical applications as well as areas for further development. C1 [Yu, Fang; Tantiwongkosi, Bundhit] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Duong, Timothy] Res Imaging Inst, San Antonio, TX 78229 USA. [Tantiwongkosi, Bundhit] South Texas Vet Hlth Care Syst, Imaging Serv, San Antonio, TX 78229 USA. RP Yu, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, 7703 Floyd Curl Dr,Mail Stop 7800, San Antonio, TX 78229 USA. EM yuf@uthscsa.edu NR 42 TC 0 Z9 0 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1052-5149 EI 1557-9867 J9 NEUROIMAG CLIN N AM JI Neuroimaging Clin. N. Am. PD AUG PY 2015 VL 25 IS 3 BP 383 EP + DI 10.1016/j.nic.2015.05.003 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CP4SY UT WOS:000359874100005 PM 26208415 ER PT J AU Goldstein, JN Ibrahim, SA Frankel, ES Mao, JJ AF Goldstein, Jennifer N. Ibrahim, Said A. Frankel, Eitan S. Mao, Jun J. TI Race, Pain, and Beliefs Associated with Interest in Complementary and Alternative Medicine among Inner City Veterans SO PAIN MEDICINE LA English DT Article DE Complementary Medicine; Complementary Therapies; Pain Management; Pain Medicine; Perception ID CHRONIC NONCANCER PAIN; LOW-BACK-PAIN; PRESCRIPTION OPIOID INITIATION; CHRONIC NONMALIGNANT PAIN; MILITARY VETERANS; UNITED-STATES; CARE-SYSTEM; HEALTH; ACUPUNCTURE; PERCEPTIONS AB ObjectiveTo investigate the prevalence and determinants of complementary and alternative medicine (CAM) interest level among a racially diverse cohort of inner city veterans who receive primary care at the VA Medical Center. DesignCross-sectional survey study SettingPhiladelphia VA Medical Center SubjectsPrimary care patients (n=258) MethodsInterest in CAM was measured using a single item question. Patient treatment beliefs were assessed using validated instruments. We evaluated factors associated with patient interest in CAM using a multivariate logistic regression model. ResultsIn this sample of 258 inner city primary care VA patients, interest in CAM was high 80% (n=206). Interest in CAM was strongly associated with African American race [adjusted odds ratio (AOR) 2.19, 95% Confidence Interval (CI) 1.05-4.60, P=0.037], higher levels of education (AOR 4.33, 95% CI 1.80-10.40, P=0.001), presence of moderate to severe pain (AOR 2.02, 95% CI 1.02-4.78, P=0.043), and expectations of benefit from CAM use (AOR 1.21, 95% CI 1.06-1.36, P=0.004). ConclusionsCAM approaches have broad appeal within this inner city cohort of veterans, particularly among African Americans, those that experience pain and those that expect greater benefit from CAM. These findings may inform the development of patient-centered integrative pain management for veterans. C1 [Goldstein, Jennifer N.] Christiana Care Hlth Syst, Dept Med, Newark, DE 19713 USA. [Ibrahim, Said A.] Philadelphia VA Med Ctr, Ctr Hlth Equ & Promot, Philadelphia, PA USA. [Frankel, Eitan S.] Univ Illinois, Coll Med, Chicago, IL USA. [Mao, Jun J.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. RP Goldstein, JN (reprint author), Christiana Care Hlth Syst, Dept Med, Ammon 2E72A,4755 Ogletown Stanton Rd, Newark, DE 19713 USA. EM jgoldstein@christianacare.org NR 37 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD AUG PY 2015 VL 16 IS 8 BP 1467 EP 1474 DI 10.1111/pme.12756 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CP7FR UT WOS:000360053100004 PM 26287564 ER PT J AU Pang, CE Sarraf, D Freund, KB AF Pang, Claudine E. Sarraf, David Freund, K. Bailey TI Untitled Reply SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Letter ID HIGHLY MYOPIC EYES; CHOROIDAL THICKNESS; VISUAL-ACUITY C1 [Pang, Claudine E.; Freund, K. Bailey] Macula Consultants New York, Retina, Vitreous, New York, NY 10022 USA. [Pang, Claudine E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA. [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA. RP Pang, CE (reprint author), Macula Consultants New York, Retina, Vitreous, New York, NY 10022 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD AUG PY 2015 VL 35 IS 8 BP e47 EP e48 DI 10.1097/IAE.0000000000000676 PG 2 WC Ophthalmology SC Ophthalmology GA CP4HZ UT WOS:000359843900002 PM 26131589 ER PT J AU Hundert, SA White, AA Reilly, DF AF Hundert, Samuel A. White, Andrew A. Reilly, Dominic F. TI Number of General Medicine Hospital Admissions Performed by Internal Medicine Residents Before and After the 2011 Duty-Hour Regulations SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE admissions; education; internal medicine; 2011 resident duty-hour regulations ID PATIENT-CARE; EDUCATION; SUPERVISION; PERCEPTIONS; DURATION; QUALITY; RISK AB Objectives In July 2011 the Accreditation Council for Graduate Medical Education implemented new resident duty-hour regulations in an effort to improve resident well-being, clinical performance, and patient care. These regulations have the potential, however, to reduce the number of new patient encounters handled by trainees and thereby could be detrimental to resident education. Our objective was to describe how the 2011 duty-hour regulations affected the volume of new inpatient general medicine encounters at two large academic medical centers. We looked specifically at new patient encounters because we assumed they provided the richest learning opportunities. We hypothesized that the implementation of the Accreditation Council for Graduate Medical Education regulations would be associated with a reduction in the number of new admissions per day and result in a decrease in the number of annual admissions performed by first-year medical residents. Methods We conducted a retrospective ecological study. We reviewed general medicine admissions data from two large academic hospitals affiliated with the University of Washington: Harborview Medical Center and the University of Washington Medical Center. We abstracted the number of admissions, source of admission, and average intern census on 56 randomly selected days before and after the regulations were implemented (academic years 2010-2011 [AY11] and 2011-2012 [AY12]). We generated descriptive statistics (means, proportions, and 95% confidence intervals) and then used a two-sample t test to compare the number of admissions per day, admission source, and average daily intern census between AY11 and AY12. Results At the University of Washington Medical Center, single-intern teams admitted 4.5 patients per day in AY11 compared with 3.1 in AY12 (P < 0.001). At Harborview Medical Center, two-intern teams admitted 11.1 patients per day in AY11 versus 7.9 in AY12 (P < 0.001). Night interns admitted 0.9 patients per shift in AY11 versus 2.4 in AY12 (P < 0.001). After implementing the new duty hours, daytime admissions from the emergency department decreased and admissions as transfers from the intensive care unit increased. The average intern census was not affected by the duty-hour regulations. Conclusions Medicine residents admit fewer patients on daytime inpatient general medicine services under the new duty-hour regulations; however, this is completely offset by an increase in the number of admissions performed on the night rotation, resulting in no net change in the total number of new inpatient encounters handled by first-year medical residents during the course of the academic year. Although this is reassuring, changes that were made in response to the work-hour rules have altered how new admissions are distributed to teams, which has important implications for curricular design and supervision. C1 [Hundert, Samuel A.; White, Andrew A.; Reilly, Dominic F.] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. RP Hundert, SA (reprint author), VA Puget Sound Healthcare Syst, Hosp & Specialty Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM hunderts@uw.edu NR 23 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD AUG PY 2015 VL 108 IS 8 BP 476 EP 481 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CP3WC UT WOS:000359812400006 PM 26280773 ER PT J AU Kahle, KT Khanna, AR Alper, SL Adragna, NC Lauf, PK Sun, DD Delpire, E AF Kahle, Kristopher T. Khanna, Arjun R. Alper, Seth L. Adragna, Norma C. Lauf, Peter K. Sun, Dandan Delpire, Eric TI K-Cl cotransporters, cell volume homeostasis, and neurological disease SO TRENDS IN MOLECULAR MEDICINE LA English DT Review DE KCC2; KCC3; NKCC1; WNK-SPAK/OSR1; cell volume; cerebral edema ID CATION-CHLORIDE COTRANSPORTERS; CONDITIONAL MOUSE MODEL; REGULATED ANION CHANNEL; CENTRAL-NERVOUS-SYSTEM; ALANINE-RICH KINASE; CORPUS-CALLOSUM; SENSORY NEUROPATHY; KCL COTRANSPORTER; HEREDITARY MOTOR; FUNCTIONAL-CHARACTERIZATION AB K+-Cl- cotransporters (KCCs) were originally characterized as regulators of red blood cell (RBC) volume. Since then, four distinct KCCs have been cloned, and their importance for volume regulation has been demonstrated in other cell types. Genetic models of certain KCCs, such as KCC3, and their inhibitory WNK-STE20/SPS1-related proline/alanine-rich kinase (SPAK) serine-threonine kinases, have demonstrated the evolutionary necessity of these molecules for nervous system cell volume regulation, structure, and function, and their involvement in neurological disease. The recent characterization of a swelling-activated dephosphorylation mechanism that potently stimulates the KCCs has pinpointed a potentially druggable switch of KCC activity. An improved understanding of WNK/SPAK-mediated KCC cell volume regulation in the nervous system might reveal novel avenues for the treatment of multiple neurological diseases. C1 [Kahle, Kristopher T.; Khanna, Arjun R.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Kahle, Kristopher T.; Khanna, Arjun R.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Kahle, Kristopher T.] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02114 USA. [Alper, Seth L.] Harvard Univ, Sch Med, Div Renal, Boston, MA 02215 USA. [Alper, Seth L.] Harvard Univ, Sch Med, Mol & Vasc Med Div, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Alper, Seth L.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. [Adragna, Norma C.; Lauf, Peter K.] Wright State Univ, Boonshoft Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA. [Lauf, Peter K.] Wright State Univ, Boonshoft Sch Med, Dept Pathol, Dayton, OH 45435 USA. [Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15217 USA. [Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA. [Delpire, Eric] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA. RP Kahle, KT (reprint author), Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02114 USA. EM kkahle@enders.tch.harvard.edu; eric.delpire@vanderbilt.edu FU NIGMS NIH HHS [R01 GM074771]; NINDS NIH HHS [R01 NS038118] NR 108 TC 19 Z9 20 U1 1 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4914 EI 1471-499X J9 TRENDS MOL MED JI Trends Mol. Med PD AUG PY 2015 VL 21 IS 8 BP 513 EP 523 DI 10.1016/j.molmed.2015.05.008 PG 11 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA CP4YJ UT WOS:000359888200008 PM 26142773 ER PT J AU Hope, TA Pampaloni, MH Nakakura, E VanBrocklin, H Slater, J Jivan, S Aparici, CM Yee, J Bergsland, E AF Hope, Thomas A. Pampaloni, Miguel Hernandez Nakakura, Eric VanBrocklin, Henry Slater, James Jivan, Salma Aparici, Carina Mari Yee, Judy Bergsland, Emily TI Simultaneous Ga-68-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor SO ABDOMINAL IMAGING LA English DT Article DE Neuroendocrine tumor; Hepatobiliary agents; PET/MRI; Ga-68 DOTA-TOC ID SOMATOSTATIN RECEPTOR SCINTIGRAPHY; EOB-DTPA; LIVER METASTASES; MRI; PET; CONTRAST; MANAGEMENT; LESIONS; CT AB To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of Ga-68-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a Ga-68-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99% vs. 46% and 64%, respectively; p values < 0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson's correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. A simultaneous PET/MRI using both Ga-68-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases. C1 [Hope, Thomas A.; Pampaloni, Miguel Hernandez; VanBrocklin, Henry; Slater, James; Jivan, Salma; Aparici, Carina Mari; Yee, Judy] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Hope, Thomas A.; Yee, Judy] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. [Nakakura, Eric] Univ Calif San Francisco, Dept Surg, Div Surg Oncol, San Francisco, CA 94143 USA. [Bergsland, Emily] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA. RP Hope, TA (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave 0628, San Francisco, CA 94143 USA. EM thomas.hope@ucsf.edu FU Wylie J. Dodds Research Award, Society of Abdominal Radiology, GE Healthcare FX Grant support from Wylie J. Dodds Research Award, Society of Abdominal Radiology, GE Healthcare. NR 19 TC 7 Z9 7 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0942-8925 EI 1432-0509 J9 ABDOM IMAGING JI Abdom. Imaging PD AUG PY 2015 VL 40 IS 6 BP 1432 EP 1440 DI 10.1007/s00261-015-0409-9 PG 9 WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging GA CO8QM UT WOS:000359435300010 PM 25820755 ER PT J AU Jenkins, TC Knepper, BC Moore, SJ Saveli, CC Pawlowski, SW Perlman, DM McCollister, BD Burman, WJ AF Jenkins, Timothy C. Knepper, Bryan C. Moore, S. Jason Saveli, Carla C. Pawlowski, Sean W. Perlman, Daniel M. McCollister, Bruce D. Burman, William J. TI Microbiology and Initial Antibiotic Therapy for Injection Drug Users and Non-Injection Drug Users with Cutaneous Abscesses in the Era of Community-associated Methicillin-resistant Staphylococcus aureus SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID SOFT-TISSUE INFECTIONS; ACUTE BACTERIAL SKIN; EMERGENCY-DEPARTMENT AB ObjectivesThe incidence of cutaneous abscesses has increased markedly since the emergence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Injection drug use is a risk factor for abscesses and may affect the microbiology and treatment of these infections. In a cohort of patients hospitalized with cutaneous abscesses in the era of CA-MRSA, the objectives were to compare the microbiology of abscesses between injection drug users and non-injection drug users and evaluate antibiotic therapy started in the emergency department (ED) in relation to microbiologic findings and national guideline treatment recommendations. MethodsThis was a secondary analysis of two published retrospective cohorts of patients requiring hospitalization for acute bacterial skin infections between January 1, 2007, and May 31, 2012, in seven academic and community hospitals in Colorado. In the subgroup of patients with cutaneous abscesses, microbiologic findings and the antibiotic regimens started in the ED were compared between injection drug users and non-injection drug users. Antibiotic regimens involving multiple agents, lack of activity against MRSA, or an agent with broad Gram-negative activity were classified as discordant with Infectious Diseases Society of America (IDSA) guideline treatment recommendations. ResultsOf 323 patients with cutaneous abscesses, 104 (32%) occurred in injection drug users. Among the 235 cases where at least one microorganism was identified by culture, S.aureus was identified less commonly among injection drug users compared with non-injection drug users (55% vs. 75%, p=0.003), with similar patterns observed for MRSA (33% vs. 47%, p=0.054) and methicillin-susceptible S.aureus (17% vs. 26%, p=0.11). In contrast to S.aureus, streptococcal species (53% vs. 25%, p<0.001) and anaerobic organisms (29% vs. 10%, p<0.001) were identified more commonly among injection drug users. Of 88 injection drug users and 186 non-injection drug users for whom antibiotics were started in the ED, the antibiotic regimens were discordant with IDSA guideline recommendations in 47 (53%) and 101 (54%), respectively (p=0.89). In cases where MRSA was ultimately identified, the antibiotic regimen started in the ED lacked activity against this pathogen in 14% of cases. ConclusionsCompared with non-injection drug users, cutaneous abscesses in injection drug users were less likely to involve S.aureus, including MRSA, and more likely to involve streptococci and anaerobes; however, MRSA was common in both groups. Antibiotic regimens started in the ED were discordant with national guidelines in over half of cases and often lacked activity against MRSA when this pathogen was present. C1 [Jenkins, Timothy C.; Burman, William J.] Denver Hlth, Dept Med, Denver, CO 80230 USA. [Jenkins, Timothy C.; Burman, William J.] Denver Hlth, Div Infect Dis, Denver, CO USA. [Knepper, Bryan C.] Denver Hlth, Dept Patient Safety & Qual, Denver, CO USA. [Burman, William J.] Denver Hlth, Denver Publ Hlth, Denver, CO USA. [Jenkins, Timothy C.; Saveli, Carla C.; McCollister, Bruce D.; Burman, William J.] Univ Colorado, Sch Med, Dept Med, Div Infect Dis, Aurora, CO USA. [Moore, S. Jason] Vail Valley Med Ctr, Dept Trauma & Crit Care Serv, Vail, CO USA. [Pawlowski, Sean W.] Colorado Infect Dis Associates, Denver, CO USA. [Perlman, Daniel M.] Porter Adventist Med Ctr, Dept Med, Denver, CO USA. [McCollister, Bruce D.] Denver Vet Affairs Med Ctr, Dept Med, Div Infect Dis, Denver, CO USA. RP Jenkins, TC (reprint author), Denver Hlth, Dept Med, Denver, CO 80230 USA. EM timothy.jenkins@dhha.org FU NIAID NIH HHS [K23 AI099082] NR 13 TC 0 Z9 1 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD AUG PY 2015 VL 22 IS 8 BP 993 EP 997 DI 10.1111/acem.12727 PG 5 WC Emergency Medicine SC Emergency Medicine GA CO8OE UT WOS:000359428400015 PM 26202847 ER PT J AU Janech, MG Rodgers, JL Arthur, JM Velez, JCQ AF Janech, Michael G. Rodgers, Jessalyn L. Arthur, John M. Velez, Juan Carlos Q. TI Letter to the editor: "Concern regarding quantification of urinary nephrin by a commercially available ELISA" SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Letter ID SPONTANEOUSLY HYPERTENSIVE-RATS; INJURY C1 [Janech, Michael G.; Rodgers, Jessalyn L.; Arthur, John M.; Velez, Juan Carlos Q.] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Arthur, John M.; Velez, Juan Carlos Q.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Arthur, John M.] Univ Arkansas Med Sci, Div Nephrol, Little Rock, AR 72205 USA. RP Janech, MG (reprint author), Med Univ S Carolina, Div Nephrol, 96 Jonathan Lucas St,829 Clinical Sci Bldg, Charleston, SC 29425 USA. EM janechmg@musc.edu RI Velez, Juan Carlos/N-3782-2016 OI Janech, Michael/0000-0002-3202-4811 NR 6 TC 1 Z9 1 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD AUG 1 PY 2015 VL 309 IS 3 BP F269 EP F270 DI 10.1152/ajprenal.00159.2015 PG 2 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA CP2TZ UT WOS:000359731400010 PM 26357486 ER PT J AU Subathra, M Korrapati, M Howell, LA Arthur, JM Shayman, JA Schnellmann, RG Siskind, LJ AF Subathra, Marimuthu Korrapati, Midhun Howell, Lauren A. Arthur, John M. Shayman, James A. Schnellmann, Rick G. Siskind, Leah J. TI Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE glycosphingolipids; kidney; diabetic nephropathy; hypertrophy; mesangial cells ID HIGH GLUCOSE; GLUCOSYLCERAMIDE SYNTHASE; INSULIN SENSITIVITY; RENAL-DISEASE; UP-REGULATION; PROLIFERATION; MICE; FIBRONECTIN; METABOLISM; INHIBITION AB Glycosphingolipids (GSLs) play a role in insulin resistance and diabetes, but their role in diabetic nephropathy (DN) has received limited attention. We used 9- and 17-wk-old nondiabetic db/m and diabetic db/db mice to examine the role of GSLs in DN. Cerebrosides or monoglycosylated GSLs [hexosylceramides (HexCers); glucosyl- and galactosylceramides] and lactosylceramide (LacCers) were elevated in db/db mouse kidney cortices, specifically in glomeruli, and also in urine. In our recent paper (25), we observed that the kidneys exhibited glomerular hypertrophy and proximal tubular vacuolization and increased fibrosis markers at these time points. Mesangial cells contribute to hyperglycemia- induced glomerular hypertrophy in DN. Hyperglycemic culture conditions, similar to that present in diabetes, were sufficient to elevate mesangial cell HexCers and increase markers of fibrosis, extracellular matrix proteins, and cellular hypertrophy. Inhibition of glucosylceramide synthase or lowering glucose levels decreased markers of fibrosis and extracellular matrix proteins and reversed mesangial cell hypertrophy. Hyperglycemia increased phosphorylated (p)SMAD3 and pAkt levels and reduced phosphatase and tensin homolog levels, which were reversed with glucosylceramide synthase inhibition. These data suggest that inhibition of glucosylceramide synthase reversed mesangial cell hypertrophy through decreased pAkt and pSmad3 and increased pathways responsible for protein degradation. Importantly, urinary GSL levels were higher in patients with DN compared with healthy control subjects, implicating a role for these lipids in human DN. Thus, hyperglycemia in type II diabetes leads to renal dysfunction at least in part by inducing accumulation of HexCers and LacCers in mesangial cells, resulting in fibrosis, extracellular matrix production, and hypertrophy. C1 [Subathra, Marimuthu; Siskind, Leah J.] Univ Louisville, Dept Pharmacol & Toxicol, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. [Korrapati, Midhun; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Howell, Lauren A.] Florida State Univ, Dept Biomed Sci, Tallahassee, FL 32306 USA. [Arthur, John M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Arthur, John M.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA. [Shayman, James A.] Univ Michigan, Sch Med, Nephrol Div, Dept Internal Med, Ann Arbor, MI 48109 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Siskind, LJ (reprint author), Univ Louisville, Dept Pharmacol & Toxicol, 505 S Hancock St,CTRB 203, Louisville, KY 40292 USA. EM leah.siskind@louisville.edu FU National Institutes of Health (NIH) [P20-RR-17677, R01-DK-093462, R01-DK-101034, R01-GM-084147]; Veterans Administration Merit Review Grant [BX-000851]; Veterans Affairs Research Enhancement Award Program; Lipidomics Shared Resource of the Hollings Cancer Center at the Medical University of South Carolina - NIH Grant [P30-CA-138313] FX This work was supported by National Institutes of Health (NIH) Grants P20-RR-17677 (COBRE in Lipidomics and Pathobiology pilot project), R01-DK-093462 (to L. J. Siskind), R01-DK-101034 (to J. M. Arthur), and R01-GM-084147 (to R. G. Schnellmann), Veterans Administration Merit Review Grant BX-000851 (to R. G. Schnellmann), Veterans Affairs Research Enhancement Award Program pilot project funding (to L. J. Siskind, J. M. Arthur, and R. G. Schnellmann), and the Lipidomics Shared Resource of the Hollings Cancer Center at the Medical University of South Carolina, supported by NIH Grant P30-CA-138313. NR 65 TC 4 Z9 6 U1 2 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD AUG 1 PY 2015 VL 309 IS 3 BP F204 EP F215 DI 10.1152/ajprenal.00150.2015 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA CP2TZ UT WOS:000359731400003 PM 26041445 ER PT J AU Mylonakis, E Clancy, CJ Ostrosky-Zeichner, L Garey, KW Alangaden, GJ Vazquez, JA Groeger, JS Judson, MA Vinagre, YM Heard, SO Zervou, FN Zacharioudakis, IM Kontoyiannis, DP Pappas, PG AF Mylonakis, Eleftherios Clancy, Cornelius J. Ostrosky-Zeichner, Luis Garey, Kevin W. Alangaden, George J. Vazquez, Jose A. Groeger, Jeffrey S. Judson, Marc A. Vinagre, Yuka-Marie Heard, Stephen O. Zervou, Fainareti N. Zacharioudakis, Ioannis M. Kontoyiannis, Dimitrios P. Pappas, Peter G. TI When Diagnostic Technology Is Ahead of the Hospital Budget: What Is Antimicrobial Stewardship to Do? Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID CANDIDEMIA; IMPACT; RISK C1 [Mylonakis, Eleftherios; Zervou, Fainareti N.; Zacharioudakis, Ioannis M.] Brown Univ, Rhode Isl Hosp, Div Infect Dis, Warren Alpert Med Sch, Providence, RI 02903 USA. [Clancy, Cornelius J.] Univ Pittsburgh, Div Infect Dis, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Ostrosky-Zeichner, Luis] Univ Texas Houston, Sch Med, Div Infect Dis, Houston, TX USA. [Ostrosky-Zeichner, Luis] Mem Hermann Texas Med Ctr, Houston, TX USA. [Garey, Kevin W.] Univ Houston, Coll Pharm, Houston, TX 77004 USA. [Alangaden, George J.] Henry Ford Hlth Syst, Div Infect Dis, Detroit, MI USA. [Vazquez, Jose A.] Georgia Regents Univ, Med Coll Georgia, Dept Med, Augusta, GA USA. [Groeger, Jeffrey S.] Mem Sloan Kettering Canc Ctr, Urgent Care Serv, New York, NY 10021 USA. [Judson, Marc A.] Albany Med, Div Pulm & Crit Care Med, New York, NY USA. [Vinagre, Yuka-Marie] St Vincent Hosp, Dept Crit Care Med, Worcester, MA 01604 USA. [Heard, Stephen O.] UMass Mem Med Ctr, Dept Anesthesiol, Worcester, MA USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA. [Pappas, Peter G.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. RP Mylonakis, E (reprint author), Brown Univ, Rhode Isl Hosp, Div Infect Dis, Warren Alpert Med Sch, 593 Eddy St,3rd Floor,Ste 328-330, Providence, RI 02903 USA. EM emylonakis@lifespan.org NR 10 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2015 VL 61 IS 3 BP 487 EP 488 DI 10.1093/cid/civ357 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MM UT WOS:000359343500030 PM 25944341 ER PT J AU Basu, PP James, N AF Basu, P. Patrick James, Niraj TI Clinical and Neurologic Manifestation of Minimal Hepatic Encephalopathy and Overt Hepatic Encephalopathy SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Neurologic manifestation; Minimal hepatic encephalopathy; MHE; Overt hepatic encephalopathy; OHE ID SLEEP DISTURBANCE; LIVER-CIRRHOSIS; MELATONIN; HYPERAMMONEMIA; INFLAMMATION; IMPAIRMENT; PREVALENCE; MECHANISMS; DIAGNOSIS; FAILURE AB Hepatic encephalopathy (HE) shows a wide spectrum of neuropsychiatric manifestations. A combined effort with neuropsychological and psychometric evaluation has to be performed to recognize the syndrome, whereas minimal HE (MHE) is largely under-recognized. Subtle symptoms of MHE can only be diagnosed through specialized neuropsychiatric testing. Early diagnosis and treatment may drastically improve the quality of life for many cirrhotic patients. Further research to gain better insight into the pathophysiology and diagnostic accuracy of HE will help determine future management strategies. C1 [Basu, P. Patrick] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Basu, P. Patrick] Kings Cty Hosp Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [James, Niraj] Icahn Sch Med Mt Sinai, Dept Med, James J Peters VA Med Ctr, New York, NY 10468 USA. RP James, N (reprint author), Icahn Sch Med Mt Sinai, Dept Med, James J Peters VA Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA. EM nirajjames@gmail.com NR 52 TC 0 Z9 0 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD AUG PY 2015 VL 31 IS 3 BP 461 EP + DI 10.1016/j.cld.2015.05.003 PG 13 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA CO9PK UT WOS:000359507500003 PM 26195201 ER PT J AU Anzueto, A AF Anzueto, Antonio TI Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease: A Family Perspective SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Editorial Material DE augmentation therapy; caregiver; chronic bronchitis; emphysema ID QUALITY-OF-LIFE; HEREDITARY ALPHA(1)-ANTITRYPSIN DEFICIENCY; AUGMENTATION THERAPY; MULTIPLE-SCLEROSIS; ANTITRYPSIN DEFICIENCY; LUNG-FUNCTION; PI-TYPES; INDIVIDUALS; HYPERTENSION; DENSITOMETRY AB Alpha-1 antitrypsin (AAT) deficiency (AATD) is a genetic condition that can lead to the early onset of chronic obstructive pulmonary disease (COPD), a disorder that comprises elements of chronic bronchitis and emphysema. AATD is characterized by reduced levels of the AAT protease inhibitor, leading to unrestricted protease activity in the lung, which promotes destruction of lung tissue. In severe cases, patients with AATD have an increased mortality risk and, potentially, a poor quality of life due to more frequent COPD exacerbations and/or limitations on daily activity. However, the burden of AATD on members of the patient's immediate family who may serve as caregivers has not been described. Because the age range at which most patients are diagnosed with AATD may affect the economic status of an individual and/or of a family, it is likely that a diagnosis of AATD may have negative effects that extend beyond those on the diagnosed person to include immediate family members. Here, we review the literature to investigate the impact of the caregiver role of family members in disease states that affect an age group similar to AATD. Furthermore, we provide a case study showing the effect of AATD on immediate family members. C1 [Anzueto, Antonio] Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Pulm Dis, Suite 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu NR 39 TC 1 Z9 1 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1541-2555 EI 1541-2563 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD AUG PY 2015 VL 12 IS 4 BP 462 EP 467 DI 10.3109/15412555.2014.974746 PG 6 WC Respiratory System SC Respiratory System GA CP4JY UT WOS:000359849000014 PM 25474273 ER PT J AU Keeling, BH Whitsitt, J Liu, A Dunnick, CA AF Keeling, Brett H. Whitsitt, Jacob Liu, Arthur Dunnick, Cory A. TI Keloid Removal by Shave Excision With Adjuvant External Beam Radiation Therapy SO DERMATOLOGIC SURGERY LA English DT Letter C1 [Keeling, Brett H.] Texas So Univ, Dept Dermatol, Austin, TX 78712 USA. [Whitsitt, Jacob] Univ Colorado, Sch Med, Aurora, CO USA. [Liu, Arthur] Univ Colorado, Dept Radiat Oncol, Aurora, CO USA. [Dunnick, Cory A.] Univ Colorado, Dept Dermatol, Aurora, CO USA. [Dunnick, Cory A.] Denver VA Med Ctr, Dermatol Serv, Denver, CO USA. RP Keeling, BH (reprint author), Texas So Univ, Dept Dermatol, Austin, TX 78712 USA. NR 5 TC 1 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-0512 EI 1524-4725 J9 DERMATOL SURG JI Dermatol. Surg. PD AUG PY 2015 VL 41 IS 8 BP 989 EP 992 DI 10.1097/DSS.0000000000000417 PG 4 WC Dermatology; Surgery SC Dermatology; Surgery GA CP1MS UT WOS:000359640500023 PM 26132894 ER PT J AU Korvatska, O Leverenz, JB Jayadev, S McMillan, P Kurtz, I Guo, XD Rumbaugh, M Matsushita, M Girirajan, S Dorschner, MO Kiianitsa, K Yu, CE Brkanac, Z Garden, GA Raskind, WH Bird, TD AF Korvatska, Olena Leverenz, James B. Jayadev, Suman McMillan, Pamela Kurtz, Irina Guo, Xindi Rumbaugh, Malia Matsushita, Mark Girirajan, Santhosh Dorschner, Michael O. Kiianitsa, Kostantin Yu, Chang-En Brkanac, Zoran Garden, Gwenn A. Raskind, Wendy H. Bird, Thomas D. TI R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family Clinical, Genetic, and Neuropathological Study SO JAMA NEUROLOGY LA English DT Article ID FRONTOTEMPORAL DEMENTIA; RISK-FACTOR; PROLIFERATION; MACROPHAGES; ACTIVATION; MUTATIONS; RELATIVES; SPECTRUM; PATHWAY; REVEAL AB IMPORTANCE The R47H variant in the triggering receptor expressed on myeloid cells 2 gene (TREM2), a modulator of the immune response of microglia, is a strong genetic risk factor for Alzheimer disease (AD) and possibly other neurodegenerative disorders. OBJECTIVE To investigate a large family with late-onset AD (LOAD), in which R47H cosegregated with 75% of cases. DESIGN, SETTING, AND PARTICIPANTS This study includes genetic and pathologic studies of families with LOAD from 1985 to 2014. A total of 131 families with LOAD (751 individuals) were included from the University of Washington Alzheimer Disease Research Center. To identify LOAD genes/risk factors in the LOAD123 family with 21 affected members and 12 autopsies, we sequenced 4 exomes. Candidate variants were tested for cosegregation with the disease. TREM2 R47H was genotyped in an additional 130 families with LOAD. We performed clinical and neuropathological assessments of patients with and without R47H and evaluated the variant's effect on brain pathology, cellular morphology, and expression of microglial markers. MAIN OUTCOMES AND MEASURES We assessed the effect of TREM2 genotype on age at onset and disease duration. We compared Braak and Consortium to Establish a Registry for Alzheimer's Disease scores, presence of a-synuclein and TAR DNA-binding protein 43 aggregates, and additional vascular or Parkinson pathology in TREM2 R47H carriers vs noncarriers. Microglial activation was assessed by quantitative immunohistochemistry and morphometry. RESULTS Twelve of 16 patients with AD in the LOAD123 family carried R47H. Eleven patients with dementia had apolipoprotein E 4 (ApoE4) and R47H genotypes. We also found a rare missense variant, D353N, in a nominated AD risk gene, unc-5 homolog C (UNC5C), in5 affected individuals in the LOAD123 family. R47H carriers demonstrated a shortened disease duration (mean [SD], 6.7 [2.8] vs 11.1 [6.6] years; 2-tailed t test; P = .04) and more frequent alpha-synucleinopathy. The panmicroglial marker ionized calcium-binding adapter molecule 1 was decreased in all AD cases and the decrease was most pronounced in R47H carriers (mean [SD], in the hilus: 0.114 [0.13] for R47H_AD vs 0.574 [0.26] for control individuals; 2-tailed t test; P = .005 and vs 0.465 [0.32] for AD; P = .02; in frontal cortex gray matter: 0.006 [0.004] for R47H_AD vs 0.016 [0.01] for AD; P = .04 and vs 0.033 [0.013] for control individuals; P < .001). Major histocompatibility complex class II, a marker of microglial activation, was increased in all patients with AD (AD: 2.5, R47H_AD: 2.7, and control: 1.0; P < .01). CONCLUSIONS AND RELEVANCE Our results demonstrate a complex genetic landscape of LOAD, even in a single pedigree with an apparent autosomal dominant pattern of inheritance. ApoE4, TREM2 R47H, and rare variants in other genes, such as UNC5C D353N, are likely responsible for the notable occurrence of AD in this family. Our findings support the role of the TREM2 receptor in microglial clearance of aggregation-prone proteins that is compromised in R47H carriers and may accelerate the course of disease. C1 [Korvatska, Olena; McMillan, Pamela; Kurtz, Irina; Guo, Xindi; Dorschner, Michael O.; Brkanac, Zoran; Raskind, Wendy H.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. [Leverenz, James B.] Cleveland Clin Fdn, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44195 USA. [Jayadev, Suman; Rumbaugh, Malia; Garden, Gwenn A.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98108 USA. [McMillan, Pamela; Raskind, Wendy H.] Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Seattle, WA USA. [Matsushita, Mark; Kiianitsa, Kostantin; Raskind, Wendy H.; Bird, Thomas D.] Univ Washington, Dept Med Med Genet, Seattle, WA 98108 USA. [Girirajan, Santhosh] Penn State Univ, Dept Biochem & Mol Biol, State Coll, PA USA. [Girirajan, Santhosh] Penn State Univ, Dept Anthropol, State Coll, PA USA. [Dorschner, Michael O.; Garden, Gwenn A.] Univ Washington, Dept Pathol, Seattle, WA 98108 USA. [Yu, Chang-En; Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Yu, Chang-En] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98108 USA. RP Bird, TD (reprint author), Univ Washington, Dept Neurol & Med Med Genet, VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S ColumbianWay, Seattle, WA 98108 USA. EM tomnroz@uw.edu FU Department of Veterans Affairs (Geriatric Research, Education, and Clinical Centers); National Institutes of Health (National Institute on Aging Genetics Initiative for Late-Onset Alzheimer's Disease) [ADRC P50 AG005136, R01 AG041797-01, R01 NS069719, R01 AG039700, RC1 AG035681]; Van Beber Alzheimer's Disease Research Fund; Washington State Life Sciences Discovery Funds grant [2065508] FX This research was supported by grants from the Department of Veterans Affairs (Geriatric Research, Education, and Clinical Centers); National Institutes of Health grants ADRC P50 AG005136, R01 AG041797-01 (National Institute on Aging Genetics Initiative for Late-Onset Alzheimer's Disease), R01 NS069719, R01 AG039700, and RC1 AG035681; the Van Beber Alzheimer's Disease Research Fund; and Washington State Life Sciences Discovery Funds grant 2065508 to the University of Washington Northwest Institute of Genetic Medicine. NR 38 TC 21 Z9 21 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD AUG PY 2015 VL 72 IS 8 BP 920 EP 927 DI 10.1001/jamaneurol.2015.0979 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CO8GE UT WOS:000359404000013 PM 26076170 ER PT J AU Kaup, AR Nettiksimmons, J Yaffe, K AF Kaup, Allison R. Nettiksimmons, Jasmine Yaffe, Kristine TI Diabetes Mellitus and Cognitive Resilience COMMENT & RESPONSE Reply SO JAMA NEUROLOGY LA English DT Letter ID RISK C1 [Kaup, Allison R.] Univ Calif San Francisco, Res Serv, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Kaup, Allison R.; Nettiksimmons, Jasmine; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Epidemiol & Biostat, San Francisco, CA 94121 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Kaup, AR (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, Res Serv, 4150 Clement St,116H, San Francisco, CA 94121 USA. EM allison.kaup@ucsf.edu FU RRD VA [IK2 RX001629] NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD AUG PY 2015 VL 72 IS 8 BP 949 EP 950 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA CO8GE UT WOS:000359404000024 PM 26258741 ER PT J AU Subotnik, KL Casaus, LR Ventura, J Luo, JS Hellemann, GS Gretchen-Doorly, D Marder, S Nuechterlein, KH AF Subotnik, Kenneth L. Casaus, Laurie R. Ventura, Joseph Luo, John S. Hellemann, Gerhard S. Gretchen-Doorly, Denise Marder, Stephen Nuechterlein, Keith H. TI Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia A Randomized Clinical Trial SO JAMA PSYCHIATRY LA English DT Article ID 1ST-EPISODE SCHIZOPHRENIA; SCHIZOAFFECTIVE DISORDER; MAINTENANCE TREATMENT; ORAL RISPERIDONE; OPEN-LABEL; INJECTION; REMISSION AB IMPORTANCE Long-acting, injectable, second-generation antipsychotic medication has tremendous potential to bring clinical stability to persons with schizophrenia. However, long-acting medications are rarely used following a first episode of schizophrenia. OBJECTIVE To compare the clinical efficacy of the long-acting injectable formulation of risperidone with the oral formulation in the early course of schizophrenia. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial performed at a university-based research clinic, between 2005 and 2012. Eighty-six patients with recent onset of schizophrenia were randomized to receive long-acting injectable risperidone or oral risperidone. Half of each group was simultaneously randomized to receive cognitive remediation to improve cognitive functioning or healthy-behaviors training to improve lifestyle habits and well-being. An intent-to-treat analysis was performed between October 4, 2012, and November 12, 2014. INTERVENTIONS A 12-month trial comparing the long-acting injectable vs oral risperidone and cognitive remediation vs healthy-behaviors training. MAIN OUTCOMES AND MEASURES Psychotic relapse and control of breakthrough psychotic symptoms. RESULTS Of the 86 patients randomized, 3 refused treatment in the long-acting injectable risperidone group. The psychotic exacerbation and/or relapse rate was lower for the long-acting risperidone group compared with the oral group (5% vs 33%; chi(2)(1) = 11.1; P < .001; relative risk reduction, 84.7%). Long-acting injectable risperidone better controlled mean levels of hallucinations and delusions throughout follow-up (beta = -0.30; t(68) = -2.6, P = .01). The cognitive remediation and healthy-behaviors training groups did not differ significantly regarding psychotic relapse, psychotic symptom control, or hospitalization rates, and there were no significant interactions between the 2 medications and the 2 psychosocial treatments. Discontinuations owing to inadequate clinical response were more common in the oral group than in the long-acting risperidone group (chi(2)(1) = 6.1; P = .01). Adherence to oral risperidone did not appear to differ before randomization but was better for the long-acting risperidone group compared with the oral group (t(80) = 5.3; P < .001). Medication adherence was associated with prevention of exacerbation and/or relapse (chi(2)(1) = 11.1; P = .003) and control of breakthrough psychotic symptoms (beta = 0.2; t(79) = 2.1; P = .04). CONCLUSIONS AND RELEVANCE The use of long-acting injectable risperidone after a first episode of schizophrenia has notable advantages for clinical outcomes. The key clinical advantages are apparently owing to the more consistent administration of the long-acting injectable. Such formulations should be offered earlier in the course of illness. C1 [Subotnik, Kenneth L.; Casaus, Laurie R.; Ventura, Joseph; Luo, John S.; Hellemann, Gerhard S.; Gretchen-Doorly, Denise; Marder, Stephen; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Marder, Stephen] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. RP Subotnik, KL (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Room 2240, Los Angeles, CA 90095 USA. EM ksubotnik@mednet.ucla.edu FU National Institute of Mental Health [MH037705, MH066286]; Janssen Scientific Affairs, LLC FX This research was supported by grants MH037705 (clinicalTrials.gov Identifier: NCT00333177) and MH066286 (clinicalTrials.gov Identifier: NCT00330551) from the National Institute of Mental Health (Dr Nuechterlein) and supplementary funding and medication was provided by Janssen Scientific Affairs, LLC. NR 23 TC 27 Z9 28 U1 4 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD AUG PY 2015 VL 72 IS 8 BP 822 EP 829 DI 10.1001/jamapsychiatry.2015.0270 PG 8 WC Psychiatry SC Psychiatry GA CO5LG UT WOS:000359200000011 PM 26107752 ER PT J AU Psotka, MA Teerlink, JR Chiswell, K Cleland, JG Cotter, G Davison, BA Givertz, MM Metra, M Ponikowski, P Voors, AA Bloomfield, DM O'Connor, CM AF Psotka, Mitchell A. Teerlink, John R. Chiswell, Karen Cleland, John G. Cotter, Gad Davison, Beth A. Givertz, Michael M. Metra, Marco Ponikowski, Piotr Voors, Adriaan A. Bloomfield, Daniel M. O'Connor, Christopher M. TI Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 19th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 26-29, 2015 CL National Harbor, MD SP Heart Failure Soc Amer C1 [Psotka, Mitchell A.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Psotka, Mitchell A.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Chiswell, Karen; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Natl Heart & Lung Inst, London, England. [Cotter, Gad; Davison, Beth A.] Momentum Res, Durham, NC USA. [Givertz, Michael M.] Brigham & Womens Hosp, Boson, MA USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Voors, Adriaan A.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 NR 0 TC 0 Z9 0 U1 0 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2015 VL 21 IS 8 SU S MA 135 BP S64 EP S64 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CO8CI UT WOS:000359392200160 ER PT J AU O'Brien, SE Schrodi, SJ Ye, Z Brilliant, MH Virani, SS Brautbar, A AF O'Brien, Sarah E. Schrodi, Steven J. Ye, Zhan Brilliant, Murray H. Virani, Salim S. Brautbar, Ariel TI Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; FENOFIBRIC ACID; WHOLE-GENOME; THERAPY; EFFICACY; COHORT; TRIAL; TOOL AB Genetic variants within the BUD13-APOA5 gene region are known to be associated with high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. Recent studies suggest that single nucleotide polymorphisms (SNPs) within this region affect HDL-C response to statin-fibrate combination therapy and low-density lipoprotein cholesterol (LDL-C) response to statin therapy. We hypothesized that SNPs within the BUD13-APOA5 region are associated with TG, HDL-C, and LDL-C response to statin therapy. We examined 1520 observations for 1086 patients from the Personalized Medicine Research Project, a large biorepository at the Marshfield Clinic Research Foundation, who had received statin therapy and been previously genotyped for polymorphisms in the 11q23 chromosomal region. A significant differential response to statin therapy was observed for 3 SNPs. The minor allele at rs11605293 significantly attenuated TG-lowering response to pravastatin (P = 0.000159), whereas the minor allele at rs12806755 was associated with a similar response to lovastatin (P = 0.000192). Genotypes at rs947990 significantly attenuated LDL-C reduction to atorvastatin therapy (P = 0.000668) with some patients with the minor allele having LDL-C increase after therapy. No SNPs within the BUD13-APOA5 region were associated with a significant effect on HDL-C reduction in response to statin therapy. In conclusion, this study suggests that common SNPs within the BUD13-APOA5 can affect TG and LDL-C response to statin therapy in a North American population. C1 [O'Brien, Sarah E.; Schrodi, Steven J.; Ye, Zhan; Brilliant, Murray H.; Brautbar, Ariel] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA. [Virani, Salim S.] Baylor Coll Med, Hlth Serv Res & Dev, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA. [Brautbar, Ariel] Cook Childrens Med Ctr, Div Genet & Endocrinol, Ft Worth, TX USA. RP Brautbar, A (reprint author), Baylor Coll Med, Dept Med, 6565 Fannin St, Houston, TX 77030 USA. EM brautbar@bcm.edu OI Schrodi, Steven/0000-0003-2304-8528; Virani, Salim/0000-0001-9541-6954 FU Marshfield Clinic Research Foundation; Clinical and Translational Science Award (CTSA) program through the National Center for Research Resources (NCRR) [1UL1RR025011]; National Center for Advancing Translational Sciences (NCATS) [9U54TR000021]; NCATS [UL1TR000427] FX Supported by Marshfield Clinic Research Foundation, generous donors to Marshfield Clinic, and the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011 and the National Center for Advancing Translational Sciences (NCATS) grant 9U54TR000021, and now by the NCATS grant UL1TR000427. NR 21 TC 1 Z9 1 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD AUG PY 2015 VL 66 IS 2 BP 183 EP 188 DI 10.1097/FJC.0000000000000261 PG 6 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA CP1WO UT WOS:000359668300008 PM 25900265 ER PT J AU Lipsky, RK McGuinness, TM AF Lipsky, Rachele K. McGuinness, Teena M. TI Binge Eating Disorder and Youth SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES LA English DT Article ID ADOLESCENT GIRLS; COMORBIDITY; CHILDREN; OBESITY; ADULTS; TRIAL AB Children and adolescents who eat unusually large amounts of food, feel guilty about it, and try to hide their overeating may be struggling with binge eating disorder (BED), a condition associated with suicidal ideation and other eating disorders. Although BED is new to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, the syndrome is becoming increasingly recognized. The study of BED in children and adolescents is in its natal phase, but the importance of recognition and possible treatment strategies are discussed in the current article along with psychiatric nursing implications. C1 [Lipsky, Rachele K.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [McGuinness, Teena M.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. RP Lipsky, RK (reprint author), Birmingham VA Med Ctr, 700 South 19th St, Birmingham, AL 35233 USA. EM Rachele.Lipsky@va.gov NR 19 TC 1 Z9 1 U1 2 U2 7 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0279-3695 EI 1938-2413 J9 J PSYCHOSOC NURS MEN JI J. Psychosoc. Nurs. Ment. Health Serv. PD AUG PY 2015 VL 53 IS 8 BP 18 EP 22 DI 10.3928/02793695-20150720-03 PG 5 WC Nursing SC Nursing GA CO6YD UT WOS:000359302800009 PM 26268477 ER PT J AU Knight, SJ Mohamed, AF Marshall, DA Ladabaum, U Phillips, KA Walsh, JME AF Knight, Sara J. Mohamed, Ateesha F. Marshall, Deborah A. Ladabaum, Uri Phillips, Kathryn A. Walsh, Judith M. E. TI Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample SO MEDICAL DECISION MAKING LA English DT Article DE genetics; oncology; internal medicine; discrete choice; utility assessment ID LYNCH-SYNDROME; PRIMARY-CARE; CHOICE EXPERIMENTS; CONJOINT-ANALYSIS; PATIENT PREFERENCES; EXPERIMENTAL-DESIGN; GENERAL-POPULATION; COST-EFFECTIVENESS; FAMILY-HISTORY; KNOWLEDGE AB Background. While choices about genetic testing are increasingly common for patients and families, and public opinion surveys suggest public interest in genomics, it is not known how adults from the general population value genetic testing for heritable conditions. We sought to understand in a US sample the relative value of the characteristics of genetic tests to identify risk of hereditary colorectal cancer, among the first genomic applications with evidence to support its translation to clinical settings. Methods. A Web-enabled choice-format conjoint survey was conducted with adults age 50 years and older from a probability-based US panel. Participants were asked to make a series of choices between 2 hypothetical blood tests that differed in risk of false-negative test, privacy, and cost. Random parameters logit models were used to estimate preferences, the dollar value of genetic information, and intent to have genetic testing. Results. A total of 355 individuals completed choice-format questions. Cost and privacy were more highly valued than reducing the chance of a false-negative result. Most (97% [95% confidence interval (CI)], 95%-99%) would have genetic testing to reduce the risk of dying of colorectal cancer in the best scenario (no false negatives, results disclosed to primary care physician). Only 41% (95% CI, 25%-57%) would have genetic testing in the worst case (20% false negatives, results disclosed to insurance company). Conclusions. Given the characteristics and levels included in the choice, if false-negative test results are unlikely and results are shared with a primary care physician, the majority would have genetic testing. As genomic services become widely available, primary care professionals will need to be increasingly knowledgeable about genetic testing decisions. C1 [Knight, Sara J.] Birmingham Vet Affairs Med Ctr, Hlth Serv Res & Dev Program, Birmingham, AL USA. [Knight, Sara J.] Univ Alabama Birmingham, Div Prevent Med, Dept Med, Birmingham, AL 35205 USA. [Mohamed, Ateesha F.] Bayer Healthcare Pharmaceut Inc, Specialty Med, CHEOR, Whippany, NJ USA. [Marshall, Deborah A.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada. [Ladabaum, Uri] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA. [Phillips, Kathryn A.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA. [Phillips, Kathryn A.] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Walsh, Judith M. E.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Walsh, Judith M. E.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Walsh, Judith M. E.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. RP Knight, SJ (reprint author), Univ Alabama Birmingham, Div Prevent Med, Med Towers Bldg,1717 11th Ave South,Suite 650, Birmingham, AL 35205 USA. EM sjknight@uab.edu FU National Cancer Institute [P01CA130818-1A1] FX Received 21 April 2013 from Health Services Research and Development Program, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA (SJK); Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA (SJK); CHEOR, Specialty Medicine, Bayer Healthcare Pharmaceuticals, Inc., Whippany, New Jersey, USA (AFM); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (DAM); Department of Medicine, Stanford University, Palo Alto, California, USA (UL); Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California at San Francisco, San Francisco, California, USA (KAP); and Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California, USA (JMEW). Uri Ladabaum, MD, MS, declares a potential perceived conflict of interest with Exact Sciences Corporation (Madison, WI) and Given Imaging Ltd. (Duluth, GA)/Covidien Plc (Dublin, Ireland), for whom he has served as consultant, and Mauna Kea Technologies, Inc. (Suwanee, GA), for whom he has served on an advisory board. This work was supported with a grant from the National Cancer Institute (P01CA130818-1A1) (Kathryn A. Phillips, principal investigator; Judith M. E. Walsh and Sara J. Knight, co-leaders of the Preferences Project). This article represents the perspective of the authors and does not necessarily represent the views of the Department of Veterans Affairs or the US government. The funding agreement ensured the authors' independence in designing the study, interpreting the data, and writing and publishing the report. Revision accepted for publication 11 November 2014. NR 56 TC 0 Z9 0 U1 4 U2 14 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X EI 1552-681X J9 MED DECIS MAKING JI Med. Decis. Mak. PD AUG PY 2015 VL 35 IS 6 BP 734 EP 744 DI 10.1177/0272989X14565820 PG 11 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA CO8NX UT WOS:000359427600007 ER PT J AU Maharshak, N Ryu, HS Fan, TJ Onyiah, JC Schulz, S Otterbein, SL Wong, R Hansen, JJ Otterbein, LE Carroll, IM Plevy, SE AF Maharshak, Nitsan Ryu, Hyungjin Sally Fan, Ting-Jia Onyiah, Joseph C. Schulz, Stephanie Otterbein, Sherrie L. Wong, Ron Hansen, Jonathan J. Otterbein, Leo E. Carroll, Ian M. Plevy, Scott E. TI Escherichia coli heme oxygenase modulates host innate immune responses SO MICROBIOLOGY AND IMMUNOLOGY LA English DT Article DE carbon monoxide; chuS; enteric microbiota; heme oxygenase ID CARBON-MONOXIDE SUPPRESSES; DENDRITIC CELLS; INTESTINAL INFLAMMATION; PSEUDOMONAS-AERUGINOSA; MURINE COLITIS; T-CELLS; MICE; TRANSCRIPTION; EXPOSURE; EXPRESSION AB Induction of mammalian heme oxygenase (HO)-1 and exposure of animals to carbon monoxide (CO) ameliorates experimental colitis. When enteric bacteria, including Escherichia coli, are exposed to low iron conditions, they express an HO-like enzyme, chuS, and metabolize heme into iron, biliverdin and CO. Given the abundance of enteric bacteria residing in the intestinal lumen, our postulate was that commensal intestinal bacteria may be a significant source of CO and those that express chuS and other Ho-like molecules suppress inflammatory immune responses through release of CO. According to real-time PCR, exposure of mice to CO results in changes in enteric bacterial composition and increases E. coli 16S and chuS DNA. Moreover, the severity of experimental colitis correlates positively with E. coli chuS expression in IL-10 deficient mice. To explore functional roles, E. coli were genetically modified to overexpress chuS or the chuS gene was deleted. Co-culture of chuS-overexpressing E. coli with bone marrow-derived macrophages resulted in less IL-12p40 and greater IL-10 secretion than in wild-type or chuS-deficient E. coli. Mice infected with chuS-overexpressing E. coli have more hepatic CO and less serum IL-12 p40 than mice infected with chuS-deficient E. coli. Thus, CO alters the composition of the commensal intestinal microbiota and expands populations of E. coli that harbor the chuS gene. These bacteria are capable of attenuating innate immune responses through expression of chuS. Bacterial HO-like molecules and bacteria-derived CO may represent novel targets for therapeutic intervention in inflammatory conditions. C1 [Maharshak, Nitsan; Ryu, Hyungjin Sally; Fan, Ting-Jia; Onyiah, Joseph C.; Hansen, Jonathan J.; Carroll, Ian M.; Plevy, Scott E.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Maharshak, Nitsan; Ryu, Hyungjin Sally; Fan, Ting-Jia; Onyiah, Joseph C.; Hansen, Jonathan J.; Carroll, Ian M.; Plevy, Scott E.] Univ N Carolina, Ctr GI Biol & Dis, Chapel Hill, NC USA. [Maharshak, Nitsan; Hansen, Jonathan J.; Plevy, Scott E.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA. [Maharshak, Nitsan] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Dept Gastroenterol & Liver Dis, IL-6997801 Tel Aviv, Israel. [Onyiah, Joseph C.] Univ Colorado, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO USA. [Onyiah, Joseph C.] Denver VA Med Ctr, Denver, CO 80220 USA. [Schulz, Stephanie; Wong, Ron; Otterbein, Leo E.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Stanford, CA 94305 USA. [Otterbein, Sherrie L.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02115 USA. RP Maharshak, N (reprint author), Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol & Liver Dis, 6 Weizman St, IL-64239 Tel Aviv, Israel. EM nitsanm@tlvmc.gov.il FU National Institutes of Health [R01 DK54452]; Crohn's and Colitis Foundation of America Research Fellowship Award; Gastroenterology Research Training Grant [T32 DK007737]; Center for Gastrointestinal Biology and Disease [P30 DK034987] FX This work was supported by National Institutes of Health Grants R01 DK54452 (S.E.P.); a Crohn's and Colitis Foundation of America Research Fellowship Award (N.M.); a Gastroenterology Research Training Grant T32 DK007737 (J.C.O.); and the Center for Gastrointestinal Biology and Disease P30 DK034987 (Immunotechnologies and Histology Core). NR 46 TC 2 Z9 2 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0385-5600 EI 1348-0421 J9 MICROBIOL IMMUNOL JI Microbiol. Immunol. PD AUG PY 2015 VL 59 IS 8 BP 452 EP 465 DI 10.1111/1348-0421.12282 PG 14 WC Immunology; Microbiology SC Immunology; Microbiology GA CP3NP UT WOS:000359787000003 PM 26146866 ER PT J AU Dai, DF Sasaki, K Lin, MY Smith, KD Nicosia, RF Alpers, CE Najafian, B AF Dai, Dao-Fu Sasaki, Kotaro Lin, Mercury Y. Smith, Kelly D. Nicosia, Roberto F. Alpers, Charles E. Najafian, Behzad TI Interstitial eosinophilic aggregates in diabetic nephropathy: allergy or not? SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE allergy; chronic injury; diabetic nephropathy; eosinophil; interstitial nephritis ID NONDIABETIC RENAL-DISEASE; PROTEINURIA; PREVALENCE; BIOPSIES AB Background. Interstitial eosinophilic aggregates (IEA) in renal biopsies often suggest allergic tubulointerstitial nephritis, yet clear associations with drug reactions are often difficult to establish. IEA are also encountered in diabetic nephropathy (DN) and thought to be attributed to medication exposure. Methods. Native medical kidney biopsies performed at the University of Washington Medical Center were reviewed, including DN (n = 64), IgA nephropathy (IgAN, n = 28), membranous nephropathy (MN, n = 14), focal and segmental glomerulosclerosis (FSGS, n = 27) and membranoproliferative glomerulonephritis (MPGN, n = 28). IEA were defined as = 5 eosinophils per high power field. The severity of interstitial fibrosis and tubular atrophy (IFTA) was scored semi-quantitatively as minimal, mild, moderate or severe. Results. IEA were remarkably more prevalent in DN (41%), when compared with IgAN (7%, P = 0.001), MN (8%, P = 0.017) or MPGN (14%, P = 0.013), but not FSGS (26%, P = 0.18). In DN cases, univariate analysis revealed that IEA were associated with greater IFTA severity, but not with the percentage of glomerulosclerosis, mesangial expansion, history of drug allergy, number of prescribed medications or particular class of medications (antibiotics, NSAIDs, aspirin, thiazide, loop diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, insulin, sulfonylurea, metformin or allopurinol). Multivariate analysis showed that the severity of IFTA was the only significant predictor for IEA (P < 0.01) after stepwise adjustment for age, number of medications, drug allergy, diabetes type, % global glomerulosclerosis and mesangial expansion. Conclusions. Our study shows that IEA are more common in DN, when compared with other types of glomerulopathy. In DN, IEA are associated with the severity of IFTA but not with prescribedmedications or clinical history of allergy. This suggests that in DN IEA are often associated with chronic tubulointerstitial injury and are not diagnostic of an allergic interstitial nephritis. C1 [Dai, Dao-Fu; Sasaki, Kotaro; Lin, Mercury Y.; Smith, Kelly D.; Nicosia, Roberto F.; Alpers, Charles E.; Najafian, Behzad] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA. [Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Pathol & Lab Med Serv, Seattle, WA USA. RP Dai, DF (reprint author), Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA. EM ddaofu@yahoo.com; najafian@uw.edu NR 23 TC 1 Z9 1 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD AUG PY 2015 VL 30 IS 8 BP 1370 EP 1376 DI 10.1093/ndt/gfv067 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA CP3LP UT WOS:000359780800021 PM 25813275 ER PT J AU Dove, ES Barlas, IO Birch, K Boehme, C Borda-Rodriguez, A Byne, WM Chaverneff, F Coskun, Y Dahl, ML Dereli, T Diwakar, S Elbeyli, L Endrenyi, L Eroglu-Kesim, B Ferguson, LR Gungor, K Gursoy, U Hekim, N Huzair, F Kaushik, K Kickbusch, I Kiroglu, O Kolker, E Kononen, E Lin, BY Llerena, A Malhan, F Nair, B Patrinos, GP Sardas, S Sert, O Srivastava, S Steuten, LMG Toraman, C Vayena, E Wang, W Warnich, L Ozdemir, V AF Dove, Edward S. Barlas, I. Omer Birch, Kean Boehme, Catharina Borda-Rodriguez, Alexander Byne, William M. Chaverneff, Florence Coskun, Yavuz Dahl, Marja-Liisa Dereli, Turkay Diwakar, Shyam Elbeyli, Levent Endrenyi, Laszlo Eroglu-Kesim, Belgin Ferguson, Lynnette R. Gungor, Kivanc Gursoy, Ulvi Hekim, Nezih Huzair, Farah Kaushik, Kabeer Kickbusch, Ilona Kiroglu, Olcay Kolker, Eugene Kononen, Eija Lin, Biaoyang Llerena, Adrian Malhan, Faruk Nair, Bipin Patrinos, George P. Sardas, Semra Sert, Ozlem Srivastava, Sanjeeva Steuten, Lotte M. G. Toraman, Cengiz Vayena, Effy Wang, Wei Warnich, Louise Ozdemir, Vural TI An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21(st) Century Science and Ethics" SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY LA English DT Review ID PERSONALIZED MEDICINE; RESPONSIBLE INNOVATION; NEXT-GENERATION; PHARMACOGENOMICS; GENOMICS; PROMISE; GOVERNANCE; ECOSYSTEM; CALL; AGE AB Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and nanotechnology, are emerging as companion tests to innovative medicines. In this Opinion, we present the rationale for promulgating an "Essential Diagnostics List." Additionally, we explain the ways in which adopting a vision for "Health in All Policies" could link essential diagnostics with robust and timely societal outcomes such as sustainable development, human rights, gender parity, and alleviation of poverty. We do so in three ways. First, we propose the need for a new, "see through" taxonomy for knowledge-based innovation as we transition from the material industries (e.g., textiles, plastic, cement, glass) dominant in the 20(th) century to the anticipated knowledge industry of the 21st century. If knowledge is the currency of the present century, then it is sensible to adopt an approach that thoroughly examines scientific knowledge, starting with the production aims, methods, quality, distribution, access, and the ends it purports to serve. Second, we explain that this knowledge trajectory focus on innovation is crucial and applicable across all sectors, including public, private, or public-private partnerships, as it underscores the fact that scientific knowledge is a co-product of technology, human values, and social systems. By making the value systems embedded in scientific design and knowledge co-production transparent, we all stand to benefit from sustainable and transparent science. Third, we appeal to the global health community to consider the necessary qualities of good governance for 21st century organizations that will embark on developing essential diagnostics. These have importance not only for science and knowledge-based innovation, but also for the ways in which we can build open, healthy, and peaceful civil societies today and for future generations. C1 [Dove, Edward S.] Univ Edinburgh, Sch Law, J Kenyon Mason Inst Med Life Sci & Law, Edinburgh, Midlothian, Scotland. [Barlas, I. Omer] Mersin Univ, Fac Med, Dept Med Biol & Genet, Mersin, Turkey. [Birch, Kean] York Univ, Fac Liberal Arts & Profess Studies, Dept Social Sci, Toronto, ON M3J 2R7, Canada. [Boehme, Catharina] Fdn Innovat New Diagnost, Geneva, Switzerland. [Borda-Rodriguez, Alexander] Secretaria Nacl Educ Super Ciencia Tecnol & Innov, Quito, Ecuador. [Borda-Rodriguez, Alexander] Open Univ, Dev Policy & Practice Grp, Milton Keynes MK7 6AA, Bucks, England. [Byne, William M.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Byne, William M.] James J Peters VA Med Ctr, Bronx, NY USA. [Chaverneff, Florence] NYU, Langone Med Ctr, Dept Neurosci & Physiol, New York, NY USA. [Coskun, Yavuz; Ozdemir, Vural] Gaziantep Univ, Off President, Gaziantep, Turkey. [Dahl, Marja-Liisa] Karolinska Inst, Div Clin Pharmacol, Stockholm, Sweden. [Dereli, Turkay; Ozdemir, Vural] Gaziantep Univ, Fac Engn, Dept Ind Engn, Gaziantep, Turkey. [Diwakar, Shyam; Nair, Bipin; Ozdemir, Vural] Amrita Univ, Amrita Vishwa Vidyapeetham, Amrita Sch Biotechnol, Kollam, Kerala, India. [Elbeyli, Levent] Gaziantep Univ, Fac Med, Gaziantep, Turkey. [Endrenyi, Laszlo] Univ Toronto, Fac Med, Dept Pharmacol, Toronto, ON M5S 1A1, Canada. [Eroglu-Kesim, Belgin] Sisli Etfal Res & Educ Hosp, Istanbul, Turkey. [Ferguson, Lynnette R.] Univ Auckland, Discipline Nutr, Auckland 1, New Zealand. [Gungor, Kivanc] Gaziantep Univ, Fac Hlth Sci, Gaziantep, Turkey. [Gursoy, Ulvi; Kononen, Eija] Univ Turku, Inst Dent, Dept Periodontol, Turku, Finland. [Hekim, Nezih] Beykent Univ, Sch Med, Istanbul, Turkey. [Huzair, Farah] Univ Edinburgh, Sch Social & Polit Sci, Sci Technol & Innovat Studies, Edinburgh, Midlothian, Scotland. [Kaushik, Kabeer] Vainteya Films Pvt Ltd, New Delhi, Delhi, India. [Kickbusch, Ilona] Grad Inst Int & Dev Studies, Global Hlth Program, Geneva, Switzerland. [Kiroglu, Olcay] Cukurova Univ, Fac Med, Dept Pharmacol, Adana, Turkey. [Kolker, Eugene] Seattle Childrens, Seattle Childrens Res Inst, Bioinformat & High Throughput Anal Lab, Seattle, WA USA. [Kolker, Eugene] Seattle Childrens, CDO Analyt, Seattle, WA USA. [Kolker, Eugene] Dept Biomed Informat & Med Educ, Seattle, WA USA. [Kolker, Eugene] Dept Pediat, Seattle, WA USA. [Kolker, Eugene] Univ Washington, Seattle, WA 98195 USA. [Kolker, Eugene; Ozdemir, Vural] Data Enabled Life Sci Alliance DELSA Global, Seattle, WA USA. [Kolker, Eugene] Northeastern Univ, Coll Sci, Dept Chem & Chem Biol, Boston, MA 02115 USA. [Lin, Biaoyang] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Lin, Biaoyang] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou 310003, Zhejiang, Peoples R China. [Llerena, Adrian] Extremadura Univ Hosp & Med Sch, Badajoz, Extremadura, Spain. [Malhan, Faruk] Istanbul Design Fdn, Istanbul, Turkey. [Patrinos, George P.] Univ Patras, Sch Hlth Sci, Dept Pharm, Patras, Greece. [Sardas, Semra] Marmara Univ, Fac Pharm, Istanbul, Turkey. [Sert, Ozlem] Hacettepe Univ, Urban Studies Ctr, Ankara, Turkey. [Sert, Ozlem] Hacettepe Univ, Dept Hist, Ankara, Turkey. [Srivastava, Sanjeeva] Indian Inst Technol, Dept Biosci & Bioengn, Prote Lab, Bombay 400076, Maharashtra, India. [Steuten, Lotte M. G.] PANAXEA Bv, Enschede, Netherlands. [Steuten, Lotte M. G.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Toraman, Cengiz; Ozdemir, Vural] Gaziantep Univ, Fac Commun, Gaziantep, Turkey. [Toraman, Cengiz; Ozdemir, Vural] Gaziantep Univ, Dept Management Sci, Gaziantep, Turkey. [Vayena, Effy] Univ Zurich, Inst Biomed Eth, Zurich, Switzerland. [Wang, Wei] Edith Cowan Univ, Sch Med Sci, Perth, WA, Australia. [Wang, Wei] Capital Med Univ, Sch Publ Hlth, Beijing Municipal Key Lab Clin Epidemiol, Beijing, Peoples R China. [Warnich, Louise] Univ Stellenbosch, Fac Sci, ZA-7600 Stellenbosch, South Africa. RP Ozdemir, V (reprint author), Mary Ann Liebert Inc, 140 Huguenot St, New Rochelle, NY 10801 USA. EM OJIB@liebertpub.com RI Diwakar, Shyam/C-2455-2015 OI Diwakar, Shyam/0000-0003-1546-0184 FU TUBITAK (The Scientific and Technological Research Council of Turkey) 2232 Career Investigator Program FX No funding was received in support of this analysis. The views expressed are the personal opinions of the authors only and do not necessarily reflect the views of their affiliated institutions or funding agencies. VO is supported in part by TUBITAK (The Scientific and Technological Research Council of Turkey) 2232 Career Investigator Program. NR 37 TC 2 Z9 2 U1 7 U2 33 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1536-2310 EI 1557-8100 J9 OMICS JI OMICS PD AUG 1 PY 2015 VL 19 IS 8 BP 435 EP 442 DI 10.1089/omi.2015.0075 PG 8 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA CO9ZH UT WOS:000359535100001 PM 26161545 ER PT J AU Bartels, CM Wong, JC Johnson, SL Thorpe, CT Barney, NP Sheibani, N Smith, MA AF Bartels, Christie M. Wong, Joanna C. Johnson, Sophia L. Thorpe, Carolyn T. Barney, Neal P. Sheibani, Nader Smith, Maureen A. TI Rheumatoid arthritis and the prevalence of diabetic retinopathy SO RHEUMATOLOGY LA English DT Article DE RA; diabetes; retinopathy; microvascular; epidemiology ID ANTIINFLAMMATORY DRUGS; ANGIOGENESIS; MEDICARE; RISK; CARE AB Objective. RA increases vascular disease and angiogenesis, yet a 1964 Lancet report paradoxically linked RA to lower diabetic retinopathy. Our objective was to examine RA as a risk factor for diabetic retinopathy compared with other vascular risk factors. Methods. This cohort study compared the prevalence of diabetic retinopathy in diabetes patients with and without RA in a 5% Medicare sample. We analysed the impact of RA on the prevalence of diabetic retinopathy using multivariate logistic regression calculating adjusted rate ratios (ARRs) controlling for sociodemographics, co-morbidity and health utilization. Sensitivity analysis examined eye exam rates. Results. Among 256 331 Medicare diabetes patients, 5572 (2%) had RA. Diabetic retinopathy was less prevalent in patients with RA compared with those without RA (13.7% vs 16.1%, P <= 0.01). Compared with patients without RA, the adjusted model demonstrated that patients with diabetes and RA were 28% less likely to have diabetic retinopathy and 4% more likely to receive an eye exam [ARR 0.72 (95% CI 0.67, 0.77), ARR 1.04 (95% CI 1.02, 1.06)]. Conclusion. Findings support the 1964 paradox observing decreased diabetic retinopathy in patients with RA. These findings pose new questions regarding whether RA physiology or treatments protect against diabetic retinopathy and how intraocular factors vary in contrast to adverse vascular changes elsewhere. C1 [Bartels, Christie M.; Wong, Joanna C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Rheumatol, Madison, WI 53706 USA. [Johnson, Sophia L.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Barney, Neal P.; Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. RP Bartels, CM (reprint author), UWMF Centennial Bldg,Room 4132,1685 Highland Ave, Madison, WI 53705 USA. EM cb4@medicine.wisc.edu FU Health Innovation Program and the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW-ICTR) [ULTR000427, KL2TR000428] FX Funding: This work was supported by the Health Innovation Program and the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW-ICTR) (ULTR000427 and KL2TR000428 to C.M.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 19 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD AUG PY 2015 VL 54 IS 8 BP 1415 EP 1419 DI 10.1093/rheumatology/kev012 PG 5 WC Rheumatology SC Rheumatology GA CP1WG UT WOS:000359667100014 PM 25731768 ER PT J AU Wills, LP Beeson, GC Hoover, DB Schnellmann, RG Beeson, CC AF Wills, Lauren P. Beeson, Gyda C. Hoover, Douglas B. Schnellmann, Rick G. Beeson, Craig C. TI Assessment of ToxCast Phase II for Mitochondrial Liabilities Using a High-Throughput Respirometric Assay SO TOXICOLOGICAL SCIENCES LA English DT Article DE cell culture; in vitro and alternatives; kidney; systems toxicology; safety evaluation ID RAT-LIVER MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; ENVIRONMENTAL CHEMICALS; PERMEABILITY TRANSITION; TOXICITY; CELLS; KIDNEY; BIOGENESIS; UNCOUPLERS; APOPTOSIS AB Previous high-throughput screens to identify mitochondrial toxicants used immortalized cell lines and focused on changes in mitochondrial membrane potential, which may not be sufficient and do not identify different types of mitochondrial dysfunction. Primary cultures of renal proximal tubule cells (RPTC) were examined with the Seahorse Extracellular Flux Analyzer to screen 676 compounds (5 mu M; 1 h) from the ToxCast Phase II library for mitochondrial toxicants. Of the 676 compounds, 19 were classified as cytotoxicants, 376 were electron transport chain (ETC) inhibitors, and 5 were uncouplers. The remaining 276 compounds were examined after a 5-h exposure to identify slower acting mitochondrial toxicants. This experiment identified 3 cytotoxicants, 110 ETC inhibitors, and 163 compounds with no effect. A subset of the ToxCast Phase II library was also examined in immortalized human renal cells (HK2) to determine differences in susceptibility to mitochondrial toxicity. Of the 131 RPTC ETC inhibitors tested, only 14 were ETC inhibitors in HK2 cells. Of the 5 RPTC uncouplers, 1 compound was an uncoupler in HK2 cells. These results demonstrate that 73% (491/676) of the compounds in the ToxCast Phase II library compounds exhibit RPTC mitochondrial toxicity, overwhelmingly ETC inhibition. In contrast, renal HK2 cells are markedly less sensitive and only identified 6% of the compounds as mitochondrial toxicants. We suggest caution is needed when studying mitochondrial toxicity in immortalized cell lines. This information will provide mechanisms and chemical-based criteria for assessing and predicting mitochondrial liabilities of new drugs, consumer products, and environmental agents. C1 [Wills, Lauren P.; Beeson, Gyda C.; Beeson, Craig C.] MitoHealth Inc, Charleston, SC USA. [Beeson, Gyda C.; Hoover, Douglas B.; Schnellmann, Rick G.; Beeson, Craig C.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Beeson, CC (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St,QF309C, Charleston, SC 29403 USA. EM beesonc@musc.edu FU [2R44-ES019378-02] FX Funding for this project was provided through grant 2R44-ES019378-02. NR 37 TC 2 Z9 2 U1 2 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 EI 1096-0929 J9 TOXICOL SCI JI Toxicol. Sci. PD AUG PY 2015 VL 146 IS 2 BP 226 EP 234 DI 10.1093/toxsci/kfv085 PG 9 WC Toxicology SC Toxicology GA CP1IU UT WOS:000359630300003 PM 25926417 ER PT J AU Elnitsky, CA Powell-Cope, G Besterman-Dahan, KL Rugs, D Ullrich, PM AF Elnitsky, C. A. Powell-Cope, G. Besterman-Dahan, K. L. Rugs, D. Ullrich, P. M. TI Implementation of Safe Patient Handling in the US Veterans Health System: A Qualitative Study of Internal Facilitators' Perceptions SO WORLDVIEWS ON EVIDENCE-BASED NURSING LA English DT Article DE facilitation; facilitator; evidence-based practice; nursing practice; implementation; care delivery system; focus group; qualitative methodology ID INJURY PREVENTION PROGRAM; MUSCULOSKELETAL INJURY; ERGONOMICS PROGRAM; NURSING PERSONNEL; CARE AB BackgroundAlthough the literature has noted the positive effects of facilitation in implementation research, little is known about what facilitators do or how they increase adoption of a program. The purpose of this study was to understand internal facilitation activities in implementing a national safe patient handling program from the perspective of facility coordinators who implemented the program. MethodsUsing a qualitative descriptive design, data were collected in five focus groups at two international Safe Patient Handling and Mobility Conferences. Participants were 38 facility coordinators implementing a safe patient handling program in the Department of Veterans Affairs medical centers throughout the United States. Data were analyzed using direct content analysis to gather descriptions of internal facilitation. ResultsThe internal facilitation process involved engaging multiple disciplines and levels of leadership for implementation. Fifty-four facilitation activities were identified, including five activities not currently listed in an existing taxonomy. Key characteristics and skills of facilitators included persistence, credibility and clinical experience, and leadership and project management experience. Themes were mapped onto an existing framework and taxonomy of facilitation activities. Linking Evidence to ActionInternal facilitation is both an implementation intervention and a process involving a wide range of activities. The findings provide an understanding of what internal facilitators are doing to support practice changes and the characteristics and skills of internal facilitators that are likely to result in long-term organizational change. Five recommendations for action address organizations, senior leaders, and internal facilitators. C1 [Elnitsky, C. A.] Univ N Carolina, Charlotte, NC 28223 USA. [Elnitsky, C. A.; Powell-Cope, G.; Besterman-Dahan, K. L.; Rugs, D.] James A Haley Vet Hosp, Ctr Innovat Disabil & Rehabil Res CINDRR, Hlth Serv Res & Dev, Tampa, FL USA. [Ullrich, P. M.] VA Puget Sound Healthcare Syst, Dept Vet Affairs Spinal Cord Injury & Disorders S, Seattle, WA USA. [Ullrich, P. M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Elnitsky, CA (reprint author), Univ N Carolina, Coll Hlth & Human Serv 412A, 9201 Univ City Blvd, Charlotte, NC 28223 USA. EM celnitsky1@gmail.com FU Occupational Health Program, Veterans Health Administration Office of Public Health FX This study is the result of work funded through a research grant from the Director, Occupational Health Program, Veterans Health Administration Office of Public Health, and resources and use of facilities at the James A. Haley Veteran's Hospital, Tampa, FL. NR 23 TC 1 Z9 1 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-102X EI 1741-6787 J9 WORLDV EVID-BASED NU JI Worldviews Evid.-Based Nurs. PD AUG PY 2015 VL 12 IS 4 BP 208 EP 216 DI 10.1111/wvn.12098 PG 9 WC Nursing SC Nursing GA CO8MU UT WOS:000359424300004 PM 26220147 ER PT J AU Nucifora, PGP AF Nucifora, Paolo G. P. TI Overdiagnosis in the Era of Neuropsychiatric Imaging SO ACADEMIC RADIOLOGY LA English DT Article DE Neuroimaging; psychiatry; overdiagnosis ID POSTTRAUMATIC-STRESS-DISORDER; MAJOR DEPRESSIVE DISORDER; BORDERLINE PERSONALITY-DISORDER; OBSESSIVE-COMPULSIVE DISORDER; PREDICTS TREATMENT RESPONSE; VOXEL-BASED MORPHOMETRY; PATTERN-CLASSIFICATION; HIGH-RISK; 1ST-EPISODE SCHIZOPHRENIA; FUNCTIONAL CONNECTIVITY AB New guidelines proposed by the National Institute of Mental Health are intended to transform the management of patients with psychiatric disorders. It is anticipated that neuroimaging and other biomarkers will play a more prominent role in diagnosis and prognosis, especially in the prodromal phase of illness. Earlier treatment of psychiatric disorders has the potential to improve outcomes significantly. However, diagnosis in the absence of symptoms can lead to overdiagnosis. Overdiagnosis is a problem in many fields of medicine but could pose additional problems in psychiatry because of the stigmatization that often accompanies a diagnosis of mental illness. This review discusses the magnetic resonance imaging methods that hold the most promise for evaluating neuropsychiatric disorders, the likelihood that they could lead to overdiagnosis, and opportunities to minimize the impact of overdiagnosis in psychiatric disorders. C1 [Nucifora, Paolo G. P.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. [Nucifora, Paolo G. P.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. RP Nucifora, PGP (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM paolo.nucifora@va.gov NR 90 TC 1 Z9 1 U1 3 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 EI 1878-4046 J9 ACAD RADIOL JI Acad. Radiol. PD AUG PY 2015 VL 22 IS 8 BP 995 EP 999 DI 10.1016/j.acra.2015.02.004 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CO6NO UT WOS:000359273600012 PM 25784322 ER PT J AU Ruutiainen, AT AF Ruutiainen, Alexander T. TI Utilization and Reporting of Bone Densitometry: What Can the Musculoskeletal Radiologist Do to Help, Rather Than to Hurt? SO ACADEMIC RADIOLOGY LA English DT Article DE DXA; densitometry; osteoporosis ID OSTEOPOROTIC FRACTURES; CLINICAL-USE; DENSITY; DISCORDANCE; OSTEOPENIA; OVERDIAGNOSIS; ALENDRONATE; SCORES; RISK AB Osteoporosis is a highly prevalent disease that predisposes patients to fragility fractures. These fractures carry serious risks, including increased mortality and the potential loss of functional independence. Effective treatments for osteoporosis are available, but these should be initiated before a fragility fracture actually occurs; to do so, osteoporosis must be diagnosed while it is still asymptomatic. The gold standard screening test used to detect low bone mass is dual-energy x-ray absorptiometry (DXA). Despite its clinical importance, the DXA report is sometimes neglected by radiologists-as though it were somehow less significant in diagnosis than our other modalities. If musculoskeletal radiologists are to-help, rather than to hurt, we must raise the profile of this critical test with evidence-based utilization and coherent reporting: detailed recommendations for doing so are available from professional organizations such as the International Society for Clinical Densitometry and the National Osteoporosis Foundation. This brief survey will seek to remind the radiologist that a good densitometry report requires more than just copying numbers from a scanner. C1 [Ruutiainen, Alexander T.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. [Ruutiainen, Alexander T.] Perelman Sch Med, Div Musculoskeletal Imaging, Dept Radiol, Philadelphia, PA USA. RP Ruutiainen, AT (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Alexander.Ruutiainen@uphs.upenn.edu NR 29 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 EI 1878-4046 J9 ACAD RADIOL JI Acad. Radiol. PD AUG PY 2015 VL 22 IS 8 BP 1030 EP 1033 DI 10.1016/j.acra.2015.02.008 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CO6NO UT WOS:000359273600019 PM 26100197 ER PT J AU Yehia, BR Stephens-Shield, AJ Momplaisir, F Taylor, L Gross, R Dube, B Glanz, K Brady, KA AF Yehia, Baligh R. Stephens-Shield, Alisa J. Momplaisir, Florence Taylor, Lynne Gross, Robert Dube, Benoit Glanz, Karen Brady, Kathleen A. TI Health Outcomes of HIV-Infected People with Mental Illness SO AIDS AND BEHAVIOR LA English DT Article DE Mental illness; HIV; Viral suppression; Retention; Antiretroviral therapy; Outcomes ID ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; BEHAVIORAL-CHARACTERISTICS; VIROLOGICAL RESPONSE; VIRAL SUPPRESSION; DRUG-USE; CARE; ADHERENCE; WOMEN; INTERVENTION AB Improving outcomes for people with HIV and mental illness will be critical to meeting the goals of the US National HIV/AIDS Strategy. In a retrospective analysis of the 2008-2010 cycles of the locally representative Philadelphia Medical Monitoring Project, we compared the proportions of HIV-infected adults with and without mental illness: (1) retained in care (a parts per thousand yen2 primary HIV visits separated by a parts per thousand yen90 days in a 12-month period); (2) prescribed antiretroviral therapy (ART) at any point in a 12-month period; and (3) virally suppressed (HIV-1 RNA a parts per thousand currency sign200 copies/mL at the last measure in the 12-month period). Multivariable regression assessed associations between mental illness and the outcomes, adjusting for age, gender, race/ethnicity, insurance, alcohol abuse, injection drug use, CD4 count, and calendar year. Of 730 HIV-infected persons, representative of 9409 persons in care for HIV in Philadelphia, 49.0 % had mental illness. In adjusted analyses, there were no significant differences in retention (91.3 vs. 90.3 %; AOR 1.30, 95 % CI 0.63-2.56) and prescription of ART (83.2 vs. 88.7 %; AOR 0.79, 95 % CI 0.49-1.25) between those with and without mental illness. However, mentally ill patients were less likely to achieve viral suppression than those without mental illness (65.9 vs. 74.4 %; AOR 0.64, 95 % CI 0.46-0.90). These findings argue for the need to optimize ART adherence in this population. C1 [Yehia, Baligh R.; Gross, Robert; Brady, Kathleen A.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Yehia, Baligh R.; Gross, Robert] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA USA. [Stephens-Shield, Alisa J.; Taylor, Lynne; Gross, Robert; Glanz, Karen] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Momplaisir, Florence] Drexel Univ, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Dube, Benoit] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Glanz, Karen] Univ Penn, Perelman Sch Med, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA. [Brady, Kathleen A.] AIDS Act Coordinating Off, Dept Publ Hlth, Philadelphia, PA USA. RP Yehia, BR (reprint author), Univ Penn, Perelman Sch Med, Dept Med, 1021 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM byehia@upenn.edu FU National Institutes of Health [K23-MH097647]; Penn Mental Health AIDS Research Center [P30-MH097488]; Penn Center for AIDS Research [P30 AI 045008]; Centers for Disease Control and Prevention [PS13-130202 U62/003959] FX We would like to acknowledge the staff of the Philadelphia Department of Health AIDS Activities Coordinating Office including Jane Baker, Coleman Terrell and Mark Shpaner. This work was supported by the National Institutes of Health (K23-MH097647 to BRY), the Penn Mental Health AIDS Research Center (P30-MH097488), the Penn Center for AIDS Research (P30 AI 045008), and the Centers for Disease Control and Prevention (PS13-130202 #U62/003959 to KAB). NR 45 TC 0 Z9 0 U1 2 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD AUG PY 2015 VL 19 IS 8 BP 1491 EP 1500 DI 10.1007/s10461-015-1080-4 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CO2VM UT WOS:000359014800014 PM 25931243 ER PT J AU Legget, KT Cornier, MA Rojas, DC Lawful, B Tregellas, JR AF Legget, Kristina T. Cornier, Marc-Andre Rojas, Donald C. Lawful, Benjamin Tregellas, Jason R. TI Harnessing the power of disgust: a randomized trial to reduce high-calorie food appeal through implicit priming SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE disgust; food preferences; implicit priming; nutrition; obesity ID EATING BEHAVIOR; LIKES; ASSOCIATIONS; PREFERENCES; ATTITUDES; DISLIKES; CHOICES AB Background: In our increasingly obesogenic environment, in which high-calorie convenience foods are readily available, food choices can drastically affect weight and overall health: Learned food preferences, which are developed through repeated pairings with positively and negatively valenced stimuli, can contribute to obesity susceptibility if positive attitudes toward high-calorie foods are developed. Thus, the modification of automatic associations with food may be a viable strategy to promote healthier eating behaviors. Objective: In this study, we investigated the ability of an implicit priming (IP) intervention to alter responses to visual food cues by using an evaluative conditioning approach. The main objective was to implicitly (i.e., below conscious perception) associate disgust with high-calorie foods with the aim of reducing liking of these foods. Design: Participants were randomly assigned to active or control IP. In active IP (n = 22), high-calorie food images were implicitly primed with negatively valenced images, and low-calorie food images were implicitly primed with positively valenced images. In control IP (n = 20), all food images were primed with neutral images of fixation crosses. Food images were rated on the desire to eat immediately before and after EP. Results: A significant main effect of calorie (high compared with low; P < 0.001) and a significant calorie-by-group (active compared with control) interaction (P = 0.025) were observed. Post hoc tests identified a significantly greater high-calorie rating decline after active IP than after control IP (P = 0.036). Furthermore, there was significantly greater change in high-calorie ratings than in low-calorie ratings in the active group (P = 0.001). Active IP effects extended to high-calorie foods not specifically included in the intervention, which suggested an effect generalization. Moreover, a greater change in high-calorie ratings than in low-calorie ratings persisted 3-5 d after active IP (P < 0.007), which suggested lasting effects. Conclusion: This study provides initial evidence that IP can be used to alter high-calorie food preferences, which could promote healthier eating habits. This trial was registered at clinicaltrials.gov as NCT02347527. C1 [Legget, Kristina T.; Lawful, Benjamin; Tregellas, Jason R.] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA. [Cornier, Marc-Andre] Univ Colorado, Sch Med, Dept Med, Div Endocrinol Metab & Diabet, Aurora, CO USA. [Cornier, Marc-Andre] Univ Colorado, Anschutz Hlth & Wellness Ctr, Aurora, CO USA. [Rojas, Donald C.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. RP Legget, KT (reprint author), Univ Colorado, Sch Med, Dept Med, Anschutz Med Campus, Aurora, CO 80045 USA. EM kristina.legget@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616; Legget, Kristina/0000-0002-2948-506X FU Colorado Nutrition Obesity Research Center [P30 DK048520]; National Institute of Mental Health [R01 MH102224]; National Institute of Diabetes and Digestive and Kidney Diseases [R21 DK102052, R01 DK089095, K01 DK100445] FX Supported by grants from the Colorado Nutrition Obesity Research Center (grant P30 DK048520; to KTL), the National Institute of Mental Health (grant R01 MH102224; to JRT), and the National Institute of Diabetes and Digestive and Kidney Diseases [grants R21 DK102052 (to JRT), R01 DK089095 (to M-AC and JRT), and K01 DK100445 (to KTL)]. NR 27 TC 1 Z9 1 U1 3 U2 19 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD AUG PY 2015 VL 102 IS 2 BP 249 EP 255 DI 10.3945/ajcn.115.106955 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CO3DW UT WOS:000359037800005 PM 26109580 ER PT J AU Mundinger, TO Cooper, E Coleman, MP Taborsky, GJ AF Mundinger, Thomas O. Cooper, Ellis Coleman, Michael P. Taborsky, Gerald J., Jr. TI Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission, thereby impairing sympathetically mediated glucagon responses SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE nicotinic acetylcholine receptors; celiac ganglia; fos; sympathetic nervous system; norepinephrine; glucagon; WLDS ID WALLERIAN DEGENERATION; IN-VIVO; NERVE-STIMULATION; CELL-DEATH; HYPOGLYCEMIA; ACTIVATION; RAT; SECRETION; INSULIN; NEURONS AB Short-term hyperglycemia suppresses superior cervical ganglia neurotransmission. If this ganglionic dysfunction also occurs in the islet sympathetic pathway, sympathetically mediated glucagon responses could be impaired. Our objectives were 1) to test for a suppressive effect of 7 days of streptozotocin (STZ) diabetes on celiac ganglia (CG) activation and on neurotransmitter and glucagon responses to preganglionic nerve stimulation, 2) to isolate the defect in the islet sympathetic pathway to the CG itself, and 3) to test for a protective effect of the WLDS mutation. We injected saline or nicotine in nondiabetic and STZ-diabetic rats and measured fos mRNA levels in whole CG. We electrically stimulated the preganglionic or postganglionic nerve trunk of the CG in nondiabetic and STZ-diabetic rats and measured portal venous norepinephrine and glucagon responses. We repeated the nicotine and preganglionic nerve stimulation studies in nondiabetic and STZ-diabetic WLDS rats. In STZ-diabetic rats, the CG fos response to nicotine was suppressed, and the norepinephrine and glucagon responses to preganglionic nerve stimulation were impaired. In contrast, the norepinephrine and glucagon responses to postganglionic nerve stimulation were normal. The CG fos response to nicotine, and the norepinephrine and glucagon responses to preganglionic nerve stimulation, were normal in STZ-diabetic WLDS rats. In conclusion, short-term hyperglycemia's suppressive effect on nicotinic acetylcholine receptors of the CG impairs sympathetically mediated glucagon responses. WLDS rats are protected from this dysfunction. The implication is that this CG dysfunction may contribute to the impaired glucagon response to insulin-induced hypoglycemia seen early in type 1 diabetes. C1 [Mundinger, Thomas O.; Taborsky, Gerald J., Jr.] Univ Washington, Dept Med, Seattle, WA 98105 USA. [Cooper, Ellis] McGill Univ, Dept Physiol, Montreal, PQ, Canada. [Coleman, Michael P.] Babraham Inst, Cambridge, England. [Taborsky, Gerald J., Jr.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Mundinger, TO (reprint author), Univ Washington, Dept Med, Seattle, WA 98105 USA. EM mundin@u.washington.edu FU Biotechnology and Biological Sciences Research Council Institute Strategic Programme Grant; Canadian Institutes for Health Research; Medical Research Service of the Department of Veterans Affairs; National Institute of Health [R01 DK-50154] FX This work was supported by the Biotechnology and Biological Sciences Research Council Institute Strategic Programme Grant (M. P. Coleman), the Canadian Institutes for Health Research (E. Cooper), the Medical Research Service of the Department of Veterans Affairs (G. J. Taborsky, Jr.), and National Institute of Health Grant R01 DK-50154 (G. J. Taborsky, Jr.). NR 50 TC 1 Z9 1 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD AUG 1 PY 2015 VL 309 IS 3 BP E246 EP E255 DI 10.1152/ajpendo.00140.2015 PG 10 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA CO1VH UT WOS:000358943400005 PM 26037249 ER PT J AU Heyanka, DJ Thaler, NS Linck, JF Pastorek, NJ Miller, B Romesser, J Sim, AH AF Heyanka, Daniel J. Thaler, Nicholas S. Linck, John F. Pastorek, Nicholas J. Miller, Brian Romesser, Jennifer Sim, Anita H. TI A Factor Analytic Approach to the Validation of the Word Memory Test and Test of Memory Malingering as Measures of Effort and Not Memory SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Forensic neuropsychology; Head injury; traumatic brain injury; Malingering/symptom validity testing; Learning and Memory ID TRAUMATIC BRAIN-INJURY; PSYCHOGENIC NONEPILEPTIC SEIZURES; SYMPTOM VALIDITY TEST; DISABILITY INCENTIVES; COGNITIVE IMPAIRMENT; EXTERNAL INCENTIVES; HEAD-INJURY; TEST-SCORES; FAILURE; TOMM AB Research has demonstrated the utility of performance validity tests (PVTs) as a method of determining adequate effort during a neuropsychological evaluation. Although some studies affirm that forced-choice PVTs measure effort rather than memory, doubts remain in the literature. The purpose of the current study was to evaluate the relationship between effort and memory variables in a mild traumatic brain injury (TBI) sample (n = 160) by separating memory and effort as distinct factors while statistically controlling for the shared covariance between the variables. A two-factor solution was extracted such that the five PVT variables loaded on Factor 1 and the four memory variables loaded on Factor 2. The pattern matrix, which controls for the covariance between variables, provided clear support of two highly distinct factors with minimal cross-loadings. Our findings support assertions that PVTs measure effort independent of memory in veterans with mild TBI. C1 [Heyanka, Daniel J.] Bay Pines Dept Vet Affairs Med Ctr, Bay Pines, FL USA. [Thaler, Nicholas S.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Linck, John F.] Oklahoma City Dept Vet Affairs Med Ctr, Oklahoma City, OK USA. [Pastorek, Nicholas J.; Miller, Brian] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. [Romesser, Jennifer] George E Wahlen Dept Vet Affairs Med Ctr, Salt Lake City, UT USA. [Sim, Anita H.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. RP Heyanka, DJ (reprint author), Bay Pines Dept Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, Bay Pines, FL 33744 USA. EM dhneuropsych@gmail.com NR 32 TC 3 Z9 3 U1 4 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD AUG PY 2015 VL 30 IS 5 BP 369 EP 376 DI 10.1093/arclin/acv025 PG 8 WC Psychology, Clinical; Psychology SC Psychology GA CO3PS UT WOS:000359071300002 PM 25964105 ER PT J AU Hilsabeck, RC Holdnack, JA Cullum, CM Drozdick, LW Edelstein, B Fiske, A Lacritz, L Mccoy, KJM Wahlstrom, D AF Hilsabeck, Robin C. Holdnack, James A. Cullum, C. Munro Drozdick, Lisa Whipple Edelstein, Barry Fiske, Amy Lacritz, Laura McCoy, Karin J. M. Wahlstrom, Dustin TI The Brief Cognitive Status Examination (BCSE): Comparing Diagnostic Utility and Equating Scores to the Mini-Mental State Examination (MMSE) SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Cognitive screening; Dementia; Mild cognitive impairment ID SCREENING INSTRUMENTS; ASSESSMENT MOCA; PRIMARY-CARE; IMPAIRMENT; DEMENTIA; SCALE; PERFORMANCE; ACCURACY; STROKE; LEVEL AB The study purpose was to compare the diagnostic utility of the Brief Cognitive Status Exam (BCSE) to that of the Mini-Mental State Examination (MMSE) and to develop equated scores to facilitate comparisons. One hundred and eighty-two patients underwent cognitive evaluation and were placed into three groups: dementia (DEM), cognitive impairment, no dementia (CIND), and no cognitive impairment (NCI). One hundred and eighty-two healthy controls from the BCSE standardization sample served as a comparison group. On both measures, the DEM group obtained significantly lower scores than the other two groups, and the CIND group scored significantly lower than the NCI group. The BCSE was more sensitive in all clinical groups, although at extremely low scores, the two tests displayed similar sensitivity. Results indicate the BCSE has diagnostic utility as a cognitive screening measure in a mixed clinical sample and is more sensitive at detecting cognitive impairment, particularly milder levels, than the MMSE. C1 [Hilsabeck, Robin C.; McCoy, Karin J. M.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Holdnack, James A.; Drozdick, Lisa Whipple; Wahlstrom, Dustin] Pearson Inc, San Antonio, TX USA. [Cullum, C. Munro; Lacritz, Laura] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Cullum, C. Munro; Lacritz, Laura] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA. [Cullum, C. Munro; Lacritz, Laura] Univ Texas SW Med Ctr Dallas, Dept Neurotherapeut, Dallas, TX 75390 USA. [Edelstein, Barry; Fiske, Amy] W Virginia Univ, Dept Psychol, Morgantown, WV 26506 USA. RP Hilsabeck, RC (reprint author), South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA. EM hilsabeck@uthscsa.edu NR 43 TC 1 Z9 1 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD AUG PY 2015 VL 30 IS 5 BP 458 EP 467 DI 10.1093/arclin/acv037 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA CO3PS UT WOS:000359071300011 PM 26085478 ER PT J AU Gay, ND Lee, SC Liel, MS Sochacki, P Recht, M Taylor, JA AF Gay, Nathan D. Lee, Sarah C. Liel, Meghan S. Sochacki, Paul Recht, Michael Taylor, Jason A. TI Increased fracture rates in people with haemophilia: a 10-year single institution retrospective analysis SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Letter DE haemophilia; fracture; bone disease; osteoporosis ID FACTOR-VIII DEFICIENCY; BONE-MINERAL DENSITY; OSTEOPOROSIS C1 [Gay, Nathan D.; Lee, Sarah C.; Taylor, Jason A.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Liel, Meghan S.; Recht, Michael; Taylor, Jason A.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Sochacki, Paul] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Taylor, Jason A.] Portland VA Med Ctr, Portland, OR USA. RP Gay, ND (reprint author), Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. EM taylojas@ohsu.edu NR 10 TC 7 Z9 7 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD AUG PY 2015 VL 170 IS 4 BP 584 EP 586 DI 10.1111/bjh.13312 PG 3 WC Hematology SC Hematology GA CO6IH UT WOS:000359259900018 PM 25659575 ER PT J AU Palacio, F Reyes, LF Levine, DJ Sanchez, JF Angel, LF Fernandez, JF Levine, SM Rello, J Abedi, A Restrepo, MI AF Palacio, Federico Reyes, Luis F. Levine, Deborah J. Sanchez, Juan F. Angel, Luis F. Fernandez, Juan F. Levine, Stephanie M. Rello, Jordi Abedi, Ali Restrepo, Marcos I. TI Understanding the Concept of Health Care-Associated Pneumonia in Lung Transplant Recipients SO CHEST LA English DT Article ID VENTILATOR-ASSOCIATED PNEUMONIA; COMMUNITY-ACQUIRED PNEUMONIA; SINGLE-CENTER EXPERIENCE; EPIDEMIOLOGY; INFECTIONS; MORTALITY; BACTERIA; OUTCOMES; THERAPY AB BACKGROUND: Limited data are available regarding the etiologic impact of health care-associated pneumonia (HCAP) in lung transplant recipients. Therefore, our aim was to evaluate the microbiologic differences between HCAP and hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) in lung transplant recipients with a radiographically confirmed diagnosis of pneumonia. METHODS: We performed a retrospective cohort study of lung transplant recipients with pneumonia at one transplant center over a 7-year period. Eligible patients included lung transplant recipients who developed a first episode of radiographically confirmed pneumonia >= 48 h following transplantation. HCAP, HAP, and VAP were classified according to the American Thoracic Society/Infectious Diseases Society of America 2005 guidelines. chi(2) and Student t tests were used to compare categorical and continuous variables, respectively. RESULTS: Sixty-eight lung transplant recipients developed at least one episode of pneumonia. HCAP (n = 42; 62%) was most common, followed by HAP/VAP (n = 26; 38%) stratified in HAP (n = 20; 77%) and VAP (n = 6; 23%). Pseudomonas aeruginosa was the predominantly isolated organism (n = 22; 32%), whereas invasive aspergillosis was uncommon (< 10%). Multiple-drug resistant (MDR) pathogens were less frequently isolated in patients with HCAP compared with HAP/VAP (5% vs 27%; P = .009). Opportunistic pathogens were less frequently identified in lung transplant recipients with HCAP than in those with HAP/VAP (7% vs 27%; P = .02). Lung transplant recipients with HCAP had a similar mortality at 90 days (n = 9 [21%] vs n = 4 [15%]; P = .3) compared with patients with HAP/VAP. CONCLUSIONS: HCAP was the most frequent infection in lung transplant recipients. MDR pathogens and opportunistic pathogens were more frequently isolated in HAP/VAP. There were no differences in 30- and 90-day mortality between lung transplant recipients with HCAP and those with HAP/VAP. C1 [Palacio, Federico; Levine, Stephanie M.; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Palacio, Federico; Reyes, Luis F.; Levine, Deborah J.; Angel, Luis F.; Fernandez, Juan F.; Levine, Stephanie M.; Abedi, Ali; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez, Juan F.] Scott & White Hlth Care Syst, Temple, TX USA. [Rello, Jordi] Univ Autonoma Barcelona, CIBERES, Vall dHebron Inst Res, Hosp Univ Vall dHebron, E-08193 Barcelona, Spain. [Reyes, Luis F.] Univ La Sabana, Bogota, Colombia. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, Audrey L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu OI Rello, Jordi/0000-0003-0676-6210 FU National Heart, Lung and Blood Institute [K23HL096054] FX Dr Restrepo receives support from the National Heart, Lung and Blood Institute [Award K23HL096054]. NR 20 TC 2 Z9 2 U1 0 U2 4 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD AUG PY 2015 VL 148 IS 2 BP 516 EP 522 DI 10.1378/chest.14-1948 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CO2SA UT WOS:000359005700051 PM 25742187 ER PT J AU Pike, F Murugan, R Keener, C Palevsky, PM Vijayan, A Unruh, M Finkel, K Wen, XY Kellum, JA AF Pike, Francis Murugan, Raghavan Keener, Christopher Palevsky, Paul M. Vijayan, Anitha Unruh, Mark Finkel, Kevin Wen, Xiaoyan Kellum, John A. CA Biol Markers Recovery Kidney TI Biomarker Enhanced Risk Prediction for Adverse Outcomes in Critically Ill Patients Receiving RRT SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE KIDNEY INJURY; CYCLE ARREST BIOMARKERS; URINARY BIOMARKERS; RENAL SUPPORT; VALIDATION; DISEASE AB Background and objectives Higher plasma concentrations of inflammatory and apoptosis markers in critically ill patients receiving RRT are associated with RRT dependence and death. This study objective was to examine whether plasma inflammatory (IL-6, -8, -10, and -18; macrophage migration inhibitory factor) and apoptosis (death receptor-5, tumor necrosis factor receptor I and II) biomarkers augment risk prediction of renal recovery and mortality compared with clinical models. Design, setting, participants, & measurements The Biologic Markers of Recovery for the Kidney study (n=817) was a prospective, nested, observational cohort study conducted as an ancillary to the Veterans Affairs/National Institutes of Health Acute renal failure Trial Network study, a randomized trial of intensive versus less intensive RRT in critically ill patients with AKI conducted between November 2003 and July 2007 at 27 Veterans Affairs- and university-affiliated centers. Primary outcomes of interest were renal recovery and mortality at day 60. Results A parsimonious clinical model consisting of only four variables (age, mean arterial pressure, mechanical ventilation, and bilirubin) predicted renal recovery (area under the receiver-operating characteristic curve [AUROC], 0.73; 95% confidence interval [95% CI], 0.68 to 0.78) and mortality (AUROC, 0.74; 95% CI, 0.69 to 0.78). By contrast, individual biomarkers were only modestly predictive of renal recovery (AUROC range, 0.55-0.63) and mortality (AUROC range, 0.54-0.68). Adding plasma IL-8 to a parsimonious model augmented prediction of recovery (AUROC, 0.76; 95% CI, 0.71 to 0.81; P=0.04) and mortality (AUROC, 0.78; 95% CI, 0.73 to 0.82; P<0.01) compared with the clinical model alone. Conclusions This study suggests that a simple four-variable clinical model with plasma IL-8 had predictive value for renal recovery and mortality. These findings require external validation but could easily be used by clinicians. C1 [Pike, Francis; Murugan, Raghavan; Keener, Christopher; Palevsky, Paul M.; Wen, Xiaoyan; Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Ctr Crit Care Nephrol, Pittsburgh, PA 15261 USA. [Pike, Francis; Murugan, Raghavan; Keener, Christopher; Unruh, Mark; Wen, Xiaoyan; Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, CRISMA Clin Res Invest & Syst Modeling Acute Illn, Pittsburgh, PA 15261 USA. [Pike, Francis; Keener, Christopher] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Vijayan, Anitha] Washington Univ, Div Renal Dis, St Louis, MO USA. [Unruh, Mark] Univ New Mexico, Dept Internal Med, Div Nephrol, Albuquerque, NM 87131 USA. [Finkel, Kevin] Univ Texas Med Sch Houston, Div Renal Dis & Hypertens, Houston, TX USA. RP Kellum, JA (reprint author), Univ Pittsburgh, Ctr Crit Care Nephrol, 604 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [Y1-DK-3508]; Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development [530] FX The BioMaRK study was conducted by the BioMaRK investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The primary data and samples from the parent trial (A Comparison of Intensive vs. Conventional Renal Support in Acute Renal Failure; the ATN study), from which the analyses reported here were performed, were supplied by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development (CSP #530) and by the NIDDK Central Repositories. This manuscript does not necessarily reflect the opinions or views of the ATN study, NIDDK Central Repositories, or the NIDDK. The VA/NIH ATN study was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development (CSP #530) and by NIDDK by interagency agreement Y1-DK-3508. NR 17 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD AUG PY 2015 VL 10 IS 8 BP 1332 EP 1339 DI 10.2215/CJN.09911014 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA CO5AU UT WOS:000359172800007 PM 26048891 ER PT J AU Yu, MK O'Hare, AM Batten, A Sulc, CA Neely, EL Liu, CF Hebert, PL AF Yu, Margaret K. O'Hare, Ann M. Batten, Adam Sulc, Christine A. Neely, Emily L. Liu, Chuan-Fen Hebert, Paul L. TI Trends in Timing of Dialysis Initiation within Versus Outside the Department of Veterans Affairs SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID RENAL REPLACEMENT THERAPY; PATIENTS STARTING DIALYSIS; HEALTH-CARE-SYSTEM; UNITED-STATES; QUALITY; SURVIVAL; OUTCOMES; DISEASE; MORTALITY; ADULTS AB Background and objectives The secular trend toward dialysis initiation at progressively higher levels of eGFR is not well understood. This study compared temporal trends in eGFR at dialysis initiation within versus outside the Department of Veterans Affairs (VA) the largest non-fee-for-service health system in the United States. Design, setting, participants, & measurements The study used linked data from the US Renal Data System, VA, and Medicare to compare temporal trends in eGFR at dialysis initiation between 2000 and 2009 (n=971,543). Veterans who initiated dialysis within the VA were compared with three groups who initiated dialysis outside the VA: (1) veterans whose dialysis was paid for by the VA, (2) veterans whose dialysis was not paid for by the VA, and (3) nonveterans. Logistic regression was used to estimate average predicted probabilities of dialysis initiation at an eGFR >= 10 ml/min per 1.73 m(2). Results The adjusted probability of starting dialysis at an eGFR:10 ml/min per 1.73 m2 increased over time for all groups but was lower for veterans who started dialysis within the VA (0.31; 95% confidence interval [95% CI], 0.30 to 0.32) than for those starting outside the VA, including veterans whose dialysis was (0.36; 95% CI, 0.35 to 0.38) and was not (0.40; 95% CI, 0.40 to 0.40) paid for by the VA and nonveterans (0.39; 95% CI, 0.39 to 0.39). Differences in eGFR at initiation within versus outside the VA were most pronounced among older patients (P for interaction <0.001) and those with a higher risk of 1-year mortality (P for interaction <0.001). Conclusions Temporal trends in eGFR at dialysis initiation within the VA mirrored those in the wider United States dialysis population, but eGFR at initiation was consistently lowest among those who initiated within the VA. Differences in eGFR at initiation within versus outside the VA were especially pronounced in older patients and those with higher 1-year mortality risk. C1 [Yu, Margaret K.; O'Hare, Ann M.; Batten, Adam; Sulc, Christine A.; Neely, Emily L.; Liu, Chuan-Fen; Hebert, Paul L.] Vet Affairs Puget Sound Hlth Care Syst, Vet Affairs Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Yu, Margaret K.; O'Hare, Ann M.] Univ Washington, Sch Publ Hlth, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Liu, Chuan-Fen; Hebert, Paul L.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Yu, Margaret K.; O'Hare, Ann M.] Kidney Res Inst, Seattle, WA USA. RP Yu, MK (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM mkyu@uw.edu FU US Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development Service [IIR 09-094]; VA Advanced Fellowship Program in Health Services Research and Development; American Kidney Fund's Clinical Scientist in Nephrology Program; VA Health Services Research and Development Service; Centers for Disease Control and Prevention; National Institutes of Health FX This material is based upon work supported by the US Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development Service, grant IIR 09-094 (P.L.H.). M.K.Y. was supported by the VA Advanced Fellowship Program in Health Services Research and Development and the American Kidney Fund's Clinical Scientist in Nephrology Program. A.M.O., C.F.L., and P.L.H. receive research funding from the VA Health Services Research and Development Service. A.M.O. also receives research funding from the Centers for Disease Control and Prevention and the National Institutes of Health and royalties from UpToDate. NR 48 TC 5 Z9 5 U1 1 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD AUG PY 2015 VL 10 IS 8 BP 1418 EP 1427 DI 10.2215/CJN.12731214 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA CO5AU UT WOS:000359172800017 PM 26206891 ER PT J AU Lim, DA AF Lim, Daniel A. TI Transcriptional and epigenetic insights from stem cells and developing tissues SO DEVELOPMENT LA English DT Review DE Developing tissues; Epigenetic regulation; Single cells; Stem cells; Transcriptional regulation; Transdifferentiation ID PLURIPOTENT CELLS; SUPER-ENHANCERS; IDENTITY GENES; SOMATIC-CELLS; GENOME; FATE; HETEROGENEITY; INDUCTION; DISTINCT; DNMT3A AB In March 2015, over 200 scientists gathered in Steamboat Springs, Colorado, USA, for the Keystone Symposium 'Transcriptional and Epigenetic Influences on Stem Cell States' to discuss the molecular mechanisms of pluripotency, cell differentiation, cell reprogramming and transdifferentiation, among other topics. In this meeting, translational research on stem cells for disease modeling and therapy was also presented. This Meeting Review describes key themes and selected findings, providing a timely update on this fast-moving area of research. C1 Univ Calif San Francisco, Dept Neurol Surg, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Lim, DA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. EM limd@neurosurg.ucsf.edu NR 31 TC 0 Z9 0 U1 1 U2 12 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0950-1991 EI 1477-9129 J9 DEVELOPMENT JI Development PD AUG 1 PY 2015 VL 142 IS 15 BP 2549 EP 2553 DI 10.1242/dev.122424 PG 5 WC Developmental Biology SC Developmental Biology GA CO1VF UT WOS:000358943200002 PM 26243867 ER PT J AU Kahn, SE Buse, JB AF Kahn, Steven E. Buse, John B. TI Medications for type 2 diabetes: how will we be treating patients in 50 years? SO DIABETOLOGIA LA English DT Article DE Basal insulin; Beta cell; Diabetes prevention; DPP-4 inhibitors; GLP-1 receptor agonists; Metformin; Pragmatic clinical trials; SGLT2 inhibitors; Stem cell therapy; Sulfonylureas; Thiazolidinediones ID REDUCTION; DESIGN; TRIAL; CARE AB The past 50 years have seen the development of many new options for treating and preventing type 2 diabetes. Despite this success, the individual and societal burden of the disease continues unabated. Thus, the next 50 years will be critical if we are going to quell the major non-communicable disease of our time. The knowledge we will gain in the next few years from clinical studies will inform treatment guidelines with regard to which agents to use in whom and whether more aggressive approaches can slow the development of hyperglycaemia in those at high risk. Beyond that, we anticipate identification of novel targets and techniques for therapeutic intervention. These advances will lead to more personalised approaches to treatment. Most importantly, we will need to focus our political and economic efforts on enhancing and implementing public health approaches aimed at prevention of diabetes and its co-morbidities. This is one of a series of commentaries under the banner '50 years forward', giving personal opinions on future perspectives in diabetes, to celebrate the 50th anniversary of Diabetologia (1965-2015). C1 [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Buse, John B.] Univ N Carolina, Sch Med, Dept Med, Div Endocrinol & Metab, Chapel Hill, NC USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@uw.edu OI Kahn, Steven/0000-0001-7307-9002 FU NCATS NIH HHS [1UL1TR001111, UL1 TR001111]; NIDDK NIH HHS [5P30DK017047, P30 DK017047] NR 15 TC 3 Z9 3 U1 1 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD AUG PY 2015 VL 58 IS 8 BP 1735 EP 1739 DI 10.1007/s00125-015-3541-8 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CO0XN UT WOS:000358877300011 PM 25773402 ER PT J AU Christodoulides, N De La Garza, R Simmons, GW McRae, MP Wong, J Newton, TF Smith, R Mahoney, JJ Hohenstein, J Gomez, S Floriano, PN Talavera, H Sloan, DJ Moody, DE Andrenyak, DM Kosten, TR Haque, A McDevitt, JT AF Christodoulides, Nicolaos De La Garza, Richard, II Simmons, Glennon W. McRae, Michael P. Wong, Jorge Newton, Thomas F. Smith, Regina Mahoney, James J., III Hohenstein, Justin Gomez, Sobeyda Floriano, Pierre N. Talavera, Humberto Sloan, Daniel J. Moody, David E. Andrenyak, David M. Kosten, Thomas R. Haque, Ahmed McDevitt, John T. TI Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Drugs of abuse; Programmable bio-nano-chip; Oral fluid; Multiplexed; On-site testing ID TANDEM MASS-SPECTROMETRY; POINT-OF-CARE; TESTING DEVICES; COCAINE; DIAGNOSTICS; PERFORMANCE; METABOLITES; MICROCHIP; PLASMA; FUTURE AB Objective: There is currently a gap in on-site drug of abuse monitoring. Current detection methods involve invasive sampling of blood and urine specimens, or collection of oral fluid, followed by qualitative screening tests using immunochromatographic cartridges. While remote laboratories then may provide confirmation and quantitative assessment of a presumptive positive, this instrumentation is expensive and decoupled from the initial sampling making the current drug-screening program inefficient and costly. The authors applied a noninvasive oral fluid sampling approach integrated with the in-development chip-based Programmable bio-nano-chip (p-BNC) platform for the detection of drugs of abuse. Method: The p-BNC assay methodology was applied for the detection of tetrahydrocannabinol, morphine, amphetamine, methamphetamine, cocaine, methadone and benzodiazepines, initially using spiked buffered samples and, ultimately, using oral fluid specimen collected from consented volunteers. Results: Rapid (similar to 10 min), sensitive detection (similar to ng/mL) and quantitation of 12 drugs of abuse was demonstrated on the p-BNC platform. Furthermore, the system provided visibility to time-course of select drug and metabolite profiles in oral fluids; for the drug cocaine, three regions of slope were observed that, when combined with concentration measurements from this and prior impairment studies, information about cocaine-induced impairment may be revealed. Conclusions: This chip-based p-BNC detection modality has significant potential to be used in the future by law enforcement officers for roadside drug testing and to serve a variety of other settings, including outpatient and inpatient drug rehabilitation centers, emergency rooms, prisons, schools, and in the workplace. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Christodoulides, Nicolaos; Simmons, Glennon W.; McRae, Michael P.; Wong, Jorge; Smith, Regina; Hohenstein, Justin; Gomez, Sobeyda; Floriano, Pierre N.; Talavera, Humberto; Sloan, Daniel J.; Haque, Ahmed; McDevitt, John T.] Rice Univ, Dept Bioengn, Houston, TX USA. [Christodoulides, Nicolaos; Simmons, Glennon W.; Wong, Jorge; Floriano, Pierre N.; McDevitt, John T.] Rice Univ, Dept Chem, Houston, TX USA. [De La Garza, Richard, II; Newton, Thomas F.; Mahoney, James J., III; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [De La Garza, Richard, II; Newton, Thomas F.; Kosten, Thomas R.] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA. [De La Garza, Richard, II; Kosten, Thomas R.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA. [Newton, Thomas F.; Kosten, Thomas R.] Dept Vet Affairs Med Ctr, Houston, TX USA. [Moody, David E.; Andrenyak, David M.] Univ Utah, Dept Pharmacol & Toxicol, Ctr Human Toxicol, Salt Lake City, UT 84112 USA. [McDevitt, John T.] NYU, Dept Biomat, Bioengn Inst, New York, NY 10010 USA. RP McDevitt, JT (reprint author), NYU, Dept Biomat, Bioengn Inst, 433 First Ave,Room 820, New York, NY 10010 USA. EM mcdevitt@nyu.edu RI Mahoney, James/I-2753-2014; McDevitt, John/P-4108-2014 OI Mahoney, James/0000-0003-0824-1776; McDevitt, John/0000-0001-8789-9351; newton, thomas/0000-0002-3198-5901 FU United Kingdom (UK) Home Office Center of Applied Science and Technology (CAST) [PO7165721]; NIH through the National Institute of Dental and Craniofacial Research [5U01 DE017793] FX Funding support for this work was provided by the United Kingdom (UK) Home Office Center of Applied Science and Technology (CAST) (PO7165721). This sponsor was involved in the design of the study and contributed suggestions on the interpretation of data and definition of the next steps. Support for the p-BNC core instrumentation work was provided also by the (NIH) through the National Institute of Dental and Craniofacial Research (award number 5U01 DE017793). NR 36 TC 7 Z9 7 U1 3 U2 28 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD AUG 1 PY 2015 VL 153 BP 306 EP 313 DI 10.1016/j.drugalcdep.2015.04.026 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CO5AP UT WOS:000359172300045 PM 26048639 ER PT J AU Niquet, J Baldwin, R Gezalian, M Wasterlain, CG AF Niquet, Jerome Baldwin, Roger Gezalian, Michael Wasterlain, Claude G. TI Deep hypothermia for the treatment of refractory status epilepticus SO EPILEPSY & BEHAVIOR LA English DT Article DE Status epilepticus; Hypothermia; EEG power ID TRAUMATIC BRAIN-INJURY; SUSTAINING STATUS EPILEPTICUS; CIRCULATORY ARREST TRIAL; THERAPEUTIC HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; BARRIER PERMEABILITY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; PROFOUND HYPOTHERMIA; MEMBRANE-PROPERTIES AB In a rat model of status epilepticus (SE) induced by lithium and pilocarpine and refractory to midazolam, deep hypothermia (20 "C for 30 min) reduced EEG power over 50-fold, stopped SE within 12 min, and reduced EEG spikes by 87%. Hypothermia deserves further investigation as a treatment of last resort for refractory SE. Published by Elsevier Inc. C1 [Niquet, Jerome; Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Niquet, Jerome; Baldwin, Roger; Gezalian, Michael; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, Los Angeles, CA USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Niquet, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, 11301 Wilshire Blvd,Bldg 114,Room 139, West Los Angeles, CA 90073 USA. EM jniquet@ucla.edu OI Niquet, Jerome/0000-0002-1005-0517; Wasterlain, Claude/0000-0002-2100-9114 FU VHA Research Service; NINDS [UO1 NS074926] FX This study was supported by VHA Research Service (CW) and NINDS (grant UO1 NS074926, CW). NR 69 TC 3 Z9 3 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD AUG PY 2015 VL 49 BP 313 EP 317 DI 10.1016/j.yebeh.2015.06.028 PG 5 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA CO7CK UT WOS:000359314900058 PM 26198217 ER PT J AU Bollerslev, J Rejnmark, L Marcocci, C Shoback, DM Sitges-Serra, A van Biesen, W Dekkers, OM AF Bollerslev, Jens Rejnmark, Lars Marcocci, Claudio Shoback, Dolores M. Sitges-Serra, Antonio van Biesen, Wim Dekkers, Olaf M. TI European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults SO EUROPEAN JOURNAL OF ENDOCRINOLOGY LA English DT Article ID CALCIUM-SENSING RECEPTOR; QUALITY-OF-LIFE; CONGENITAL HYPERPARATHYROIDISM SECONDARY; PARATHYROID-HORMONE SECRETION; VITAMIN-D DEFICIENCY; SERUM-CALCIUM; MATERNAL HYPOPARATHYROIDISM; TOTAL THYROIDECTOMY; BONE METABOLISM; URINARY CALCIUM AB Hypoparathyroidism (HypoPT) is a rare (orphan) endocrine disease with low calcium and inappropriately low (insufficient) circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. Standard treatment is activated vitamin D analogues and calcium supplementation and not replacement of the lacking hormone, as in other hormonal deficiency states. The purpose of this guideline is to provide clinicians with guidance on the treatment and monitoring of chronic HypoPT in adults who do not have end-stage renal disease. We intend to draft a practical guideline, focusing on operationalized recommendations deemed to be useful in the daily management of patients. This guideline was developed and solely sponsored by The European Society of Endocrinology, supported by CBO (Dutch Institute for Health Care Improvement) and based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles as a methodological base. The clinical question on which the systematic literature search was based and for which available evidence was synthesized was: what is the best treatment for adult patients with chronic HypoPT? This systematic search found 1100 articles, which was reduced to 312 based on title and abstract. The working group assessed these for eligibility in more detail, and 32 full-text articles were assessed. For the final recommendations, other literature was also taken into account. Little evidence is available on how best to treat HypoPT. Data on quality of life and the risk of complications have just started to emerge, and clinical trials on how to optimize therapy are essentially non-existent. Most studies are of limited sample size, hampering firm conclusions. No studies are available relating target calcium levels with clinically relevant endpoints. Hence it is not possible to formulate recommendations based on strict evidence. This guideline is therefore mainly based on how patients are managed in clinical practice, as reported in small case series and based on the experiences of the authors. C1 [Bollerslev, Jens] Oslo Univ Hosp, Med Clin, Sect Specialized Endocrinol, Oslo, Norway. [Bollerslev, Jens] Univ Oslo, Fac Med, Oslo, Norway. [Rejnmark, Lars] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, DK-8000 Aarhus, Denmark. [Marcocci, Claudio] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy. [Shoback, Dolores M.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Vet Affairs, Endocrine Res Unit, San Francisco, CA 94143 USA. [Sitges-Serra, Antonio] Hosp Univ Mar, Endocrine Surg Unit, Barcelona, Spain. [van Biesen, Wim] Ghent Univ Hosp, Div Renal, Ghent, Belgium. [Dekkers, Olaf M.] Leiden Univ Med Ctr, Dept Med, Div Endocrinol, Leiden, Netherlands. [Dekkers, Olaf M.] Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands. [Dekkers, Olaf M.] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark. RP Bollerslev, J (reprint author), Oslo Univ Hosp, Med Clin, Sect Specialized Endocrinol, Oslo, Norway. EM Jens.bollerslev@medisin.uio.no FU European Society of Endocrinology FX This guideline was sponsored by the European Society of Endocrinology. NR 107 TC 18 Z9 20 U1 0 U2 9 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0804-4643 EI 1479-683X J9 EUR J ENDOCRINOL JI Eur. J. Endocrinol. PD AUG PY 2015 VL 173 IS 2 BP EG1 EP EG20 DI 10.1530/EJE-15-0628 PG 20 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CO1XH UT WOS:000358949000003 PM 26160136 ER PT J AU Psotka, MA Teerlink, JR AF Psotka, Mitchell A. Teerlink, John R. TI Cardiac myosin activators: up and coming SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Editorial Material ID SYSTOLIC HEART-FAILURE; OMECAMTIV MECARBIL; PHASE-2 TRIAL; MUSCLE; CONTRACTILITY; ATP C1 [Psotka, Mitchell A.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol, 111C,Bldg 203,Room 2A-49,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu NR 15 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD AUG PY 2015 VL 17 IS 8 BP 750 EP 752 DI 10.1002/ejhf.313 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CO3JF UT WOS:000359052400002 PM 26179667 ER PT J AU Jhund, PS Anand, IS Komajda, M Claggett, BL McKelvie, RS Zile, MR Carson, PE McMurray, JJV AF Jhund, Pardeep S. Anand, Inder S. Komajda, Michel Claggett, Brian L. McKelvie, Robert S. Zile, Michael R. Carson, Peter E. McMurray, John J. V. TI Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Heart failure; Biological markers; Prognosis; Natriuretic peptide ID VENTRICULAR SYSTOLIC DYSFUNCTION; RANDOMIZED CONTROLLED-TRIAL; PROGNOSTIC VALUE; VAL-HEFT; AMBULATORY PATIENTS; BASE-LINE; SPIRONOLACTONE; NEUROHORMONES; IRBESARTAN; MORTALITY AB AimsIn patients with heart failure (HF) and reduced ejection fraction, decreases or increases in NT-proBNP levels are associated with better and worse outcomes, respectively. The association in HF and preserved ejection fraction (HF-PEF) is unknown. We examined the association between change in level of NT-proBNP and prognosis in patients with HF-PEF. Methods and resultsWe examined the association between change in NT-proBNP from baseline to 6 months and cardiovascular (CV) death or HF hospitalization in 2612 participants in the Irbesartan in Patients with Heart Failure and Preserved Systolic Function Study (I-Preserve). Change in NT-proBNP was modelled as a restricted cubic spline in a Cox model after adjusting for baseline NT-proBNP and known prognostic variables. Median change in NT-proBNP from baseline was -7pg/mL (interquartile range -143 to +108). After adjustment, a 1000pg/mL decrease in NT-proBNP from baseline was associated with a reduction in the risk of CV death or HF hospitalization [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.53-1.02]; a 1000pg/mL increase was associated with an increase in risk (HR 2.01, 95% CI 1.50-2.69). Beyond a 1000pg/mL rise or fall, there was little additional change in risk. Addition of change in NT-proBNP at 6 months to a model with only baseline NT-proBNP improved the C-statistic from 0.752 to 0.769 (P = 0.013). ConclusionIn HF-PEF, a rise in NT-proBNP was associated with an increase in risk of CV death or HF hospitalization and a fall was associated with a trend towards a decrease in risk. NT-proBNP may be a useful marker to monitor prognosis in this condition. C1 [Jhund, Pardeep S.; McMurray, John J. V.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow G12 9QZ, Lanark, Scotland. [Anand, Inder S.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Anand, Inder S.] Univ Minnesota, Minneapolis, MN USA. [Komajda, Michel] Univ Paris 06, Paris, France. [Komajda, Michel] Grp Hosp Pitie Salpetriere, F-75634 Paris, France. [Claggett, Brian L.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [McKelvie, Robert S.] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA. RP McMurray, JJV (reprint author), Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, 126 Univ Ave, Glasgow G12 9QZ, Lanark, Scotland. EM John.McMurray@glasgow.ac.uk OI Jhund, Pardeep/0000-0003-4306-5317; mcmurray, john/0000-0002-6317-3975 NR 28 TC 13 Z9 13 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD AUG PY 2015 VL 17 IS 8 BP 809 EP 817 DI 10.1002/ejhf.274 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CO3JF UT WOS:000359052400012 PM 25921853 ER PT J AU Collins, GT Chen, Y Tschumi, C Rush, EL Mensah, A Koek, W France, CP AF Collins, Gregory T. Chen, Yu Tschumi, Chris Rush, Elise L. Mensah, Ayele Koek, Wouter France, Charles P. TI Effects of Consuming a Diet High in Fat and/or Sugar on the Locomotor Effects of Acute and Repeated Cocaine in Male and Female C57BL/6J Mice SO EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE high-fat diet; sucrose; cocaine; behavioral sensitization; sex differences ID BEHAVIORAL SENSITIZATION; FOOD-DEPRIVATION; GENE-EXPRESSION; RATS; QUINPIROLE; SUCROSE; OBESITY; CHOW; NEUROPLASTICITY; SENSITIVITY AB Drug abuse and obesity are serious public health problems. Dopamine plays a central role in mediating the reinforcing effects of drugs and food. Prolonged use of drugs is known to alter the function and/or sensitivity of many neurotransmitter systems, including dopamine; however, the impact of consuming foods high in fat and/or sugar is less clear. These studies characterized the locomotor effects of acute and repeated cocaine in male and female C57BL/6J mice consuming 1 of 4 diets: (a) standard chow + water; (b) standard chow + 10% sucrose solution; (c) high-fat chow + water; or (d) high-fat chow + 10% sucrose solution. The acute locomotor effects of cocaine (3.2-32.0 mg/kg) were evaluated 4 weeks after initiating dietary conditions; the effects of repeated cocaine administration were evaluated after 5, 6, 7, and 12 weeks. During acute tests, mice consuming a diet high in fat and/or sucrose exhibited greater locomotor responses to cocaine than mice consuming standard chow and water, regardless of sex. Although diet-induced enhancements persisted across repeated cocaine testing, locomotor sensitization developed more rapidly in females drinking sucrose (and consuming either standard or high-fat chow) than in females consuming standard chow and water. In addition to providing evidence that consuming a diet high in fat and/or sugar enhances abuse-related effects of cocaine in ways that might increase vulnerability to abuse cocaine, these studies identified a potentially important sex-related difference in the interaction between nutrition and cocaine effects, with the impacts of sucrose consumption being greater in females than in males. C1 [Collins, Gregory T.; Chen, Yu; Tschumi, Chris; Rush, Elise L.; Mensah, Ayele; Koek, Wouter; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Collins, Gregory T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Koek, Wouter; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Collins, GT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM collinsg@uthscsa.edu RI Collins, Gregory/K-3125-2012 FU National Institutes of Health [K05 DA017918]; American Society for Pharmacology and Experimental Therapeutics FX Charles P. France was supported by a grant from the National Institutes of Health (K05 DA017918), and Elise L. Rush was supported by a Summer Undergraduate Research Fellowship through the American Society for Pharmacology and Experimental Therapeutics. These funding sources provided financial support, but had no other role in the design and completion of the studies. All authors contributed in a significant way to the completion of the studies and/or the writing of the manuscript, and all authors have approved the final manuscript. We thank Melson Mesmin for his technical assistance in completing these studies. NR 38 TC 6 Z9 7 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1064-1297 EI 1936-2293 J9 EXP CLIN PSYCHOPHARM JI Exp. Clin. Psychopharmacol. PD AUG PY 2015 VL 23 IS 4 BP 228 EP 237 DI 10.1037/pha0000019 PG 10 WC Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry SC Psychology; Pharmacology & Pharmacy; Psychiatry GA CN9VI UT WOS:000358797800005 PM 26237320 ER PT J AU Shahid, H Singh, JA AF Shahid, Hania Singh, Jasvinder A. TI Investigational drugs for hyperuricemia SO EXPERT OPINION ON INVESTIGATIONAL DRUGS LA English DT Review DE AC-201; arhalofenate; KX1151; LC350189; lesinurad; levotofisopam; Marine Active; OAT4; purine nucleoside phosphorylase; RDEA; tranilast; ulodesine (BCX-4208); UR1102; urate anion transporter 1 ID NUTRITION EXAMINATION SURVEY; URATE-LOWERING THERAPIES; CHRONIC KIDNEY-DISEASE; URIC-ACID; NATIONAL-HEALTH; GOUT PATIENTS; RISK-FACTORS; GENERAL-POPULATION; COST-EFFECTIVENESS; ADVERSE-REACTIONS AB Introduction: The unmet need and the growing prevalence of hyperuricemia and its complications worldwide have pushed investigators to identify new agents to manage hyperuricemia. Areas covered: This review discusses the drugs in preclinical and early clinical trials for hyperuricemia, their mechanisms of action and available results. This article reviews a total of 10 novel agents: i) drugs in Phase II/III trials - arhalofenate (MBX201), AC201, RDEA group of drugs (including lesinurad), tranilast, ulodesine (BCX4208); and ii) drugs in Phase I trials, including levotofisopam, UR1102, KX1151, LC350189 and Marine Active. Expert opinion: The goal of emerging therapies is to address the unsatisfactory control of serum uric acid in patients with symptomatic hyperuricemia such as those with gout, to provide better tolerability compared to traditional agents and minimize the risk of adverse events, especially in patients with comorbidities and the elderly. Some drugs like arhalofenate, ulodesine (BCX-4208) and lesinurad are in or have completed Phase II and Phase III trials. The growing knowledge about the urate transporters in the kidney have advanced our knowledge of pathophysiology of hyperuricennia and have led to the development of several new potential treatment options. Availability of new drugs will lead to better management and address the unmet need in patients with symptomatic hyperuricemia in the coming years. C1 [Shahid, Hania; Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA. [Shahid, Hania; Singh, Jasvinder A.] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Shahid, Hania] Rawalpindi Med Coll, Rawalpindi, Pakistan. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases [P50 AR060772, U34 AR062891]; National Institute of Aging [U01 AG018947]; National Cancer Institute [U10 CA149950]; Patient Centered Outcomes Research Institute [CE-1304-6631] FX JA Singh is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases P50 AR060772 and U34 AR062891, National Institute of Aging U01 AG018947, National Cancer Institute U10 CA149950 and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute. JA Singh is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 90 TC 9 Z9 11 U1 3 U2 19 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1354-3784 EI 1744-7658 J9 EXPERT OPIN INV DRUG JI Expert Opin. Investig. Drugs PD AUG PY 2015 VL 24 IS 8 BP 1013 EP 1030 DI 10.1517/13543784.2015.1051617 PG 18 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CN9FA UT WOS:000358751200003 PM 26073200 ER PT J AU Saeki, M Sato, N Kawasaki, M Tanaka, R Nagaya, M Watanabe, T Ono, K Noda, T Zile, MR Minatoguchi, S AF Saeki, Maki Sato, Noriaki Kawasaki, Masanori Tanaka, Ryuhei Nagaya, Maki Watanabe, Takatomo Ono, Koji Noda, Toshiyuki Zile, Michael R. Minatoguchi, Shinya TI Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates SO HYPERTENSION RESEARCH LA English DT Article DE left ventricular function; left ventricular layer function; real-time three-dimensional echocardiography; speckle-tracking echocardiography ID DIASTOLIC HEART-FAILURE; LEFT ATRIAL STRUCTURE; SYSTOLIC FUNCTION; TISSUE DOPPLER; LONGITUDINAL STRAIN; FILLING PRESSURES; EJECTION FRACTION; RADIAL STRAIN; HYPERTROPHY; DEFORMATION AB We recently developed novel software to measure phasic strain rate (SR) using automated one-beat real-time three-dimensional speckle tracking echocardiography (3D-STE) with high volume rates. We tested the hypothesis that left ventricular (LV) systolic function and relaxation analyzed by SR with the novel 3D-STE in hypertension (HTN) with hypertrophy may be impaired in the endocardium before there is LV systolic dysfunction. We measured LV longitudinal, radial and circumferential SR in patients with HTN (n=80, 69 +/- 7 years) and age-matched normotensive controls (n=60, 69 +/- 10 years) using 3D-STE. HTN patients were divided into four groups according to LV geometry: normal, concentric remodeling, concentric hypertrophy and eccentric hypertrophy. We measured SR during systole as an index of systolic function, SR during isovolumic relaxation (IVR) as an index of relaxation and E/e' as an index of filling pressure. Endocardial SR during systole in HTN with concentric and eccentric hypertrophy decreased compared with that in controls despite no reduction in ejection fraction or epicardial SR. Endocardial radial SR during IVR decreased even in normal geometry, and it was further reduced in concentric remodeling and hypertrophy despite no reduction in epicardial SR. LV phasic SR assessed by 3D-STE with high volume rates is a useful index to detect early decreases in LV systolic function and to predict subclinical LV layer dysfunction in patients with HTN. C1 [Saeki, Maki; Sato, Noriaki; Tanaka, Ryuhei; Nagaya, Maki; Ono, Koji; Noda, Toshiyuki] Gifu Prefectural Gen Med Ctr, Dept Cardiol, Gifu, Japan. [Kawasaki, Masanori; Watanabe, Takatomo; Minatoguchi, Shinya] Gifu Univ, Dept Cardiol, Grad Sch Med, Gifu 5011194, Japan. [Zile, Michael R.] Med Univ S Carolina, Med Cardiol, Charleston, SC 29425 USA. [Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Kawasaki, M (reprint author), Gifu Univ, Dept Cardiol, Grad Sch Med, 1-1 Yanagido, Gifu 5011194, Japan. EM masanori@ya2.so-net.ne.jp NR 38 TC 2 Z9 2 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0916-9636 EI 1348-4214 J9 HYPERTENS RES JI Hypertens. Res. PD AUG PY 2015 VL 38 IS 8 BP 551 EP 559 DI 10.1038/hr.2015.47 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CO2VV UT WOS:000359015800006 PM 25832918 ER PT J AU Zhang, Z Adappa, ND Doghramji, LJ Chiu, AG Cohen, NA Palmer, JN AF Zhang, Zi Adappa, Nithin D. Doghramji, Laurel J. Chiu, Alexander G. Cohen, Noam A. Palmer, James N. TI Different clinical factors associated with Staphylococcus aureus and Pseudomonas aeruginosa in chronic rhinosinusitis SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; Staphylococcus aureus; Pseudomonas aeruginosa; nasal polyps; functional endoscopic sinus surgery ID REFRACTORY CHRONIC RHINOSINUSITIS; ENDOSCOPIC SINUS SURGERY; ANTIMICROBIAL RESISTANCE; NASAL POLYPS; BACTERIOLOGICAL FINDINGS; MAXILLARY SINUSITIS; ASTHMA; MICROBIOLOGY; INFLAMMATION; FEATURES AB BackgroundStaphylococcus aureus and Pseudomonas aeruginosa are common culture isolates in chronic rhinosinusitis (CRS). We aimed to determine whether they were associated with different clinical factors of CRS. MethodsAdult CRS patients who underwent functional endoscopic sinus surgery (FESS) between October 1, 2007 and December 31, 2011 were recruited. Patient demographics, Lund-Mackay computed tomography (CT) scores, 22-item Sino-Nasal Outcome Test (SNOT-22) scores, disease characteristics, and medication use were collected prior to FESS. Intraoperative culture was obtained in a standard manner. We compared patients with isolates of S. aureus or P. aeruginosa to patients with other culture results and no bacterial growth, respectively. Multivariate logistic regression was performed. ResultsA total of 376 patients met criteria; 104 patients (28%) had S. aureus, 32 (9%) had P. aeruginosa, and 10 patients (3%) had no bacterial growth. After adjusting for all clinical factors, compared to patients with positive culture other than S. aureus, patients with S. aureus had 1.9 times increased odds of having nasal polyps (odds ratio [OR] = 1.9; 95% confidence interval [CI], 1.0 to 3.3; p = 0.036); when compared to patients with positive culture other than P. aeruginosa, patients with P. aeruginosa had 7.8 times increased odds of having prior FESS (OR = 7.8; 95% CI, 2.1 to 28.9; p = 0.002) (91% vs 58%; p < 0.001) and 3.6 times increased odds of having diabetes with marginal significance (OR = 3.6; 95% CI, 1.0 to 13.2; p = 0.053). The sample size in the no bacterial growth group was too small to draw firm conclusions. ConclusionS. aureus was more common in CRS patients with nasal polyps, whereas P. aeruginosa was more common in CRS patients with prior FESS history and possibly diabetes. C1 [Zhang, Zi] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Adappa, Nithin D.; Doghramji, Laurel J.; Cohen, Noam A.; Palmer, James N.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Zhang, Z (reprint author), 8th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM zizhang@mail.med.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 NR 40 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD AUG PY 2015 VL 5 IS 8 BP 724 EP 733 DI 10.1002/alr.21532 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA CO3JQ UT WOS:000359053700009 PM 25899601 ER PT J AU Nathaniel, JD Garrido, MM Chai, EJ Goldberg, G Goldstein, NE AF Nathaniel, Jeremy D. Garrido, Melissa M. Chai, Emily J. Goldberg, Gabrielle Goldstein, Nathan E. TI Cost Savings Associated With an Inpatient Palliative Care Unit: Results From the First Two Years SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Palliative medicine; palliative care unit; cost savings; cost; longitudinal study ID OF-LIFE CARE; CONSULTATION SERVICE; PROPENSITY SCORES; CANCER CARE; OUTCOMES; IMPACT AB Context. Palliative care consultation services (PCCS) decrease costs for patients by matching treatments received to patients' and families' goals of care. However, few studies have examined the costs of a specialized palliative care unit (PCU). Objectives. To quantitatively describe Mount Sinai Hospital's PCU's first two years of operation; to examine how patient-related costs changed in the days before and after transfer to PCU; and to compare cost savings of PCU to those of PCCS. Methods. Cost and administrative data from PCU patients from the first 24.5 months of our PCU's operation were analyzed. To compare costs between PCU and PCCS patients, we matched PCU patients to similar PCCS patients and used propensity scores to adjust for differences across groups. Results. The PCU admitted 1107 patients in its first 24.5 months. Over this time frame, there was a statistically significant (P < 0.001) decrease in average daily direct costs per patient. The mean of patients' average cost per day was $687 less while on the PCU than before transfer to PCU. Among patients who died in the hospital, average daily direct cost per patient in the days after transfer to PCU was $240 lower as compared with patients being followed by PCCS on the general hospital wards (SE = $45, P < 0.001). Conclusion. Among patients who died in the hospital, transfer to a PCU is associated with significant cost savings as compared with patients on hospital wards who are seen by a PCCS. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. C1 [Nathaniel, Jeremy D.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Garrido, Melissa M.; Goldstein, Nathan E.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Garrido, Melissa M.; Chai, Emily J.; Goldstein, Nathan E.] Icahn Sch Med Mt Sinai, Lilian & Benjamin Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Goldberg, Gabrielle] Hofstra North Shore LIJ Sch Med, Hempstead, NY USA. RP Goldstein, NE (reprint author), Mt Sinai Med Ctr, Dept Geriatr & Palliat Med, One Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM nathan.goldstein@mssm.edu FU Medical Student Training in Aging Research (MSTAR) Program through the American Geriatrics Society; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service [CDA 11-201/CDP12-255] FX Mr. Nathaniel is supported by the Medical Student Training in Aging Research (MSTAR) Program through the American Geriatrics Society. Dr. Garrido is supported by CDA 11-201/CDP12-255 from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service. NR 30 TC 5 Z9 5 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD AUG PY 2015 VL 50 IS 2 BP 147 EP 154 DI 10.1016/j.jpainsymman.2015.02.023 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA CO1YL UT WOS:000358952100005 PM 25847851 ER PT J AU Yawn, J Lawrence, LA Carroll, WW Mulligan, JK AF Yawn, James Lawrence, Lauren A. Carroll, William W. Mulligan, Jennifer K. TI Vitamin D for the treatment of respiratory diseases: Is it the end or just the beginning? (vol 148, pg 326, 2015) SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Correction C1 [Yawn, James; Lawrence, Lauren A.; Carroll, William W.; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Mulligan, JK (reprint author), 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD AUG PY 2015 VL 152 BP 193 EP 193 DI 10.1016/j.jsbmb.2015.04.013 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA CN9ZQ UT WOS:000358810100021 ER PT J AU Rehwald, CM Tripathy, A Bhargava, P AF Rehwald, Christine M. Tripathy, Arindam Bhargava, Puneet TI Systems Redesign: A Quality Improvement Initiative at a Tertiary-Care Veterans Affairs Medical Center SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Rehwald, Christine M.; Bhargava, Puneet] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Rehwald, Christine M.; Bhargava, Puneet] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Diagnost Imaging Serv, Seattle, WA 98108 USA. [Tripathy, Arindam] Univ Washington, Milgard Sch Business, Tacoma, WA USA. RP Bhargava, P (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Mail Box 358280,S-114 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD AUG PY 2015 VL 12 IS 8 BP 842 EP 844 DI 10.1016/j.jacr.2015.01.020 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CO5CK UT WOS:000359177000021 PM 25841865 ER PT J AU Ge, BH Weber, CN Wildenberg, JC Nadolski, GJ Gade, TP Hunt, SJ Soulen, MC Itkin, M AF Ge, Benjamin H. Weber, Charles N. Wildenberg, Joseph C. Nadolski, Gregory J. Gade, Terence P. Hunt, Stephen J. Soulen, Michael C. Itkin, Maxim TI Magnetic Resonance-Monitored Coaxial Electrochemical Ablation-Preliminary Evaluation of Technical Feasibility SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID ELECTRICAL-CURRENT THERAPY; EX-VIVO; ELECTROLYTIC ABLATION; HEPATIC METASTASES; LOCAL TREATMENT; MR THERMOMETRY; LIVER; TUMORS; MODEL; RAT AB Purpose: To evaluate the technical feasibility of a coaxial electrode configuration to rapidly create a mechanically defined electrochemical ablation zone monitored by magnetic resonance (MR) imaging in real time. Materials and Methods: A direct current generator supplied the nitinol cathode cage and central platinum anode for coaxial electrochemical ablation. Safety and efficacy were evaluated by measuring local pH, temperature, and current scatter in saline solutions. Ablation zone diameters of 3-6 cm (n = 72) were created on ex vivo bovine liver and verified by gross pathology. Feasibility of MR monitoring was evaluated using 8 swine livers to create ablations of 3 cm (n = 12), 4 cm (n = 4), and 5 cm (n = 4) verified by histology. Results: Local pH was 3.2 at the anode and 13.8 at the cathode. Current scatter was negligible. Ablation progress increased relative to local ion concentration, and MR signal changes corresponded to histologic findings. In the ex vivo model, the times to achieve complete ablation were 15 minutes, 20 minutes, 35 minutes, and 40 minutes for diameters of 3 cm, 4 cm, 5 cm, and 6 cm, respectively. Ablation times for the in situ model were 15 minutes, 35 minutes, and 50 minutes for 3 cm, 4 cm, and 5 cm, respectively. Conclusions: The coaxial configuration mechanically defined the electrochemical ablation zone with times similar to comparably sized thermal ablations. MR compatibility allowed for real-time monitoring of ablation progress. C1 [Ge, Benjamin H.; Weber, Charles N.; Wildenberg, Joseph C.; Nadolski, Gregory J.; Gade, Terence P.; Hunt, Stephen J.; Soulen, Michael C.; Itkin, Maxim] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Ge, Benjamin H.; Weber, Charles N.; Wildenberg, Joseph C.; Nadolski, Gregory J.; Gade, Terence P.; Hunt, Stephen J.; Itkin, Maxim] Hosp Univ Penn, Penn Image Guided Intervent Lab, Philadelphia, PA 19104 USA. [Itkin, Maxim] Philadelphia Vet Affairs Med Ctr, Dept Radiol, Philadelphia, PA USA. RP Ge, BH (reprint author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. EM ge.benjamin@gmail.com OI Wildenberg, Joe/0000-0001-5489-8467 FU T32 Training Grant; University of Pennsylvania Institute of Translational Medicine and Therapeutics; CareFusion; SIR Foundation; National Center for Research Resources [UL1RR024134]; National Center for Advancing Translational Sciences [UL1TR000003]; Radiological Society of North America; Guerbet LLC; BTG; Merit Medical; Sirtex Medical; Cambridge University Press FX B.H.G., C.N.W., and M.I. have patent ownership or part ownership of a coaxial probe ablation device developed as a result of these experiments with a preliminary patent filing in progress. C.N.W. received funding from a T32 Training Grant and University of Pennsylvania Institute of Translational Medicine and Therapeutics for research outside of the submitted work. G.J.N. is a paid consultant for CareFusion for work outside of the submitted work. T.P.G. received funding from the SIR Foundation, National Center for Research Resources Grant No. UL1RR024134, National Center for Advancing Translational Sciences Grant No. UL1TR000003, Radiological Society of North America, T32 Training Grant, and Guerbet LLC for research outside of the submitted work. S.J.H. received funding from a T32 Training Grant and SIR Foundation Pilot Grant for research outside of the submitted work. M.C.S. is a paid consultant for, and received funding from, Guerbet LLC, BTG, Merit Medical, Sirtex Medical, and Cambridge University Press for research and work outside of the submitted work. The other author has not identified a conflict of interest. NR 29 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD AUG PY 2015 VL 26 IS 8 BP 1238 EP 1246 DI 10.1016/j.jvir.2015.05.015 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA CO3YP UT WOS:000359097500023 PM 26210247 ER PT J AU Pascoe, S Locantore, N Dransfield, MT Barnes, NC Pavord, I AF Pascoe, Steven Locantore, Nicholas Dransfield, Mark T. Barnes, Neil C. Pavord, Ian TI Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD? Reply SO LANCET RESPIRATORY MEDICINE LA English DT Letter ID OBSTRUCTIVE PULMONARY-DISEASE; EXACERBATIONS C1 [Pascoe, Steven; Locantore, Nicholas] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA. [Dransfield, Mark T.] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. [Barnes, Neil C.] GlaxoSmithKline, Uxbridge, Middx, England. [Barnes, Neil C.] Barts & London Queen Marys Sch Med & Dent, William Harvey Inst, London, England. [Pavord, Ian] Univ Oxford, Nuffield Dept Clin Med, Resp Med Unit, Oxford OX1 2JD, England. RP Pascoe, S (reprint author), GlaxoSmithKline, Res Triangle Pk, NC 27709 USA. EM steven.j.pascoe@gsk.com NR 10 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD AUG PY 2015 VL 3 IS 8 BP E27 EP E27 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CO2AE UT WOS:000358956800005 PM 26282479 ER PT J AU Labus, JS Van Horn, JD Gupta, A Alayerdyan, M Torgerson, C Ashe-McNalley, C Irimia, A Hong, JY Naliboff, B Tillisch, K Mayer, EA AF Labus, Jennifer S. Van Horn, John D. Gupta, Arpana Alayerdyan, Mher Torgerson, Carinna Ashe-McNalley, Cody Irimia, Andrei Hong, Jui-Yang Naliboff, Bruce Tillisch, Kirsten Mayer, Emeran A. TI Multivariate morphological brain signatures predict patients with chronic abdominal pain from healthy control subjects SO PAIN LA English DT Article DE Structural magnetic resonance imaging; Brain; Females; Abdominal pain; Classification ID IRRITABLE-BOWEL-SYNDROME; PARTIAL LEAST-SQUARES; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; CYSTITIS/PAINFUL BLADDER SYNDROME; SURFACE-BASED ANALYSIS; GRAY-MATTER; SOMATOSENSORY CORTEX; VARIABLE SELECTION; AUDITORY-STIMULI; HUMAN AWARENESS AB Irritable bowel syndrome (IBS) is the most common chronic visceral pain disorder. The pathophysiology of IBS is incompletely understood; however, evidence strongly suggests dysregulation of the brain-gut axis. The aim of this study was to apply multivariate pattern analysis to identify an IBS-related morphometric brain signature that could serve as a central biological marker and provide new mechanistic insights into the pathophysiology of IBS. Parcellation of 165 cortical and subcortical regions was performed using FreeSurfer and the Destrieux and Harvard-Oxford atlases. Volume, mean curvature, surface area, and cortical thickness were calculated for each region. Sparse partial least squares discriminant analysis was applied to develop a diagnostic model using a training set of 160 females (80 healthy controls and 80 patients with IBS). Predictive accuracy was assessed in an age-matched holdout test set of 52 females (26 healthy controls and 26 patients with IBS). A 2-component classification algorithm comprising the morphometry of (1) primary somatosensory and motor regions and (2) multimodal network regions explained 36% of the variance. Overall predictive accuracy of the classification algorithm was 70%. Small effect size associations were observed between the somatosensory and motor signature and nongastrointestinal somatic symptoms. The findings demonstrate that the predictive accuracy of a classification algorithm based solely on regional brain morphometry is not sufficient, but they do provide support for the utility of multivariate pattern analysis for identifying meaningful neurobiological markers in IBS. C1 [Labus, Jennifer S.; Gupta, Arpana; Alayerdyan, Mher; Ashe-McNalley, Cody; Hong, Jui-Yang; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Oppenheimer Family Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Gupta, Arpana; Alayerdyan, Mher; Ashe-McNalley, Cody; Hong, Jui-Yang; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Gupta, Arpana; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Pain & Interocept Network PAIN, Los Angeles, CA USA. [Van Horn, John D.; Torgerson, Carinna; Irimia, Andrei] Univ So Calif, Keck Sch Med, INI, Los Angeles, CA 90033 USA. [Van Horn, John D.; Torgerson, Carinna; Irimia, Andrei] Univ So Calif, Keck Sch Med, Lab Neuro Imaging LONI, Los Angeles, CA 90033 USA. [Hong, Jui-Yang] Univ Calif Los Angeles, Dept Biomed Engn, Los Angeles, CA 90095 USA. [Tillisch, Kirsten] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Labus, JS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Oppenheimer Family Ctr Neurobiol Stress, CHS 42-210 MC737818,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM jlabus@ucla.edu FU National Institutes of Health [R01 DK048351, P50DK64539, R01 AT007137, K23 DK073451, K08 DK071626, R03 DK084169] FX This research was supported in part by grants from the National Institutes of Health: R01 DK048351 (E.A.M.), P50DK64539 (E.A.M.), R01 AT007137 (K.T.), K23 DK073451 (K.T.), K08 DK071626 (J.S.L.), and R03 DK084169 (J.S.L.). Pilot scans were provided by the Ahmanson-Lovelace Brain Mapping Center, UCLA. NR 67 TC 8 Z9 10 U1 5 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD AUG PY 2015 VL 156 IS 8 BP 1545 EP 1554 DI 10.1097/j.pain.0000000000000196 PG 10 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA CO0BQ UT WOS:000358815500022 PM 25906347 ER PT J AU Hoo, GWS AF Hoo, Guy W. Soo TI The Role of Noninvasive Ventilation in the Hospital and Outpatient Management of Chronic Obstructive Pulmonary Disease SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE COPD; noninvasive ventilation; hypercapnia; chronic respiratory failure ID POSITIVE-PRESSURE VENTILATION; ACUTE RESPIRATORY-FAILURE; RANDOMIZED CONTROLLED-TRIAL; COMMUNITY-ACQUIRED-PNEUMONIA; STABLE HYPERCAPNIC COPD; PROPORTIONAL ASSIST VENTILATION; NOCTURNAL NASAL VENTILATION; INTENSIVE-CARE UNITS; AIR-FLOW LIMITATION; TERM-FOLLOW-UP AB Positive pressure noninvasive ventilation (NIV) has become widely accepted in the treatment of both hospitalized and outpatient subjects with chronic obstructive pulmonary disease (COPD). The support has evolved over the past two decades to be part of first-line management in acute exacerbations of COPD and is also instrumental in discontinuing mechanical ventilation in COPD patients with acute respiratory failure. It is also suitable for treatment of COPD with other associated conditions including pneumonia, following lung resectional surgery, with concomitant obstructive sleep apnea and as part of end-of-life care. Short-term application can also facilitate some endoscopic procedures that may otherwise require endotracheal intubation. Outpatient use of NIV in COPD has garnered much attention, but the support has not been as robust as with NIV in hospitalized patients. However, an approach with higher pressures with a goal of significant reduction in daytime PaCO2 may be an effective strategy. NIV can also facilitate exercise training in pulmonary rehabilitation. A portable device which can augment tidal volume during ambulation and other activities of daily living may further expand the use of NIV in COPD patients. C1 [Hoo, Guy W. Soo] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Pulm & Crit Care Sect,West Los Angeles VA Healthc, Los Angeles, CA 90073 USA. RP Hoo, GWS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Pulm & Crit Care Sect 111Q,West Los Angeles VA He, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Guy.SooHoo@va.gov NR 127 TC 1 Z9 1 U1 1 U2 6 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD AUG PY 2015 VL 36 IS 4 BP 616 EP 629 DI 10.1055/s-0035-1556074 PG 14 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CO0CI UT WOS:000358817300014 PM 26238646 ER PT J AU Froehlich, JC Hausauer, B Fischer, S Wise, B Rasmussen, DD AF Froehlich, Janice C. Hausauer, Brett Fischer, Stephen Wise, Bradley Rasmussen, Dennis D. TI Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol Preferring Rats; Prazosin; Alcohol Deprivation Effect; Alcohol Relapse ID PREFERRING P RATS; REPEATED DEPRIVATIONS; USE DISORDERS; ALPHA-1-ADRENERGIC ANTAGONIST; ANTIHYPERTENSIVE AGENTS; ESSENTIAL-HYPERTENSION; RECEPTOR ANTAGONIST; ETHANOL DEPRIVATION; PHYSICAL-DEPENDENCE; ANXIETY DISORDERS AB BackgroundMany alcoholics and heavy drinkers undergo repeated cycles of alcohol abstinence followed by relapse to alcohol drinking; a pattern that contributes to escalated alcohol intake over time. In rodents, alcohol drinking that is interspersed with periods of alcohol deprivation (imposed abstinence) increases alcohol intake during reaccess to alcohol. This is termed the alcohol deprivation effect or ADE and is a model of alcohol relapse in humans. We have previously reported that prazosin reduces alcohol drinking during both brief and prolonged treatment in rats selectively bred for alcohol preference (P rats). This study explores whether prazosin prevents alcohol relapse in P rats, as reflected by a reduced or abolished ADE. MethodsAdult male P rats were given 24-hour access to food and water and scheduled access to alcohol (15 and 30% v/v solutions presented concurrently) for 2h/d. After 5weeks, rats underwent imposed alcohol deprivation for 2weeks, followed by alcohol reaccess for 2weeks, and this pattern was repeated for a total of 3 cycles. Rats were injected with prazosin (0, 0.5, 1.0, or 2.0mg/kg body weight, intraperitoneally) once a day for the first 5days of each alcohol reaccess cycle. ResultsAlcohol intake increased on the first day of each alcohol reaccess cycle, demonstrating the formation of an ADE. The ADE was short-lived, lasting only 1day, during each of the 3 cycles. Prazosin, in all doses tested, prevented the expression of an ADE in all 3 alcohol reaccess cycles. ConclusionsPrazosin decreases alcohol intake in P rats even in a situation that would be expected to increase alcohol drinking, namely following periods of alcohol deprivation. This suggests that prazosin may be effective in reducing alcohol relapse that often occurs during attempts to achieve permanent alcohol abstinence in treatment-seeking alcoholics and heavy drinkers. C1 [Froehlich, Janice C.; Hausauer, Brett; Fischer, Stephen; Wise, Bradley] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Froehlich, JC (reprint author), Indiana Univ Sch Med, 975 West Walnut St IB 424, Indianapolis, IN 46202 USA. EM jcfroehl@iupui.edu FU NIH [AA018604, AA07611, AA13881] FX We thank Dr. Ting-Kai Li and the Indiana Alcohol Research Center for supplying the selectively bred rats used in this study. This work was supported by NIH grants AA018604 (JCF and DDR), AA07611 (JCF), and AA13881 (DDR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism or the National Institutes of Health. NR 63 TC 7 Z9 7 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD AUG PY 2015 VL 39 IS 8 BP 1538 EP 1546 DI 10.1111/acer.12789 PG 9 WC Substance Abuse SC Substance Abuse GA CN7NL UT WOS:000358621200027 PM 26207767 ER PT J AU Jinadatha, C Villamaria, FC Restrepo, MI Ganachari-Mallappa, N Liao, IC Stock, EM Copeland, LA Zeber, JE AF Jinadatha, Chetan Villamaria, Frank C. Restrepo, Marcos I. Ganachari-Mallappa, Nagaraja Liao, I-Chia Stock, Eileen M. Copeland, Laurel A. Zeber, John E. TI Is the pulsed xenon ultraviolet light no-touch disinfection system effective on methicillin-resistant Staphylococcus aureus in the absence of manual cleaning? SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Hospital-acquired infections; Supplemental terminal cleaning; Environmental contamination; High touch surfaces ID ACUTE-CARE HOSPITALS; PATHOGENS; DEVICE; DECONTAMINATION; CONTAMINATION; ENVIRONMENT; INFECTIONS; RADIATION; BACTERIA; SURFACES AB Background: Methicillin-resistant Staphylococcus aureus (MRSA) has been shown to survive on ambient surfaces for extended periods of time. Leftover MRSA environmental contamination in a hospital room places future patients at risk. Manual disinfection supplemented by pulsed xenon ultraviolet (PX-UV) light disinfection has been shown to greatly decrease the MRSA bioburden in hospital rooms. However, the effect of PX-UV in the absence of manual disinfection has not been evaluated. Methods: Rooms that were previously occupied by a MRSA-positive patient (current colonization or infection) were selected for the study immediately postdischarge. Five high-touch surfaces were sampled, before and after PX-UV disinfection, in each hospital room. The effectiveness of the PX-UV device on the concentration of MRSA was assessed employing a Wilcoxon signed-rank test for all 70 samples with MRSA in 14 rooms, as well as by surface location. Results: The final analysis included 14 rooms. Before PX-UV disinfection there were a total of 393 MRSA colonies isolated from the 5 high-touch surfaces. There were 100 MRSA colonies after disinfection by the PX-UV device and the overall reduction was statistically significant (P < .01). Conclusions: Our study results suggest that PX-UV light effectively reduces MRSA colony counts in the absence of manual disinfection. These findings are important for hospital and environmental services supervisors who plan to adapt new technologies as an adjunct to routine manual disinfection. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Jinadatha, Chetan; Villamaria, Frank C.; Ganachari-Mallappa, Nagaraja; Liao, I-Chia; Copeland, Laurel A.; Zeber, John E.] Cent Texas Vet Healthcare Syst, Dept Med, Temple, TX 76504 USA. [Jinadatha, Chetan; Copeland, Laurel A.; Zeber, John E.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Med, Bryan, TX USA. [Villamaria, Frank C.; Liao, I-Chia] Texas A&M Univ, Sch Publ Hlth, College Stn, TX USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Stock, Eileen M.; Copeland, Laurel A.; Zeber, John E.] Ctr Appl Hlth Res, Temple, TX USA. RP Jinadatha, C (reprint author), Cent Texas Vet Healthcare Syst, Dept Med, 1901 S Vet Dr, Temple, TX 76504 USA. EM chetan.jinadatha@va.gov OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs [IIR 12-347]; Xenex Healthcare Services, LLC; Central Texas Veterans Health Care System (Temple, Tex); Scott & White Healthcare (Temple, Tex); Center for Applied Health Research (Temple, Tex); National Heart, Lung, and Blood Institute [K23HL096054] FX This work was supported by a Merit Review grant from the Department of Veterans Affairs to JZ (IIR 12-347) and the study's laboratory activity was funded by a grant from Xenex Healthcare Services, LLC. Further, this work was supported by the Central Texas Veterans Health Care System (Temple, Tex), with additional support from Scott & White Healthcare (Temple, Tex) and the jointly sponsored Center for Applied Health Research (Temple, Tex). MIR is partially supported by award No. K23HL096054 from the National Heart, Lung, and Blood Institute. The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs or the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. Xenex Healthcare Service did not participate in the study design or in the collection, analysis, and interpretation of data, the writing of the report, or in the decision to submit the manuscript for publication. The device used in this study is owned by Central Texas Veterans Health Care System. NR 16 TC 3 Z9 3 U1 0 U2 14 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD AUG 1 PY 2015 VL 43 IS 8 BP 878 EP 881 DI 10.1016/j.ajic.2015.04.005 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CN9WY UT WOS:000358802400021 PM 26014583 ER PT J AU Blakney, R Yanke, E Fink, C Wigton, R Safdar, N AF Blakney, Rebekah Yanke, Eric Fink, Cory Wigton, Robert Safdar, Nasia TI Optimizing diagnostic testing for Clostridium difficile: The perceptions of physicians and nurses on when to order testing for C difficile SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Decision-making; Judgement; Healthcare-acquired infection ID INFECTION; ADULTS; OUTBREAK; DIARRHEA; RATES; ODOR AB Physicians and nurses at a single hospital were surveyed on which risk factors were most important in deciding to order Clostridium difficile diagnostic testing. Disagreement between physicians and nurses on the relative importance of several of the risk factors warrants further investigation. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Blakney, Rebekah; Safdar, Nasia] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. [Blakney, Rebekah; Safdar, Nasia] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53705 USA. [Yanke, Eric; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Fink, Cory] William S Middleton Mem Vet Adm Med Ctr, Coronary Care Unit, Madison, WI USA. [Wigton, Robert] Univ Nebraska Med Ctr, Coll Med, Omaha, NE USA. [Safdar, Nasia] Univ Wisconsin, Sch Med, Dept Med, Infect Dis, Madison, WI 53705 USA. RP Safdar, N (reprint author), Univ Wisconsin, Sch Med, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu NR 10 TC 1 Z9 1 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD AUG 1 PY 2015 VL 43 IS 8 BP 889 EP 891 DI 10.1016/j.ajic.2015.03.025 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CN9WY UT WOS:000358802400024 PM 25957816 ER PT J AU Andrews, JS Trupin, L Schmajuk, G Barton, J Margaretten, M Yazdany, J Yelin, EH Katz, PP AF Andrews, James S. Trupin, Laura Schmajuk, Gabriela Barton, Jennifer Margaretten, Mary Yazdany, Jinoos Yelin, Edward H. Katz, Patricia P. TI Muscle Strength and Changes in Physical Function in Women With Systemic Lupus Erythematosus SO ARTHRITIS CARE & RESEARCH LA English DT Article ID LOWER-EXTREMITY FUNCTION; DUAL-PHOTON ABSORPTIOMETRY; TEST-RETEST RELIABILITY; POPULATION-BASED COHORT; BODY-COMPOSITION; RHEUMATOID-ARTHRITIS; OLDER-ADULTS; ACTIVITY QUESTIONNAIRE; KNEE OSTEOARTHRITIS; SUBSEQUENT DISABILITY AB Objective. Cross-sectional studies have observed that muscle weakness is associated with worse physical function among women with systemic lupus erythematosus (SLE). The present study examines whether reduced upper and lower extremity muscle strength predict declines in function over time among adult women with SLE. Methods. One hundred forty-six women from a longitudinal SLE cohort participated in the study. All measures were collected during in-person research visits approximately 2 years apart. Upper extremity muscle strength was assessed by grip strength. Lower extremity muscle strength was assessed by peak knee torque of extension and flexion. Physical function was assessed using the Short Physical Performance Battery (SPPB). Regression analyses modeled associations of baseline upper and lower extremity muscle strength with followup SPPB scores controlling for baseline SPPB, age, SLE duration, SLE disease activity (Systemic Lupus Activity Questionnaire), physical activity level, prednisone use, body composition, and depression. Secondary analyses tested whether associations of baseline muscle strength with followup in SPPB scores differed between intervals of varying baseline muscle strength. Results. Lower extremity muscle strength strongly predicted changes over 2 years in physical function even when controlling for covariates. The association of reduced lower extremity muscle strength with reduced physical function in the future was greatest among the weakest women. Conclusion. Reduced lower extremity muscle strength predicted clinically significant declines in physical function, especially among the weakest women. Future studies should test whether therapies that promote preservation of lower extremity muscle strength may prevent declines in function among women with SLE. C1 [Andrews, James S.; Trupin, Laura; Schmajuk, Gabriela; Margaretten, Mary; Yazdany, Jinoos; Yelin, Edward H.; Katz, Patricia P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schmajuk, Gabriela] VA Med Ctr, San Francisco, CA USA. [Barton, Jennifer] Portland VA Med Ctr, Portland, OR USA. [Barton, Jennifer] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Katz, PP (reprint author), Univ Calif San Francisco, Dept Med, Box 0920, San Francisco, CA 94143 USA. EM patti.katz@ucsf.edu OI Barton, Jennifer/0000-0002-6771-3465 FU NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR-053308]; NIH/National Center for Research Resources University of California San Francisco-Clinical and Translational Science Institute [UL1-RR-024131]; Rosalind Russell Medical Research Center for Arthritis; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases Academic Rheumatology; Clinical Immunology Training Grant at the University of California, San Francisco FX Supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant P60-AR-053308), the NIH/National Center for Research Resources University of California, San Francisco-Clinical and Translational Science Institute (grant UL1-RR-024131), and the Rosalind Russell Medical Research Center for Arthritis. Dr. Andrews' work was supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases Academic Rheumatology and Clinical Immunology Training Grant at the University of California, San Francisco. NR 52 TC 4 Z9 4 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD AUG PY 2015 VL 67 IS 8 BP 1070 EP 1077 DI 10.1002/acr.22560 PG 8 WC Rheumatology SC Rheumatology GA CN7LW UT WOS:000358617000005 PM 25623919 ER PT J AU Hicks, JK Bishop, JR Sangkuhl, K Muller, DJ Ji, Y Leckband, SG Leeder, JS Graham, RL Chiulli, DL LLerena, A Skaar, TC Scott, SA Stingl, JC Klein, TE Caudle, KE Gaedigk, A AF Hicks, J. K. Bishop, J. R. Sangkuhl, K. Mueller, D. J. Ji, Y. Leckband, S. G. Leeder, J. S. Graham, R. L. Chiulli, D. L. LLerena, A. Skaar, T. C. Scott, S. A. Stingl, J. C. Klein, T. E. Caudle, K. E. Gaedigk, A. TI Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PLASMA-CONCENTRATIONS; PSYCHIATRIC-PATIENTS; ANTIDEPRESSANT TREATMENT; PERSONALIZED MEDICINE; SERUM CONCENTRATIONS; GENETIC-VARIABILITY; PAROXETINE; UPDATE; POLYMORPHISMS; METABOLISM AB Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org). C1 [Hicks, J. K.] Cleveland Clin, Dept Pharm, Cleveland, OH 44106 USA. [Hicks, J. K.] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA. [Hicks, J. K.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Dept Med, Cleveland, OH 44106 USA. [Bishop, J. R.] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA. [Sangkuhl, K.; Klein, T. E.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA. [Mueller, D. J.] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada. [Mueller, D. J.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Ji, Y.] Mayo Clin, Div Lab Genet, Dept Lab Med & Pathol, Rochester, MN USA. [Leckband, S. G.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Mental Hlth Care Line, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA. [Leckband, S. G.] Dept Psychiat, San Diego, CA USA. [Leeder, J. S.; Gaedigk, A.] Childrens Mercy Hosp, Div Clin Pharmacol Toxicol & Innovat Therapeut, Kansas City, MO 64108 USA. [Leeder, J. S.; Gaedigk, A.] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA. [Graham, R. L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chiulli, D. L.] Vet Affairs Palo Alto Hlth Care Syst, San Jose Div, San Jose, CA USA. [LLerena, A.] Extremadura Univ Hosp, CICAB Clin Res Ctr, Badajoz, Spain. [LLerena, A.] Sch Med, Badajoz, Spain. [Skaar, T. C.] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA. [Scott, S. A.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Stingl, J. C.] Fed Inst Drugs & Med Devices, Bonn, Germany. [Caudle, K. E.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA. RP Gaedigk, A (reprint author), Childrens Mercy Hosp, Div Clin Pharmacol Toxicol & Innovat Therapeut, Kansas City, MO 64108 USA. EM agaedigk@cmh.edu RI ; Bishop, Jeffrey/K-6559-2015; Mueller, Daniel/L-4159-2016 OI LLerena, Adrian/0000-0002-5663-7081; Bishop, Jeffrey/0000-0001-7653-8980; Mueller, Daniel/0000-0003-4978-4400; Llerena, Addrian/0000-0002-2602-1569 FU National Institutes of Health/National Institute of General Medical Science (NIH/NIGMS); PAAR4Kids [U01 GM92666]; PharmGKB [R24 GM61374]; NIH [K08MH083888, K23GM104401, 2R01GM088076]; [U01 HL0105198] FX We acknowledge the critical input of members of the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network, funded by the National Institutes of Health/National Institute of General Medical Science (NIH/NIGMS), PAAR4Kids (U01 GM92666), PharmGKB (R24 GM61374), and U01 HL0105198. We acknowledge the critical input of Dr. Mary V. Relling (St Jude Children's Research Hospital), Houda Hachad (Translational Software), and Andria L. Del Tredici (Millennium Health). This work is also funded by NIH grants K08MH083888 (to JRB), K23GM104401 (to SAS), and 2R01GM088076 (to TCS/AG). On behalf of CPIC, the authors are dedicating this guideline to the late David A. Mrazek, MD, a pioneer and advocate of psychiatric pharmacogenetics. NR 36 TC 65 Z9 66 U1 5 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD AUG PY 2015 VL 98 IS 2 BP 127 EP 134 DI 10.1002/cpt.147 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CN5WN UT WOS:000358503400005 PM 25974703 ER PT J AU Cefalu, WT Bray, GA Home, PD Garvey, WT Klein, S Pi-Sunyer, FX Hu, FB Raz, I Van Gaal, L Wolfe, BM Ryan, DH AF Cefalu, William T. Bray, George A. Home, Philip D. Garvey, W. Timothy Klein, Samuel Pi-Sunyer, F. Xavier Hu, Frank B. Raz, Itamar Van Gaal, Luc Wolfe, Bruce M. Ryan, Donna H. TI Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Ref lections From a Diabetes Care Editors' Expert Forum SO DIABETES CARE LA English DT Article ID BODY-MASS INDEX; METABOLICALLY-HEALTHY OBESITY; FATTY LIVER-DISEASE; RANDOMIZED-CONTROLLED-TRIAL; POLYCYSTIC-OVARY-SYNDROME; LIFE-STYLE INTERVENTION; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; TOPIRAMATE EXTENDED-RELEASE; PATIENT-CENTERED APPROACH; OBSTRUCTIVE SLEEP-APNEA AB As obesity rates increase, so too do the risks of type 2 diabetes, cardiovascular disease, and numerous other detrimental conditions. The prevalence of obesity in U.S. adults more than doubled between 1980 and 2010, from 15.0 to 36.1%. Although this trend may be leveling off, obesity and its individual, societal, and economic costs remain of grave concern. In June 2014, a Diabetes Care Editors' Expert Forum convened to review the state of obesity research and discuss the latest prevention initiatives and behavioral, medical, and surgical therapies. This article, an outgrowth of the forum, offers an expansive view of the obesity epidemic, beginning with a discussion of its root causes. Recent insights into the genetic and physiological factors that influence body weight are reviewed, as are the pathophysiology of obesity-related metabolic dysfunction and the concept of metabolically healthy obesity. The authors address the crucial question of how much weight loss is necessary to yield meaningful benefits. They describe the challenges of behavioral modification and predictors of its success. The effects of diabetes pharmacotherapies on body weight are reviewed, including potential weight-neutral combination therapies. The authors also summarize the evidence for safety and efficacy of pharmacotherapeutic and surgical obesity treatments. The article concludes with an impassioned call for researchers, clinicians, governmental agencies, health policymakers, and health-related industries to collectively embrace the urgent mandate to improve prevention and treatment and for society at large to acknowledge and manage obesity as a serious disease. C1 [Cefalu, William T.; Bray, George A.; Ryan, Donna H.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA. [Home, Philip D.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Klein, Samuel] Washington Univ, Sch Med, Ctr Human Nutr, St Louis, MO USA. [Pi-Sunyer, F. Xavier] Columbia Univ, Dept Med, Obes Res Ctr, New York, NY USA. [Hu, Frank B.] Harvard Univ, Dept Nutr, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Hu, Frank B.] Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Raz, Itamar] Hadassah Hebrew Univ Hosp, Diabet Unit, Dept Internal Med, Jerusalem, Israel. [Van Gaal, Luc] Univ Antwerp Hosp, Dept Endocrinol Diabetol & Metab, Antwerp, Belgium. [Wolfe, Bruce M.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. RP Cefalu, WT (reprint author), Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA. EM william.cefalu@pbrc.edu FU National Institute of General Medical Sciences of the National Institutes of Health [1-U54-GM-104940] FX W.T.C. is supported in part by grant number 1-U54-GM-104940 from the National Institute of General Medical Sciences of the National Institutes of Health. NR 198 TC 19 Z9 21 U1 4 U2 15 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD AUG PY 2015 VL 38 IS 8 BP 1567 EP 1582 DI 10.2337/dc15-1081 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN8EY UT WOS:000358673200035 PM 26421334 ER PT J AU Toth, DJA Gundlapalli, AV Khader, K Pettey, WBP Rubin, MA Adler, FR Samore, MH AF Toth, Damon J. A. Gundlapalli, Adi V. Khader, Karim Pettey, Warren B. P. Rubin, Michael A. Adler, Frederick R. Samore, Matthew H. TI Estimates of Outbreak Risk from New Introductions of Ebola with Immediate and Delayed Transmission Control SO EMERGING INFECTIOUS DISEASES LA English DT Article ID VIRUS DISEASE; BRANCHING-PROCESSES; SEPTEMBER 2014; DISTRIBUTIONS; IMPORTATION AB While the ongoing Ebola outbreak continues in the West Africa countries of Guinea, Sierra Leone, and Liberia, health officials elsewhere prepare for new introductions of Ebola from infected evacuees or travelers. We analyzed transmission data from patients (i.e., evacuees, international travelers, and those with locally acquired illness) in countries other than the 3 with continuing Ebola epidemics and quantitatively assessed the outbreak risk from new introductions by using different assumptions for transmission control (i.e., immediate and delayed). Results showed that, even in countries that can quickly limit expected number of transmissions per case to <1, the probability that a single introduction will lead to a substantial number of transmissions is not negligible, particularly if transmission variability is high. Identifying incoming infected travelers before symptom onset can decrease worst-case outbreak sizes more than reducing transmissions from patients with locally acquired cases, but performing both actions can have a synergistic effect. C1 [Toth, Damon J. A.] Univ Utah, Sch Med, Dept Internal Med, Div Epidemiol, Salt Lake City, UT 84132 USA. [Toth, Damon J. A.; Gundlapalli, Adi V.; Khader, Karim; Pettey, Warren B. P.; Rubin, Michael A.; Adler, Frederick R.; Samore, Matthew H.] Univ Utah, Salt Lake City, UT 84132 USA. [Toth, Damon J. A.; Gundlapalli, Adi V.; Khader, Karim; Pettey, Warren B. P.; Rubin, Michael A.; Samore, Matthew H.] US Dept Vet Affairs, Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. RP Toth, DJA (reprint author), Univ Utah, Sch Med, Dept Internal Med, Div Epidemiol, 295 Chipeta Way, Salt Lake City, UT 84132 USA. EM Damon.Toth@hsc.utah.edu NR 34 TC 5 Z9 5 U1 5 U2 14 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2015 VL 21 IS 8 BP 1402 EP 1408 DI 10.3201/eid2108.150170 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN5GR UT WOS:000358458300016 PM 26196264 ER PT J AU Ryan, AM Burgess, JF Dimick, JB AF Ryan, Andrew M. Burgess, James F., Jr. Dimick, Justin B. TI Why We Should Not Be Indifferent to Specification Choices for Difference-in-Differences SO HEALTH SERVICES RESEARCH LA English DT Article DE Hospitals; econometrics; health economics; quality of care; health policy ID HEALTH-INSURANCE COVERAGE; PAY-FOR-PERFORMANCE; BARIATRIC SURGERY; MEDICARE BENEFICIARIES; FINANCIAL INCENTIVES; QUALITY IMPROVEMENT; PHYSICIAN PRACTICES; FEDERAL-EMPLOYEES; MENTAL-HEALTH; HOSPITAL PAY AB ObjectiveTo evaluate the effects of specification choices on the accuracy of estimates in difference-in-differences (DID) models. Data SourcesProcess-of-care quality data from Hospital Compare between 2003 and 2009. Study DesignWe performed a Monte Carlo simulation experiment to estimate the effect of an imaginary policy on quality. The experiment was performed for three different scenarios in which the probability of treatment was (1) unrelated to pre-intervention performance; (2) positively correlated with pre-intervention levels of performance; and (3) positively correlated with pre-intervention trends in performance. We estimated alternative DID models that varied with respect to the choice of data intervals, the comparison group, and the method of obtaining inference. We assessed estimator bias as the mean absolute deviation between estimated program effects and their true value. We evaluated the accuracy of inferences through statistical power and rates of false rejection of the null hypothesis. Principal FindingsPerformance of alternative specifications varied dramatically when the probability of treatment was correlated with pre-intervention levels or trends. In these cases, propensity score matching resulted in much more accurate point estimates. The use of permutation tests resulted in lower false rejection rates for the highly biased estimators, but the use of clustered standard errors resulted in slightly lower false rejection rates for the matching estimators. ConclusionsWhen treatment and comparison groups differed on pre-intervention levels or trends, our results supported specifications for DID models that include matching for more accurate point estimates and models using clustered standard errors or permutation tests for better inference. Based on our findings, we propose a checklist for DID analysis. C1 [Ryan, Andrew M.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Burgess, James F., Jr.] Boston Univ, Sch Publ Hlth, US Dept Vet Affairs, Vet Affairs Boston Hlth Care Syst, Boston, MA USA. [Dimick, Justin B.] Univ Michigan, Sch Med, Dept Surg, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI USA. RP Ryan, AM (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts,SPH 2 RM M3124, Ann Arbor, MI 48109 USA. EM amryan@umich.edu FU Agency for Healthcare Research and Quality [1 K01 HS018546]; National Institute on Aging [R01AG039434] FX Joint Acknowledgment/Disclosure Statement: The authors would like to acknowledge Jayme Mendelsohn for research assistance. Funding for Dr. Ryan was provided by a career development award from the Agency for Healthcare Research and Quality (1 K01 HS018546). Dr. Dimick was supported by a grant from the National Institute on Aging (R01AG039434). Dr. Dimick is a paid consultant and equity owner in ArborMetrix Inc., a company that provides software and analytic services for assessing hospital quality and efficiency. NR 66 TC 16 Z9 16 U1 1 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2015 VL 50 IS 4 BP 1211 EP 1235 DI 10.1111/1475-6773.12270 PG 25 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CN7KG UT WOS:000358612600016 PM 25495529 ER PT J AU Umezaki, Y Badran, BW Gonzales, TS George, MS AF Umezaki, Y. Badran, B. W. Gonzales, T. S. George, M. S. TI Daily left prefrontal repetitive transcranial magnetic stimulation for medication-resistant burning mouth syndrome SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article DE burning mouth syndrome; transcranial magnetic stimulation; chronic pain; left dorsolateral prefrontal cortex ID PAIN; CORTEX AB Burning mouth syndrome (BMS) is a persistent and chronic burning sensation in the mouth in the absence of any abnormal organic findings. The pathophysiology of BMS is unclear and its treatment is not fully established. Although antidepressant medication is commonly used for treatment, there are some medication-resistant patients, and a new treatment for medication-resistant BMS is needed. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technology approved by the US Food and Drug Administration (FDA) for the treatment of depression. Recent studies have found beneficial effects of TMS for the treatment of pain. A case of BMS treated successfully with daily left prefrontal rTMS over a 2-week period is reported here. Based on this patient's clinical course and a recent pain study, the mechanism by which TMS may act to decrease the burning pain is discussed. C1 [Umezaki, Y.; Badran, B. W.; George, M. S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [Gonzales, T. S.] Med Univ S Carolina, Coll Dent Med, Div Oral Pathol, Charleston, SC 29425 USA. [George, M. S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Umezaki, Y (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St, Charleston, SC 29425 USA. EM umezaki@yahoo.com NR 10 TC 0 Z9 0 U1 5 U2 5 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0901-5027 EI 1399-0020 J9 INT J ORAL MAX SURG JI Int. J. Oral Maxillofac. Surg. PD AUG PY 2015 VL 44 IS 8 BP 1048 EP 1051 DI 10.1016/j.ijom.2015.04.008 PG 4 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA CN7PR UT WOS:000358627000019 PM 25979192 ER PT J AU Oestreich, LKL Mifsud, NG Ford, JM Roach, BJ Mathalon, DH Whitford, TJ AF Oestreich, Lena K. L. Mifsud, Nathan G. Ford, Judith M. Roach, Brian J. Mathalon, Daniel H. Whitford, Thomas J. TI Subnormal sensory attenuation to self-generated speech in schizotypy: Electrophysiological evidence for a 'continuum of psychosis' SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Article DE Electroencephalography (EEG); Sensory suppression; Schizophrenia; Schizotypy; Continuum of psychosis; Self-monitoring; Event-related potential (ERP) ID COROLLARY DISCHARGE DYSFUNCTION; PRIMATE AUDITORY-CORTEX; SCHIZOPHRENIA; RESPONSES; DISORDERS; CRITERIA; THINKING; TALKING; HUMANS; AGENCY AB Background: A 'continuum of psychosis' refers to the concept that psychotic-like experiences occur to certain extents in the healthy population and to more severe extents in individuals with psychotic disorders. If this concept is valid, neurophysiological abnormalities exhibited by patients with schizophrenia should also be present, to some degree, in non-clinical individuals who score highly on the personality dimension of schizotypy. Patients with schizophrenia have consistently been shown to exhibit electrophysiological suppression abnormalities to self-generated speech. The present study aimed to investigate whether these electrophysiological suppression abnormalities were also present in non-clinical individuals who scored highly on schizotypy. Methods: Thirty-seven non-clinical individuals scoring High (above median) and 37 individuals scoring Low (below median) on the Schizotypal Personality Questionnaire (SPQ; a commonly used schizotypy scale) underwent electroencephalographic (EEG) recording. The amplitude of the N1 component of the auditory-evoked potential was measured while participants (a) vocalized simple syllables (Talk condition), (b) passively listened to a recording of these vocalizations (Listen condition) and (c) listened to a recording of the vocalizations while simultaneously watching a video depicting the sound-wave of the forthcoming vocalizations, allowing them to be temporally predicted (Cued Listen condition). Results: The Low Schizotypy group exhibited significantly reduced N1-amplitude in the Talk condition relative to both the Listen and Cued Listen conditions; that is, they exhibited significant N1-suppression. The High Schizotypy group exhibited significantly lower levels of N1-suppression compared to the Low Schizotypy group. Furthermore, while the Cued Listen condition induced significantly lower N1-amplitudes compared to the Listen condition in the Low Schizotypy group, this was not the case for the High Schizotypy group. Conclusions: The results suggest that non-clinical, highly schizotypal individuals exhibit subnormal levels of N1-suppression to self-generated speech, similar to the N1-suppression abnormalities which have previously been reported in patients with schizophrenia. This finding provides empirical support for the existence of a neurophysiological 'continuum of psychosis'. (C) 2015 Elsevier B.V. All rights reserved. C1 [Oestreich, Lena K. L.; Mifsud, Nathan G.; Whitford, Thomas J.] UNSW Australia, Sch Psychol, Sydney, NSW 2052, Australia. [Ford, Judith M.; Roach, Brian J.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, Brain Imaging & EEG Lab BIEEGL, San Francisco, CA USA. [Oestreich, Lena K. L.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Whitford, TJ (reprint author), UNSW Australia, Sch Psychol, Sydney, NSW 2052, Australia. EM t.whitford@unsw.edu.au OI Mifsud, Nathan/0000-0001-7794-8041; Oestreich, Lena/0000-0002-4978-7794 FU Australian Research Council [DP140104394]; National Health and Medical Research Council of Australia [APP1090507]; NARSAD Brain and Behavior Research Foundation [17537]; VA Merit Review [I01 CX000497]; NIMH [R01 MH-58262] FX Thomas Whitford is supported by a Discovery Project from the Australian Research Council (DP140104394), a Career Development Fellowship from the National Health and Medical Research Council of Australia (APP1090507), and a Young Investigator Award (Barbara and John Streicker Investigator) from the NARSAD Brain and Behavior Research Foundation (17537). Judith Ford's contributions to this work were supported by VA Merit Review (I01 CX000497) and NIMH (R01 MH-58262) grants. NR 50 TC 6 Z9 6 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 EI 1872-7697 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD AUG PY 2015 VL 97 IS 2 BP 131 EP 138 DI 10.1016/j.ijpsycho.2015.05.014 PG 8 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA CN5JT UT WOS:000358466300007 PM 26027781 ER PT J AU Probst, MA Kanzaria, HK Hoffman, JR Mower, WR Moheimani, RS Sun, BC Quigley, DD AF Probst, Marc A. Kanzaria, Hemal K. Hoffman, Jerome R. Mower, William R. Moheimani, Roya S. Sun, Benjamin C. Quigley, Denise D. TI EMERGENCY PHYSICIANS' PERCEPTIONS AND DECISION-MAKING PROCESSES REGARDING PATIENTS PRESENTING WITH PALPITATIONS SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE palpitations; emergency medicine; clinical decision-making; interviews ID MANAGEMENT; SYNCOPE; CARE AB Background: Palpitations are a common emergency department (ED) complaint, yet relatively little research exists on this topic from an emergency care perspective. Objectives: We sought to describe the perceptions and clinical decision-making processes of emergency physicians (EP) surrounding patients with palpitations. Methods: We conducted 21 semistructured interviews with a convenience sample of EPs. We recruited participants from academic and community practice settings from four regions of the United States. The transcribed interviews were analyzed using a combination of structural coding and grounded theory approaches with ATLAS.ti, a qualitative data analysis software program (version 7; Atlas.ti Scientific Software Development GmbH, Berlin, Germany). Results: EPs perceive palpitations to be a common but generally benign chief complaint. EPs' clinical approach to palpitations, with regards to testing, treatment, and ED management, can be classified as relating to one or more of the following themes: 1) risk stratification, 2) diagnostic categorization, 3) algorithmic management, and 4) case-specific gestalt. With regard to disposition decisions, four main themes emerged: 1) presence of a serious diagnosis, 2) perceived need for further cardiac testing/monitoring, 3) presence of key associated symptoms, 4) request of other physician or patient desire. The interrater reliability exercise yielded a Fleiss' kappa measure of 0.69, indicating substantial agreement between coders. Conclusion: EPs perceive palpitations to be a common but generally benign chief complaint. EPs rely on one or more of four main clinical approaches to manage these patients. These findings could help guide future efforts at developing risk-stratification tools and clinical algorithms for patients with palpitations. (C) 2015 Elsevier Inc. C1 [Probst, Marc A.; Kanzaria, Hemal K.; Hoffman, Jerome R.; Mower, William R.; Moheimani, Roya S.] Univ Calif Los Angeles, Sch Med, Dept Emergency Med, Los Angeles, CA USA. [Probst, Marc A.] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA. [Kanzaria, Hemal K.] W Los Angeles Vet Affairs Med Ctr, US Dept Vet Affairs, Los Angeles, CA 90073 USA. [Sun, Benjamin C.] Oregon Hlth & Sci Univ, Ctr Policy Res Emergency Med, Dept Emergency Med, Portland, OR 97201 USA. [Quigley, Denise D.] RAND Corp, Santa Monica, CA USA. RP Probst, MA (reprint author), Icahn Sch Med Mt Sinai, Dept Emergency Med, 3 East 101st St,2nd Floor, New York, NY 10029 USA. FU Robert Wood Johnson Foundation Clinical Scholars Program; National Heart, Lung, and Blood Institute of the National Institutes of Health [5K12 HL109005, R01 HL111033]; National Heart, Lung, and Blood Institute FX This work was supported by the Robert Wood Johnson Foundation Clinical Scholars Program (HKK) and by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number 5K12 HL109005 (MAP) and Award Number R01 HL111033 (BCS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Robert Wood Johnson Foundation. There are no conflicts of interest. The authors would like to thank all of the emergency physicians who generously offered their time to participate in these interviews. The authors would also like to thank the National Heart, Lung, and Blood Institute and the Robert Wood Johnson Foundation Clinical Scholars Program for their support. NR 22 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 EI 1090-1280 J9 J EMERG MED JI J. Emerg. Med. PD AUG PY 2015 VL 49 IS 2 BP 236 EP + DI 10.1016/j.jemermed.2015.02.013 PG 10 WC Emergency Medicine SC Emergency Medicine GA CN7EV UT WOS:000358597800029 PM 25943288 ER PT J AU Pelak, M Pettit, AR Terwiesch, C Gutierrez, JC Marcus, SC AF Pelak, Mary Pettit, Amy R. Terwiesch, Christian Gutierrez, Jennifer C. Marcus, Steven C. TI Rethinking primary care visits: how much can be eliminated, delegated or performed outside of the face-to-face visit? SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE LA English DT Article DE face-to-face visits; patient-centred medical home; practice revision; primary care; routine practice; videotaping ID PRACTICE TRANSFORMATION; HEALTH-CARE; PHYSICIANS; QUALITY AB Rationale, aims and objectivesOffice visits represent the core component of primary care practice, but little is known about what percentage of primary care provider (PCP) visit time could be suitable for reassignment to another medical home team member or to a non-face-to-face modality (e.g. secure messaging) in order to optimize face-to-face PCP visit time. MethodWe videotaped 121 PCP office visits at four Veterans Health Administration Medical Centers and divided visits into discrete activity segments. Two physicians reviewed each visit recording and provided independent clinical judgments regarding which segments might be suitable for reassignment. We examined the activity category distribution of visit time rated as needing face-to-face time with a PCP. ResultsReviewers judged 53% of the 5398 minutes of rated visit time as suitable for reassignment to another team member or modality. The percentage of time rated as needing face-to-face PCP care varied greatly by activity category, from a high of 73.9% (for examining patients) to a low of 16.2% (for medication review). Rater agreement regarding tasks' suitability for reassignment varied across activity categories. ConclusionsThese data offer an example of how face-to-face PCP visit time might be optimized as practices seek to shift components of patient care to other team members and other modalities. Given variations in provider preferences and judgments, successful redesign efforts will need to involve stakeholders in decisions about how to best utilize medical home resources. C1 [Pelak, Mary; Terwiesch, Christian; Gutierrez, Jennifer C.; Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, CEPACT, Philadelphia, PA USA. [Terwiesch, Christian] Univ Penn, Wharton Sch & Prof Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Marcus, SC (reprint author), Univ Penn, Sch Social Policy & Practice, 3701 Locust Walk, Philadelphia, PA 19104 USA. EM marcuss@upenn.edu FU VA Office of Patient Care Services FX Support: The VISN 4 Center for Evaluation of PACT Demonstration Laboratory is funded by the VA Office of Patient Care Services. NR 24 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1356-1294 EI 1365-2753 J9 J EVAL CLIN PRACT JI J. Eval. Clin. Pract. PD AUG PY 2015 VL 21 IS 4 BP 591 EP 596 DI 10.1111/jep.12341 PG 6 WC Health Care Sciences & Services; Medical Informatics; Medicine, General & Internal SC Health Care Sciences & Services; Medical Informatics; General & Internal Medicine GA CN8LX UT WOS:000358693200007 PM 25756943 ER PT J AU Hull, RL Baskin, DG AF Hull, Rebecca L. Baskin, Denis G. TI Histochemical Insights into Pancreatic Islet Biology SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Editorial Material C1 [Hull, Rebecca L.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA 98108 USA. [Hull, Rebecca L.; Baskin, Denis G.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. RP Hull, RL (reprint author), VA Puget Sound Hlth Care Syst, Res & Dev Serv, 1660 S Columbian Way,Mail Stop S-151, Seattle, WA 98108 USA. EM rhull@uw.edu NR 12 TC 1 Z9 1 U1 1 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD AUG PY 2015 VL 63 IS 8 SI SI BP 541 EP 542 DI 10.1369/0022155415586442 PG 2 WC Cell Biology SC Cell Biology GA CN7ES UT WOS:000358597500001 PM 26216132 ER PT J AU Baskin, DG AF Baskin, Denis G. TI A Historical Perspective on the Identification of Cell Types in Pancreatic Islets of Langerhans by Staining and Histochemical Techniques SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Review DE diabetes; beta cells; glucagon; immunocytochemistry; immunohistochemistry; insulin; islet cells; pancreas; staining; somatostatin ID HORMONE-PRODUCING CELLS; EMBRYONIC STEM-CELLS; ADULT HUMAN PANCREAS; GUINEA-PIG PANCREAS; NEURAL CREST ORIGIN; ALDEHYDE-FUCHSIN; BETA-CELL; B-CELL; ULTRASTRUCTURAL-LOCALIZATION; AMYLOID POLYPEPTIDE AB Before the middle of the previous century, cell types of the pancreatic islets of Langerhans were identified primarily on the basis of their color reactions with histological dyes. At that time, the chemical basis for the staining properties of islet cells in relation to the identity, chemistry and structure of their hormones was not fully understood. Nevertheless, the definitive islet cell types that secrete glucagon, insulin, and somatostatin (A, B, and D cells, respectively) could reliably be differentiated from each other with staining protocols that involved variations of one or more tinctorial techniques, such as the Mallory-Heidenhain azan trichrome, chromium hematoxylin and phloxine, aldehyde fuchsin, and silver impregnation methods, which were popularly used until supplanted by immunohistochemical techniques. Before antibody-based staining methods, the most bona fide histochemical techniques for the identification of islet B cells were based on the detection of sulfhydryl and disulfide groups of insulin. The application of the classical islet tinctorial staining methods for pathophysiological studies and physiological experiments was fundamental to our understanding of islet architecture and the physiological roles of A and B cells in glucose regulation and diabetes. C1 [Baskin, Denis G.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA 98108 USA. [Baskin, Denis G.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. RP Baskin, DG (reprint author), VA Puget Sound Hlth Care Syst, Res & Dev Serv, 1660 S Columbian Way,Mail Stop S-151, Seattle, WA 98108 USA. EM baskindg@uw.edu FU Office of Research and Development of the Department of Veterans Affairs; Cellular and Molecular Imaging Core of the University of Washington Diabetes Research Center from the NIH National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK017047]; VA Senior Research Career Scientist award FX The author disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This material is based upon work supported by the Office of Research and Development of the Department of Veterans Affairs, and by the Cellular and Molecular Imaging Core of the University of Washington Diabetes Research Center (grant P30 DK017047 from the NIH National Institute of Diabetes and Digestive and Kidney Diseases). DGB is the recipient of a VA Senior Research Career Scientist award. NR 111 TC 0 Z9 0 U1 7 U2 17 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD AUG PY 2015 VL 63 IS 8 SI SI BP 543 EP 558 DI 10.1369/0022155415589119 PG 16 WC Cell Biology SC Cell Biology GA CN7ES UT WOS:000358597500002 PM 26216133 ER PT J AU Hull, RL Bogdani, M Nagy, N Johnson, PY Wight, TN AF Hull, Rebecca L. Bogdani, Marika Nagy, Nadine Johnson, Pamela Y. Wight, Thomas N. TI Hyaluronan: A Mediator of Islet Dysfunction and Destruction in Diabetes? SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE diabetes; extracellular matrix; islet; hyaluronan; hyaladherins ID STIMULATED-INSULIN-SECRETION; ALPHA-TRYPSIN INHIBITOR; HUMAN PANCREATIC-ISLETS; SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; BETA-CELLS; BINDING-PROTEINS; POLYCYTIDYLIC ACID; CROSS-LINKING AB Hyaluronan (HA) is an extracellular matrix (ECM) component that is present in mouse and human islet ECM. HA is localized in peri-islet and intra-islet regions adjacent to microvessels. HA normally exists in a high molecular weight form, which is anti-inflammatory. However, under inflammatory conditions, HA is degraded into fragments that are proinflammatory. HA accumulates in islets of human subjects with recent onset type 1 diabetes (T1D), and is associated with myeloid and lymphocytic islet infiltration, suggesting a possible role for HA in insulitis. A similar accumulation of HA, in amount and location, occurs in non-obese diabetic (NOD) and DORmO mouse models of T1D. Furthermore, HA accumulates in follicular germinal centers and in T-cell areas in lymph nodes and spleen in both human and mouse models of T1D, as compared with control tissues. Whether HA accumulates in islets in type 2 diabetes (T2D) or models thereof has not been previously described. Here we show evidence that HA accumulates in a mouse model of islet amyloid deposition, a well-known component of islet pathology in T2D. In summary, islet HA accumulation is a feature of both T1D and a model of T2D, and may represent a novel inflammatory mediator of islet pathology. C1 [Hull, Rebecca L.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Hull, Rebecca L.] Univ Washington, Seattle, WA 98108 USA. [Wight, Thomas N.] Univ Washington, Dept Pathol, Seattle, WA 98108 USA. [Bogdani, Marika; Nagy, Nadine; Johnson, Pamela Y.; Wight, Thomas N.] Benaroya Res Inst Virginia Mason, Matrix Biol Program, Seattle, WA USA. RP Hull, RL (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM rhull@uw.edu OI Hull, Rebecca/0000-0001-9690-4087 FU Department of Veterans Affairs; VA Puget Sound Health Care System (Seattle, WA, USA); National Institutes of Health [DK088082, DK017047, U01 AI101990, U01 AI101984]; Juvenile Diabetes Research Foundation [nPOD 25-2010-648]; Deutsche Forschungsgemeinschaft [NA 965/2-1] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Department of Veterans Affairs, VA Puget Sound Health Care System (Seattle, WA, USA), National Institutes of Health grants DK088082 (RLH); DK017047 (University of Washington Diabetes Research Center); and U01 AI101990 Pilot Project, U01 AI101984, and the Juvenile Diabetes Research Foundation [nPOD 25-2010-648 (TNW)]. NN was supported by research grant NA 965/2-1 from the Deutsche Forschungsgemeinschaft. NR 91 TC 1 Z9 1 U1 2 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD AUG PY 2015 VL 63 IS 8 SI SI BP 592 EP 603 DI 10.1369/0022155415576542 PG 12 WC Cell Biology SC Cell Biology GA CN7ES UT WOS:000358597500005 PM 26216136 ER PT J AU Brissova, M Shostak, A Fligner, CL Revetta, FL Washington, MK Powers, AC Hull, RL AF Brissova, Marcela Shostak, Alena Fligner, Corinne L. Revetta, Frank L. Washington, Mary K. Powers, Alvin C. Hull, Rebecca L. TI Human Islets Have Fewer Blood Vessels than Mouse Islets and the Density of Islet Vascular Structures Is Increased in Type 2 Diabetes SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE amyloid; diabetes; islet; pancreas; vasculature ID GROWTH FACTOR-A; HUMAN PANCREATIC-ISLETS; BETA-CELL APOPTOSIS; ENDOTHELIAL-CELL; AMYLOID POLYPEPTIDE; INSULIN-SECRETION; BASEMENT-MEMBRANE; GLUCOSE-TRANSPORTER; ELECTRON-MICROSCOPY; ENDOCRINE PANCREAS AB Human and rodent islets differ substantially in several features, including architecture, cell composition, gene expression and some aspects of insulin secretion. Mouse pancreatic islets are highly vascularized with interactions between islet endothelial and endocrine cells being important for islet cell differentiation and function. To determine whether human islets have a similar high degree of vascularization and whether this is altered with diabetes, we examined the vascularization of islets from normal human subjects, subjects with type 2 diabetes (T2D), and normal mice. Using an integrated morphometry approach to quantify intra-islet capillary density in human and mouse pancreatic sections, we found that human islets have five-fold fewer vessels per islet area than mouse islets. Islets in pancreatic sections from T2D subjects showed capillary thickening, some capillary fragmentation and had increased vessel density as compared with non-diabetic controls. These changes in islet vasculature in T2D islets appeared to be associated with amyloid deposition, which was noted in islets from 8/9 T2D subjects (and occupied 14% +/- 4% of islet area), especially around the intra-islet capillaries. The physiological implications of the differences in the angioarchitecture of mouse and human islets are not known. Islet vascular changes in T2D may exacerbate cell/islet dysfunction and cell loss. C1 [Brissova, Marcela; Shostak, Alena; Powers, Alvin C.] Vanderbilt Univ, Dept Med, Nashville Med Ctr, Div Diabet Endocrinol & Metab, Nashville, TN USA. [Revetta, Frank L.; Washington, Mary K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA. [Powers, Alvin C.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Med Ctr, Nashville, TN 37232 USA. [Powers, Alvin C.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA. [Fligner, Corinne L.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Hull, Rebecca L.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Hull, Rebecca L.] Univ Washington, Seattle, WA 98195 USA. RP Hull, RL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM rhull@uw.edu OI Hull, Rebecca/0000-0001-9690-4087 FU Department of Veterans Affairs; VA Tennessee Valley and Puget Sound Health Care Systems; Department of Veterans Affairs (Merit Review); NIH [DK69603, DK88082, DK89572, DK89538]; Vanderbilt Diabetes Research and Training Center [DK20593]; University of Washington Diabetes Research Center (Cellular and Molecular Imaging Core) [DK17047] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Department of Veterans Affairs, VA Tennessee Valley and Puget Sound Health Care Systems and grant support from the Department of Veterans Affairs (Merit Review), the NIH (DK69603, DK88082, DK89572, DK89538), the Vanderbilt Diabetes Research and Training Center (DK20593) and the University of Washington Diabetes Research Center (Cellular and Molecular Imaging Core; DK17047). NR 57 TC 7 Z9 7 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD AUG PY 2015 VL 63 IS 8 SI SI BP 637 EP 645 DI 10.1369/0022155415573324 PG 9 WC Cell Biology SC Cell Biology GA CN7ES UT WOS:000358597500009 PM 26216139 ER PT J AU Meier, DT Entrup, L Templin, AT Hogan, MF Samarasekera, T Zraika, S Boyko, EJ Kahn, SE AF Meier, Daniel T. Entrup, Leon Templin, Andrew T. Hogan, Meghan F. Samarasekera, Thanya Zraika, Sakeneh Boyko, Edward J. Kahn, Steven E. TI Determination of Optimal Sample Size for Quantification of beta-Cell Area, Amyloid Area and beta-Cell Apoptosis in Isolated Islets SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE amyloid; apoptosis; beta cell; histology; insulin; islet isolation; immunohistochemistry; pancreatic islet; staining ID DIABETES-MELLITUS; FIBRIL FORMATION; TRANSGENIC MICE; POLYPEPTIDE; GLUCOSE; PANCREAS; HYPERGLYCEMIA; EXPRESSION; RATHER; TYPE-1 AB Culture of isolated rodent islets is widely used in diabetes research to assess different endpoints, including outcomes requiring histochemical staining. As islet yields during isolation are limited, we determined the number of islets required to obtain reliable data by histology. We found that mean values for insulin-positive -cell area/islet area, thioflavin S-positive amyloid area/islet area and -cell apoptosis do not vary markedly when more than 30 islets are examined. Measurement variability declines as more islets are quantified, so that the variability of the coefficient of variation (CV) in human islet amyloid polypeptide (hIAPP) transgenic islets for -cell area/islet area, amyloid area/islet area and -cell apoptosis are 13.20% +/- 1.52%, 10.03% +/- 1.76% and 6.78% +/- 1.53%, respectively (non-transgenic: 7.65% +/- 1.17% -cell area/islet area and 8.93% +/- 1.56% -cell apoptosis). Increasing the number of islets beyond 30 had marginal effects on the CV. Using 30 islets, 6 hIAPP-transgenic preparations are required to detect treatment effects of 14% for -cell area/islet area, 30% for amyloid area/islet area and 23% for -cell apoptosis (non-transgenic: 9% for -cell area/islet area and 45% for -cell apoptosis). This information will be of value in the design of studies using isolated islets to examine cells and islet amyloid. C1 [Meier, Daniel T.; Entrup, Leon; Templin, Andrew T.; Hogan, Meghan F.; Samarasekera, Thanya; Zraika, Sakeneh; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Meier, Daniel T.; Entrup, Leon; Templin, Andrew T.; Hogan, Meghan F.; Samarasekera, Thanya; Zraika, Sakeneh; Boyko, Edward J.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Div Gen Internal Med, Seattle, WA USA. RP Meier, DT (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM meierdan@uw.edu FU Department of Veterans Affairs [BX001060]; NIH [DK-007247, DK-080945, DK-017047]; Swiss National Science Foundation Fellowship; Dick and Julia McAbee Endowed Fellowship in Diabetes Research from the University of Washington; American Diabetes Association Mentor-Based Fellowship FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Department of Veterans Affairs grant BX001060 and NIH grants DK-007247, DK-080945 and DK-017047. DTM was supported by a Swiss National Science Foundation Fellowship and the Dick and Julia McAbee Endowed Fellowship in Diabetes Research from the University of Washington. TS and ATT were supported by an American Diabetes Association Mentor-Based Fellowship. NR 32 TC 7 Z9 7 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD AUG PY 2015 VL 63 IS 8 SI SI BP 663 EP 673 DI 10.1369/0022155415585995 PG 11 WC Cell Biology SC Cell Biology GA CN7ES UT WOS:000358597500011 PM 26216141 ER PT J AU Miller, DM Schapira, MM Visotcky, AM Laud, P Arora, VM Kordus, A Whittle, J Singh, S Fletcher, KE AF Miller, Donna M. Schapira, Marilyn M. Visotcky, Alexis M. Laud, Purushottam Arora, Vineet M. Kordus, Andrew Whittle, Jeff Singh, Siddhartha Fletcher, Kathlyn E. TI Changes in written sign-out composition across hospitalization SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID HANDOFFS; COMMUNICATION; CHECKLIST; WORKLOAD; INTERNS; CARE AB BACKGROUNDInaccurate or incomplete information in the written portion of the patient handoff, or sign-out, may be associated with adverse events in hospitalized patients. Little is known about what information providers actually include in written sign-out documents and how sign-outs change over time. OBJECTIVES(1) Provide a descriptive analysis of initial and subsequent hospital day-written sign-out content, and (2) evaluate the relationship between team workload and sign-out composition. DESIGNRetrospective review of sign-out documents from a larger observational study of general medicine patients admitted to housestaff and hospitalist teams at 3 hospitals. MAIN MEASURESThe presence of 13 components of a high-quality sign-out. We performed descriptive analyses and compared initial and subsequent day sign-outs for content. KEY RESULTSWe reviewed 200 patient hospitalizations (200 initial handoffs, 580 subsequent day handoffs). Initial sign-out entries contained a mean of 7.54 (standard deviation: 2.27) key sign-out components. Subsequent day sign-outs contained a higher percentage of certain key elements but had more vague language. The number of elements present in the sign-out was reduced as patient census increased (r=-0.295, P<0.01). CONCLUSIONSSign-out composition changes over time, and is associated with workload. Future interventions to improve quality should take these factors into consideration. Journal of Hospital Medicine 2015;10:534-536. (c) 2015 Society of Hospital Medicine. C1 [Miller, Donna M.] Mayo Clin, Sch Med, Dept Internal Med, Div Hosp Internal Med, Rochester, MN USA. [Schapira, Marilyn M.] Univ Penn, Dept Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Visotcky, Alexis M.; Laud, Purushottam] Med Coll Wisconsin, Dept Biostat, Milwaukee, WI 53295 USA. [Arora, Vineet M.] Univ Chicago, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA. [Kordus, Andrew] Nova SE Univ, Coll Osteopath Med, Davie, FL USA. [Whittle, Jeff; Singh, Siddhartha; Fletcher, Kathlyn E.] Clement J Zablocki VAMC, Dept Internal Med, Milwaukee, WI USA. [Whittle, Jeff; Singh, Siddhartha; Fletcher, Kathlyn E.] Med Coll Wisconsin, Milwaukee, WI 53295 USA. RP Fletcher, KE (reprint author), Med Coll Wisconsin, Clement J Zablocki VAMC, 5000 W Natl Ave, Milwaukee, WI 53295 USA. EM kfletche@mcw.edu OI Arora, Vineet/0000-0002-4745-7599 FU Veterans Affairs Health Services Research & Development grant IIR [07-201] FX This work was supported by Veterans Affairs Health Services Research & Development grant IIR #07-201. The authors report no conflicts of interest. NR 15 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD AUG PY 2015 VL 10 IS 8 BP 534 EP 536 DI 10.1002/jhm.2390 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CN8LZ UT WOS:000358693600010 PM 26061434 ER PT J AU Sheehy, AM Kolehmainen, C Carnes, M AF Sheehy, Ann M. Kolehmainen, Christine Carnes, Molly TI We specialize in change leadership: A call for hospitalists to lead the quest for workforce gender equity SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID ACADEMIC MEDICINE; WOMEN; METAANALYSIS; FACULTY; NEGOTIATIONS; ADVANCEMENT; PHYSICIANS; EMOTION; BIAS C1 [Sheehy, Ann M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hosp Med, Madison, WI 53705 USA. [Kolehmainen, Christine] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Kolehmainen, Christine] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA. [Carnes, Molly] Univ Wisconsin, Women Sci & Engn Leadership Inst, Ctr Womens Hlth Res, Dept Med, Madison, WI 53705 USA. [Carnes, Molly] Univ Wisconsin, Women Sci & Engn Leadership Inst, Ctr Womens Hlth Res, Dept Psychiat, Madison, WI 53705 USA. [Carnes, Molly] Univ Wisconsin, Women Sci & Engn Leadership Inst, Ctr Womens Hlth Res, Dept Ind & Syst Engn, Madison, WI 53705 USA. RP Sheehy, AM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hosp Med, 1685 Highland Ave,MFCB 3126, Madison, WI 53705 USA. EM asr@medicine.wisc.edu NR 33 TC 0 Z9 0 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD AUG PY 2015 VL 10 IS 8 BP 551 EP 552 DI 10.1002/jhm.2399 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CN8LZ UT WOS:000358693600014 PM 26122268 ER PT J AU Polewski, MA Burhans, MS Zhao, MH Colman, RJ Shanmuganayagam, D Lindstrom, MJ Ntambi, JM Anderson, RM AF Polewski, Michael A. Burhans, Maggie S. Zhao, Minghui Colman, Ricki J. Shanmuganayagam, Dhanansayan Lindstrom, Mary J. Ntambi, James M. Anderson, Rozalyn M. TI Plasma diacylglycerol composition is a biomarker of metabolic syndrome onset in rhesus monkeys SO JOURNAL OF LIPID RESEARCH LA English DT Article DE lipids; lipoproteins; insulin; obesity; adipose tissue; cholesteryl esters; free fatty acids; phospholipids; triacylglycerols; adiponectin ID FATTY-ACID-COMPOSITION; TYPE-2 DIABETES-MELLITUS; LINKING ADIPOSE-TISSUE; CARDIOVASCULAR-DISEASE; DIETARY RESTRICTION; BODY-COMPOSITION; INFLAMMATION; ADIPONECTIN; OBESITY; SERUM AB Metabolic syndrome is linked with obesity and is often first identified clinically by elevated BMI and elevated levels of fasting blood glucose that are generally secondary to insulin resistance. Using the highly translatable rhesus monkey (Macaca mulatta) model, we asked if metabolic syndrome risk could be identified earlier. The study involved 16 overweight but healthy, euglycemic monkeys, one-half of which spontaneously developed metabolic syndrome over the course of 2 years while the other half remained healthy. We conducted a series of biometric and plasma measures focusing on adiposity, lipid metabolism, and adipose tissue-derived hormones, which led to a diagnosis of metabolic syndrome in the insulin-resistant animals. Plasma fatty acid composition was determined by gas chromatography for cholesteryl ester, FFA, diacylglycerol (DAG), phospholipid, and triacylglycerol lipid classes; plasma lipoprotein profiles were generated by NMR; and circulating levels of adipose-derived signaling peptides were determined by ELISA. We identified biomarker models including a DAG model, two lipoprotein models, and a multiterm model that includes the adipose-derived peptide adiponectin. Correlations among circulating lipids and lipoproteins revealed shifts in lipid metabolism during disease development.Jlr We propose that lipid profiling may be valuable for early metabolic syndrome detection in a clinical setting. C1 [Polewski, Michael A.; Burhans, Maggie S.; Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Zhao, Minghui; Ntambi, James M.] Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA. [Colman, Ricki J.; Shanmuganayagam, Dhanansayan] Univ Wisconsin, Natl Primate Res Ctr, Madison, WI USA. [Lindstrom, Mary J.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Ntambi, James M.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. [Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. RP Anderson, RM (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA. EM rmanderson@medicine.wisc.edu FU National Institutes of Health/National Institute on Aging [AG037000, AG11915, AG040178]; National Institutes of Health/National Center for Research Resources/Clinical and Translational Science Award [UL1RR025011]; Research Facilities Improvement Program [RR15459-01, RR020141-01]; [P51OD011106] FX This work was supported by National Institutes of Health/National Institute on Aging Grants AG037000, AG11915, and AG040178, and by National Institutes of Health/National Center for Research Resources/Clinical and Translational Science Award UL1RR025011. The study was conducted with the use of resources and facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The Wisconsin National Primate Research Center is supported by P51OD011106 and Research Facilities Improvement Program Grants RR15459-01 and RR020141-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No potential conflicts of interest relevant to this article are reported. NR 47 TC 2 Z9 2 U1 3 U2 14 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD AUG PY 2015 VL 56 IS 8 BP 1461 EP 1470 DI 10.1194/jlr.M057562 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CN8CT UT WOS:000358666000008 PM 26063458 ER PT J AU Stey, AM Russell, MM Zingmond, DS Gibbons, MM Hall, BL Needleman, J Lawson, EH Liu, N Ko, CY AF Stey, Anne M. Russell, Marcia M. Zingmond, David S. Gibbons, Melinda M. Hall, Bruce L. Needleman, Jack Lawson, Elise H. Liu, Nancy Ko, Clifford Y. TI Using Merged Clinical and Claims Registry Data to Identify High Utilizers of Surgical Inpatient Care 1 Year after Colectomy SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID OUTPATIENT PREOPERATIVE EVALUATION; 30-DAY POSTOPERATIVE READMISSIONS; MAJOR GASTROINTESTINAL RESECTIONS; COLORECTAL SURGERY; RISK-FACTORS; LIVER-TRANSPLANTATION; EARLY REHABILITATION; QUALITY IMPROVEMENT; GENERAL-SURGERY; OPERATING-ROOM AB BACKGROUND: Under bundled payment initiatives, providers will be held financially responsible for patients' acute and post-acute care costs. Certain patients, termed high utilizers, use disproportionate shares of resources during 1 year. The aim of this study was to identify high utilizers, describe their costs, and determine whether preoperative characteristics predict high utilizer status. STUDY DESIGN: Colectomy patients with 1-year follow-up were identified in a linked clinical (American College of Surgeons NSQIP) and administrative (Medicare inpatient claims) dataset (2005 to 2008). Cost of inpatient care was calculated by multiplying patient Medicare charges in each cost center by cost-to-charge ratios from the Medicare cost reports. A mixed-effects logistic model quantified the association between preoperative characteristics and being a high utilizer after elective and emergent colectomies. RESULTS: One thousand and fifty-five of 10,561 colectomy patients accounted for >50% of the inpatient care cost of the entire cohort during 1 year postoperatively. This top decile of patients were labeled high utilizers and had substantially greater costs in the following cost centers: intensive care ($36,322 vs $0), respiratory ($2,875 vs $22), radiology ($649 vs $29), and cardiology ($5,057 vs $166) (all p < 0.001). High utilizers more frequently had emergent index colectomies (43% vs 17%; p < 0.001). Patients with American Society of Anesthesiologists class IV and V had 2-fold increased odds of being high utilizers after both elective (odds ratio = 2.72; 95% CI, 1.89-3.90) and emergent colectomies (odds ratio = 2.09; 95% CI, 1.23-3.55). CONCLUSIONS: Patients in the top cost decile account for the majority of costs in the year after colectomy, disproportionately accumulate those costs in particular cost centers, and can be identified preoperatively. (C) 2015 by the American College of Surgeons C1 [Stey, Anne M.] Mt Sinai Med Ctr, Icahn Sch Med, New York, NY 10029 USA. [Stey, Anne M.; Russell, Marcia M.; Zingmond, David S.; Gibbons, Melinda M.; Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Needleman, Jack] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA. [Russell, Marcia M.; Liu, Nancy] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.; Ko, Clifford Y.] Amer Coll Surg, Chicago, IL USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] St Louis VA Med Ctr, St Louis, MO USA. [Hall, Bruce L.] BJC Healthcare St Louis, St Louis, MO USA. RP Stey, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA. EM as013j@gmail.com FU Robert Wood Johnson Foundation Clinical Scholars(R) program; US Department of Veterans Affairs FX Dr Stey was supported by The Robert Wood Johnson Foundation Clinical Scholars (R) program and the US Department of Veterans Affairs. NR 41 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD AUG PY 2015 VL 221 IS 2 BP 441 EP U706 DI 10.1016/j.jamcollsurg.2015.03.024 PG 12 WC Surgery SC Surgery GA CN4EZ UT WOS:000358384400029 PM 26141469 ER PT J AU Egede, LE Acierno, R Knapp, RG Lejuez, C Hernandez-Tejada, M Payne, EH Frueh, BC AF Egede, Leonard E. Acierno, Ron Knapp, Rebecca G. Lejuez, Carl Hernandez-Tejada, Melba Payne, Elizabeth H. Frueh, B. Christopher TI Psychotherapy for depression in older veterans via telemedicine: a randomised, open-label, non-inferiority trial SO LANCET PSYCHIATRY LA English DT Article ID BEHAVIORAL ACTIVATION TREATMENT; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH RESEARCH; MAJOR DEPRESSION; COLLABORATIVE CARE; LATER LIFE; ADULTS; POPULATION; THERAPY; PROGRAM AB Background Many older adults with major depression, particularly veterans, do not have access to evidence-based psychotherapy. Telemedicine could increase access to best-practice care for older adults facing barriers of mobility, stigma, and geographical isolation. We aimed to establish non-inferiority of behavioural activation therapy for major depression delivered via telemedicine to same-room care in largely male, older adult veterans. Methods In this randomised, controlled, open-label, non-inferiority trial, we recruited veterans (aged >= 58 years) meeting DSM-IV criteria for major depressive disorder from the Ralph H Johnson Veterans Affairs Medical Center and four associated community outpatient-based clinics in the USA. We excluded actively psychotic or demented people, those with both suicidal ideation and clear intent, and those with substance dependence. The study coordinator randomly assigned participants (1:1; block size 2-6; stratified by race; computer-generated randomisation sequence by RGK) to eight sessions of behavioural activation for depression either via telemedicine or in the same room. The primary outcome was treatment response according to the Geriatric Depression Scale (GDS) and Beck Depression Inventory (BDI; defined as a 50% reduction in symptoms from baseline at 12 months), and Structured Clinical Interview for DSM-IV, clinician version (defined as no longer being diagnosed with major depressive disorder at 12 months follow-up), in the per-protocol population (those who completed at least four treatment sessions and for whom all outcome measurements were done). Those assessing outcomes were masked. The non-inferiority margin was 15%. This trial is registered with ClinicalTrials.gov, number NCT00324701. Findings Between April 1, 2007, and July 31, 2011, we screened 780 patients, and the study coordinator randomly assigned participants to either telemedicine (120 [50%]) or same-room treatment (121 [50%]). We included 100 (83%) patients in the per-protocol analysis in the telemedicine group and 104 (86%) in the same-room group. Treatment response according to GDS did not differ significantly between the telemedicine (22 [22.45%, 90% CI 15.52-29.38] patients) and same-room (21 [20.39%, 90% CI 13.86-26.92]) groups, with an absolute difference of 2.06% (90% CI -7.46 to 11.58). Response according to BDI also did not differ significantly (telemedicine 19 [24.05%, 90% CI 16.14-31.96] patients; same room 19 [23.17%, 90% CI 15.51-30.83]), with an absolute difference of 0.88% (90% CI -10.13 to 11.89). Response on the Structured Clinical Interview for DSM-IV, clinician version, also did not differ significantly (39 [43.33%, 90% CI 34.74-51.93] patients in the telemedicine group and 46 [48.42%, 90% CI 39.99-56.85] in the same-room group), with a difference of -5.09% (-17.13 to 6.95; p=0.487). Results from the intention-to-treat population were similar. MEM analyses showed that no significant differences existed between treatment trajectories over time for BDI and GDS. The criteria for non-inferiority were met. We did not note any adverse events. Interpretation Telemedicine-delivered psychotherapy for older adults with major depression is not inferior to same-room treatment. This finding shows that evidence-based psychotherapy can be delivered, without modification, via home-based telemedicine, and that this method can be used to overcome barriers to care associated with distance from and difficulty with attendance at in-person sessions in older adults. C1 [Egede, Leonard E.; Acierno, Ron; Knapp, Rebecca G.; Lejuez, Carl; Payne, Elizabeth H.; Frueh, B. Christopher] Ralph H Johnson Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Egede, Leonard E.; Hernandez-Tejada, Melba] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA. [Acierno, Ron; Hernandez-Tejada, Melba] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Knapp, Rebecca G.; Payne, Elizabeth H.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Lejuez, Carl] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. EM egedel@musc.edu FU Veterans Affairs Health Services Research and Development Program [IIR-04-421-3] FX This work was supported by grants IIR-04-421-3 from the Veterans Affairs Health Services Research and Development Program. We are deeply appreciative of the veterans and Veterans Affairs primary care and mental health providers who contributed to this research effort. All views and opinions expressed herein are those of the authors and do not necessarily reflect those of our respective institutions or the Department of Veterans Affairs. NR 53 TC 14 Z9 14 U1 4 U2 27 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2215-0374 J9 LANCET PSYCHIAT JI Lancet Psychiatry PD AUG PY 2015 VL 2 IS 8 BP 693 EP 701 DI 10.1016/S2215-0366(15)00122-4 PG 9 WC Psychiatry SC Psychiatry GA CN9CH UT WOS:000358743200021 PM 26249300 ER PT J AU Jensen, KP Herman, AI Morean, ME Kranzler, HR Gelernter, J Sofuoglu, M AF Jensen, K. P. Herman, A. I. Morean, M. E. Kranzler, H. R. Gelernter, J. Sofuoglu, M. TI FKBP5 variation is associated with the acute and chronic effects of nicotine SO PHARMACOGENOMICS JOURNAL LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD TRAUMA; GLUCOCORTICOID RESISTANCE; ACETYLCHOLINE-RECEPTOR; INTRAVENOUS NICOTINE; WITHDRAWAL SYMPTOMS; SMOKING ABSTINENCE; NUCLEUS-ACCUMBENS; MAJOR DEPRESSION; DRUG-DEPENDENCE AB Stress and hormones released in response to stress influence the effects of nicotine and the severity of nicotine withdrawal. Here, we systematically examine the contribution of a stress response gene, FKBP5, to the acute and chronic behavioral effects of nicotine in smokers. Subjects were European- and African-American (EA and AA) heavy smokers who participated in an intravenous (IV) nicotine administration study (total n = 169). FKBP5 rs3800373 genotype was analyzed for association to several outcomes, including nicotine withdrawal and the acute subjective, heart rate (HR), blood pressure and plasma cortisol responses to IV nicotine. Nicotine withdrawal was also examined in relation to rs3800373 allele frequencies in an independent cohort of EA and AA current smokers (n = 3821). For a subset of laboratory subjects FKBP5 mRNA (n = 48) expression was explored for an association to the same outcomes. The rs3800373 minor allele was associated with less severe nicotine withdrawal in laboratory subjects and the independent cohort of smokers. The rs3800373 minor allele was also associated with lower subjective ratings of negative drug effects in response to IV nicotine. Low FKBP5 mRNA expression was associated lower cortisol levels, lower subjective ratings of negative drug effects and a blunted HR response to nicotine. Stress hormone regulation via FKBP5 warrants further investigation as a potential contributor to the effects of nicotine withdrawal, which occurs commonly, and has an important role in the maintenance of smoking behavior and relapse following a quit attempt. C1 [Jensen, K. P.; Herman, A. I.; Morean, M. E.; Gelernter, J.; Sofuoglu, M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Jensen, K. P.; Herman, A. I.; Gelernter, J.; Sofuoglu, M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Kranzler, H. R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Kranzler, H. R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. RP Jensen, KP (reprint author), Yale Univ, Sch Med, VA Connecticut Healthcare Syst, Dept Psychiat, 950 Campbell Ave, West Haven, CT 06516 USA. EM kevin.jensen@yale.edu FU NIH [R01 AA011330, R01 AA017535, R01 DA030976, R01 DA12690, R03 DA027474, K24 AA013736, K12 DA00167, T32 MH014276, T32 AA015496]; US Department of Veterans Affairs (VA) [575B]; VISN 1 New England Mental Illness Research; Education and Clinical Center (MIRECC); VA National Center for PTSD; VA VISN 1 CDA; VA MERIT; National Institutes of Health [N01-HG-65403] FX This work was supported in part by NIH grants, R01 AA011330, R01 AA017535, R01 DA030976, R01 DA12690, R03 DA027474, K24 AA013736, K12 DA00167, T32 MH014276 and T32 AA015496. This work also received support from the US Department of Veterans Affairs (VA) through Cooperative Study #575B, the VISN 1 New England Mental Illness Research, Education and Clinical Center (MIRECC) and VA National Center for PTSD, and a VA VISN 1 CDA and VA MERIT. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University (contract number N01-HG-65403). NR 54 TC 7 Z9 7 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1470-269X EI 1473-1150 J9 PHARMACOGENOMICS J JI Pharmacogenomics J. PD AUG PY 2015 VL 15 IS 4 BP 340 EP 346 DI 10.1038/tpj.2014.76 PG 7 WC Genetics & Heredity; Pharmacology & Pharmacy SC Genetics & Heredity; Pharmacology & Pharmacy GA CN5CY UT WOS:000358448500008 PM 25532758 ER PT J AU Sautter, FJ Glynn, SM Cretu, JB Senturk, D Vaught, AS AF Sautter, Frederic J. Glynn, Shirley M. Cretu, Julia Becker Senturk, Damla Vaught, Amanda S. TI Efficacy of Structured Approach Therapy in Reducing PTSD in Returning Veterans: A Randomized Clinical Trial SO PSYCHOLOGICAL SERVICES LA English DT Article DE couple therapy; posttraumatic stress disorder; returning veterans; behavior therapy; treatment ID POSTTRAUMATIC-STRESS-DISORDER; BEHAVIORAL CONJOINT THERAPY; COGNITIVE-PROCESSING THERAPY; PROLONGED EXPOSURE; COMBAT VETERANS; INTIMATE-RELATIONSHIPS; EMOTION REGULATION; COUPLE ADJUSTMENT; VIETNAM VETERANS; INITIAL FINDINGS AB The U.S. military deployed in support to Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) show high rates of posttraumatic stress disorder (PTSD) and relationship, partner, and parenting distress. Given the pervasive effect of combat-related PTSD on returning veterans and its effect on their loved ones, the investigators have developed a couples-based treatment, structured approach therapy (SAT), to reduce PTSD while simultaneously decreasing relationship and partner distress. This study presents treatment outcome data measuring PTSD and relationship outcomes from a randomized clinical trial (RCT) comparing SAT, a manualized 12-session novel couples-based PTSD treatment, to a manualized 12-session couples-based educational intervention (PTSD Family Education [PFE]). Data were collected from 57 returning veterans meeting Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text revision; DSM-IV-TR) criteria for PTSD and their cohabiting partners; data collection was scheduled for pretreatment, posttreatment, and 3-month follow-up. Findings from an intent-to-treat analysis revealed that veterans receiving SAT showed significantly greater reductions in self-rated (PTSD Checklist; p < .0006) and Clinician-Administered PTSD Scale (CAPS)-rated PTSD (p < .0001) through the 3-month follow-up compared with veterans receiving PFE; 15 of 29 (52%) veterans receiving SAT and 2 of 28 (7%) receiving PFE no longer met DSM-IV-TR criteria for PTSD. Furthermore, SAT was associated with significant improvements in veteran relationship adjustment, attachment avoidance, and state anxiety. Partners showed significant reductions in attachment anxiety. This couples-based treatment for combat-related PTSD appears to have a strong therapeutic effect on combat-related PTSD in recently returned veterans. C1 [Sautter, Frederic J.] Southeast Louisiana Vet Hlth Care Syst, Family Mental Hlth Program, New Orleans, LA USA. [Sautter, Frederic J.] Tulane Univ, Sch Med, Dept Psychiat, New Orleans, LA 70112 USA. [Glynn, Shirley M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Glynn, Shirley M.] UCLA Welcome Back Vet Family Resilience Ctr, Los Angeles, CA USA. [Cretu, Julia Becker] Tulane Univ, Sch Med, Dept Psychiat & Behav Sci, New Orleans, LA 70112 USA. [Cretu, Julia Becker] Southeast Louisiana Vet Hlth Care Syst, Dept Res, New Orleans, LA USA. [Senturk, Damla] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. [Senturk, Damla] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90024 USA. [Vaught, Amanda S.] Southeast Louisiana Vet Hlth Care Syst, PTSD Clin Team, New Orleans, LA USA. RP Sautter, FJ (reprint author), Tulane Univ, Sch Med, Dept Psychiat & Behav Sci, 1440 Canal St TB 53, New Orleans, LA 70112 USA. EM fsautter@tulane.edu FU VA Research Rehabilitation and Development program [B6756R]; South Central Mental Illness Research Education and Clinical Center FX This work was supported in part by a Merit Review grant (B6756R) from the VA Research Rehabilitation and Development program and a Supplemental Funding Award from the South Central Mental Illness Research Education and Clinical Center to Frederic J. Sautter. NR 76 TC 2 Z9 2 U1 2 U2 13 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD AUG PY 2015 VL 12 IS 3 BP 199 EP 212 DI 10.1037/ser0000032 PG 14 WC Psychology, Clinical SC Psychology GA CN8KN UT WOS:000358689300002 PM 26213789 ER PT J AU Price, M Yuen, EK Davidson, TM Hubel, G Ruggiero, KJ AF Price, Matthew Yuen, Erica K. Davidson, Tatiana M. Hubel, Grace Ruggiero, Kenneth J. TI Access and Completion of a Web-based Treatment in a Population-Based Sample of Tornado-Affected Adolescents SO PSYCHOLOGICAL SERVICES LA English DT Article DE adolescents; Internet interventions; traumatic stress; natural disaster ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL TREATMENT; MENTAL-HEALTH INTERVENTION; PSYCHOLOGICAL DISTRESS; RANDOMIZED-TRIALS; HURRICANE-ANDREW; NATIONAL SAMPLE; SYMPTOMS; PREDICTORS; SERVICES AB Although Web-based treatments have significant potential to assess and treat difficult-to-reach populations, such as trauma-exposed adolescents, the extent that such treatments are accessed and used is unclear. The present study evaluated the proportion of adolescents who accessed and completed a Web-based treatment for postdisaster mental health symptoms. Correlates of access and completion were examined. A sample of 2,000 adolescents living in tornado-affected communities was assessed via structured telephone interview and invited to a Web-based treatment. The modular treatment addressed symptoms of posttraumatic stress disorder, depression, and alcohol and tobacco use. Participants were randomized to experimental or control conditions after accessing the site. Overall access for the intervention was 35.8%. Module completion for those who accessed ranged from 52.8% to 85.6%. Adolescents with parents who used the Internet to obtain health-related information were more likely to access the treatment. Adolescent males were less likely to access the treatment. Future work is needed to identify strategies to further increase the reach of Web-based treatments to provide clinical services in a postdisaster context. C1 [Price, Matthew] Univ Vermont, Dept Psychol Sci, Burlington, VT 05405 USA. [Yuen, Erica K.] Univ Tampa, Dept Psychol, Tampa, FL USA. [Davidson, Tatiana M.] Med Univ S Carolina, Coll Nursing, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC USA. [Davidson, Tatiana M.] Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, Charleston, SC USA. [Hubel, Grace] Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, MUSC Charleston Hlth Equ & Rural Outreach Innovat, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, Charleston, SC USA. RP Price, M (reprint author), Univ Vermont, Dept Psychol Sci, John Dewey Hall,2 Colchester Ave, Burlington, VT 05405 USA. EM matthew.price@uvm.edu FU NIMH NIH HHS [R01 MH081056] NR 52 TC 1 Z9 1 U1 1 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD AUG PY 2015 VL 12 IS 3 BP 283 EP 290 DI 10.1037/ser0000017 PG 8 WC Psychology, Clinical SC Psychology GA CN8KN UT WOS:000358689300011 PM 25622071 ER PT J AU Kuna, ST Shuttleworth, D Chi, LQ Schutte-Rodin, S Friedman, E Guo, HY Dhand, S Yang, L Zhu, JS Bellamy, SL Volpp, KG Asch, DA AF Kuna, Samuel T. Shuttleworth, David Chi, Luqi Schutte-Rodin, Sharon Friedman, Eliot Guo, Hengyi Dhand, Sandeep Yang, Lin Zhu, Jingsan Bellamy, Scarlett L. Volpp, Kevin G. Asch, David A. TI Web-Based Access to Positive Airway Pressure Usage with or without an Initial Financial Incentive Improves Treatment Use in Patients with Obstructive Sleep Apnea SO SLEEP LA English DT Article DE adherence; telehealth; internet ID RANDOMIZED CONTROLLED-TRIAL; FORM HEALTH SURVEY; CPAP THERAPY; DAYTIME SLEEPINESS; NASAL CPAP; HEART HEALTH; ADHERENCE; SUPPORT; ADULTS; IMPLEMENTATION AB Study Objectives: We tested whether providing adults with obstructive sleep apnea (OSA) with daily Web-based access to their positive airway pressure (PAP) usage over 3 mo with or without a financial incentive in the first week improves adherence and functional outcomes. Setting: Academic-and community-based sleep centers. Participants: One hundred thirty-eight adults with newly diagnosed OSA starting PAP treatment. Interventions: Participants were randomized to: usual care, usual care with access to PAP usage, or usual care with access to PAP usage and a financial incentive. PAP data were transmitted daily by wireless modem from the participants' PAP unit to a website where hours of usage were displayed. Participants in the financial incentive group could earn up to $30/day in the first week for objective PAP use >= 4 h/day. Measurements and Results: Mean hours of daily PAP use in the two groups with access to PAP usage data did not differ from each other but was significantly greater than that in the usual care group in the first week and over 3 mo (P < 0.0001). Average daily use (mean +/- standard deviation) during the first week of PAP intervention was 4.7 +/- 3.3 h in the usual care group, and 5.9 +/- 2.5 h and 6.3 +/- 2.5 h in the Web access groups with and without financial incentive respectively. Adherence over the 3-mo intervention decreased at a relatively constant rate in all three groups. Functional Outcomes of Sleep Questionnaire change scores at 3 mo improved within each group (P < 0.0001) but change scores of the two groups with Web access to PAP data were not different than those in the control group (P > 0.124). Conclusions: Positive airway pressure adherence is significantly improved by giving patients Web access to information about their use of the treatment. Inclusion of a financial incentive in the first week had no additive effect in improving adherence. C1 [Kuna, Samuel T.; Volpp, Kevin G.; Asch, David A.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Kuna, Samuel T.; Volpp, Kevin G.; Asch, David A.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Kuna, Samuel T.; Shuttleworth, David; Schutte-Rodin, Sharon; Guo, Hengyi; Volpp, Kevin G.; Asch, David A.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Shuttleworth, David; Yang, Lin; Zhu, Jingsan; Volpp, Kevin G.; Asch, David A.] Ctr Hlth Incent & Behav Econ, Leonard Davis Inst, Philadelphia, PA USA. [Chi, Luqi] Lankenau Med Ctr, Wynnewood, PA USA. [Friedman, Eliot] Paoli Hosp, Paoli, PA USA. [Dhand, Sandeep] Holy Redeemer Hosp, Meadowbrook, PA USA. [Bellamy, Scarlett L.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Asch, David A.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. RP Kuna, ST (reprint author), Philadelphia Vet Affairs Med Ctr, 111P,3900 Woodland Ave, Philadelphia, PA 19104 USA. FU NIH [RC2-AG036592-01, 1P01-1HL094307]; Philips Respironics; Humana; Weight Watchers; CVS FX NIH RC2-AG036592-01; NIH 1P01-1HL094307. P'unk Ave, Inc., a Web-based software company in Philadelphia, PA, created the Way to Health website for the University of Pennsylvania and continued to support the website during the project. Dr. Kuna and Dr. Schutte-Rodin receive grant support from Philips Respironics. Dr. Asch is a Principal at VAL Health (Philadelphia, PA). Dr. Volpp has received research support from Humana, Weight Watchers, and CVS, and has consulted for Val Health. The other authors have indicated no financial conflicts of interest. NR 42 TC 7 Z9 7 U1 0 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD AUG 1 PY 2015 VL 38 IS 8 BP 1229 EP 1236 AR PII sp-00550-14 DI 10.5665/sleep.4898 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CO0JV UT WOS:000358838100012 PM 25581921 ER PT J AU Azarbarzin, A Ostrowski, M Younes, M Keenan, BT Pack, AI Staley, B Kuna, ST AF Azarbarzin, Ali Ostrowski, Michele Younes, Magdy Keenan, Brendan T. Pack, Allan I. Staley, Bethany Kuna, Samuel T. TI Arousal Responses during Overnight Polysomnography and their Reproducibility in Healthy Young Adults SO SLEEP LA English DT Article DE arousal; EEG; heart rate; night-to-night ID OBSTRUCTIVE SLEEP-APNEA; NIGHT; HYPERTENSION; VARIABILITY; ASSOCIATION; PERFORMANCE; ACTIVATION; CHILDREN; HUMANS; AGE AB Study Objectives: Arousal intensity and heart rate (HR) response to arousal during polysomnography (PSG) vary considerably between patients with sleep disorders. Our objective was to determine the range of these arousal characteristics in healthy young adults and whether they are consistent on repeated testing. Design: Post hoc analysis of 56 preexisting PSG files recorded from 28 healthy adults on 2 consecutive nights. Setting: Academic medical center and Research and Development Laboratory (YRT Limited, Winnipeg, Manitoba, Canada). Participants: Twenty-eight healthy young adults. Interventions: None. Measurements and Results: Arousals were identified using an automatic system followed by manual editing. The intensity of arousals was scaled (between 0 and 9) using an automatic algorithm based on the change in the electroencephalography (EEG) signals' wavelet characteristics. 4,751 arousals in 28 pairs of PSGs (night 1 and night 2) were scaled. HR responses (Delta HR) to all arousals were determined and averaged at each arousal scale per file. Overall average arousal intensity ranged 3.0-7.1 in different subjects, and average Delta HR ranged 1.9-18.3 beats.min(-1). Heart rate response at a given arousal intensity, expressed as Delta HR at a moderate arousal scale of 5.0 (Delta HR5), ranged 4.1-18.1 beats.min(-1). There was a strong correlation between arousal intensity and Delta HR within each subject. More importantly, there were excellent intraclass correlations (ICC) between night 1 and night 2 results for all three variables (ICC = 0.72 for average intensity, 0.92 for average Delta HR4, and 0.91 for Delta HR5). Conclusions: Average arousal intensity and heart rate response to arousal are highly variable among healthy young adults and stable within individuals. C1 [Azarbarzin, Ali; Ostrowski, Michele; Younes, Magdy] YRT Ltd, Winnipeg, MB, Canada. [Younes, Magdy] Univ Manitoba, Sleep Disorders Ctr, Winnipeg, MB, Canada. [Keenan, Brendan T.; Pack, Allan I.; Staley, Bethany; Kuna, Samuel T.] Univ Penn, Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Pack, Allan I.; Staley, Bethany; Kuna, Samuel T.] Univ Penn, Pereleman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA USA. RP Younes, M (reprint author), 1001 Wellington Crescent, Winnipeg, MB R3M 0A7, Canada. EM mkyounes@shaw.ca FU YRT Limited, Winnipeg, Manitoba, Canada; NIH [P50 HL060287, 1P01-1HL094307]; Philips Respironics FX This study was supported by YRT Limited, Winnipeg, Manitoba, Canada; NIH P50 HL060287; NIH 1P01-1HL094307. Dr. Younes is majority owner of YRT Ltd., and receives royalties from Covidien and Philips Respironics. Michele Ostrowski is part owner of YRT. Dr. Azarbarzin is currently employed by YRT. Dr Kuna has received grant support from Philips Respironics and has consulted for Vivus, Astra Zeneca, and Zephyr Sleep Technologies The other authors have indicated no financial conflicts of interest. NR 26 TC 3 Z9 3 U1 1 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD AUG 1 PY 2015 VL 38 IS 8 BP 1313 EP 1321 DI 10.5665/sleep.4916 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CO0JV UT WOS:000358838100021 PM 25581917 ER PT J AU Rhee, CM Nguyen, DV Moradi, H Brunelli, SM Dukkipati, R Jing, J Nakata, T Kovesdy, CP Brent, GA Kalantar-Zadeh, K AF Rhee, Connie M. Nguyen, Danh V. Moradi, Hamid Brunelli, Steven M. Dukkipati, Ramanath Jing, Jennie Nakata, Tracy Kovesdy, Csaba P. Brent, Gregory A. Kalantar-Zadeh, Kamyar TI Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Adiponectin; mortality; hemodialysis; body composition; anthropometry; body fat; body mass index (BMI); lipids; cardiovascular disease (CVD); renal replacement therapy (RRT); end-stage renal disease; MADRAD (Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease) study ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; ALL-CAUSE MORTALITY; CHRONIC HEART-FAILURE; QUALITY-OF-LIFE; DIALYSIS PATIENTS; CARDIOVASCULAR MORTALITY; MYOCARDIAL-INFARCTION; REVERSE EPIDEMIOLOGY; PLASMA-PROTEIN AB Background: In the general population, circulating adiponectin is associated with a favorable cardiovascular risk profile (eg, lower triglycerides and body fat) and decreased mortality. Hemodialysis (HD) patients have comparatively higher adiponectin concentrations, but prior studies examining the adiponectin-mortality association in this population have not accounted for body composition or shown a consistent relationship. Study Design: Prospective cohort study. Settings & Participants: We examined baseline serum adiponectin concentrations in 501 HD patients across 13 dialysis centers from the prospective MADRAD (Malnutrition, Diet, and Racial Disparities in Chronic Kidney Disease) cohort (entry period, October 2011 to February 2013; follow-up through August 2013). Predictor: Serum adiponectin concentration in tertiles (tertiles 1, 2, and 3 defined as <= 16.1, >16.1-<30.1, and >= 30.1-100.0 mu g/mL, respectively). Adjustment variables included case-mix and laboratory test results (age, sex, race, ethnicity, vintage, diabetes, serum albumin, total iron-binding capacity, serum creatinine, white blood cell count, phosphate, hemoglobin, and normalized protein catabolic rate), body composition surrogates (subcutaneous, visceral, and total-body fat and lean body mass), and serum lipid levels (cholesterol, high-density lipoprotein cholesterol, and triglycerides). Outcomes: All-cause mortality using survival (Cox) models incrementally adjusted for case-mix and laboratory test results. Results: Among 501 HD patients, 50 deaths were observed during 631.1 person-years of follow-up. In case-mix- and laboratory-adjusted Cox analyses, the highest adiponectin tertile was associated with increased mortality versus the lowest tertile (HR, 3.35; 95% CI, 1.50-7.47). These associations were robust in analyses that additionally accounted for body composition (HR, 3.18; 95% CI, 1.61-8.24) and lipid levels (HR, 3.64; 95% CI, 1.34-7.58). Limitations: Residual confounding cannot be excluded. Conclusions: Higher adiponectin level is associated with a 3-fold higher death risk in HD patients independent of body composition and lipid levels. Future studies are needed to elucidate underlying mechanisms and determine therapeutic targets associated with improved outcomes in HD patients. (C) 2015 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Rhee, Connie M.; Moradi, Hamid; Jing, Jennie; Nakata, Tracy; Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Harold Simmons Ctr Kidney Dis Res & Epidemiol, Div Nephrol & Hypertens, Orange, CA 92868 USA. [Nguyen, Danh V.] Univ Calif Irvine, Div Gen Internal Med, Orange, CA 92868 USA. [Brunelli, Steven M.] DaVita Healthcare Partners Inc, Minneapolis, MN USA. [Dukkipati, Ramanath] Harbor UCLA Med Ctr, Div Nephrol, Torrance, CA 90509 USA. [Kovesdy, Csaba P.] Univ Tennessee, Hlth Sci Ctr, Knoxville, TN 37996 USA. [Kovesdy, Csaba P.] Memphis VA Med Ctr, Div Nephrol, Memphis, TN USA. [Brent, Gregory A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. RP Rhee, CM (reprint author), Univ Calif Irvine, Harold Simmons Ctr Kidney Dis Res & Epidemiol, Div Nephrol & Hypertens, Med Ctr, 101 City Dr S, Orange, CA 92868 USA. EM crhee1@uci.edu OI Kalantar-Zadeh, Kamyar/0000-0002-8666-0725 FU National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [K23-DK102903, K24-DK091419, R01-DK078106]; National Center for Advancing Translational Sciences grant [UL1 TR000153] FX Support: This study is supported by research grants from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, including K23-DK102903 (Dr Rhee) and K24-DK091419 and R01-DK078106 (both Dr Kalantar-Zadeh), and philanthropic grants from Mr Harold Simmons and Mr Louis Chang. Dr Nguyen is supported by a National Center for Advancing Translational Sciences grant (UL1 TR000153). The study sponsors did not have a role in the study design; collection, analysis, or interpretation of data; writing the report; or the decision to submit the report for publication. NR 53 TC 10 Z9 10 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD AUG PY 2015 VL 66 IS 2 BP 313 EP 321 DI 10.1053/j.ajkd.2015.02.325 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CN4ED UT WOS:000358382100027 PM 25824125 ER PT J AU Trbovich, M Yang, HQ AF Trbovich, Michelle Yang, Huiqing TI Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury Two Case Reports SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Capsaicin; Neuropathic Pain; Spinal Cord Injury; Transient Receptor Potential Vanilloid Receptor ID QUALITY-OF-LIFE; BASIC DATA SET; MANAGEMENT; NOCICEPTORS; MECHANISMS AB Neuropathic pain after spinal cord injury is common and often refractory to standard treatments. The capsaicin 8% patch is a Food and Drug Administration-approved treatment of neuropathic pain in postherpetic neuralgia and has demonstrated significant efficacy in human immunodeficiency virus-autonomic neuropathy. The patch defunctionalizes transient receptor potential vanilloid 1 receptors, impairing cutaneous nociceptors for a prolonged period (i.e., 8-12 wks) with no systemic side effects. A retrospective review was conducted on the effects of the patch in two patients with spinal cord injury and neuropathic pain refractory to standard treatments. Two weeks after application, both patients reported complete pain relief. Average onset of relief of 4 days and average duration of relief of 197 days, requiring only one to four applications per year, paralleled findings reported in postherpetic neuralgia and human immunodeficiency virus-autonomic neuropathy trials. Upregulation of capsaicin-sensitive transient receptor potential vanilloid 1 receptors after spinal cord injury has been reported. The capsaicin 8% patch is a promising therapeutic agent for neuropathic pain in spinal cord injury. C1 [Trbovich, Michelle; Yang, Huiqing] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, San Antonio, TX 78229 USA. [Trbovich, Michelle] Audie L Murphy Mem Vet Adm Med Ctr, Spinal Cord Injury Serv, San Antonio, TX USA. RP Trbovich, M (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, Mail Code 7798,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 35 TC 1 Z9 1 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD AUG PY 2015 VL 94 IS 8 BP E66 EP E72 DI 10.1097/PHM.0000000000000301 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CN0RY UT WOS:000358122300001 PM 26035723 ER PT J AU Stewart, MO Karlin, BE Murphy, JL Raffa, SD Miller, SA McKellar, J Kerns, RD AF Stewart, Michael O. Karlin, Bradley E. Murphy, Jennifer L. Raffa, Susan D. Miller, Sarah A. McKellar, John Kerns, Robert D. TI National Dissemination of Cognitive-Behavioral Therapy for Chronic Pain in Veterans Therapist and Patient-level Outcomes SO CLINICAL JOURNAL OF PAIN LA English DT Article DE cognitive-behavioral therapy; chronic pain; dissemination; training; Veterans; US Department of Veterans Affairs ID LOW-BACK-PAIN; HEALTH-CARE-SYSTEM; QUALITY-OF-LIFE; WORKING ALLIANCE INVENTORY; BECK DEPRESSION INVENTORY; PSYCHOMETRIC PROPERTIES; CONTROLLED-TRIAL; AFFAIRS; IMPLEMENTATION; METAANALYSIS AB Objective: This paper assesses the effects of training in and implementation of Cognitive-Behavioral Therapy for Chronic Pain (CBT-CP) in the US Department of Veterans Affairs (VA) health care system on therapists' CBT-CP competencies and patients' pain-related outcomes. Methods: A total of 71 therapists participated in the VA CBT-CP Training Program. Patients included 148 Veterans treated by therapist training participants. Therapists completed a 3-day workshop followed by 6 months of weekly consultation. Therapy session tapes were rated by expert training consultants using a standardized competency rating form. Patient outcomes were assessed with measures of patient-reported pain intensity, pain-related cognitions, overall distress, depression, pain interference, and quality of life. The therapeutic alliance was also assessed. Results: Among the 71 therapists who participated in the training program, 60 (85%) completed all training requirements, including competency-based performance criteria. Of the 148 Veteran patients treated, 117 (79%) completed all CBT-CP protocol sessions. Intent-to-treat analyses indicated significant improvements in pain catastrophizing, interference, quality of life, and other domains, as well as on the therapeutic alliance. Discussion: Training in and implementation of CBT-CP in the VA health care system were associated with significant increases in therapist competencies to deliver CBT-CP and improvements in several domains for Veteran patients. Results support the feasibility and effectiveness of broad dissemination of CBT-CP in routine, nonpain specialty settings. C1 [Stewart, Michael O.; Karlin, Bradley E.; Raffa, Susan D.; Miller, Sarah A.] US Dept Vet Affairs, Mental Hlth Serv, Cent Off, Washington, DC USA. [Karlin, Bradley E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Murphy, Jennifer L.] James A Haley Vet Hosp, Tampa, FL USA. [Murphy, Jennifer L.] Univ S Florida, Tampa, FL USA. [Raffa, Susan D.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [McKellar, John] Bay Area Pain & Wellness Ctr, Los Gatos, CA USA. [Kerns, Robert D.] VA Connecticut Healthcare Syst, PRIME Ctr, Newington, CT USA. [Kerns, Robert D.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Kerns, Robert D.] Yale Univ, Dept Neurol, New Haven, CT USA. RP Stewart, MO (reprint author), VA Tennessee Valley Healthcare Syst, 3400 Lebanon Pike Bldg 147, Murfreesboro, TN 37129 USA. EM michael.stewart@va.gov FU Mental Health Services, US Department of Veterans Affairs Central Office, Washington, DC FX Supported by Mental Health Services, US Department of Veterans Affairs Central Office, Washington, DC. The authors declare no conflict of interest. NR 43 TC 1 Z9 1 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0749-8047 EI 1536-5409 J9 CLIN J PAIN JI Clin. J. Pain PD AUG PY 2015 VL 31 IS 8 BP 722 EP 729 DI 10.1097/AJP.0000000000000151 PG 8 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA CN1VH UT WOS:000358207900007 PM 25171637 ER PT J AU Wong, CA Asch, DA Vinoya, CM Ford, CA Baker, T Town, R Merchant, RM AF Wong, Charlene A. Asch, David A. Vinoya, Cjloe M. Ford, Carol A. Baker, Tom Town, Robert Merchant, Raina M. TI Seeing Health Insurance and HealthCare.gov Through the Eyes of Young Adults SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Young adults; Health insurance; Health reform; Affordable Care Act; Health insurance exchange ID UNITED-STATES; CARE ACCESS; UNINSURANCE AB Purpose: We describe young adults' perspectives on health insurance and HealthCare.gov, including their attitudes toward health insurance, health insurance literacy, and benefit and plan preferences. Methods: We observed young adults aged 19-30 years in Philadelphia from January to March 2014 as they shopped for health insurance on HealthCare.gov. Participants were then interviewed to elicit their perceived advantages and disadvantages of insurance and factors considered important for plan selection. A 1-month follow-up interview assessed participants' plan enrollment decisions and intended use of health insurance. Data were analyzed using qualitative methodology, and salience scores were calculated for free-listing responses. Results: We enrolled 33 highly educated young adults; 27 completed the follow-up interview. The most salient advantages of health insurance for young adults were access to preventive or primary care (salience score.28) and peace of mind (. 27). The most salient disadvantage was the financial strain of paying for health insurance (. 72). Participants revealed poor health insurance literacy with 48% incorrectly defining deductible and 78% incorrectly defining coinsurance. The most salient factors reported to influence plan selection were deductible (. 48) and premium (. 45) amounts as well as preventive care (. 21) coverage. The most common intended health insurance use was primary care. Eight participants enrolled in HealthCare.gov plans: six selected silver plans, and three qualified for tax credits. Conclusions: Young adults' perspective on health insurance and enrollment via HealthCare.gov can inform strategies to design health insurance plans and communication about these plans in a way that engages and meets the needs of young adult populations. (C) 2015 Society for Adolescent Health and Medicine. All rights reserved. C1 [Wong, Charlene A.; Asch, David A.; Vinoya, Cjloe M.; Merchant, Raina M.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. [Wong, Charlene A.; Asch, David A.; Vinoya, Cjloe M.; Baker, Tom; Town, Robert; Merchant, Raina M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Wong, Charlene A.; Ford, Carol A.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Adolescent Med, Philadelphia, PA 19104 USA. [Asch, David A.; Town, Robert] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Baker, Tom] Univ Penn, Sch Law, Philadelphia, PA 19104 USA. RP Wong, CA (reprint author), Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, 1303 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM charwong@upenn.edu FU Leonard Davis Institute Health Insurance Exchange Research Group at the University of Pennsylvania; Robert Wood Johnson Foundation Clinical Scholars Program at the University of Pennsylvania FX The study was funded by the Leonard Davis Institute Health Insurance Exchange Research Group and the Robert Wood Johnson Foundation Clinical Scholars Program, both at the University of Pennsylvania. NR 28 TC 3 Z9 3 U1 3 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD AUG PY 2015 VL 57 IS 2 BP 137 EP 143 DI 10.1016/j.jadohealth.2015.04.017 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA CN2OZ UT WOS:000358262900004 PM 26092178 ER PT J AU Raines, BT Ponce, BA Reed, RD Richman, JS Hawn, MT AF Raines, Benjamin Todd Ponce, Brent A. Reed, Rhiannon D. Richman, Joshua S. Hawn, Mary T. TI Hospital Acquired Conditions Are the Strongest Predictor for Early Readmission: An Analysis of 26,710 Arthroplasties SO JOURNAL OF ARTHROPLASTY LA English DT Article DE arthroplasty; hospital acquired conditions; readmission; strongest predictor; predictors; HAC ID TOTAL JOINT ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; KNEE ARTHROPLASTY; SURGICAL CARE; UNITED-STATES; RISK-FACTORS; QUALITY; PROGRAM; REPLACEMENT; MORTALITY AB Hospital readmission is a metric of hospital quality of care, yet little is known what factors predict hospital readmission following arthroplasty. Our aim was to identify variables associated with early readmission following knee and hip arthroplasty, with focus upon hospital acquired conditions (HACs). Retrospective cohort analysis using Surgical Care Improvement Project (SCIP) and Veteran's Affairs Surgical Quality Improvement Program (VASQIP) data was performed over a five-year period. Following 26,710 total and partial primary arthroplasties (16,808 knees and 9902 hips), the overall 30-day readmission was 7.3% (1940) with readmission rates of 6.6% for knee arthroplasty and 8.4% for hip arthroplasty. HACs accounted for 42% of all complications and were the strongest predictor of readmission. Efforts to reduce these events may improve cost and safety of arthroplasty. Published by Elsevier Inc. C1 [Raines, Benjamin Todd] Univ Missouri, Dept Orthopaed Surg, Columbia, MO 65211 USA. [Raines, Benjamin Todd] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Ponce, Brent A.] Univ Alabama Birmingham, Div Orthopaed Surg, Birmingham, AL USA. [Reed, Rhiannon D.; Richman, Joshua S.; Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Reed, Rhiannon D.; Richman, Joshua S.; Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL USA. RP Ponce, BA (reprint author), Orthopaed Specialties Bldg,1313 13th St South, Birmingham, AL USA. NR 36 TC 7 Z9 7 U1 2 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD AUG PY 2015 VL 30 IS 8 BP 1299 EP 1307 DI 10.1016/j.arth.2015.02.024 PG 9 WC Orthopedics SC Orthopedics GA CN0DN UT WOS:000358083400002 PM 25770864 ER PT J AU Schafer, AL Weaver, CM Black, DM Wheeler, AL Chang, HL Szefc, GV Stewart, L Rogers, SJ Carter, JT Posselt, AM Shoback, DM Sellmeyer, DE AF Schafer, Anne L. Weaver, Connie M. Black, Dennis M. Wheeler, Amber L. Chang, Hanling Szefc, Gina V. Stewart, Lygia Rogers, Stanley J. Carter, Jonathan T. Posselt, Andrew M. Shoback, Dolores M. Sellmeyer, Deborah E. TI Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization of Vitamin D Status SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE CALCIUM ABSORPTION; VITAMIN D; NUTRITION; BARIATRIC SURGERY; GASTRIC BYPASS SURGERY; BIOCHEMICAL MARKERS OF BONE TURNOVER ID BONE-MINERAL DENSITY; MORBIDLY OBESE-PATIENTS; BARIATRIC SURGERY; WEIGHT-LOSS; DIETARY CALCIUM; WOMEN; ASSOCIATION; VALIDATION; DEFICIENCY; INCREASES AB Roux-en-Y gastric bypass (RYGB) surgery has negative effects on bone, mediated in part by effects on nutrient absorption. Not only can RYGB result in vitamin D malabsorption, but the bypassed duodenum and proximal jejunum are also the predominant sites of active, transcellular, 1,25(OH)(2)D-mediated calcium (Ca) uptake. However, Ca absorption occurs throughout the intestine, and those who undergo RYGB might maintain sufficient Ca absorption, particularly if vitamin D status and Ca intake are robust. We determined the effects of RYGB on intestinal fractional Ca absorption (FCA) while maintaining ample 25OHD levels (goal 30ng/mL) and Ca intake (1200mg daily) in a prospective cohort of 33 obese adults (BMI 44.7 +/- 7.4kg/m(2)). FCA was measured preoperatively and 6 months postoperatively with a dual stable isotope method. Other measures included calciotropic hormones, bone turnover markers, and BMD by DXA and QCT. Mean 6-month weight loss was 32.5 +/- 8.4kg (25.8%+/- 5.2% of preoperative weight). FCA decreased from 32.7%+/- 14.0% preoperatively to 6.9%+/- 3.8% postoperatively (p<0.0001), despite median (interquartile range) 25OHD levels of 41.0 (33.1 to 48.5) and 36.5 (28.8 to 40.4) ng/mL, respectively. Consistent with the FCA decline, 24-hour urinary Ca decreased, PTH increased, and 1,25(OH)(2)D increased (p0.02). Bone turnover markers increased markedly, areal BMD decreased at the proximal femur, and volumetric BMD decreased at the spine (p<0.001). Those with lower postoperative FCA had greater increases in serum CTx (=-0.43, p=0.01). Declines in FCA and BMD were not correlated over the 6 months. In conclusion, FCA decreased dramatically after RYGB, even with most 25OHD levels 30ng/mL and with recommended Ca intake. RYGB patients may need high Ca intake to prevent perturbations in Ca homeostasis, although the approach to Ca supplementation needs further study. Decline in FCA could contribute to the decline in BMD after RYGB, and strategies to avoid long-term skeletal consequences should be investigated. (c) 2015 American Society for Bone and Mineral Research. C1 [Schafer, Anne L.; Wheeler, Amber L.; Chang, Hanling; Szefc, Gina V.; Shoback, Dolores M.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA 94158 USA. [Schafer, Anne L.; Wheeler, Amber L.; Chang, Hanling; Shoback, Dolores M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Weaver, Connie M.] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA. [Black, Dennis M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Stewart, Lygia; Rogers, Stanley J.; Carter, Jonathan T.; Posselt, Andrew M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Stewart, Lygia] San Francisco VA Med Ctr, Surg Serv, San Francisco, CA USA. [Sellmeyer, Deborah E.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. RP Schafer, AL (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA. EM anne.schafer@ucsf.edu OI Wheeler, Amber/0000-0002-9926-1301 FU US Department of Veterans Affairs, VHA, CSRD Service [2 5 IK2 CX000549-04]; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [UL1 TR000004]; NIH [5 K12 HD052163-15]; Endocrine Society FX This study was supported by the US Department of Veterans Affairs, VHA, CSR&D Service (Career Development Award-2 5 IK2 CX000549-04, to ALS, SFVAMC). Additional support was provided by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI grant UL1 TR000004, by NIH grant 5 K12 HD052163-15, and by an Endocrine Society Summer Research Fellowship. The contents of the article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Laboratory assay kits were provided by Immunodiagnostic Systems (IDS), and calcium citrate supplements were supplied by Bariatric Advantage. We thank Berdine Martin, PhD for her work in isotope ratio assessment; Barbara Arnold for study coordination and data collection; Viva Tai, RD, MPH for test meal preparation and DXA scan acquisition; Lisa Palermo, MA and Lucy Wu, MPH, for their work in data management; Nooshin Yashar, MD for study support; Saunak Sen, PhD for biostatistical advice; and Aldric Chau, Dimitry Petrenko, and Thomas Lang, PhD for CT image analysis. NR 45 TC 14 Z9 14 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD AUG PY 2015 VL 30 IS 8 BP 1377 EP 1385 DI 10.1002/jbmr.2467 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN1JL UT WOS:000358175500005 PM 25640580 ER PT J AU Swanson, CM Srikanth, P Lee, CG Cummings, SR Jans, I Cauley, JA Bouillon, R Vanderschueren, D Orwoll, ES Nielson, CM AF Swanson, Christine M. Srikanth, Priya Lee, Christine G. Cummings, Steven R. Jans, Ivo Cauley, Jane A. Bouillon, Roger Vanderschueren, Dirk Orwoll, Eric S. Nielson, Carrie M. CA Osteoporotic Fractures Men MrOS TI Associations of 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D With Bone Mineral Density, Bone Mineral Density Change, and Incident Nonvertebral Fracture SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE 1,25-DIHYDROXYVITAMIN D; CALCITRIOL; FRACTURE; BONE MINERAL DENSITY (BMD); 25-HYDROXYVITAMIN D ID VITAMIN-D DEFICIENCY; GROWTH-FACTOR 23; OSTEOPOROTIC FRACTURES; OLDER MEN; PARATHYROID-HORMONE; ELDERLY-MEN; HIP FRACTURE; SERUM; RISK; MROS AB Relationships between 1,25-dihydroxyvitamin D (1,25(OH)(2)D) and skeletal outcomes are uncertain. We examined the associations of 1,25(OH)(2)D with bone mineral density (BMD), BMD change, and incident non-vertebral fractures in a cohort of older men and compared them with those of 25-hydroxyvitamin D (25OHD). The study population included 1000 men (aged 74.6 +/- 6.2 years) in the Osteoporotic Fractures in Men (MrOS) study, of which 537 men had longitudinal dual-energy X-ray absorptiometry (DXA) data (4.5 years of follow-up). A case-cohort design and Cox proportional hazards models were used to test the association between vitamin D metabolite levels and incident nonvertebral and hip fractures. Linear regression models were used to estimate the association between vitamin D measures and baseline BMD and BMD change. Interactions between 25OHD and 1,25(OH)(2)D were tested for each outcome. Over an average follow-up of 5.1 years, 432 men experienced incident nonvertebral fractures, including 81 hip fractures. Higher 25OHD was associated with higher baseline BMD, slower BMD loss, and lower hip fracture risk. Conversely, men with higher 1,25(OH)(2)D had lower baseline BMD. 1,25(OH)(2)D was not associated with BMD loss or nonvertebral fracture. Compared with higher levels of calcitriol, the risk of hip fracture was higher in men with the lowest 1,25(OH)(2)D levels (8.70 to 51.60pg/mL) after adjustment for baseline hip BMD (hazard ratio [HR]=1.99, 95% confidence interval [CI] 1.19-3.33). Adjustment of 1,25(OH)(2)D data for 25OHD (and vice versa) had little effect on the associations observed but did attenuate the hip fracture association of both vitamin D metabolites. In older men, higher 1,25(OH)(2)D was associated with lower baseline BMD but was not related to the rate of bone loss or nonvertebral fracture risk. However, with BMD adjustment, a protective association for hip fracture was found with higher 1,25(OH)(2)D. The associations of 25OHD with skeletal outcomes were generally stronger than those for 1,25(OH)(2)D. These results do not support the hypothesis that measures of 1,25(OH)(2)D improve the ability to predict adverse skeletal outcomes when 25OHD measures are available. (c) 2015 American Society for Bone and Mineral Research. C1 [Swanson, Christine M.; Lee, Christine G.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Div Endocrinol, Portland, OR 97239 USA. [Swanson, Christine M.; Lee, Christine G.; Orwoll, Eric S.; Nielson, Carrie M.] Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97239 USA. [Srikanth, Priya; Nielson, Carrie M.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Lee, Christine G.] Portland VA Med Ctr, Res Serv, Portland, OR USA. [Cummings, Steven R.] Calif Pacific Med Res Inst, San Francisco, CA USA. [Jans, Ivo; Vanderschueren, Dirk] Univ Hosp Leuven, KU Leuven, Lab Diagnost Med, Leuven, Belgium. [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Bouillon, Roger; Vanderschueren, Dirk] Univ Hosp Leuven, KU Leuven, Lab Clin & Expt Endocrinol, Leuven, Belgium. RP Nielson, CM (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM Nielsoca@ohsu.edu RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU National Institutes of Health; National Institute on Aging (NIA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; Merck Co., Inc. [SRA-12-009]; National Institute of Diabetes and Digestive and Kidney Diseases [T32DK007674-20]; VA Clinical Science Research and Development (CSR&D) Career Development Award [5IK2CW000729-02] FX The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. This study was supported in part by an independent investigator grant (SRA-12-009) from Merck & Co., Inc. CMS is supported by the National Institute of Diabetes and Digestive and Kidney Diseases Grant T32DK007674-20. CGL receives support from a VA Clinical Science Research and Development (CSR&D) Career Development Award, project number 5IK2CW000729-02. NR 45 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD AUG PY 2015 VL 30 IS 8 BP 1403 EP 1413 DI 10.1002/jbmr.2487 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN1JL UT WOS:000358175500008 PM 25707402 ER PT J AU Lalama, CM Jennings, C Johnson, VA Coombs, RW McKinnon, JE Bremer, JW Cobb, BR Cloherty, GA Mellors, JW Ribaudo, HJ AF Lalama, Christina M. Jennings, Cheryl Johnson, Victoria A. Coombs, Robert W. McKinnon, John E. Bremer, James W. Cobb, Bryan R. Cloherty, Gavin A. Mellors, John W. Ribaudo, Heather J. CA AIDS Clin Trials Grp TI Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID VIRUS TYPE-1 RNA; INITIAL TREATMENT; VERSION 2.0; INFECTION; REGIMENS AB Discrepancies between HIV-1 RNA results assayed by different FDA-approved platforms have been reported. Plasma samples collected from 332 randomly selected clinical trial participants during the second year of antiretroviral treatment were assayed with three FDA-approved platforms: UltraSensitive Roche Amplicor Monitor, v1.5 (Monitor), the Abbott RealTime HIV-1 test on the m2000 system (Abbott), and the Roche TaqMan HIV-1 test, v2.0 (TaqMan). Samples from 61 additional participants with confirmed HIV-1 RNA levels of >50 copies/ml during trial follow-up were also included. Endpoints were HIV-1 RNA quantification of <= 50 copies/ml versus >50 copies/ml at an individual-sample level (primary) and determination of confirmed virologic failure (VF) from longitudinal samples. A total of 389 participants had results obtained from all assays on at least one sample (median = 6). Proportions of results of >50 copies/ml were 19% (Monitor), 22% (TaqMan), and 25% (Abbott). Despite indication of strong agreement (Cohen's kappa, 0.76 to 0.82), Abbott was more likely to detect HIV-1 RNA levels of >50 copies/ml than Monitor (matched-pair odds ratio [mOR] = 4.2; modified Obuchowski P < 0.001) and TaqMan (mOR = 2.1; P < 0.001); TaqMan was more likely than Monitor (mOR = 2.6; P < 0.001). Despite strong agreement in classifying VF across assay comparisons (kappa, 0.75 to 0.92), at a 50-copies/ml threshold, differences in the probability of VF classification (in the same direction as primary) were apparent (all McNemar's P < 0.007). At a 200-copies/ml VF threshold, no differences between assays were apparent (all P > 0.13). Despite strong agreement among assays, significant differences were observed with respect to detecting HIV-1 RNA levels of >50 copies/ml and identifying VF at the 50-copies/ml threshold. This has important implications for the definition of VF in clinical trials and clinical practice. C1 [Lalama, Christina M.; Ribaudo, Heather J.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Jennings, Cheryl; Bremer, James W.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Johnson, Victoria A.] Univ Alabama Birmingham, Birmingham, AL USA. [Coombs, Robert W.] Univ Washington, Seattle, WA 98195 USA. [McKinnon, John E.] Case Western Reserve Univ, Henry Ford Hosp, Dept Psychiat, Detroit, MI 48202 USA. [Cobb, Bryan R.] Roche Mol Syst, Pleasanton, CA USA. [Cloherty, Gavin A.] Abbott Mol, Des Plaines, IL USA. [Mellors, John W.] Univ Pittsburgh, Pittsburgh, PA USA. RP Lalama, CM (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. EM lalama@sdac.harvard.edu FU National Institute of Allergy and Infectious Diseases (NIAID) [UM1 AI068636, AI38858]; Statistical and Data Management Center of the AIDS Clinical Trials Group [UM1 AI068634, AI38855]; NIAID [HHSN272201200023C, HHSN266200500044C]; Abbott Molecular FX This project was supported by award numbers UM1 AI068636 and AI38858 from the National Institute of Allergy and Infectious Diseases (NIAID). This work was also supported by the Statistical and Data Management Center of the AIDS Clinical Trials Group (UM1 AI068634 and AI38855) and the Virology Quality Assurance Program (HHSN272201200023C and HHSN266200500044C) from NIAID.; V.A.J. has had Roche laboratory equipment with training support. R.W.C. has served on Roche and Abbott Molecular expert panels. J.E.M. has received grant funding from Abbott Molecular. B.R.C. is an employee of Roche Molecular Systems. G.A.C. is an employee of Abbott Molecular. J.W.M. is a consultant to Gilead Sciences and holds share options in RFS Pharmaceuticals. H.J.R. has served on a Roche expert panel. There are no other conflicts of interest to report. NR 16 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD AUG PY 2015 VL 53 IS 8 BP 2659 EP 2666 DI 10.1128/JCM.00801-15 PG 8 WC Microbiology SC Microbiology GA CN2YV UT WOS:000358290200035 PM 26063861 ER PT J AU Simonetti, JA Lapham, GT Williams, EC AF Simonetti, Joseph A. Lapham, Gwen T. Williams, Emily C. TI Association Between Receipt of Brief Alcohol Intervention and Quality of Care among Veteran Outpatients with Unhealthy Alcohol Use SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Alcoholism and addictive behavior; Quality assessment; Veterans; Patient satisfaction ID PRIMARY-HEALTH-CARE; BEHAVIORAL-COUNSELING INTERVENTIONS; SERVICES-TASK-FORCE; SCREENING SCORES; RECOMMENDATION STATEMENT; GENERAL-PRACTITIONERS; PHYSICIANS ATTITUDES; AFFAIRS OUTPATIENTS; PATIENT; CONSUMPTION AB Brief alcohol intervention, including advice to reduce or abstain from drinking, is widely recommended for general medical outpatients with unhealthy alcohol use, but it is challenging to implement. Among other implementation challenges, providers report reluctance to deliver such interventions, citing concerns about negatively affecting their patient relationships. The purpose of this study was to determine whether patient-reported receipt of brief intervention was associated with patient-reported indicators of high-quality care among veteran outpatients with unhealthy alcohol use. Cross-sectional secondary data analysis was performed using the Veterans Health Administration (VA) Survey of Healthcare Experiences of Patients (SHEP). The study included veteran outpatients who (1) responded to the outpatient long-form SHEP (2009-2011), (2) screened positive for unhealthy alcohol use (Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaire score a parts per thousand yen 3 for women, a parts per thousand yen 4 for men), and (3) responded to questions assessing receipt of brief intervention and quality of care. We used logistic regression models to estimate the adjusted predicted prevalence of reporting two indicators of high-quality care-patient ratings of their VA provider and of overall VA healthcare (range 0-10, dichotomized as a parts per thousand yen 9 indicating high quality)-for both patients who did and did not report receipt of brief intervention (receiving alcohol-related advice from a provider) within the previous year. Among 10,612 eligible veterans, 43.8 % reported having received brief intervention, and 84.2 % and 79.1 % rated their quality of care as high from their provider and the VA healthcare system, respectively. In adjusted analyses, compared to veterans who reported receiving no brief intervention, a higher proportion of veterans reporting receipt of brief intervention rated the quality of healthcare from their provider (86.9 % vs. 82.0 %, p < 0.01) and the VA overall (82.7 % vs. 75.9 %, p < 0.01) as high. In this cross-sectional analysis of veterans with unhealthy alcohol use, a higher proportion of those who reported receipt of brief intervention reported receiving high-quality care compared to those who reported having received no such intervention. These findings do not support provider concerns that delivering brief intervention adversely affects patients' perceptions of care. C1 [Simonetti, Joseph A.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. [Simonetti, Joseph A.; Lapham, Gwen T.; Williams, Emily C.] VA Hlth Serv Res & Dev, VA Puget Sound Healthcare Syst, Seattle Denver Ctr Innovat, Seattle, WA USA. [Simonetti, Joseph A.; Williams, Emily C.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Lapham, Gwen T.] Grp Hlth Res Inst, Seattle, WA USA. [Simonetti, Joseph A.] VA Puget Sound Healthcare Syst, Ctr Innovat Vet Ctr Value Driven Care, Seattle, WA USA. RP Simonetti, JA (reprint author), VA Hlth Serv Res Dev, VA Puget Sound Healthcare Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM simonja@uw.edu FU Ruth L. Kirschstein National Research Service Award [T32HP10002]; VA Health Services Research Development [CDA 12-276]; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI) FX During the preparation of this manuscript, Dr. Simonetti received fellowship support from the Ruth L. Kirschstein National Research Service Award (T32HP10002), administered by the Health Resources and Services Administration. Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276) and is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis, MO. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of any organization. Preliminary findings of this study were presented at the 2014 annual meeting of the Society of General Internal Medicine (San Diego, CA). NR 54 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2015 VL 30 IS 8 BP 1097 EP 1104 DI 10.1007/s11606-015-3218-5 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN3WR UT WOS:000358359400015 PM 25691238 ER PT J AU Williams, EC Achtmeyer, CE Thomas, RM Grossbard, JR Lapham, GT Chavez, LJ Ludman, EJ Berger, D Bradley, KA AF Williams, Emily C. Achtmeyer, Carol E. Thomas, Rachel M. Grossbard, Joel R. Lapham, Gwen T. Chavez, Laura J. Ludman, Evette J. Berger, Douglas Bradley, Katharine A. TI Factors Underlying Quality Problems with Alcohol Screening Prompted by a Clinical Reminder in Primary Care: A Multi-site Qualitative Study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE alcohol screening; qualitative; clinical reminders; quality ID IDENTIFICATION TEST AUDIT; HEALTH-SERVICES RESEARCH; DECISION-SUPPORT-SYSTEM; BRIEF INTERVENTION; IMPLEMENTATION STRATEGIES; PREVENTIVE SERVICES; USE DISORDERS; PERFORMANCE; SETTINGS; MISUSE AB Population-based alcohol screening is recommended in primary care, and increasingly incentivized by policies, yet is challenging to implement. The U.S. Veterans Health Administration (VA) achieved high rates of screening using a national performance measure and associated electronic clinical reminder to prompt and facilitate screening and document results. However, the sensitivity of alcohol screening for identifying unhealthy alcohol use is low in VA clinics. We aimed to understand factors that might contribute to low sensitivity of alcohol screening. This was an observational, qualitative study. Participants included clinical staff responsible for conducting alcohol screening and nine independently managed primary care clinics of a single VA medical center in the Northwestern U.S. Four researchers observed clinical staff as they conducted alcohol screening. Observers took handwritten notes, which were transcribed and coded iteratively. Template analysis identified a priori and emergent themes. We observed 72 instances of alcohol screening conducted by 31 participating staff. Observations confirmed known challenges to implementation of care using clinical reminders, including workflow and flexibility limitations. Three themes specific to alcohol screening emerged. First, most observed screening was conducted verbally, guided by the clinical reminder, although some variability in approaches to screening (e.g., paper-based or laminate-based screening) was observed. Second, specific verbal screening practices that might contribute to low sensitivity of clinical screening were identified, including conducting non-verbatim screening and making inferences, assumptions, and/or suggestions to input responses. Third, staff introduced and adapted screening questions to enhance patient comfort. This qualitative study in nine clinics found that implementation of alcohol screening facilitated by a clinical reminder resulted primarily in verbal screening in which questions were not asked vertbatim and were otherwise adapted. Non-verbal approaches to screening, or patient self-administration, may enhance validity and standardization of screening while simultaneously addressing limitations of the clinical reminder and issues related to perceived discomfort. C1 [Williams, Emily C.; Achtmeyer, Carol E.; Thomas, Rachel M.; Lapham, Gwen T.; Chavez, Laura J.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Hlth Serv Res & Dev HSR&D, Seattle, WA USA. [Achtmeyer, Carol E.; Berger, Douglas] VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA 98101 USA. [Grossbard, Joel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ C, Seattle, WA 98101 USA. [Berger, Douglas; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Chavez, Laura J.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Ludman, Evette J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lapham, Gwen T.; Ludman, Evette J.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM emily.williams3@va.gov FU VA Health Services Research Development; VA Quality Enhancement Research Initiative [RRP 09-178]; Career Development Award from VA Health Services Research Development [CDA 12-276]; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI); Agency for Healthcare Research and Quality (AHRQ) [NIH 1R36HS022800-01] FX This study was funded by VA Health Services Research & Development and VA Quality Enhancement Research Initiative (RRP 09-178). Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276), and is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). Dr. Bradley's time on this study was supported by the Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound. Ms. Chavez is supported by an Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH 1R36HS022800-01). NR 62 TC 15 Z9 15 U1 4 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2015 VL 30 IS 8 BP 1125 EP 1132 DI 10.1007/s11606-015-3248-z PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN3WR UT WOS:000358359400019 PM 25731916 ER PT J AU Shelton, JB Ochotorena, L Bennett, C Shekelle, P Kwan, L Skolarus, T Goldzweig, C AF Shelton, Jeremy B. Ochotorena, Lee Bennett, Carol Shekelle, Paul Kwan, Lorna Skolarus, Ted Goldzweig, Caroline TI Reducing PSA-Based Prostate Cancer Screening in Men Aged 75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE electronic health records; physician decision support; cancer screening; applied informatics; implementation research; quality improvement ID HEALTH INFORMATION-TECHNOLOGY; ORDER ENTRY; CARE; INTERVENTIONS; MORTALITY; ALERTS; PHYSICIANS; IMPLEMENT; BENEFITS; DELIVERY AB In 2012, the Veterans Health Administration (VHA) implemented guidelines seeking to reduce PSA-based screening for prostate cancer in men aged 75 years and older. To reduce the use of inappropriate PSA-based prostate cancer screening among men aged 75 and over. The Veterans Affairs Greater Los Angeles Healthcare System (VA GLA) We developed a highly specific computerized clinical decision support (CCDS) alert to remind providers, at the moment of PSA screening order entry, of the current guidelines and institutional policy. We implemented the tool in a prospective interrupted time series study design over 15 months, and compared the trends in monthly PSA screening rate at baseline to the CCDS on and off periods of the intervention. A total of 30,150 men were at risk, or eligible, for screening, and 2,001 men were screened. The mean monthly screening rate during the 15-month baseline period was 8.3 %, and during the 15-month intervention period, was 4.6 %. The screening rate declined by 38 % during the baseline period and by 40 % and 30 %, respectively, during the two periods when the CCDS tool was turned on. The screening rate ratios for the baseline and two periods when the CCDS tool was on were 0.97, 0.78, and 0.90, respectively, with a significant difference between baseline and the first CCDS-on period (p < 0.0001), and a trend toward a difference between baseline and the second CCDS-on period (p = 0.056). Implementation of a highly specific CCDS tool alone significantly reduced inappropriate PSA screening in men aged 75 years and older in a reproducible fashion. With this simple intervention, evidence-based guidelines were brought to bear at the point of care, precisely for the patients and providers for whom they were most helpful, resulting in more appropriate use of medical resources. C1 [Shelton, Jeremy B.; Ochotorena, Lee; Bennett, Carol; Shekelle, Paul; Goldzweig, Caroline] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shelton, Jeremy B.; Bennett, Carol; Kwan, Lorna] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Skolarus, Ted] Vet Adm Ann Arbor Healthcare Syst, Hlth Serv Res & Dev, Ann Arbor, MI USA. RP Shelton, JB (reprint author), Greater Los Angeles VA, Los Angeles, CA 90073 USA. EM jeremybshelton@gmail.com NR 34 TC 2 Z9 2 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2015 VL 30 IS 8 BP 1133 EP 1139 DI 10.1007/s11606-015-3249-y PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN3WR UT WOS:000358359400020 PM 25740462 ER PT J AU Gelber, SE Brent, E Redecha, P Perino, G Tomlinson, S Davisson, RL Salmon, JE AF Gelber, Shari E. Brent, Elyssa Redecha, Patricia Perino, Giorgio Tomlinson, Stephen Davisson, Robin L. Salmon, Jane E. TI Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency SO JOURNAL OF IMMUNOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; COLLAGEN-INDUCED ARTHRITIS; TNF-ALPHA; NEUTROPHIL ACTIVATION; GROWTH RESTRICTION; MOUSE MODEL; ANGIOGENIC FACTORS; TROPHOBLAST CELLS; FETAL INJURY; COMPLEMENT AB Defective placentation and subsequent placental insufficiency lead to maternal and fetal adverse pregnancy outcome, but their pathologic mechanisms are unclear, and treatment remains elusive. The mildly hypertensive BPH/5 mouse recapitulates many features of human adverse pregnancy outcome, with pregnancies characterized by fetal loss, growth restriction, abnormal placental development, and defects in maternal decidual arteries. Using this model, we show that recruitment of neutrophils triggered by complement activation at the maternal/fetal interface leads to elevation in local TNF-alpha levels, reduction of the essential angiogenic factor vascular endothelial growth factor, and, ultimately, abnormal placentation and fetal death. Blockade of complement with inhibitors specifically targeted to sites of complement activation, depletion of neutrophils, or blockade of TNF-alpha improves spiral artery remodeling and rescues pregnancies. These data underscore the importance of innate immune system activation in the pathogenesis of placental insufficiency and identify novel methods for treatment of pregnancy loss mediated by abnormal placentation. C1 [Gelber, Shari E.; Brent, Elyssa] Weill Cornell Med Ctr, Dept Obstet & Gynecol, New York, NY 10065 USA. [Redecha, Patricia; Salmon, Jane E.] Hosp Special Surg, Cornell Med Ctr, Dept Med, New York, NY 10021 USA. [Perino, Giorgio] Hosp Special Surg, Dept Pathol & Lab Med, New York, NY 10021 USA. [Tomlinson, Stephen] Med Univ S Carolina, Darby Childrens Res Inst, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Davisson, Robin L.] Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA. [Davisson, Robin L.] Weill Cornell Med Ctr, Dept Cell & Dev Biol, New York, NY 10065 USA. RP Salmon, JE (reprint author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. EM SalmonJ@hss.edu FU March of Dimes; National Institute of Child Health and Human Development [NIHK12HD000849]; Clinical and Translation Science Center at Weill Cornell Medical Center [UL1RR024996]; National Institutes of Health [R01 HL086576]; Veterans Affairs Grants [1I01RX001141, 5I01BX001218]; Qatar National Research Fund Grant [NPRP09-1099-279]; National Cancer Institute [P30 CA008748] FX This work was supported by the March of Dimes, National Institute of Child Health and Human Development Grant NIHK12HD000849, and Clinical and Translation Science Center at Weill Cornell Medical Center Grant UL1RR024996 (all to S.E.G.); by National Institutes of Health Grant R01 HL086576 and Veterans Affairs Grants 1I01RX001141 and 5I01BX001218 (all to S.T.); and by Qatar National Research Fund Grant NPRP09-1099-279 (to R.L.D.). Immunohistochemistry was performed at the Molecular Cytology Core Facility of Memorial Sloan Kettering Cancer Center, which is supported by National Cancer Institute Grant P30 CA008748. NR 62 TC 8 Z9 8 U1 0 U2 5 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD AUG 1 PY 2015 VL 195 IS 3 BP 1129 EP 1138 DI 10.4049/jimmunol.1402220 PG 10 WC Immunology SC Immunology GA CM9ZO UT WOS:000358070400042 PM 26071558 ER PT J AU Reyhan, M Wang, Z Li, M Kim, HJ Gupta, HS Lloyd, SG Dell'Italia, LJ Denney, T Ennis, DB AF Reyhan, Meral Wang, Zhe Li, Ming Kim, Hyun J. Gupta, Himanshu Lloyd, Steven G. Dell'Italia, Louis J. Denney, Thomas Ennis, Daniel B. TI Left ventricular twist and shear in patients with primary mitral regurgitation SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE mitral regurgitation; left ventricle; twist; shear; torsion ID CARDIOVASCULAR MAGNETIC-RESONANCE; CARDIAC-FUNCTION; TORSION; MECHANICS; IMAGES; MODEL AB PurposeTo evaluate the relationship between left ventricular (LV) twist, shear, and twist-per-volume and the severity of mitral regurgitation (MR). Primary MR is a valvular disorder that induces LV dysfunction. There exist several measures of LV rotational mechanics, but it remains unclear which measure of LV dysfunction best accords with the severity of MR. We hypothesized that LV systolic twist-per-volume slope would decrease with increasing severity of MR because of both decreases in rotational mechanics and increases in stroke volumes. Materials and MethodsNormal subjects (n=54), moderate MR patients (n=29), and severe MR patients (n=54) were studied. Magnetic resonance imaging (MRI) was performed on a 1.5T scanner and grid-tagged LV images were collected at the LV base and LV apex. Measures of LV rotational mechanics were derived from tagged images using Fourier Analysis of STimulated echoes (FAST). ResultsPeak systolic twist-per-volume slope was significantly different for all pairwise comparisons (P<0.0001) and compared to normal subjects (-0.140.05 degrees/mL) was decreased in moderate MR (-0.12 +/- 0.04 degrees/mL) and further decreased in severe MR (-0.07 +/- 0.03 degrees/mL). ConclusionPeak systolic twist-per-volume slope significantly decreased with increasing severity of MR and is therefore a suitable quantitative imaging biomarker for LV dysfunction in patients with MR. J. Magn. Reson. Imaging 2015;42:400-406. C1 [Reyhan, Meral; Ennis, Daniel B.] Univ Calif Los Angeles, Biomed Phys Interdept Program, Los Angeles, CA USA. [Reyhan, Meral; Wang, Zhe; Ennis, Daniel B.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA. [Wang, Zhe; Kim, Hyun J.; Ennis, Daniel B.] Univ Calif Los Angeles, Dept Radiol Sci, Los Angeles, CA USA. [Li, Ming; Denney, Thomas] Auburn Univ, Dept Elect & Comp Engn, Auburn, AL 36849 USA. [Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Birmingham, AL USA. [Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Ennis, DB (reprint author), 10945 LeConte Ave,Ste 1417, Los Angeles, CA 90095 USA. EM Daniel.Ennis@ucla.edu FU American Heart Association [AHA 11PRE6080005]; National Institutes of Health National Heart, Lung, and Blood Institute [NIH/NHLIB R00-HL087614, NIH/NHLIB grant P50-HL077100] FX Contract grant sponsor: American Heart Association and the National Institutes of Health National Heart, Lung, and Blood Institute; Contract grant numbers: AHA 11PRE6080005 (to M.R.), NIH/NHLIB R00-HL087614 (to D.E.), NIH/NHLIB grant P50-HL077100 (to T.D.). NR 23 TC 2 Z9 2 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-1807 EI 1522-2586 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD AUG PY 2015 VL 42 IS 2 BP 400 EP 406 DI 10.1002/jmri.24811 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CN2NM UT WOS:000358258600018 PM 25408263 ER PT J AU Krieg, TD Salinas, FS Narayana, S Fox, PT Mogul, DJ AF Krieg, Todd D. Salinas, Felipe S. Narayana, Shalini Fox, Peter T. Mogul, David J. TI Computational and experimental analysis of TMS-induced electric field vectors critical to neuronal activation SO JOURNAL OF NEURAL ENGINEERING LA English DT Article DE transcranial magnetic stimulation; PET; finite element modeling; neocortex ID TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; DORSOLATERAL PREFRONTAL CORTEX; SURFACE-BASED ANALYSIS; DESCENDING VOLLEYS; CONSCIOUS HUMANS; CEREBRAL-CORTEX; BRAIN; EXCITATION; NERVE AB Objective. Transcranial magnetic stimulation (TMS) represents a powerful technique to noninvasively modulate cortical neurophysiology in the brain. However, the relationship between the magnetic fields created by TMS coils and neuronal activation in the cortex is still not well-understood, making predictable cortical activation by TMS difficult to achieve. Our goal in this study was to investigate the relationship between induced electric fields and cortical activation measured by blood flow response. Particularly, we sought to discover the E-field characteristics that lead to cortical activation. Approach. Subject-specific finite element models (FEMs) of the head and brain were constructed for each of six subjects using magnetic resonance image scans. Positron emission tomography (PET) measured each subject's cortical response to image-guided robotically-positioned TMS to the primary motor cortex. FEM models that employed the given coil position, orientation, and stimulus intensity in experimental applications of TMS were used to calculate the electric field (E-field) vectors within a region of interest for each subject. TMS-induced E-fields were analyzed to better understand what vector components led to regional cerebral blood flow (CBF) responses recorded by PET. Main results. This study found that decomposing the E-field into orthogonal vector components based on the cortical surface geometry (and hence, cortical neuron directions) led to significant differences between the regions of cortex that were active and nonactive. Specifically, active regions had significantly higher E-field components in the normal inward direction (i.e., parallel to pyramidal neurons in the dendrite-to-axon orientation) and in the tangential direction (i.e., parallel to interneurons) at high gradient. In contrast, nonactive regions had higher E-field vectors in the outward normal direction suggesting inhibitory responses. Significance. These results provide critical new understanding of the factors by which TMS induces cortical activation necessary for predictive and repeatable use of this noninvasive stimulation modality. C1 [Krieg, Todd D.; Mogul, David J.] IIT, Dept Biomed Engn, Chicago, IL 60616 USA. [Salinas, Felipe S.; Narayana, Shalini; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Narayana, Shalini] Univ Tennessee Hlth Sci Ctr, Dept Pediat, Memphis, TN USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Krieg, TD (reprint author), IIT, Dept Biomed Engn, Chicago, IL 60616 USA. EM mogul@iit.edu NR 53 TC 5 Z9 5 U1 6 U2 13 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 EI 1741-2552 J9 J NEURAL ENG JI J. Neural Eng. PD AUG PY 2015 VL 12 IS 4 AR 046014 DI 10.1088/1741-2560/12/4/046014 PG 11 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA CN1KM UT WOS:000358178900016 PM 26052136 ER PT J AU Wang, XY Pierre, JF Heneghan, AF Busch, RA Kudsk, KA AF Wang, Xinying Pierre, Joseph F. Heneghan, Aaron F. Busch, Rebecca A. Kudsk, Kenneth A. TI Glutamine Improves Innate Immunity and Prevents Bacterial Enteroinvasion During Parenteral Nutrition SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE parenteral nutrition; glutamine; innate immunity; intestinal mucosa; lysozyme; cryptdin 4 ID RESPIRATORY-TRACT IMMUNITY; SMALL-INTESTINE; LYMPHOID-TISSUE; ESCHERICHIA-COLI; MUCOSAL IMMUNITY; GENE-EXPRESSION; MICE; DEFENSINS; SUPPLEMENTATION; PRESERVES AB Background: Patients receiving parenteral nutrition (PN) are at increased risk of infectious complications compared with enteral feeding, which is in part explained by impaired mucosal immune function during PN. Adding glutamine (GLN) to PN has improved outcome in some clinical patient groups. Although GLN improves acquired mucosal immunity, its effect on innate mucosal immunity (defensins, mucus, lysozymes) has not been investigated. Methods: Forty-eight hours following venous cannulation, male Institute of Cancer Research mice were randomized to chow (n = 10), PN (n = 12), or PN + GLN (n = 13) for 5 days. Small intestine tissue and luminal fluid were collected for mucin 2 (MUC2), lysozyme, cryptdin 4 analysis, and luminal interleukin (IL)-4, IL-10, and IL-13 level measurement. Tissue was also harvested for ex vivo intestinal segment culture to assess tissue susceptibility to enteroinvasive Escherichia coli. Results: In both luminal and tissue samples, PN reduced MUC2 and lysozyme (P < .0001, respectively) compared with chow, whereas GLN addition increased MUC2 and lysozyme (luminal, P < .05; tissue, P < .0001, respectively) compared with PN alone. PN significantly suppressed cryptdin 4 expression, while GLN supplementation significantly enhanced expression. IL-4, IL-10, and IL-13 decreased significantly with PN compared with chow, whereas GLN significantly increased these cytokines compared with PN. Functionally, bacterial invasion increased with PN compared with chow (P < .05), while GLN significantly decreased enteroinvasion to chow levels (P < .05). Conclusions: GLN-supplemented PN improves innate immunity and resistance to bacterial mucosal invasion lost with PN alone. This work confirms a clinical rationale for providing glutamine for the protection of the intestinal mucosa. C1 [Wang, Xinying; Pierre, Joseph F.; Heneghan, Aaron F.; Busch, Rebecca A.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Wang, Xinying] Nanjing Univ, Dept Surg, Jinling Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China. [Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Clin Sci Ctr G5 341, 600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX001672]; NIH Surgical Oncology Research Training Program [T32CA090217-13] FX The project described was supported by Award Number I01BX001672 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development and by NIH Surgical Oncology Research Training Program T32CA090217-13. The contents of this article do not represent the views of the Veterans Affairs or the United States government. NR 46 TC 4 Z9 8 U1 1 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD AUG PY 2015 VL 39 IS 6 BP 688 EP 697 DI 10.1177/0148607114535265 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CN5DM UT WOS:000358450000008 PM 24836948 ER PT J AU Kougias, P Collins, R Pastorek, N Sharath, S Barshes, NR McCulloch, K Pisimisis, G Berger, DH AF Kougias, Panos Collins, Robert Pastorek, Nicholas Sharath, Sherene Barshes, Neal R. McCulloch, Katie Pisimisis, George Berger, David H. TI Comparison of domain-specific cognitive function after carotid endarterectomy and stenting SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT Vascular Annual Meeting of the Society-for-Vascular-Surgery / Spring Meeting of the Vascular-and-Endovascular-Surgery-Society CY JUN 04-07, 2014 CL Boston, MA SP Soc Vasc Surg, Vasc & Endovascular Surg Soc ID HIGH-RISK PATIENTS; ARTERY STENOSIS; SURGERY; PERFORMANCE; DECLINE; ANGIOPLASTY; DEMENTIA; BRAIN AB Background: Observational data indicate that carotid artery stenting (CAS) is associated with higher incidence of subclinical cerebral microemboli than carotid endarterectomy (CEA). We hypothesized that CEA would be associated with superior performance on detailed domain-specific cognitive testing compared with CAS. Methods: Patients with >80% asymptomatic carotid artery stenosis were randomized to CEA or CAS with side of stenosis balanced across condition. A robust battery of tests was used to assess the cognitive domains of attention, memory, mood, visual-spatial skills, motor ability, processing speed, and executive functioning <= 10 days preoperatively and postoperatively at 6 weeks and 6 months. Tests were administered using standardized conditions and were scored by individuals blinded to treatment allocation. Results: Baseline cognitive performance was similar between CAS (n=29) and CEA (n=31) groups (P > .05). Relative to baseline, verbal and visual memory and attention functions substantially improved in the CAS and CEA groups at 6 months (multiple cognitive tests achieved statistical significance). Compared with CEA, cognitive processing speed (Stroop Color test: 9.0 vs 7.3, P = .04; and Stroop Word test: 9.0 vs 7.4, P = .05) was superior in the CAS group at 6 weeks. Executive functioning (phonemic verbal fluency: 10.6 vs 8.4, P = .043) and motor function (Grooved Pegboard of nondominant extremity: 45.7 vs 38.9, P = .022) were also superior in the CAS group at 6 months. Tests of attention, memory, and visual-spatial skills were similar between CAS and CEA patients at 6 weeks and 6 months. Conclusions: Carotid revascularization improves memory and attention within the first 6 postoperative months. Compared with CEA, CAS produces improvements in cognitive processing speed, executive functioning, and motor function. C1 [Kougias, Panos; Collins, Robert; Pastorek, Nicholas; Sharath, Sherene; Barshes, Neal R.; Pisimisis, George; Berger, David H.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Kougias, Panos; Barshes, Neal R.; Pisimisis, George] Baylor Coll Med, Div Vasc Surg, Houston, TX 77030 USA. [Collins, Robert] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Pastorek, Nicholas] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Berger, David H.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. [McCulloch, Katie] Univ Houston, Dept Psychol, Houston, TX 77004 USA. RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM pkougias@bcm.edu NR 25 TC 4 Z9 4 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD AUG PY 2015 VL 62 IS 2 BP 355 EP 361 DI 10.1016/j.jvs.2015.02.057 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CN4WT UT WOS:000358431900014 PM 26211378 ER PT J AU Azarbal, AF Harris, S Mitchell, EL Liem, TK Landry, GJ McLafferty, RB Edwards, J Moneta, GL AF Azarbal, Amir F. Harris, Sheena Mitchell, Erica L. Liem, Timothy K. Landry, Gregory J. McLafferty, Robert B. Edwards, James Moneta, Greg L. TI Nasal methicillin-resistant Staphylococcus aureus colonization is associated with increased wound occurrence after major lower extremity amputation SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID LOWER-LIMB AMPUTATION; RISK-FACTORS; ANTIBIOTIC-PROPHYLAXIS; SURGICAL AMPUTATIONS; MUPIROCIN OINTMENT; EARLY FAILURE; INFECTION; ERADICATION; CARRIAGE; DECOLONIZATION AB Objective: Wound occurrence (WO) after major lower extremity amputation (MLEA) can be due to wound infection or sterile dehiscence. We sought to determine the association of nasal methicillin-resistant Staphylococcus aureus (MRSA) colonization and other patient factors with overall WO, WO due to wound infection, and WO due to sterile dehiscence. Methods: The medical records of all patients undergoing MLEA from August 1, 2011, to November 1, 2013, were reviewed. Demographic data, hemoglobin A1c level, albumin concentration, dialysis dependence, peripheral vascular disease (PVD), nasal MRSA colonization, and diabetes mellitus (DM) were examined as variables. The overall WO rate was determined, and the cause of WO was categorized as either a sterile dehiscence or a wound infection. Results: Eighty-three patients underwent 96 MLEAs during a 27-month period. The rates of overall WO, WO due to infection, and WO due to sterile dehiscence were 39%, 19%, and 19%, respectively (1% developed a traumatic wound). On univariate analysis, PVD, MRSA colonization, DM, and dialysis dependence were all associated with higher rates of overall WO (P < .05). On multivariate analysis, MRSA colonization was associated with higher rates of overall WO (P =.03) and WO due to wound infection (11% vs 45%; P < .01). DM and PVD were associated with higher rates of overall WO and WO due to sterile dehiscence on both univariate and multivariate analysis (P < .05). Conclusions: Nasal MRSA colonization is associated with higher rates of overall WO and WO due to wound infection. DM and PVD are associated with higher rates of overall WO and WO due to sterile dehiscence but are not associated with WO due to wound infection. Further studies addressing the effect of nasal MRSA eradication on postoperative wound outcomes after MLEA are warranted. C1 [Azarbal, Amir F.; Harris, Sheena; Mitchell, Erica L.; Liem, Timothy K.; Landry, Gregory J.; McLafferty, Robert B.; Edwards, James; Moneta, Greg L.] Oregon Hlth & Sci Univ, Div Vasc Surg, Dept Surg, Portland, OR 97201 USA. [Azarbal, Amir F.; Mitchell, Erica L.; Liem, Timothy K.; Landry, Gregory J.; McLafferty, Robert B.; Edwards, James; Moneta, Greg L.] Portland VA Med Ctr, Operat Care Div, Portland, OR USA. RP Azarbal, AF (reprint author), Mail Code OP-11,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM azarbala@ohsu.edu NR 22 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD AUG PY 2015 VL 62 IS 2 BP 401 EP 405 DI 10.1016/j.jvs.2015.02.052 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CN4WT UT WOS:000358431900023 PM 25935268 ER PT J AU Wang, TY McElroy, A Halaney, D Vela, D Fung, E Hossain, S Phipps, J Wang, BQ Yin, BW Feldman, MD Milner, TE AF Wang, Tianyi McElroy, Austin Halaney, David Vela, Deborah Fung, Edmund Hossain, Shafat Phipps, Jennifer Wang, Bingqing Yin, Biwei Feldman, Marc D. Milner, Thomas E. TI Detection of plaque structure and composition using OCT combined with two-photon luminescence (TPL) imaging SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE atherosclerotic plaque; lipid; oxidized-LDL; calcium; collagen; elastin fiber; hybrid imaging; optical coherence tomography; two-photon luminescence imaging; photonic crystal fiber ID OPTICAL COHERENCE TOMOGRAPHY; THIN-CAP FIBROATHEROMA; CORONARY-ARTERY; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC LESIONS; RUPTURED PLAQUES; VIVO VALIDATION; FREQUENCY; MICROSCOPY; CELL AB Background and ObjectivesAtherosclerosis and plaque rupture leads to myocardial infarction and stroke. A novel hybrid optical coherence tomography (OCT) and two-photon luminescence (TPL) fiber-based imaging system was developed to characterize tissue constituents in the context of plaque morphology. Study Design/Materials and MethodsEx vivo coronary arteries (34 regions of interest) from three human hearts with atherosclerotic plaques were examined by OCT-TPL imaging. Histological sections (4m in thickness) were stained with Oil Red O for lipid, Von Kossa for calcium, and Verhoeff-Masson Tri-Elastic for collagen/elastin fibers and compared with imaging results. ResultsBiochemical components in plaques including lipid, oxidized-LDL, and calcium, as well as a non-tissue component (metal) are distinguished by multi-channel TPL images with statistical significance (P<0.001). TPL imaging provides complementary optical contrast to OCT (two-photon absorption/emission vs scattering). Merged OCT-TPL images demonstrate the distribution of lipid deposits in registration with detailed plaque surface profile. ConclusionsResults suggest that multi-channel TPL imaging can effectively identify lipid sub-types and different plaque components. Furthermore, fiber-based hybrid OCT-TPL imaging simultaneously detects plaque structure and composition, improving the efficacy of vulnerable plaque detection and characterization. Lasers Surg. Med. 47:485-494, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Wang, Tianyi; McElroy, Austin; Fung, Edmund; Hossain, Shafat; Wang, Bingqing; Yin, Biwei; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Halaney, David; Phipps, Jennifer; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Halaney, David; Feldman, Marc D.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Vela, Deborah] Texas Heart Inst, Houston, TX 77025 USA. RP Wang, TY (reprint author), Dept Biomed Engn, 1 Univ Stn C0800, Austin, TX 78712 USA. EM Tianyi.Wang@utexas.edu OI Halaney, David/0000-0003-4437-0516 FU ASLMS Research Grant; Veterans Health Administration Merit Grant [I01 BX000397]; American Heart Association Grant [13POST17080074]; Clayton Foundation for Biomedical Research; University of Texas FX Contract grant sponsor: ASLMS Research Grant; Contract grant sponsor: Veterans Health Administration Merit Grant; Contract grant number: I01 BX000397; Contract grant sponsor: American Heart Association Grant; Contract grant number: 13POST17080074; Contract grant sponsor: Clayton Foundation for Biomedical Research; Contract grant sponsor: University of Texas. NR 49 TC 1 Z9 1 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD AUG PY 2015 VL 47 IS 6 BP 485 EP 494 DI 10.1002/lsm.22366 PG 10 WC Dermatology; Surgery SC Dermatology; Surgery GA CN4CF UT WOS:000358375800005 PM 26018531 ER PT J AU Denneson, LM Teo, AR Ganzini, L Helmer, DA Bair, MJ Dobscha, SK AF Denneson, Lauren M. Teo, Alan R. Ganzini, Linda Helmer, Drew A. Bair, Matthew J. Dobscha, Steven K. TI Military Veterans' Experiences with Suicidal Ideation: Implications for Intervention and Prevention SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID OEF/OIF VETERANS; CARE; IRAQ; DECEDENTS; MORTALITY; CULTURE; OREGON; SYSTEM; LIFE AB We sought to understand Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans' experiences with suicidal ideation. Semi-structured interviews with 34 OEF/OIF veterans addressed circumstances leading up to disclosure of suicidal ideation during brief clinical assessments. We used an iterative, inductive and deductive thematic analysis approach. Results revealed three pervasive, persistent domains that reinforce the uniqueness of veteran suicidal thoughts: military culture, difficult deployment experiences, and postdeployment adjustment challenges. Within postdeployment, we identified four themes that serve as intervention targets: adjusting to civilian culture, changes to sense of self, feeling overwhelmed by stressors, and lacking life purpose or meaning. C1 [Denneson, Lauren M.; Teo, Alan R.; Ganzini, Linda; Dobscha, Steven K.] Portland VA Med Ctr, Portland CIVIC, Portland, OR 97207 USA. [Denneson, Lauren M.; Teo, Alan R.; Ganzini, Linda; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Helmer, Drew A.] VA New Jersey Hlth Care Syst, War Related Illness & Injury Study Ctr, E Orange, NJ USA. [Helmer, Drew A.] Rutgers State Univ, New Jersey Med Sch, Dept Med, Newark, NJ 07102 USA. [Bair, Matthew J.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA. RP Denneson, LM (reprint author), Portland VA Med Ctr, POB 1034 R&D66, Portland, OR 97207 USA. EM lauren.denneson@va.gov FU Department of Veterans Affairs, Veterans Health Administration and Health Services Research and Development Service [DHI-08-096] FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service Project DHI-08-096. Dr. Denneson is a core investigator in the Center to Improve Veteran Involvement in Care (CIVIC) at the Portland VA Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. Government. We gratefully acknowledge Monica Huffman, MA, for assisting with conducting interviews and Megan Crutchfield, MPH, for participant recruitment. NR 34 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD AUG PY 2015 VL 45 IS 4 BP 399 EP 414 DI 10.1111/sltb.12136 PG 16 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CN2KY UT WOS:000358251100002 PM 25367753 ER PT J AU Jensen, ET Shah, ND Hoffman, K Sonnenberg, A Genta, RM Dellon, ES AF Jensen, E. T. Shah, N. D. Hoffman, K. Sonnenberg, A. Genta, R. M. Dellon, E. S. TI Seasonal variation in detection of oesophageal eosinophilia and eosinophilic oesophagitis SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID INCREASING INCIDENCE; PATHOLOGY DATABASE; ELIMINATION DIET; UNITED-STATES; CHILDREN; ADULTS; EPIDEMIOLOGY; PREVALENCE; AEROALLERGENS; MANAGEMENT AB BackgroundSeasonal variation has been reported in diagnosis of eosinophilic oesophagitis (EoE), but results are not consistent across studies and there are no national-level data in the USA. AimTo determine if there is seasonal variation in diagnosis of oesophageal eosinophilia and EoE in the USA, while accounting for factors such as climate zone and geographic variation. MethodsThis was a cross-sectional study using a USA national pathology database. Patients with oesophageal eosinophilia (15 eosinophils per high-power field) comprised the primary case definition and were compared to those with normal oesophageal biopsies. We calculated the crude and adjusted odds of oesophageal eosinophilia by season, as well as by day of the year. Sensitivity analyses were performed using more restrictive case definitions of EoE, and after stratification by climate zone. ResultsExactly, 14524 cases with oesophageal eosinophilia and 90459 normal controls were analysed. The adjusted odds of oesophageal eosinophilia were higher in the late spring and summer months, with the highest odds in July (aOR: 1.13; 95% CI: 1.03-1.24). These findings persisted with increasing levels of oesophageal eosinophilia, as well as across EoE case definitions. Seasonal variation was strongest in temperate and cold climates, and peak diagnosis varied by climate zone. ConclusionsThere is a mild but consistent seasonal variation in the diagnosis of oesophageal eosinophilia and EoE, with cases more frequently diagnosed during summer months. These findings take into account climate and geographic differences, suggesting that aeroallergens may contribute to disease development or flare. C1 [Jensen, E. T.; Shah, N. D.; Dellon, E. S.] Univ North Carolina Sch Med, Div Gastroenterol & Hepatol, Dept Med, Ctr Esophageal Dis & Swallowing, Chapel Hill, NC USA. [Jensen, E. T.] Univ North Carolina Sch Med, Div Gastroenterol & Hepatol, Dept Med, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA. [Hoffman, K.; Dellon, E. S.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Hoffman, K.] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA. [Sonnenberg, A.] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Genta, R. M.] Miraca Life Sci Res Inst, Irving, TX USA. [Genta, R. M.] Univ Texas SW Med Ctr Dallas, Dallas Vet Affairs Med Ctr, Dallas, TX 75390 USA. RP Dellon, ES (reprint author), UNC CH, CB 7080,Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27599 USA. EM edellon@med.unc.edu RI Jensen, Elizabeth/L-1466-2016 FU NIH [K23DK090073] FX Declaration of funding interests: This research was conducted with support, in part, by NIH award K23DK090073 (ESD). NR 39 TC 9 Z9 10 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD AUG PY 2015 VL 42 IS 4 BP 461 EP 469 DI 10.1111/apt.13273 PG 9 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA CM7TU UT WOS:000357900200007 PM 26059636 ER PT J AU Saez, JC Cisterna, BA Vargas, A Cardozo, CP AF Saez, Juan C. Cisterna, Bruno A. Vargas, Anibal Cardozo, Christopher P. TI Regulation of pannexin and connexin channels and their functional role in skeletal muscles SO CELLULAR AND MOLECULAR LIFE SCIENCES LA English DT Review DE Pannexons; Connexons; Myoblasts; Myotubes; Striate muscles; Myogenesis; Denervation ID GAP-JUNCTION PROTEINS; MYOBLAST DIFFERENTIATION; PHARMACOLOGICAL-PROPERTIES; CELLS; ATP; HEMICHANNELS; EXPRESSION; MYOGENESIS; ACTIVATION; RECEPTORS AB Myogenic precursor cells express connexins (Cx) and pannexins (Panx), proteins that form different membrane channels involved in cell-cell communication. Cx channels connect either the cytoplasm of adjacent cells, called gap junction channels (GJC), or link the cytoplasm with the extracellular space, termed hemichannels (HC), while Panx channels only support the latter. In myoblasts, Panx1 HCs play a critical role in myogenic differentiation, and Cx GJCs and possibly Cx HCs coordinate metabolic responses during later steps of myogenesis. After innervation, myofibers do not express Cxs, but still express Panx1. In myotubes and innervated myofibers, Panx1 HCs allow release of adenosine triphosphate and thus they might be involved in skeletal muscle plasticity. In addition, Panx1 HCs present in adult myofibers mediate adenosine triphosphate release and glucose uptake required for potentiation of muscle contraction. Under pathological conditions, such as upon denervation and spinal cord injury, levels of Panx1 are upregulated. However, Panx1(-/-) mice show similar degree of atrophy as denervated wild-type muscles. Skeletal muscles also express Cx HCs in the sarcolemma after denervation or spinal cord injury, plus other non-selective membrane channels, including purinergic P2X7 receptors and transient receptor potential type V2 channels. The absence of Cx43 and Cx45 is sufficient to drastically reduce denervation atrophy. Moreover, inflammatory cytokines also induce the expression of Cxs in myofibers, suggesting the expression of these Cxs as a common factor for myofiber degeneration under diverse pathological conditions. Inhibitors of skeletal muscle Cx HCs could be promising tools to prevent muscle wasting induced by conditions associated with synaptic dysfunction and inflammation. C1 [Saez, Juan C.; Cisterna, Bruno A.; Vargas, Anibal] Pontificia Univ Catolica Chile, Dept Fisiol, Santiago, Chile. [Saez, Juan C.; Cisterna, Bruno A.; Vargas, Anibal] Univ Valparaiso, Inst Milenio, Ctr Interdisciplinario Neurociencias Valparaiso, Valparaiso, Chile. [Cardozo, Christopher P.] James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10039 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10039 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10039 USA. RP Saez, JC (reprint author), Pontificia Univ Catolica Chile, Dept Fisiol, Alameda 340, Santiago, Chile. EM jsaez@bio.puc.cl FU FONDECYT [1150291]; ICM-Economia Centro Interdisciplinario de Neurociencias de Valparaiso [P09-022-F]; Department of Veterans Affairs Rehabilitation Research and Development Service [B9212C]; James J. Peters VA Medical Center; CONICYT FX This work was partially funded by FONDECYT grants 1150291 (to Juan C. Saez), ICM-Economia P09-022-F Centro Interdisciplinario de Neurociencias de Valparaiso (to Juan C. Saez) and the Department of Veterans Affairs Rehabilitation Research and Development Service (B9212C) and the James J. Peters VA Medical Center. Bruno A. Cisterna and Anibal Vargas acknowledge the support of a CONICYT fellowship. NR 47 TC 1 Z9 2 U1 2 U2 6 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1420-682X EI 1420-9071 J9 CELL MOL LIFE SCI JI Cell. Mol. Life Sci. PD AUG PY 2015 VL 72 IS 15 BP 2929 EP 2935 DI 10.1007/s00018-015-1968-1 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CN0FD UT WOS:000358088600011 PM 26084874 ER PT J AU Graff, JN Beer, TM Liu, B Sonpavde, G Taioli, E AF Graff, Julie N. Beer, Tomasz M. Liu, Bian Sonpavde, Guru Taioli, Emanuela TI Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients SO CLINICAL GENITOURINARY CANCER LA English DT Article DE Epidemiological methods; Outcome; Prognostic markers; Systemic inflammation; Urological cancer ID SYSTEMIC INFLAMMATORY RESPONSE; PREDICTING SURVIVAL; METAANALYSIS; ASSOCIATION; RESECTION; ADENOCARCINOMA; HETEROGENEITY; STATISTICS; THERAPY; COHORT AB This was a pooled analysis of studies on C-reactive protein (CRP) and prostate cancer mortality. Two hundred thirty-five patients were included. CRP was significantly associated with mortality; the best predictor cutoff was CRP < 12 mg/L. CRP is a routine assay that could be tested at diagnosis to improve prognostication of prostate cancer patients. Introduction: Previous studies have reported that higher C-reactive protein (CRP) levels are significantly associated with worse outcome in prostate cancer patients. The size of each individual study was not large enough to allow sufficient statistical power to draw conclusions. We conducted a pooled analysis of individual data of published studies to evaluate the association between increased CRP level and risk of death in prostate cancer, and to find the best CRP cutoff that could predict mortality. Materials and Methods: Original research studies on prostate cancer survival and CRP levels were identified (n = 6). Corresponding authors were contacted and invited to share individual data. Two data sets were received (235 patients). The combined hazard ratio (HR) was calculated and adjusted for age, prostate-specific antigen, hemoglobin, and alkaline phosphatase. The best cutoff of CRP was explored using X-title software version 3.6.1. Results: High CRP level was statistically significantly associated with mortality (meta-HR, 1.83 [95% confidence interval (CI), 1.51-2.21]), without evidence of heterogeneity among studies. At pooled analysis, adjusted pooled HR for CRP < 5 versus > 5 mg/L was 1.44 (95% CI, 1.02-20.4). The best CRP cutoff was 12 mg/ L: the adjusted HRpooled for CRP < 12 versus >= 12 mg/L was 1.53 (95% CI, 1.01-2.32). Conclusion: Increased CRP levels are associated with overall survival in prostate cancer patients. Because CRP is an affordable and readily available assay, it might hold promise in improving prognostication and potentially to predict the activity of specific therapeutic agents. C1 [Graff, Julie N.] Portland VA Med Ctr, Portland, OR USA. [Graff, Julie N.; Beer, Tomasz M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Liu, Bian; Taioli, Emanuela] Hofstra North Shore LIJ Sch Med, Manhasset, NY 11021 USA. [Sonpavde, Guru] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. RP Taioli, E (reprint author), Hofstra North Shore LIJ Sch Med, 175 Community Dr,Rm 203, Manhasset, NY 11021 USA. EM taiolema@gmail.com FU DOD [PC120302]; NIH [U01 OH010396] FX This work was partially supported by DOD PC120302 and NIH U01 OH010396 to E.T. NR 31 TC 2 Z9 2 U1 0 U2 2 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1558-7673 EI 1938-0682 J9 CLIN GENITOURIN CANC JI Clin. Genitourin. Cancer PD AUG PY 2015 VL 13 IS 4 BP E217 EP E221 DI 10.1016/j.clgc.2015.01.011 PG 5 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA CM7NF UT WOS:000357880000004 PM 25735198 ER PT J AU Genta, RM Sonnenberg, A AF Genta, Robert M. Sonnenberg, Amnon TI The yield of colonic biopsy in the evaluation of chronic unexplained diarrhea SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE adenomatous polyps; colon biopsy; histopathology of the intestine; inflammatory bowel disease; microscopic colitis ID HELICOBACTER-PYLORI; ESOPHAGEAL EOSINOPHILIA; PATHOLOGY DATABASE; COLONOSCOPY; RISK AB Background and aimsIn clinical practice, colonoscopy is widely used for the workup of chronic unexplained diarrhea. The aim of this study was to determine the yield of colonic biopsy in such an endeavor.MethodsIn a computerized database of 130204 patients evaluated for chronic diarrhea, we tested the influence of biopsy site, number of tissue fragments, patient symptoms, and indication on the outcome of histopathologic evaluation.ResultsThe population comprised 69% women and 31% men aged (meanSD) 52.8 +/- 17.4 years. In 19% of patients, histopathological analysis revealed various types of mucosal lesion, the most common being microscopic colitis (8.6%), ulcerative colitis (2.2%), Crohn's disease (0.6%), active colitis (5.0%), diverticulitis (0.1%), and colonic ischemia (0.5%). In 29% of patients, the colonoscopy also revealed the presence of colon polyps. Endoscopists tended to take significantly more tissue samples from endoscopically visible lesions than for random biopsies of macroscopically normal-appearing mucosa.ConclusionOverall, these associations suggest that specific diagnoses lead to more biopsies, rather than more biopsies leading to more diagnoses. Colonoscopy is a successful tool in the workup of chronic diarrhea, yielding a definitive diagnosis in almost one-fifth of all patients. As an added benefit, it also contributes to cancer prevention through the incidental findings of colonic neoplasm. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Genta, Robert M.] Miraca Life Sci, Irving, TX USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 11 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0954-691X EI 1473-5687 J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD AUG PY 2015 VL 27 IS 8 BP 963 EP 967 DI 10.1097/MEG.0000000000000365 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CM4HZ UT WOS:000357646700014 PM 26114907 ER PT J AU Rogus-Pulia, NM Pierce, M Mittal, BB Zecker, SG Logemann, J AF Rogus-Pulia, Nicole M. Pierce, Margaret Mittal, Bharat B. Zecker, Steven G. Logemann, Jeri TI Bolus effects on patient awareness of swallowing difficulty and swallow physiology after chemoradiation for head and neck cancer SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE dysphagia; chemoradiation; head and neck cancer; perception; bolus; volume; consistency ID UPPER ESOPHAGEAL SPHINCTER; ORAL-CANCER; OROPHARYNGEAL CANCER; TONGUE STRENGTH; PHARYNGEAL; DYSPHAGIA; VOLUME; RADIOTHERAPY; VARIABLES; AGE AB BackgroundPatients treated for head and neck cancer frequently develop dysphagia. Bolus characteristics are altered during fluoroscopic swallowing studies to observe the impact on swallowing function. The purpose of this study was to determine bolus volume and consistency effects on oropharyngeal swallowing physiology and patient awareness of swallowing difficulty. MethodsTwenty-one patients with head and neck cancer were assessed pre-chemoradiation and post-chemoradiation. The Modified Barium Swallow Study (MBSS) was utilized to examine swallow physiology. Each patient provided perceptual ratings of swallowing difficulty after each swallow of varying bolus types. ResultsOral transit times were significantly longer with pudding boluses. There were trends for higher residue percentages as well as perceptual ratings for pudding and cookie boluses. One correlation between perceptual ratings and physiology was significant. ConclusionPatient awareness of swallowing difficulty and aspects of swallowing physiology vary with bolus consistency. Patient awareness does not correlate with observed changes in swallowing physiology. (c) 2014 Wiley Periodicals, Inc. Head Neck37: 1122-1129, 2015 C1 [Rogus-Pulia, Nicole M.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Div Gastroenterol & Hepatol, Dept Med,Sch Med & Publ Hlth, Madison, WI USA. [Pierce, Margaret] NW Mem Hosp, Dept Radiat Oncol, Chicago, IL 60611 USA. [Mittal, Bharat B.] Northwestern Univ, Dept Radiat Oncol, Feinberg Sch Med, Chicago, IL 60611 USA. [Zecker, Steven G.; Logemann, Jeri] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60611 USA. RP Rogus-Pulia, NM (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Madison GRECC 11G, Madison, WI 53705 USA. EM nicolepulia@gmail.com NR 41 TC 4 Z9 5 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD AUG PY 2015 VL 37 IS 8 BP 1122 EP 1129 DI 10.1002/hed.23720 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CM8JM UT WOS:000357946400011 PM 24841209 ER PT J AU Barakat, LA Juthani-Mehta, M Allore, H Trentalange, M Tate, J Rimland, D Pisani, M Akgun, KM Goetz, MB Butt, AA Rodriguez-Barradas, M Duggal, M Crothers, K Justice, AC Quagliarello, VJ AF Barakat, L. A. Juthani-Mehta, M. Allore, H. Trentalange, M. Tate, J. Rimland, D. Pisani, M. Akguen, K. M. Goetz, M. B. Butt, A. A. Rodriguez-Barradas, M. Duggal, M. Crothers, K. Justice, A. C. Quagliarello, V. J. TI Comparing clinical outcomes in HIV-infected and uninfected older men hospitalized with community-acquired pneumonia SO HIV MEDICINE LA English DT Article DE HIV; outcomes; pneumonia ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; VETERANS AGING COHORT; BACTERIAL PNEUMONIA; PULMONARY MANIFESTATIONS; ERA; INDEX; MANAGEMENT; MORTALITY; SEVERITY AB ObjectivesOutcomes of community-acquired pneumonia (CAP) among HIV-infected older adults are unclear. MethodsAssociations between HIV infection and three CAP outcomes (30-day mortality, readmission within 30 days post-discharge, and hospital length of stay [LOS]) were examined in the Veterans Aging Cohort Study (VACS) of male Veterans, age 50 years, hospitalized for CAP from 10/1/2002 through 08/31/2010. Associations between the VACS Index and CAP outcomes were assessed in multivariable models. ResultsAmong 117557 Veterans (36922 HIV-infected and 80635 uninfected), 1203 met our eligibility criteria. The 30-day mortality rate was 5.3%, the mean LOS was 7.3 days, and 13.2% were readmitted within 30 days of discharge. In unadjusted analyses, there were no significant differences between HIV-infected and uninfected participants regarding the three CAP outcomes (P>0.2). A higher VACS Index was associated with increased 30-day mortality, readmission, and LOS in both HIV-infected and uninfected groups. Generic organ system components of the VACS Index were associated with adverse CAP outcomes; HIV-specific components were not. Among HIV-infected participants, those not on antiretroviral therapy (ART) had a higher 30-day mortality (HR 2.94 [95% CI 1.51, 5.72]; P=0.002) and a longer LOS (slope 2.69 days [95% CI 0.65, 4.73]; P=0.008), after accounting for VACS Index. Readmission was not associated with ART use (OR 1.12 [95% CI 0.62, 2.00] P=0.714). ConclusionAmong HIV-infected and uninfected older adults hospitalized for CAP, organ system components of the VACS Index were associated with adverse CAP outcomes. Among HIV-infected individuals, ART was associated with decreased 30-day mortality and LOS. C1 [Barakat, L. A.; Juthani-Mehta, M.; Quagliarello, V. J.] Yale Univ, Sch Med, Infect Dis, New Haven, CT 06510 USA. [Barakat, L. A.; Juthani-Mehta, M.; Allore, H.; Trentalange, M.; Pisani, M.; Akguen, K. M.; Justice, A. C.; Quagliarello, V. J.] Yale Univ, Sch Med, Internal Med, New Haven, CT 06510 USA. [Tate, J.; Akguen, K. M.; Duggal, M.; Justice, A. C.] VA Connecticut Healthcare Syst, Internal Med, West Haven, CT USA. [Rimland, D.] VA Med Ctr, Infect Dis, Decatur, GA USA. [Pisani, M.; Akguen, K. M.] Yale Univ, Sch Med, Pulm Dis & Crit Care, New Haven, CT 06510 USA. [Goetz, M. B.] VA Greater Los Angles Healthcare Syst, Infect Dis, Los Angeles, CA USA. [Butt, A. A.] Univ Pittsburgh, Internal Med, Pittsburgh, PA USA. [Rodriguez-Barradas, M.] Michael E Debakey VA Med Ctr, Infect Dis MS 111G, Houston, TX USA. [Crothers, K.] Univ Washington, Pulm Dis & Crit Care, Seattle, WA 98195 USA. RP Barakat, LA (reprint author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06510 USA. EM lydia.barakat@yale.edu OI Butt, Adeel/0000-0002-1118-1826; Justice, Amy/0000-0003-0139-5502; Allore, Heather/0000-0001-7685-8175 FU NIA NIH HHS [P30AG021342, K07 AG030093, K07AG030093, K23 AG028691, K23AG028691, P30 AG021342]; NIAAA NIH HHS [U10 AA013566, U10AA013566] NR 40 TC 3 Z9 3 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD AUG PY 2015 VL 16 IS 7 BP 421 EP 430 DI 10.1111/hiv.12244 PG 10 WC Infectious Diseases SC Infectious Diseases GA CM9CF UT WOS:000358002900004 PM 25959543 ER PT J AU Hoste, E Bagshaw, S Bellomo, R Cely, C Colman, R Cruz, D Edipidis, K Forni, L Gomersall, C Govil, D Honore, PM Joannes-Boyau, O Joannidis, M Korhonen, AM Lavrentieva, A Mehta, R Palevsky, P Roessler, E Ronco, C Uchino, S Vazquez, J Vidal Andrade, E Webb, S Kellum, J AF Hoste, Eric A. J. Bagshaw, Sean M. Bellomo, Rinaldo Cely, Cynthia M. Colman, Roos Cruz, Dinna N. Edipidis, Kyriakos Forni, Lui G. Gomersall, Charles D. Govil, Deepak Honore, Patrick M. Joannes-Boyau, Olivier Joannidis, Michael Korhonen, Anna-Maija Lavrentieva, Athina Mehta, Ravindra L. Palevsky, Paul Roessler, Eric Ronco, Claudio Uchino, Shigehiko Vazquez, Jorge A. Vidal Andrade, Erick Webb, Steve Kellum, John A. TI Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study SO INTENSIVE CARE MEDICINE LA English DT Article DE Acute kidney injury; Critically ill; Renal replacement therapy; Epidemiology; Kidney function; Hospital mortality ID RENAL REPLACEMENT THERAPY; GLOMERULAR-FILTRATION; 90-DAY MORTALITY; RISK-FACTORS; FAILURE; ICU; CLASSIFICATION; DEFINITION; CREATININE; PROGNOSIS AB Current reports on acute kidney injury (AKI) in the intensive care unit (ICU) show wide variation in occurrence rate and are limited by study biases such as use of incomplete AKI definition, selected cohorts, or retrospective design. Our aim was to prospectively investigate the occurrence and outcomes of AKI in ICU patients. The Acute Kidney Injury-Epidemiologic Prospective Investigation (AKI-EPI) study was an international cross-sectional study performed in 97 centers on patients during the first week of ICU admission. We measured AKI by Kidney Disease: Improving Global Outcomes (KDIGO) criteria, and outcomes at hospital discharge. A total of 1032 ICU patients out of 1802 [57.3 %; 95 % confidence interval (CI) 55.0-59.6] had AKI. Increasing AKI severity was associated with hospital mortality when adjusted for other variables; odds ratio of stage 1 = 1.679 (95 % CI 0.890-3.169; p = 0.109), stage 2 = 2.945 (95 % CI 1.382-6.276; p = 0.005), and stage 3 = 6.884 (95 % CI 3.876-12.228; p < 0.001). Risk-adjusted rates of AKI and mortality were similar across the world. Patients developing AKI had worse kidney function at hospital discharge with estimated glomerular filtration rate less than 60 mL/min/1.73 m(2) in 47.7 % (95 % CI 43.6-51.7) versus 14.8 % (95 % CI 11.9-18.2) in those without AKI, p < 0.001. This is the first multinational cross-sectional study on the epidemiology of AKI in ICU patients using the complete KDIGO criteria. We found that AKI occurred in more than half of ICU patients. Increasing AKI severity was associated with increased mortality, and AKI patients had worse renal function at the time of hospital discharge. Adjusted risks for AKI and mortality were similar across different continents and regions. C1 [Hoste, Eric A. J.] Univ Ghent, Ghent Univ Hosp, Dept Intens Care Med, B-9000 Ghent, Belgium. [Hoste, Eric A. J.] Res Fdn Flanders, Brussels, Belgium. [Hoste, Eric A. J.; Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modelling Acute Illnes CRI, Pittsburgh, PA USA. [Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB, Canada. [Bellomo, Rinaldo] Austin Hosp, Dept Intens Care, Melbourne, Vic 3084, Australia. [Cely, Cynthia M.] Univ Miami, Miller Sch Med, Div Pulm Crit Care & Sleep Med, Miami, FL 33136 USA. [Colman, Roos] Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium. [Cruz, Dinna N.] Univ Calif San Diego, Dept Med, Div Nephrol Hypertens, San Diego, CA 92103 USA. [Edipidis, Kyriakos] Hygeia Med Ctr, Athens, Greece. [Forni, Lui G.] Univ Surrey, Fac Hlth & Med Sci, Dept Intens Care Med, Guildford GU2 7TE, Surrey, England. [Forni, Lui G.] Univ Surrey, Surrey Peri Operat Anaesthesia Crit Care Res Grp, Royal Surrey Cty Hosp NHS Fdn Trust, Guildford GU2 7TE, Surrey, England. [Gomersall, Charles D.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China. [Govil, Deepak] Medanta, Inst Crit Care & Anesthesia, Gurgaon, India. [Honore, Patrick M.] VUB Univ, Univ Ziekenhuis Brussel, Dept Intens Care, Brussels, Belgium. [Joannes-Boyau, Olivier] CHU Bordeaux, Serv Anesthesie Reanimat 2, F-33000 Bordeaux, France. [Joannidis, Michael] Med Univ Innsbruck, Dept Internal Med, Div Intens Care & Emergency Med, A-6020 Innsbruck, Austria. [Korhonen, Anna-Maija] Meilahti Univ Hosp, Cent Hosp, Dept Surg, Intens Care Unit,Div Anaesthesia & Intens Care Me, Helsinki, Finland. [Korhonen, Anna-Maija] Univ Helsinki, Dept Clin Sci, Helsinki, Finland. [Lavrentieva, Athina] Papanikolaou Gen Hosp, Burn ICU, Thessaloniki, Greece. [Mehta, Ravindra L.] Univ Calif San Diego, Dept Med, Med Ctr, San Diego, CA 92103 USA. [Palevsky, Paul] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Palevsky, Paul] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Palevsky, Paul; Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Ctr Crit Care Nephrol, Pittsburgh, PA 15213 USA. [Roessler, Eric] Pontificia Univ Catolica Chile, Fac Med, Dept Nephrol, Santiago, Chile. [Ronco, Claudio] San Bortolo Hosp, Int Renal Res Inst, Dept Nephrol Dialysis & Transplantat, Vicenza, Italy. [Uchino, Shigehiko] Jikei Univ, Sch Med, Dept Anesthesiol, Intens Care Unit, Tokyo, Japan. [Vazquez, Jorge A.] Clin Modelo Lanus, Dept Crit Care Med, Buenos Aires, DF, Argentina. [Vidal Andrade, Erick] Hosp Angeles Lomas, Dept Crit Care Med, Mexico City, DF, Mexico. [Webb, Steve] Univ Western Australia, Dept Crit Care Med, Perth, WA 6009, Australia. [Webb, Steve] Royal Perth Hosp, Perth, WA 6001, Australia. RP Hoste, E (reprint author), Univ Ghent, Ghent Univ Hosp, Dept Intens Care Med, De Pintelaan 185, B-9000 Ghent, Belgium. EM eric.hoste@ugent.be OI Hoste, Eric/0000-0001-9301-8055; Palevsky, Paul/0000-0002-7334-5400 FU Astute Medical; Industrial Research Fund (IOF) from Ghent University; Gambro; BBraun; Fresenius; Baxter; Alere; AM Pharma; Spectral; Grifols; Cytosorbents; Alung; Atox Bio; Bard; Kaneka; International Safety Adverse Events Consortium; Thrasos FX EH received speakers fee from Astute Medical, and an Industrial Research Fund (IOF) from Ghent University for a validation study on a biomarker for AKI. SMB has consulted for and received honoraria from Gambro-Baxter. CG has received sponsorship for an academic conference from Gambro. OJB has received grants and non-financial support from Gambro, BBraun, Fresenius, and Astute Medical. MJ has consulted for and received honoraria from Baxter, Gambro, Fresenius, CLS Behring, BBraun, AM Pharma, Sanofi, Astute. JK has received grant support and/or consulting fees from Fresenius, Gambro, Baxter, Astute Medical, Alere, AM Pharma, Spectral, Grifols, Cytosorbents, Alung, Atox Bio, Bard, Kaneka. RM has received grants from the International Safety Adverse Events Consortium and Thrasos, he has options in Astute Medical and served in the scientific advisory board for trials for Abbvie, AM Pharma, and Eli Lilly, and consulted for CSL Behring, GSK, Baxter, Sova, Astellas, and Sanofi-Aventis. PP has consulted for Complexa Inc. SW is Director and Shareholder of Aalix Healthcare Services Consulting, which has provided services related to AKI. NR 40 TC 102 Z9 103 U1 3 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD AUG PY 2015 VL 41 IS 8 BP 1411 EP 1423 DI 10.1007/s00134-015-3934-7 PG 13 WC Critical Care Medicine SC General & Internal Medicine GA CM9VI UT WOS:000358057000003 PM 26162677 ER PT J AU Zhu, CW Cosentino, S Ornstein, K Gu, Y Andrews, H Stern, Y AF Zhu, Carolyn W. Cosentino, Stephanie Ornstein, Katherine Gu, Yian Andrews, Howard Stern, Yaakov TI Use and cost of hospitalization in dementia: longitudinal results from a community-based study SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE dementia; hospitalization; healthcare expenditures; longitudinal follow-up ID ALZHEIMERS-DISEASE; INCIDENT DEMENTIA; CARE; ASSOCIATION; DIAGNOSIS; ADMISSIONS; REASONS; ILLNESS; IMPACT; RISK AB ObjectivesThe aim of this study is to examine the relative contribution of functional impairment and cognitive deficits on risk of hospitalization and costs. MethodsA prospective cohort of Medicare beneficiaries aged 65 and older who participated in the Washington Heights-Inwood Columbia Aging Project (WHICAP) were followed approximately every 18months for over 10years (1805 never diagnosed with dementia during study period, 221 diagnosed with dementia at enrollment). Hospitalization and Medicare expenditures data (1999-2010) were obtained from Medicare claims. Multivariate analyses were conducted to examine (1) risk of all-cause hospitalizations, (2) hospitalizations from ambulatory care sensitive (ACSs) conditions, (3) hospital length of stay (LOS), and (4) Medicare expenditures. Propensity score matching methods were used to reduce observed differences between demented and non-demented groups at study enrollment. Analyses took into account repeated observations within each individual. ResultsCompared to propensity-matched individuals without dementia, individuals with dementia had significantly higher risk for all-cause hospitalization, longer LOS, and higher Medicare expenditures. Functional and cognitive deficits were significantly associated with higher risks for hospitalizations, hospital LOS, and Medicare expenditures. Functional and cognitive deficits were associated with higher risks of for some ACS but not all admissions. ConclusionsThese results allow us to differentiate the impact of functional and cognitive deficits on hospitalizations. To develop strategies to reduce hospitalizations and expenditures, better understanding of which types of hospitalizations and which disease characteristics impact these outcomes will be critical. Copyright (c) 2014 John Wiley & Sons, Ltd. C1 [Zhu, Carolyn W.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Zhu, Carolyn W.] James J Peters VA Med Ctr, Bronx, NY USA. [Cosentino, Stephanie; Gu, Yian; Stern, Yaakov] Columbia Univ Med Ctr, Cognit Neurosci Div, Gertrude H Sergievsky Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. [Cosentino, Stephanie; Gu, Yian; Stern, Yaakov] Columbia Univ Med Ctr, Dept Neurol, New York, NY USA. [Ornstein, Katherine] Icahn Sch Med Mt Sinai, Samuel Bronfman Dept Med, Div Gen Internal Med, New York, NY 10029 USA. [Andrews, Howard] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA. RP Zhu, CW (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. EM carolyn.zhu@mssm.edu FU National Institute on Aging [AG07370, AG037212] FX This research was supported by grants from the National Institute on Aging (AG07370, AG037212). NR 36 TC 9 Z9 9 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD AUG PY 2015 VL 30 IS 8 BP 833 EP 841 DI 10.1002/gps.4222 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CM7OM UT WOS:000357884200006 PM 25351909 ER PT J AU Chodosh, J Colaiaco, BA Connor, KI Cope, DW Liu, HS Ganz, DA Richman, MJ Cherry, DL Blank, JM Carbone, RD Wolf, SM Vickrey, BG AF Chodosh, Joshua Colaiaco, Benjamin A. Connor, Karen Ilene Cope, Dennis Wesley Liu, Hangsheng Ganz, David Avram Richman, Mark Jason Cherry, Debra Lynn Blank, Joseph Moshe Carbone, Raquel del Pilar Wolf, Sheldon Mark Vickrey, Barbara Grace TI Dementia Care Management in an Underserved Community: The Comparative Effectiveness of Two Different Approaches SO JOURNAL OF AGING AND HEALTH LA English DT Article DE dementia; Alzheimer's; care management; comparative effectiveness; health care delivery ID NURSING-HOME PLACEMENT; ALZHEIMER-DISEASE; CONTROLLED-TRIAL; COLLABORATIVE CARE; CHRONIC ILLNESS; CAREGIVERS; HISPANICS; QUALITY; INTERVENTION; UTILITY AB Objectives: To compare the effectiveness and costs of telephone-only approach to in-person plus telephone for delivering an evidence-based, coordinated care management program for dementia. Methods: We randomized 151 patient-caregiver dyads from an underserved predominantly Latino community to two arms that shared a care management protocol but implemented in different formats: in-person visits at home and/or in the community plus telephone and mail, versus telephone and mail only. We compared between-arm caregiver burden and care-recipient problem behaviors (primary outcomes) and patient-caregiver dyad retention, care quality, health care utilization, and costs (secondary outcomes) at 6- and 12-months follow-up. Results: Care quality improved substantially over time in both arms. Caregiver burden, care-recipient problem behaviors, retention, and health care utilization did not differ across arms but the in-person program cost more to deliver. Discussion: Dementia care quality improved regardless of how care management was delivered; large differences in effectiveness or cost offsets were not detected. C1 [Chodosh, Joshua; Connor, Karen Ilene; Cope, Dennis Wesley; Ganz, David Avram; Richman, Mark Jason; Cherry, Debra Lynn; Blank, Joseph Moshe; Wolf, Sheldon Mark; Vickrey, Barbara Grace] Univ Calif Los Angeles, Los Angeles, CA USA. [Chodosh, Joshua; Connor, Karen Ilene; Ganz, David Avram; Carbone, Raquel del Pilar; Vickrey, Barbara Grace] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Chodosh, Joshua; Colaiaco, Benjamin A.; Liu, Hangsheng; Ganz, David Avram; Vickrey, Barbara Grace] RAND Corp, Santa Monica, CA USA. [Cope, Dennis Wesley; Richman, Mark Jason; Blank, Joseph Moshe; Wolf, Sheldon Mark] Olive View UCLA Med Ctr, Los Angeles, CA USA. [Liu, Hangsheng] RAND Corp, Boston, MA USA. [Cherry, Debra Lynn] Alzheimers Assoc, Los Angeles, CA USA. [Cherry, Debra Lynn] Univ So Calif, Los Angeles, CA USA. RP Chodosh, J (reprint author), VA Greater Los Angeles Healthcare Syst, GRECC Sepulveda COE 11G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM JChodosh@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU National Institute on Aging [RC4AG038804] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by Award Number RC4AG038804 from the National Institute on Aging. NR 33 TC 3 Z9 3 U1 5 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 EI 1552-6887 J9 J AGING HEALTH JI J. Aging Health PD AUG PY 2015 VL 27 IS 5 BP 864 EP 893 DI 10.1177/0898264315569454 PG 30 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA CM5SO UT WOS:000357749100006 PM 25656074 ER PT J AU Cortes-Briones, J Skosnik, PD Mathalon, D Cahill, J Pittman, B Williams, A Sewell, RA Ranganathan, M Roach, B Ford, J D'Souza, DC AF Cortes-Briones, Jose Skosnik, Patrick D. Mathalon, Daniel Cahill, John Pittman, Brian Williams, Ashley Sewell, R. Andrew Ranganathan, Mohini Roach, Brian Ford, Judith D'Souza, Deepak Cyril TI Delta(9)-THC Disrupts Gamma (gamma)-Band Neural Oscillations in Humans SO NEUROPSYCHOPHARMACOLOGY LA English DT Article ID LONGITUDINAL DATA-ANALYSIS; CANNABINOID CB1 RECEPTOR; BASKET CELLS; GABAERGIC INTERNEURONS; GLUTAMATERGIC NEURONS; NETWORK OSCILLATIONS; STEADY-STATE; SCHIZOPHRENIA; HIPPOCAMPUS; CHOLECYSTOKININ AB Gamma (gamma)-band oscillations play a key role in perception, associative learning, and conscious awareness and have been shown to be disrupted by cannabinoids in animal studies. The goal of this study was to determine whether cannabinoids disrupt gamma-oscillations in humans and whether these effects relate to their psychosis-relevant behavioral effects. The acute, dose-related effects of Delta-9-tetrahydrocannabinol (Delta(9)-THC) on the auditory steady-state response (ASSR) were studied in humans (n=20) who completed 3 test days during which they received intravenous Delta(9)-THC (placebo, 0.015, and 0.03 mg/kg) in a double-blind, randomized, crossover, and counterbalanced design. Electroencephalography (EEG) was recorded while subjects listened to auditory click trains presented at 20, 30, and 40 Hz. Psychosis-relevant effects were measured with the Positive and Negative Syndrome scale (PANSS). Delta(9)-THC (0.03 mg/kg) reduced intertrialcoherence (ITC) in the 40 Hz condition compared with 0.015 mg/kg and placebo. No significant effects were detected for 30 and 20 Hz stimulation. Furthermore, there was a negative correlation between 40 Hz ITC and PANSS subscales and total scores under the influence of Delta(9)-THC. Delta(9)-THC (0.03 mg/kg) reduced evoked power during 40 Hz stimulation at a trend level. Recent users of cannabis showed blunted Delta(9)-THC effects on ITC and evoked power. We show for the first time in humans that cannabinoids disrupt gamma-band neural oscillations. Furthermore, there is a relationship between disruption of gamma-band neural oscillations and psychosis-relevant phenomena induced by cannabinoids. These findings add to a growing literature suggesting some overlap between the acute effects of cannabinoids and the behavioral and psychophysiological alterations observed in psychotic disorders. C1 [Cortes-Briones, Jose; Skosnik, Patrick D.; Cahill, John; Williams, Ashley; Sewell, R. Andrew; Ranganathan, Mohini; D'Souza, Deepak Cyril] VA Connecticut Healthcare Syst, Psychiat Serv, West Haven, CT 06516 USA. [Cortes-Briones, Jose; Skosnik, Patrick D.; Mathalon, Daniel; Cahill, John; Pittman, Brian; Sewell, R. Andrew; Ranganathan, Mohini; Ford, Judith; D'Souza, Deepak Cyril] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Skosnik, Patrick D.; Cahill, John; Pittman, Brian; Williams, Ashley; Sewell, R. Andrew; Ranganathan, Mohini; D'Souza, Deepak Cyril] Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, New Haven, CT USA. [Mathalon, Daniel; Roach, Brian; Ford, Judith] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Mathalon, Daniel; Roach, Brian; Ford, Judith] San Francisco VA Med Ctr, Mental Hlth Serv Line, San Francisco, CA USA. RP D'Souza, DC (reprint author), VA Connecticut Healthcare Syst, Psychiat Serv, 950 Campbell Ave, West Haven, CT 06516 USA. EM deepak.dsouza@yale.edu RI Skosnik, Patrick/D-6466-2016 FU Yale University School of Medicine from AbbVie; Pfizer FX Jose Cortes-Briones, Patrick Skosnik, John Cahill, Ashley Williams, Brian Roach, Mohini Ranganathan, and R Andrew Sewell (deceased) declare no conflict of interest. Deepak Cyril D'Souza has in the past 3 years or currently receives research grant support administered through Yale University School of Medicine from AbbVie and Pfizer, and is a consultant for Bristol-Myers Squibb and Johnson and Johnson. Dr Mathalon is a consultant for Bristol-Myers Squibb, and Amgen. NR 79 TC 4 Z9 4 U1 3 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD AUG PY 2015 VL 40 IS 9 BP 2124 EP 2134 DI 10.1038/npp.2015.53 PG 11 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CM8OY UT WOS:000357962700009 PM 25709097 ER PT J AU Drapkin, M Epstein, EE McCrady, B Eddie, D AF Drapkin, Michelle Epstein, Elizabeth E. McCrady, Barbara Eddie, David TI Sudden gains among women receiving treatment for alcohol use disorders SO ADDICTION RESEARCH & THEORY LA English DT Article DE Alcohol; mechanisms of change; sudden gains; treatment ID COGNITIVE-BEHAVIORAL THERAPY; TIMELINE FOLLOWBACK; CRITICAL SESSIONS; DEPRESSION; PSYCHOTHERAPY; DRINKING; INTERVENTIONS; COMPLEXITY; DRINKERS; RELAPSE AB Understanding the timing and types of change during treatment for mental health disorders is an important step toward elucidating possible mechanisms of behaviour change in response to therapeutic interventions, yet these issues have not been adequately addressed in the alcohol dependence treatment literature. The current study applied sudden gains (SGs) methodology, an approach originally developed in depression treatment studies, to a sample of women receiving treatment for alcohol use disorders. SGs are drastic improvements in symptoms that occur between two psychotherapy sessions and are hypothesised to be the result of what occurred in the first of those two sessions. SGs can happen at any time during the course of treatment, can happen more than once, and are individualised, as opposed to aggregated for a sample. For the current study, SGs were examined across three variables: percent drinking days (PDD), urge frequency (UF), and urge intensity (UI) in a sample of 102 women receiving either individual or couple cognitive-behavioural therapy for alcohol use disorders. Results indicated the presence of SGs; one-third of the sample experienced at least one SG in either alcohol use or urges to drink; the most common SGs were in frequency of urges to drink. SGs in urge frequency during treatment predicted better post-treatment drinking outcome. C1 [Drapkin, Michelle] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Drapkin, Michelle] Vet Affairs Med Ctr, Mental Hlth Serv, Philadelphia, PA USA. [Epstein, Elizabeth E.; Eddie, David] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ USA. [McCrady, Barbara] Univ New Mexico, Ctr Alcoholism Substance Abuse & Addict, Albuquerque, NM 87131 USA. RP Drapkin, M (reprint author), Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. EM michelledrapkinmet@gmail.com FU NIAAA [R37 AA07070, T32 AA07569] FX This research was supported by NIAAA Grants R37 AA07070 and T32 AA07569. Parts of these findings were presented at the 2006 and 2007 Annual Meetings of the Research Society on Alcoholism as well as at the 13th world congress of the International Society for Biomedical Research on Alcoholism, Sydney, Australia. NR 42 TC 0 Z9 0 U1 3 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1606-6359 EI 1476-7392 J9 ADDICT RES THEORY JI Addict. Res. Theory PD AUG PY 2015 VL 23 IS 4 BP 273 EP 279 DI 10.3109/16066359.2014.981809 PG 7 WC Substance Abuse; Social Issues SC Substance Abuse; Social Issues GA CL8OY UT WOS:000357235200003 ER PT J AU Nedjat-Haiem, FR Carrion, IV AF Nedjat-Haiem, Frances R. Carrion, Iraida V. TI Assessing Challenges in End-of-Life Conversations With Patients Utilizing a Public Safety-Net Health Care System SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE safety-net health care; Latinos; Hispanics; providers; barriers; end-of-life communication; qualitative ID PALLIATIVE CARE; LATINO PATIENTS; PHYSICIANS; RISK AB Multiple factors influence end-of-life (EOL) care discussions that occur in health care systems, within organizations, among individuals working within these systems and in patients and family/friend support networks. This study examined barriers to EOL care discussions as experienced by health care providers working in a public safety-net health care system where the majority of their patients were low-income and immigrant Latinos seeking medical treatment. Qualitative data were collected in South Central Los Angeles through semistructured interviews with 46 health care providers from different disciplines in medicine, nursing, social work, and chaplaincy. The themes indicated communication barriers in the public sector health care setting and sociocultural patient- and family-level factors. All providers made valuable contributions to clarify the complexity of the problems. Universal strategies are needed to improve communication. C1 [Nedjat-Haiem, Frances R.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Nedjat-Haiem, Frances R.] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA. [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL USA. RP Nedjat-Haiem, FR (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence, Off Acad Affiliat, VA Associated Hlth Postdoctoral Fellowship Progra, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM nedjatha@gmail.com OI Carrion, Iraida/0000-0003-4076-6644 FU American Cancer Society [DSW-06-220-01-SW]; US Department of Veterans Affairs, Hartford/VA Social Work Scholars Program FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the American Cancer Society Doctoral Training Grants in Oncology Social Work DSW-06-220-01-SW (F. R. Nedjat-Haiem, PI), and US Department of Veterans Affairs, Hartford/VA Social Work Scholars Program. NR 33 TC 3 Z9 3 U1 2 U2 12 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD AUG PY 2015 VL 32 IS 5 BP 528 EP 536 DI 10.1177/1049909114530550 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CM5QZ UT WOS:000357745000008 PM 24752233 ER PT J AU Bodhankar, S Chen, YX Lapato, A Vandenbark, AA Murphy, SJ Saugstad, JA Offner, H AF Bodhankar, Sheetal Chen, Yingxin Lapato, Andrew Vandenbark, Arthur A. Murphy, Stephanie J. Saugstad, Julie A. Offner, Halina TI Regulatory CD8(+)CD122(+) T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells SO METABOLIC BRAIN DISEASE LA English DT Article DE MCAO; IL-10-secreting B-cells; IL-10(+)CD8(+)CD122(+) regulatory T-cells; Inflammatory cells ID FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFARCT SIZE; INFLAMMATORY RESPONSES; RAT-BRAIN; IL-10; INTERLEUKIN-10; NEUROINFLAMMATION; PERMANENT; PROTECTS AB Clinical stroke induces inflammatory processes leading to cerebral and splenic injury and profound peripheral immunosuppression. IL-10 expression is elevated during major CNS diseases and limits inflammation in the brain. Recent evidence demonstrated that transfer of IL-10(+) B-cells reduced infarct volume in male C57BL/6J (wild-type, WT) recipient mice when given 24 h prior to or 4 h after middle cerebral artery occlusion (MCAO). The purpose of this study was to determine if passively transferred IL-10(+) B-cells can exert therapeutic and immunoregulatory effects when injected 24 h after MCAO induction in B-cell-sufficient male WT mice. The results demonstrated that IL-10(+) B-cell treated mice had significantly reduced infarct volumes in the ipsilateral cortex and hemisphere and improved neurological deficits vs. Vehicle-treated control mice after 60 min occlusion and 96 h of reperfusion. The MCAO-protected B-cell recipient mice had less splenic atrophy and reduced numbers of activated, inflammatory T-cells, decreased infiltration of T-cells and a less inflammatory milieu in the ischemic hemispheres compared with Vehicle-treated control mice. These immunoregulatory changes occurred in concert with the predominant appearance of IL-10-secreting CD8(+)CD122(+) Treg cells in both the spleen and the MCAO-affected brain hemisphere. This study for the first time demonstrates a major neuroprotective role for IL-10(+) B-cells in treating MCAO in male WT mice at a time point well beyond the similar to 4 h tPA treatment window, leading to the generation of a dominant IL-10(+)CD8(+)CD122(+) Treg population associated with spleen preservation and reduced CNS inflammation. C1 [Bodhankar, Sheetal; Lapato, Andrew; Vandenbark, Arthur A.; Offner, Halina] VA Med Ctr, Neuroimmunol Res, Portland, OR USA. [Bodhankar, Sheetal; Lapato, Andrew; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Chen, Yingxin; Murphy, Stephanie J.; Saugstad, Julie A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Neuroimmunol Res, R&D 31, Portland, OR 97239 USA. RP Offner, H (reprint author), Portland VA Med Ctr, Neuroimmunol Res, R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu OI Lapato, Andrew/0000-0002-4931-7370 FU NIH/NINDS [1RO1 NS075887]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Gail Kent for the submission of the manuscript. This work was supported by NIH/NINDS 1RO1 NS075887. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 39 TC 4 Z9 4 U1 1 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 EI 1573-7365 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD AUG PY 2015 VL 30 IS 4 BP 911 EP 924 DI 10.1007/s11011-014-9639-8 PG 14 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA CM1VT UT WOS:000357469300007 PM 25537181 ER PT J AU Shunmugavel, A Khan, M Hughes, FM Purves, JT Singh, A Singh, I AF Shunmugavel, Anandakumar Khan, Mushfiquddin Hughes, Francis M. Purves, J. Todd Singh, Avtar Singh, Inderjit TI y S-Nitrosoglutathione protects the spinal bladder: Novel therapeutic approach to post-spinal cord injury bladder remodeling SO NEUROUROLOGY AND URODYNAMICS LA English DT Article DE bladder dysfunction; GSNO; ICAM-1; inflammation; iNOS; spinal cord injury ID EXTERNAL URETHRAL SPHINCTER; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; RAT URINARY-BLADDER; NEUROGENIC BLADDER; OXIDATIVE INJURY; EXPRESSION; INFLAMMATION; MECHANISMS; CELLS AB AimsBladder and renal dysfunction are secondary events of the inflammatory processes induced by spinal cord injury (SCI). S-Nitrosoglutathione (GSNO), an endogenous nitrosylating agent is pleiotropic and has anti-inflammatory property. Hence, GSNO ameliorates inflammatory sequelae observed in bladder and renal tissues after SCI. Thus, we postulate that GSNO will improve the recovery of micturition dysfunction by quenching the bladder tissue inflammation associated with SCI. MethodsContusion-based mild SCI was induced in female Sprague-Dawley rats. Sham operated rats served as the controls. SCI rats were gavaged daily with GSNO (50 mu g/kg) or vehicle. Bladder function was assessed by urodynamics at 2 and 14 days following SCI. Urine protein concentration and osmolality were measured. Bladder and kidney tissues were analyzed by histology and immunofluorescence for a variety of endpoints related to inflammation. ResultsTwo days after SCI, urodynamics demonstrated a hyperreflexive bladder with overflow and no clear micturition events. By Day 14, vehicle animals regained a semblance of a voiding cycle but with no definite intercontraction intervals. GSNO-treated SCI-rats showed nearly normal cystometrograms. Vehicle-treated SCI rats had increased bladder wet weight, proteinuria, and urine osmolality at Day 14, which was reversed by GSNO treatment. In addition, the SCI-induced increase in immune cell infiltration, collagen deposition, iNOS, and ICAM-1 expression and apoptosis were attenuated by GSNO. ConclusionsThese results indicate that oral administration of GSNO hastens the recovery of bladder function after mild contusion-induced SCI through dampening the inflammation sequelae. These findings also suggest that GSNO-mediated redox modulation may be a novel therapeutic target for the treatment of mild SCI-induced renal and bladder dysfunction. Neurourol. Urodynam. 34:519-526, 2015. (c) 2014 Wiley Periodicals, Inc. C1 [Shunmugavel, Anandakumar; Khan, Mushfiquddin; Singh, Inderjit] Med Univ S Carolina, Charles P Darby Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA. [Hughes, Francis M.; Purves, J. Todd] Med Univ S Carolina, Charles P Darby Childrens Res Inst, Dept Urol, Charleston, SC 29425 USA. [Purves, J. Todd] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Pathol & Lab Med Serv, Charleston, SC 29425 USA. [Singh, Avtar] Med Univ S Carolina, Pathol & Lab Med Serv, Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Darby Childrens Res Inst, 173 Ashley Ave, Charleston, SC 29425 USA. EM saklaks@gmail.com FU NIH [NS-72511]; Extramural Research Facilities Program of the National Center for Research Resources [CO6 RR0015455]; Spinal Research Foundation VA; Heather Perkins Trew Foundation FX Grant sponsor: NIH; Grant number: NS-72511; Grant sponsor: Extramural Research Facilities Program of the National Center for Research Resources; Grant number: CO6 RR0015455; Grant sponsor: The Spinal Research Foundation VA; Grant sponsor: Heather Perkins Trew Foundation NR 45 TC 1 Z9 1 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD AUG PY 2015 VL 34 IS 6 BP 519 EP 526 DI 10.1002/nau.22619 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA CM3UF UT WOS:000357609500005 PM 24853799 ER PT J AU Probst, MA Kanzaria, HK Gbedemah, M Richardson, LD Sun, BC AF Probst, Marc A. Kanzaria, Hemal K. Gbedemah, Misato Richardson, Lynne D. Sun, Benjamin C. TI National trends in resource utilization associated with ED visits for syncope SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID US EMERGENCY-DEPARTMENTS; RISK STRATIFICATION; MANAGEMENT; OUTCOMES AB Background: Over the last 20 years, numerous research articles and clinical guidelines aimed at optimizing resource utilization for emergency department (ED) patients presenting with syncope have been published. Hypothesis: We hypothesized that there would be temporal trends in syncope-related ED visits and associated trends in imaging, hospital admissions, and diagnostic frequencies. Methods: The ED component of National Hospital Ambulatory Medical Care Survey was analyzed from 2001 through 2010, comprising more than 358000 visits (representing an estimated 1.18 billion visits nationally). We selected ED visits with a reason for visit of syncope or fainting and calculated nationally representative weighted estimates for prevalence of such visits and associated rates of advanced imaging utilization and admission. For admitted patients from 2005 to 2010, the most frequent hospital discharge diagnoses were tabulated. Results: During the study period, there were more than 3500 actual ED visits (representing 11.9 million visits nationally) related to syncope, representing roughly 1% of all ED visits. Admission rates for syncope patients ranged from 27% to 35% and showed no significant downward trend (P = .1). Advanced imaging rates increased from about 21% to 45% and showed a significant upward trend (P < .001). For admitted patients, the most common hospital discharge diagnosis was the symptomatic diagnosis of "syncope and collapse" (36.4%). Conclusions: Despite substantial efforts by medical researchers and professional societies, resource utilization associated with ED visits for syncope appears to have actually increased. There have been no apparent improvements in diagnostic yield for admissions. Novel strategies may be needed to change practice patterns for such patients. (C) 2015 Elsevier Inc. All rights reserved. C1 [Probst, Marc A.; Gbedemah, Misato; Richardson, Lynne D.] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA. [Kanzaria, Hemal K.] UCLA, Robert Wood Johnson Fdn Clin Scholar, Dept Emergency Med, Los Angeles, CA USA. [Kanzaria, Hemal K.] Univ Calif Los Angeles, Sch Med, Ctr Emergency Med, US Dept Vet Affairs, Los Angeles, CA 90095 USA. [Sun, Benjamin C.] Oregon Hlth & Sci Univ, CDW EM, Dept Emergency Med, Portland, OR 97239 USA. RP Probst, MA (reprint author), Icahn Sch Med Mt Sinai, Dept Emergency Med, 3 East 101st St,Second Floor,Room 209, New York, NY 10029 USA. EM mprobst@gmail.com; hemal.kanzaria@gmail.com; misato.gbedemah@mountsinai.org; lynne.richardson@mountsinai.org; sunb@ohsu.edu FU NHLBI NIH HHS [R01 HL111033, 5K12 HL109005-03, K12 HL109005] NR 13 TC 2 Z9 2 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD AUG PY 2015 VL 33 IS 8 BP 998 EP 1001 DI 10.1016/j.ajem.2015.04.030 PG 4 WC Emergency Medicine SC Emergency Medicine GA CL0BR UT WOS:000356604000002 PM 25943042 ER PT J AU Sosenko, JM Skyler, JS Palmer, JP AF Sosenko, Jay M. Skyler, Jay S. Palmer, Jerry P. CA Diabet Type 1 TrialNet Grp Diabet Prevention Trial-Type 1 TI The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) SO CURRENT DIABETES REPORTS LA English DT Article DE Type 1 diabetes; Glucose; C-peptide; Prediction; Diagnosis ID GLUCOSE-TOLERANCE; RELATIVES; INSULIN; TRIAL-TYPE-1; PREDICTION; ACCURACY; MELLITUS AB This report details the development, validation, and utility of the Diabetes Prevention Trial-Type 1 (DPT-1) Risk Score (DPTRS) for type 1 diabetes (T1D). Proportional hazards regression was used to develop the DPTRS model which includes the glucose and C-peptide sums from oral glucose tolerance tests at 30, 60, 90, and 120 min, the log fasting C-peptide, age, and the log BMI. The DPTRS was externally validated in the TrialNet Natural History Study cohort (TNNHS). In a study of the application of the DPTRS, the findings showed that it could be used to identify normoglycemic individuals who were at a similar risk for T1D as those with dysglycemia. The DPTRS could also be used to identify lower risk dysglycemic individuals. Risk estimates of individuals deemed to be at higher risk according to DPTRS values did not differ significantly between the DPT-1 and the TNNHS; whereas, the risk estimates for those with dysglycemia were significantly higher in DPT-1. Individuals with very high DPTRS values were found to be at such marked risk for T1D that they could reasonably be considered to be in a pre-diabetic state. The findings indicate that the DPTRS has utility in T1D prevention trials and for identifying pre-diabetic individuals. C1 [Sosenko, Jay M.; Skyler, Jay S.] Univ Miami, Div Endocrinol, Miami, FL 33101 USA. [Palmer, Jerry P.] Univ Washington, Div Endocrinol Metab & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Sosenko, JM (reprint author), Univ Miami, Div Endocrinol, POB 016960,D110, Miami, FL 33101 USA. EM jsosenko@med.miami.edu RI Skyler, Jay/F-4211-2016 FU National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01 DK061010, U01 DK061016, U01 DK061034, U01 DK061036, U01 DK061040, U01 DK061041, U01 DK061042, U01 DK061055, U01 DK061058, U01 DK084565, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085505, U01 DK085509, HHSN267200800019C]; National Center for Research Resources, through Clinical Translational Science Awards [UL1 RR024131, UL1 RR024139, UL1 RR024153, UL1 RR024975, UL1 RR024982, UL1 RR025744, UL1 RR025761, UL1 RR025780, UL1 RR029890, UL1 RR031986, P30 DK017047]; General Clinical Research Center Award [M01 RR00400]; Juvenile Diabetes Research Foundation International (JDRF); American Diabetes Association (ADA) FX The sponsor of the trial was the Type 1 Diabetes TrialNet Study Group (see Appendix 1). Type 1 Diabetes TrialNet Study Group is a clinical trial network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061016, U01 DK061034, U01 DK061036, U01 DK061040, U01 DK061041, U01 DK061042, U01 DK061055, U01 DK061058, U01 DK084565, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085505, U01 DK085509, and a contract HHSN267200800019C; the National Center for Research Resources, through Clinical Translational Science Awards UL1 RR024131, UL1 RR024139, UL1 RR024153, UL1 RR024975, UL1 RR024982, UL1 RR025744, UL1 RR025761, UL1 RR025780, UL1 RR029890, UL1 RR031986, P30 DK017047, and General Clinical Research Center Award M01 RR00400; the Juvenile Diabetes Research Foundation International (JDRF); and the American Diabetes Association (ADA). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, JDRF, or ADA. NR 16 TC 1 Z9 2 U1 2 U2 5 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 EI 1539-0829 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD AUG PY 2015 VL 15 IS 8 DI 10.1007/s11892-015-0626-1 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK6NB UT WOS:000356343700003 PM 26077017 ER PT J AU Winter, L Moriarty, HJ Atte, F Gitlin, LN AF Winter, Laraine Moriarty, Helene J. Atte, Faith Gitlin, Laura N. TI Depressed Affect and Dimensions of Religiosity in Family Caregivers of Individuals with Dementia SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE Depression; Religiosity; Dementia caregiving ID OLDER DUTCH CITIZENS; MENTAL-HEALTH; LIFE EVENTS; ADULTS; SPIRITUALITY; INVOLVEMENT; SYMPTOMS; OUTCOMES; REACH; RESOURCES AB Religiosity and mood have long been recognized as associated, but some patterns of associations suggest complex relationships. Using a multidimensional measure of religiosity, we explored the possibility that dimensions of religiosity may have (1) different strengths of association and (2) directions of association with depressed mood. We measured five dimensions of religiosity in 1227 family caregivers of persons with dementia, testing associations of each dimension to caregivers' depressive symptoms. In zero-order associations, higher scores on each religiosity dimension were associated with lower depression. Yet in hierarchical multiple regressions models, adjusting for other religiosity dimensions, different dimensions showed either no independent association, an independent association, or an inverse association with depressed mood. Frequency of prayer reversed directions of association-showing higher depression in caregivers who prayed more. Findings underscore the complex and sometimes bidirectional association between depressed mood and religiosity and argue for recognition of distinct dimensions of religiosity. C1 [Winter, Laraine] Philadelphia VA Med Ctr, Dept Vet Affairs Med Ctr, Philadelphia Res & Educ Fdn, Philadelphia, PA 19104 USA. [Winter, Laraine; Moriarty, Helene J.] Dept Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA 19104 USA. [Moriarty, Helene J.; Atte, Faith] Villanova Univ Coll Nursing, Villanova, PA USA. [Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Ctr Innovat Care Aging, Baltimore, MD USA. RP Winter, L (reprint author), Philadelphia VA Med Ctr, Dept Vet Affairs Med Ctr, Philadelphia Res & Educ Fdn, Philadelphia, PA 19104 USA. EM laraine.winter@gmail.com NR 52 TC 0 Z9 0 U1 4 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 EI 1573-6571 J9 J RELIG HEALTH JI J. Relig. Health PD AUG PY 2015 VL 54 IS 4 BP 1490 EP 1502 DI 10.1007/s10943-015-0033-6 PG 13 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA CK0YN UT WOS:000355931900027 PM 25794545 ER PT J AU Heinz, AJ Bui, L Thomas, KM Blonigen, DM AF Heinz, Adrienne J. Bui, Leena Thomas, Katherine M. Blonigen, Daniel M. TI Distinct Facets of Impulsivity Exhibit Differential Associations with Substance Use Disorder Treatment Processes: A Cross-Sectional and Prospective Investigation Among Military Veterans SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Impulsivity; Substance use disorder; Treatment; Executive functioning; Treatment processes; Veterans ID ALCOHOL-USE DISORDERS; 5 FACTOR MODEL; INTERPERSONAL PROBLEMS; BEHAVIOR SCALE; SELF-EFFICACY; EXECUTIVE FUNCTION; DRUG-ADDICTION; NEURAL SYSTEMS; 4-FACTOR MODEL; COPING SKILLS AB Impulsivity, a multi-faceted construct characterized by rash, unplanned actions and a disregard for long-term consequences, is associated with poor substance use disorder (SUD) treatment outcomes. Little is known though about the influence of impulsivity on treatment process variables critical for initiating and maintaining behavioral change. This knowledge gap is important as different aspects of impulsivity may be susceptible to diverse cognitive, behavioral and pharmacological influences. The present study examined two distinct facets of impulsivity (lack of planning and immoderation a proxy of urgency) as predictors of processes that impact SUD treatment success (active coping, avoidant coping, self-efficacy, and interpersonal problems). Participants were 200 Veterans who completed impulsivity and treatment process assessments upon entering an SUD treatment program and treatment process assessments at treatment discharge. Results from multivariate models revealed that lack of planning was associated with lower active coping and higher avoidant coping and interpersonal problems at intake, though not with lower self-efficacy to abstain from substances. Immoderation was associated with higher avoidant coping and lower self-efficacy to abstain from substances at intake, but not with lower active coping or higher interpersonal problems. Higher immoderation, but not lack of planning, predicted lower self-efficacy to abstain from substances at treatment discharge. These findings suggest that different facets of impulsivity confer risk for different SUD treatment process indicators and that clinicians should consider the behavioral expression of patients' impulse control problems in treatment planning and delivery. Published by Elsevier Inc. C1 [Heinz, Adrienne J.; Bui, Leena; Blonigen, Daniel M.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Heinz, Adrienne J.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr Posttraumat Stress Disorder, Menlo Pk, CA USA. [Thomas, Katherine M.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. [Thomas, Katherine M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Heinz, AJ (reprint author), 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. EM adrienneheinz@gmail.com FU VA Clinical Science Research and Development (CSR&D) Career Development Award-2; VA Rehabilitation Research and Development (RR&D) Career Development Award-2 FX Support for this research was provided by a VA Clinical Science Research and Development (CSR&D) Career Development Award-2 granted to Dr. Blonigen and a VA Rehabilitation Research and Development (RR&D) Career Development Award-2 granted to Dr. Heinz. The expressed views do not necessarily represent those of the Department of Veterans Affairs. NR 85 TC 3 Z9 3 U1 1 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD AUG PY 2015 VL 55 BP 21 EP 28 DI 10.1016/j.jsat.2015.02.005 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CK2FT UT WOS:000356026900004 PM 25770869 ER PT J AU Wylie, KP Kronberg, E Maharajh, K Smucny, J Cornier, MA Tregellas, JR AF Wylie, Korey P. Kronberg, Eugene Maharajh, Keeran Smucny, Jason Cornier, Marc-Andre Tregellas, Jason R. TI Between-network connectivity occurs in brain regions lacking layer IV input SO NEUROIMAGE LA English DT Article DE fMRI; Cytology; Independent components analysis; Resting state; Paralimbic ID INTRINSIC FUNCTIONAL CONNECTIVITY; HUMAN CEREBRAL-CORTEX; CORTICOCORTICAL CONNECTIONS; CORTICAL AREAS; ORGANIZATION; CYTOARCHITECTURE; CINGULATE; CIRCUITS; DYNAMICS; INSULA AB To better understand the cortical circuitry underlying connectivity between large-scale neural networks, we develop a novel, data-driven approach to identify potential integration subregions. Between-network connectivity (BNC) associated with any anatomical region is the amount of connectivity between that point and all large-scale networks, as measured using simple and multiple correlations. It is straightforward to calculate and applicable to functional networks identified using independent components analysis. We calculated BNC for all fMRI voxels within the brain and compared the results to known regional cytoarchitectural patterns. Based on previous observations of the relationship between macroscopic connectivity and microscopic cytoarchitecture, we predicted that areas with high BNC will be located in paralimbic subregions with an undifferentiated laminar structure. Results suggest that the anterior insula and dorsal posterior cingulate cortices play prominent roles in information integration. Cytoarchitecturely, these areas show agranular or dysgranular cytologies with absent or disrupted cortical layer IV. Since layer IV is the primary recipient of feed-forward thalamocortical connections, and due to the exclusive nature of driving connections to this layer, we suggest that the absence of cortical layer IV might allow for information to be exchanged across networks, and is an organizational characteristic of brain-subregions serving as inter-network communication hubs. (C) 2015 Elsevier Inc. All rights reserved. C1 [Wylie, Korey P.; Kronberg, Eugene; Maharajh, Keeran; Smucny, Jason; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. [Cornier, Marc-Andre] Univ Colorado, Div Endocrinol Metab & Diabet, Aurora, CO 80045 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv 151, Res Serv, Denver, CO 80220 USA. RP Tregellas, JR (reprint author), Anschutz Med Campus Bldg 500,Mail Stop F546, Aurora, CO 80045 USA. EM Jason.Tregellas@UCDenver.edu RI Tregellas, Jason/J-3637-2015 OI Kronberg, Eugene/0000-0002-5166-1875; Smucny, Jason/0000-0001-5656-7987 FU Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service; National Institutes of Mental Health [R01DK089095, MH-086383]; Brain and Behavior Research Foundation; Blowitz-Ridgeway Foundation FX This work was supported by the Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service, the National Institutes of Mental Health grants R01DK089095 and MH-086383, the Brain and Behavior Research Foundation, and the Blowitz-Ridgeway Foundation. NR 52 TC 2 Z9 2 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD AUG 1 PY 2015 VL 116 BP 50 EP 58 DI 10.1016/j.neuroimage.2015.05.010 PG 9 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CK0XY UT WOS:000355930200005 PM 25979667 ER PT J AU Rosenthal, SL Bamne, MN Wang, XB Berman, S Snitz, BE Klunk, WE Sweet, RA Demirci, FY Lopez, OL Kamboh, MI AF Rosenthal, Samantha L. Bamne, Mikhil N. Wang, Xingbin Berman, Sarah Snitz, Beth E. Klunk, William E. Sweet, Robert A. Demirci, F. Yesim Lopez, Oscar L. Kamboh, M. Ilyas TI More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk SO NEUROBIOLOGY OF AGING LA English DT Article DE TREM2; Rare variants; LOAD ID GENOME-WIDE ASSOCIATION; FRONTOTEMPORAL DEMENTIA; COMMON VARIANTS; ONSET; PSYCHOSIS; EXPRESSION; CELLS; INDIVIDUALS; PREVENTION; MICROGLIA AB Over 20 risk loci have been identified for late-onset Alzheimer's disease (LOAD), most of which display relatively small effect sizes. Recently, a rare missense (R47H) variant, rs75932628 in TREM2, has been shown to mediate LOAD risk substantially in Icelandic and Caucasian populations. Here, we present more evidence for the association of the R47H with LOAD risk in a Caucasian population comprising 4567 LOAD cases and controls. Our results show that carriers of the R47H variant have a significantly increased risk for LOAD (odds ratio = 7.40, p = 3.66E-06). In addition to Alzheimer's disease risk, we also examined the association of R47H with Alzheimer's diseaseerelated phenotypes, including age-at-onset, psychosis, and amyloid deposition but found no significant association. Our results corroborate those of other studies implicating TREM2 as an LOAD risk locus and indicate the need to determine its biological role in the context of neurodegeneration. (C) 2015 Elsevier Inc. All rights reserved. C1 [Rosenthal, Samantha L.; Bamne, Mikhil N.; Wang, Xingbin; Demirci, F. Yesim; Kamboh, M. Ilyas] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Berman, Sarah; Snitz, Beth E.; Sweet, Robert A.; Lopez, Oscar L.] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15261 USA. [Klunk, William E.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. RP Kamboh, MI (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. EM kamboh@pitt.edu OI Demirci, F. Yesim/0000-0001-6907-9843; Kamboh, M. Ilyas/0000-0002-3453-1438 FU National Institute on Aging [AG041718, AG030653, AG027224, AG005133, P01 AG025204]; National Center for Complementary and Alternative Medicine [U01 AT000162] FX This study was supported by the National Institute on Aging grants AG041718, AG030653, AG027224, AG005133, and P01 AG025204, and by U01 AT000162 from the National Center for Complementary and Alternative Medicine. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 50 TC 4 Z9 4 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD AUG PY 2015 VL 36 IS 8 AR 2443.e26 DI 10.1016/j.neurobiolaging.2015.04.012 PG 6 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA CJ8RL UT WOS:000355771100013 ER PT J AU Thames, AD Briones, MS Magpantay, LI Martinez-Maza, O Singer, EJ Hinkin, CH Morgello, S Gelman, BB Moore, DJ Heizerling, K Levine, AJ AF Thames, April D. Briones, Marisa S. Magpantay, Larry I. Martinez-Maza, Otoniel Singer, Elyse J. Hinkin, Charles H. Morgello, Susan Gelman, Benjamin B. Moore, David J. Heizerling, Keith Levine, Andrew J. TI The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients SO AIDS LA English DT Article ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MILD COGNITIVE IMPAIRMENT; SOLUBLE TNF RECEPTORS; ALZHEIMERS-DISEASE; AIDS DEMENTIA; MCP-1; ASTROCYTES; EXPRESSION; CELLS; INFLAMMATION AB Objectives:We examined interrelationships between chemokine C-C motif ligand 2 (CCL2) genotype and expression of inflammatory markers in the cerebrospinal fluid (CSF), plasma viral load, CD4(+) cell count and neurocognitive functioning among HIV-infected adults. We hypothesized that HIV-positive carriers of the risk' CCL2 -2578G allele, caused by a single nucleotide polymorphism (SNP) at rs1024611, would have a higher concentration of CCL2 in CSF, and that CSF CCL2 would be associated with both higher concentrations of other proinflammatory markers in CSF and worse neurocognitive functioning. Design:A cross-sectional study of 145 HIV-infected individuals enrolled in the National NeuroAIDS Tissue Consortium cohort for whom genotyping, CSF and neurocognitive data were available. Methods:Genomic DNA was extracted from peripheral blood mononuclear cells and/or frozen tissue specimens. CSF levels of CCL2, interleukin (IL)-2, IL-6, tumour necrosis factor-alpha (TNF-), interferon-gamma (IFN-), soluble tumor necrosis factor receptor 2, sIL-6R, sIL-2, sCD14 and B-cell activating factor were quantified. Neurocognitive functioning was measured using a comprehensive battery of neuropsychological tests. Results:Carriers of the CCL2 -2578G allele had a significantly higher concentration of CCL2 in CSF. CSF CCL2 level was positively and significantly associated with other CSF neuroinflammatory markers and worse cognitive functioning. There was a significant association between genotype and plasma viral load, such that carriers of the CCL2 -2578G allele with high viral load expressed greater levels of CCL2 and had higher neurocognitive deficit scores than other genotype/viral load groups. Conclusion:Individuals with the CCL2 -2578G allele had higher levels of CCL2 in CSF, which was associated with increased pro-inflammatory markers in CSF and worse neurocognitive functioning. The results highlight the potential role of intermediate phenotypes in studies of genotype and cognition. C1 [Thames, April D.; Hinkin, Charles H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Briones, Marisa S.; Heizerling, Keith] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA. [Magpantay, Larry I.; Martinez-Maza, Otoniel] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA. [Magpantay, Larry I.; Martinez-Maza, Otoniel] Univ Calif Los Angeles, Dept Epidemiol & Microbiol, Los Angeles, CA USA. [Magpantay, Larry I.; Martinez-Maza, Otoniel] Univ Calif Los Angeles, Dept Immunol & Human Genet, Los Angeles, CA USA. [Singer, Elyse J.; Levine, Andrew J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Hinkin, Charles H.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Morgello, Susan] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Morgello, Susan] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA. [Morgello, Susan] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Gelman, Benjamin B.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Gelman, Benjamin B.] Univ Texas Med Branch, Dept Neurosci, Galveston, TX 77555 USA. [Gelman, Benjamin B.] Univ Texas Med Branch, Dept Cell Biol, Galveston, TX 77555 USA. [Moore, David J.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Thames, AD (reprint author), 740 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA. EM athames@mednet.ucla.edu RI Martinez-Maza, Otoniel/B-2667-2009 OI Martinez-Maza, Otoniel/0000-0003-1364-0675 FU National Institute of Mental Health (NIMH) [R25 MH080661, NIMH K23 MH096551]; Translational Research in NeuroAIDS and Mental Health [NIH K23 MH096551]; California HIV/AIDS Research Program grant [ID06-LA-187]; Texas NeuroAIDS Research Center [U24MH100930]; California NeuroAIDS Tissue Network [U24MH100928]; National Neurological AIDS Bank [U24MH100929]; Manhattan HIV Brain Bank [U24MH100931]; Data Coordinating Center [U24MH100925] FX This work was supported by the National Institute of Mental Health (NIMH) grant R25 MH080661 (subaward PI: A.T.). A.T. is also currently supported by a career development award from the National Institute of Mental Health (NIMH K23 MH096551). A.T., M.B., C.H. and A.J. designed the current study. A.T. and M. B. drafted the manuscript. A.T. performed statistical analysis and prepared figures. L.I.M. and O.M.M. performed the multiplex assays for CSF samples. B.B.G., S.M., E.J.S and D.J.M. supervised and managed clinical cohorts that were used in this study. All authors read, participated in editing the manuscript, providing scientific input on the study design and approved the final manuscript.; R25 MH080661; PI: J. MacArthur subaward PI: A. Thames Translational Research in NeuroAIDS and Mental Health, NIH K23 MH096551 (PI: A. Thames); California HIV/AIDS Research Program grant ID06-LA-187 (Levine); Texas NeuroAIDS Research Center: U24MH100930; California NeuroAIDS Tissue Network: U24MH100928; National Neurological AIDS Bank: U24MH100929; Manhattan HIV Brain Bank: U24MH100931; Data Coordinating Center: U24MH100925. NR 47 TC 1 Z9 2 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JUL 31 PY 2015 VL 29 IS 12 BP 1483 EP 1491 DI 10.1097/QAD.0000000000000706 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CV6QL UT WOS:000364395000001 PM 26244388 ER PT J AU Basak, SK Zinabadi, A Wu, AW Venkatesan, N Duarte, VM Kang, JJ Dalgard, CL Srivastava, M Sarkar, FH Wang, MB Srivatsan, ES AF Basak, Saroj K. Zinabadi, Alborz Wu, Arthur W. Venkatesan, Natarajan Duarte, Victor M. Kang, James J. Dalgard, Clifton L. Srivastava, Meera Sarkar, Fazlul H. Wang, Marilene B. Srivatsan, Eri S. TI Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells SO ONCOTARGET LA English DT Article DE head and neck cancer; cisplatin; drug resistance; curcumin-difluorinated (CDF); cancer stem cell (CSC) ID NF-KAPPA-B; IN-VITRO; SIGNALING PATHWAYS; PANCREATIC-CANCER; SUPPRESSES GROWTH; COLON-CANCER; ORAL-CANCER; BETA KINASE; CARCINOMA; SENESCENCE AB Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer, with 600,000 new cases every year worldwide. Although chemotherapeutics exist, five-year survival is only 50%. New strategies to overcome drug resistance are required to improve HNSCC treatment. Curcumin-difluorinated (CDF), a synthetic analog of curcumin, was packaged in liposomes and used to evaluate growth inhibition of cisplatin resistant HNSCC cell lines CCL-23R and UM-SCC-1R generated from the parental cell lines CCL-23 and UM-SCC-1 respectively. Growth inhibition in vitro and expression levels of the CD44 (cancer stem cell marker), cytokines, and growth factors were investigated after liposomal CDF treatment. The in vivo growth inhibitory effect of liposomal CDF was evaluated in the nude mice xenograft tumor model of UM-SCC1R and the inhibition of CD44 was measured. Treatment of the resistant cell lines in vitro with liposomal CDF resulted in a statistically significant growth inhibition (p<0.05). The nude mice xenograft study showed a statistically significant tumor growth inhibition of UM-SCC-1R cells and a reduction in the expression of CD44 (p<0.05), indicating an inhibitory effect of liposomal CDF on CSCs. Our results demonstrate that delivery of CDF through liposomes may be an effective method for the treatment of cisplatin resistant HNSCC. C1 [Basak, Saroj K.; Zinabadi, Alborz; Wu, Arthur W.; Venkatesan, Natarajan; Duarte, Victor M.; Kang, James J.; Wang, Marilene B.; Srivatsan, Eri S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Duarte, Victor M.; Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Dalgard, Clifton L.; Srivastava, Meera] Uniformed Serv Univ Hlth Sci, Dept Anat, Bethesda, MD 20814 USA. [Dalgard, Clifton L.; Srivastava, Meera] Uniformed Serv Univ Hlth Sci, Dept Physiol & Genet, Bethesda, MD 20814 USA. [Dalgard, Clifton L.; Srivastava, Meera] Uniformed Serv Univ Hlth Sci, Dept Mol & Cell Biol, Bethesda, MD 20814 USA. [Sarkar, Fazlul H.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. [Wang, Marilene B.; Srivatsan, Eri S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. RP Srivatsan, ES (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. EM esrivats@g.ucla.edu FU VAGLAHS; West Los Angeles Surgical Education Research Center; UCLA Academic Senate grants; Merit; Veterans Administration, Washington, D.C. FX The study was supported by funds from VAGLAHS, West Los Angeles Surgical Education Research Center, UCLA Academic Senate grants (M. B. Wang), and Merit grant from the Veterans Administration, Washington, D.C. (E.S. Srivatsan). NR 42 TC 14 Z9 14 U1 1 U2 7 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JUL 30 PY 2015 VL 6 IS 21 BP 18504 EP 18517 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CO2VW UT WOS:000359015900025 PM 26098778 ER PT J AU Di Narzo, AF Kozlenkov, A Ge, YC Zhang, B Sanelli, L May, Z Li, YQ Fouad, K Cardozo, C Koonin, EV Bennett, DJ Dracheva, S AF Di Narzo, Antonio Fabio Kozlenkov, Alexey Ge, Yongchao Zhang, Bin Sanelli, Leo May, Zacnicte Li, Yanqing Fouad, Karim Cardozo, Christopher Koonin, Eugene V. Bennett, David J. Dracheva, Stella TI Decrease of mRNA Editing after Spinal Cord Injury is Caused by Down-regulation of ADAR2 that is Triggered by Inflammatory Response SO SCIENTIFIC REPORTS LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; SEROTONIN 2C; CONSTITUTIVE ACTIVITY; PREFRONTAL CORTEX; PERSISTENT SODIUM; EXPRESSION DATA; 2A RECEPTORS; HUMAN BRAIN; MOTONEURONS; RATS AB We recently showed that spinal cord injury (SCI) leads to a decrease in mRNA editing of serotonin receptor 2C (5-HT2CR) contributing to post-SCI spasticity. Here we study post-SCI mRNA editing and global gene expression using massively parallel sequencing. Evidence is presented that the decrease in 5-HT2CR editing is caused by down-regulation of adenosine deaminase ADAR2 and that editing of at least one other ADAR2 target, potassium channel Kv1.1, is decreased after SCI. Bayesian network analysis of genome-wide transcriptome data indicates that down-regulation of ADAR2 (1) is triggered by persistent inflammatory response to SCI that is associated with activation of microglia and (2) results in changes in neuronal gene expression that are likely to contribute both to post-SCI restoration of neuronal excitability and muscle spasms. These findings have broad implications for other diseases of the Central Nervous System and could open new avenues for developing efficacious antispastic treatments. C1 [Di Narzo, Antonio Fabio; Zhang, Bin] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Kozlenkov, Alexey; Dracheva, Stella] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Kozlenkov, Alexey; Dracheva, Stella] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Kozlenkov, Alexey; Cardozo, Christopher; Dracheva, Stella] James J Peters VA Med Ctr, Bronx, NY USA. [Ge, Yongchao] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Sanelli, Leo; May, Zacnicte; Li, Yanqing; Fouad, Karim; Bennett, David J.] Univ Alberta, Fac Rehabil Med, Ctr Neurosci, Edmonton, AB, Canada. [Koonin, Eugene V.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA. RP Dracheva, S (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. EM Stella.Dracheva@mssm.edu FU VISN3 Mental Illness Research and Education Clinical Center (MIRECC); VA Merit Review Award [BX002343]; intramural funds of the US Department of Health and Human Services FX The work was supported with resources and the use of facilities at the James J Peters VA Medical Center, Bronx, New York and funded by: VISN3 Mental Illness Research and Education Clinical Center (MIRECC) and VA Merit Review Award (BX002343 to S.D.). E.V.K. is supported by intramural funds of the US Department of Health and Human Services to National Library of Medicine. NR 57 TC 4 Z9 4 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD JUL 30 PY 2015 VL 5 AR 12615 DI 10.1038/srep12615 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO0UY UT WOS:000358870200001 PM 26223940 ER PT J AU La Fountaine, MF Cirnigliaro, CM Emmons, RR Kirshblum, SC Galea, M Spungen, AM Bauman, WA AF La Fountaine, Michael F. Cirnigliaro, Christopher M. Emmons, Racine R. Kirshblum, Steven C. Galea, Marinella Spungen, Ann M. Bauman, William A. TI Lipoprotein heterogeneity in persons with Spinal Cord Injury: a model of prolonged sitting and restricted physical activity SO LIPIDS IN HEALTH AND DISEASE LA English DT Article DE Cardiovascular disease; Insulin resistance; Lipids and lipoproteins; Nuclear magnetic resonance spectroscopy; Paraplegia; Special populations; Tetraplegia ID HIGH-DENSITY-LIPOPROTEIN; NUCLEAR-MAGNETIC-RESONANCE; CORONARY HEART-DISEASE; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; PARTICLE-SIZE; SKELETAL-MUSCLE; RISK; CHOLESTEROL; ATHEROSCLEROSIS AB Background: Persons with spinal cord injury (SCI) often have low levels of physical activity, which predispose to increased adiposity and decreased high density lipoprotein cholesterol (HDL-C) concentrations, and, generally, normal low density lipoprotein cholesterol (LDL-C) concentrations. In spite of the mixed lipoprotein profile, the SCI population has been reported to have an elevated risk of cardiovascular-related morbidity and mortality. Nuclear magnetic resonance spectroscopy may permit a more precise quantification of lipoprotein particle (P) species, enabling a more accurate inference of risk for cardiovascular disease (CVD) in the SCI population. Methods: Fasting blood samples were obtained on 83 persons with chronic SCI and 62 able-bodied (AB) subjects. Fasting plasma insulin (FPI), triglycerides (TG), and P number and size of VLDL (very low density lipoprotein), LDL, and HDL subclasses were determined. AB and SCI subjects were stratified based on HDL-C (i.e., Low < 40 and Normal >= 40 mg/dl): AB-Normal (n = 48), AB-Low (n = 14), SCI-Normal (n = 49), and SCI-Low (n = 34). Factorial analyses of variance were performed to identify group differences in lipoprotein measurements. Pearson correlations were performed between the number of P by lipoprotein subclass, size, FPI, and TG. Results: The SCI-Normal group was not significantly different from the AB-Normal group for body composition, FPI, TG or LP-IR and had negligible differences in the lipoprotein P profile, except for fewer number and smaller size of HDL-P. The SCI-Low group had a similar lipoprotein profile to that of the AB-Low group, but with a lipid P composition associated with a heightened atherogenic risk and greater tendency toward insulin resistance by the Lipoprotein-Insulin Resistance (LP-IR) score. In the SCI-Low group, the decreased number and reduced size of lipoprotein P were more prevalent and may be associated with increased waist circumference (i.e., abdominal adiposity), relatively elevated TG values (compared to the other subgroups), and an underlying subclinical state of insulin resistance. Conclusions: Prolonged sitting and restricted physical activity in individuals with SCI had the most profound effect on the HDL-C and its lipoprotein P subclasses, but not on LDL-C, however its P subclasses were also unfavorably affected but not to the same degree. The quantification of lipoprotein P characteristics may be a potent tool for the determination of risk for CVD in persons with SCI. C1 [La Fountaine, Michael F.; Cirnigliaro, Christopher M.; Spungen, Ann M.; Bauman, William A.] James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs Rehabil Res & Dev Serv, Bronx, NY 10468 USA. [La Fountaine, Michael F.; Spungen, Ann M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, Inst Adv Study Rehabil & Sports Sci, S Orange, NJ 07079 USA. [La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, Dept Phys Therapy, S Orange, NJ 07079 USA. [Emmons, Racine R.] William Patterson Univ, Dept Kinesiol, Wayne, NJ USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA. [Galea, Marinella] James J Peters VA Med Ctr, SCI Med Serv, Bronx, NY USA. [Spungen, Ann M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. RP La Fountaine, MF (reprint author), James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs Rehabil Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM michael.lafountaine@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B9212-C]; James J. Peters VA Medical Center FX Veterans Affairs Rehabilitation Research and Development Service (#B9212-C) and the James J. Peters VA Medical Center. NR 51 TC 0 Z9 0 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-511X J9 LIPIDS HEALTH DIS JI Lipids Health Dis. PD JUL 28 PY 2015 VL 14 AR 81 DI 10.1186/s12944-015-0084-4 PG 10 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA CN5QL UT WOS:000358484000001 PM 26215870 ER PT J AU Alfandre, D Sharpe, VA Berkowitz, K AF Alfandre, David Sharpe, Virginia Ashby Berkowitz, Kenneth TI Surrogate Decision Making for Patients Without Nuclear Family SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Alfandre, David; Sharpe, Virginia Ashby; Berkowitz, Kenneth] US Dept Vet Affairs, VHA Natl Ctr Eth Hlth Care, Washington, DC USA. RP Alfandre, D (reprint author), US Dept Vet Affairs, VHA Natl Ctr Eth Hlth Care, 423 E 23rd St, New York, NY 10010 USA. EM david.alfandre@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 28 PY 2015 VL 314 IS 4 BP 407 EP 408 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CN6YY UT WOS:000358581700027 PM 26219061 ER PT J AU Dzierzewski, JM Song, Y Fung, CH Rodriguez, JC Jouldjian, S Alessi, CA Breen, EC Irwin, MR Martin, JL AF Dzierzewski, Joseph M. Song, Yeonsu Fung, Constance H. Rodriguez, Juan C. Jouldjian, Stella Alessi, Cathy A. Breen, Elizabeth C. Irwin, Michael R. Martin, Jennifer L. TI Self-reported sleep duration mitigates the association between inflammation and cognitive functioning in hospitalized older men SO FRONTIERS IN PSYCHOLOGY LA English DT Article DE sleep duration; inflammation; cognition; hospitalization; older adults ID ILLNESS RATING-SCALE; C-REACTIVE PROTEIN; AGING POPULATION; ADULTS; DECLINE; WOMEN; INTERLEUKIN-6; PERFORMANCE; VALIDATION; CYTOKINE AB Examination of predictors of late-life cognitive functioning is particularly salient in at-risk older adults, such as those who have been recently hospitalized. Sleep and inflammation are independently related to late-life cognitive functioning. The potential role of sleep as a moderator of the relationship between inflammation and global cognitive functioning has not been adequately addressed. We examined the relationship between self-reported sleep duration, inflammatory markers, and general cognitive functioning in hospitalized older men. Older men (n = 135; Mean age = 72.9 +/- 9.7 years) were recruited from inpatient rehabilitation units at a VA Medical Center to participate in a cross-sectional study of sleep. Participants completed the Mini-Mental State Examination and Pittsburgh Sleep Quality Index, and underwent an 8 a.m. blood draw to measure inflammatory markers [i.e., C-reactive protein (CRP), tumor necrosis factor alpha (TNFot), soluble intercellular adhesion molecule-1 (5ICAM-1), and interleukin-6 (IL-6)]. Hierarchical regression analyses (controlling for age, education, race, depression, pain, health comorbidity, and BMI) revealed that higher levels of CRP and sICAM are associated with higher global cognitive functioning in older men with sleep duration >6h (beta = -0.19, beta = -0.18, p's < 0.05, respectively), but not in those with short sleep durations (p's > 0.05). In elderly hospitalized men, sleep duration moderates the association between inflammation and cognitive functioning. These findings have implications for the clinical care of older men within medical settings. C1 [Dzierzewski, Joseph M.; Song, Yeonsu; Fung, Constance H.; Rodriguez, Juan C.; Jouldjian, Stella; Alessi, Cathy A.; Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, Geriatr Res, Los Angeles, CA USA. [Dzierzewski, Joseph M.; Fung, Constance H.; Rodriguez, Juan C.; Alessi, Cathy A.; Breen, Elizabeth C.; Irwin, Michael R.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Breen, Elizabeth C.; Irwin, Michael R.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA 90024 USA. RP Dzierzewski, JM (reprint author), VA Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, Geriatr Res, 16111 Plummer St 11E, North Hills, CA 91343 USA. EM joseph.dzierzewski@va.gov RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431 FU National Institute on Aging [K23AG028452, K23AG045937]; UCLA Claude D. Pepper Older Americans Independence Center [NIA 5P30 AG028748]; National Center for Advancing Translational Sciences UCLA CTSI [UL1TR000124]; VA Health Services Research Development [IIR 04-321-3]; VA Advanced Geriatrics Fellowship Program; Beeson Career Development in Aging research award program; NIA; AFAR; John A. Hartford Foundation; Atlantic Philanthropies; VA Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center FX This work was supported by the National Institute on Aging (K23AG028452, K23AG045937), UCLA Claude D. Pepper Older Americans Independence Center (NIA 5P30 AG028748), National Center for Advancing Translational Sciences UCLA CTSI (UL1TR000124), VA Health Services Research & Development (IIR 04-321-3), VA Advanced Geriatrics Fellowship Program, the Beeson Career Development in Aging research award program (supported by NIA, AFAR, the John A. Hartford Foundation, and the Atlantic Philanthropies), and VA Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center. The authors would like to thank Mr. Sergio Martinez, Ms. Terry Vandenberg, and Ms. Karen Josephson, and the laboratory staff of the Inflammatory Biology Core of the UCLA Older Americans Independence Center and the Cousins Center for Psychoneuroimmunology, for their assistance with the project. NR 34 TC 0 Z9 0 U1 1 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-1078 J9 FRONT PSYCHOL JI Front. Psychol. PD JUL 21 PY 2015 VL 6 AR 1004 DI 10.3389/fpsyg.2015.01004 PG 8 WC Psychology, Multidisciplinary SC Psychology GA CN9VE UT WOS:000358797300002 PM 26257670 ER PT J AU Zhang, N Liang, HY Farese, RV Li, J Musi, N Hussey, SE AF Zhang, Ning Liang, Hanyu Farese, Robert V. Li, Ji Musi, Nicolas Hussey, Sophie E. TI Pharmacological TLR4 Inhibition Protects against Acute and Chronic Fat-Induced Insulin Resistance in Rats SO PLOS ONE LA English DT Article ID TOLL-LIKE RECEPTOR-4; ADIPOSE-TISSUE; ENDOTOXIN ANTAGONIST; SEVERE SEPSIS; TAK-242; OBESITY; ACID; MICE; MUTATION; INFLAMMATION AB Aims To evaluate whether pharmacological TLR4 inhibition protects against acute and chronic fat-induced insulin resistance in rats. Materials and Methods For the acute experiment, rats received a TLR4 inhibitor [TAK-242 or E5564 (2x5 mg/kg i.v. bolus)] or vehicle, and an 8-h Intralipid (20%, 8.5 mg/kg/min) or saline infusion, followed by a two-step hyperinsulinemic-euglycemic clamp. For the chronic experiment, rats were subcutaneously implanted with a slow-release pellet of TAK-242 (1.5 mg/d) or placebo. Rats then received a high fat diet (HFD) or a low fat control diet (LFD) for 10 weeks, followed by a two-step insulin clamp. Results Acute experiment; the lipid-induced reduction (18%) in insulin-stimulated glucose disposal (Rd) was attenuated by TAK-242 and E5564 (the effect of E5564 was more robust), suggesting improved peripheral insulin action. Insulin was able to suppress hepatic glucose production (HGP) in saline-but not lipid-treated rats. TAK-242, but not E5564, partially restored this effect, suggesting improved HGP. Chronic experiment; insulin-stimulated Rd was reduced similar to 30% by the HFD, but completely restored by TAK-242. Insulin could not suppress HGP in rats fed a HFD and TAK-242 had no effect on HGP. Conclusions Pharmacological TLR4 inhibition provides partial protection against acute and chronic fat-induced insulin resistance in vivo. C1 [Zhang, Ning; Liang, Hanyu; Li, Ji; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Liang, Hanyu; Li, Ji; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Liang, Hanyu; Musi, Nicolas] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Farese, Robert V.; Hussey, Sophie E.] Univ S Florida, Dept Internal Med, Tampa, FL 33620 USA. [Farese, Robert V.; Hussey, Sophie E.] James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA. RP Musi, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. EM musi@uthscsa.edu; sophiehussey@icloud.com FU NIH [1F32DK095565-01A1, RO1-DK80157, RO1-DK089229]; American Diabetes Association FX This work was supported by grants from the NIH (1F32DK095565-01A1) to S. Hussey, and the NIH (RO1-DK80157 and RO1-DK089229) and American Diabetes Association to N. Musi. NR 37 TC 3 Z9 3 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 21 PY 2015 VL 10 IS 7 AR e0132575 DI 10.1371/journal.pone.0132575 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN6LZ UT WOS:000358547600040 PM 26196892 ER PT J AU Jones, BE Sauer, B Jones, MM Campo, J Damal, K He, T Ying, J Greene, T Goetz, MB Neuhauser, MM Hicks, LA Samore, MH AF Jones, Barbara Ellen Sauer, Brian Jones, Makoto M. Campo, Jose Damal, Kavitha He, Tao Ying, Jian Greene, Tom Goetz, Matthew Bidwell Neuhauser, Melinda M. Hicks, Lauri A. Samore, Matthew H. TI Variation in Outpatient Antibiotic Prescribing for Acute Respiratory Infections in the Veteran Population A Cross-sectional Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID UNITED-STATES; TRACT INFECTIONS; DISEASES SOCIETY; ACUTE BRONCHITIS; AMBULATORY-CARE; ADULTS; AMERICA; TRENDS; RATES AB Background: Despite efforts to reduce antibiotic prescribing for acute respiratory infections (ARIs), information on factors that drive prescribing is limited. Objective: To examine trends in antibiotic prescribing in the Veterans Affairs population over an 8-year period and to identify patient, provider, and setting sources of variation. Design: Retrospective, cross-sectional study. Setting: All emergency departments and primary and urgent care clinics in the Veterans Affairs health system. Participants: All patient visits between 2005 and 2012 with primary diagnoses of ARIs that typically had low proportions of bacterial infection. Patients with infections or comorbid conditions that indicated antibiotic use were excluded. Measurements: Overall antibiotic prescription; macrolide prescription; and patient, provider, and setting characteristics extracted from the electronic health record. Results: The proportion of 1 million visits with ARI diagnoses that resulted in antibiotic prescriptions increased from 67.5% in 2005 to 69.2% in 2012 (P < 0.001). The proportion of macrolide antibiotics prescribed increased from 36.8% to 47.0% (P < 0.001). Antibiotic prescribing was highest for sinusitis (adjusted proportion, 86%) and bronchitis (85%) and varied little according to fever, age, setting, or comorbid conditions. Substantial variation was identified in prescribing at the provider level: The 10% of providers who prescribed the most antibiotics did so during at least 95% of their ARI visits, and the 10% who prescribed the least did so during 40% or fewer of their ARI visits. Limitation: Some clinical data that may have influenced the prescribing decision were missing. Conclusion: Veterans with ARIs commonly receive antibiotics, regardless of patient, provider, or setting characteristics. Macrolide use has increased, and substantial variation was identified in antibiotic prescribing at the provider level. C1 Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. Univ Utah, Salt Lake City, UT 84112 USA. Vet Affairs Kansas City Hlth Care Syst, Kansas City, MO USA. Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. US Dept Vet Affairs, Hines, IL USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Jones, BE (reprint author), George E Wahlen Dept Vet Affairs Med Ctr, Decision Enhancement & Analyt Sci Ctr, 500 Foothill Blvd,Mail Code 182, Salt Lake City, UT 84148 USA. EM barbara.jones@hsc.utah.edu OI Goetz, Matthew/0000-0003-4542-992X FU U.S. Department of Veterans Affairs, Centers for Disease Control and Prevention FX U.S. Department of Veterans Affairs, Centers for Disease Control and Prevention. NR 32 TC 7 Z9 8 U1 0 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 21 PY 2015 VL 163 IS 2 BP 73 EP + DI 10.7326/M14-1933 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA CN4NS UT WOS:000358407500014 PM 26192562 ER PT J AU Simon, TG Butt, AA AF Simon, Tracey G. Butt, Adeel A. TI Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Review DE Hepatitis C virus; Lipid profiles; Cholesterol; Statin; Fibrosis; Cirrhosis ID DENSITY-LIPOPROTEIN RECEPTOR; FATTY LIVER-DISEASE; B TYPE-I; TRIGLYCERIDE TRANSFER PROTEIN; LOVASTATIN-INDUCED APOPTOSIS; CORE PROTEIN; HEPATOCELLULAR-CARCINOMA; CHOLESTEROL-SYNTHESIS; PNPLA3 POLYMORPHISM; DRUG-INTERACTIONS AB The hepatitis C virus (HCV) is one of the most common causes of chronic liver disease and the leading indication for liver transplantation worldwide. Every aspect of the HCV life cycle is closely tied to human lipid metabolism. The virus circulates as a lipid-rich particle, utilizing lipoprotein cell receptors to gain entry into the hepatocyte. It has also been shown to upregulate lipid biosynthesis and impair lipid degradation, resulting in significant intracellular lipid accumulation and circulating hypocholesterolemia. Patients with chronic hepatitis C (CHC) are at increased risk of hepatic steatosis, fibrosis, and cardiovascular disease including accelerated atherosclerosis. HMG CoA Reductase inhibitors, or statins, have been shown to play an important role in the modulation of hepatic steatosis and fibrosis, and recent attention has focused upon their potential therapeutic role in CHC. This article reviews the hepatitis C viral life cycle as it impacts host lipoproteins and lipid metabolism. It then describes the pathogenesis of HCV-related hepatic steatosis, hypocholesterolemia and atherosclerosis, and finally describes the promising anti-viral and anti-fibrotic effects of statins, for the treatment of CHC. C1 [Simon, Tracey G.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Simon, Tracey G.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha 3050, Qatar. [Butt, Adeel A.] Hamad Med Corp, Doha 3050, Qatar. RP Butt, AA (reprint author), Univ Pittsburgh, Sch Med, 3601 Fifth Ave,Suite 3A, Pittsburgh, PA 15213 USA. EM aabutt@pitt.edu OI Butt, Adeel/0000-0002-1118-1826 NR 132 TC 4 Z9 4 U1 0 U2 9 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD JUL 21 PY 2015 VL 21 IS 27 BP 8293 EP 8303 DI 10.3748/wjg.v21.i27.8293 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CN2CS UT WOS:000358228600009 PM 26217081 ER PT J AU Ross, JD Cullen, DK Harris, JP LaPlaca, MC DeWeerth, SP AF Ross, James D. Cullen, D. Kacy Harris, James P. LaPlaca, Michelle C. DeWeerth, Stephen P. TI A three-dimensional image processing program for accurate, rapid, and semi-automated segmentation of neuronal somata with dense neurite outgrowth SO FRONTIERS IN NEUROANATOMY LA English DT Article DE image processing; segmentation; fluorescent microscopy; confocal; neural constructs ID HISTOPATHOLOGICAL IMAGES; ALGORITHM; MICROSCOPY; CYTOMETRY; TISSUE; DEFORMATION; STACKS; NUCLEI; CORTEX; MODEL AB Three-dimensional (3-D) image analysis techniques provide a powerful means to rapidly and accurately assess complex morphological and functional interactions between neural cells. Current software-based identification methods of neural cells generally fall into two applications: (1) segmentation of cell nuclei in high-density constructs or (2) tracing of cell neurites in single cell investigations. We have developed novel methodologies to permit the systematic identification of populations of neuronal somata possessing rich morphological detail and dense neurite arborization throughout thick tissue or 3-D in vitro constructs. The image analysis incorporates several novel automated features for the discrimination of neurites and somata by initially classifying features in 2-D and merging these classifications into 3-D objects; the 3-D reconstructions automatically identify and adjust for over and under segmentation errors. Additionally, the platform provides for software-assisted error corrections to further minimize error. These features attain very accurate cell boundary identifications to handle a wide range of morphological complexities. We validated these tools using confocal z-stacks from thick 3-D neural constructs where neuronal somata had varying degrees of neurite arborization and complexity, achieving an accuracy of >95%. We demonstrated the robustness of these algorithms in a more complex arena through the automated segmentation of neural cells in ex vivo brain slices. These novel methods surpass previous techniques by improving the robustness and accuracy by: (1) the ability to process neurites and somata, (2) bidirectional segmentation correction, and (3) validation via software-assisted user input. This 3-D image analysis platform provides valuable tools for the unbiased analysis of neural tissue or tissue surrogates within a 3D context, appropriate for the study of multi-dimensional cell-cell and cell-extracellular matrix interactions. C1 [Ross, James D.; LaPlaca, Michelle C.; DeWeerth, Stephen P.] Georgia Inst Technol Emory, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA. [Ross, James D.; DeWeerth, Stephen P.] Georgia Inst Technol, Sch Elect & Comp Engn, Atlanta, GA 30332 USA. [Cullen, D. Kacy; Harris, James P.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA. [Cullen, D. Kacy; Harris, James P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP DeWeerth, SP (reprint author), Georgia Inst Technol Emory, Sch Elect & Comp Engn, Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA. EM steve.deweerth@ece.gatech.edu FU National Institutes of Health [EB00786-01, T32-N5043126] FX The authors gratefully acknowledge Mr. Chintan Patel for his valuable feedback on the software and for his help generating the test image database. Additionally, the authors wish to thank Dr. Oskar Skrinjar and Mr. Edgar Brown for their insightful discussions on image processing and algorithm implementation. The National Institutes of Health supported this research through a Bioengineering Research Partnership (award no. EB00786-01) and an Institutional Training Grant (award no. T32-N5043126). The custom Matlab code presented here is available upon request. NR 34 TC 2 Z9 2 U1 5 U2 7 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5129 J9 FRONT NEUROANAT JI Front. Neuroanat. PD JUL 20 PY 2015 VL 9 AR 87 DI 10.3389/fnana.2015.00087 PG 15 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA CQ2LE UT WOS:000360431000001 PM 26257609 ER PT J AU Han, S Lear, TB Jerome, JA Rajbhandari, S Snavely, CA Gulick, DL Gibson, KF Zou, CB Chen, BB Mallampalli, RK AF Han, SeungHye Lear, Travis B. Jerome, Jacob A. Rajbhandari, Shristi Snavely, Courtney A. Gulick, Dexter L. Gibson, Kevin F. Zou, Chunbin Chen, Bill B. Mallampalli, Rama K. TI Lipopolysaccharide Primes the NALP3 Inflammasome by Inhibiting Its Ubiquitination and Degradation Mediated by the SCFFBXL2 E3 Ligase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NLRP3 INFLAMMASOME; ACTIVATION; DEUBIQUITINATION; MOTIF AB The inflammasome is a multiprotein complex that augments the proinflammatory response by increasing the generation and cellular release of key cytokines. Specifically, the NALP3 inflammasome requires two-step signaling, priming and activation, to be functional to release the proinflammatory cytokines IL-1 beta and IL-18. The priming process, through unknown mechanisms, increases the protein levels of NALP3 and pro-IL-1 beta in cells. Here we show that LPS increases the NALP3 protein life-span without significantly altering steady-state mRNA in human cells. LPS exposure reduces the ubiquitin-mediated proteasomal processing of NALP3 by inducing levels of an E3 ligase component, FBXO3, which targets FBXL2. The latter is an endogenous mediator of NALP3 degradation. FBXL2 recognizes Trp-73 within NALP3 for interaction and targets Lys-689 within NALP3 for ubiquitin ligation and degradation. A unique small molecule inhibitor of FBXO3 restores FBXL2 levels, resulting in decreased NALP3 protein levels in cells and, thereby, reducing the release of IL-1 beta and IL-18 in human inflammatory cells after NALP3 activation. Our findings uncover NALP3 as a molecular target for FBXL2 and suggest that therapeutic targeting of the inflammasome may serve as a platform for preclinical intervention. C1 [Han, SeungHye; Lear, Travis B.; Jerome, Jacob A.; Rajbhandari, Shristi; Snavely, Courtney A.; Gulick, Dexter L.; Gibson, Kevin F.; Zou, Chunbin; Chen, Bill B.; Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol Physiol & Bioengn, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Pulm Allergy & Crit Care Med, Dept Med, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health R01 [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01HL114453, HL116472]; Department of Veterans Affairs; Flight Attendant Medical Research Institute; American Heart Association [12SDG12040330] FX This work was performed on the basis of work supported, in part, by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported, in whole or in part, by National Institutes of Health R01 Grants HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01HL114453 (to R. K. M.), and HL116472 (to B. B. C.). This work was also supported by a merit review award from the Department of Veterans Affairs, the Flight Attendant Medical Research Institute, and American Heart Association Award 12SDG12040330 (to C. Z.). The authors declare that they have no conflicts of interest with the contents of this article. NR 25 TC 8 Z9 8 U1 0 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 17 PY 2015 VL 290 IS 29 BP 18124 EP 18133 DI 10.1074/jbc.M115.645549 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CN5ZB UT WOS:000358511700043 PM 26037928 ER PT J AU Richardson, DM Medvedeva, EL Roberts, CB Linkin, DR AF Richardson, Diane M. Medvedeva, Elina L. Roberts, Christopher B. Linkin, Darren R. CA Ctr Dis Control Prevention Epictr Program TI Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination in Community-Dwelling Veterans SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza vaccines; influenza human; comparative effectiveness research; elderly ID RESPIRATORY SYNCYTIAL VIRUS; UNITED-STATES; OLDER-ADULTS; PROPENSITY SCORE; ELDERLY-PEOPLE; HOSPITALIZATIONS; VACCINES; MORTALITY; EFFICACY; SEASON AB Background. Influenza is a significant cause of morbidity and mortality in older adults. High-dose (HD) trivalent inactivated vaccine has increased immunogenicity in older adults compared with standard-dose (SD) vaccine. We assessed the relative effectiveness of HD influenza vaccination (vs SD influenza vaccination). Methods. We conducted a retrospective cohort study among patients who receive primary care at Veteran Health Administration (VHA) medical centers, and who received influenza vaccine in the 2010-2011 influenza season. The primary outcome was hospitalization for influenza or pneumonia. We also conducted an analysis in subgroups defined by age. Results. We evaluated 25 714 patients who received HD vaccine and 139 511 who received SD vaccine in 23 VHA medical centers. The rate of hospitalization for influenza or pneumonia was 0.3% in both groups in the influenza season. After accounting for patient characteristics in propensity-adjusted analyses, the risk of hospitalization for influenza or pneumonia was not significantly lower among patients receiving HD vaccine vs those receiving SD vaccine (risk ratio, 0.98; 95% confidence interval,.68-1.40). In the subgroup of patients >= 85 years of age, receiving HD (compared with SD) vaccine was associated with lower rates of hospitalization for influenza or pneumonia. Conclusions. HD vaccine was not found to be more effective than SD vaccine in protecting against hospitalization for influenza or pneumonia; however, we found a protective effect in the oldest subgroup of patients. Additional studies are needed to evaluate the effectiveness of HD vaccine. C1 [Richardson, Diane M.; Medvedeva, Elina L.; Roberts, Christopher B.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Linkin, Darren R.] Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Linkin, Darren R.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Linkin, Darren R.] Philadelphia Vet Affairs Med Ctr, Div Infect Dis, Dept Med, Philadelphia, PA USA. RP Linkin, DR (reprint author), Philadelphia VA Med Ctr, Dept Med, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM linkin@mail.med.upenn.edu FU Veterans Integrated Service Network 4 Competitive Pilot Project Fund; Centers for Disease Control and Prevention Epicenters Program [U54-CK000163] FX This work was supported by the Veterans Integrated Service Network 4 Competitive Pilot Project Fund. The study was also supported in part by the Centers for Disease Control and Prevention Epicenters Program (U54-CK000163 [Ebbing Lautenbach]). NR 32 TC 9 Z9 9 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2015 VL 61 IS 2 BP 171 EP 176 DI 10.1093/cid/civ261 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7MD UT WOS:000359342500006 PM 25829001 ER PT J AU Tanner, NT Gebregziabher, M Halbert, CH Payne, E Egede, LE Silvestri, GA AF Tanner, Nichole T. Gebregziabher, Mulugeta Halbert, Chanita Hughes Payne, Elizabeth Egede, Leonard E. Silvestri, Gerard A. TI Racial Differences in Outcomes within the National Lung Screening Trial SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE lung cancer screening; race; mortality ID AFRICAN-AMERICANS; SOCIOECONOMIC-STATUS; SMOKING-CESSATION; COLORECTAL-CANCER; SMOKERS; STAGE; ATTITUDES; HEALTH; RISK; PHARMACOTHERAPY AB Rationale: Black individuals with lung cancer (LC) experience higher mortality because they present with more advanced disease and are less likely to undergo curative resection for early-stage disease. The National Lung Screening Trial (NLST) demonstrated improved LC mortality by screening high-risk patients with low-dose computed tomography (LDCT). The benefit of LDCT screening in black individuals is unknown. Objectives: Examine results of the NLST by race. Methods: This was a secondary analysis of a randomized trial (NCT00047385) performed in 33 U.S. centers. Measurements and Main Results: Overall and lung cancer-specific mortality were measured. Screening with LDCT reduced LC mortality in all racial groups but more so in black individuals (hazard ratio [HR], 0.61 vs. 0.86). Smoking increased the likelihood of death from LC, and when stratified by race black smokers were twice as likely to die as white smokers (HR, 4.10 vs. 2.25). Adjusting for sociodemographic and behavioral characteristics, black individuals experienced higher all-cause mortality than white individuals (HR, 1.35; 95% confidence interval, 1.22-1.49); however, black individuals screened with LDCT had a reduction in all-cause mortality. Black individuals were younger, were more likely to be current smokers, had more comorbidities, and had fewer years of formal education than white individuals (P < 0.05). Conclusions: Black individuals screened with LDCT had decreased mortality from lung cancer. However, the demographics associated with improved LC survival were less commonly found in black individuals. The overall mortality in the NLST was higher for black individuals than white individuals, but improved in black individuals screened, suggesting that this subgroup may have had improved access to care. To realize the reductions in mortality from LC screening, dissemination efforts need to be tailored to meet the needs of this community. C1 [Tanner, Nichole T.; Gebregziabher, Mulugeta; Halbert, Chanita Hughes; Egede, Leonard E.] Ralph H Johnson Vet Affairs Hosp, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Tanner, Nichole T.; Silvestri, Gerard A.] Med Univ S Carolina, Div Pulm & Crit Care Med, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Payne, Elizabeth] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Halbert, Chanita Hughes] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Halbert, Chanita Hughes] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Tanner, NT (reprint author), 96 Jonathan Lucas St,CSB 810, Charleston, SC 29425 USA. EM tripici@musc.edu FU OneBreath Foundation FX Funded by the OneBreath Foundation. NR 53 TC 9 Z9 9 U1 1 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUL 15 PY 2015 VL 192 IS 2 BP 200 EP 208 DI 10.1164/rccm.201502-0259OC PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CN2CW UT WOS:000358229100018 PM 25928649 ER PT J AU Rubenstein, LV AF Rubenstein, Lisa V. TI Managing physician lipid management: a population wide, risk-based decision support approach SO ISRAEL JOURNAL OF HEALTH POLICY RESEARCH LA English DT Editorial Material ID HEALTH-CARE AB Successful implementation of clinical guidelines for preventing complications of dyslipidemias has been an ongoing challenge. The article by Vinker and colleagues in this journal investigates the results of implementing risk-based guidelines for LDL (Low Density Lipoprotein) management in comparison to the prior approach of using the same LDL cutoff for patients at all levels of risk. Results show LDL levels dropped across the primary care population using the new risk-based approach, suggesting that clinical decision aids that link to individual patient characteristics, rather than promoting a universal target for all, may provide a particularly strong stimulus for changing provider and patient behavior. Results also challenge healthcare organizations, providers and patients to learn more about the pathway from guidelines to clinical reminders and from reminders to lower LDL levels and better population health. C1 [Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Sepulveda, CA 91343 USA. [Rubenstein, Lisa V.] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA QUERI Ctr Implementat Practice & Res Support, Sepulveda, CA USA. [Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Rubenstein, Lisa V.] UCLA Geffen Sch Med, Los Angeles, CA USA. [Rubenstein, Lisa V.] RAND Corp, RAND Hlth, Santa Monica, CA USA. RP Rubenstein, LV (reprint author), VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Sepulveda, CA 91343 USA. EM lisar@rand.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2045-4015 J9 ISR J HEALTH POLICY JI Isr. J. Health Policy Res. PD JUL 15 PY 2015 VL 4 AR 34 DI 10.1186/s13584-015-0032-9 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CM7DT UT WOS:000357851300001 PM 26175893 ER PT J AU Khan, M Dhammu, TS Matsuda, F Singh, AK Singh, I AF Khan, Mushfiquddin Dhammu, Tajinder S. Matsuda, Fumiyo Singh, Avtar K. Singh, Inderjit TI Blocking a vicious cycle nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy SO BMC NEUROSCIENCE LA English DT Article DE AMP-activated protein kinase; Neuronal nitric oxide synthase; Neuroprotection; Peroxynitrite; S-nitrosoglutathione; Stroke; Cerebral ischemia reperfusion ID NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; RAT MODEL; NEUROPROTECTIVE EFFICACY; PEROXYNITRITE FORMATION; NEUROVASCULAR UNIT; INFARCT VOLUME; BLOOD-FLOW AB Background: Stroke immediately sets into motion sustained excitotoxicity and calcium dysregulation, causing aberrant activity in neuronal nitric oxide synthase (nNOS) and an imbalance in the levels of nitric oxide (NO). Drugs targeting nNOS-originated toxicity may therefore reduce stroke-induced damage. Recently, we observed that a redox-modulating agent of the NO metabolome, S-nitrosoglutathione (GSNO), confers neurovascular protection by reducing the levels of peroxynitrite, a product of aberrant NOS activity. We therefore investigated whether GSNO-mediated neuroprotection and improved neurological functions depend on blocking nNOS/peroxynitrite-associated injurious mechanisms using a rat model of cerebral ischemia reperfusion (IR). Results: IR increased the activity of nNOS, the levels of neuronal peroxynitrite and phosphorylation at Ser(1412) of nNOS. GSNO treatment of IR animals decreased IR-activated nNOS activity and neuronal peroxynitrite levels by reducing nNOS phosphorylation at Ser(1412). The Ser(1412) phosphorylation is associated with increased nNOS activity. Supporting the notion that nNOS activity and peroxynitrite are deleterious following IR, inhibition of nNOS by its inhibitor 7-nitroindazole or reducing peroxynitrite by its scavenger FeTPPS decreased IR injury. GSNO also decreased the activation of AMP Kinase (AMPK) and its upstream kinase LKB1, both of which were activated in IR brain. AMPK has been implicated in nNOS activation via Ser(1412) phosphorylation. To determine whether AMPK activation is deleterious in the acute phase of IR, we treated animals after IR with AICAR (an AMPK activator) and compound c (an AMPK inhibitor). While AICAR potentiated, compound c reduced the IR injury. Conclusions: Taken together, these results indicate an injurious nNOS/peroxynitrite/AMPK cycle following stroke, and GSNO treatment of IR inhibits this vicious cycle, resulting in neuroprotection and improved neurological function. GSNO is a natural component of the human body, and its exogenous administration to humans is not associated with any known side effects. Currently, the FDA-approved thrombolytic therapy suffers from a lack of neuronal protective activity. Because GSNO provides neuroprotection by ameliorating stroke's initial and causative injuries, it is a candidate of translational value for stroke therapy. C1 [Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan. [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu; singhi@musc.edu FU NIH [NS-72511]; VA merit award [BX001062, BX002829]; NIH, National Center for Research Resources [C06 RR018823, C06 RR015455] FX This work was supported by grants from NIH (NS-72511) and VA merit award (BX001062 and BX002829). This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan and Ms. Terry Hope for their technical help and secretarial assistance. We are grateful to Drs. Harutoshi Sakakima and Yoshihiro Yoshida for their scientific input and to Ms. Danielle Lowe (MD/PhD student at the MUSC) for statistical analysis. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing of the manuscript. NR 62 TC 7 Z9 7 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2202 J9 BMC NEUROSCI JI BMC Neurosci. PD JUL 15 PY 2015 VL 16 AR 42 DI 10.1186/s12868-015-0179-x PG 12 WC Neurosciences SC Neurosciences & Neurology GA CM7CM UT WOS:000357848000001 PM 26174015 ER PT J AU Bauml, JM Chokshi, S Schapira, MM Im, EO Li, SQ Langer, CJ Ibrahim, SA Mao, JJ AF Bauml, Joshua M. Chokshi, Sagar Schapira, Marilyn M. Im, Eun-Ok Li, Susan Q. Langer, Corey J. Ibrahim, Said A. Mao, Jun J. TI Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey SO CANCER LA English DT Article DE CAM; complementary and alternative medicine; cancer; attitudes and beliefs; clinical characteristics; demographics ID PLANNED BEHAVIOR; BREAST-CANCER; LUNG-CANCER; SURVIVORS; TRIAL; QUALITY; CAM; ELECTROACUPUNCTURE; POPULATIONS; ARTHRALGIA AB BACKGROUNDComplementary and alternative medicine (CAM) incorporates treatments used by cancer survivors in an attempt to improve their quality of life. Although population studies have identified factors associated with its use, to the best of the authors knowledge, assessment of why patients use CAM or the barriers against its use have not been examined to date. METHODSThe authors conducted a cross-sectional survey study in the thoracic, breast, and gastrointestinal medical oncology clinics at an academic cancer center. Clinical and demographic variables were collected by self-report and chart abstraction. Attitudes and beliefs were measured using the validated Attitudes and Beliefs about CAM (ABCAM) instrument. This instrument divides attitudes and beliefs into 3 domains: expected benefits, perceived barriers, and subjective norms. RESULTSAmong 969 participants (response rate, 82.7%) surveyed between June 2010 and September 2011, patient age 65 years, female sex, and college education were associated with a significantly greater expected benefit from CAM (P<.0001 for all). Nonwhite patients reported more perceived barriers to CAM use compared with white patients (P<.0001), but had a similar degree of expected benefit (P=.76). In a multivariate logistic regression analysis, all domains of the ABCAM instrument were found to be significantly associated with CAM use (P<.01 for all) among patients with cancer. Attitudes and beliefs regarding CAM explained much more variance in CAM use than clinical and demographic variables alone. CONCLUSIONSAttitudes and beliefs varied by key clinical and demographic characteristics, and predicted CAM use. By developing CAM programs based upon attitudes and beliefs, barriers among underserved patient populations may be removed and more patient centered care may be provided. Cancer 2015;121:2431-2438. (c) 2015 American Cancer Society. Although population studies have identified factors associated with the use of complementary and alternative medicine (CAM), to the authors' knowledge assessment of why patients with cancer use CAM or the barriers against CAM use have not been examined to date. The results of the current study demonstrate that patients' attitudes and beliefs about CAM vary by key clinical and demographic characteristics, and appear to be predictive of CAM use. C1 [Bauml, Joshua M.; Schapira, Marilyn M.; Langer, Corey J.; Mao, Jun J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Bauml, Joshua M.; Langer, Corey J.] Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA. [Bauml, Joshua M.; Schapira, Marilyn M.; Ibrahim, Said A.] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA. [Schapira, Marilyn M.; Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Chokshi, Sagar] Rowan Univ Sch Osteopath Med, Stratford, NJ USA. [Schapira, Marilyn M.; Li, Susan Q.; Ibrahim, Said A.; Mao, Jun J.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Im, Eun-Ok] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Li, Susan Q.; Mao, Jun J.] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. RP Mao, JJ (reprint author), Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, 3400 Spruce St 2 Gates, Philadelphia, PA 19104 USA. EM jun.mao@uphs.upenn.edu FU Penn Institute on Aging Pilot Research Grants; National Institutes of Health [1K23 AT004112-05] FX Funded in part by the Penn Institute on Aging Pilot Research Grants. Dr. Mao is supported by the National Institutes of Health (grant 1K23 AT004112-05). NR 28 TC 7 Z9 7 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD JUL 15 PY 2015 VL 121 IS 14 BP 2431 EP 2438 DI 10.1002/cncr.29173 PG 8 WC Oncology SC Oncology GA CM0AI UT WOS:000357340200020 PM 26011157 ER PT J AU Hebenstreit, CL Maguen, S Koo, KH DePrince, AP AF Hebenstreit, Claire L. Maguen, Shira Koo, Kelly H. DePrince, Anne P. TI Latent profiles of PTSD symptoms in women exposed to intimate partner violence SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Intimate partner violence; Posttraumatic stress disorder; Appraisal; Female ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL ASSAULT; SOCIAL SUPPORT; SELF-BLAME; PSYCHOLOGICAL DISTRESS; DISSOCIATIVE SUBTYPE; PREDICTING PTSD; ABUSE; IMPACT; MODEL AB Background: Studies have utilized latent class analysis ([CA) and latent profile analysis ([PA) to examine posttraumatic stress disorder (PTSD) symptom profiles in a range of populations. Further study is needed to explore symptom profiles among women exposed to intimate partner violence (IPV). The current study examined latent symptom profiles in a sample of IPV-exposed women, and explored traumarelated cognitive appraisals associated with these PTSD symptom presentations. Methods: An LPA was conducted using cross-sectional data from a non-treatment seeking community sample of women recruited following a police-reported incident of IPV by a male perpetrator (N_229), Nlultinomial regression analyses determined associations between latent profile membership and trauma-related appraisals. Results: The LPA identified five PTSD symptom profiles: Low Symptom (46% of the sample); Low Symptom with High Hypervigilance (17%); Intermediate Symptom (16%); Intermediate Symptom with High Hypervigilance (11%); and High Symptom (10%). Trauma-related appraisals, including fear, alienation, and self-blame, were the strongest independent predictors of PTSD symptom profile membership. Limitations: The study focused on female victims of IPV by a male partner, and findings may not generalize to other gender configurations (e.g. same sex couples, male victims, etc.). The LPA is crosssectional, and the stability of these profiles over time warrants further study. Conclusions: These findings suggest the need for careful consideration of differences among IPV-exposed women within the larger context of PTSD research and clinical intervention. Identifying latent subgroups may provide an empirical basis for practitioners to design and implement PTSD intervention efforts that are tailored to specific symptom profiles. Published by Elsevier B.V. C1 [Hebenstreit, Claire L.; Maguen, Shira; Koo, Kelly H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Hebenstreit, Claire L.; Maguen, Shira; Koo, Kelly H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [DePrince, Anne P.] Univ Denver, Denver, CO 80208 USA. RP Hebenstreit, CL (reprint author), San Francisco VA Med Ctr, Gen Internal Med 111A1, 4150 Clement St, San Francisco, CA 94121 USA. EM Claire.Hebenstreit@va.gov OI Hebenstreit, Claire/0000-0001-5970-2195 FU National Institute of Justice Office of Justice Programs, U.S. Department of Justice [2007-WG-RX-0002]; Department of Veterans Affairs Advanced Fellowship Program in Women's Health FX This project was supported by Award no. 2007-WG-RX-0002 awarded by the National Institute of Justice Office of Justice Programs, U.S. Department of Justice, and by the Department of Veterans Affairs Advanced Fellowship Program in Women's Health. The opinions, findings, and conclusions or recommendations expressed in this manuscript are those of the authors and do not necessarily reflect those of the Department of Justice or the U.S. Department of Veterans Affairs. NR 54 TC 2 Z9 2 U1 8 U2 32 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JUL 15 PY 2015 VL 180 BP 122 EP 128 DI 10.1016/j.jad.2015.03.047 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CI2WF UT WOS:000354607700018 PM 25898332 ER PT J AU Bradley, SM O'Donnell, CI Grunwald, GK Liu, CF Hebert, PL Maddox, TM Jesse, RL Fihn, SD Rumsfeld, JS Ho, PM AF Bradley, Steven M. O'Donnell, Colin I. Grunwald, Gary K. Liu, Chuan-Fen Hebert, Paul L. Maddox, Thomas M. Jesse, Robert L. Fihn, Stephan D. Rumsfeld, John S. Ho, P. Michael TI Facility-Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention Insights on Short-Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Program SO CIRCULATION LA English DT Article DE costs and cost analysis; hospitalization; outcome assessment (health care); percutaneous coronary intervention ID MEDICARE BENEFICIARIES; READMISSION RATES; QUALITY; PERFORMANCE; EFFICIENCY; OUTCOMES; ACCESS; SITE AB Background-Policies to reduce unnecessary hospitalizations after percutaneous coronary intervention (PCI) are intended to improve healthcare value by reducing costs while maintaining patient outcomes. Whether facility-level hospitalization rates after PCI are associated with cost of care is unknown. Methods and Results-We studied 32 080 patients who received PCI at any 1 of 62 Veterans Affairs hospitals from 2008 to 2011. We identified facility outliers for 30-day risk-standardized hospitalization, mortality, and cost. Compared with the risk-standardized average, 2 hospitals (3.2%) had a lower-than-expected hospitalization rate, and 2 hospitals (3.2%) had a higher-than-expected hospitalization rate. We observed no statistically significant variation in facility-level risk-standardized mortality. The facility-level unadjusted median per patient 30-day total cost was $23 820 (interquartile range, $19604-$29958). Compared with the risk-standardized average, 17 hospitals (27.4%) had lower-than-expected costs, and 14 hospitals (22.6%) had higher-than-expected costs. At the facility level, the index PCI accounted for 83.1% of the total cost (range, 60.3%-92.2%), whereas hospitalization after PCI accounted for only 5.8% (range, 2.0%-12.7%) of the 30-day total cost. Facilities with higher hospitalization rates were not more expensive (Spearman rho= 0.16; 95% confidence interval, -0.09 to 0.39; P=0.21). Conclusions-In this national study, hospitalizations in the 30 day after PCI accounted for only 5.8% of 30-day cost, and facility-level cost was not correlated with hospitalization rates. This challenges the focus on reducing hospitalizations after PCI as an effective means of improving healthcare value. Opportunities remain to improve PCI value by reducing the variation in total cost of PCI without compromising patient outcomes. C1 [Bradley, Steven M.; O'Donnell, Colin I.; Grunwald, Gary K.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. [Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael] Univ Colorado, Sch Med, Aurora, CO USA. [O'Donnell, Colin I.; Grunwald, Gary K.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA. [Liu, Chuan-Fen; Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Jesse, Robert L.; Fihn, Stephan D.] US Dept Vet Affairs, Vet Hlth Adm, Washington, DC USA. RP Bradley, SM (reprint author), VA Eastern Colorado Hlth Care Syst, Dept Vet Affairs, 1055 Clermont St 111B, Denver, CO 80220 USA. EM Steven.Bradley@va.gov FU VA Health Services Research Development [HSRD-CDA2 10-199, HSRD-CDA2 08-021] FX Drs Bradley and Maddox are supported by Career Development Awards (HSR&D-CDA2 10-199 and HSR&D-CDA2 08-021, respectively) from the VA Health Services Research & Development. NR 38 TC 3 Z9 3 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD JUL 14 PY 2015 VL 132 IS 2 BP 101 EP 108 DI 10.1161/CIRCULATIONAHA.115.015351 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DC5IN UT WOS:000369254800011 PM 25951833 ER PT J AU Toledo, JB Bjerke, M Chen, KW Rozycki, M Jack, CR Weiner, MW Arnold, SE Reiman, EM Davatzikos, C Shaw, LM Trojanowski, JQ AF Toledo, Jon B. Bjerke, Maria Chen, Kewei Rozycki, Martin Jack, Clifford R. Weiner, Michael W. Arnold, Steven E. Reiman, Eric M. Davatzikos, Christos Shaw, Leslie M. Trojanowski, John Q. TI Memory, executive, and multidomain subtle cognitive impairment Clinical and biomarker findings SO NEUROLOGY LA English DT Article ID ALZHEIMERS ASSOCIATION WORKGROUPS; NEUROIMAGING INITIATIVE ADNI; DIAGNOSTIC GUIDELINES; CEREBROSPINAL-FLUID; NATIONAL INSTITUTE; COMPOSITE SCORE; CSF BIOMARKERS; DISEASE; DECLINE; RECOMMENDATIONS AB Objective: We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. Methods: We studied 522 healthy controls in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cutoffs for executive, memory, and multidomain SCI were defined using participants who remained cognitively normal (CN) for 7 years. CSF Alzheimer disease (AD) biomarkers, composite and region-of-interest (ROI) MRI, and fluorodeoxyglucose-PET measures were compared in these participants. Results: Using a stringent cutoff (fifth percentile), 27.6% of the ADNI participants were classified as SCI. Most single ROI or global-based measures were not sensitive to detect differences between groups. Only MRI-SPARE-AD (Spatial Pattern of Abnormalities for Recognition of Early AD), a quantitative MRI pattern-based global index, showed differences between all groups, excluding the executive SCI group. Atrophy patterns differed in memory SCI and SMC. The CN and the SMC groups presented a similar distribution of preclinical dementia stages. Fifty percent of the participants with executive, memory, and multidomain SCI progressed to mild cognitive impairment or dementia at 7, 5, and 2 years, respectively. Conclusions: Our results indicate that (1) the different SCI categories have different clinical prognoses and biomarker signatures, (2) longitudinally followed CN subjects are needed to establish clinical cutoffs, (3) subjects with SMC show a frontal pattern of brain atrophy, and (4) pattern-based analyses outperform commonly used single ROI-based neuroimaging biomarkers and are needed to detect initial stages of cognitive impairment. C1 [Toledo, Jon B.; Bjerke, Maria; Shaw, Leslie M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med,Inst Aging, Philadelphia, PA 19104 USA. [Arnold, Steven E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Chen, Kewei; Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ USA. [Rozycki, Martin; Davatzikos, Christos] Ctr Biomed Image Comp & Analyt, Philadelphia, PA USA. [Jack, Clifford R.] Mayo Clin, Coll Med, Rochester, MN USA. [Weiner, Michael W.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Radiol, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94143 USA. RP Trojanowski, JQ (reprint author), Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med,Inst Aging, Philadelphia, PA 19104 USA. EM trojanow@mail.med.upenn.edu RI Kowall, Neil/G-6364-2012; Jack, Clifford/F-2508-2010 OI Kowall, Neil/0000-0002-6624-0213; Jack, Clifford/0000-0001-7916-622X; Toledo, Jon/0000-0003-4366-9268; Preda, Adrian /0000-0003-3373-2438 FU ADNI (NIH) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes Health Research; NIH [R01AG039478, P30AG10124, R01DA025201, U01DK057135, U01AG024904, R01-AG011378, U01-HL096917, U01-AG024904, RO1 AG041851, R01 AG37551, R01AG043392, U01-AG06786]; BrightFocus Foundation; Marian S. Ware Charitable Giving Fund; Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation; Nomis Foundation; Banner Alzheimer's Foundation; state of Arizona; [P01 AG032953]; [PO1 AG017586]; [P30 AG010124]; [P50 NS053488] FX Dr. Toledo is supported by P01 AG032953, PO1 AG017586, P30 AG010124, and P50 NS053488. Dr. Trojanowski is the William Maul Measey-Truman G. Schnabel Jr., Professor of Geriatric Medicine and Gerontology. Data collection and sharing for this project was funded by the ADNI (NIH grant U01 AG024904) and DOD ADNI (Department of Defense award W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the NIH (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Dr. Arnold receives research funding from NIH (R01AG039478, P30AG10124, R01DA025201, U01DK057135, U01AG024904), the BrightFocus Foundation (principal investigator), and the Marian S. Ware Charitable Giving Fund. Dr. Jack receives research funding from the NIH (R01-AG011378, U01-HL096917, U01-AG024904, RO1 AG041851, R01 AG37551, R01AG043392, U01-AG06786) and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. Dr. Reiman receives research funding from National Institute on Aging, Nomis Foundation, Banner Alzheimer's Foundation, and the state of Arizona. NR 38 TC 10 Z9 10 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD JUL 14 PY 2015 VL 85 IS 2 BP 144 EP 153 DI 10.1212/WNL.0000000000001738 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA CM6NG UT WOS:000357804900007 PM 26085606 ER PT J AU Thiruvoipati, T Kielhorn, CE Armstrong, EJ AF Thiruvoipati, Thejasvi Kielhorn, Caitlin E. Armstrong, Ehrin J. TI Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes SO WORLD JOURNAL OF DIABETES LA English DT Review DE Peripheral artery disease; Epidemiology; Pathophysiology; Outcomes; Diabetes ID ENDOTHELIUM-DEPENDENT VASODILATION; ACUTE MYOCARDIAL-INFARCTION; CRITICAL LIMB ISCHEMIA; C-REACTIVE PROTEIN; VASCULAR-DISEASE; NITRIC-OXIDE; CARDIOVASCULAR-DISEASE; CLINICAL CONSEQUENCES; INSULIN-RESISTANCE; METABOLIC SYNDROME AB Peripheral artery disease (PAD) is the atherosclerosis of lower extremity arteries and is also associated with atherothrombosis of other vascular beds, including the cardiovascular and cerebrovascular systems. The presence of diabetes mellitus greatly increases the risk of PAD, as well as accelerates its course, making these patients more susceptible to ischemic events and impaired functional status compared to patients without diabetes. To minimize these cardiovascular risks it is critical to understand the pathophysiology of atherosclerosis in diabetic patients. This, in turn, can offer insights into the therapeutic avenues available for these patients. This article provides an overview of the epidemiology of PAD in diabetic patients, followed by an analysis of the mechanisms by which altered metabolism in diabetes promotes atherosclerosis and plaque instability. Outcomes of PAD in diabetic patients are also discussed, with a focus on diabetic ulcers and critical limb ischemia. C1 [Thiruvoipati, Thejasvi; Kielhorn, Caitlin E.; Armstrong, Ehrin J.] Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. [Thiruvoipati, Thejasvi; Kielhorn, Caitlin E.; Armstrong, Ehrin J.] Univ Colorado, Sch Med, Denver, CO 80220 USA. RP Armstrong, EJ (reprint author), Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. EM ehrin.armstrong@ucdenver.edu NR 86 TC 5 Z9 6 U1 0 U2 2 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1948-9358 J9 WORLD J DIABETES JI World J. Diabetes PD JUL 10 PY 2015 VL 6 IS 7 BP 961 EP 969 DI 10.4239/wjd.v6.i7.961 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CR0EA UT WOS:000360989900007 PM 26185603 ER PT J AU Feng, S Wang, JH Zhang, YQ Creighton, CJ Ittmann, M AF Feng, Shu Wang, Jianghua Zhang, Yiqun Creighton, Chad J. Ittmann, Michael TI FGF23 promotes prostate cancer progression SO ONCOTARGET LA English DT Article DE prostate cancer; FGF23; signal transduction; fibroblast growth factors; endocrine fibroblast growth factors ID GROWTH-FACTOR; SERUM-CALCIUM; FUSION; GENE; RECEPTOR; CELLS; DIFFERENTIATION; EXPRESSION; PROGNOSIS; PATHWAYS AB Prostate cancer is the most common cancer in US men and the second leading cause of cancer deaths. Fibroblast growth factor 23 (FGF23) is an endocrine FGF, normally expressed by osteocytes, which plays a critical role in phosphate homeostasis via a feedback loop involving the kidney and vitamin D. We now show that FGF23 is expressed as an autocrine growth factor in all prostate cancer cell lines tested and is present at increased levels in prostate cancer tissues. Exogenous FGF23 enhances proliferation, invasion and anchorage independent growth in vitro while FGF23 knockdown in prostate cancer cell lines decreases these phenotypes. FGF23 knockdown also decreases tumor growth in vivo. Given that classical FGFs and FGF19 are also increased in prostate cancer, we analyzed expression microarrays hybridized with RNAs from of LNCaP cells stimulated with FGF2, FGF19 or FGF23. The different FGF ligands induce overlapping as well as unique patterns of gene expression changes and thus are not redundant. We identified multiple genes whose expression is altered by FGF23 that are associated with prostate cancer initiation and progression. Thus FGF23 can potentially also act as an autocrine, paracrine and/or endocrine growth factor in prostate cancer that can promote prostate cancer progression. C1 [Feng, Shu; Wang, Jianghua; Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Feng, Shu; Wang, Jianghua; Ittmann, Michael] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. [Zhang, Yiqun; Creighton, Chad J.] Baylor Coll Med, Div Biostat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu FU Dept of Veterans Affairs Merit Review program; Prostate Cancer Foundation; National Cancer Institute [P30 CA125123] FX This work was supported by grants from the Dept of Veterans Affairs Merit Review program (MI); the Prostate Cancer Foundation (MI); the National Cancer Institute to the Dan L. Duncan Cancer (P30 CA125123) supporting Human Tissue Acquisition and Pathology Core and by the use of the facilities of the Michael E. DeBakey VAMC. NR 39 TC 7 Z9 8 U1 0 U2 2 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JUL 10 PY 2015 VL 6 IS 19 BP 17291 EP 17301 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CO2VB UT WOS:000359013600056 PM 26019137 ER PT J AU Adragna, NC Ravilla, NB Lauf, PK Begum, G Khanna, AR Sun, D Kahle, KT AF Adragna, Norma C. Ravilla, Nagendra B. Lauf, Peter K. Begum, Gulnaz Khanna, Arjun R. Sun, Dandan Kahle, Kristopher T. TI Regulated phosphorylation of the K-Cl cotransporter KCC3 is a molecular switch of intracellular potassium content and cell volume homeostasis SO FRONTIERS IN CELLULAR NEUROSCIENCE LA English DT Article DE K-Cl cotransporters; KCC3; NKCC1; SPAK; cell volume homeostasis; regulatory volume decrease; cerebral edema; neurodegeneration ID SMOOTH-MUSCLE-CELLS; CATION-CHLORIDE COTRANSPORTERS; VASCULAR ENDOTHELIAL-CELLS; PROTEIN-KINASE-G; RED-BLOOD-CELLS; ION-TRANSPORT; N-ETHYLMALEIMIDE; KCL COTRANSPORT; DEPENDENT K; ERYTHROCYTES AB The defense of cell volume against excessive shrinkage or swelling is a requirement for cell function and organismal survival. Cell swelling triggers a coordinated homeostatic response termed regulatory volume decrease (RVD), resulting in K+ and Cl- efflux via activation of K+ channels, volume-regulated anion channels (VRACs), and the K+-Cl- cotransporters, including KCC3. Here, we show genetic alanine (Ala) substitution at threonines (Thr) 991 and 1048 in the KCC3a isoform carboxyl-terminus, preventing inhibitory phosphorylation at these sites, not only significantly up-regulates KCC3a activity up to 25-fold in normally inhibitory isotonic conditions, but is also accompanied by reversal of activity of the related bumetanide-sensitive Na+-K+-2Cl(-) cotransporter isoform 1 (NKCC1). This results in a rapid (<10 min) and significant (>90%) reduction in intracellular K+ content (K-i) via both Cl-dependent (KCC3a + NKCC1) and Cl-independent [DCPIB (VRAC inhibitor)-sensitive] pathways, which collectively renders cells less prone to acute swelling in hypotonic osmotic stress. Together, these data demonstrate the phosphorylation state of Thr991/Thr1048 in KCC3a encodes a potent switch of transporter activity, K-i homeostasis, and cell volume regulation, and reveal novel observations into the functional interaction among ion transport molecules involved in RVD. C1 [Adragna, Norma C.; Ravilla, Nagendra B.; Lauf, Peter K.] Wright State Univ, Boonshoft Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA. [Lauf, Peter K.] Wright State Univ, Boonshoft Sch Med, Dept Pathol, Dayton, OH 45435 USA. [Begum, Gulnaz; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Khanna, Arjun R.; Kahle, Kristopher T.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA USA. [Khanna, Arjun R.; Kahle, Kristopher T.] Harvard Univ, Harvard Med Sch, Boston, MA USA. [Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Kahle, Kristopher T.] Harvard Univ, Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA. RP Adragna, NC (reprint author), Wright State Univ, Boonshoft Sch Med, Dept Pharmacol & Toxicol, Math & Microbiol 002D, Bldg 3640 Col Glenn Hwy, Dayton, OH 45435 USA. EM norma.adragna@wright.edu; kkahle@enders.tch.harvard.edu FU Pharmacology and Toxicology Master in Science Program; Wright State University Foundation; NIH [R01 NS38118, R01 NS075995]; Manton Center for Orphan Disease Research; Harvard-MIT Basic Neuroscience Grant FX We thank Kathy Leonard who trained NBR in the essentials of our long established ion flux techniques. We also thank David Clapham (Harvard) for his critical insights and comments on this manuscript. This work has been presented in part as abstracts and posters at the EB 2013 meeting in Boston, MA, and at the Lake Cumberland Biological Transport Conference in June 2013. This work has been supported, in part, by the Pharmacology and Toxicology Master in Science Program (NBR) and Wright State University Foundation; NIH R01 NS38118 and R01 NS075995 (DS); the Manton Center for Orphan Disease Research (KK), and a Harvard-MIT Basic Neuroscience Grant. NR 61 TC 5 Z9 5 U1 3 U2 5 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5102 J9 FRONT CELL NEUROSCI JI Front. Cell. Neurosci. PD JUL 9 PY 2015 VL 9 AR 255 DI 10.3389/fncel.2015.00255 PG 13 WC Neurosciences SC Neurosciences & Neurology GA CM4SZ UT WOS:000357676300001 PM 26217182 ER PT J AU Weisbart, RH Chan, G Jordaan, G Noble, PW Liu, YF Glazer, PM Nishimura, RN Hansen, JE AF Weisbart, Richard H. Chan, Grace Jordaan, Gwen Noble, Philip W. Liu, Yanfeng Glazer, Peter M. Nishimura, Robert N. Hansen, James E. TI DNA-dependent targeting of cell nuclei by a lupus autoantibody SO SCIENTIFIC REPORTS LA English DT Article AB A nuclear-penetrating lupus anti-DNA autoantibody, 3E10, has been found to inhibit DNA repair and selectively kill certain cancer cells that are highly vulnerable to DNA damage. In addition, a 3E10 single chain variable fragment (scFv) has been developed for use as a delivery vehicle to carry therapeutic cargo proteins into cell nuclei. A greater understanding of the mechanism by which 3E10 penetrates cell nuclei is needed to help determine the scope of its potential therapeutic applications. Here we show that the presence of extracellular DNA significantly enhances the nuclear uptake of 3E10 scFv. In addition, we find that 3E10 scFv preferentially localizes into tumor cell nuclei in vivo, likely due to increased DNA in the local environment released from ischemic and necrotic regions of tumor. These data provide insight into the mechanism of nuclear penetration by 3E10 and demonstrate the potential for use of 3E10 in therapeutic approaches to diseases ranging from malignancy to ischemic conditions such as stroke. C1 [Weisbart, Richard H.; Chan, Grace; Jordaan, Gwen; Nishimura, Robert N.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res, Sepulveda, CA 91343 USA. [Noble, Philip W.; Liu, Yanfeng; Glazer, Peter M.; Hansen, James E.] Yale Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA. [Glazer, Peter M.] Yale Sch Med, Dept Genet, New Haven, CT 06520 USA. [Glazer, Peter M.; Hansen, James E.] Yale Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA. [Nishimura, Robert N.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. RP Weisbart, RH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res, Sepulveda, CA 91343 USA. EM rweisbar@ucla.edu; james.e.hansen@yale.edu FU Veterans Affairs Merit Review Grant; Yale Center for Clinical Investigation CTSA Scholar Award; National Center for Advancing Translational Science (NCATS) of the National Institutes of Health (NIH) [UL1 TR000142]; NIH roadmap for Medical Research FX Veterans Affairs Merit Review Grant (RHW). Yale Center for Clinical Investigation CTSA Scholar Award (JEH). This publication was made possible by CTSA Grant Number UL1 TR000142 from the National Center for Advancing Translational Science (NCATS), components of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. NR 13 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD JUL 9 PY 2015 VL 5 AR 12022 DI 10.1038/srep12022 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA V46JC UT WOS:000209879500001 PM 26156563 ER PT J AU Xi, M Fung, SJ Yamuy, J Chase, MH AF Xi, M. Fung, S. J. Yamuy, J. Chase, M. H. TI INTERACTIONS BETWEEN HYPOCRETINERGIC AND GABAERGIC SYSTEMS IN THE CONTROL OF ACTIVITY OF NEURONS IN THE CAT PONTINE RETICULAR FORMATION SO NEUROSCIENCE LA English DT Article DE REM sleep; orexin; inhibition; electrical stimulation; intracellular recording ID EYE-MOVEMENT SLEEP; INDUCED MOTOR INHIBITION; LUMBAR MOTONEURONS; REM-SLEEP; POSTSYNAPTIC POTENTIALS; MASSETER MOTONEURONS; CENTRAL NUCLEUS; GABA(A) RECEPTORS; OREXIN RECEPTORS; FEEDING-BEHAVIOR AB Anatomical studies have demonstrated that hypocretinergic and GABAergic neurons innervate cells in the nucleus pontis oralis (NPO), a nucleus responsible for the generation of active (rapid eye movement (REM)) sleep (AS) and wakefulness (W). Behavioral and electrophysiological studies have shown that hypocretinergic and GABAergic processes in the NPO are involved in the generation of AS as well as W. An increase in hypocretin in the NPO is associated with both AS and W, whereas GABA levels in the NPO are elevated during W. We therefore examined the manner in which GABA modulates NPO neuronal responses to hypocretin. We hypothesized that interactions between the hypocretinergic and GABAergic systems in the NPO play an important role in determining the occurrence of AS or W. To determine the veracity of this hypothesis, we examined the effects of the juxtacellular application of hypocretin-1 and GABA on the activity of NPO neurons, which were recorded intracellularly, in chloralose-anesthetized cats. The juxtacellular application of hypocretin-1 significantly increased the mean amplitude of spontaneous EPSPs and the frequency of discharge of NPO neurons; in contrast, the juxtacellular microinjection of GABA produced the opposite effects, i.e., there was a significant reduction in the mean amplitude of spontaneous EPSPs and a decrease in the discharge of these cells. When hypocretin-1 and GABA were applied simultaneously, the inhibitory effect of GABA on the activity of NPO neurons was reduced or completely blocked. In addition, hypocretin-1 also blocked GABAergic inhibition of EPSPs evoked by stimulation of the laterodorsal tegmental nucleus. These data indicate that hypocretin and GABA function within the context of a neuronal gate that controls the activity of AS-on neurons. Therefore, we suggest that the occurrence of either AS or W depends upon interactions between hypocretinergic and GABAergic processes as well as inputs from other sites that project to AS-on neurons in the NPO. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Xi, M.; Fung, S. J.; Chase, M. H.] Websci Int, Los Angeles, CA 90024 USA. [Xi, M.; Fung, S. J.; Yamuy, J.; Chase, M. H.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Yamuy, J.; Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. RP Xi, M (reprint author), Websci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA. EM mxi@websciences.org FU U.S. Public Health Service [MH 43362] FX This work was supported by the following grant from the U.S. Public Health Service: MH 43362. We thank Mr. Oscar Ramos, Mr. Trent Wenzel, Ms. Ricki-Leigh Malaguti and Ms. Emi Koda for their excellent technical assistance. NR 75 TC 1 Z9 1 U1 0 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD JUL 9 PY 2015 VL 298 BP 190 EP 199 DI 10.1016/j.neuroscience.2015.04.022 PG 10 WC Neurosciences SC Neurosciences & Neurology GA CI5GT UT WOS:000354783300018 PM 25892701 ER PT J AU Evans, TM Jaramillo, CA Sataranatarajan, K Watts, L Sabia, M Qi, W Van Remmen, H AF Evans, T. M. Jaramillo, C. A. Sataranatarajan, K. Watts, L. Sabia, M. Qi, W. Van Remmen, H. TI THE EFFECT OF MILD TRAUMATIC BRAIN INJURY ON PERIPHERAL NERVOUS SYSTEM PATHOLOGY IN WILD-TYPE MICE AND THE G93A MUTANT MOUSE MODEL OF MOTOR NEURON DISEASE SO NEUROSCIENCE LA English DT Article DE TBI; amyotrophic lateral sclerosis; mouse model; oxidative stress; spinal cord ID AMYOTROPHIC-LATERAL-SCLEROSIS; SPINAL-CORD-INJURY; OXIDATIVE STRESS; SKELETAL-MUSCLE; HEAD-INJURY; ANTIOXIDANT THERAPIES; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; TRANSGENIC MODEL; HIGH-SCHOOL AB Traumatic brain injury (TBI) is associated with a risk of neurodegenerative disease. Some suggest a link between TBI and motor neuron disease (MND), including amyotrophic lateral sclerosis (ALS). To investigate the potential mechanisms linking TBI to MND, we measured motor function and neuropathology following mild-TBI in wild-type and a transgenic model of ALS, G93A mutant mice. Mild-TBI did not alter the lifespan of G93A mice or age of onset; however, rotarod performance was impaired in G93A verses wild-type mice. Grip strength was reduced only in G93A mice after mild-TBI. Increased electromyography (EMG) abnormalities and markers of denervation (AchR, Runx1) indicate that mild-TBI may result in peripheral effects that are exaggerated in G93A mice. Markers of inflammation (cell edema, astrogliosis and microgliosis) were detected at 24 and 72 h in the brain and spinal cord in wild-type and G93A mice. Levels of F2-isoprostanes, a marker of oxidative stress, were increased in the spinal cord 24 h post mild-TBI in wild-type mice but were not affected by TBI in G93A mice. In summary, our data demonstrate that mild-TBI induces inflammation and oxidative stress and negatively impacts muscle denervation and motor performance, suggesting mild-TBI can potentiate motor neuron pathology and influence the development of MND in mice. Published by Elsevier Ltd. on behalf of IBRO. C1 [Evans, T. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Watts, L.; Van Remmen, H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Watts, L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Watts, L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Res, Imaging Inst, San Antonio, TX 78229 USA. [Jaramillo, C. A.] Polytrauma Rehabil Ctr, San Antonio, TX USA. [Jaramillo, C. A.; Sabia, M.; Qi, W.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Jaramillo, C. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, San Antonio, TX 78229 USA. [Sataranatarajan, K.; Van Remmen, H.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Sataranatarajan, K.; Van Remmen, H.] Oklahoma City VA Med Ctr, Oklahoma City, OK USA. RP Van Remmen, H (reprint author), Oklahoma Med Res Fdn, Free Rad Biol & Aging Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM EvansTM@uthscsa.edu; jaramilloc3@uthscsa.edu; Kavithalakshmi-Sataranatarajan@omrf.org; wattsl@uthscsa.edu; sabia@uthscsa.edu; Qi@uthscsa.edu; holly-vanremmen@omrf.org FU independent National Research Service Award, National Institute for Neurological Diseases and Stroke [1F31NS080508-01]; Hartford Foundation/American Federation for Aging Research Scholars in Geriatric Medicine Program; VA Merit Review grant FX This research was funded in part by an independent National Research Service Award, National Institute for Neurological Diseases and Stroke (1F31NS080508-01; Evans TM) and the Hartford Foundation/American Federation for Aging Research Scholars in Geriatric Medicine Program (Jaramillo CA) and a VA Merit Review grant to Dr. Van Remmen. We also acknowledge the assistance of Vivian Diaz and the Nathan Shock Center in animal care and maintenance and collection of body weight and body composition data. We would also like to acknowledge the help and guidance of Shane Sprague and the Neurosurgery Department Brain Injury Core for their support in establishing our TBI procedures. NR 54 TC 2 Z9 2 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD JUL 9 PY 2015 VL 298 BP 410 EP 423 DI 10.1016/j.neuroscience.2015.04.041 PG 14 WC Neurosciences SC Neurosciences & Neurology GA CI5GT UT WOS:000354783300032 PM 25921732 ER PT J AU Friedman, MJ AF Friedman, Matthew J. TI Suicide Among US Military Personnel Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Friedman, Matthew J.] US Dept Vet Affairs, Natl Ctr PTSD, White River Jct, VT 05009 USA. RP Friedman, MJ (reprint author), US Dept Vet Affairs, Dept Vet Affairs, Natl Ctr PTSD, 215 N Main St, White River Jct, VT 05009 USA. EM matthew.friedman@dartmouth.edu NR 1 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 7 PY 2015 VL 314 IS 1 BP 84 EP 85 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CM1QR UT WOS:000357455900024 PM 26151276 ER PT J AU Logue, E Marceaux, J Balldin, V Hilsabeck, RC AF Logue, Erin Marceaux, Janice Balldin, Valerie Hilsabeck, Robin C. TI Further Validation of the Pillbox Test in a Mixed Clinical Sample SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Medication management; IADLs; Executive functioning.; Cognitive impairment/dementia; Validity ID COGNITIVE FUNCTION; PERFORMANCE AB Objective: The purpose of this research was to provide further criterion and construct validation of the Pillbox Test, a brief, ecologically valid measure designed to assess executive functioning(EF). Method: Participants were 179 older male veterans who completed the Pillbox Test as part of a neuropsychological evaluation. Results: Performance on the Pillbox Test differed significantly between patients with and without dementia, with total error scores of >= 5 and >= 7 showing similar levels of sensitivity and specificity at 67% and at or near 70%, respectively. Hierarchical multiple regression analysis revealed that measures of EF predicted performance on the Pillbox Test above and beyond measures of processing speed, but not above and beyond measures in other cognitive domains. Conclusions: Findings suggest the Pillbox Test is a promising new performance-based measure of executive functioning that can discriminate between patients with and without dementia. C1 [Logue, Erin; Marceaux, Janice; Balldin, Valerie; Hilsabeck, Robin C.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Hilsabeck, RC (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. EM hilsabeck@uthscsa.edu NR 34 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PD JUL 4 PY 2015 VL 29 IS 5 BP 611 EP 623 DI 10.1080/13854046.2015.1061054 PG 13 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA CR3DU UT WOS:000361211600003 PM 26133227 ER PT J AU Medina, J Hopkins, L Powers, M Baird, SO Smits, J AF Medina, Johnna Hopkins, Lindsey Powers, Mark Baird, Scarlett O. Smits, Jasper TI The Effects of a Hatha Yoga Intervention on Facets of Distress Tolerance SO COGNITIVE BEHAVIOUR THERAPY LA English DT Article DE exercise; intervention; distress tolerance; Hatha yoga ID OBSESSIVE-COMPULSIVE DISORDER; ANXIETY SENSITIVITY; PERCEIVED STRESS; YOUNG-ADULTS; CANNABIS USE; SAMPLE-SIZE; EARLY-LAPSE; INTOLERANCE; MINDFULNESS; MEDIATION AB Individuals with low distress tolerance (DT) experience negative emotion as particularly threatening and are highly motivated to reduce or avoid such affective experiences. Consequently, these individuals have difficulty regulating emotions and tend to engage in maladaptive strategies, such as overeating, as a means to reduce or avoid distress. Hatha yoga encourages one to implement present-centered awareness and non-reaction in the face of physical and psychological discomfort and, thus, emerges as a potential strategy for increasing DT. To test whether a hatha yoga intervention can enhance DT, a transdiagnostic risk and maintenance factor, this study randomly assigned females high in emotional eating in response to stress (N=52) either to an 8-week, twice-weekly hatha (Bikram) yoga intervention or to a waitlist control condition. Self-reported DT and emotional eating were measured at baseline, weekly during treatment, and 1-week post-treatment. Consistent with prediction, participants in the yoga condition reported greater increases in DT over the course of the intervention relative to waitlist participants (Cohen's d=.82). Also consistent with prediction, the reduction in emotional eating was greater for the yoga condition than the waitlist condition (Cohen's d=.92). Importantly, reductions distress absorption, a specific sub-facet of DT, accounted for 15% of the variance in emotional eating, a hallmark behavior of eating pathology and risk factor for obesity. C1 [Medina, Johnna; Powers, Mark; Baird, Scarlett O.; Smits, Jasper] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Hopkins, Lindsey] San Francisco VA Med Ctr, San Francisco, CA USA. RP Medina, J (reprint author), Univ Texas Austin, Dept Psychol, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA. EM johnnam@utexas.edu RI Hopkins, Lindsey/D-4408-2015 OI Hopkins, Lindsey/0000-0002-0577-2961; Powers, Mark/0000-0001-7898-073X FU National Institute on Drug Addiction [R01 DA027533, K01 DA035930] FX Portions of this research were funded by grants from the National Institute on Drug Addiction, R01 DA027533 & K01 DA035930. NR 69 TC 2 Z9 2 U1 7 U2 26 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1650-6073 EI 1651-2316 J9 COGN BEHAV THERAPY JI Cogn. Behav. Ther. PD JUL 4 PY 2015 VL 44 IS 4 SI SI BP 288 EP 300 DI 10.1080/16506073.2015.1028433 PG 13 WC Behavioral Sciences; Psychology, Clinical SC Behavioral Sciences; Psychology GA CJ9HB UT WOS:000355812000006 PM 25952547 ER PT J AU Gordon, AJ Haibach, J AF Gordon, Adam J. Haibach, Jeffrey TI Screening and Intervening on Alcohol and Other Drug Use in General Wellness Programs: Challenges and Opportunities SO SUBSTANCE ABUSE LA English DT Editorial Material C1 [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Sect Treatment Res & Educ Addict Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Gordon, Adam J.; Haibach, Jeffrey] VA Pittsburgh Healthcare Syst, VA Pittsburghs Interdisciplinary Addict Program E, Pittsburgh, PA 15240 USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C,Bldg 30,Mailcode 151-C, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 17 TC 1 Z9 1 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD JUL 3 PY 2015 VL 36 IS 3 BP 255 EP 256 DI 10.1080/08897077.2015.1073975 PG 2 WC Substance Abuse SC Substance Abuse GA CQ0OA UT WOS:000360294600001 PM 26275177 ER PT J AU Thomas, ML Brown, GG Gur, RC Moore, TM Patt, VM Nock, MK Naifeh, JA Heeringa, S Ursano, RJ Stein, MB AF Thomas, Michael L. Brown, Gregory G. Gur, Ruben C. Moore, Tyler M. Patt, Virginie M. Nock, Matthew K. Naifeh, James A. Heeringa, Steven Ursano, Robert J. Stein, Murray B. CA Army STARRS Collaborators TI Measurement of latent cognitive abilities involved in concept identification learning SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Neuropsychology; Concept identification learning; Item response theory; Penn Conditional Exclusion Test; Army STARRS; Latent variable measurement ID SERVICEMEMBERS ARMY STARRS; ITEM RESPONSE THEORY; FRONTAL-LOBE DAMAGE; ASSESS RISK; CONSTRUCT-VALIDITY; INDIVIDUAL-DIFFERENCES; PARKINSONS-DISEASE; SUICIDAL IDEATION; RESILIENCE; MODEL AB Introduction: We used cognitive and psychometric modeling techniques to evaluate the construct validity and measurement precision of latent cognitive abilities measured by a test of concept identification learning: the Penn Conditional Exclusion Test (PCET). Method: Item response theory parameters were embedded within classic associative- and hypothesis-based Markov learning models and were fitted to 35,553 Army soldiers' PCET data from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). Results: Data were consistent with a hypothesis-testing model with multiple latent abilities-abstraction and set shifting. Latent abstraction ability was positively correlated with number of concepts learned, and latent set-shifting ability was negatively correlated with number of perseverative errors, supporting the construct validity of the two parameters. Abstraction was most precisely assessed for participants with abilities ranging from 1.5 standard deviations below the mean to the mean itself. Measurement of set shifting was acceptably precise only for participants making a high number of perseverative errors. Conclusions: The PCET precisely measures latent abstraction ability in the Army STARRS sample, especially within the range of mildly impaired to average ability. This precision pattern is ideal for a test developed to measure cognitive impairment as opposed to cognitive strength. The PCET also measures latent set-shifting ability, but reliable assessment is limited to the impaired range of ability, reflecting that perseverative errors are rare among cognitively healthy adults. Integrating cognitive and psychometric models can provide information about construct validity and measurement precision within a single analytical framework. C1 [Thomas, Michael L.; Brown, Gregory G.; Patt, Virginie M.; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Brown, Gregory G.] VA San Diego Healthcare Syst, San Diego, CA 92161 USA. [Gur, Ruben C.; Moore, Tyler M.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gur, Ruben C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Nock, Matthew K.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Naifeh, James A.; Ursano, Robert J.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Heeringa, Steven] Univ Michigan, Inst Social Res, Ann Arbor, MI USA. RP Brown, GG (reprint author), VA San Diego Healthcare Syst, Psychol Serv 116B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM gbrown@ucsd.edu FU Department of the Army; U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH) [U01MH087981] FX Army STARRS was sponsored by the Department of the Army and funded with the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH) [cooperative agreement number U01MH087981]. The contents are solely the responsibility of the authors and do not necessarily represent the views of the Department of Health and Human Services, NIMH, the Department of the Army, or the Department of Defense. NR 78 TC 0 Z9 0 U1 3 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1380-3395 EI 1744-411X J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JUL 3 PY 2015 VL 37 IS 6 BP 653 EP 669 DI 10.1080/13803395.2015.1042358 PG 17 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA CM8GZ UT WOS:000357938300009 PM 26147832 ER PT J AU Williams, BR Wang, MQ Holt, CL Schulz, E Clark, EM AF Williams, Beverly Rosa Wang, Min Qi Holt, Cheryl L. Schulz, Emily Clark, Eddie M. TI Social Integration and Health Insurance Status Among African American Men and Women SO JOURNAL OF WOMEN & AGING LA English DT Article DE spiritual identity; health insurance; religiosity; African Americans; conjugal unit ID OLDER WOMEN; GENDER-DIFFERENCES; RACIAL INEQUITIES; PERCEIVED HEALTH; BLACK-WOMEN; LATE-LIFE; CARE; AGE; RETIREMENT; COMMUNITY AB Using 2010 national data, we investigate the relationship between social integration and health insurance for African American adults. During the previous year 21.6% of men and 19.8% of women lacked continuous health insurance. The effect of marital status, income, and employment on insurance coverage differed by age and gender. Additionally, frequency of church attendance was positively associated with continuous health insurance for women aged 51-64. Spiritual/religious identity was marginally associated with insurance status for men aged 36-50. As provisions of the Affordable Care Act take effect, implementation programs should expand enrollment efforts to include the conjugal unit and the church. C1 [Williams, Beverly Rosa] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Williams, Beverly Rosa] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL USA. [Wang, Min Qi; Holt, Cheryl L.] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA. [Schulz, Emily] AT Still Univ, Sch Hlth Sci, Dept Occupat Therapy, Mesa, AZ USA. [Clark, Eddie M.] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA. RP Williams, BR (reprint author), 700 South 19th St,11-G, Birmingham, AL 35233 USA. EM bwilliams@aging.uab.edu FU Duke University Center for Spirituality, Theology, and Health through John Templeton Foundation [11993] FX This work was supported by a grant from the Duke University Center for Spirituality, Theology, and Health, through the John Templeton Foundation (#11993) and was approved by the University of Maryland Institutional Review Board (#08-0329). NR 93 TC 1 Z9 1 U1 5 U2 19 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0895-2841 EI 1540-7322 J9 J WOMEN AGING JI J. Women Aging PD JUL 3 PY 2015 VL 27 IS 3 BP 195 EP 215 DI 10.1080/08952841.2014.933635 PG 21 WC Gerontology; Women's Studies SC Geriatrics & Gerontology; Women's Studies GA CF9KB UT WOS:000352882500002 PM 25607717 ER PT J AU Addington, J Heinssen, RK Robinson, DG Schooler, NR Marcy, P Brunette, MF Correll, CU Estroff, S Mueser, KT Penn, D Robinson, JA Rosenheck, RA Azrin, ST Goldstein, AB Severe, J Kane, JM AF Addington, Jean Heinssen, Robert K. Robinson, Delbert G. Schooler, Nina R. Marcy, Patricia Brunette, Mary F. Correll, Christoph U. Estroff, Sue Mueser, Kim T. Penn, David Robinson, James A. Rosenheck, Robert A. Azrin, Susan T. Goldstein, Amy B. Severe, Joanne Kane, John M. TI Duration of Untreated Psychosis in Community Treatment Settings in the United States SO PSYCHIATRIC SERVICES LA English DT Article ID 1ST-EPISODE SCHIZOPHRENIA; METAANALYSIS; EPISODE AB Objective: This study is the first to examine duration of untreated psychosis (DUP) among persons receiving care in community mental health centers in the United States. Methods: Participants were 404 individuals (ages 15-40) who presented for treatment for first-episode psychosis at 34 nonacademic clinics in 21 states. DUP and individual- and site-level variables were measured. Results: Median DUP was 74 weeks (mean=193.5 +/- 262.2 weeks; 68% of participants had DUP of greater than six months). Correlates of longer DUP included earlier age at first psychotic symptoms, substance use disorder, positive and general symptom severity, poorer functioning, and referral from outpatient treatment settings. Conclusions: This study reported longer DUP than studies conducted in academic settings but found similar correlates of DUP. Reducing DUP in the United States will require examination of factors in treatment delay in local service settings and targeted strategies for closing gaps in pathways to specialty FEP care. C1 [Addington, Jean] Univ Calgary, Dept Psychiat, Calgary, AB, Canada. [Heinssen, Robert K.; Azrin, Susan T.; Goldstein, Amy B.; Severe, Joanne] NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA. [Robinson, Delbert G.; Correll, Christoph U.; Kane, John M.] Zucker Hillside Hosp, Dept Psychiat Res, Glen Oaks, NY USA. [Marcy, Patricia] Zucker Hillside Hosp, Glen Oaks, NY USA. [Marcy, Patricia] Feinstein Inst Med Res, Manhasset, NY USA. [Schooler, Nina R.] Georgetown Univ, Sch Med, Dept Psychiat, Washington, DC USA. [Brunette, Mary F.] Geisel Sch Med, Dept Psychiat, Lebanon, NH USA. [Estroff, Sue] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA. [Penn, David] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. [Penn, David] Australian Catholic Univ, Melbourne, Vic, Australia. [Mueser, Kim T.] Boston Univ, Ctr Psychiat Rehabil, Boston, MA 02215 USA. [Robinson, James A.] Nathan S Kline Inst Psychiat Res, Informat Sci Div, Orangeburg, NY USA. [Rosenheck, Robert A.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. [Rosenheck, Robert A.] US Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. RP Addington, J (reprint author), Univ Calgary, Dept Psychiat, Calgary, AB, Canada. EM jmadding@ucalgary.ca FU American Recovery and Reinvestment Act; National Institute of Mental Health (NIMH) [HHSN271200900019C]; Asubio; Bristol-Myers Squibb; Janssen; Otsuka; Shire; Genentech; Neurocrine; Roche; Sunovion; Alkermes; Bristol-Myers Squibb Foundation; Janssen/JJ FX This work has been funded in whole or in part with funds from the American Recovery and Reinvestment Act and the National Institute of Mental Health (NIMH) under contract HHSN271200900019C. The authors thank RAISE-ETP participants, their families, and clinical and research staff at our 34 sites. The contents are solely the responsibility of the authors and do not necessarily represent the views of NIMH or the U.S. Department of Health and Human Services.; Dr. Delbert G. Robinson has been a consultant to or has received grants from Asubio, Bristol-Myers Squibb, Janssen, Otsuka, and Shire. Dr. Schooler has received research grants from, served on the advisory boards for, or served as a consultant to Forum (formerly EnVivo), Genentech, Neurocrine, Otsuka, Roche, and Sunovion. Ms. Marcy reports owning shares of Pfizer stock. Dr. Brunette has received research grants from Alkermes and Bristol-Myers Squibb Foundation. Dr. Correll has been a consultant or advisor to or has received honoraria from Actelion, Alexza, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, GersonLehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, Medavante, Medscape, Merck, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He also received grant or material support in the form of free medications from Bristol-Myers Squibb, Janssen/J&J, and Otsuka. Dr. Kane has been a consultant or advisor to or has received honoraria from Alkermes, Amgen, Bristol-Myers Squibb, Eli Lilly, Esai, Forrest Labs, Genentech, Gerson Lehman Group, IntraCellular Therapies, Janssen, Jazz, J&J, Lundbeck, MedAvante, Merck, Novartis, Otsuka, Pierre Fabre, Proteus, Pfizer, Roche, Reviva, Sunovion, Takeda, Targacept, and Vanda, and he is a shareholder of MedAvante. The other authors report no financial relationships with commercial interests. NR 15 TC 9 Z9 9 U1 5 U2 9 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL PY 2015 VL 66 IS 7 BP 753 EP 756 DI 10.1176/appi.ps.201400124 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE5RO UT WOS:000370689600016 PM 25588418 ER PT J AU Chew, KW Bhattacharya, D McGinnis, KA Horwich, TB Tseng, CH Currier, JS Butt, AA AF Chew, Kara W. Bhattacharya, Debika McGinnis, Kathleen A. Horwich, Tamara B. Tseng, Chi-hong Currier, Judith S. Butt, Adeel A. CA ERCHIVES Elect Retrieved Cohort HC TI Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID HIV-INFECTED PATIENTS; COMBINATION ANTIRETROVIRAL THERAPY; CHRONIC HCV INFECTION; INSULIN-RESISTANCE; CARDIOVASCULAR RISK; VIRUS-INFECTION; LIVER-DISEASE; ASSOCIATION; ATHEROSCLEROSIS; STEATOSIS AB We compared the Framingham risk score (FRS) for 10-year coronary heart disease (CHD) risk in age- and race-matched hepatitis C virus (HCV)-infected and HCV-uninfected persons: 114,073 HCV-infected (111,436 HCV-monoinfected and 2,637 HIV/HCV-coinfected) and 122,996 HCV-uninfected (121,380 HIV and HCV-uninfected and 1,616 HIV-monoinfected) males without cardiovascular disease, diabetes, or hepatitis B. In unadjusted analyses, FRS was similar between the HCV-infected and HCV-uninfected groups [median (interquartile range, IQR) risk points 13 (10-14) vs. 13 (10-14), p = 0.192]. Cholesterol levels were lower and current smoking more prevalent in the HCV groups (both HCV and HIV/HCV) compared with the uninfected groups (p < 0.001 for both). Prevalence of non-FRS CHD risk factors, such as substance abuse and chronic kidney disease, in the cohort was high, and differed by HCV and HIV status. Adjusting for age, race/ethnicity, body mass index, chronic kidney disease, drug and alcohol use, and HIV status, HCV infection was associated with minimally lower FRS (beta = -0.095 risk points, p < 0.001), suggesting a small but significant difference in 10-year CHD risk estimation in HCV-infected as compared to HCV-uninfected persons when measuring risk by FRS. Given the complex relationship between HCV, HIV, and CHD risk factors, some of which are not captured by the FRS, the FRS may underestimate CHD risk in HCV-monoinfected and HIV/HCV-coinfected persons. HCV-and HIV/HCV-specific risk scores may be needed to optimize CHD risk stratification. C1 [Chew, Kara W.; Bhattacharya, Debika; Horwich, Tamara B.; Tseng, Chi-hong; Currier, Judith S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90025 USA. [McGinnis, Kathleen A.; Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Butt, Adeel A.] Hamad Med Corp, Doha, Qatar. [Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar. RP Chew, KW (reprint author), Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, 11075 Santa Monica Blvd,Suite 100, Los Angeles, CA 90025 USA. EM kchew@mednet.ucla.edu OI Butt, Adeel/0000-0002-1118-1826 FU UCLA AIDS Institute and Center for AIDS Research [NIH P30AI028697] FX This project was supported by the UCLA AIDS Institute and Center for AIDS Research (NIH P30AI028697). This material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System and the central data repositories maintained by the VA Information Resource Center, including the National Patient Care Database, Decisions Support System Database, and Pharmacy Benefits Management Database. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 38 TC 5 Z9 5 U1 0 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JUL PY 2015 VL 31 IS 7 BP 718 EP 722 DI 10.1089/aid.2014.0284 PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DD4IJ UT WOS:000369885400009 PM 25858663 ER PT J AU Jonker, MA Heneghan, AF Fechner, JH Pierre, JF Sano, Y Lan, JG Kudsk, KA AF Jonker, Mark A. Heneghan, Aaron F. Fechner, John H. Pierre, Joseph F. Sano, Yoshifumi Lan, Jinggang Kudsk, Kenneth A. TI Gut Lymphocyte Phenotype Changes After Parenteral Nutrition and Neuropeptide Administration SO ANNALS OF SURGERY LA English DT Article DE bombesin; lymphocyte phenotype; mucosal immunity; parenteral nutrition; T regulatory cells ID UPPER RESPIRATORY-TRACT; B-CELL DIFFERENTIATION; MAJOR ABDOMINAL-TRAUMA; A IMMUNE-RESPONSE; MUCOSAL IMMUNITY; BACTERIAL PNEUMONIA; SEPTIC MORBIDITY; IN-VITRO; FED MICE; BOMBESIN AB Objective: To define gut-associated lymphoid tissue (GALT) phenotype changes with parenteral nutrition (PN) and PN with bombesin (BBS). Background: PN reduces respiratory tract (RT) and GALT Peyer patch and lamina propria lymphocytes, lowers gut and RT immunoglobulin A (IgA) levels, and destroys established RT antiviral and antibacterial immunity. BBS, an enteric nervous system neuropeptide, reverses PN-induced IgA and RT immune defects. Methods: Experiment 1: Intravenously cannulated ICR mice received chow, PN, or PN + BBS injections for 5 days. LSR-II flow cytometer analyzed Peyer patches and lamina propria isolated lymphocytes for homing phenotypes (L-selectin(+) and LPAM-1(+)) and state of activation (CD25(+), CD44(+)) in T (CD3(+))-cell subsets (CD4(+) and CD8(+)) along with homing phenotype (L-selectin(+) and LPAM-1(+)) in naive B (IgD(+)) and antigen-activated (Ig(-) Dor IgM(+)) B (CD45R/B220(+)) cells. Experiment 2: Following the initial experiment 1 protocol, lamina propria T regulatory cell phenotype was evaluated by Foxp3 expression. Results: Experiment 1: PN significantly reduced lamina propria (1) CD4(+) CD25(+) (activated) and (2) CD4(+) CD25(+) LPAM-1(+) (activated cells homed to the lamina propria) T cells, whereas PN-BBS assimilated chow levels. PN significantly reduced lamina propria (1) IgD+ (naive), (2) IgD-LPAM(+) (antigen-activated homed to the lamina propria) and CD44(+) memory B cells, whereas PN-BBS assimilated chow levels. Experiment 2: PN significantly reduced lamina propria CD4(+) CD25(+) Foxp3(+) T regulatory cells compared with chow-fed mice, whereas PN + BBS assimilated chow levels. Conclusions: PN reduces lamina propria activated and T regulatory cells and also naive and memory B cells. BBS addition to PN maintains these cell phenotypes, demonstrating the intimate involvement of the enteric nervous system in mucosal immunity. C1 [Jonker, Mark A.; Heneghan, Aaron F.; Fechner, John H.; Pierre, Joseph F.; Sano, Yoshifumi; Lan, Jinggang; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, 600 Highland Ave,G5-341 CSC, Madison, WI 53792 USA. [Heneghan, Aaron F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, 600 Highland Ave,G5-341 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu RI Fechner, John/C-5962-2016 OI Fechner, John/0000-0002-8220-7237 FU Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX001672]; National Institute of Health (NIH) [R01 GM53439] FX This research is supported by Award Number I01BX001672 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. This work is also supported by National Institute of Health (NIH) grant R01 GM53439. NR 50 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD JUL PY 2015 VL 262 IS 1 BP 194 EP 201 DI 10.1097/SLA.0000000000000878 PG 8 WC Surgery SC Surgery GA DD0LV UT WOS:000369612400057 PM 25563877 ER PT J AU Badar, AA Perez-Moreno, AC Hawkins, NM Jhund, PS Brunton, APT Anand, IS McKelvie, RS Komajda, M Zile, MR Carson, PE Gardner, RS Petrie, MC McMurray, JJV AF Badar, Athar A. Perez-Moreno, Ana Cristina Hawkins, Nathaniel M. Jhund, Pardeep S. Brunton, Alan P. T. Anand, Inder S. McKelvie, Robert S. Komajda, Michel Zile, Michael R. Carson, Peter E. Gardner, Roy S. Petrie, Mark C. McMurray, John J. V. TI Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial SO CIRCULATION-HEART FAILURE LA English DT Article DE angina pectoris; coronary artery disease; heart failure; human; irbesartan ID SUDDEN CARDIAC DEATH; REDUCED EJECTION FRACTION; POPULATION; MODEL; RISK AB Background-The aim of our study was to investigate the relationship between coronary artery disease (CAD), angina, and clinical outcomes in patients with heart failure and preserved ejection fraction enrolled in the irbesartan in patients with heart failure and preserved systolic function (I-Preserve) trial. Methods and Results-The mean follow-up period for the 4128 patients enrolled in I-Preserve was 49.5 months. Patients were divided into 4 mutually exclusive groups according to history of CAD and angina: patients with no history of CAD or angina (n=2008), patients with no history of CAD but a history of angina (n=649), patients with a history of CAD but no angina (n=468), and patients with a history of CAD and angina (n=1003); patients with no known CAD or angina were the reference group. After adjustment for other prognostic variables using Cox proportional-hazard models, patients with CAD but no angina were found to be at higher risk of all-cause mortality (hazard ratio [HR], 1.58 [1.22-2.04]; P<0.01) and sudden death (HR, 2.12 [1.33-3.39]; P<0.01), compared with patients with no CAD or angina. Patients with CAD and angina were also at higher risk of all-cause mortality (HR, 1.29 [1.05-1.59]; P=0.02) and sudden death (HR, 1.83 [1.24-2.69]; P<0.01) compared with the same reference group and had the highest risk of unstable angina or myocardial infarction (HR, 5.84 [3.43-9.95]; P<0.01). Conclusions-Patients with heart failure and preserved ejection fraction and CAD are at higher risk of all-cause mortality and sudden death when compared with those without CAD. C1 [Badar, Athar A.; Perez-Moreno, Ana Cristina; Jhund, Pardeep S.; Brunton, Alan P. T.; Gardner, Roy S.; Petrie, Mark C.; McMurray, John J. V.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland. [Badar, Athar A.; Gardner, Roy S.; Petrie, Mark C.] Golden Jubilee Natl Hosp, Scottish Natl Adv Heart Failure Serv, Glasgow, Lanark, Scotland. [Hawkins, Nathaniel M.] Univ British Columbia, Div Cardiol, Vancouver, BC V5Z 1M9, Canada. [Anand, Inder S.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Anand, Inder S.] Univ Minnesota, Minneapolis, MN USA. [McKelvie, Robert S.] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada. [Komajda, Michel] Hop La Pitie Salpetriere, Paris, France. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC USA. [Carson, Peter E.] Georgetown Univ, Washington, DC 20057 USA. [Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA. RP McMurray, JJV (reprint author), Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. EM john.mcmurray@glasgow.ac.uk OI Perez Moreno, Ana Cristina/0000-0001-9265-6880; Jhund, Pardeep/0000-0003-4306-5317; mcmurray, john/0000-0002-6317-3975 NR 18 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JUL PY 2015 VL 8 IS 4 BP 717 EP 724 DI 10.1161/CIRCHEARTFAILURE.114.002024 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DD1XZ UT WOS:000369717800006 PM 26067854 ER PT J AU Kheirbek, RE Fletcher, RD Bakitas, MA Fonarow, GC Parvataneni, S Bearden, D Bailey, FA Morgan, CJ Singh, S Blackman, MR Zile, MR Patel, K Ahmed, MB Tucker, RO Brown, CJ Love, TE Aronow, WS Roseman, JM Rich, MW Allman, RM Ahmed, A AF Kheirbek, Raya E. Fletcher, Ross D. Bakitas, Marie A. Fonarow, Gregg C. Parvataneni, Sridivya Bearden, Donna Bailey, Frank A. Morgan, Charity J. Singh, Steven Blackman, Marc R. Zile, Michael R. Patel, Kanan Ahmed, Momanna B. Tucker, Rodney O. Brown, Cynthia J. Love, Thomas E. Aronow, Wilbert S. Roseman, Jeffrey M. Rich, Michael W. Allman, Richard M. Ahmed, Ali TI Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE heart failure; hospice; Medicare; readmission ID RENIN-ANGIOTENSIN INHIBITION; PRESERVED EJECTION FRACTION; CHRONIC KIDNEY-DISEASE; LAST 6 MONTHS; PALLIATIVE CARE; PROPENSITY SCORE; OLDER PATIENTS; DIGOXIN; MORTALITY; OUTCOMES AB Background-Heart failure (HF) is the leading cause for hospital readmission. Hospice care may help palliate HF symptoms but its association with 30-day all-cause readmission remains unknown. Methods and Results-Of the 8032 Medicare beneficiaries hospitalized for HF in 106 Alabama hospitals (1998-2001), 182 (2%) received discharge hospice referrals. Of the 7850 patients not receiving hospice referrals, 1608 (20%) died within 6 months post discharge (the hospice-eligible group). Propensity scores for hospice referral were estimated for each of the 1790 (182+1608) patients and were used to match 179 hospice-referral patients with 179 hospice-eligible patients who were balanced on 28 baseline characteristics (mean age, 79 years; 58% women; 18% non-white). Overall, 22% (1742/8032) died in 6 months, of whom 8% (134/1742) received hospice referrals. Among the 358 matched patients, 30-day all-cause readmission occurred in 5% and 41% of hospice-referral and hospice-eligible patients, respectively (hazard ratio associated with hospice referral, 0.12; 95% confidence interval, 0.06-0.24). Hazard ratios (95% confidence intervals) for 30-day all-cause readmission associated with hospice referral among the 126 patients who died and 232 patients who survived 30-day post discharge were 0.03 (0.04-0.21) and 0.17 (0.08-0.36), respectively. Although 30-day mortality was higher in the hospice referral group (43% versus 27%), it was similar at 90 days (64% versus 67% among hospice-eligible patients). Conclusions-A discharge hospice referral was associated with lower 30-day all-cause readmission among hospitalized patients with HF. However, most patients with HF who died within 6 months of hospital discharge did not receive a discharge hospice referral. C1 [Kheirbek, Raya E.; Fletcher, Ross D.; Bakitas, Marie A.; Singh, Steven; Ahmed, Ali] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Kheirbek, Raya E.; Bakitas, Marie A.] George Washington Univ, Dept Med, Washington, DC USA. [Fletcher, Ross D.; Singh, Steven; Blackman, Marc R.; Ahmed, Ali] Georgetown Univ, Dept Med, Washington, DC USA. [Bakitas, Marie A.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. [Bakitas, Marie A.; Bearden, Donna; Ahmed, Momanna B.; Tucker, Rodney O.; Brown, Cynthia J.; Ahmed, Ali] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Roseman, Jeffrey M.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Parvataneni, Sridivya] E Tennessee State Univ, Dept Med, Johnson City, TN 37614 USA. [Bailey, Frank A.] Univ Colorado, Dept Med, Denver, CO 80202 USA. [Zile, Michael R.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC USA. [Patel, Kanan] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Brown, Cynthia J.] Vet Affairs Med Ctr, Dept Med, Birmingham, AL USA. [Love, Thomas E.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Aronow, Wilbert S.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA. [Rich, Michael W.] Washington Univ, Dept Med, St Louis, MO USA. [Allman, Richard M.] Dept Vet Affairs, Geriatr & Extended Care Serv, Washington, DC USA. RP Ahmed, A (reprint author), Washington DC Vet Affairs Med Ctr, Ctr Hlth & Aging, 50 Irving St NW, Washington, DC 20422 USA. EM aliahmedmdmph@gmail.com FU Veterans Affairs Capitol Healthcare Network [VISN 5]; National Institutes of Health from the National Heart, Lung, and Blood Institute [R01-HL085561, R01-HL085561-S, R01-HL097047]; National Palliative Care Research Center FX Dr Ahmed is supported by funds from the Veterans Affairs Capitol Healthcare Network (VISN 5) to the Center for Health and Aging and was also, in part, supported by the National Institutes of Health through grants (R01-HL085561, R01-HL085561-S, and R01-HL097047) from the National Heart, Lung, and Blood Institute. Dr Bakitas was, in part, supported by a pilot/exploratory grant from the National Palliative Care Research Center. NR 40 TC 4 Z9 4 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JUL PY 2015 VL 8 IS 4 BP 733 EP 740 DI 10.1161/CIRCHEARTFAILURE.115.002153 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DD1XZ UT WOS:000369717800008 PM 26019151 ER PT J AU Johnson, SG Gruntowicz, D Chua, T Morlock, RJ AF Johnson, Samuel G. Gruntowicz, Don Chua, Theresa Morlock, Robert J. TI Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY LA English DT Article ID COST-EFFECTIVENESS; CLINICAL PHARMACOGENETICS; ATRIAL-FIBRILLATION; CLOPIDOGREL; OUTCOMES; IMPLEMENTATION; METAANALYSIS; PRASUGREL; WARFARIN; TRIAL AB BACKGROUND: Dual antiplatelet therapy is an established standard of care for patients with acute coronary syndrome (ACS) to reduce thrombotic risk. Raduced CYP2C19 activity impairs dopidogrel bio-activation and increases risk of adverse clinical outcomes. Patients with poor and intermediate CYP2C19 metabolizers treated with dopidogrel incur higher cardiovascular event rates, including myocardial infarction, stroke, and stent thrombosis, following ACS than patients with normal CYP2C19 function. Tests are available to identify the CYP2C19 genotype and can be used to support individualization of antiplatelet therapy. OBJECTIVE: To estimate the financial impact of CYP2C19 genotyping in a theoretical cohort of 1,000 patients with ACS, who received percutaneous coronary intervention and coronary stent implantation and were treated with dopidogrel, prasugrel, or ticagrelor in a managed care setting. METHODS: Differences in overall and average cost per patient were estimated based on the rate of CYP2C19 genotyping in a theoretical cohort of 1,000 patients. Sensitivity analysis was carried out for varying costs, adherence, and the percentage of patients treated according to genotyping results. All clinical event costs were reported in terms of 2012 U.S. dollars. The budget impact analysis used published event rates from primary literature to estimate costs of events analysis for 3 different scenarios: Scenario A, no CYP2C19 genotyping; Scenario B, 50% of patients received CYP2C19 genotyping with appropriate treatment based on genotype; and Scenario C, 100% of patients received CYP2C19 genotyping with appropriate treatment based on genotype. RESULTS: According to this model, there was no change in the market share for the 3 antiplatelet agents in Scenario A Initial market share for dopidogrel, prasugrel, and ticagrelor was 93%, 5%, and 2%, respectively; however, use of CYP2C19 genotyping is expected to shift market share from dopidogrel to either prasugrel or ticagrelor. In Scenario B, where 50% of the patients received genotyping, dopidogrel market share was reduced to 83%, while prasugrel increased to 12.1% and ticagrelor increased to 4.9%. In Scenario C; where all patients received genotyping, dopidogrel market share was reduced to 73%, prasugrel increased to 19.3%, and ticagrelor increased to 7.7%. Total estimated cost differences when all possible patients were genotyped included annual savings of roughly $444,852. CONCLUSIONS: Important financial benefits may be realized through use of genotype-guided antiplatelet therapy to reserve prasugrel or ticagrelor use for patients with reduced CYP2C19 activity to avoid costs associated with adverse cardiac events. Copyright (C) 2015, Academy of Managed Care Pharmacy. Al rights reserved. C1 [Johnson, Samuel G.; Chua, Theresa] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Denver, CO 80202 USA. [Johnson, Samuel G.] Kaiser Permanente Colorado, Clin Pharm Serv, Appl Pharmacogen, Aurora, CO USA. [Gruntowicz, Don] Genelex Corp, Seattle, WA USA. [Gruntowicz, Don] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Gruntowicz, Don] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Morlock, Robert J.] YourCareChoice, Ann Arbor, MI USA. RP Johnson, SG (reprint author), Kaiser Permanente Colorado, 16601 E Centretech Pkwy, Aurora, CO 80011 USA. EM samuel.gjohnson@kp.org FU Genelex; Institute of Medicine Anniversary Fellowship FX Morlock and Gruntowicz received funding for this research from Genelex. Johnson received an Institute of Medicine Anniversary Fellowship Grant to support this project. The authors declare no other potential conflicts of interest, financial or otherwise. NR 25 TC 5 Z9 5 U1 1 U2 1 PU ACAD MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 2376-0540 EI 2376-1032 J9 J MANAG CARE SPEC PH JI J. Manag. Care Spec. Pharm. PD JUL PY 2015 VL 21 IS 7 BP 552 EP 557 PG 6 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA DC4KV UT WOS:000369190700003 PM 26108379 ER PT J AU Serper, M Kaplan, DE AF Serper, Marina Kaplan, David E. TI The Burden of Immunosuppression Non-Adherence and Post-Transplant Complications among US Veterans SO TRANSPLANTATION LA English DT Meeting Abstract CT 21st Annual International Congress of the International-Liver-Transplant-Society (ILTS) CY JUL 08-11, 2015 CL Chicago, IL SP Int Liver Transplant Soc C1 [Serper, Marina; Kaplan, David E.] Univ Penn, Sect Gastroenterol & Hepatol, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD JUL PY 2015 VL 99 SU 1 MA O-80 BP 110 EP 110 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DB6LM UT WOS:000368626500081 ER PT J AU Ramaswami, B Yoshida, O Ippolito, R Marrari, M Bentlejewski, C Metes, D Zeevi, A Thomson, A Mazariegos, G Chalasani, G AF Ramaswami, Balathiripurasundari Yoshida, Osamu Ippolito, Renee Marrari, Marilyn Bentlejewski, Carol Metes, Diana Zeevi, Adriana Thomson, Angus Mazariegos, George Chalasani, Geetha TI Pediatric Liver Transplant Recipients With Operational Tolerance Exhibit Features of Immune Activation and Exhaustion SO TRANSPLANTATION LA English DT Meeting Abstract CT 21st Annual International Congress of the International-Liver-Transplant-Society (ILTS) CY JUL 08-11, 2015 CL Chicago, IL SP Int Liver Transplant Soc C1 [Ramaswami, Balathiripurasundari; Yoshida, Osamu; Ippolito, Renee; Marrari, Marilyn; Bentlejewski, Carol; Metes, Diana; Zeevi, Adriana; Thomson, Angus; Mazariegos, George; Chalasani, Geetha] Univ Pittsburgh, Starzl Transplantat Inst, Hiilman Ctr Pediat Transplantat, Surg,Pathol,Renal Electrolyte,Childrens Hosp, Pittsburgh, PA USA. [Chalasani, Geetha] VA Pittsburgh Healthcare Syst, VA, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD JUL PY 2015 VL 99 SU 1 MA O-95 BP 115 EP 116 PG 2 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DB6LM UT WOS:000368626500096 ER PT J AU Basu, PP Shah, NJ Perez, A John, N Gress, F AF Basu, P. Patrick Shah, Niraj James Perez, Audrik John, Nimy Gress, Frank TI Novel Colonoscopy Preparation of Organic Coconut Water With Miralax and Dulcolax in Split Doses for Decompensated Cirrhotics. A Randomized Double Blinded Open Labelled Clinical Pilot Single Centered Observational Study. COSMIC Study SO TRANSPLANTATION LA English DT Meeting Abstract CT 21st Annual International Congress of the International-Liver-Transplant-Society (ILTS) CY JUL 08-11, 2015 CL Chicago, IL SP Int Liver Transplant Soc C1 [Basu, P. Patrick; Gress, Frank] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Basu, P. Patrick; Perez, Audrik; John, Nimy] Kings Cty Hosp, Med Ctr, Brooklyn, NY USA. [Shah, Niraj James] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD JUL PY 2015 VL 99 SU 1 MA P-115 BP 166 EP 166 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DB6LM UT WOS:000368626500267 ER PT J AU Kertesz, SG Austin, EL Holmes, SK Pollio, DE Lukas, CV AF Kertesz, Stefan G. Austin, Erika Laine Holmes, Sally K. Pollio, David E. Lukas, Carol VanDeusen TI Housing First and the Risk of Failure A Comment on Westermeyer and Lee (2013) SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Editorial Material DE Homelessness; housing first; substance use treatment; veterans ID CASE-MANAGEMENT PROGRAM; ILL HOMELESS ADULTS; ENDING HOMELESSNESS; TREATMENT OUTCOMES; RANDOMIZED-TRIAL; MENTAL-ILLNESS; DRUG-USE; INTERVENTION; VETERANS; ALCOHOL AB Over the last 5 years, community policies in response to homelessness have shifted toward offering permanent housing accompanied by treatment supports, without requiring treatment success as a precondition. The US Department of Veterans Affairs (VA) has embraced this "Housing First" approach. A 2013 report sounds a contrarian note. In a 16-person quasi-experimental study, 8 veterans who entered VA's permanent supportive housing did poorly, whereas 8 veterans who remained inmore traditional treatment did well. In this commentary, we suggest that the report was problematic in the conceptualization of the matters it sought to address and in its science. Nonetheless, it highlights challenges that must not be ignored. From this report and other research, we now know that even more attention is required to support clinical recovery for Housing First clients. Successful implementation of Housing First requires guidance from agency leaders, and their support for clinical staff when individual clients fare poorly. C1 [Kertesz, Stefan G.; Austin, Erika Laine] Birmingham VA Med Ctr, Mail Stop 151,700 South 19th St, Birmingham, AL 35233 USA. [Kertesz, Stefan G.; Austin, Erika Laine; Pollio, David E.] Univ Alabama Birmingham, Birmingham, AL USA. [Holmes, Sally K.] Boston VA Med Ctr, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Lukas, Carol VanDeusen] Boston Univ, Boston, MA 02215 USA. RP Kertesz, SG (reprint author), Birmingham VA Med Ctr, Mail Stop 151,700 South 19th St, Birmingham, AL 35233 USA. EM skertesz@uabmc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health [SDR-11233] FX Supported by grant SDR-11233 from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health. NR 36 TC 0 Z9 0 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JUL PY 2015 VL 203 IS 7 BP 559 EP 562 DI 10.1097/NMD.0000000000000328 PG 4 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DC2VL UT WOS:000369076000013 PM 26121153 ER PT J AU Flory, JD AF Flory, Janine D. TI Defining the Construct of Reactive Aggression in Borderline Personality Disorder: Commentary on "Aggression in Borderline Personality Disorder-A Multidimensional Model" SO PERSONALITY DISORDERS-THEORY RESEARCH AND TREATMENT LA English DT Editorial Material ID EMOTION DYSREGULATION; BIOMARKERS C1 [Flory, Janine D.] James J Peters Vet Affairs Med Ctr, 526 OOMll PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Flory, Janine D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. RP Flory, JD (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMll PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Janine.Flory@mssm.edu NR 11 TC 1 Z9 1 U1 1 U2 1 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1949-2715 EI 1949-2723 J9 PERSONAL DISORD JI Personal. Disord. PD JUL PY 2015 VL 6 IS 3 BP 294 EP 295 DI 10.1037/per0000134 PG 2 WC Psychology, Clinical SC Psychology GA DB6BQ UT WOS:000368598500010 PM 26191824 ER PT J AU Watts, LT Shen, Q Deng, SW Chemello, J Duong, TQ AF Watts, Lora Talley Shen, Qiang Deng, Shengwen Chemello, Jonathan Duong, Timothy Q. TI Manganese-Enhanced Magnetic Resonance Imaging of Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE calcium activity; controlled cortical impact; cortical spreading depolarization; gliosis; MEMRI; TBI ID REACTIVE GLIOSIS; MRI; CALCIUM; ACTIVATION; VISUALIZATION; CONNECTIVITY; PERFUSION; ISCHEMIA; MICE AB Calcium dysfunction is involved in secondary traumatic brain injury (TBI). Manganese-enhanced MRI (MEMRI), in which the manganese ion acts as a calcium analog and a MRI contrast agent, was used to study rats subjected to a controlled cortical impact. Comparisons were made with conventional T2 MRI, sensorimotor behavior, and immunohistology. The major findings were: (1) Low-dose manganese (29mg/kg) yielded excellent contrast with no negative effects on behavior scores relative to vehicle; (2) T1-weighted MEMRI was hyperintense in the impact area at 1-3h, hypointense on day 2, and markedly hypointense with a hyperintense area surrounding the core on days 7 and/or 14, in contrast to the vehicle group, which did not show a biphasic profile; (3) in the hyperacute phase, the area of hyperintense T1-weighted MEMRI was larger than that of T2 MRI; (4) glial fibrillary acidic protein staining revealed that the MEMRI signal void in the impact core and the hyperintense area surrounding the core on day 7 and/or 14 corresponded to tissue cavitation and reactive gliosis, respectively; (5) T2 MRI showed little contrast in the impact core at 2h, hyperintense on day 2 (indicative of vasogenic edema), hyperintense in some animals but pseudonormalized in others on day 7 and/or 14; (6) behavioral deficit peaked on day 2. We concluded that MEMRI detected early excitotoxic injury in the hyperacute phase, preceding vasogenic edema. In the subacute phase, MEMRI detected contrast consistent with tissue cavitation and reactive gliosis. MEMRI offers novel contrasts of biological processes that complement conventional MRI in TBI. C1 [Watts, Lora Talley; Shen, Qiang; Deng, Shengwen; Chemello, Jonathan; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu NR 28 TC 5 Z9 6 U1 1 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL 1 PY 2015 VL 32 IS 13 BP 1001 EP 1010 DI 10.1089/neu.2014.3737 PG 10 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CV0SU UT WOS:000363964200009 ER PT J AU Martinez, ME Kearney, DJ Simpson, T Felleman, BI Bernardi, N Sayre, G AF Martinez, Michelle E. Kearney, David J. Simpson, Tracy Felleman, Benjamin I. Bernardi, Nicole Sayre, George TI Challenges to Enrollment and Participation in Mindfulness-Based Stress Reduction Among Veterans: A Qualitative Study SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE DISORDERS; COGNITIVE THERAPY; CHRONIC PAIN; OF-LIFE; OEF/OIF VETERANS; MENTAL-HEALTH; CARE-SYSTEM; MEDITATION; DEPRESSION AB Background: Mindfulness-Based Stress Reduction (MBSR) is associated with reduced depressive symptoms, quality of life improvements, behavioral activation, and increased acceptance among veterans. This study was conducted to increase the reach and impact of a veterans' MBSR program by identifying barriers to enrollment and participation to inform modifications in program delivery. Objective: Verify or challenge suspected barriers, and identify previously unrecognized barriers, to enrollment and participation in MBSR among veterans. Design: A retrospective qualitative analysis of semistructured interviews. Setting/location: VA Puget Sound Health Care System (Seattle, WA). Subjects: 68 interviewed, and 48 coded and analyzed before reaching saturation. Approach: Content analysis of semistructured interviews. Results: Of the participants who enrolled, most (78%) completed the program and described MBSR positively. Veterans identified insufficient or inaccurate information, scheduling issues, and an aversion to groups as barriers to enrollment. Participants who discontinued the program cited logistics (e.g., scheduling and medical issues), negative reactions to instructors or group members, difficulty understanding the MBSR practice purposes, and struggling to find time for the practices as barriers to completion. Other challenges (cohort dynamics, teacher impact on group structure and focus, instructor lack of military service, and physical and psychological challenges) did not impede participation; we interpreted these as growth-facilitating challenges. Common conditions among veterans (chronic pain, posttraumatic stress disorder, and depression) were not described as barriers to enrollment or completion. Conclusions: Women-only MBSR groups and tele-health MBSR groups could improve accessibility to MBSR for veterans by addressing barriers such as commute anxiety, time restrictions, and an aversion to mixed gender groups among women. Educating MBSR teachers about veteran culture and health challenges faced by veterans, adding psychoeducation materials that relate mindfulness practice to conditions common among veterans, and improving visual aids for mindful movement exercises in the workbook could better accommodate veterans who participate in MBSR. C1 [Martinez, Michelle E.; Felleman, Benjamin I.; Bernardi, Nicole; Sayre, George] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kearney, David J.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Simpson, Tracy] VA Puget Sound Hlth Care Syst, Dept Mental Hlth, Seattle, WA USA. [Kearney, David J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Simpson, Tracy] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Sayre, George] Univ Washington, Sch Med, Dept Hlth Serv, Seattle, WA 98195 USA. RP Kearney, DJ (reprint author), Seattle VAMC 111GI, 1660 S Columbian Way, Seattle, WA 98108 USA. EM david.kearney@VA.gov FU VA Puget Sound Office of Patient Centered Care & Cultural Transformation (OPCCCT) FX We would like to thank and acknowledge Emily Hu, MS, and Victoria Sanborn, MSW, for their contributions to this project. The study was funded by the VA Puget Sound Office of Patient Centered Care & Cultural Transformation (OPCC&CT). NR 57 TC 0 Z9 0 U1 4 U2 16 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 EI 1557-7708 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD JUL 1 PY 2015 VL 21 IS 7 BP 409 EP 421 DI 10.1089/acm.2014.0324 PG 13 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA CU9RM UT WOS:000363882600006 PM 26133205 ER PT J AU Brown, RT Miao, YH Mitchell, SL Bharel, M Patel, M Ard, KL Grande, LJ Blazey-Martin, D Floru, D Steinman, MA AF Brown, Rebecca T. Miao, Yinghui Mitchell, Susan L. Bharel, Monica Patel, Mitkumar Ard, Kevin L. Grande, Laura J. Blazey-Martin, Deborah Floru, Daniella Steinman, Michael A. TI Health Outcomes of Obtaining Housing Among Older Homeless Adults SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID EMERGENCY-DEPARTMENT VISITS; MINI-MENTAL-STATE; POPULATION; INDEX; INTERVENTIONS; INDIVIDUALS; VALIDATION; DEPRESSION; IMPROVE; ILLNESS AB Objectives. We determined the impact of obtaining housing on geriatric conditions and acute care utilization among older homeless adults. Methods. We conducted a 12-month prospective cohort study of 250 older homeless adults recruited from shelters in Boston, Massachusetts, between January and June 2010. We determined housing status at follow-up, determined number of emergency department visits and hospitalizations over 12 months, and examined 4 measures of geriatric conditions at baseline and 12 months. Using multivariable regression models, we evaluated the association between obtaining housing and our outcomes of interest. Results. At 12-month follow-up, 41% of participants had obtained housing. Compared with participants who remained homeless, those with housing had fewer depressive symptoms. Other measures of health status did not differ by housing status. Participants who obtained housing had a lower rate of acute care use, with an adjusted annualized rate of acute care visits of 2.5 per year among participants who obtained housing and 5.3 per year among participants who remained homeless. Conclusions. Older homeless adults who obtained housing experienced improved depressive symptoms and reduced acute care utilization compared with those who remained homeless. C1 [Brown, Rebecca T.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Miao, Yinghui] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Mitchell, Susan L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [Bharel, Monica] Boston Hlth Care Homeless Program, Boston, MA USA. [Ard, Kevin L.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Patel, Mitkumar] St Elizabeths Med Ctr, Dept Med, Boston, MA USA. [Grande, Laura J.] Vet Affairs Boston Healthcare Syst, Psychol Serv, Boston, MA USA. [Blazey-Martin, Deborah] Tufts Med Ctr, Dept Med, Boston, MA USA. [Floru, Daniella] Lemuel Shattuck Hosp, Div Geriatr Med, Boston, MA USA. RP Brown, RT (reprint author), San Francisco VA Med Ctr, 4150 Clement St,UCSF Box VA-181G, San Francisco, CA 94121 USA. EM rebecca.brown@ucsf.edu FU National Institute on Aging [K23 AG045290, P30 AG044281, K24 AG033640]; National Center for Advancing Translational Sciences through the University of California, San Francisco, Clinical and Translational Science Institute [KL2 TR000143]; National Institute on Aging; American Federation for Aging Research [1K23 AG030999] FX R. T. Brown was supported by the National Institute on Aging (K23 AG045290 and P30 AG044281) and by the National Center for Advancing Translational Sciences through the University of California, San Francisco, Clinical and Translational Science Institute (KL2 TR000143). S. L. Mitchell was supported by the National Institute on Aging (K24 AG033640). M. A. Steinman was supported by the National Institute on Aging and the American Federation for Aging Research (1K23 AG030999). NR 43 TC 2 Z9 2 U1 5 U2 11 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUL PY 2015 VL 105 IS 7 BP 1482 EP 1488 DI 10.2105/AJPH.2014.302539 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6FX UT WOS:000362909400038 PM 25973822 ER PT J AU Sieverdes, JC Nemeth, LS Magwood, GS Baliga, PK Chavin, KD Brunner-Jackson, B Patel, SK Ruggiero, KJ Treiber, FA AF Sieverdes, John Christopher Nemeth, Lynne S. Magwood, Gayenell S. Baliga, Prabhakar K. Chavin, Kenneth D. Brunner-Jackson, Brenda Patel, Sachin K. Ruggiero, Kenneth J. Treiber, Frank A. TI Patient-Centered mHealth Living Donor Transplant Education Program for African Americans: Development and Analysis SO JMIR RESEARCH PROTOCOLS LA English DT Article DE kidney transplantation; living donors; mobile apps; qualitative research; telemedicine ID SELF-DETERMINATION THEORY; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; KIDNEY-TRANSPLANTATION; RENAL-TRANSPLANTATION; INTRINSIC MOTIVATION; HEALTH-CARE; INTERVENTION; CANDIDATES; RECIPIENTS AB Background: There is a critical need to expand the pool of available kidneys for African Americans who are on the transplant wait-list due to the disproportionally lower availability of deceased donor kidneys compared with other races/ethnic groups. Encouraging living donation is one method to fill this need. Incorporating mHealth strategies may be a way to deliver educational and supportive services to African American transplant-eligible patients and improve reach to those living in remote areas or unable to attend traditional group-session-based programs. Before program development, it is essential to perform formative research with target populations to determine acceptability and cultivate a patient-centered and culturally relevant approach to be used for program development. Objective: The objectives of this study were to investigate African American kidney transplant recipients' and kidney donors'/potential donors' attitudes and perceptions toward mobile technology and its viability in an mHealth program aimed at educating patients about the process of living kidney donation. Methods: Using frameworks from the technology acceptance model and self-determination theory, 9 focus groups (n=57) were administered to African Americans at a southeastern medical center, which included deceased/living donor kidney recipients and living donors/potential donors. After a demonstration of a tablet-based video education session and explanation of a group-based videoconferencing session, focus groups examined members' perceptions about how educational messages should be presented on topics pertaining to the process of living kidney donation and the transplantation. Questionnaires were administered on technology use and perceptions of the potential program communication platform. Transcripts were coded and themes were examined using NVivo 10 software. Results: Qualitative findings found 5 major themes common among all participants. These included the following: (1) strong support for mobile technology use; (2) different media formats were preferred; (3) willingness to engage in video chats, but face-to-face interaction sometimes preferred; (4) media needs to be user friendly; (5) high prevalence of technology access. Our results show that recipients were willing to spend more time on education than the donors group, they wanted to build conversation skills to approach others, and preferred getting information from many sources, whereas the donor group wanted to hear from other living donors. The questionnaires revealed 85% or more of the sample scored 4+ on a 5-point Liken scale, which indicates high degree of interest to use the proposed program, belief that other mHealth technologies would help with adherence to medical regimens, and doctors would make regimen adjustments quicker. In addition, high utilization of mobile technology was reported; 71.9% of the participants had a mobile phone and 43.9% had a tablet. Conclusions: Our study supports the use of an mHealth education platform for African Americans to learn about living donation. However, potential recipients and potential donors have differing needs, and therefore, programs should be tailored to each target audience. C1 [Sieverdes, John Christopher; Brunner-Jackson, Brenda; Patel, Sachin K.; Ruggiero, Kenneth J.; Treiber, Frank A.] Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, Charleston, SC 29425 USA. [Nemeth, Lynne S.; Magwood, Gayenell S.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Baliga, Prabhakar K.; Chavin, Kenneth D.] Med Univ S Carolina, Coll Med, Dept Surg, Div Transplant Surg, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Psychiat Inst, Charleston, SC USA. [Treiber, Frank A.] Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA. RP Treiber, FA (reprint author), Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, 99 Jonathan Lucas St,MSC 160, Charleston, SC 29425 USA. EM treiberf@musc.edu RI Emchi, Karma/Q-1952-2016 OI Brunner-Jackson, Brenda/0000-0002-1518-758X; Magwood, Gayenell/0000-0002-2451-4888; Nemeth, Lynne/0000-0001-8691-1400 FU NCATS NIH HHS [UL1 TR000062]; NIDDK NIH HHS [R01 DK098777] NR 44 TC 1 Z9 1 U1 3 U2 7 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1929-0748 J9 JMIR RES PROTOC JI JMIR RES. Protoc. PD JUL-SEP PY 2015 VL 4 IS 3 AR UNSP e84 DI 10.2196/resprot.3715 PG 14 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CT3TR UT WOS:000362730300019 PM 26265532 ER PT J AU Pulliam, L Gupta, A AF Pulliam, Lynn Gupta, Archana TI Modulation of Cellular Function Through Immune-Activated Exosomes SO DNA AND CELL BIOLOGY LA English DT Review ID EXTRACELLULAR VESICLES; DENDRITIC CELLS; T-CELLS; MICROVESICLES; MACROPHAGES; MICRORNAS; MIR-155; INDUCTION; PHENOTYPE; MIGRATION AB Extracellular vesicles classified as exosomes, microvesicles, or apoptotic bodies based on size are shed from most cells under normal as well as pathological conditions. They are released into the surrounding milieu, including plasma, urine, saliva, and tissues. Exosomes are highly enriched in microRNAs (miRs), which function in recipient cells by regulating posttranscriptional processing of targeted genes. Interaction of a miR with its mRNA target typically results in suppression of its gene expression. Peripheral inflammatory conditions can modulate miR expression in immune cells such as circulating monocytes that can influence their migration and differentiation. Changes within monocyte-derived macrophage miR expression can influence exosome content and further affect end-organ target cells. C1 [Pulliam, Lynn] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Lab Med, San Francisco, CA 94121 USA. [Pulliam, Lynn] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Gupta, Archana] Syst Biosci SBI, Mountain View, CA USA. RP Pulliam, L (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Lab Med, 4150 Clement St, San Francisco, CA 94121 USA. EM lynn.pulliam@ucsf.edu FU NIH [MH085538, MH096673] FX The experiments from the authors in this article were funded by the NIH to LP (MH085538, MH096673). NR 40 TC 4 Z9 5 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5498 EI 1557-7430 J9 DNA CELL BIOL JI DNA Cell Biol. PD JUL 1 PY 2015 VL 34 IS 7 BP 459 EP 463 DI 10.1089/dna.2015.2884 PG 5 WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity GA CT0SJ UT WOS:000362506500001 PM 25945690 ER PT J AU Holden, TR Smith, MA Bartels, CM Campbell, TC Yu, MG Kind, AJH AF Holden, Timothy R. Smith, Maureen A. Bartels, Christie M. Campbell, Toby C. Yu, Menggang Kind, Amy J. H. TI Hospice Enrollment, Local Hospice Utilization Patterns, and Rehospitalization in Medicare Patients SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; HEALTH-CARE; PATIENTS PREFERENCES; REGIONAL-VARIATIONS; MENTAL-HEALTH; LAST YEAR; END; CANCER; DEATH; QUALITY AB Background: Rehospitalizations are prevalent and associated with decreased quality of life. Although hospice has been advocated to reduce rehospitalizations, it is not known how area-level hospice utilization patterns affect rehospitalization risk. Objectives: The study objective was to examine the association between hospice enrollment, local hospice utilization patterns, and 30-day rehospitalization in Medicare patients. Methods: With a retrospective cohort design, 1,997,506 hospitalizations were assessed between 2005 and 2009 from a 5% national sample of Medicare beneficiaries. Local hospice utilization was defined using tertiles representing the percentage of all deaths occurring in hospice within each Hospital Service Area (HSA). Cox proportional hazard models were used to assess the relationship between 30-day rehospitalization, hospice enrollment, and local hospice utilization, adjusting for patient sociodemographics, medical history, and hospital characteristics. Results: Rates of patients dying in hospice were 27% in the lowest hospice utilization tertile, 41% in the middle tertile, and 53% in the highest tertile. Patients enrolled in hospice had lower rates of 30-day rehospitalization than those not enrolled (2.2% versus 18.8%; adjusted hazard ratio [HR], 0.12; 95% confidence interval [CI], 0.118-0.131). Patients residing in areas of low hospice utilization were at greater rehospitalization risk than those residing in areas of high utilization (19.1% versus 17.5%; HR, 1.05; 95% CI, 1.04-1.06), which persisted beyond that accounted for by individual hospice enrollment. Conclusions: Area-level hospice utilization is inversely proportional to rehospitalization rates. This relationship is not fully explained by direct hospice enrollment, and may reflect a spillover effect of the benefits of hospice extending to nonenrollees. C1 [Holden, Timothy R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53705 USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI 53705 USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53705 USA. [Bartels, Christie M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Rheumatol, Madison, WI 53705 USA. [Campbell, Toby C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Hematol Oncol & Palliat Care Med Div, Madison, WI 53705 USA. [Yu, Menggang] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53705 USA. [Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr, Madison, WI 53705 USA. [Kind, Amy J. H.] US Dept Vet Affairs, William S Middleton Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Kind, AJH (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ajk@medicine.wisc.edu FU National Institutes of Health (NIH) T32 Training Grant [5T32HS000083-15]; University of Wisconsin (UW) Health Innovation Program; National Institute on Aging Beeson Career Development Award - National Institute on Aging [K23AG034551]; American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases Mentored Patient-Oriented Research Career Development Award [K23 AR062381]; UW Health Innovation Program; Clinical and Translational Science Award (CTSA) program through National Center for Advancing Translational Sciences (NCATS) [1UL1RR025011]; UW School of Medicine and Public Health from The Wisconsin Partnership Program; National Center for Advancing Translational Sciences (NCATS) [9U54TR000021] FX Thank you to Katie Ronk for data management and variable creation, Jacquelyn Mirr for manuscript preparation, and to Bill Buckingham for map creation. Funding for this project was provided by National Institutes of Health (NIH) T32 Training Grant 5T32HS000083-15 and the University of Wisconsin (UW) Health Innovation Program. Dr. Kind is supported by a National Institute on Aging Beeson Career Development Award (K23AG034551, PI Kind), funded by National Institute on Aging, The American Federation for Aging Research, The John A. Hartford Foundation, The Atlantic Philanthropies, and The Starr Foundation. Dr. Christie Bartels is supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases Mentored Patient-Oriented Research Career Development Award K23 AR062381. Further support was provided by the UW Health Innovation Program and the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021. Additional funding for this project was provided by the UW School of Medicine and Public Health from The Wisconsin Partnership Program. NR 47 TC 1 Z9 1 U1 2 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD JUL 1 PY 2015 VL 18 IS 7 BP 601 EP 612 DI 10.1089/jpm.2014.0395 PG 12 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CS2EM UT WOS:000361880600007 PM 25879990 ER PT J AU Friedlander, AH El Saden, SM Hazboun, RC Chang, TI Wong, WK Garrett, NR AF Friedlander, A. H. El Saden, S. M. Hazboun, R. C. Chang, T. I. Wong, W. K. Garrett, N. R. TI Detection of carotid artery calcification on the panoramic images of post-menopausal females is significantly associated with severe abdominal aortic calcification: a risk indicator of future adverse vascular events SO DENTOMAXILLOFACIAL RADIOLOGY LA English DT Article DE atherosclerosis; panoramic radiography; carotid arteries; abdominal aorta; abdominal radiography ID ATHEROSCLEROSIS; STROKE; RADIOGRAPHS; PROGRESSION; FRAMINGHAM; ROTTERDAM; ATHEROMA; DEPOSITS; DISEASE AB Objectives: Outcome studies among post-menopausal females with calcified carotid artery plaque (CCAP) on their panoramic images have not been previously undertaken. We sought to compare the extent of abdominal aortic calcification (AAC) on lateral lumbar spine radiographs (LLSRs), among groups of females with (CCAP+) and without (CCAP) carotid lesions on their panoramic images. "Severe" levels of AAC have previously been validated as a risk indicator of future adverse cardiovascular events. Methods: This cross-sectional case control study included a "CCAP+ group" consisting of females more than 50 years of age having the carotid lesion diagnosed by their dentists and an atherogenic risk factor (age, body mass index, hypertension, diabetes and dyslipidaemia)matched "CCAP- group". A physician radiologist, using the Framingham index, evaluated the LLSRs for the magnitude of AAC. Summary statistics for key variables were computed and conditional logistic regression techniques were considered. Results: Members of the CCAP+ group were significantly (p = 0.038) more likely to demonstrate "severe" levels of AAC on their LLSRs than members of the CCAP group. Conclusions: This is the first published study demonstrating that CCAP on panoramic images of post-menopausal females is significantly associated with "severe" levels of AACs on LLSRs independent of traditional risk factors. Given that these levels of AAC are a validated risk indicator of future myocardial infarction and stroke, dentists must evaluate the panoramic images of post-menopausal females for the presence of CCAP. Patients with carotid atheromas should be referred to their physicians for further evaluation given the systemic implications. C1 [Friedlander, A. H.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Grad Med Educ, Los Angeles, CA 90095 USA. [Friedlander, A. H.; Chang, T. I.] Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [El Saden, S. M.] Vet Affairs Greater Los Angeles Healthcare Syst, Imaging Serv, Los Angeles, CA USA. [El Saden, S. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. [Hazboun, R. C.; Chang, T. I.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Div, Dent Serv, Los Angeles, CA USA. [Wong, W. K.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Garrett, N. R.] Univ Calif Los Angeles, Sch Dent, Deans Off, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Grad Med Educ, Los Angeles, CA 90095 USA. EM arthur.friedlander@va.gov FU National Center for Research Resources, National Institutes of Health [CO6 RR-14529-01] FX Elements of this investigation were conducted in a facility constructed with support from Research Facilities Improvement Program grant number CO6 RR-14529-01 from the National Center for Research Resources, National Institutes of Health. NR 27 TC 1 Z9 2 U1 0 U2 0 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0250-832X EI 1476-542X J9 DENTOMAXILLOFAC RAD JI Dentomaxillofac. Radiol. PD JUL PY 2015 VL 44 IS 7 AR 20150094 DI 10.1259/dmfr.20150094 PG 7 WC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine & Medical Imaging SC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine & Medical Imaging GA CR9AI UT WOS:000361645200006 PM 25945511 ER PT J AU Hamner, MB AF Hamner, Mark B. TI Smoking Cessation in Homeless Veterans SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Editorial Material ID TOBACCO; SMOKERS C1 Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Hamner, MB (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM mark.hamner@va.gov NR 8 TC 0 Z9 0 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUL PY 2015 VL 76 IS 7 BP E911 EP E912 DI 10.4088/JCP.14com09726 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CR7MU UT WOS:000361535200019 PM 26231027 ER PT J AU Herr, DJ Aune, SE Menick, DR AF Herr, Daniel J. Aune, Sverre E. Menick, Donald R. TI Induction and Assessment of Ischemia-reperfusion Injury in Langendorff-perfused Rat Hearts SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Medicine; Issue 101; Ischemia reperfusion; isolated heart; cardiac preconditioning; infarct staining; histone deacetylase; cardiac function ID INHIBITION; PROTECTION; MYOCARDIUM; MECHANISM; STRESS AB The biochemical events surrounding ischemia reperfusion injury in the acute setting are of great importance to furthering novel treatment options for myocardial infarction and cardiac complications of thoracic surgery. The ability of certain drugs to precondition the myocardium against ischemia reperfusion injury has led to multiple clinical trials, with little success. The isolated heart model allows acute observation of the functional effects of ischemia reperfusion injury in real time, including the effects of various pharmacological interventions administered at any time-point before or within the ischemia-reperfusion injury window. Since brief periods of ischemia can precondition the heart against ischemic injury, in situ aortic cannulation is performed to allow for functional assessment of non-preconditioned myocardium. A saline filled balloon is placed into the left ventricle to allow for real-time measurement of pressure generation. Ischemic injury is simulated by the cessation of perfusion buffer flow, followed by reperfusion. The duration of both ischemia and reperfusion can be modulated to examine biochemical events at any given time-point. Although the Langendorff isolated heart model does not allow for the consideration of systemic events affecting ischemia and reperfusion, it is an excellent model for the examination of acute functional and biochemical events within the window of ischemia reperfusion injury as well as the effect of pharmacological intervention on cardiac pre-and postconditioning. The goal of this protocol is to demonstrate how to perform in situ aortic cannulation and heart excision followed by ischemia/reperfusion injury in the Langendorff model. C1 [Herr, Daniel J.; Aune, Sverre E.; Menick, Donald R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med Cardiol, Charleston, SC 29403 USA. [Menick, Donald R.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Menick, DR (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med Cardiol, Charleston, SC 29403 USA. EM menickd@musc.edu OI Herr, Daniel/0000-0002-5593-4965 FU South Carolina Clinical & Translational Research (SCTR) Institute; Medical University of South Carolina, NIH/NCATS [UL1 TR000062]; VA merit award [BX002327-01]; NIH/NCATS [TL1 TR000061]; NIH [T32 GM008716, T32 HL07260] FX This publication was supported by the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, NIH/NCATS Grant Number UL1 TR000062. Further support was provided by VA merit award BX002327-01 to DRM. DJH was supported by NIH/NCATS Grant Number TL1 TR000061 and by NIH Grant Number T32 GM008716. SEA was supported by NIH Grant Number T32 HL07260. NR 18 TC 1 Z9 1 U1 0 U2 2 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD JUL PY 2015 IS 101 AR e52908 DI 10.3791/52908 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CR7ND UT WOS:000361536200039 PM 26274877 ER PT J AU Lin, XC Zhang, X Guo, JJ Roberts, CK McKenzie, S Wu, WC Liu, SM Song, YQ AF Lin, Xiaochen Zhang, Xi Guo, Jianjun Roberts, Christian K. McKenzie, Steve Wu, Wen-Chih Liu, Simin Song, Yiqing TI Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE biomarker; cardiometabolic health; cardiovascular disease prevention; exercise training ID CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK-FACTORS; TYPE-2 DIABETES-MELLITUS; HIGH-INTENSITY EXERCISE; IMPROVED INSULIN SENSITIVITY; OBESE POSTMENOPAUSAL WOMEN; MODERATE AEROBIC EXERCISE; RESTING METABOLIC-RATE; MIDDLE-AGED ADULTS AB Background-Guidelines recommend exercise for cardiovascular health, although evidence from trials linking exercise to cardiovascular health through intermediate biomarkers remains inconsistent. We performed a meta-analysis of randomized controlled trials to quantify the impact of exercise on cardiorespiratory fitness and a variety of conventional and novel cardiometabolic biomarkers in adults without cardiovascular disease. Methods and Results-Two researchers selected 160 randomized controlled trials (7487 participants) based on literature searches of Medline, Embase, and Cochrane Central (January 1965 to March 2014). Data were extracted using a standardized protocol. A random-effects meta-analysis and systematic review was conducted to evaluate the effects of exercise interventions on cardiorespiratory fitness and circulating biomarkers. Exercise significantly raised absolute and relative cardiorespiratory fitness. Lipid profiles were improved in exercise groups, with lower levels of triglycerides and higher levels of high-density lipoprotein cholesterol and apolipoprotein A1. Lower levels of fasting insulin, homeostatic model assessment-insulin resistance, and glycosylated hemoglobin A1c were found in exercise groups. Compared with controls, exercise groups had higher levels of interleukin-18 and lower levels of leptin, fibrinogen, and angiotensin II. In addition, we found that the exercise effects were modified by age, sex, and health status such that people aged <50 years, men, and people with type 2 diabetes, hypertension, dyslipidemia, or metabolic syndrome appeared to benefit more. Conclusions-This meta-analysis showed that exercise significantly improved cardiorespiratory fitness and some cardiometabolic biomarkers. The effects of exercise were modified by age, sex, and health status. Findings from this study have significant implications for future design of targeted lifestyle interventions. C1 [Lin, Xiaochen; Wu, Wen-Chih; Liu, Simin] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02903 USA. [Wu, Wen-Chih; Liu, Simin] Brown Univ, Alpert Med Sch, Dept Med, Div Cardiol, Providence, RI 02903 USA. [Wu, Wen-Chih; Liu, Simin] Brown Univ, Alpert Med Sch, Dept Med, Vet Affairs Med Ctr, Providence, RI 02903 USA. [Zhang, Xi; Song, Yiqing] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46204 USA. [Guo, Jianjun] China Inst Sport Sci, Ctr Youth Sport Res & Dev, Beijing, Peoples R China. [Roberts, Christian K.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [McKenzie, Steve] Indiana Univ Purdue Univ, Dept Kinesiol, Ctr Phys Act Wellness & Prevent, Indianapolis, IN 46202 USA. [Liu, Simin] Rhode Isl Hosp, Dept Med, Div Endocrinol, Providence, RI 02903 USA. RP Liu, SM (reprint author), Brown Univ, Dept Epidemiol & Med, 121 South Main St, Providence, RI 02903 USA. EM Simin_liu@brown.edu; yiqsong@iu.edu RI Lin, Xiaochen/P-6460-2015 FU Indiana University Health-Indiana University School of Medicine Strategic Research Initiative Grant; National Institutes of Health (NIH) [R01DK09406, P50HL105188]; Brown University FX The study was supported by the Indiana University Health-Indiana University School of Medicine Strategic Research Initiative Grant (Zhang and Song), R01DK09406 (Roberts) and P50HL105188 (Roberts) from the National Institutes of Health (NIH), and Brown University. The NIH, Brown University, or Indiana University had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. NR 217 TC 26 Z9 26 U1 8 U2 31 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD JUL PY 2015 VL 4 IS 7 AR e002014 DI 10.1161/JAHA.115.002014 PG 28 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CR6WR UT WOS:000361489400031 ER PT J AU Rothenberg, KG Wiechers, IR AF Rothenberg, Kasia Gustaw Wiechers, Ilse R. TI Antipsychotics for Neuropsychiatric Symptoms of Dementia-Safety and Efficacy in the Context of Informed Consent SO PSYCHIATRIC ANNALS LA English DT Article ID SEVERE ALZHEIMERS-DISEASE; PLACEBO-CONTROLLED TRIALS; POPULATION-BASED COHORT; ATYPICAL ANTIPSYCHOTICS; ADVERSE OUTCOMES; CATIE-AD; DRUGS; RISK; METAANALYSIS; MEDICATIONS AB Appropriate use of antipsychotic medications in older adults with dementia can be challenging due to several important safety concerns. This article reviews the risks and benefits of using antipsychotic medications in the treatment of patients with neuropsychiatric symptoms of dementia through the framework of an informed-consent conversation. Informed-consent discussions help provide patients, surrogate decision-makers, and caregivers with the essential data necessary to make informed treatment choices. C1 [Rothenberg, Kasia Gustaw] Yale Univ, Sch Med, Geriatr Psychiat, New Haven, CT 06520 USA. [Wiechers, Ilse R.] Northeast Program Evaluat Ctr, West Haven, CT USA. [Wiechers, Ilse R.] US Dept Vet Affairs, Psychotrop Drug Safety Initiat, Off Mental Hlth Operat, Washington, DC USA. [Wiechers, Ilse R.] Yale Univ, Sch Med, Psychiat, New Haven, CT 06520 USA. RP Wiechers, IR (reprint author), VA Connecticut Healthcare Syst, NEPEC 182,950 Campbell Ave, West Haven, CT 06516 USA. EM Ilse.Wiechers@va.gov NR 33 TC 0 Z9 0 U1 1 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 EI 1938-2456 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD JUL PY 2015 VL 45 IS 7 BP 348 EP 353 DI 10.3928/00485713-20150626-06 PG 6 WC Psychiatry SC Psychiatry GA CR6OV UT WOS:000361467900006 ER PT J AU Gros, DF AF Gros, Daniel F. TI Design challenges in transdiagnostic psychotherapy research: Comparing Transdiagnostic Behavior Therapy (TBT) to existing evidence-based psychotherapy in veterans with affective disorders SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Transdiagnostic; Comorbidity; RDoC; Psychotherapy; Transdiagnostic Behavior Therapy; TBT ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; RESEARCH DOMAIN CRITERIA; PRIMARY-CARE; CLINICAL-TRIALS; PSYCHOMETRIC PROPERTIES; ACTIVATION TREATMENTS; SYMPTOM OVERLAP; MOOD DISORDERS; PANIC DISORDER AB Background: To address the limitations of disorder-specific approaches, newer transdiagnostic approaches to psychotherapy have been developed to provide a single treatment that is capable of addressing several, related disorders. However, the recruitment of multiple diagnoses presents many challenges to the traditional design of psychotherapy randomized controlled trials (RCTs). Objective: The goal of the manuscript is to present the challenges and rationale for designing a RCT for transdiagnostic treatment to inform and aid in the development of future investigations. Methods: A recently funded and ongoing RCT for Transdiagnostic Behavior Therapy (TBT) is used as an example to discuss the related design challenges. The TBT study involves the recruitment of 96 veteran participants with any of the following eight principal diagnoses: posttraumatic stress disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, generalized anxiety disorder, specific phobia, major depressive disorder, or persistent depressive disorder. Within the TBT study, participants will complete a semi-structured diagnostic interview and a series of transdiagnostic self-report measures to determine eligibility and assess baseline symptomatology. Qualifying participants will be randomized to TBT or control psychotherapy. Additional assessments will be completed at post-treatment and 6-month follow-up. Conclusions: Due to the transdiagnostic nature of the sample, adjustments to the recruitment and randomization procedures, selection of measures, selection of control psychotherapy, and analysis plan were required. These adjustments have implications to future trials on transdiagnostic psychotherapy protocols as well as future research in line with the transdiagnostic focus of the National Institute of Mental Health's Research Domain Criteria (RDoC) funding strategy. Published by Elsevier Inc. C1 [Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Gros, Daniel F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Department of Veterans Affairs Clinical Sciences Research and Development Career Development Award [CX000845] FX This study is supported by Department of Veterans Affairs Clinical Sciences Research and Development Career Development Award CX000845 (PI: Gros). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government There are no conflicts of interest to disclose. NR 45 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD JUL PY 2015 VL 43 BP 114 EP 119 DI 10.1016/j.cct.2015.05.011 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA CQ7HI UT WOS:000360773200015 PM 26003434 ER PT J AU Linnemann, AK Neuman, JC Battiola, TJ Wisinski, JA Kimple, ME Davis, DB AF Linnemann, Amelia K. Neuman, Joshua C. Battiola, Therese J. Wisinski, Jaclyn A. Kimple, Michelle E. Davis, Dawn Belt TI Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in beta-Cells to Protect From Apoptosis SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID FAT-FED MICE; INSULIN-SECRETION; PANCREATIC-ISLETS; RECEPTOR; GLP-1; GENE; MASS; TRANSCRIPTION; ACTIVATION; HORMONES AB Cholecystokinin (CCK) is a classic gut hormone that is also expressed in the pancreatic islet, where it is highly up-regulated with obesity. Loss of CCK results in increased beta-cell apoptosis in obese mice. Similarly, islet alpha-cells produce increased amounts of another gut peptide, glucagon-like peptide 1 (GLP-1), in response to cytokine and nutrient stimulation. GLP-1 also protects beta-cells from apoptosis via cAMP-mediated mechanisms. Therefore, we hypothesized that the activation of islet-derived CCK and GLP-1 may be linked. We show here that both human and mouse islets secrete active GLP-1 as a function of body mass index/obesity. Furthermore, GLP-1 can rapidly stimulate beta-cell CCK production and secretion through direct targeting by the cAMP-modulated transcription factor, cAMP response element binding protein (CREB). We find that cAMP-mediated signaling is required for Cck expression, but CCK regulation by cAMP does not require stimulatory levels of glucose or insulin secretion. We also show that CREB directly targets the Cck promoter in islets from obese (Leptin(ob/ob)) mice. Finally, we demonstrate that the ability of GLP-1 to protect beta-cells from cytokine-induced apoptosis is partially dependent on CCK receptor signaling. Taken together, our work suggests that in obesity, active GLP-1 produced in the islet stimulates CCK production and secretion in a paracrine manner via cAMP and CREB. This intraislet incretin loop may be one mechanism whereby GLP-1 protects beta-cells from apoptosis. C1 [Linnemann, Amelia K.; Battiola, Therese J.; Wisinski, Jaclyn A.; Kimple, Michelle E.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53705 USA. [Neuman, Joshua C.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Davis, DB (reprint author), Univ Wisconsin, 4147 MFCB,MC5148,1685 Highland Ave, Madison, WI 53705 USA. EM dbd@medicine.wisc.edu FU National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases (NIH-NIDDK) [1K01DK102492]; National Institute on Aging [5T32AG000213]; NIH-NIDDK [1RO1DK102598, DK083442]; United States Department of Veterans Affairs [1101BX001880]; University of Wisconsin; Wisconsin Partnership Program FX This work was supported by the National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases (NIH-NIDDK) Grant 1K01DK102492 (to A.K.L.); the National Institute on Aging Grant 5T32AG000213 (to J.C.N.); the NIH-NIDDK Grant 1RO1DK102598 (to M.E.K.); and the NIH-NIDDK Grant DK083442, the United States Department of Veterans Affairs Grant 1101BX001880, the University of Wisconsin, and the Wisconsin Partnership Program (D.B.D.). NR 37 TC 6 Z9 6 U1 1 U2 5 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JUL PY 2015 VL 29 IS 7 BP 978 EP 987 DI 10.1210/me.2015-1030 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CR0DH UT WOS:000360987900004 PM 25984632 ER PT J AU Mitchell, JC Dick, MB Wood, AE Tapp, AM Ziegler, R AF Mitchell, Joel C. Dick, Malcolm B. Wood, Amanda E. Tapp, Andre M. Ziegler, Raphael TI The Utility of the Dementia Severity Rating Scale in Differentiating Mild Cognitive Impairment and Alzheimer Disease From Controls SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE dementia assessment; mild cognitive impairment; Alzheimer disease; screening; Dementia Severity Rating Scale ID ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DEPRESSION; CARE; RECOMMENDATIONS; INDIVIDUALS; PERFORMANCE; PREVALENCE; COMMUNITY AB The current study investigated the utility of the Dementia Severity Rating Scale (DSRS) total score to identify individuals at the earliest stage of impairment (ie, mild cognitive impairment/MCI). In addition, the authors sought to investigate how well the measure correlates with an expanded battery of cognitive tests and other measures of functional abilities. Of the 320 participants included in this study, 85 were normal controls, 96 had single-domain or multiple-domain amnestic MCI, and 139 had possible or probable Alzheimer disease (AD). Each participant underwent a thorough cognitive, neurological, and physical examination. Results from this study indicated that the DSRS total scores differed significantly between the 3 groups (P<0.001) and accurately identified 81% of the control group, 60% of the MCI group, and 78% of the AD group in a post hoc discriminant analysis. When combined with a brief cognitive measure (ie, Consortium to Establish a Registry for Alzheimer's Disease Word List 5 min recall test), the DSRS accurately identified 98% of the control group, 76% of the MCI group, and 82% of the AD group. Implications for clinical practice and proposed areas of future research are discussed. C1 [Mitchell, Joel C.; Wood, Amanda E.; Tapp, Andre M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Mitchell, Joel C.; Wood, Amanda E.; Tapp, Andre M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Dick, Malcolm B.; Ziegler, Raphael] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA. RP Mitchell, JC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM joel.mitchell@va.gov FU National Institute on Aging (NIA) [P50 AG16573] FX Supported by the National Institute on Aging (NIA) (grant number P50 AG16573 to the University of California at Irvine, Alzheimer's Disease Research Center). NR 39 TC 0 Z9 0 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD JUL-SEP PY 2015 VL 29 IS 3 BP 222 EP 228 DI 10.1097/WAD.0000000000000057 PG 7 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA CQ5PX UT WOS:000360658900007 PM 25187220 ER PT J AU Keyt, H Faverio, P Restrepo, MI AF Keyt, H. Faverio, P. Restrepo, M. I. TI Selective digestive decontamination saves lives whilst preventing resistance Response SO INDIAN JOURNAL OF MEDICAL RESEARCH LA English DT Letter ID INTENSIVE-CARE-UNIT; TRACT; TRIAL; PNEUMONIA C1 [Keyt, H.; Restrepo, M. I.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Keyt, H.; Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Faverio, P.] Univ Milano Bicocca, Dept Hlth Sci, San Gerardo Hosp, Resp Unit, Monza, Italy. RP Keyt, H (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu NR 11 TC 0 Z9 0 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0971-5916 J9 INDIAN J MED RES JI Indian J. Med. Res. PD JUL PY 2015 VL 142 PG 2 WC Immunology; Medicine, General & Internal; Medicine, Research & Experimental SC Immunology; General & Internal Medicine; Research & Experimental Medicine GA CQ5NQ UT WOS:000360652400016 ER PT J AU Sonnenberg, A Genta, RM AF Sonnenberg, Amnon Genta, Robert M. TI Low Prevalence of Colon Polyps in Chronic Inflammatory Conditions of the Colon SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID HELICOBACTER-PYLORI; ESOPHAGEAL EOSINOPHILIA; MICROSCOPIC COLITIS; PATHOLOGY DATABASE; COLORECTAL-CANCER; RISK; DISORDERS; DISEASE AB OBJECTIVES: Previous studies have reported a low prevalence of colon polyps in patients with microscopic colitis. The aim of the study was to test whether such inverse associations applied to other inflammatory diseases of the colon. METHODS: In a case-control study among 130,204 patients undergoing colonoscopy for the work-up of diarrhea, we compared the prevalence of colon polyps in a case population of patients with inflammatory bowel disease (IBD), microscopic colitis, histologic signs of active colitis, diverticulitis, or ischemic colitis, and in a control population with normal colon mucosa. Case and control subjects were compared using odds ratios and their 95% confidence intervals adjusted for age and sex. RESULTS: In 11,176 patients with microscopic colitis, the prevalence of hyperplastic polyps, serrated adenomas, and tubular adenomas were all reduced: odds ratios= 0.46 (95% confidence intervals= 0.43-0.49), 0.24 (0.19-0.30), and 0.35 (0.33-0.38), respectively. In 4,435 patients with IBD, the corresponding values were: 0.18 (0.15-0.21), 0.24 (0.16-0.35), and 0.18 (0.15-0.21), respectively. In 6,501 patients with histologically active colitis, the corresponding values were: 0.58 (0.53-0.63), 0.57 (0.46-0.70), and 0.63 (0.58-0.68), respectively. No such consistent reduction in polyp prevalence was found in patients with diverticulitis or ischemic colitis. CONCLUSIONS: Chronic inflammatory conditions of the colon are associated with a decreased prevalence of colon polyps. C1 [Sonnenberg, Amnon; Genta, Robert M.] Miraca Life Sci, Irving, TX USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Gastroenterol, P3 GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 14 TC 7 Z9 8 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUL PY 2015 VL 110 IS 7 BP 1056 EP 1061 DI 10.1038/ajg.2015.130 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CP9FV UT WOS:000360200100018 PM 25916222 ER PT J AU Stengel, A Karasawa, H Tache, Y AF Stengel, Andreas Karasawa, Hiroshi Tache, Yvette TI The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior SO HORMONES AND BEHAVIOR LA English DT Review DE Body weight; Brain-gut axis; Food intake; Hypothalamus; Satiation; Satiety; Somatostatin receptor; Stress; Water intake ID CENTRAL-NERVOUS-SYSTEM; CORTICOTROPIN-RELEASING-FACTOR; STRESS-INDUCED INHIBITION; FOOD-INTAKE; NEUROPEPTIDE-Y; GROWTH-HORMONE; RAT-BRAIN; MESSENGER-RNA; IN-VITRO; OREXINS HYPOCRETINS AB Somatostatin was discovered four decades ago as hypothalamic factor inhibiting growth hormone release. Subsequently, somatostatin was found to be widely distributed throughout the brain and to exert pleiotropic actions via interaction with five somatostatin receptors (sst(1-5)) that are also widely expressed throughout the brain. Interestingly, in contrast to the predominantly inhibitory actions of peripheral somatostatin, the activation of brain sst(2) signaling by intracerebroventricular injection of stable somatostatin agonists potently stimulates food intake and independently, drinking behavior in rodents. The orexigenic response involves downstream orexin-1, neuropeptide Y-1 and mu receptor signaling while the dipsogenic effect is mediated through the activation of the brain angiotensin 1 receptor. Brain sst2 activation is part of mechanisms underlying the stimulation of feeding and more prominently water intake in the dark phase and is able to counteract the anorexic response to visceral stressors. Published by Elsevier Inc. C1 [Stengel, Andreas] Charite Univ Med Berlin, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, Berlin, Germany. [Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress & Womens Hlth, Dept Med,Digest Dis Div, Los Angeles, CA 90024 USA. [Tache, Yvette] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), VA GLA Healthcare Syst, Ctr Neurobiol Stress, Cure Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIH Center [DK-41301]; German Research Foundation [STE 1765/3-1]; Charite University [UFF 88-226-168] FX This work was supported by NIH Center Grant DK-41301 (Animal Core), VA Research Career Scientist (Y.T.), German Research Foundation STE 1765/3-1 (A.S.) and Charite University Funding UFF 88-226-168 (A.S.). NR 111 TC 4 Z9 4 U1 2 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0018-506X EI 1095-6867 J9 HORM BEHAV JI Horm. Behav. PD JUL PY 2015 VL 73 BP 15 EP 22 DI 10.1016/j.yhbeh.2015.05.009 PG 8 WC Behavioral Sciences; Endocrinology & Metabolism SC Behavioral Sciences; Endocrinology & Metabolism GA CP9YM UT WOS:000360251800003 PM 26026616 ER PT J AU Delgado, C AF Delgado, Cynthia TI Characterization of Physical Activity and Sitting Time Among Patients on Hemodialysis Using a New Physical Activity Instrument (vol 25, pg 25, 2015) SO JOURNAL OF RENAL NUTRITION LA English DT Correction C1 [Delgado, Cynthia] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. RP Delgado, C (reprint author), San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. NR 1 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 EI 1532-8503 J9 J RENAL NUTR JI J. Renal Nutr. PD JUL PY 2015 VL 25 IS 4 BP 397 EP 397 PG 1 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA CQ0KA UT WOS:000360282800016 ER PT J AU Fitzgerald, A Johnson, M Hirsch, J Rich, MA Fidler, R AF Fitzgerald, Abi Johnson, Meshell Hirsch, Jan Rich, Mary-Ann Fidler, Richard TI Inconsistent shock advisories for monomorphic VT and Torsade de Pointes - A prospective experimental study on AEDs and defibrillators SO RESUSCITATION LA English DT Article DE Defibrillation; Automated external defibrillator; AED; Ventricular arrhythmias; Ventricular tachycardia; Torsade de Pointes ID AMERICAN-HEART-ASSOCIATION; HOSPITAL CARDIAC-ARREST AB Background: Cardiovascular disease and sudden cardiac arrest are the leading causes of death in the United States. Early defibrillation is key to successful resuscitation for patients who experience shockable rhythms during a cardiac arrest. It is therefore vital that the shock advisory of AEDs (automated external defibrillators) or defibrillators in AED mode be reliable and appropriate. The goal of this study was to better understand the performance of multiple lay-rescuer and hospital professional defibrillators in AED mode in their analysis of ventricular arrhythmias. The measurable objectives of this study sought to quantify: 1. No shock advisory for sinus rhythms at any rate. 2. Recognition and shock advisory for ventricular fibrillation (VF). 3. Recognition and shock advisory for monomorphic ventricular tachycardia (VT). 4. Recognition and shock advisory for Torsades de Pointes (TdP). Methods: This is a prospective evaluation of two AEDs and four semi-automatic, hospital professional defibrillators. This study represents post-marketing evaluation of FDA approved devices. Each defibrillator was connected to multiple rhythm simulators and presented with simulated ECG waveforms 20 consecutive times at various rates when possible. Results: All four defibrillators and both AEDs tested consistently recognized normal sinus rhythm (NSR) from all rhythm sources, and did not recommend a shock for NSR at any rate (from 80 to 220 bpm). All four defibrillators and both AEDs recognized VF from all rhythm sources tested and recommended a shock 100% of the time. Variations were found in the shock advisory rates among defibrillators when testing simulated VT heart rates at or below 150 bpm. One AED tested did not consistently advise a shock for monomorphic VT or TdP at any tested rate. Conclusion: Lay-rescuer AEDs and professional hospital defibrillators tested in AED mode did not reliably recommend a shock for sustained monomorphic VT or TdP at certain rates, despite the fact that it is a critical component of the currently recommended treatment. These findings require further examination of the risk benefit analysis of shocking or not shocking rhythms such as TdP or pulseless VT. Published by Elsevier Ireland Ltd. C1 [Fitzgerald, Abi; Johnson, Meshell; Hirsch, Jan; Rich, Mary-Ann; Fidler, Richard] San Francisco VA Med Ctr, Simulat Lab, San Francisco, CA 94121 USA. RP Fitzgerald, A (reprint author), San Francisco VA Med Ctr, Simulat Lab, 4150 Clement St, San Francisco, CA 94121 USA. EM abirankin@gmail.com OI Rich, Mary-Ann/0000-0002-1660-9887 FU United States Department of Veterans Affairs, Biomedical Laboratory Research and Development Program [IK2 BX001707] FX Dr. M. Johnson is supported by Career Development Award #IK2 BX001707 from the United States Department of Veterans Affairs, Biomedical Laboratory Research and Development Program. This material is the result of work supported with resources and the use of facilities at the San Francisco VA Medical Center. NR 11 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD JUL PY 2015 VL 92 BP 137 EP 140 DI 10.1016/j.resuscitation.2015.02.016 PG 4 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA CQ1JD UT WOS:000360352500035 PM 25724355 ER PT J AU Paterson, NE Darby, WC Sandhu, PS AF Paterson, Neil E. Darby, W. Connor Sandhu, Preetpal S. TI N,N-Dimethyltryptamine-Induced Psychosis SO CLINICAL NEUROPHARMACOLOGY LA English DT Review DE DMT; Cannabis; hallucinogen; substance-induced psychosis; quetiapine ID PHARMACOKINETICS; AYAHUASCA; HUMANS; ABUSE AB Background: N,N-dimethyltryptamine (DMT) is a 5-hydroxytryptamine 2A and 1A receptor agonist that exhibits potent psychoactive properties in humans. Recreational use of this drug has increased precipitously and is likely to result in an increase in patients presenting with substance-induced psychoses. The present case provides an early example of substance-induced psychosis attributable to repeated use of DMT. Case: A 42-year-old white man, with no significant past psychiatric history, was brought to the emergency department by the police and was found to exhibit disinhibited behavior, elevated affect, disorganized thought process, and delusions of reference. Laboratory studies revealed elevated creatinine kinase level indicative of rhabdomyolysis. The patient endorsed recent and repeated use of DMT, as well as long-term Cannabis (marijuana) use. Over the course of the next 3 weeks, the patient was successfully treated with quetiapine for psychosis, divalproex sodium (Depakote) for impulsivity, gabapentin for anxiety, and hydroxyzine for sleep, which resulted in the resolution of his symptoms and development of reasonable insight and judgment. Approximately 6 months after discharge, the patient remained treatment compliant, as well as drug and symptom free. Conclusions: This case report illustrates an important example of substance-induced psychosis that resolved with antipsychotic treatment in a 42-year-old white man with no past psychiatric history likely attributable to the use of DMT. Given the increasing use of this substance, the emergency department, primary care, and inpatient services are likely to see a significant increase in similar cases. C1 [Paterson, Neil E.; Darby, W. Connor] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Psychiat Residency Training Program, Los Angeles, CA USA. [Sandhu, Preetpal S.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Sandhu, PS (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Preetpal.Sandhu@va.gov NR 17 TC 0 Z9 0 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0362-5664 EI 1537-162X J9 CLIN NEUROPHARMACOL JI Clin. Neuropharmacol. PD JUL-AUG PY 2015 VL 38 IS 4 BP 141 EP 143 DI 10.1097/WNF.0000000000000078 PG 3 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA CP3JJ UT WOS:000359774900005 PM 26166234 ER PT J AU Qiu, ZF Mishra, A Li, M Farnsworth, SL Guerra, B Lanford, RE Hornsby, PJ AF Qiu, Zhifang Mishra, Anuja Li, Miao Farnsworth, Steven L. Guerra, Bernadette Lanford, Robert E. Hornsby, Peter J. TI Marmoset induced pluripotent stem cells: Robust neural differentiation following pretreatment with dimethyl sulfoxide SO STEM CELL RESEARCH LA English DT Article ID BIOMEDICAL-RESEARCH; LINES; BIOLOGY AB The marmoset is an important nonhuman primate model for regenerative medicine. For experimental autologous cell therapy based on induced pluripotent (iPS) cells in the marmoset, cells must be able to undergo robust and reliable directed differentiation that will not require customization for each specific iPS cell clone. When marmoset iPS cells were aggregated in a hanging drop format for 3 days, followed by exposure to dual SMAD inhibitors and retinoic acid in monolayer culture for 3 days, we found substantial variability in the response of different iPS cell clones. However, when clones were pretreated with 0.05-2% dimethyl sulfoxide (DMSO) for 24 hours, all clones showed a very similar maximal response to the directed differentiation scheme. Peak responses were observed at 0.5% DMSO in two clones and at 1% DMSO in a third clone. When patterns of gene expression were examined by microarray analysis, hierarchical clustering showed very similar responses in all 3 clones when they were pretreated with optimal DMSO concentrations. The change in phenotype following exposure to DMSO and the 6 day hanging drop/monolayer treatment was confirmed by immunocytochemistry. Analysis of DNA content in DMSO-exposed cells indicated that it is unlikely that DMSO acts by causing cells to exit from the cell cycle. This approach should be generally valuable in the directed neural differentiation of pluripotent cells for experimental cell therapy. Published by Elsevier B.V. C1 [Qiu, Zhifang; Mishra, Anuja; Li, Miao; Farnsworth, Steven L.; Hornsby, Peter J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. [Qiu, Zhifang; Mishra, Anuja; Li, Miao; Farnsworth, Steven L.; Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, Dept Physiol, San Antonio, TX 78229 USA. [Guerra, Bernadette; Lanford, Robert E.] Southwest Natl Primate Res Ctr, San Antonio, TX USA. [Guerra, Bernadette; Lanford, Robert E.] Texas Biomed Res Inst, San Antonio, TX USA. RP Hornsby, PJ (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. EM hornsby@uthscsa.edu FU VA grant [I01BX001454]; NIH [R21AG033286, R03AG045481]; Owens Medical Research Foundation; Ted Nash Long Life Foundation; China Scholarship Council FX This work was supported by VA grant I01BX001454, NIH grants R21AG033286 and R03AG045481, and by grants from the Owens Medical Research Foundation and the Ted Nash Long Life Foundation. Miao Li acknowledges the support of the China Scholarship Council. NR 20 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1873-5061 EI 1876-7753 J9 STEM CELL RES JI Stem Cell Res. PD JUL PY 2015 VL 15 IS 1 BP 141 EP 150 DI 10.1016/j.scr.2015.05.010 PG 10 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA CP6JZ UT WOS:000359994400014 PM 26070112 ER PT J AU Knapp, H Chan, K AF Knapp, Herschel Chan, Kee TI HIV Rapid Testing in a VA Emergency Department Setting: Cost Analysis at 5 Years SO VALUE IN HEALTH LA English DT Article DE AIDS; cost analysis; emergency; HIV; screening ID OF-VETERANS-AFFAIRS; HEALTH-CARE-SYSTEM; UNITED-STATES; IMPLEMENTATION AB Objectives: To conduct a comprehensive cost-minimization analysis to comprehend the financial attributes of the first 5 years of an implementation wherein emergency department (ED) registered nurses administered HIV oral rapid tests to patients. Methods: A health science research implementation team coordinated with ED stakeholders and staff to provide training, implementation guidelines, and support to launch ED registered nurse administered HIV oral rapid testing. Deidentified quantitative data were gathered from the electronic medical records detailing quarterly HIV rapid test rates in the Ell setting spanning the first 5 years. Comprehensive cost analyses were conducted to evaluate the financial impact of this implementation. Results: At 5 years, a total of 2,620 tests were conducted with a quarterly mean of 131 +/- 81. Despite quarterly variability in testing rates, regression analysis revealed an average increase of 3.58 tests per quarter. Over the course of this implementation, Veterans Health Administration policy transitioned from written to verbal consent for HIV testing, serving to reduce the time and cost(s) associated with the testing process. Conclusions: Our data indicated salient health outcome benefits for patients with respect to the potential for earlier detection, and associated long-run cost savings. (C) 2015 Published by Elsevier inc. on behalf of international Society for Pharmacoeconomics and Outcomes Research (ISPOR). C1 [Knapp, Herschel] Vet Affairs VA Qual Enhancement Res Initiat HIV &, Los Angeles, CA USA. [Knapp, Herschel] Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Knapp, Herschel] Greater Los Angeles Hlth Serv Res & Dev HSR&D Ctr, Los Angeles, CA USA. [Knapp, Herschel] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Chan, Kee] Univ Illinois, Sch Publ Hlth, Chicago, IL 60612 USA. [Chan, Kee] Edith Nourse Rogers Mem Vet Hosp Home, Bedford, MA 01730 USA. [Chan, Kee] CHOIR, Boston, MA 02118 USA. RP Knapp, H (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210,Room 210, Los Angeles, CA 90073 USA. EM Herschel.Knapp@va.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD JUL PY 2015 VL 18 IS 5 BP 735 EP 737 DI 10.1016/j.jval.2015.02.019 PG 3 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CP7VR UT WOS:000360097700023 PM 26297102 ER PT J AU Durazzo, TC Meyerhoff, DJ Murray, DE AF Durazzo, Timothy C. Meyerhoff, Dieter J. Murray, Donna E. TI Comparison of Regional Brain Perfusion Levels in Chronically Smoking and Non-Smoking Adults SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article; Proceedings Paper CT 11th International Symposium on Recent Advances in Environmental Health Research CY SEP 14-18, 2014 CL Jackson, MS SP Jackson State Univ DE cigarette smoking; nicotine; brain perfusion; arterial spin labeling; brain blood flow; magnetic resonance ID CHRONIC CIGARETTE-SMOKING; CEREBRAL BLOOD-FLOW; NEAR-INFRARED SPECTROSCOPY; ORBITOFRONTAL CORTEX; ALCOHOL DEPENDENCE; MAGNETIC-RESONANCE; ALZHEIMERS-DISEASE; DOPPLER SONOGRAPHY; SMOKERS; MRI AB Chronic cigarette smoking is associated with numerous abnormalities in brain neurobiology, but few studies specifically investigated the chronic effects of smoking (compared to the acute effects of smoking, nicotine administration, or nicotine withdrawal) on cerebral perfusion (i.e., blood flow). Predominately middle-aged male (47 +/- 11 years of age) smokers (n = 34) and non-smokers (n = 27) were compared on regional cortical perfusion measured by continuous arterial spin labeling magnetic resonance studies at 4 Tesla. Smokers showed significantly lower perfusion than non-smokers in the bilateral medial and lateral orbitofrontal cortices, bilateral inferior parietal lobules, bilateral superior temporal gyri, left posterior cingulate, right isthmus of cingulate, and right supramarginal gyrus. Greater lifetime duration of smoking (adjusted for age) was related to lower perfusion in multiple brain regions. The results indicated smokers showed significant perfusion deficits in anterior cortical regions implicated in the development, progression, and maintenance of all addictive disorders. Smokers concurrently demonstrated reduced blood flow in posterior brain regions that show morphological and metabolic aberrations as well as elevated beta amyloid deposition demonstrated by those with early stage Alzheimer disease. The findings provide additional novel evidence of the adverse effects of cigarette smoking on the human brain. C1 [Durazzo, Timothy C.; Meyerhoff, Dieter J.; Murray, Donna E.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Durazzo, Timothy C.; Meyerhoff, Dieter J.; Murray, Donna E.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. RP Durazzo, TC (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. EM timothy.durazzo@va.gov; dieter.meyerhoff@ucsf.edu; donna.murray@ucsf.edu FU NIH/NIDA [DA24136]; NIH/NIAAA [AA10788] FX This material is the result of work supported by NIH/NIDA DA24136 to Timothy C. Durazzo and NIH/NIAAA AA10788 to Dieter J. Meyerhoff, with resources and the use of facilities at the San Francisco Veterans Administration Medical Center, San Francisco CA. NR 61 TC 6 Z9 7 U1 2 U2 6 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD JUL PY 2015 VL 12 IS 7 BP 8198 EP 8213 DI 10.3390/ijerph120708198 PG 16 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CO7MB UT WOS:000359342300074 PM 26193290 ER PT J AU Garcia, JM Chen, JA Guillory, B Donehower, LA Smith, RG Lamb, DJ AF Garcia, Jose M. Chen, Ji-an Guillory, Bobby Donehower, Lawrence A. Smith, Roy G. Lamb, Dolores J. TI Ghrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating Repair of DNA Double Strand Breaks Through Activation of p53 in Mice SO BIOLOGY OF REPRODUCTION LA English DT Article DE GHSR; growth hormone secretagogue; infertility; testis ID HORMONE SECRETAGOGUE RECEPTOR; GERM-CELL CANCER; RAT TESTIS; C57/BL/6J MICE; MESSENGER-RNA; MOUSE TESTIS; FOOD-INTAKE; CHEMOTHERAPY; EXPRESSION; APOPTOSIS AB Cisplatin administration induces DNA damage resulting in germ cell apoptosis and subsequent testicular atrophy. Although 50 percent of male cancer patients receiving cisplatin-based chemotherapy develop long-term secondary infertility, medical treatment to prevent spermatogenic failure after chemotherapy is not available. Under normal conditions, testicular p53 promotes cell cycle arrest, which allows time for DNA repair and reshuffling during meiosis. However, its role in the setting of cisplatin-induced infertility has not been studied. Ghrelin administration ameliorates the spermatogenic failure that follows cisplatin administration in mice, but the mechanisms mediating these effects have not been well established. The aim of the current study was to characterize the mechanisms of ghrelin and p53 action in the testis after cisplatin-induced testicular damage. Here we show that cisplatin induces germ cell damage through inhibition of p53-dependent DNA repair mechanisms involving gamma-H2AX and ataxia telangiectasia mutated protein kinase. As a result, testicular weight and sperm count and motility were decreased with an associated increase in sperm DNA damage. Ghrelin administration prevented these sequelae by restoring the normal expression of gamma-H2AX, ataxia telangiectasia mutated, and p53, which in turn allows repair of DNA double stranded breaks. In conclusion, these findings indicate that ghrelin has the potential to prevent or diminish infertility caused by cisplatin and other chemotherapeutic agents by restoring p53-dependent DNA repair mechanisms. C1 [Garcia, Jose M.; Chen, Ji-an; Guillory, Bobby] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, CTRID, Div Endocrinol Diabet & Metab,Dept Med,MCL, Houston, TX 77030 USA. [Chen, Ji-an] Third Mil Med Univ, Coll Prevent Med, Dept Hlth Educ, Chongqing, Peoples R China. [Garcia, Jose M.; Lamb, Dolores J.] Baylor Coll Med, Ctr Reprod Med, Houston, TX 77030 USA. [Garcia, Jose M.; Smith, Roy G.; Lamb, Dolores J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Garcia, Jose M.; Guillory, Bobby; Smith, Roy G.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. [Donehower, Lawrence A.; Lamb, Dolores J.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Smith, Roy G.] Scripps Res Inst Florida, Dept Metab & Aging, Jupiter, FL USA. [Lamb, Dolores J.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. RP Garcia, JM (reprint author), Michael E DeBakey VA Med Ctr, Div Endocrinol Diabet & Metab, 2002 Holcombe Blvd,Bldg 109,Rm 210, Houston, TX 77030 USA. EM Jgarcia1@bcm.edu FU NICHD [U54-HD28934] FX We thank the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core (supported by NICHD U54-HD28934) and Baylor DERC (P30 DK079638) for their help. NR 61 TC 5 Z9 5 U1 1 U2 5 PU SOC STUDY REPRODUCTION PI MADISON PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA SN 0006-3363 EI 1529-7268 J9 BIOL REPROD JI Biol. Reprod. PD JUL 1 PY 2015 VL 93 IS 1 AR 24 DI 10.1095/biolreprod.115.129759 PG 8 WC Reproductive Biology SC Reproductive Biology GA CO8SP UT WOS:000359441800018 PM 26019260 ER PT J AU Mody, L Meddings, J Edson, BS McNamara, SE Trautner, BW Stone, ND Krein, SL Saint, S AF Mody, Lona Meddings, Jennifer Edson, Barbara S. McNamara, Sara E. Trautner, Barbara W. Stone, Nimalie D. Krein, Sarah L. Saint, Sanjay TI Enhancing Resident Safety by Preventing Healthcare-Associated Infection: A National Initiative to Reduce Catheter-Associated Urinary Tract Infections in Nursing Homes SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE nursing homes; post-acute care facilities; patient safety; CAUTIs ID LONG-TERM-CARE; QUALITY IMPROVEMENT; FACILITIES; MORTALITY; IMPLEMENTATION; COLONIZATION; SURVEILLANCE; DEFINITIONS; GUIDELINE; CRITERIA AB Preventing healthcare-associated infection (HAI) is a key contributor to enhancing resident safety in nursing homes. In 2013, the U.S. Department of Health and Human Services approved a plan to enhance resident safety by reducing HAIs in nursing homes, with particular emphasis on reducing indwelling catheter use and catheter-associated urinary tract infection (CAUTI). Lessons learned from a recent multimodal Targeted Infection Prevention program in a group of nursing homes as well as a national initiative to prevent CAUTI in over 950 acute care hospitals called "On the CUSP: STOP CAUTI" will now be implemented in nearly 500 nursing homes in all 50 states through a project funded by the Agency for Healthcare Research and Quality (AHRQ). This "AHRQ Safety Program in Long-Term Care: HAIs/CAUTI" will emphasize professional development in catheter utilization, catheter care and maintenance, and antimicrobial stewardship as well as promoting patient safety culture, team building, and leadership engagement. We anticipate that an approach integrating technical and socio-adaptive principles will serve as a model for future initiatives to reduce other infections, multidrug resistant organisms, and noninfectious adverse events among nursing home residents. C1 [Mody, Lona] Univ Michigan, Sch Med, Geriatr Res Educ & Clin Ctr, Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA. [Mody, Lona; McNamara, Sara E.] Univ Michigan, Sch Med, Div Geriatr & Palliat Care Med, Ann Arbor, MI 48109 USA. [Meddings, Jennifer; Krein, Sarah L.; Saint, Sanjay] Univ Michigan, Sch Med, Div Gen Med, Ann Arbor, MI 48109 USA. [Meddings, Jennifer] Univ Michigan, Sch Med, Department Internal Med, Div Gen Pediat, Ann Arbor, MI 48109 USA. [Meddings, Jennifer] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Div Gen Pediat, Ann Arbor, MI 48109 USA. [Edson, Barbara S.] Hlth Res & Educ Trust, Chicago, IL USA. [Edson, Barbara S.] Baylor Coll Med, Ctr Innovat Qual Effectiveness & Safety IQuESt, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Trautner, Barbara W.] Baylor Coll Med, Dept Med, Sect Infect Dis, Houston, TX USA. [Edson, Barbara S.] Baylor Coll Med, Dept Surg, Houston, TX USA. [Stone, Nimalie D.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Krein, Sarah L.; Saint, Sanjay] Ctr Clin Management Res, Ann Arbor, MI USA. [Saint, Sanjay] Vet Affairs Ann Arbor Healthcare Syst, Med Serv, Ann Arbor, MI USA. RP Mody, L (reprint author), Univ Michigan, Sch Med, Div Geriatr & Palliat Care Med, 300 N Ingalls Rd,Rm 905, Ann Arbor, MI 48109 USA. EM lonamody@umich.edu FU Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [HHSA 2902010000251]; National Institutes of Health (NIH) [R01 AG032298, R01 AG41780, R18 HS019979, NIH DK092293]; University of Michigan Claude D. Pepper Older Americans Independence Center (NIA) [P30 AG024824]; AHRQ [1K08-HS019767-01]; National Institutes of Health Clinical Loan Repayment Program; Department of Veterans Affairs [VA] [RRP 12-433]; Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, Texas [CIN13-413] FX This work was supported by a contract from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, Contract Number: HHSA 2902010000251. Other Funding/Support provided by the National Institutes of Health (NIH) (R01 AG032298, R01 AG41780, R18 HS019979 to L. M.; NIH DK092293 to B. W. T.); the University of Michigan Claude D. Pepper Older Americans Independence Center (NIA P30 AG024824 to L. M.); AHRQ (1K08-HS019767-01to J. M.); National Institutes of Health Clinical Loan Repayment Program (2009-2015 to J. M.); Department of Veterans Affairs [VA RRP 12-433 to B. W. T.]; Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, Texas [CIN13-413 to B. W. T.]. NR 51 TC 9 Z9 9 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 1 PY 2015 VL 61 IS 1 BP 86 EP 94 DI 10.1093/cid/civ236 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7EX UT WOS:000359323500015 PM 25814630 ER PT J AU Gant-Clark, V Skipper, J McCrackin, M Gaillard, S Coxe, DN AF Gant-Clark, Vanessa Skipper, Janice McCrackin, Monica Gaillard, Stacy Coxe, D. Nicole TI Veterans and HIV Screening Rates: Why Veterans Are Not Getting Tested, a Veterans Affairs Nursing Academic Partnership (VANAP) Study SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE LA English DT Article DE barriers to HIV screening; HIV testing; veterans; Veterans Affairs Nursing Academic Partnership C1 [Gant-Clark, Vanessa; Skipper, Janice; Gaillard, Stacy] Ralph H Johnson VA Med Ctr VAMC, Clin Fac, VANAP, Charleston, SC 29401 USA. [McCrackin, Monica; Coxe, D. Nicole] Ralph H Johnson VAMC, Charleston, SC USA. RP Gant-Clark, V (reprint author), Ralph H Johnson VA Med Ctr VAMC, Clin Fac, VANAP, Charleston, SC 29401 USA. FU Center for Community Health Partnerships for the Community Engaged Scholars Program (MUSC) FX This study was an initiative of the Veterans Affairs Nursing Academic Partnership (VANAP) Clinical Nursing Faculty, and their academic partners, the Medical University of South Carolina's College of Nursing (MUSC CON) in cooperation with the VA Office of Academic Affiliations. It was funded by a collaborative grant from the Center for Community Health Partnerships for the Community Engaged Scholars Program (MUSC, 2012). Charlene Pope, PhD, MPH, RN, Associate Nurse Executive for Research at the Ralph H. Johnson VA Medical Center (VAMC), was instrumental in the grant writing and mentoring through the institutional review board process. During the implementation of the method, MUSC CON Community Health Students were involved for three different semesters. They were instrumental in conducting focus groups, marketing, recruiting, and data collection. Low Country AIDS Services provided initial data regarding the state of South Carolina's HIV infection test results, broken down by counties. Ms. Lynn Nes, PhD, RN, provided assistance with the NVivo program. Dr. Jan York, PhD, RN, brought expertise in the writing for journal specificity. Preston Church, MD, Chief of Infectious Diseases at Ralph H. Johnson VAMC, was supportive in assisting veterans with access to care. Stephen Lesieur, MSN, RN, and Erica Grate-Simmons, MSN, RN, were contributing VANAP Faculty. Finally, we wish to thank our veterans for their continued service to our country and their enthusiasm in helping conduct this research study. NR 10 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1055-3290 EI 1552-6917 J9 J ASSOC NURSE AIDS C JI J. Assoc. Nurses Aids Care PD JUL-AUG PY 2015 VL 26 IS 4 BP 485 EP 491 DI 10.1016/j.jana.2015.03.002 PG 7 WC Nursing SC Nursing GA CO2QI UT WOS:000359001300019 PM 26066698 ER PT J AU Tse, JR Zhang, ZY Long, JL AF Tse, Justin R. Zhang, Zhaoyan Long, Jennifer L. TI Effects of vocal fold epithelium removal on vibration in an excised human larynx model SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID PHONATION THRESHOLD PRESSURE AB This study investigated the impact of selective epithelial injury on phonation in an excised human larynx apparatus. With intact epithelium, the vocal folds exhibited a symmetrical vibration pattern with complete glottal closure during vibration. The epithelium was then enzymatically removed from one, then both vocal folds, which led to left-right asymmetric vibration and a decreased closed quotient. Although the mechanisms underlying these vibratory changes are unclear, these results demonstrate that some component of an intact surface layer may play an important role in achieving normal symmetric vibration and glottal closure. (C) 2015 Acoustical Society of America C1 [Tse, Justin R.; Zhang, Zhaoyan; Long, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Long, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90074 USA. RP Long, JL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, CHS Room 62-132,650 Charles Young Dr, Los Angeles, CA 90095 USA. EM jrtse@mednet.ucla.edu; zyzhang@ucla.edu; jlong@mednet.ucla.edu RI Zhang, Zhaoyan/E-5215-2013 OI Zhang, Zhaoyan/0000-0002-2379-6086; Long, Jennifer/0000-0002-4185-2328 FU National Institute on Deafness and Other Communication Disorders at the National Institutes of Health [R01DC011299]; Department of Veteran's Affairs Career Development Award [IK2BX001944]; AOmegaA Carolyn L. Kuckien Student Research Fellowship FX This study was supported by Research Grant No. R01DC011299 from the National Institute on Deafness and Other Communication Disorders at the National Institutes of Health (Z.Z.); Research Grant No. IK2BX001944 from the Department of Veteran's Affairs Career Development Award (J.L.L.); and the A Omega A Carolyn L. Kuckien Student Research Fellowship (J.R.T.). We would like to thank Dr. Yue Xuan for technical support. NR 12 TC 3 Z9 3 U1 0 U2 0 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 EI 1520-8524 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD JUL PY 2015 VL 138 IS 1 BP EL60 EP EL64 DI 10.1121/1.4922765 PG 5 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA CO1QB UT WOS:000358929000011 PM 26233062 ER PT J AU Lin, AP Abbas, S Kim, SW Ortega, M Bouamar, H Escobedo, Y Varadarajan, P Qin, YJ Sudderth, J Schulz, E Deutsch, A Mohan, S Ulz, P Neumeister, P Rakheja, D Gao, XL Hinck, A Weintraub, ST DeBerardinis, RJ Sill, H Dahia, PLM Aguiar, RCT AF Lin, An-Ping Abbas, Saman Kim, Sang-Woo Ortega, Manoela Bouamar, Hakim Escobedo, Yissela Varadarajan, Prakash Qin, Yuejuan Sudderth, Jessica Schulz, Eduard Deutsch, Alexander Mohan, Sumitra Ulz, Peter Neumeister, Peter Rakheja, Dinesh Gao, Xiaoli Hinck, Andrew Weintraub, Susan T. DeBerardinis, Ralph J. Sill, Heinz Dahia, Patricia L. M. Aguiar, Ricardo C. T. TI D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2 SO NATURE COMMUNICATIONS LA English DT Article ID B-CELL LYMPHOMA; D-2-HYDROXYGLUTARIC ACIDURIA; L-2-HYDROXYGLUTARATE DEHYDROGENASE; GENETIC-HETEROGENEITY; TUMOR-CELLS; MUTATIONS; CANCER; 2-HYDROXYGLUTARATE; ONCOMETABOLITE; PATHWAY AB Isocitrate dehydrogenases (IDH) convert isocitrate to alpha-ketoglutarate (alpha-KG). In cancer, mutant IDH1/2 reduces alpha-KG to D2-hydroxyglutarate (D2-HG) disrupting alpha-KG-dependent dioxygenases. However, the physiological relevance of controlling the interconversion of D2-HG into alpha-KG, mediated by D2-hydroxyglutarate dehydrogenase (D2HGDH), remains obscure. Here we show that wild-type D2HGDH elevates alpha-KG levels, influencing histone and DNA methylation, and HIF1 alpha hydroxylation. Conversely, the D2HGDH mutants that we find in diffuse large B-cell lymphoma are enzymatically inert. D2-HG is a low-abundance metabolite, but we show that it can meaningfully elevate alpha-KG levels by positively modulating mitochondrial IDH activity and inducing IDH2 expression. Accordingly, genetic depletion of IDH2 abrogates D2HGDH effects, whereas ectopic IDH2 rescues D2HGDH-deficient cells. Our data link D2HGDH to cancer and describe an additional role for the enzyme: the regulation of IDH2 activity and alpha-KG-mediated epigenetic remodelling. These data further expose the intricacies of mitochondrial metabolism and inform on the pathogenesis of D2HGDH-deficient diseases. C1 [Lin, An-Ping; Abbas, Saman; Kim, Sang-Woo; Ortega, Manoela; Bouamar, Hakim; Escobedo, Yissela; Varadarajan, Prakash; Qin, Yuejuan; Dahia, Patricia L. M.; Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, San Antonio, TX 78229 USA. [Sudderth, Jessica; Rakheja, Dinesh; DeBerardinis, Ralph J.] Univ Texas Southwestern, Dept Pediat, Childrens Med Ctr, Res Inst, Dallas, TX 75390 USA. [Schulz, Eduard; Deutsch, Alexander; Neumeister, Peter; Sill, Heinz] Med Univ Graz, Div Hematol, A-8036 Graz, Austria. [Mohan, Sumitra; Ulz, Peter] Med Univ Graz, Inst Human Genet, A-8036 Graz, Austria. [Rakheja, Dinesh] Univ Texas SW Med Ctr Dallas, Dept Pathol & Pediat, Dallas, TX 75390 USA. [Gao, Xiaoli; Hinck, Andrew; Weintraub, Susan T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Dahia, Patricia L. M.; Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA. [Dahia, Patricia L. M.; Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Aguiar, Ricardo C. T.] South Texas Vet Hlth Care Syst, Audie Murphy VA Hosp, San Antonio, TX 78229 USA. RP Aguiar, RCT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, San Antonio, TX 78229 USA. EM aguiarr@uthscsa.edu OI Ulz, Peter/0000-0001-5941-1160; Sill, Heinz/0000-0003-0993-4371 FU NIH [R01-CA138747]; CPRIT [RP140452]; Voelcker Fund; Leukamiehilfe Steiermark; Cancer Center support grant [P30 CA054174]; UTHSCSA; National Institutes of Health [1S10RR031586-01] FX We thank Marsha Kinney and the Pathology Core Laboratory at the University of Texas HSC San Antonio for procurement of the primary DLBCL samples; C. Beham-Schmid for providing bone marrow specimens; K. Lind and S. Hofer for VNTR analyses. This work was supported by an NIH grant R01-CA138747 (to R.C.T.A.), a CPRIT award RP140452 (to R.C.T.A.), Young Investigator Awards from the Voelcker Fund (to P.L.M.D. and R.C.T.A.), Leukamiehilfe Steiermark (to H.S.), and a Cancer Center support grant P30 CA054174. Mass spectrometry analyses were conducted in the metabolomics component of the UTHSCSA Mass Spectrometry Laboratory, supported by UTHSCSA and by an award from the National Institutes of Health, 1S10RR031586-01 (S.T.W.). NR 45 TC 6 Z9 6 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUL PY 2015 VL 6 AR 7768 DI 10.1038/ncomms8768 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO0RK UT WOS:000358859700005 PM 26178471 ER PT J AU Mehta, SJ Polsky, D Zhu, JS Lewis, JD Kolstad, JT Loewenstein, G Volpp, KG AF Mehta, Shivan J. Polsky, Daniel Zhu, Jingsan Lewis, James D. Kolstad, Jonathan T. Loewenstein, George Volpp, Kevin G. TI ACA-Mandated Elimination of Cost Sharing for Preventive Screening Has Had Limited Early Impact SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID DIRECTED HEALTH PLANS; MYOCARDIAL-INFARCTION; MEDICATION ADHERENCE; COLONOSCOPY; COPAYMENTS; INSURANCE; SERVICES; CARE AB Objectives: The Affordable Care Act eliminated patient cost sharing for evidence-based preventive care, yet the impact of this policy on colonoscopy and mammography rates is unclear. We examined the elimination of cost sharing among small business beneficiaries of Humana, a large national insurer. Study Design: This was a retrospective interrupted time series analysis of whether the change in cost-sharing policy was associated with a change in screening utilization, using grandfathered plans as a comparison group. Methods: We compared beneficiaries in small business non-grandfathered plans that were required to eliminate cost sharing (intervention) with those in grandfathered plans that did not have to change cost sharing (control). There were 63,246 men and women aged 50 to 64 years eligible for colorectal cancer screening, and 30,802 women aged 50 to 64 years eligible for breast cancer screening. The primary outcome variables were rates of colonoscopy and mammography per person-month, with secondary analysis of colonoscopy rates coded as preventive only. Results: There was no significant change in the level or slope of colonoscopy and mammography utilization for intervention plans relative to the control plans. There was also no significant relevant change among those colonoscopies coded as preventive. Conclusions: The results suggest that the implementation of the policy is not having its intended effects, as cost sharing rates for colonoscopy and mammography did not change substantially, and utilization of colonoscopy and mammography changed little, following this new policy approach. C1 [Mehta, Shivan J.; Polsky, Daniel; Lewis, James D.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Lewis, James D.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lewis, James D.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Mehta, Shivan J.; Polsky, Daniel; Zhu, Jingsan; Lewis, James D.; Kolstad, Jonathan T.; Loewenstein, George; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Mehta, Shivan J.; Volpp, Kevin G.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA. [Kolstad, Jonathan T.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Mehta, SJ (reprint author), Univ Penn, Perelman Sch Med, 1318 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shivan.mehta@uphs.upenn.edu FU Humana, National Institutes of Health [K24 DK078228, T32 DK007740] FX Humana, National Institutes of Health (K24 DK078228, T32 DK007740). NR 24 TC 3 Z9 3 U1 1 U2 7 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JUL PY 2015 VL 21 IS 7 BP 511 EP U59 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN8CC UT WOS:000358664000007 PM 26247741 ER PT J AU Hershenberg, R Paulson, D Gros, DF Acierno, R AF Hershenberg, Rachel Paulson, Daniel Gros, Daniel F. Acierno, Ron TI Does Amount and Type of Activity Matter in Behavioral Activation? A Preliminary Investigation of the Relationship between Pleasant, Functional, and Social Activities and Outcome SO BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY LA English DT Article DE Behavioral activation; positive events; functional events; social events; depression; bereavement ID BECK DEPRESSION INVENTORY; COMPLICATED GRIEF; POSTPARTUM DEPRESSION; THERAPEUTIC EXPOSURE; COGNITIVE THERAPY; DAILY EVENTS; BEREAVEMENT; DISORDER; ADULTS; METAANALYSIS AB Background: Accumulating evidence supports behavioral activation (BA) as an effective stand-alone treatment for improving depression and related conditions, though little is known about the factors that influence positive outcomes. Such research is ripe for future dissemination and implementation efforts, particularly among vulnerable older adult populations in need of such efficacious and transportable treatments. Aims: Given the central but largely unexamined role that increasing activities plays in BA, we investigated the association between participation in weekly activities and treatment outcome. Method: As a preliminary study of this research question, we report on a sample of 20 older adults with symptoms of depression and complicated bereavement who completed 5 weeks of BA, pre-and posttreatment measures, and weekly planners of BA activities. All activities were coded as either functional or pleasurable (by participants) and if they were social in nature (by trained coders). Results: Overall, BA was associated with reductions in symptomatology. However, participants' total number of reported activities, and their relative proportion of functional, pleasurable, and social activities, did not significantly relate to their improvement in symptoms. Conclusion: One interpretation of the findings suggests that countering avoidance more generally, potentially independent of the specific type or total amount of activation activities, may be associated with amelioration of symptomatology. C1 [Hershenberg, Rachel] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Hershenberg, Rachel] Univ Penn, Philadelphia, PA 19104 USA. [Paulson, Daniel] Univ Cent Florida, Orlando, FL 32816 USA. [Gros, Daniel F.; Acierno, Ron] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Gros, Daniel F.; Acierno, Ron] Med Univ S Carolina, Charleston, SC USA. RP Hershenberg, R (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM rhersh@mail.med.upenn.edu FU National Institute of Aging [R21-AG023495-01A2]; VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA FX This work was partially supported by a grant from the National Institute of Aging (R21-AG023495-01A2). This paper was prepared with the support of the VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA. The views expressed in the article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. There were no conflicts of interest related to this project or its authors. We would like to thank Carl Lejuez and Julia Rossi for their feedback during the preparation of this manuscript. NR 45 TC 2 Z9 2 U1 1 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1352-4658 EI 1469-1833 J9 BEHAV COGN PSYCHOTH JI Behav. Cognit. Psychther. PD JUL PY 2015 VL 43 IS 4 BP 396 EP 411 DI 10.1017/S1352465813001185 PG 16 WC Psychology, Clinical SC Psychology GA CN8VM UT WOS:000358723500002 PM 24621452 ER PT J AU Vidaurre, OG Haines, JD Sand, IK Adula, KP Huynh, JL McGraw, CA Zhang, F Varghese, M Sotirchos, E Bhargava, P Venkata, V Bandaru, R Pasinetti, G Zhang, WJ Inglese, M Calabresi, PA Wu, G Miller, AE Haughey, NJ Lublin, FD Casaccia, P AF Vidaurre, Oscar G. Haines, Jeffery D. Sand, Ilana Katz Adula, Kadidia P. Huynh, Jimmy L. McGraw, Corey A. Zhang, Fan Varghese, Merina Sotirchos, Elias Bhargava, Pavan Venkata, Veera Bandaru, Ratnam Pasinetti, Giulio Zhang, Weijia Inglese, Matilde Calabresi, Peter A. Wu, Gang Miller, Aaron E. Haughey, Norman J. Lublin, Fred D. Casaccia, Patrizia TI Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics (vol 137, pg 2271, 2014) SO BRAIN LA English DT Correction C1 [Pasinetti, Giulio] James J Peters Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD JUL 1 PY 2015 VL 138 AR e367 DI 10.1093/brain/awv090 PN 7 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CN6HY UT WOS:000358536600008 ER PT J AU Folmer, RL Theodoroff, S AF Folmer, Robert L. Theodoroff, Sarah TI Response to: "All treatments in tinnitus are Experimental, Controversial and Futuristic" by De Ridder et al (2015) SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Letter ID TRANSCRANIAL MAGNETIC STIMULATION; EFFICACY C1 [Folmer, Robert L.; Theodoroff, Sarah] Oregon Hlth & Sci Univ, NCRAR, Portland VA Med Ctr, Dept Otolaryngol, Portland, OR 97201 USA. RP Folmer, RL (reprint author), Oregon Hlth & Sci Univ, NCRAR, Portland VA Med Ctr, Dept Otolaryngol, Portland, OR 97201 USA. NR 10 TC 0 Z9 0 U1 0 U2 3 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 EI 2157-3107 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD JUL-AUG PY 2015 VL 26 IS 7 BP 678 EP 679 DI 10.3766/jaaa.14049 PG 2 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA CN5JL UT WOS:000358465500009 PM 26218056 ER PT J AU Henly, SJ McCarthy, DO Wyman, JF Heitkemper, MM Redeker, NS Titler, MG McCarthy, AM Stone, PW Moore, SM Alt-White, AC Conley, YP Dunbar-Jacob, J AF Henly, Susan J. McCarthy, Donna O. Wyman, Jean F. Heitkemper, Margaret M. Redeker, Nancy S. Titler, Marita G. McCarthy, Ann Marie Stone, Patricia W. Moore, Shirley M. Alt-White, Anna C. Conley, Yvette P. Dunbar-Jacob, Jacqueline TI Emerging areas of science: Recommendations for Nursing Science Education from the Council for the Advancement of Nursing Science Idea Festival SO NURSING OUTLOOK LA English DT Article DE Nursing research; Nursing science ID TEAM SCIENCE; HEALTH; COLLABORATION; SCIENTISTS AB The Council for the Advancement of Nursing Science aims to "facilitate and recognize life-long nursing science career development" as an important part of its mission. In light of fast-paced advances in science and technology that are inspiring new questions and methods of investigation in the health sciences, the Council for the Advancement of Nursing Science convened the Idea Festival for Nursing Science Education and appointed the Idea Festival Advisory Committee (IFAC) to stimulate dialogue about linking PhD education with a renewed vision for preparation of the next generation of nursing scientists. Building on the 2005 National Research Council report Advancing The Nation's Health Needs and the 2010 American Association of Colleges of Nursing Position Statement on the Research-Focused Doctorate Pathways to Excellence, the IFAC specifically addressed the capacity of PhD programs to prepare nursing scientists to conduct cutting-edge research in the following key emerging and priority areas of health sciences research: omics and the microbiome; health behavior, behavior change, and biobehavioral science; patient-reported outcomes; big data, e-science, and informatics; quantitative sciences; translation science; and health economics. The purpose of this article is to (a) describe IFAC activities, (b) summarize 2014 discussions hosted as part of the Idea Festival, and (c) present IFAC recommendations for incorporating these emerging areas of science and technology into research-focused doctoral programs committed to preparing graduates for lifelong, competitive careers in nursing science. The recommendations address clearer articulation of program focus areas; inclusion of foundational knowledge in emerging areas of science in core courses on nursing science and research methods; faculty composition; prerequisite student knowledge and skills; and in-depth, interdisciplinary training in supporting area of science content and methods. C1 [Henly, Susan J.; Wyman, Jean F.] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA. [McCarthy, Donna O.] Marquette Univ, Coll Nursing, Milwaukee, WI 53233 USA. [Heitkemper, Margaret M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Redeker, Nancy S.] Yale Univ, Sch Nursing, West Haven, CT USA. [Titler, Marita G.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [McCarthy, Ann Marie] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA. [Stone, Patricia W.] Columbia Univ, Sch Nursing, New York, NY USA. [Moore, Shirley M.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. [Alt-White, Anna C.] US Dept Vet Affairs, Off Nursing Serv, Washington, DC USA. [Conley, Yvette P.; Dunbar-Jacob, Jacqueline] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. RP Henly, SJ (reprint author), Univ Minnesota, Sch Nursing, 5-140 WDH,308 Harvard St SE, Minneapolis, MN 55455 USA. EM henly003@umn.edu RI Redeker, Nancy/Q-8252-2016 OI Redeker, Nancy/0000-0001-7817-2708; Moore, Shirley M./0000-0003-2712-6896; Henly, Susan/0000-0002-2995-4161 NR 28 TC 14 Z9 14 U1 4 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD JUL-AUG PY 2015 VL 63 IS 4 BP 398 EP 407 DI 10.1016/j.outlook.2015.04.007 PG 10 WC Nursing SC Nursing GA CN6NT UT WOS:000358552200006 PM 26187079 ER PT J AU Henly, SJ McCarthy, DO Wyman, JF Stone, PW Redeker, NS McCarthy, AM Alt-White, AC Dunbar-Jacob, J Titler, MG Moore, SM Heitkemper, MM Conley, YP AF Henly, Susan J. McCarthy, Donna O. Wyman, Jean F. Stone, Patricia W. Redeker, Nancy S. McCarthy, Ann Marie Alt-White, Anna C. Dunbar-Jacob, Jacqueline Titler, Marita G. Moore, Shirley M. Heitkemper, Margaret M. Conley, Yvette P. TI Integrating emerging areas of nursing science into PhD programs SO NURSING OUTLOOK LA English DT Article DE Nursing research; Nursing science; Nursing scientist education; Research-focused doctorate ID TRANSLATIONAL RESEARCH; DOCTORAL EDUCATION; HUMAN GENOME; HEALTH; PATIENT; INFORMATION; MODEL; COMMUNICATION; ADVANCEMENT; MICROBIOME AB The Council for the Advancement of Nursing Science aims to "facilitate and recognize life-long nursing science career development" as an important part of its mission. In light of fast-paced advances in science and technology that are inspiring new questions and methods of investigation in the health sciences, the Council for the Advancement of Nursing Science convened the Idea Festival for Nursing Science Education and appointed the Idea Festival Advisory Committee to stimulate dialogue about linking PhD education with a renewed vision for preparation of the next generation of nursing scientists. Building on the 2010 American Association of Colleges of Nursing Position Statement "The Research-Focused Doctoral Program in Nursing: Pathways to Excellence," Idea Festival Advisory Committee members focused on emerging areas of science and technology that impact the ability of research-focused doctoral programs to prepare graduates for competitive and sustained programs of nursing research using scientific advances in emerging areas of science and technology. The purpose of this article is to describe the educational and scientific contexts for the Idea Festival, which will serve as the foundation for recommendations for incorporating emerging areas of science and technology into research-focused doctoral programs in nursing. C1 [Henly, Susan J.; Wyman, Jean F.] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA. [McCarthy, Donna O.] Marquette Univ, Milwaukee, WI 53233 USA. [Stone, Patricia W.] Columbia Univ, Sch Nursing, New York, NY USA. [Redeker, Nancy S.] Yale Univ, Sch Nursing, West Haven, CT USA. [McCarthy, Ann Marie] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA. [Alt-White, Anna C.] US Dept Vet Affairs, Off Nursing Serv, Washington, DC USA. [Dunbar-Jacob, Jacqueline; Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Titler, Marita G.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Moore, Shirley M.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. [Heitkemper, Margaret M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. RP Henly, SJ (reprint author), Univ Minnesota, Sch Nursing, 5-140 WDH,308 Harvard St SE, Minneapolis, MN 55455 USA. EM henly003@umn.edu RI Redeker, Nancy/Q-8252-2016 OI Redeker, Nancy/0000-0001-7817-2708; Henly, Susan/0000-0002-2995-4161 NR 89 TC 14 Z9 14 U1 5 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD JUL-AUG PY 2015 VL 63 IS 4 BP 408 EP 416 DI 10.1016/j.outlook.2015.04.010 PG 9 WC Nursing SC Nursing GA CN6NT UT WOS:000358552200007 PM 26187080 ER PT J AU Henly, SJ McCarthy, DO Wyman, JF Alt-White, AC Stone, PW McCarthy, AM Redeker, NS Dunbar-Jacob, J Titler, MG Conley, YP Heitkemper, MM Moore, SM AF Henly, Susan J. McCarthy, Donna O. Wyman, Jean F. Alt-White, Anna C. Stone, Patricia W. McCarthy, Ann Marie Redeker, Nancy S. Dunbar-Jacob, Jacqueline Titler, Marita G. Conley, Yvette P. Heitkemper, Margaret M. Moore, Shirley M. TI Emerging areas of nursing science and PhD education for the 21st century: Response to commentaries SO NURSING OUTLOOK LA English DT Article DE Doctoral education; Health; Nursing science; Nursing research; Research-focused doctorate ID BIOBEHAVIORAL RESEARCH; IDEA FESTIVAL; HEALTH; PROGRAMS; RECOMMENDATIONS; SCIENTISTS; BIOLOGY; FUTURE; HOLISM AB We respond to commentaries from the American Academy of Nursing, the American Association of Colleges of Nursing, and the National Institute of Nursing Research on our thoughts about integrating emerging areas of science into nursing PhD programs. We identify areas of agreement and focus our response on cross-cutting issues arising from cautions about the unique focus of nursing science and how best to proceed with incorporation of emerging areas of science into nursing PhD programs. C1 [Henly, Susan J.; Wyman, Jean F.] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA. [McCarthy, Donna O.] Marquette Univ, Milwaukee, WI 53233 USA. [Alt-White, Anna C.] US Dept Vet Affairs, Off Nursing Serv, Washington, DC USA. [Stone, Patricia W.] Columbia Univ, Sch Nursing, New York, NY USA. [McCarthy, Ann Marie] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA. [Redeker, Nancy S.] Yale Univ, Sch Nursing, West Haven, CT USA. [Dunbar-Jacob, Jacqueline; Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Titler, Marita G.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Heitkemper, Margaret M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Moore, Shirley M.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. RP Henly, SJ (reprint author), Univ Minnesota, Sch Nursing, 5-140 WDH,308 Harvard St SE, Minneapolis, MN 55455 USA. EM henly003@umn.edu RI Redeker, Nancy/Q-8252-2016 OI Redeker, Nancy/0000-0001-7817-2708; Henly, Susan/0000-0002-2995-4161 NR 42 TC 2 Z9 2 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD JUL-AUG PY 2015 VL 63 IS 4 BP 439 EP 445 DI 10.1016/j.outlook.2015.05.003 PG 7 WC Nursing SC Nursing GA CN6NT UT WOS:000358552200012 PM 26187083 ER PT J AU Jack, CR Barnes, J Bernstein, MA Borowski, BJ Brewer, J Clegg, S Dale, AM Carmichael, O Ching, C DeCarli, C Desikan, RS Fennema-Notestine, C Fjell, AM Fletcher, E Fox, NC Gunter, J Gutman, BA Holland, D Hua, X Insel, P Kantarci, K Killiany, RJ Krueger, G Leung, KK Mackin, S Maillard, P Malone, IB Mattsson, N McEvoy, L Modat, M Mueller, S Nosheny, R Ourselin, S Schuff, N Senjem, ML Simonson, A Thompson, PM Rettmann, D Vemuri, P Walhovd, K Zhao, YS Zuk, S Weiner, M AF Jack, Clifford R., Jr. Barnes, Josephine Bernstein, Matt A. Borowski, Bret J. Brewer, James Clegg, Shona Dale, Anders M. Carmichael, Owen Ching, Christopher DeCarli, Charles Desikan, Rahul S. Fennema-Notestine, Christine Fjell, Anders M. Fletcher, Evan Fox, Nick C. Gunter, Jeff Gutman, Boris A. Holland, Dominic Hua, Xue Insel, Philip Kantarci, Kejal Killiany, Ron J. Krueger, Gunnar Leung, Kelvin K. Mackin, Scott Maillard, Pauline Malone, Ian B. Mattsson, Niklas McEvoy, Linda Modat, Marc Mueller, Susanne Nosheny, Rachel Ourselin, Sebastien Schuff, Norbert Senjem, Matthew L. Simonson, Alix Thompson, Paul M. Rettmann, Dan Vemuri, Prashanthi Walhovd, Kristine Zhao, Yansong Zuk, Samantha Weiner, Michael TI Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 SO ALZHEIMERS & DEMENTIA LA English DT Review DE Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; ADNI; Diffusion; MRI; Neuroimaging; Perfusion; Resting functional MRI ID MILD COGNITIVE IMPAIRMENT; TENSOR-BASED MORPHOMETRY; PREDICT BRAIN ATROPHY; CSF BIOMARKERS; AMYLOID-BETA; NATIONAL INSTITUTE; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; CLINICAL-TRIALS; NEURODEGENERATIVE DISEASE AB Introduction: Alzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders. Methods: We review the contributions of the MRI core from present and past cycles of ADNI (ADNI-1, -Grand Opportunity and -2). We also review plans for the future-ADNI-3. Results: Contributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials. Discussion: Over the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. C1 [Jack, Clifford R., Jr.; Bernstein, Matt A.; Borowski, Bret J.; Gunter, Jeff; Kantarci, Kejal; Senjem, Matthew L.; Vemuri, Prashanthi; Zuk, Samantha] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA. [Barnes, Josephine; Clegg, Shona; Fox, Nick C.; Malone, Ian B.; Modat, Marc; Ourselin, Sebastien] UCL, Dementia Res Ctr, Inst Neurol, Dept Neurodegenerat Dis, London, England. [Brewer, James; Dale, Anders M.; Gutman, Boris A.; Holland, Dominic; Hua, Xue] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Carmichael, Owen; DeCarli, Charles; Fletcher, Evan; Maillard, Pauline] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA. [Ching, Christopher; Thompson, Paul M.] Univ So Calif, Imaging Genet Ctr, Inst Neuroimaging & Informat, Dept Neurol, Marina Del Rey, CA USA. [DeCarli, Charles; Fletcher, Evan; Maillard, Pauline] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA. [Desikan, Rahul S.; Fennema-Notestine, Christine; McEvoy, Linda] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. [Fennema-Notestine, Christine] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Fjell, Anders M.; Walhovd, Kristine] Univ Oslo, Dept Psychol, Oslo, Norway. [Insel, Philip; Mackin, Scott; Mueller, Susanne; Nosheny, Rachel; Schuff, Norbert; Simonson, Alix; Weiner, Michael] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, Dept Radiol & Biomed Imaging, San Francisco, CA USA. [Killiany, Ron J.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA. [Krueger, Gunnar] Siemens Med Solut, Boston, MA USA. [Leung, Kelvin K.; Modat, Marc; Ourselin, Sebastien] UCL, Ctr Med Image Comp, Translat Imaging Grp, London, England. [Mackin, Scott; Weiner, Michael] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Mattsson, Niklas] Univ Gothenburg, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden. [Mueller, Susanne; Nosheny, Rachel; Schuff, Norbert; Weiner, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Rettmann, Dan] GE Healthcare, MR Applicat & Workflow, Rochester, MN USA. [Zhao, Yansong] Philips Healthcare, Cleveland, OH USA. [Weiner, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Weiner, Michael] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Jack, CR (reprint author), Mayo Clin, Dept Radiol, Rochester, MN 55905 USA. EM jack.clifford@mayo.edu RI Ourselin, Sebastien/K-6960-2015; Barnes, Josesphine/P-5698-2014; Fox, Nick/B-1319-2009; Jack, Clifford/F-2508-2010 OI Ourselin, Sebastien/0000-0002-5694-5340; Fox, Nick/0000-0002-6660-657X; Jack, Clifford/0000-0001-7916-622X; Bernstein, Matt/0000-0003-3770-0441 FU NIA NIH HHS [R01 AG011378, R01 AG040060, R01 AG041851, U01 AG024904]; NIBIB NIH HHS [P41 EB015922]; NIMH NIH HHS [R01 MH098062] NR 177 TC 7 Z9 7 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JUL PY 2015 VL 11 IS 7 BP 740 EP 756 DI 10.1016/j.jalz.2015.05.002 PG 17 WC Clinical Neurology SC Neurosciences & Neurology GA CN1RS UT WOS:000358198400004 PM 26194310 ER PT J AU Saykin, AJ Shen, L Yao, X Kim, S Nho, K Risacher, SL Ramanan, VK Foroud, TM Faber, KM Sarwar, N Munsie, LM Hu, X Soares, HD Potkin, SG Thompson, PM Kauwe, JSK Kaddurah-Daouk, R Green, RC Toga, AW Weiner, MW AF Saykin, Andrew J. Shen, Li Yao, Xiaohui Kim, Sungeun Nho, Kwangsik Risacher, Shannon L. Ramanan, Vijay K. Foroud, Tatiana M. Faber, Kelley M. Sarwar, Nadeem Munsie, Leanne M. Hu, Xiaolan Soares, Holly D. Potkin, Steven G. Thompson, Paul M. Kauwe, John S. K. Kaddurah-Daouk, Rima Green, Robert C. Toga, Arthur W. Weiner, Michael W. CA Alzheimer's Dis Neuroimaging Init TI Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans SO ALZHEIMERS & DEMENTIA LA English DT Review DE Alzheimer's disease (AD); Mild cognitive impairment (MCI); Genome-wide association studies (GWAS); Next generation sequencing (NGS); Copy number variation (CNV); Biomarkers; Magnetic resonance imaging (MRI); Positron emission tomography (PET); Cerebrospinal fluid (CSF); DNA; RNA; Memory; Cognition; Bioethical issues; Precision medicine ID GENOME-WIDE ASSOCIATION; MILD COGNITIVE IMPAIRMENT; PLURIPOTENT STEM-CELLS; MANAGING INCIDENTAL FINDINGS; FAMILIAL ALZHEIMERS-DISEASE; ALLELE-SPECIFIC PCR; APOLIPOPROTEIN-E; HUMAN-MEMORY; HIPPOCAMPAL ATROPHY; CEREBROSPINAL-FLUID AB Introduction: Genetic data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) have been crucial in advancing the understanding of Alzheimer's disease (AD) pathophysiology. Here, we provide an update on sample collection, scientific progress and opportunities, conceptual issues, and future plans. Methods: Lymphoblastoid cell lines and DNA and RNA samples from blood have been collected and banked, and data and biosamples have been widely disseminated. To date, APOE genotyping, genome-wide association study (GWAS), and whole exome and whole genome sequencing data have been obtained and disseminated. Results: ADNI genetic data have been downloaded thousands of times, and >300 publications have resulted, including reports of large-scale GWAS by consortia to which ADNI contributed. Many of the first applications of quantitative endophenotype association studies used ADNI data, including some of the earliest GWAS and pathway-based studies of biospecimen and imaging biomarkers, as well as memory and other clinical/cognitive variables. Other contributions include some of the first whole exome and whole genome sequencing data sets and reports in healthy controls, mild cognitive impairment, and AD. Discussion: Numerous genetic susceptibility and protective markers for AD and disease biomarkers have been identified and replicated using ADNI data and have heavily implicated immune, mitochondrial, cell cycle/fate, and other biological processes. Early sequencing studies suggest that rare and structural variants are likely to account for significant additional phenotypic variation. Longitudinal analyses of transcriptomic, proteomic, metabolomic, and epigenomic changes will also further elucidate dynamic processes underlying preclinical and prodromal stages of disease. Integration of this unique collection of multiomics data within a systems biology framework will help to separate truly informative markers of early disease mechanisms and potential novel therapeutic targets from the vast background of less relevant biological processes. Fortunately, a broad swath of the scientific community has accepted this grand challenge. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. C1 [Saykin, Andrew J.; Shen, Li; Yao, Xiaohui; Kim, Sungeun; Nho, Kwangsik; Risacher, Shannon L.; Ramanan, Vijay K.] Indiana Univ, Ctr Neuroimaging, Dept Radiol & Imaging Sci, Sch Med, Indianapolis, IN 46204 USA. [Saykin, Andrew J.; Shen, Li; Kim, Sungeun; Nho, Kwangsik; Risacher, Shannon L.; Ramanan, Vijay K.; Foroud, Tatiana M.] Indiana Univ, Indiana Alzheimer Dis Ctr, Sch Med, Indianapolis, IN 46204 USA. [Saykin, Andrew J.; Ramanan, Vijay K.; Foroud, Tatiana M.; Faber, Kelley M.] Indiana Univ, Dept Med & Mol Genet, Sch Med, Indianapolis, IN 46204 USA. [Shen, Li] Indiana Univ, Ctr Computat Biol & Bioinformat, Sch Med, Indianapolis, IN 46204 USA. [Yao, Xiaohui] Indiana Univ, Sch Informat & Comp, Purdue Univ, Indianapolis, IN 46204 USA. [Sarwar, Nadeem] Eisai Ltd, Hatfield, Herts, England. [Munsie, Leanne M.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Hu, Xiaolan; Soares, Holly D.] Bristol Myers Squibb, Wallingford, CT USA. [Potkin, Steven G.] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA. [Thompson, Paul M.] Univ So Calif, Dept Neurol, Keck Sch Med, Marina Del Rey, CA USA. [Thompson, Paul M.] Univ So Calif, Imaging Genet Ctr, Keck Sch Med, Marina Del Rey, CA USA. [Kauwe, John S. K.] Brigham Young Univ, Dept Biol, Provo, UT 84602 USA. [Kauwe, John S. K.] Brigham Young Univ, Dept Neurosci, Provo, UT USA. [Kaddurah-Daouk, Rima] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. [Kaddurah-Daouk, Rima] Duke Univ, Duke Inst Brain Sci, Durham, NC USA. [Green, Robert C.] Partners Ctr Personalized Genet Med, Boston, MA USA. [Green, Robert C.] Brigham & Womens Hosp, Div Genet, Dept Med, Boston, MA 02115 USA. [Green, Robert C.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Toga, Arthur W.] Univ So Calif, Lab Neuroimaging, Inst Neuroimaging & Neuroinformat, Keck Sch Med, Los Angeles, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. RP Saykin, AJ (reprint author), Indiana Univ, Ctr Neuroimaging, Dept Radiol & Imaging Sci, Sch Med, Indianapolis, IN 46204 USA. EM asaykin@iupui.edu OI Shen, Li/0000-0002-5443-0503 FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; DOD ADNI (Department of Defense [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; National Institute on Aging [U24AG021886]; NIH [U01 AG024904, R01 LM011360, RC2 AG036535, R01 AG19771, P30 AG10133, UL1 TR001108]; DOD [W81XWH-14-2-0151]; NCAA [14132004]; Alzheimer's Association; NSF [IIS-1117335] FX Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica; Biogen Idec.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace; Merck & Co., Inc.; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer; Piramal Imaging; Servier; Synarc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Samples from the National Cell Repository for Alzheimer's Disease (NCRAD), which receives government support under a cooperative agreement (U24AG021886) awarded by the National Institute on Aging, were used in this study. Data analysis was supported in part by NIH R01 LM011360, U01 AG024904, RC2 AG036535, R01 AG19771, P30 AG10133, UL1 TR001108, DOD W81XWH-14-2-0151, NCAA 14132004, the Alzheimer's Association, and NSF IIS-1117335. NR 173 TC 21 Z9 21 U1 4 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JUL PY 2015 VL 11 IS 7 BP 792 EP 814 DI 10.1016/j.jalz.2015.05.009 PG 23 WC Clinical Neurology SC Neurosciences & Neurology GA CN1RS UT WOS:000358198400007 PM 26194313 ER PT J AU Hendrix, JA Finger, B Weiner, MW Frisoni, GB Iwatsubo, T Rowe, CC Kim, SY Guinjoan, SM Sevlever, G Carrillo, MC AF Hendrix, James A. Finger, Brad Weiner, Michael W. Frisoni, Giovanni B. Iwatsubo, Takeshi Rowe, Christopher C. Kim, Seong Yoon Guinjoan, Salvador M. Sevlever, Gustavo Carrillo, Maria C. TI The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update SO ALZHEIMERS & DEMENTIA LA English DT Review DE Alzheimer's disease; Neuroimaging; Biomarkers; Cerebrospinal fluid ID MILD COGNITIVE IMPAIRMENT; HIPPOCAMPAL VOLUME; AMYLOID-BETA; CEREBROSPINAL-FLUID; LIFE-STYLE; PATHOLOGICAL CASCADE; COMMON VARIANTS; ALPHA-SYNUCLEIN; A-BETA; BIOMARKERS AB The Alzheimer's Disease Neuroimaging Initiative (ADNI), launched in 2004, has worked to accelerate drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public-private partnership, the initiative has set a new standard for data sharing without embargo and for the use of biomarkers in dementia research. The ADNI effort in North America is not the only such effort in the world. The Alzheimer's Association recognized these global efforts and formed Worldwide ADNI (WW-ADNI). By creating a platform for international collaboration and cooperation, WW-ADNI's goals are to harmonize projects and results across geographical regions and to facilitate data management and availability to investigators around the world. WW-ADNI projects include those based in North America, Europe, Japan, Australia, Korea, and Argentina. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Hendrix, James A.; Carrillo, Maria C.] Alzheimers Assoc, Med & Sci Relat, Chicago, IL 60631 USA. [Finger, Brad] Independent Sci Writer, Evanston, IL USA. [Weiner, Michael W.] San Francisco VA Med Ctr, CIND, Northern Calif Inst Res, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Frisoni, Giovanni B.] Univ Hosp, Lab Neuroimaging Aging, Geneva, Switzerland. [Frisoni, Giovanni B.] Univ Geneva, Geneva, Switzerland. [Iwatsubo, Takeshi] Univ Hosp, Grad Sch Med, Dept Neuropathol, Tokyo, Japan. [Rowe, Christopher C.] Austin Hlth, Dept Mol Imaging, Melbourne, Australia. [Kim, Seong Yoon] Asian Med Ctr, Dept Psychiat, Seoul, South Korea. [Guinjoan, Salvador M.; Sevlever, Gustavo] Inst Invest Neurol Raul Carrea FLENI, Aging & Memory Ctr, Buenos Aires, DF, Argentina. RP Hendrix, JA (reprint author), Alzheimers Assoc, Med & Sci Relat, Chicago, IL 60631 USA. EM jhendrix@alz.org RI Frisoni, Giovanni B/K-1360-2016 OI Frisoni, Giovanni B/0000-0002-6419-1753 FU National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; Takeda Pharmaceutical Company; Canadian Institutes of Health Research; European Commission; EFPIA in the context of the IMI - Innovative Medicines Initiative funding scheme; Ministry of Health, Labor and Welfare; Ministry of Economy, Trade and Industry (through New Energy and Development Organization), Japan; Astellas; Bristol Myers-Squibb; Chugai; Daiichi-Sankyo; Dainippon-Sumitomo; Eisai; Eli-Lilly; MSD; Novartis; Pfizer; Shionogi; Takeda; Tanabe-Mitsubishi; Australian Government sources - CSIRO; Science Industry Endowment Fund; NHMRC; Dementia CRC; CRC for Mental Health; Commercial sources - Janssen; Avid Radiopharmaceuticals; Navidea Biopharmaceuticals; Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI12C0713]; FLENI foundation; Perez Companc Foundation; Pan American Energy FX NA-ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. Pharmacog/E-ADNI is funded by the European Commission and EFPIA in the context of the IMI - Innovative Medicines Initiative funding scheme.; J-ADNI-1 and J-ADNI-2 research projects are supported by public funding from the Ministry of Health, Labor and Welfare, and the Ministry of Economy, Trade and Industry (through New Energy and Development Organization), Japan. Industry Scientific Advisory Board of J-ADNI, comprised of 13 pharma companies (Astellas, Bristol Myers-Squibb, Chugai, Daiichi-Sankyo, Dainippon-Sumitomo, Eisai, Eli-Lilly, MSD, Novartis, Pfizer, Shionogi, Takeda, Tanabe-Mitsubishi), contributed funding for J-ADNI-1/2 as a public research.; Funding for AIBL has been provided by Australian Government sources - CSIRO, the Science Industry Endowment Fund, NHMRC, the Dementia CRC and the CRC for Mental Health; Commercial sources - Janssen, GE Healthcare, Avid Radiopharmaceuticals, Navidea Biopharmaceuticals; and Alzheimer's Association, The Alzheimer's Drug Discovery Foundation, and an anonymous foundation.; Funding for K-ADNI is provided by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI12C0713).; Funding for ARG-ADNI is provided by the FLENI foundation, the Perez Companc Foundation and Pan American Energy. NR 86 TC 6 Z9 6 U1 0 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JUL PY 2015 VL 11 IS 7 BP 850 EP 859 DI 10.1016/j.jalz.2015.05.008 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA CN1RS UT WOS:000358198400012 PM 26194318 ER PT J AU Grewal, SK Chren, MM Parvataneni, R Stuart, SE Galles, E Linos, E AF Grewal, S. K. Chren, M. M. Parvataneni, R. Stuart, S. E. Galles, E. Linos, E. TI 'What is it about your skin cancer that bothers you the most?': 700 patients respond SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Letter ID SQUAMOUS-CELL CARCINOMA C1 [Grewal, S. K.] Commonwealth Med Coll, Scranton, PA USA. [Chren, M. M.; Parvataneni, R.; Stuart, S. E.; Linos, E.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Chren, M. M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Galles, E.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. RP Linos, E (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St, San Francisco, CA 94143 USA. EM linose@derm.ucsf.edu OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700 FU NCATS NIH HHS [KL2 TR000143]; NCRR NIH HHS [KL2RR024130]; NIAMS NIH HHS [K24 AR052667, R01 AR054983] NR 4 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JUL PY 2015 VL 173 IS 1 BP 296 EP 297 DI 10.1111/bjd.13618 PG 2 WC Dermatology SC Dermatology GA CN3IK UT WOS:000358318700060 PM 25523523 ER PT J AU Bauman, WA Cirnigliaro, CM La Fountaine, MF Martinez, L Kirshblum, SC Spungen, AM AF Bauman, William A. Cirnigliaro, Christopher M. La Fountaine, Michael F. Martinez, LeighAnn Kirshblum, Steven C. Spungen, Ann M. TI Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study SO JOURNAL OF BONE AND MINERAL METABOLISM LA English DT Article DE Spinal cord injury; Zoledronate; Bisphosphonates; Osteoporosis; Knee ID X-RAY ABSORPTIOMETRY; DISUSE OSTEOPOROSIS; MINERAL DENSITY; PAMIDRONATE; TERM; IMMOBILIZATION; TURNOVER; FRACTURE; INDIVIDUALS; METABOLISM AB After acute spinal cord injury (SCI), rapid depletion of the sublesional skeleton occurs, particularly at the distal femur and proximal tibia. Subsequently, fragility fractures of the knee may occur. We determined the efficacy of zoledronic acid to prevent sublesional bone mineral density (BMD) loss at 6 and 12 months after acute SCI. Thirteen subjects with acute motor-complete SCI were prospectively studied: 6 patients received zoledronic acid (5 mg) and 7 subjects did not receive the drug (controls). Zoledronic acid was administered intravenously within 16 weeks of acute injury. Areal BMD was performed by dual energy X-ray absorptiometry at baseline, 6, and 12 months after administration of drug. The treatment group demonstrated sparing of BMD at the total hip at month 6 (p < 0.0006) and at month 12 (p < 0.01). In contrast to the findings at the hip, the treatment group had a greater loss of BMD compared to the control group at the distal femur and proximal tibia at month 6 (-7.9 % +/- 3.4 vs.-2.7 % +/- 5.0, respectively, p = 0.054; and -10.5 % +/- 6.4 vs. -4.8 % +/- 6.8, respectively, p = NS) and at month 12 (-18.5 % +/- 3.9 vs. -8.4 % +/- 7.2, respectively, p = 0.01; and -20.4 % +/- 8.8 vs.-7.9 % +/- 12.3, respectively, p = 0.06). A single dose of zoledronic acid administered soon after acute SCI reduced the %BMD loss at the hip, but appeared to have no effect to prevent %BMD loss at the knee, the site where fracture risk is greatest in persons with SCI. C1 [Bauman, William A.; Cirnigliaro, Christopher M.; La Fountaine, Michael F.; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, Bronx, NY 10468 USA. [Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Bauman, William A.; La Fountaine, Michael F.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med & Rehabil Med, New York, NY 10029 USA. [La Fountaine, Michael F.] Seton Hall Univ, Dept Phys Therapy, Sch Hlth & Med Sci, S Orange, NJ USA. [Martinez, LeighAnn; Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Bauman, WA (reprint author), James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM william.bauman@va.gov FU James J. Peters Veterans Affairs Medical Center; Kessler Institute for Rehabilitation, West Orange, NJ; Rehabilitation Research & Development Center of Excellence [B9212-C, B4162-C]; Veteran Affairs Rehabilitation Research and Development Service [B9212-C, B4162-C] FX The authors would like to thank the James J. Peters Veterans Affairs Medical Center, Bronx, NY, Department of Veterans Affairs Rehabilitation Research & Development Service, and Kessler Institute for Rehabilitation, West Orange, NJ, for their support to perform this work. Novartis Pharmaceuticals Corporation provided drug gratis to perform this clinical trial. This work was funded by a Rehabilitation Research & Development Center of Excellence for the Medical Consequences of Spinal Cord Injury grant (#B9212-C, B4162-C). Veteran Affairs Rehabilitation Research and Development Service (#B9212-C, #B4162-C) and the James J. Peters Veterans Affairs Medical Center. Novartis Pharmaceuticals graciously provided zoledronic acid (Reclast 5 mg) for use in our clinical trial. NR 44 TC 7 Z9 7 U1 2 U2 3 PU SPRINGER JAPAN KK PI TOKYO PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN SN 0914-8779 EI 1435-5604 J9 J BONE MINER METAB JI J. Bone Miner. Metab. PD JUL PY 2015 VL 33 IS 4 BP 410 EP 421 DI 10.1007/s00774-014-0602-x PG 12 WC Endocrinology & Metabolism; Medicine, Research & Experimental SC Endocrinology & Metabolism; Research & Experimental Medicine GA CN1QT UT WOS:000358195600006 PM 25158630 ER PT J AU Li, JT Melton, AC Su, G Hamm, DE LaFemina, M Howard, J Fang, XH Bhat, S Huynh, KM O'Kane, CM Ingram, RJ Muir, RR McAuley, DF Matthay, MA Sheppard, D AF Li, John T. Melton, Andrew C. Su, George Hamm, David E. LaFemina, Michael Howard, James Fang, Xiaohui Bhat, Sudarshan Huynh, Kieu-My O'Kane, Cecilia M. Ingram, Rebecca J. Muir, Roshell R. McAuley, Daniel F. Matthay, Michael A. Sheppard, Dean TI Unexpected Role for Adaptive alpha beta Th17 Cells in Acute Respiratory Distress Syndrome SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ACUTE LUNG INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EVANS BLUE-DYE; T-CELLS; TH17 CELLS; ALBUMIN CLEARANCE; HOST-DEFENSE; IL-17; MICE; INTERLEUKIN-17 AB Acute respiratory distress syndrome (ARDS) is a devastating disorder characterized by increased alveolar permeability with no effective treatment beyond supportive care. Current mechanisms underlying ARDS focus on alveolar endothelial and epithelial injury caused by products of innate immune cells and platelets. However, the role of adaptive immune cells in ARDS remains largely unknown. In this study, we report that expansion of Ag-specific alpha beta Th17 cells contributes to ARDS by local secretion of IL-17A, which in turn directly increases alveolar epithelial permeability. Mice with a highly restrictive defect in Ag-specific alpha beta Th17 cells were protected from experimental ARDS induced by a single dose of endotracheal LPS. Loss of IL-17 receptor C or Ab blockade of IL-17A was similarly protective, further suggesting that IL-17A released by these cells was responsible for this effect. LPS induced a rapid and specific clonal expansion of alpha beta Th17 cells in the lung, as determined by deep sequencing of the hypervariable CD3R beta VJ region of the TCR. Our findings could be relevant to ARDS in humans, because we found significant elevation of IL-17A in bronchoalveolar lavage fluid from patients with ARDS, and rIL-17A directly increased permeability across cultured human alveolar epithelial monolayers. These results reveal a previously unexpected role for adaptive immune responses that increase alveolar permeability in ARDS and suggest that alpha beta Th17 cells and IL-17A could be novel therapeutic targets for this currently untreatable disease. C1 [Li, John T.; Melton, Andrew C.; Huynh, Kieu-My; Sheppard, Dean] Univ Calif San Francisco, Lung Biol Ctr, Dept Med, San Francisco, CA 94143 USA. [Li, John T.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94110 USA. [Su, George] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Hamm, David E.] Adapt Biotechnol, Seattle, WA 98102 USA. [LaFemina, Michael] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Howard, James] UCSF Benioff Childrens Hosp Oakland, Dept Pediat, Oakland, CA 94609 USA. [Matthay, Michael A.] Cardiovasc Res Inst, Dept Anesthesia, San Francisco, CA 94158 USA. [Fang, Xiaohui; Matthay, Michael A.] Cardiovasc Res Inst, Dept Med, San Francisco, CA 94158 USA. [Bhat, Sudarshan] Univ Calif Berkeley, Berkeley, CA 94720 USA. [O'Kane, Cecilia M.; Ingram, Rebecca J.; Muir, Roshell R.; McAuley, Daniel F.] Queens Univ Belfast, Ctr Infect & Immun, Belfast BT7 1NN, Antrim, North Ireland. RP Sheppard, D (reprint author), Univ Calif San Francisco, Lung Biol Ctr, 1550 4th St,Mission Bay, San Francisco, CA 94143 USA. EM dean.sheppard@ucsf.edu RI Ingram, Rebecca/F-9711-2013 OI Ingram, Rebecca/0000-0003-1832-2457 FU National Institutes of Health [R37HL53949, K08HL111208, R37HL51856]; Health and Social Care Research and Development Division, Public Health Agency Northern Ireland FX This work was supported by National Institutes of Health Grants R37HL53949 (to D.S.), K08HL111208 (to J.T.L.), and R37HL51856 (to M.A.M.), as well as by a grant from the Health and Social Care Research and Development Division, Public Health Agency Northern Ireland (to C.M.O. and D.F.M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funders. NR 41 TC 9 Z9 9 U1 1 U2 5 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD JUL 1 PY 2015 VL 195 IS 1 BP 87 EP 95 DI 10.4049/jimmunol.1500054 PG 9 WC Immunology SC Immunology GA CM9XU UT WOS:000358064500015 PM 26002979 ER PT J AU Lisi, AJ Breuer, P Gallagher, RM Rodriguez, E Rossi, MI Schmader, K Scholten, JD Weiner, DK AF Lisi, Anthony J. Breuer, Paula Gallagher, Rollin M. Rodriguez, Eric Rossi, Michelle I. Schmader, Kenneth Scholten, Joel D. Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part II: Myofascial Pain SO PAIN MEDICINE LA English DT Review DE Low Back Pain; Myofascial Pain; Chronic Pain; Degenerative Disc Disease; Elderly; Chronic Low Back Pain; Lumbar; Older Adults; Pain Disorder; Spinal Stenosis ID POSTTRAUMATIC-STRESS-DISORDER; MUSCULOSKELETAL PAIN; TRIGGER POINT; SKELETAL-MUSCLE; MANAGEMENT; CARE; PREVALENCE; PHYSICIANS; DIAGNOSIS; FRAMEWORK AB ObjectiveTo present an algorithm of sequential treatment options for managing myofascial pain (MP) in older adults, along with a representative clinical case. MethodsA modified Delphi process was used to synthesize evidence-based recommendations. A multidisciplinary expert panel developed the algorithm, which was subsequently refined through an iterative process of input from a primary care physician panel. ResultsWe present an algorithm and supportive materials to help guide the care of older adults with MP, an important contributor to chronic low back pain (CLBP). Addressing any perpetuating factors should be the first step of managing MP. Patients should be educated on self-care approaches, home exercise, and the use of safe analgesics when indicated. Trigger point deactivation can be accomplished by manual therapy, injection therapy, dry needling, and/or acupuncture. ConclusionsThe algorithm presented gives a structured approach to guide primary care providers in planning treatment for patients with MP as a contributor to CLBP. C1 [Lisi, Anthony J.] VA Connecticut Healthcare Syst, Newington, CT USA. [Lisi, Anthony J.] Univ Bridgeport, Coll Chiropract, Bridgeport, CT 06601 USA. [Breuer, Paula] Univ Pittsburgh, Med Ctr, Ctr Rehab Serv, Pittsburgh, PA 15260 USA. [Gallagher, Rollin M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.] Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.] Philadelphia VA Med Ctr, Pain Serv, Philadelphia, PA USA. [Rodriguez, Eric; Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15260 USA. [Rossi, Michelle I.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA 15240 USA. [Schmader, Kenneth] Durham VA Med Ctr, GRECC, Durham, NC USA. [Schmader, Kenneth] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27706 USA. [Scholten, Joel D.] Washington DC VA Med Ctr, Washington, DC USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU Veterans Administration Rehabilitation Research & Development Service FX Veterans Administration Rehabilitation Research & Development Service. NR 43 TC 3 Z9 3 U1 7 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JUL PY 2015 VL 16 IS 7 BP 1282 EP 1289 DI 10.1111/pme.12821 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CM9GY UT WOS:000358017000011 PM 26087225 ER PT J AU Boyers, LN Karimkhani, C Guild, SR Dellavalle, RP AF Boyers, Lindsay N. Karimkhani, Chante Guild, Samantha R. Dellavalle, Robert P. TI Lessons from a Legislative Struggle to Ban Indoor Tanning for Children Younger than 18 SO PEDIATRIC DERMATOLOGY LA English DT Editorial Material C1 [Boyers, Lindsay N.] Georgetown Univ, Sch Med, Washington, DC USA. [Karimkhani, Chante] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Guild, Samantha R.] AIM Melanoma, Richmond, CA USA. [Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, Denver, CO USA. [Dellavalle, Robert P.] Univ Colorado, Sch Med, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. RP Dellavalle, RP (reprint author), Dept Veteran Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu NR 8 TC 0 Z9 0 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-8046 EI 1525-1470 J9 PEDIATR DERMATOL JI Pediatr. Dermatol. PD JUL-AUG PY 2015 VL 32 IS 4 BP 553 EP 556 DI 10.1111/pde.12491 PG 4 WC Dermatology; Pediatrics SC Dermatology; Pediatrics GA CN1FJ UT WOS:000358163100047 PM 26184402 ER PT J AU Bachhuber, MA McGinty, EE Kennedy-Hendricks, A Niederdeppe, J Barry, CL AF Bachhuber, Marcus A. McGinty, Emma E. Kennedy-Hendricks, Alene Niederdeppe, Jeff Barry, Colleen L. TI Messaging to Increase Public Support for Naloxone Distribution Policies in the United States: Results from a Randomized Survey Experiment SO PLOS ONE LA English DT Article ID OPIATE SUBSTITUTION TREATMENT; EMERGENCY MEDICAL-SERVICES; TAKE-HOME NALOXONE; OPIOID OVERDOSE; HEROIN OVERDOSE; INTRANASAL NALOXONE; SAN-FRANCISCO; DRUG-USERS; PREVENTION; DEATHS AB Background Barriers to public support for naloxone distribution include lack of knowledge, concerns about potential unintended consequences, and lack of sympathy for people at risk of overdose. Methods A randomized survey experiment was conducted with a nationally-representative web-based survey research panel (GfK KnowledgePanel). Participants were randomly assigned to read different messages alone or in combination: 1) factual information about naloxone; 2) pre-emptive refutation of potential concerns about naloxone distribution; and 3) a sympathetic narrative about a mother whose daughter died of an opioid overdose. Participants were then asked if they support or oppose policies related to naloxone distribution. For each policy item, logistic regression models were used to test the effect of each message exposure compared with the no-exposure control group. Results The final sample consisted of 1,598 participants (completion rate: 72.6%). Factual information and the sympathetic narrative alone each led to higher support for training first responders to use naloxone, providing naloxone to friends and family members of people using opioids, and passing laws to protect people who administer naloxone. Participants receiving the combination of the sympathetic narrative and factual information, compared to factual information alone, were more likely to support all policies: providing naloxone to friends and family members (OR: 2.0 [95% CI: 1.4 to 2.9]), training first responders to use naloxone (OR: 2.0 [95% CI: 1.2 to 3.4]), passing laws to protect people if they administer naloxone (OR: 1.5 [95% CI: 1.04 to 2.2]), and passing laws to protect people if they call for medical help for an overdose (OR: 1.7 [95% CI: 1.2 to 2.5]). Conclusions All messages increased public support, but combining factual information and the sympathetic narrative was most effective. Public support for naloxone distribution can be improved through education and sympathetic portrayals of the population who stands to benefit from these policies. C1 [Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. [Bachhuber, Marcus A.; Barry, Colleen L.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Bachhuber, Marcus A.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. [McGinty, Emma E.; Kennedy-Hendricks, Alene; Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [McGinty, Emma E.; Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Niederdeppe, Jeff] Cornell Univ, Dept Commun, Ithaca, NY USA. RP Bachhuber, MA (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. EM marcus.bachhuber@gmail.com OI Bachhuber, Marcus/0000-0002-5610-8382 FU American International Group, Inc.; National Institute on Drug Abuse [R01DA026414] FX This work was funded by an unrestricted research grant from American International Group, Inc., and by the National Institute on Drug Abuse (R01DA026414). The funding bodies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. NR 49 TC 4 Z9 4 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 1 PY 2015 VL 10 IS 7 AR e0130050 DI 10.1371/journal.pone.0130050 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1CG UT WOS:000358153000050 PM 26132859 ER PT J AU Katon, JG Washington, DL Cordasco, KM Reiber, GE Yano, EM Zephyrin, LC AF Katon, Jodie G. Washington, Donna L. Cordasco, Kristina M. Reiber, Gayle E. Yano, Elizabeth M. Zephyrin, Laurie C. TI Prenatal Care for Women Veterans Who Use Department of Veterans Affairs Health Care SO WOMENS HEALTH ISSUES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; PRETERM BIRTH; MEDICAL-CENTER; MENTAL-HEALTH; VA; PREGNANCY; RISK; AVAILABILITY; AFGHANISTAN; DEPRESSION AB Objective: The number of women Veterans of childbearing age enrolling in Department of Veterans Affairs (VA) health care is increasing. Our objective was to describe characteristics of women veterans and resumption of VA care after delivery by use of VA prenatal benefits. Study design: We used data from the National Survey of Women Veterans, a population-based survey. VA-eligible women veterans with at least one live birth who had ever used VA and were younger than 45 years when VA pre-natal benefits became available were categorized based on self-reported receipt of VA prenatal benefits. Characteristics of by use of VA prenatal benefits were compared using chi(2) tests with Rao-Scott adjustment. All analyses used sampling weights. Results: In our analytic sample, of those who potentially had the opportunity to use VA prenatal benefits, 25% used these benefits and 75% did not. Compared with women veterans not using VA prenatal benefits, those who did were more likely to be 18 to 24 years old (39.9% vs. 3.7%; p = .03), and more likely to have self-reported diagnosed depression (62.5% vs. 24.5%; p = .02) and current depression or posttraumatic stress disorder (PTSD) symptoms (depression, 46.1% vs. 8% [ p - .02]; PTSD, 52.5% vs. 14.8% [ p - .02]). Compared with women veterans not using VA prenatal benefits, those who did were more likely to resume VA use after delivery (p < .001). Conclusion: Pregnant women veterans who use VA prenatal benefits are a high-risk group. Among those who opt not to use these benefits, pregnancy is an important point of attrition from VA health care, raising concerns regarding retention of women veterans within VA and continuity of care. Published by Elsevier Inc. C1 [Katon, Jodie G.; Reiber, Gayle E.] VA Med Ctr, HSR&D, Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Katon, Jodie G.; Zephyrin, Laurie C.] VA Cent Off, Womens Vet Hlth Serv, Off Patient Serv, Washington, DC USA. [Katon, Jodie G.; Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Washington, Donna L.; Cordasco, Kristina M.; Yano, Elizabeth M.] VA Greater Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implement &, North Hills, CA USA. [Washington, Donna L.; Cordasco, Kristina M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Zephyrin, Laurie C.] NYU, Dept Obstet & Gynecol, Langone Sch Med, New York, NY 10016 USA. RP Katon, JG (reprint author), VA Med Ctr, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM jkaton@u.washington.edu FU Department of Veterans Affairs (VA), Women's Health Services in the Office of Patient Care Services; Health Services Research and Development (HSRD) Service [SDR-08-270]; Office of Academic Affiliations' Associated Health Postdoctoral Fellowship [TTP 61-026]; VA HSR&D Senior Research Career Scientist awards [RCS-98-353, RCS-05-195] FX This study used data from the National Survey of Women Veterans, which was funded by the Department of Veterans Affairs (VA), Women's Health Services in the Office of Patient Care Services and the Health Services Research and Development (HSR&D) Service (#SDR-08-270). Dr. Katon was supported by an Office of Academic Affiliations' Associated Health Postdoctoral Fellowship (#TTP 61-026). Drs. Reiber (#RCS-98-353) and Yano (#RCS-05-195) are supported by VA HSR&D Senior Research Career Scientist awards. The authors gratefully acknowledge Su Sun Mor for data analysis support and Mark Canning for project management. NR 24 TC 1 Z9 1 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JUL-AUG PY 2015 VL 25 IS 4 BP 377 EP 381 DI 10.1016/j.whi.2015.03.004 PG 5 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA CN7HK UT WOS:000358604800010 PM 25935821 ER PT J AU Slane, JD Levine, MD AF Slane, Jennifer D. Levine, Michele D. TI Association of Restraint and Disinhibition to Gestational Weight Gain among Pregnant Former Smokers SO WOMENS HEALTH ISSUES LA English DT Article ID POSTPARTUM SMOKING RELAPSE; BODY-MASS INDEX; DIETARY RESTRAINT; EATING BEHAVIORS; WOMEN; CESSATION; BIRTH; INTERVENTIONS; MANAGEMENT; BRAZIL AB Introduction: Gaining excessive weight during pregnancy is associated with immediate maternal and fetal complications as well as longer term obesity. Prepregnancy body mass index, age, and smoking cessation have been related to gestational weight gain (GWG); however, less is known about how eating behaviors, that may be amenable to modification and have been related to weight gain outside of pregnancy, affect GWG. Methods: The present study evaluated the relationship of dietary restraint and disinhibition to GWG in a sample of women (n = 248) who quit smoking before or early in pregnancy. Women self-reported height and prepregnancy weight during their third trimester. GWG was calculated by subtracting prepregnancy weight from third trimester weight. The Three-Factor Eating Questionnaire assessed restraint and disinhibition. Results: Average GWG was 14.60 (+/- 7.64) kg and 47% of women had a GWG greater than the Institute of Medicine recommendations. Linear regression models were used to examine restraint and disinhibition as correlates of GWG, and multinomial logistic regressions were utilized to determine whether eating behaviors were associated with inadequate or excessive GWG. Restraint was associated positively with total GWG, but disinhibition was not associated with GWG. Thus, conscious attempts to restrict intake were associated with GWG beyond the influence of covariates. Conclusion: These findings highlight the potential influence of modifiable eating behaviors on GWG and demonstrate the need for additional research to determine how these behaviors relate to GWG over the course of pregnancy. Copyright (C) 2015 by the Jacobs Institute of Women's Health. Published by Elsevier Inc. C1 [Slane, Jennifer D.] VA Pittsburgh Healthcare Syst, VISN 4 Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Slane, Jennifer D.; Levine, Michele D.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA. RP Levine, MD (reprint author), Univ Pittsburgh, Med Ctr, 3811 OHara St, Pittsburgh, PA 15213 USA. EM levinem@upmc.edu FU NIH [K01 DA15396, R01 DA021608] FX NIH grants: K01 DA15396 and R01 DA021608; PI: Michele Levine, PhD. The authors do not have any financial conflicts of interest to disclose. This material is the result of work supported, in part, with resources and the use of facilities at the VISN 4 Mental Illness Research, Education, and Clinical Center, VA Pittsburgh Healthcare System. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 33 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JUL-AUG PY 2015 VL 25 IS 4 BP 390 EP 395 DI 10.1016/j.whi.2015.03.005 PG 6 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA CN7HK UT WOS:000358604800012 PM 26048757 ER PT J AU Drapkin, ML Eddie, D Buffington, AJ McCrady, BS AF Drapkin, Michelle L. Eddie, David Buffington, Angela J. McCrady, Barbara S. TI Alcohol-Specific Coping Styles of Adult Children of Individuals with Alcohol Use Disorders and Associations with Psychosocial Functioning SO ALCOHOL AND ALCOHOLISM LA English DT Article ID PARENTAL ALCOHOL; COMMUNITY SAMPLE; FAMILY-HISTORY; YOUNG-ADULTS; PERSONALITY; DRUG; LIFE; DRINKING; EVENTS; SYMPTOMATOLOGY AB Parental alcohol use disorders (AUDs) have been conceptualized as a chronic stressor that can lead to deleterious long-term outcomes in children of individuals with AUDs. Yet, while many individuals are detrimentally affected by their parents' problematic alcohol use, and go on to manifest psychological problems, others do not. How individuals cope with the stress of having a parent with an AUD is believed to be an important moderator of this differential outcome. This study assessed whether individuals' alcohol-specific coping styles predicted alcohol use, positive or negative life events, and depression, using a sample of 465 college students, of whom 20% were adult children of individuals with alcohol use disorders, colloquially known as adult children of alcoholics (ACOAs), and a battery of well-validated, self-report measures. Participant ACOAs reported less 'engaged' and 'total' alcohol-specific coping strategies and more 'withdrawal' alcohol-specific coping strategies than their non adult children of alcoholics (NACOAs) counterparts. Across participants, women reported more 'engaged', 'tolerant/inactive', and 'total' coping than men. Although ACOAs reported significantly more negative life events, which predicted more passive coping styles, they did not differ significantly from NACOAs on measures of problematic alcohol use or depression, supporting theories of resilience in ACOAs regardless of their alcohol-specific coping styles. For NACOAs, 'tolerant' coping predicted greater depression and alcohol-related problems; 'engaged' coping predicted fewer alcohol problems. Results suggest that ACOAs cope differently with problematic alcohol use among relatives and friends compared with NACOAs and are more likely to experience negative life events. Additionally, alcohol-related coping strategies have more predictive utility in NACOAs than ACOAs. C1 [Drapkin, Michelle L.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Drapkin, Michelle L.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Eddie, David] Rutgers State Univ, Ctr Alcohol Studies, New Brunswick, NJ USA. [Buffington, Angela J.] Fielding Grad Univ, Sch Psychol, Santa Barbara, CA USA. [McCrady, Barbara S.] Univ New Mexico, Ctr Alcoholism Substance Abuse & Addict, Albuquerque, NM 87131 USA. RP Drapkin, ML (reprint author), Univ Penn, Dept Psychiat, Philadelphia VA Med Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA. EM michelledrapkin@gmail.com NR 39 TC 0 Z9 0 U1 5 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0735-0414 EI 1464-3502 J9 ALCOHOL ALCOHOLISM JI Alcohol Alcohol. PD JUL-AUG PY 2015 VL 50 IS 4 BP 463 EP 469 DI 10.1093/alcalc/agv023 PG 7 WC Substance Abuse SC Substance Abuse GA CM7JF UT WOS:000357867100014 PM 25802055 ER PT J AU Lakkis, FG Palevsky, PM AF Lakkis, Fadi G. Palevsky, Paul M. TI A New CJASN Series: Renal Immunology for the Clinician SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material C1 [Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA. [Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA. [Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Mail Stop 111 F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM ppalevsky@cjasn.org OI Palevsky, Paul/0000-0002-7334-5400 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUL PY 2015 VL 10 IS 7 BP 1273 EP 1273 DI 10.2215/CJN.03870415 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CM5UJ UT WOS:000357754200020 PM 26153102 ER PT J AU Nguyen, T Alsarraj, A El-Serag, HB AF Nguyen, T. Alsarraj, A. El-Serag, H. B. TI Brief report: the length of newly diagnosed Barrett's esophagus may be decreasing SO DISEASES OF THE ESOPHAGUS LA English DT Article DE Barrett's esophagus; epidemiological study; esophageal adenocarcinoma; length; risk factor; Veterans Affair ID HIGH-GRADE DYSPLASIA; RISK-FACTORS; PRAGUE C; ADENOCARCINOMA; THERAPY; TRENDS; METAANALYSIS; VALIDATION; CRITERIA; CANCER AB Few studies have examined the temporal trends of length in newly diagnosed Barrett's esophagus (BE) and arrived at conflicting results. The aim of this study was to identify whether there has been a change over time in the length of BE at the time of diagnosis. This is a retrospective, single-center, observational study from Houston, Texas on newly diagnosed BE between 2008 and 2013. All cases were defined by the presence of endoscopically visible BE and histologic confirmation of intestinalized columnar epithelium with goblet cells. The length of BE was measured using the Prague classification. We examined temporal changes in 1-year intervals in the length of BE at the time of diagnosis. Both the frequency and mean length of BE at diagnosis seemed to decrease over time from February 2008 to July 2013. The proportion of patients diagnosed with BE 3cm per year declined during the study period, while the proportion of patients with BE 1 and <3cm increased, and those with <1cm remained stable. The mean age and the gender of patients diagnosed with BE 3cm did not differ significantly by BE length or year of diagnosis. The mean length of newly diagnosed BE may be decreasing as a result of a decline in BE 3cm. These observations cannot be explained by changes in age and gender. C1 [Nguyen, T.; El-Serag, H. B.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA. [El-Serag, H. B.] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [El-Serag, H. B.] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Nguyen, T.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.edu FU VA HSR&D Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, TX, USA [CIN 13-413] FX This research reported here was supported in part with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX, USA. NR 22 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1120-8694 EI 1442-2050 J9 DIS ESOPHAGUS JI Dis. Esophagus PD JUL PY 2015 VL 28 IS 5 BP 418 EP 421 DI 10.1111/dote.12216 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CM8LY UT WOS:000357954000003 PM 24708395 ER PT J AU Kuehlewein, L Sadda, SR Sarraf, D AF Kuehlewein, L. Sadda, S. R. Sarraf, D. TI OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy SO EYE LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; MOTION CORRECTION AB Purpose To study the precise structural aspects of a type 2 neovascular membrane in a patient with age-related macular degeneration (AMD) using optical coherence tomography (OCT) angiography and perform sequential quantitative analysis of the membrane after ranibizumab therapy. Patients and methods Split-spectrum amplitude-decorrelation (SSADA) OCT angiography macular cubes (3x3 mm) were acquired with a light source centered at 840 nm, a bandwidth of 45 nm, and an A-scan-rate of 70 000 scans per second. Visible pathologic vessels were outlined manually on average intensity projection en face images, and the area of the lesion and the vessel density were measured at baseline and follow-up. Results At baseline, the neovascular lesion measured 4.12 mm(2) and the vessel density was 19.83 mm(-1). Four weeks after the first, and 2 and 4 weeks after the second ranibizumab injection, OCT angiography revealed a progressively smaller vascular lesion (2.32, 1.77 and 1.64 mm(2)), and vessel density (10.24, 8.52 and 7.57 mm(-1)), although the large central trunks of the lesion were unchanged. Conclusions In this study, an obvious reduction in size and vessel density of the neovascular lesion was noted after treatment with ranibizumab using SSADA OCT angiography technology. Microvascular components can be delineated with precision, suggesting that this technique may be useful for the management of patients with neovascular AMD in a clinical setting as well as for future clinical trials. C1 [Kuehlewein, L.; Sadda, S. R.] Doheny Eye Inst, Los Angeles, CA 90033 USA. [Kuehlewein, L.; Sadda, S. R.; Sarraf, D.] Stein Eye Inst, Los Angeles, CA USA. [Sarraf, D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Sarraf, D.] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Carl Zeiss Meditec; Optos; Allergan FX Dr Sadda is a co-inventor of Doheny intellectual property related to optical coherence tomography that has been licensed by Topcon Medical Systems and is a member of the scientific advisory board for Heidelberg Engineering. Dr Sadda receives research support from and serves as a consultant for Carl Zeiss Meditec, Optos, and Allergan. He also serves as a consultant for Alcon, Novartis, and Iconic. NR 10 TC 36 Z9 38 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-222X EI 1476-5454 J9 EYE JI Eye PD JUL PY 2015 VL 29 IS 7 BP 932 EP 935 DI 10.1038/eye.2015.80 PG 4 WC Ophthalmology SC Ophthalmology GA CM5LC UT WOS:000357728300014 PM 25976641 ER PT J AU Zhang, Z Adappa, ND Chiu, AG Doghramji, LJ Cohen, NA Palmer, JN AF Zhang, Zi Adappa, Nithin D. Chiu, Alexander G. Doghramji, Laurel J. Cohen, Noam A. Palmer, James N. TI Biofilm-forming bacteria and quality of life improvement after sinus surgery SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; quality of life; biofilm; bacteria; functional endoscopic sinus surgery ID CHRONIC RHINOSINUSITIS; ANTIMICROBIAL RESISTANCE; BACTERIOLOGICAL FINDINGS; MAXILLARY SINUSITIS; SUSCEPTIBILITY; INFECTIONS; MICROSCOPY; OUTCOMES; TRENDS AB BackgroundIt remains unclear how much chronic rhinosinusitis (CRS) patients with bacterial biofilms can benefit from functional endoscopic sinus surgery (FESS). We aimed to evaluate whether biofilm-forming bacteria was associated with quality of life (QOL) improvement after FESS. MethodsThis retrospective cohort study included adult CRS patients who underwent FESS from 2008 to 2011. Sinus samples were taken to evaluate for biofilm-formation in vitro using a modified Calgary Biofilm Detection Assay. QOL was measured before FESS, and 1-month, 3-month, and 6-month after FESS using 22-item Sino-Nasal Outcome Test (SNOT-22) scores. Patients' characteristics and medications were collected. Clinical significant QOL change was defined as a difference of at least 0.5 standard deviation (SD) of baseline SNOT-22 score in the reference group. ResultsA total of 156 patients had complete data, and 15% had biofilm-forming bacteria (n = 24). Patients with biofilm-forming bacteria had significantly worse preoperative SNOT-22 scores compared to patients without biofilm-forming bacteria (48 20 vs 38 +/- 23, p = 0.048). Both groups had clinically significant QOL improvement after FESS, and the differences in their 1-month (23 +/- 19 vs 17 +/- 20) and 3-month (27 +/- 18 vs 18 +/- 19) post-FESS SNOT-22 scores were not significant. However, patients with biofilm-forming bacteria demonstrated significantly less QOL improvement than patients without biofilm-forming bacteria from pre-FESS to 6-month post-FESS visits after adjusting for clinical factors (35 +/- 25 vs 14 +/- 15; -coefficient = 0.71; 95% confidence interval [CI], 0.13 to 1.28; p = 0.016). ConclusionCRS patients with biofilm-forming bacteria demonstrated clinically significant QOL improvement following FESS, but the degree of improvement was decreased overtime and became significantly worse than patients without biofilm-forming bacteria by 6-month follow-up. This QOL worsening was independent of other risk factors for CRS. (C) 2015 ARS-AAOA, LLC. C1 [Zhang, Zi] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Adappa, Nithin D.; Doghramji, Laurel J.; Cohen, Noam A.; Palmer, James N.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Zhang, Z (reprint author), 8th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM zizhang@mail.med.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 NR 38 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD JUL PY 2015 VL 5 IS 7 BP 643 EP 649 DI 10.1002/alr.21505 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA CM7PT UT WOS:000357888100015 PM 25763837 ER PT J AU Goldstein, JE Jackson, ML Fox, SM Deremeik, JT Massof, RW AF Goldstein, Judith E. Jackson, Mary Lou Fox, Sandra M. Deremeik, James T. Massof, Robert W. CA Low Vision Res Network Study Grp TI Clinically Meaningful Rehabilitation Outcomes of Low Vision Patients Served by Outpatient Clinical Centers SO JAMA OPHTHALMOLOGY LA English DT Article ID QUALITY-OF-LIFE; VISUAL DISABILITY VARIABLES; RANDOMIZED CONTROLLED-TRIAL; MACULAR DEGENERATION; INTERVENTION TRIAL; SERVICE; QUESTIONNAIRE; PARTICIPATION; DIFFICULTY; PEOPLE AB IMPORTANCE To facilitate comparative clinical outcome research in low vision rehabilitation, we must use patient-centered measurements that reflect clinically meaningful changes in visual ability. OBJECTIVE To quantify the effects of currently provided low vision rehabilitation (LVR) on patients who present for outpatient LVR services in the United States. DESIGN, SETTING, AND PARTICIPANTS Prospective, observational study of new patients seeking outpatient LVR services. From April 2008 through May 2011, 779 patients from 28 clinical centers in the United States were enrolled in the Low Vision Rehabilitation Outcomes Study. The Activity Inventory, a visual function questionnaire, was administered to measure overall visual ability and visual ability in 4 functional domains (reading, mobility, visual motor function, and visual information processing) at baseline and 6 to 9 months after usual LVR care. The Geriatric Depression Scale, Telephone Interview for Cognitive Status, and Medical Outcomes Study 36-Item Short-Form Health Survey physical functioning questionnaires were also administered to measure patients' psychological, cognitive, and physical health states, respectively, and clinical findings of patients were provided by study centers. MAIN OUTCOMES AND MEASURES Mean changes in the study population and minimum clinically important differences in the individual in overall visual ability and in visual ability in 4 functional domains as measured by the Activity Inventory. RESULTS Baseline and post-rehabilitation measures were obtained for 468 patients. Minimum clinically important differences (95% CIs) were observed in nearly half (47%[95% CI, 44%-50%]) of patients in overall visual ability. The prevalence rates of patients with minimum clinically important differences in visual ability in functional domains were reading (44%[95% CI, 42%-48%]), visual motor function (38%[95% CI, 36%-42%]), visual information processing (33%[95% CI, 31%-37%]), and mobility (27%[95% CI, 25%-31%]). The largest average effect size (Cohen d = 0.87) for the population was observed in overall visual ability. Age (P = .006) was an independent predictor of changes in overall visual ability, and logMAR visual acuity (P = .002) was predictive of changes in visual information processing. CONCLUSIONS AND RELEVANCE Forty-four to fifty percent of patients presenting for outpatient LVR show clinically meaningful differences in overall visual ability after LVR, and the average effect sizes in overall visual ability are large, close to 1 SD. C1 [Goldstein, Judith E.; Deremeik, James T.; Massof, Robert W.] Johns Hopkins Univ, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Sch Med, Baltimore, MD 21287 USA. [Jackson, Mary Lou] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA USA. [Fox, Sandra M.] South Texas Vet Hlth Care Syst, San Antonio Polytrauma Rehabil Ctr, San Antonio, TX USA. [Fox, Sandra M.] Univ Texas Hlth Sci Ctr San Antonio, Lions Low Vis Ctr Texas, San Antonio, TX 78229 USA. RP Goldstein, JE (reprint author), Johns Hopkins Univ, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Sch Med, 600 N Wolfe St,Wilmer 317, Baltimore, MD 21287 USA. EM jgolds28@jhmi.edu FU National Eye Institute, National Institutes of Health, Bethesda, Maryland [EY012045, EY018696]; Reader's Digest Partners for Sight Foundation FX This work was supported by grants EY012045 and EY018696 from the National Eye Institute, National Institutes of Health, Bethesda, Maryland, and a grant from Reader's Digest Partners for Sight Foundation. NR 35 TC 6 Z9 6 U1 2 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD JUL PY 2015 VL 133 IS 7 BP 762 EP 769 DI 10.1001/jamaophthalmol.2015.0693 PG 8 WC Ophthalmology SC Ophthalmology GA CM6TO UT WOS:000357823100008 PM 25856370 ER PT J AU Teodorescu, M Broytman, O Curran-Everett, D Sorkness, RL Crisafi, G Bleecker, ER Erzurum, S Gaston, BM Wenzel, SE Jarjour, NN AF Teodorescu, Mihaela Broytman, Oleg Curran-Everett, Douglas Sorkness, Ronald L. Crisafi, Gina Bleecker, Eugene R. Erzurum, Serpil Gaston, Benjamin M. Wenzel, Sally E. Jarjour, Nizar N. CA Natl Inst Hlth Natl Heart Lung Blood Inst Severe Asthma Res Program SARP Inv TI Obstructive Sleep Apnea Risk, Asthma Burden, and Lower Airway Inflammation in Adults in the Severe Asthma Research Program (SARP) II SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Article DE Asthma; Sleep apnea; Obstructive; Airway inflammation ID QUALITY-OF-LIFE; TO-CONTROL ASTHMA; BODY-MASS INDEX; DAYTIME SLEEPINESS; PERSISTENT ASTHMA; NOCTURNAL ASTHMA; TREAT ASTHMA; QUESTIONNAIRE; ASSOCIATION; PHENOTYPE AB BACKGROUND: Obstructive sleep apnea (OSA) may worsen asthma, but large studies are lacking and the underlying mechanisms are unknown. OBJECTIVE: The objective of this study was to determine the prevalence of OSA risk among patients with asthma of different severity compared with normal controls (NC), and among asthmatics, to test the relationship of OSA risk with asthma burden and airway inflammation. METHODS: Subjects with severe (SA, n = 94) and nonsevere asthma (NSA, n = 161), and NC (n = 146) were recruited in an add-on substudy, to the observational Severe Asthma Research Program (SARP) II; subjects completed sleep quality, sleepiness and OSA risk (Sleep Apnea scale of the Sleep Disorders Questionnaire [SA-SDQ]) questionnaires, and clinical assessments. Sputum was induced in a subset of asthmatics. RESULTS: Relative to NC, despite similar sleep duration, the subjects with SA and NSA had worse sleep quality, were sleepier, and had higher SA-SDQ scores. Among asthmatics, higher SA-SDQ was associated with increased asthma symptoms, beta-agonist use, health care utilization, and worse asthma quality of life. A significant association of SA-SDQ with sputum polymorphonuclear cells% was noted: each increase in SA-SDQ by its standard deviation (6.85 units) was associated with a rise in % sputum neutrophils of 7.78 (95% CI 2.33-13.22, P = .0006), independent of obesity and other confounders. CONCLUSIONS: OSA symptoms are more prevalent among asthmatics, in whom they are associated with higher disease burden. OSA risk is associated with a neutrophilic airway inflammation in asthma, which suggests that OSA may be an important contributor to the neutrophilic asthma. Further studies are necessary to confirm these findings and better understand the mechanistic underpinnings of this relationship. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology C1 [Teodorescu, Mihaela; Broytman, Oleg] William S Middleton Mem Vet Adm Med Ctr, Med Serv, James B Skatrud Pulm Sleep Res Lab, Madison, WI USA. [Teodorescu, Mihaela; Broytman, Oleg; Sorkness, Ronald L.; Crisafi, Gina; Jarjour, Nizar N.] Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy Pulm & Crit Care Med, Madison, WI 53792 USA. [Teodorescu, Mihaela] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Sleep Med & Sleep Res Wisconsin Sleep, Madison, WI 53792 USA. [Curran-Everett, Douglas] Natl Jewish Hlth, Div Biostat & Bioinformat, Denver, CO USA. [Curran-Everett, Douglas] Univ Colorado, Colorado Sch Publ Hlth, Dept Biostat & Informat, Denver, CO 80202 USA. [Bleecker, Eugene R.] Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27103 USA. [Erzurum, Serpil] Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44106 USA. [Gaston, Benjamin M.] Univ Virginia, Sch Med, Dept Pediat, Div Resp Med, Charlottesville, VA 22908 USA. [Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Asthma Inst, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. RP Teodorescu, M (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA. EM mt3@medicine.wisc.edu FU National Institutes of Health (NIH) [HL069170, HL069174, HL069167, HL069116, UL1RR025011]; Department of Medicine and University of Wisconsin School of Medicine and Public Health; Medical Education and Research Committee-New Investigator Award; University of Wisconsin; Department of Veterans Affairs for asthma-sleep apnea research FX National Institutes of Health (NIH) HL069170, HL069174, HL069167, HL069116, UL1RR025011; and additional resources from the William S. Middleton Memorial Veterans Hospital, Madison, Wis. Dr. Teodorescu received funding from the Department of Medicine and University of Wisconsin School of Medicine and Public Health, Medical Education and Research Committee-New Investigator Award, University of Wisconsin, and Department of Veterans Affairs for asthma-sleep apnea research. Mrs. Crisafi, Drs. Broytman, Curran-Everett, Sorkness, Bleecker, Erzurum, Gaston, Wenzel, and Jarjour report no conflicts of interest related to this work. The content of this article is solely the responsibility of the authors and does not represent the views of the Department of Veterans Affairs, NIH, or the United States Government. NR 61 TC 11 Z9 11 U1 2 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD JUL-AUG PY 2015 VL 3 IS 4 BP 566 EP + DI 10.1016/j.jaip.2015.04.002 PG 11 WC Allergy; Immunology SC Allergy; Immunology GA CM4XX UT WOS:000357690800015 PM 26004304 ER PT J AU Zharikov, AD Cannon, JR Tapias, V Bai, Q Horowitz, MP Shah, V El Ayadi, A Hastings, TG Greenamyre, JT Burton, EA AF Zharikov, Alevtina D. Cannon, Jason R. Tapias, Victor Bai, Qing Horowitz, Max P. Shah, Vipul El Ayadi, Amina Hastings, Teresa G. Greenamyre, J. Timothy Burton, Edward A. TI shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID GENOME-WIDE ASSOCIATION; TRANSGENIC MICE; IN-VIVO; DOPAMINE NEURONS; LEWY BODIES; LOCUS TRIPLICATION; OXIDATIVE STRESS; ROTENONE MODEL; GENE-THERAPY; DOUBLE-BLIND AB Multiple convergent lines of evidence implicate both alpha-synuclein (encoded by SCNA) and mitochondrial dysfunction in the pathogenesis of sporadic Parkinson's disease (PD). Occupational exposure to the mitochondrial complex I inhibitor rotenone increases PD risk; rotenone-exposed rats show systemic mitochondrial defects but develop specific neuropathology, including alpha-synuclein aggregation and degeneration of substantia nigra dopaminergic neurons. Here, we inhibited expression of endogenous alpha-synuclein in the adult rat substantia nigra by adeno-associated virus-mediated delivery of a short hairpin RNA (shRNA) targeting the endogenous rat Snca transcript. Knockdown of alpha-synuclein by similar to 35% did not affect motor function or cause degeneration of nigral dopaminergic neurons in control rats. However, in rotenone-exposed rats, progressive motor deficits were substantially attenuated contralateral to alpha-synuclein knockdown. Correspondingly, rotenone-induced degeneration of nigral dopaminergic neurons, their dendrites, and their striatel terminals was decreased ipsilateral to alpha-synuclein knockdown. These data show that alpha-synuclein knockdown is neuroprotective in the rotenone model of PD and indicate that endogenous alpha-synuclein contributes to the specific vulnerability of dopaminergic neurons to systemic mitochondrial inhibition. Our findings are consistent with a model in which genetic variants influencing alpha-synuclein expression modulate cellular susceptibility to environmental exposures in PD patients. shRNA targeting the SNCA transcript should be further evaluated as a possible neuroprotective therapy in PD. C1 [Zharikov, Alevtina D.; Cannon, Jason R.; Tapias, Victor; Bai, Qing; Horowitz, Max P.; Shah, Vipul; El Ayadi, Amina; Hastings, Teresa G.; Greenamyre, J. Timothy; Burton, Edward A.] Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15213 USA. [Zharikov, Alevtina D.; Cannon, Jason R.; Tapias, Victor; Bai, Qing; Horowitz, Max P.; Shah, Vipul; El Ayadi, Amina; Hastings, Teresa G.; Greenamyre, J. Timothy; Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Zharikov, Alevtina D.; Cannon, Jason R.; Greenamyre, J. Timothy; Burton, Edward A.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15213 USA. RP Burton, EA (reprint author), Univ Pittsburgh, 7015 BST 3,3501 Fifth Ave, Pittsburgh, PA 15213 USA. EM eab25@pitt.edu OI Burton, Edward/0000-0002-8072-4636 FU BLRD VA [I01 BX000548]; NIEHS NIH HHS [ES020718, ES018058, ES019879, ES020327, ES022644, K99 ES019879, R00 ES019879, R01 ES020327, R01 ES020718, R01 ES022644, RC1 ES018058]; NINDS NIH HHS [NS059806, P01 NS059806] NR 71 TC 12 Z9 12 U1 2 U2 9 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD JUL PY 2015 VL 125 IS 7 BP 2721 EP 2735 DI 10.1172/JCI64502 PG 15 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CM3AK UT WOS:000357553300020 PM 26075822 ER PT J AU Li, H Fu, YX Wu, Q Zhou, Y Crossman, DK Yang, PA Li, J Luo, B Morel, LM Kabarowski, JH Yagita, H Ware, CF Hsu, HC Mountz, JD AF Li, Hao Fu, Yang-Xin Wu, Qi Zhou, Yong Crossman, David K. Yang, PingAr Li, Jun Luo, Bao Morel, Laurence M. Kabarowski, Janusz H. Yagita, Hideo Ware, Carl F. Hsu, Hui-Chen Mountz, John D. TI Interferon-induced mechanosensing defects impede apoptotic cell clearance in lupus SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID SPLENIC MARGINAL ZONE; AUTOIMMUNE BXD2 MICE; PRECURSOR B-CELLS; DENDRITIC CELLS; I INTERFERON; T-CELL; PATHOGENIC AUTOANTIBODIES; ADAPTIVE IMMUNITY; LYMPHOID-TISSUES; ACTIN DYNAMICS AB Systemic lupus erythematosus (SLE) is a severe autoimmune disease that is associated with increased circulating apoptotic cell autoantigens (AC-Ags) as well as increased type I IFN signaling. Here, we describe a pathogenic mechanism in which follicular translocation of marginal zone (MZ) B cells in the spleens of BXD2 lupus mice disrupts marginal zone macrophages (MZMs), which normally clear AC debris and prevent follicular entry of AC-Ags. Phagocytosis of ACs by splenic MZMs required the megakaryoblastic leukemia 1 (MKL1) transcriptional coactivator-mediated mechanosensing pathway, which was maintained by MZ B cells through expression of membrane lymphotoxin-alpha 1 beta 2 (mLT). Specifically, type I IFN-induced follicular shuttling of mLT-expressing MZ B cells disengaged interactions between these MZ B cells and up receptor-expressing MZMs, thereby downregulating MKL1 in MZMs. Loss of MKL1 expression in MZMs led to defective F-actin polymerization, inability to clear ACs, and, eventually, MZM dissipation. Aggregation of plasmacytoid DCs in the splenic perifollicular region, follicular translocation of MZ B cells, and loss of MKL1 and MZMs were also observed in an additional murine lupus model and in the spleens of patients with SLE. Collectively, the results suggest that lupus might be interrupted by strategies that maintain or enhance mechanosensing signaling in the MZM barrier to prevent follicular entry of AC-Ags. C1 [Li, Hao; Wu, Qi; Yang, PingAr; Li, Jun; Luo, Bao; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Fu, Yang-Xin] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. [Zhou, Yong] UAB, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Crossman, David K.] UAB, Heflin Ctr Genom Sci, Birmingham, AL USA. [Crossman, David K.] UAB, Dept Genet, Div Genet Res, Birmingham, AL USA. [Morel, Laurence M.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. [Kabarowski, Janusz H.; Mountz, John D.] UAB, Dept Microbiol, Birmingham, AL USA. [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan. [Ware, Carl F.] Sanford Burnham Med Res Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Hsu, HC (reprint author), Shelby Rm 311,1825 Univ Blvd, Birmingham, AL 35294 USA. EM rheu078@uab.edu; jdmountz@uab.edu RI Li, Hao/N-7406-2015 OI Li, Hao/0000-0002-2171-8826; fu, yang-xin/0000-0001-8441-6617; Crossman, David/0000-0002-0981-169X FU NIH [R01-AI-071110, R01-AI-083705, R01-A1058150, R01-HL-124076, 5 R01-AI048073, P30-AR-048311, P30-AI-027767]; Department of Veterans Affairs [1I01BX000600-01]; Lupus Research Institute; Rheumatology Research Foundation; American Heart Association [14GRNT20180023]; American Thoracic Society Recognition Award; UAB RDCC [P30-AR-048311]; Cancer Center [CA-013148]; Center for AIDS Research grant [AI-027767] FX This worked was supported by grants from the NIH (R01-AI-071110, to J.D. Mountz; R01-AI-083705, to H.C. Hsu; R01-A1058150, to L.M. Morel; R01-HL-124076, to Y. Zhou; 5 R01-AI048073, to C.F. Ware; P30-AR-048311, to the UAB Rheumatic Diseases Core Centers [RDCC], including the Comprehensive Flow Cytometry Core and the Analytic Imaging and Immunore-agent Core; and P30-AI-027767, to the UAB Center for AIDS Research Comprehensive Flow Cytometry Core). Support was also provided by a Merit Review grant from the Department of Veterans Affairs (1I01BX000600-01, to J.D. Mountz); Novel Research grants from the Lupus Research Institute (to J.H. Kabarowski and H.C. Hsu); the Rheumatology Research Foundation (to J.D. Mountz); the American Heart Association (14GRNT20180023, to Y. Zhou); an American Thoracic Society Recognition Award (to Y. Zhou); and the UAB RDCC P30 Pilot and Feasibility Project (P30-AR-048311, to J. Li). We thank Michael Crowley and Bing Xue, supported by a Cancer Center grant (CA-013148) and a Center for AIDS Research grant (AI-027767), for performing the GeneChip analysis. We thank UAB Tissue Procurement for providing normal and SLE splenic tissue sections. We also thank Fiona Hunter for careful review of the manuscript. NR 62 TC 9 Z9 9 U1 2 U2 6 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD JUL PY 2015 VL 125 IS 7 BP 2877 EP 2890 DI 10.1172/JCI81059 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CM3AK UT WOS:000357553300032 PM 26098211 ER PT J AU Schiehser, DM Twamley, EW Liu, L Matevosyan, A Filoteo, JV Jak, AJ Orff, HJ Hanson, KL Sorg, SF Delano-Wood, L AF Schiehser, Dawn M. Twamley, Elizabeth W. Liu, Lin Matevosyan, Adelina Filoteo, J. Vincent Jak, Amy J. Orff, Henry J. Hanson, Karen L. Sorg, Scott F. Delano-Wood, Lisa TI The Relationship Between Postconcussive Symptoms and Quality of Life in Veterans With Mild to Moderate Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article ID WORLD-HEALTH-ORGANIZATION; WHOQOL-BREF; HEAD-INJURY; FATIGUE; COMPLAINTS; INSOMNIA; SWEDEN AB Objective: To assess the relationship between postconcussive symptoms and quality of life (QOL) in Veterans with mild to moderate traumatic brain injury (TBI). Methods: Sixty-one Operation Enduring Freedom/Operation Iraqi Freedom/Persian Gulf War Veterans with a history of mild or moderate TBI, more than 6 months postinjury, and 21 demographically matched Veteran controls were administered self-report measures of QOL (World Health Organization Quality of Life-BREF) and postconcussive symptom severity (Neurobehavioral Symptom Inventory). Results: Perceived QOL was significantly worse in Veterans with mild-moderate TBI than in controls. In the TBI group, QOL was predominantly associated with affective symptoms, and moderate to strong correlations with fatigue and depression were evident across all QOL areas. Multivariate analyses revealed depression and fatigue to be the best predictors of Psychological, Social, and Environmental QOL, whereas sleep difficulty best predicted Physical QOL in mild-moderate TBI. Conclusion: Veterans with post-acute mild-moderate TBI evidence worse QOL than demographically matched Veteran controls. Affective symptoms, and specifically those of fatigue, depression, and sleep difficulty, appear to be the most relevant postconcussive symptoms predicting QOL in this population. These findings underscore the importance of examining specific symptoms as they relate to post-acute TBI QOL and provide guidance for treatment and intervention studies. C1 [Schiehser, Dawn M.; Twamley, Elizabeth W.; Matevosyan, Adelina; Filoteo, J. Vincent; Jak, Amy J.; Hanson, Karen L.; Delano-Wood, Lisa] VA San Diego Healthcare Syst, San Diego, CA USA. [Schiehser, Dawn M.; Twamley, Elizabeth W.; Filoteo, J. Vincent; Jak, Amy J.; Orff, Henry J.; Hanson, Karen L.; Delano-Wood, Lisa] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA. [Liu, Lin] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Twamley, Elizabeth W.; Jak, Amy J.; Orff, Henry J.; Hanson, Karen L.; Delano-Wood, Lisa] VASDHS, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Sorg, Scott F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Schiehser, DM (reprint author), VA San Diego Healthcare Syst 151B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM dschiehser@ucsd.edu FU VA Career Development award; Department of Defense award FX This study was supported by VA Career Development (D.M.S. and L.D-W.) and Department of Defense (L.D-W.) awards. The authors thank Russell Kim, Elisa Lanni, and Norman Luc for their help with data collection and compilation. They also thank the patients, staff, and volunteers associated with the VA San Diego Healthcare System for their involvement in this study. NR 31 TC 4 Z9 4 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JUL-AUG PY 2015 VL 30 IS 4 BP E21 EP E28 DI 10.1097/HTR.0000000000000065 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CM8JB UT WOS:000357944800003 PM 24922041 ER PT J AU Perry, DJ Kwan, SW Bhargava, P AF Perry, Don J. Kwan, Sharon W. Bhargava, Puneet TI Patient-Centered Clinical Training in Radiology SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Perry, Don J.; Kwan, Sharon W.; Bhargava, Puneet] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Diagnost Imaging Serv, Seattle, WA USA. RP Perry, DJ (reprint author), Univ Washington, Med Ctr, Dept Radiol, RR215,Mailbox 357115,1959 NE Pacific St, Seattle, WA 98195 USA. EM perrymed@gmail.com NR 12 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUL PY 2015 VL 12 IS 7 BP 724 EP 727 DI 10.1016/j.jacr.2014.12.013 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CM8QR UT WOS:000357967200021 PM 26143566 ER PT J AU Melrose, RJ Brewster, P Marquine, MJ MacKay-Brandt, A Reed, B Farias, ST Mungas, D AF Melrose, Rebecca J. Brewster, Paul Marquine, Maria J. MacKay-Brandt, Anna Reed, Bruce Farias, Sarah T. Mungas, Dan TI Early Life Development in a Multiethnic Sample and the Relation to Late Life Cognition SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Cognition; Longitudinal change; Minority and diverse populations ID NEUROPSYCHOLOGICAL ASSESSMENT SCALES; INCIDENT ALZHEIMERS-DISEASE; HEAD CIRCUMFERENCE; RISK-FACTORS; SOCIOECONOMIC POSITION; LEG LENGTH; OLD-AGE; MAXIMUM-LIKELIHOOD; MEXICAN-AMERICANS; AFRICAN-AMERICANS AB Objectives. Poor quality of early life conditions has been associated with poorer late life cognition and increased risk of dementia. Early life physical development can be captured using adult measures of height and head circumference. Availability of resources may be reflected by socioeconomic indicators, such as parental education and family size. We sought to determine the association between early life development and experience and late life semantic memory, episodic memory, and executive functioning abilities, as well as rate of cognitive decline. Method. This study was conducted using the UC Davis Aging Diversity cohort, an ethnically diverse sample of Caucasian, African American, and Hispanic individuals from northern California. We used latent variable modeling to measure growth and childhood socioeconomic environment (SES) and examine their associations with longitudinal cognitive outcomes using mixed effects modeling. Results. Growth was positively related to higher childhood SES. Higher childhood SES was associated with better semantic memory. Both low growth and low SES were associated with increased rate of cognitive decline. Discussion. These findings demonstrate that early life experiences influence the trajectory of cognitive aging. Early life development and experience appears to provide a distal basis upon which additional risk and protective factors interact in the development of dementia. C1 [Melrose, Rebecca J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Melrose, Rebecca J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Brewster, Paul] Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada. [Marquine, Maria J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [MacKay-Brandt, Anna] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. [Reed, Bruce; Farias, Sarah T.; Mungas, Dan] Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA. RP Melrose, RJ (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rebecca.melrose@va.gov FU National Institute on Aging at the National Institutes of Health [R13 AG030995, R01 AG10220, P30 AG10129, R01 AG AG031563, R01 AG021028, P50 CA098252]; VA Career Development Award; Canadian Institutes for Health Research; Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN) [T32DA031098]; [T32 MH02004] FX This work was supported by the National Institute on Aging at the National Institutes of Health (R13 AG030995 to D. Mungas, R01 AG10220 to D. Mungas, P30 AG10129 to DeCarli, R01 AG AG031563 to B. Reed, R01 AG021028 to S. Tomaszewski Farias, P50 CA098252); VA Career Development Award (R. J. Melrose); Doctoral Research Award from the Canadian Institutes for Health Research (P. Brewster); Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN, T32DA031098 to M. J. Marquine) and a T32 MH02004 (A. MacKay-Brandt). NR 71 TC 4 Z9 4 U1 3 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD JUL PY 2015 VL 70 IS 4 BP 519 EP 531 DI 10.1093/geronb/gbt126 PG 13 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA CM7NC UT WOS:000357879600003 PM 24389122 ER PT J AU Schneider, BC Gross, AL Bangen, KJ Skinner, JC Benitez, A Glymour, MM Sachs, BC Shih, RA Sisco, S Manly, JJ Luchsinger, JA AF Schneider, Brooke C. Gross, Alden L. Bangen, Katherine J. Skinner, Jeannine C. Benitez, Andreana Glymour, M. Maria Sachs, Bonnie C. Shih, Regina A. Sisco, Shannon Manly, Jennifer J. Luchsinger, Jose A. TI Association of Vascular Risk Factors With Cognition in a Multiethnic Sample SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Cardiovascular disease; Cognitive decline; Ethnic differences; Racial differences ID HIGH BLOOD-PRESSURE; OLDER-ADULTS; ALZHEIMERS-DISEASE; AFRICAN-AMERICANS; ETHNIC DISPARITIES; HEART-FAILURE; DIABETES-MELLITUS; METABOLIC DISEASE; IMPAIRMENT; DECLINE AB Objectives. To examine the relationship between cardiovascular risk factors (CVRFs) and cognitive performance in a multiethnic sample of older adults. Method. We used longitudinal data from the Washington Heights-Inwood Columbia Aging Project. A composite score including smoking, stroke, heart disease, diabetes, hypertension, and central obesity represented CVRFs. Multiple group parallel process multivariate random effects regression models were used to model cognitive functioning and examine the contribution of CVRFs to baseline performance and change in general cognitive processing, memory, and executive functioning. Results. Presence of each CVRF was associated with a 0.1 SD lower score in general cognitive processing, memory, and executive functioning in black and Hispanic participants relative to whites. Baseline CVRFs were associated with poorer baseline cognitive performances among black women and Hispanic men. CVRF increase was related to baseline cognitive performance only among Hispanics. CVRFs were not related to cognitive decline. After adjustment for medications, CVRFs were not associated with cognition in Hispanic participants. Discussion. CVRFs are associated with poorer cognitive functioning, but not cognitive decline, among minority older adults. These relationships vary by gender and medication use. Consideration of unique racial, ethnic, and cultural factors is needed when examining relationships between CVRFs and cognition. C1 [Schneider, Brooke C.] VA Greater Los Angeles Healthcare Syst, Psychol Serv, Los Angeles, CA USA. [Gross, Alden L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Gross, Alden L.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD USA. [Bangen, Katherine J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Skinner, Jeannine C.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Benitez, Andreana] Med Univ S Carolina, Ctr Biomed Imaging, Dept Radiol & Radiol Sci, Charleston, SC USA. [Glymour, M. Maria] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Sachs, Bonnie C.] Virginia Commonwealth Univ, Sch Med, Dept Neurol, Richmond, VA 23284 USA. [Shih, Regina A.] RAND Corp, Arlington, VA USA. [Sisco, Shannon] North Florida South Georgia Vet Hlth Syst, Dept Vet Affairs, Gainesville, FL USA. [Manly, Jennifer J.] Columbia Univ Coll Phys & Surg, Dept Neurol, Cognit Neurosci Div, New York, NY 10032 USA. [Luchsinger, Jose A.] Columbia Univ, Med Ctr, Joseph P Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Luchsinger, Jose A.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA. RP Luchsinger, JA (reprint author), Columbia Univ, Med Ctr, Dept Med, PH9 Ctr,Room 210,630 West 168th St, New York, NY 10032 USA. EM jal94@columbia.edu OI Glymour, M. Maria/0000-0001-9644-3081 FU National Institute on Aging [T32AG023480, R03 AG045494-01, T32AG000258, R21 AG03438501, R01 AG028786, 1R01AG037212-01]; National Institutes of Health [T32 MH1993417, UL1 TR000062, KL2 TR000060]; National Institute of Minority Health and Health Disparities [P60 MD000206] FX A. L. Gross was supported by a National Institute on Aging (T32AG023480 and R03 AG045494-01). K. J. Bangen was supported by the National Institutes of Health (T32 MH1993417). J. C. Skinner was supported by the National Institute on Aging (T32AG000258). A. Benitez was supported by the Litwin Foundation and National Institutes of Health grants (UL1 TR000062 and KL2 TR000060). M. M. Glymour was partially supported by a pilot grant from the National Institute on Aging-funded Harvard Program on the Global Development of Aging and by a National Institute on Aging grant (R21 AG03438501). J. J. Manly was supported by the National Institute on Aging (R01 AG028786). J. A. Luchsinger was supported by grants from the National Institute of Minority Health and Health Disparities (P60 MD000206) and National Institute on Aging (1R01AG037212-01). This content is solely the responsibility of the authors and does not necessarily represent the official view of the supporting institutions. NR 74 TC 3 Z9 3 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD JUL PY 2015 VL 70 IS 4 BP 532 EP 544 DI 10.1093/geronb/gbu040 PG 13 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA CM7NC UT WOS:000357879600004 PM 24821298 ER PT J AU Carvalho, JO Tommet, D Crane, PK Thomas, ML Claxton, A Habeck, C Manly, JJ Romero, HR AF Carvalho, Janessa O. Tommet, Doug Crane, Paul K. Thomas, Michael L. Claxton, Amy Habeck, Christian Manly, Jennifer J. Romero, Heather R. TI Deconstructing Racial Differences: The Effects of Quality of Education and Cerebrovascular Risk Factors SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE African American; Cognitive decline; Education quality; Latent growth curve modeling; Race; Vascular ID NEUROPSYCHOLOGICAL TEST-PERFORMANCE; ETHNICALLY DIVERSE ELDERS; OLDER AFRICAN-AMERICANS; ALZHEIMERS-DISEASE; ATRIAL-FIBRILLATION; CARDIOVASCULAR HEALTH; COGNITIVE DYSFUNCTION; MULTIETHNIC COHORT; BIFACTOR MODEL; READING LEVEL AB Objectives. To evaluate the effects of vascular conditions and education quality on cognition over time in White and African American (AA) older adults. Method. We investigated cross-sectional and longitudinal racial differences in executive functioning (EF) and memory composites among Whites (n = 461) and AAs (n = 118) enrolled in a cohort study. We examined whether cerebrovascular risk factors and Shipley Vocabulary scores (a proxy for education quality) accounted for racial differences. Results. On average, AAs had lower quality of education and more cerebrovascular risk factors including hypertension, diabetes, and obesity. AAs had lower mean EF and memory at baseline, but there were no group differences in rates of decline. Cross-sectional racial differences in EF and memory persisted after controlling for vascular disease, but disappeared when controlling for Shipley Vocabulary. Discussion. Quality of education appears to be more important than cerebrovascular risk factors in explaining cross-sectional differences in memory and EF performance between White and AA older adults. Further investigation is needed regarding the relative contribution of education quality and cerebrovascular risk factors to cognitive decline among ethnically/racially diverse older adults. C1 [Carvalho, Janessa O.; Tommet, Doug] Brown Univ, Dept Psychiat & Human Behav, Alpert Med Sch, Providence, RI 02912 USA. [Carvalho, Janessa O.] Bridgewater State Univ, Dept Psychol, Bridgewater, MA USA. [Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA. [Thomas, Michael L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Claxton, Amy] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Claxton, Amy] Univ Washington, Sch Med, Seattle, WA USA. [Habeck, Christian; Manly, Jennifer J.] Columbia Univ, Dept Neurol, Cognit Neurosci Div, New York, NY USA. [Romero, Heather R.] Duke Univ, Med Ctr, Dept Psychiat, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC 27710 USA. [Romero, Heather R.] Univ Notre Dame, Dept Psychol, Indiana, PA USA. RP Romero, HR (reprint author), Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Box 3503, Durham, NC 27710 USA. EM heather.romero@duke.edu FU National Institute on Aging (NIA) [P30 AG028377, R13 AG030995]; National Institute of Health/NIA [5R01AG026114-02] FX Data provided by the Joseph and Kathleen Bryan Alzheimer's Disease Research Center were supported by National Institute on Aging (NIA) (P30 AG028377). This research project began at the 2012 Friday Harbor Advanced Psychometrics Workshop, which is supported by NIA (R13 AG030995). C. Habeck received support from National Institute of Health/NIA (5R01AG026114-02). The contents do not necessarily represent views of the funding entities. Funders had no deciding roles in the design and conduct of this study. NR 52 TC 3 Z9 3 U1 1 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD JUL PY 2015 VL 70 IS 4 BP 545 EP 556 DI 10.1093/geronb/gbu086 PG 12 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA CM7NC UT WOS:000357879600005 PM 25098527 ER PT J AU Sisco, S Gross, AL Shih, RA Sachs, BC Glymour, MM Bangen, KJ Benitez, A Skinner, J Schneider, BC Manly, JJ AF Sisco, Shannon Gross, Alden L. Shih, Regina A. Sachs, Bonnie C. Glymour, M. Maria Bangen, Katherine J. Benitez, Andreana Skinner, Jeannine Schneider, Brooke C. Manly, Jennifer J. TI The Role of Early-Life Educational Quality and Literacy in Explaining Racial Disparities in Cognition in Late Life SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Cognition; Life events and contexts; Minority and diverse populations ID NEUROPSYCHOLOGICAL TEST-PERFORMANCE; DIVERSE OLDER PERSONS; AFRICAN-AMERICAN; ALZHEIMERS-DISEASE; WHITE ELDERS; DECLINE; MEMORY; ADULTS; SCORES; RACE AB Objectives. Racial disparities in late-life cognition persist even after accounting for educational attainment. We examined whether early-life educational quality and literacy in later life help explain these disparities. Method. We used longitudinal data from the Washington Heights-Inwood Columbia Aging Project (WHICAP). Educational quality (percent white students; urban/rural school; combined grades in classroom) was operationalized using canonical correlation analysis. Late-life literacy (reading comprehension and ability, writing) was operationalized using confirmatory factor analysis. We examined whether these factors attenuated race-related differences in late-life cognition. Results. The sample consisted of 1,679 U.S.-born, non-Hispanic, community-living adults aged 65-102 (71% black, 29% white; 70% women). Accounting for educational quality and literacy reduced disparities by 29% for general cognitive functioning, 26% for memory, and 32% for executive functioning but did not predict differences in rate of cognitive change. Discussion. Early-life educational quality and literacy in late life explain a substantial portion of race-related disparities in late-life cognitive function. C1 [Sisco, Shannon] North Florida South Georgia Vet Hlth Syst, Dept Vet Affairs, Gainesville, FL 32608 USA. [Gross, Alden L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Gross, Alden L.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD USA. [Shih, Regina A.] RAND Corp, Arlington, VA USA. [Sachs, Bonnie C.] Virginia Commonwealth Univ, Dept Neurol, Sch Med, Richmond, VA 23284 USA. [Glymour, M. Maria] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Bangen, Katherine J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Benitez, Andreana] Med Univ S Carolina, Ctr Biomed Imaging, Dept Radiol & Radiol Sci, Charleston, SC USA. [Skinner, Jeannine] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Schneider, Brooke C.] VA Greater Los Angeles Healthcare Syst, Dept Psychol, Los Angeles, CA USA. [Manly, Jennifer J.] Columbia Univ Coll Phys & Surg, Dept Neurol, Cognit Neurosci Div, New York, NY 10032 USA. RP Sisco, S (reprint author), North Florida South Georgia Vet Hlth Syst, Dept Vet Affairs, 1601 SW Archer Rd, Gainesville, FL 32608 USA. EM Shannon.Sisco@va.gov OI Glymour, M. Maria/0000-0001-9644-3081 FU National Institute on Aging [T32 AG023480, R03 AG045494, R01 AG043960, R21 AG03438501, T32 AG000258, R01 AG028786]; National Institutes of Health [T32 MH1993417, UL1 TR000062, KL2 TR000060]; Litwin Foundation FX A. L. Gross was supported by the National Institute on Aging (T32 AG023480 and R03 AG045494). R. A. Shih was supported by the National Institute on Aging (R01 AG043960). M. M. Glymour was partially supported by a pilot grant from the National Institute on Aging-funded Harvard Program on the Global Demography of Aging and by a National Institute on Aging grant (R21 AG03438501). K. J. Bangen was supported by the National Institutes of Health (T32 MH1993417). A. Benitez was supported by the Litwin Foundation and National Institutes of Health (UL1 TR000062 and KL2 TR000060). J. Skinner was supported by the National Institute on Aging (T32 AG000258). J. J. Manly was supported by the National Institute on Aging (R01 AG028786). The content is solely the responsibility of the authors and does not necessarily represent the official views of the supporting institutions. NR 58 TC 9 Z9 9 U1 5 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD JUL PY 2015 VL 70 IS 4 BP 557 EP 567 DI 10.1093/geronb/gbt133 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA CM7NC UT WOS:000357879600006 PM 24584038 ER PT J AU Figlewicz, DP AF Figlewicz, Dianne P. TI Modulation of Food Reward by Endocrine and Environmental Factors: Update and Perspective SO PSYCHOSOMATIC MEDICINE LA English DT Review ID NUCLEUS-ACCUMBENS DOPAMINE; CONDITIONED PLACE PREFERENCE; STRESS-INDUCED REINSTATEMENT; OPIOID RECEPTOR STIMULATION; HIGH-FAT DIET; REINFORCING EFFICACY; INTRAVENTRICULAR INSULIN; SUBTHALAMIC NUCLEUS; METABOLIC SYNDROME; PROGRESSIVE RATIO AB Objective Palatable foods are frequently high in energy density. Chronic consumption of high-energy density foods can contribute to the development of cardiometabolic pathology including obesity, diabetes, and cardiovascular disease. This article reviews the contributions of extrinsic and intrinsic factors that influence the reward components of food intake. Methods A narrative review was conducted to determine the behavioral and central nervous system (CNS) related processes involved in the reward components of high-energy density food intake. Results The rewarding aspects of food, particularly palatable and preferred foods, are regulated by CNS circuitry. Overlaying this regulation is modulation by intrinsic endocrine systems and metabolic hormones relating to energy homeostasis, developmental stage, or gender. It is now recognized that extrinsic or environmental factors, including ambient diet composition and the provocation of stress or anxiety, also contribute substantially to the expression of food reward behaviors such as motivation for, and seeking of, preferred foods. Conclusions High-energy density food intake is influenced by both physiological and pathophysiological processes. Contextual, behavioral, and psychological factors and CNS-related processes represent potential targets for multiple types of therapeutic intervention. C1 [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, BSR&D Program, Seattle, WA 98108 USA. [Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 South Columbian Way, Seattle, WA 98108 USA. EM latte@uw.edu FU National Institutes of Health [DK40963]; American Recovery and Reinvestment Act FX The author's research described in this article is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, WA, and was supported by National Institutes of Health Grant DK40963 and by the American Recovery and Reinvestment Act. The author declared no conflicts of interest. NR 98 TC 3 Z9 3 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD JUL-AUG PY 2015 VL 77 IS 6 BP 664 EP 670 DI 10.1097/PSY.0000000000000146 PG 7 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CM5KI UT WOS:000357726300007 PM 25738439 ER PT J AU Karambelkar, A Kasekar, R Palevsky, PM AF Karambelkar, Ameet Kasekar, Riyaj Palevsky, Paul M. TI Perioperative Pharmacologic Management of Patients with End Stage Renal Disease SO SEMINARS IN DIALYSIS LA English DT Article ID SUCCINYLCHOLINE-INDUCED HYPERKALEMIA; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; PHARMACOKINETICS; FAILURE; MORPHINE; HYDROMORPHONE; INSUFFICIENCY; SUXAMETHONIUM; METABOLISM AB The pharmacokinetics of numerous medications used in the perioperative period are altered in patients with end-stage renal disease. Clearance of drugs, or their metabolites, that are normally excreted by the kidney is markedly reduced in ESRD. In addition, patients with ESRD may also have alterations in gastrointestinal absorption, volume of distribution, protein binding, and metabolic clearance of pharmacologic agents. Finally, drug removal may be augmented during dialysis. All of these factors contribute to the need for dose adjustment of medications, including analgesics, anesthetics, neuromuscular blockers, and antimicrobial agents, which may be used in the perioperative management of the ESRD patient. C1 [Karambelkar, Ameet; Kasekar, Riyaj; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Med Serv, Renal Sect, Pittsburgh, PA 15240 USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 54 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD JUL-AUG PY 2015 VL 28 IS 4 BP 392 EP 396 DI 10.1111/sdi.12384 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA CM4WZ UT WOS:000357687800012 PM 25876523 ER PT J AU Reddy, A Shea, JA Canamucio, A Werner, RM AF Reddy, Ashok Shea, Judy A. Canamucio, Anne Werner, Rachel M. TI The Effect of Organizational Climate on Patient-Centered Medical Home Implementation SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE medical home; organizational climate; veterans; primary care delivery ID HEALTH-CARE; PERFORMANCE; READINESS; SERVICES; CULTURE; SAFETY; MODEL AB Organizational climate is a key determinant of successful adoption of innovations; however, its relation to medical home implementation is unknown. This study examined the association between primary care providers' (PCPs') perception of organization climate and medical home implementation in the Veterans Health Administration. Multivariate regression was used to test the hypothesis that organizational climate predicts medical home implementation. This analysis of 191 PCPs found that higher scores in 2 domains of organizational climate (communication and cooperation, and orientation to quality improvement) were associated with a statistically significantly higher percentage (from 7 to 10 percentage points) of PCPs implementing structural changes to support the medical home model. In addition, some aspects of a better organizational climate were associated with improved organizational processes of care, including a higher percentage of patients contacted within 2 days of hospital discharge (by 2 to 3 percentage points) and appointments made within 3 days of a patient request (by 2 percentage points). C1 [Reddy, Ashok; Shea, Judy A.; Canamucio, Anne; Werner, Rachel M.] Philadelphia VA Med Ctr, VISN Ctr Evaluat PACT 4, Philadelphia, PA USA. [Reddy, Ashok; Shea, Judy A.; Werner, Rachel M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Reddy, Ashok; Shea, Judy A.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Reddy, Ashok] Univ Penn, Robert Wood Johnson Clin Scholar Program, Philadelphia, PA 19104 USA. RP Reddy, A (reprint author), Univ Penn, Perelman Sch Med, Blockley Hall 1303,423 Guardian Dr, Philadelphia, PA 19104 USA. EM ashokr@upenn.edu FU Veterans Administration's PACT (Patient-Aligned Care Team) Demonstration Laboratory initiative; VA Office of Patient Care Services FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was undertaken as part of the Veterans Administration's PACT (Patient-Aligned Care Team) Demonstration Laboratory initiative, supporting and evaluating VA's transition to a patient-centered medical home. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. Ashok Reddy MD, is a Robert Wood Johnson Foundation Clinical Scholar at University of Pennsylvania. NR 20 TC 1 Z9 1 U1 2 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1062-8606 EI 1555-824X J9 AM J MED QUAL JI Am. J. Med. Qual. PD JUL-AUG PY 2015 VL 30 IS 4 BP 309 EP 316 DI 10.1177/1062860614532516 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CM5AQ UT WOS:000357698700001 PM 24788252 ER PT J AU Palen, BN Kapur, VK AF Palen, Brian N. Kapur, Vishesh K. TI Tailoring Therapy for Obesity Hypoventilation Syndrome SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID POSITIVE-PRESSURE VENTILATION; NONINVASIVE VENTILATION; RANDOMIZED-TRIAL; SLEEP; SUPPORT; MANAGEMENT; EFFICACY; IMPACT C1 [Palen, Brian N.; Kapur, Vishesh K.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Palen, Brian N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Palen, BN (reprint author), Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. OI Kapur, Vishesh/0000-0002-5417-1097 NR 14 TC 1 Z9 1 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUL 1 PY 2015 VL 192 IS 1 BP 8 EP 10 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CM6YY UT WOS:000357838800006 PM 26131989 ER PT J AU Giordano, S Hage, FG Xing, DQ Chen, YF Allon, S Chen, CJ Oparil, S AF Giordano, Samantha Hage, Fadi G. Xing, Dongqi Chen, Yiu-Fai Allon, Steven Chen, Chongjia Oparil, Suzanne TI Estrogen and Cardiovascular Disease: Is Timing Everything? SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article ID POSTMENOPAUSAL HORMONE-THERAPY; RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; RAT CAROTID-ARTERY; ADVENTITIAL FIBROBLAST MIGRATION; PROTEIN TRANSGENIC MICE; SMOOTH-MUSCLE-CELLS; REPLACEMENT THERAPY; NEOINTIMA FORMATION; BALLOON INJURY C1 [Giordano, Samantha; Hage, Fadi G.; Xing, Dongqi; Chen, Yiu-Fai; Allon, Steven; Chen, Chongjia; Oparil, Suzanne] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Giordano, S (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 703 19th St South,Zeigler Res Bldg,Room 1047, Birmingham, AL 35294 USA. EM sgiordan@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU National Heart, Lung and Blood Institute [R01 HL087980, T32 HL07457]; Veterans Affairs Biomedical Laboratory Research & Development Service Merit Award OMB [4040-0001] FX Supported, in part, by National Heart, Lung and Blood Institute Grant R01 HL087980 (S.O.) and T32 HL07457 (S.O. and S.G.) and by Veterans Affairs Biomedical Laboratory Research & Development Service Merit Award OMB 4040-0001 (F.G.H.). NR 58 TC 5 Z9 5 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD JUL PY 2015 VL 350 IS 1 BP 27 EP 35 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CM2KA UT WOS:000357507400002 PM 26110752 ER PT J AU Baker, JF Billig, E Michaud, K Ibrahim, S Caplan, L Cannon, GW Stokes, A Majithia, V Mikuls, TR AF Baker, Joshua F. Billig, Erica Michaud, Kaleb Ibrahim, Said Caplan, Liron Cannon, Grant W. Stokes, Andrew Majithia, Vikas Mikuls, Ted R. TI Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID BODY-MASS INDEX; DISEASE-ACTIVITY; US VETERANS; MORTALITY-RISKS; OLDER-ADULTS; HEALTH; ASSOCIATION; POPULATION; CATEGORIES; OVERWEIGHT AB ObjectiveIn contrast to what is observed in the general population, a low body mass index (BMI) has been associated with accelerated mortality in patients with rheumatoid arthritis (RA). The aim of this study was to assess whether weight loss might explain these seemingly paradoxical observations. MethodsOur study included patients identified from the Veterans Affairs (VA) RA Registry. Dates of death were abstracted from VA electronic medical records. The BMI at each study visit and the change from the previous visit were determined. The maximum BMI of each patient was also obtained from medical records. The annualized rate of BMI loss was determined from the slope of change (per year) in BMI over visits within the preceding 13 months. Cox multivariable proportional hazards models were used to assess associations between BMI measures and mortality. ResultsIn a sample of 1,674 patients, 312 deaths occurred over 9,183 person-years. A loss in BMI of 1 kg/m(2) was associated with a greater risk of death, after adjustment for demographics, comorbidities, BMI, smoking, and RA therapies (hazard ratio [HR] 1.99, 95% confidence interval [95% CI] 1.53-2.59, P<0.001). This association remained significant in a subsample analysis adjusting for C-reactive protein and physical function (HR 1.81, 95% CI 1.36-2.41, P<0.001). Weight loss at an annualized rate of 3 kg/m(2) was associated with the greatest risk of death (HR 2.49, 95% CI 1.73-3.57, P<0.001). Low BMI (<20 kg/m(2)) in patients with a history of obesity (>30 kg/m(2)) was associated with the greatest risk (HR 8.52, 95% CI 4.10-17.71, P<0.001). ConclusionWeight loss is a strong predictor of death in patients with RA. These observations may explain the observed obesity paradox and do not support a biologically protective role of obesity. C1 [Baker, Joshua F.; Ibrahim, Said] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.; Billig, Erica; Ibrahim, Said] Univ Penn, Philadelphia, PA 19104 USA. [Michaud, Kaleb; Mikuls, Ted R.] Nebraska Western Iowa VA Med Ctr, Omaha, NE USA. [Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Cannon, Grant W.] Salt Lake City VA Med Ctr, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Stokes, Andrew] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Majithia, Vikas] GV Sonny Montgomery VA Med Ctr, Montgomery, MS USA. [Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS USA. RP Baker, JF (reprint author), Hosp Univ Penn, Div Rheumatol, Dept Med, 8 Penn Tower Bldg,3600 Spruce St, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu OI Stokes, Andrew/0000-0002-8502-3636 FU VA Clinical Science Research and Development Career Development Award [IK2 CX000955]; Rheumatology Research Foundation; NIH from National Institute of Arthritis and Musculoskeletal and Skin Diseases [1-K24-AR-055259-01]; VA Health Service Research and Development Career Development Award [07-221]; VA Merit Award; Nebraska Arthritis Outcomes Research Center at the University of Nebraska Medical Center; VA Health Services Research and Development Program of the Veterans Health Administration FX Dr. Baker's work was supported by a VA Clinical Science Research and Development Career Development Award (IK2 CX000955). Dr. Michaud's work was supported by a Rheumatology Research Foundation Investigator Award. Dr. Ibrahim's work was supported by the NIH (grant 1-K24-AR-055259-01 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). Dr. Caplan's work was supported by a VA Health Service Research and Development Career Development Award (07-221). Dr. Mikuls' work was supported by a VA Merit Award. The VA Rheumatoid Arthritis Registry is supported by the Nebraska Arthritis Outcomes Research Center at the University of Nebraska Medical Center and by the VA Health Services Research and Development Program of the Veterans Health Administration. NR 33 TC 14 Z9 14 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD JUL PY 2015 VL 67 IS 7 BP 1711 EP 1717 DI 10.1002/art.39136 PG 7 WC Rheumatology SC Rheumatology GA CL5QA UT WOS:000357013500005 PM 25940140 ER PT J AU Leuchter, AF Cook, IA Feifel, D Goethe, JW Husain, M Carpenter, LL Thase, ME Krystal, AD Philip, NS Bhati, MT Burke, WJ Howland, RH Sheline, YI Aaronson, ST Iosifescu, DV O'Reardon, JP Gilmer, WS Jain, R Burgoyne, KS Phillips, B Manberg, PJ Massaro, J Hunter, AM Lisanby, SH George, MS AF Leuchter, Andrew F. Cook, Ian A. Feifel, David Goethe, John W. Husain, Mustafa Carpenter, Linda L. Thase, Michael E. Krystal, Andrew D. Philip, Noah S. Bhati, Mahendra T. Burke, William J. Howland, Robert H. Sheline, Yvette I. Aaronson, Scott T. Iosifescu, Dan V. O'Reardon, John P. Gilmer, William S. Jain, Rakesh Burgoyne, Karl S. Phillips, Bill Manberg, Paul J. Massaro, Joseph Hunter, Aimee M. Lisanby, Sarah H. George, Mark S. TI Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression SO BRAIN STIMULATION LA English DT Article DE Synchronized Transcranial Magnetic Stimulation (sTMS); Low-intensity magnetic field; Static magnet; Major Depressive Disorder; Clinical treatment trial; Neuromodulation; Individual Alpha Frequency (IAF); Alpha oscillations; Electroencephalogram (EEG); Oscillatory synchrony ID SHAM-CONTROLLED TRIALS; ALPHA-FREQUENCY; RATING-SCALE; DOUBLE-BLIND; METAANALYSIS; RTMS; TMS; MEDICATION; MULTISITE; EEG AB Background: Transcranial Magnetic Stimulation (TMS) customarily uses high-field electromagnets to achieve therapeutic efficacy in Major Depressive Disorder (MDD). Low-field magnetic stimulation also may be useful for treatment of MDD, with fewer treatment-emergent adverse events. Objective/Hypothesis: To examine efficacy, safety, and tolerability of low-field magnetic stimulation synchronized to an individual's alpha frequency (IAF) (synchronized TMS, or sTMS) for treatment of MDD. Methods: Six-week double-blind sham-controlled treatment trial of a novel device that used three rotating neodymium magnets to deliver sTMS treatment. IAF was determined from a single-channel EEG prior to first treatment. Subjects had baseline 17-item Hamilton Depression Rating Scale (HamD(17)) >= 17. Results: 202 subjects comprised the intent-to-treat (ITT) sample, and 120 subjects completed treatment per-protocol (PP). There was no difference in efficacy between active and sham in the ITT sample. Subjects in the PP sample (N = 59), however, had significantly greater mean decrease in HamD(17) than sham (N = 60) (-9.00 vs. -6.56, P = 0.033). PP subjects with a history of poor response or intolerance to medication showed greater improvement with sTMS than did treatment-naive subjects (-8.58 vs. -4.25, P = 0.017). Efficacy in the PP sample reflects exclusion of subjects who received fewer than 80% of scheduled treatments or were inadvertently treated at the incorrect IAF; these subgroups failed to separate from sham. There was no difference in adverse events between sTMS and sham, and no serious adverse events attributable to sTMS. Conclusions: Results suggest that sTMS may be effective, safe, and well tolerated for treating MDD when administered as intended. (C) 2015 Elsevier Inc. All rights reserved. C1 [Leuchter, Andrew F.; Cook, Ian A.; Hunter, Aimee M.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Leuchter, Andrew F.; Cook, Ian A.; Hunter, Aimee M.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Neuromodulat Div, Los Angeles, CA 90024 USA. [Feifel, David] UCSD Sch Med, Dept Psychiat, San Diego, CA USA. [Goethe, John W.] Hartford Hosp, Inst Living, Hartford, CT 06115 USA. [Husain, Mustafa] UT Southwestern Med Sch, Dept Psychiat, Dallas, TX USA. [Carpenter, Linda L.; Philip, Noah S.] Brown Univ, Alpert Med Sch, Butler Hosp, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Thase, Michael E.; Bhati, Mahendra T.; Sheline, Yvette I.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Husain, Mustafa; Krystal, Andrew D.; Lisanby, Sarah H.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA. [Burke, William J.] Univ Nebraska, Sch Med, Dept Psychiat, Omaha, NE 68198 USA. [Howland, Robert H.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. [Sheline, Yvette I.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Aaronson, Scott T.] Sheppard Pratt Hlth Syst, Baltimore, MD USA. [Iosifescu, Dan V.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [O'Reardon, John P.] Rowan Univ, Sch Osteopath Med, Dept Psychiat, Stratford, NJ USA. [Gilmer, William S.] Chicago TMS Specialists, Chicago, IL USA. [Jain, Rakesh] RD Clin Res, Lake Jackson, TX USA. [Burgoyne, Karl S.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Massaro, Joseph] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Phillips, Bill; Manberg, Paul J.] NeoSync Inc, Waltham, MA USA. [Manberg, Paul J.] NeoSync Inc, Newport Beach, CA USA. RP Leuchter, AF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav,Neuromodulat Di, 760 Westwood Plaza, Los Angeles, CA 90024 USA. EM afl@ucla.edu RI Philip, Noah/C-3714-2016; Burke, William/C-1203-2012; Howland, Robert/K-6937-2015 OI Philip, Noah/0000-0002-4889-8775; Howland, Robert/0000-0002-6533-6010 FU NeoSync, Inc. FX Sponsorship of and financial support for the conduct of this research was provided by NeoSync, Inc. As the study sponsor, the company was involved in study design, as well in the collection, analysis, and interpretation of data. The authors of this article have final authority and responsibility for the data analyses and interpretation of the results presented here. All individuals who participated in the writing of this report and in the decision to submit the article for publication are listed as co-authors on this manuscript. Because this was an industry-sponsored study, most of the authors have some financial relationship to the study sponsor. NR 48 TC 7 Z9 7 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD JUL-AUG PY 2015 VL 8 IS 4 BP 787 EP 794 DI 10.1016/j.brs.2015.05.005 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CM2WD UT WOS:000357542100014 PM 26143022 ER PT J AU Larsen, PM Teerlink, JR AF Larsen, Paul M. Teerlink, John R. TI Team-based Care for Patients Hospitalized with Heart Failure SO HEART FAILURE CLINICS LA English DT Article DE Acute heart failure; Team-based; Hospitalized; Interdisciplinary; Therapeutics ID PRESERVED EJECTION FRACTION; ASSOCIATION TASK-FORCE; LOW-DOSE FUROSEMIDE; RELAX-AHF; EMERGENCY-DEPARTMENT; NATRIURETIC PEPTIDE; CARDIAC TROPONIN; RANDOMIZED-TRIAL; MANAGEMENT TEAM; OUTCOMES AB Hospitalizations for acute heart failure (HF) and subsequent readmissions have received increased attention because of the burden they place on patients, providers, and the health care system. These hospitalizations represent a significant portion of the total cost of HF care and health care in general. Although much of the care of the patient with HF occurs outside of the hospital, the genesis of the programs that attempt to limit repeat hospitalizations begin in the impatient setting. By using evidence-based guidelines, interdisciplinary teams, and comprehensive discharge planning, costly readmissions can be reduced and outcomes improved. C1 [Larsen, Paul M.] Univ Calif San Francisco, Div Internal Med, Sch Med, San Francisco, CA 94143 USA. [Teerlink, John R.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, Sch Med, San Francisco, CA 94121 USA. RP Teerlink, JR (reprint author), Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, Sch Med, Cardiol 111C,Bldg 203 Room 2A49,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu NR 66 TC 1 Z9 1 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7136 J9 HEART FAIL CLIN JI Heart Fail. Clin. PD JUL PY 2015 VL 11 IS 3 BP 359 EP + DI 10.1016/j.hfc.2015.03.002 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CM3GU UT WOS:000357570900004 PM 26142635 ER PT J AU Sullivan, CA Kahn, SE Fujimoto, WY Hayashi, T Leonetti, DL Boyko, EJ AF Sullivan, Catherine A. Kahn, Steven E. Fujimoto, Wilfred Y. Hayashi, Tomoshige Leonetti, Donna L. Boyko, Edward J. TI Change in Intra-Abdominal Fat Predicts the Risk of Hypertension in Japanese Americans SO HYPERTENSION LA English DT Article DE adiposity; Asian Americans; hypertension; intra-abdominal fat ID VISCERAL ADIPOSE-TISSUE; IMPAIRED GLUCOSE-TOLERANCE; METABOLIC SYNDROME; INCIDENT HYPERTENSION; INSULIN-RESISTANCE; LIPOPROTEIN LEVELS; MEN; ASSOCIATION; PREVALENCE; OBESITY AB In Japanese Americans, intra-abdominal fat area measured by computed tomography is positively associated with the prevalence and incidence of hypertension. Evidence in other populations suggests that other fat areas may be protective. We sought to determine whether a change in specific fat depots predicts the development of hypertension. We prospectively followed up 286 subjects (mean age, 49.5 years; 50.4% men) from the Japanese American Community Diabetes Study for 10 years. At baseline, subjects did not have hypertension (defined as blood pressure 140/90 mmHg) and were not taking blood pressure or glucose-lowering medications. Mid-thigh subcutaneous fat area, abdominal subcutaneous fat area, and intra-abdominal fat area were directly measured by computed tomography at baseline and 5 years. Logistic regression was used to estimate odds of incident hypertension over 10 years in relation to a 5-year change in fat area. The relative odds of developing hypertension for a 5-year increase in intra-abdominal fat was 1.74 (95% confidence interval, 1.28-2.37), after adjusting for age, sex, body mass index, baseline intra-abdominal fat, alcohol use, smoking status, and weekly exercise energy expenditure. This relationship remained significant when adjusted for baseline fasting insulin and 2-hour glucose levels or for diabetes mellitus and pre-diabetes mellitus classification. There were no significant associations between baseline and change in thigh or abdominal subcutaneous fat areas and incident hypertension. In conclusion, in this cohort of Japanese Americans, the risk of developing hypertension is related to the accumulation of intra-abdominal fat rather than the accrual of subcutaneous fat in either the thigh or the abdominal areas. C1 [Kahn, Steven E.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Gen Med & Hosp Serv, Seattle, WA USA. [Kahn, Steven E.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Specialty Med Serv, Seattle, WA USA. [Sullivan, Catherine A.; Kahn, Steven E.] Univ Washington, Dept Med, Div Endocrinol Metab & Nutr, Seattle, WA USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. [Hayashi, Tomoshige] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Boyko, EJ (reprint author), VA Puget Sound S 123 PCC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM eboyko@uw.edu RI Hayashi, Tomoshige/N-8508-2015 OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU Medical Research Service and Cooperative Studies Program of the Department of Veterans Affairs, Seattle, WA; National Institutes of Health [DK-031170, HL-049293, DK-002654, DK-017047, DK-035816, RR-000037] FX This study was supported, in part, by the Medical Research Service and Cooperative Studies Program of the Department of Veterans Affairs, Seattle, WA, as well as National Institutes of Health grants DK-031170, HL-049293, DK-002654, DK-017047, DK-035816, and RR-000037. NR 39 TC 9 Z9 9 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD JUL PY 2015 VL 66 IS 1 BP 134 EP 140 DI 10.1161/HYPERTENSIONAHA.114.04990 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CL6MD UT WOS:000357080300021 PM 26063668 ER PT J AU Koren, D Chirinos, JA Katz, LEL Mohler, ER Gallagher, PR Mitchell, GF Marcus, CL AF Koren, D. Chirinos, J. A. Katz, L. E. L. Mohler, E. R. Gallagher, P. R. Mitchell, G. F. Marcus, C. L. TI Interrelationships between obesity, obstructive sleep apnea syndrome and cardiovascular risk in obese adolescents SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article ID INTIMA-MEDIA THICKNESS; PULSE-WAVE VELOCITY; ARTERIAL STIFFNESS; CAROTID-ARTERY; YOUNG-ADULTS; INSULIN-RESISTANCE; METABOLIC SYNDROME; UNITED-STATES; CHILDREN; ATHEROSCLEROSIS AB BACKGROUND/OBJECTIVES: Obstructive sleep apnea syndrome (OSAS) may be a cardiovascular disease (CVD) risk factor independently of obesity in adults. Pediatric studies have associated OSAS with endothelial dysfunction, but few studies have examined relationships between OSAS and macrovascular sequelae. Our objective was to examine OSAS's independent contribution to macrovascular CVD risk measures in obese adolescents. SUBJECTS/METHODS: This cross-sectional observational study was conducted at Children's Hospital of Philadelphia Clinical Research and Academic Sleep Centers, and University of Pennsylvania Vascular Research Unit. Thirty-one obese non-diabetic adolescents underwent anthropometric measurements, overnight polysomnography, fasting laboratory draw and cardiovascular imaging. Cardiovascular outcome measures included maximal carotid intima-media thickness (cIMTmax), a measure of carotid structural changes, and carotid-femoral pulse wave velocity (CFPWV), an aortic stiffness measure whose relationship vis-a-vis OSAS in children has not been previously examined. Carotid diameter and augmentation index (AIx, measuring central pressure augmentation from wave reflections) were assessed. Potential confounding variables examined included blood pressure, lipoproteins, high-sensitivity C-reactive protein, insulin and glucose. RESULTS: The apnea hypopnea index, a primary OSAS measure, was not associated with cIMTmax, carotid diameter, CFPWV or AIx. body mass index (BMI) associated positively with cIMTmax (r = 0.52, P = 0.006) and CFPWV (r = 0.45, P = 0.01). Mean asleep end-tidal CO2 was negatively associated with carotid diameter (r = -0.63, P < 0.0005). Insulin levels were negatively associated with AIx (r = -0.53, P = 0.02). CONCLUSIONS: OSAS did not predict carotid structural changes or arterial stiffness independently of BMI in obese adolescents. Higher insulin levels associated with lower central pressure wave augmentation. Finally, long-term hypercapnia may predispose to carotid narrowing. C1 [Koren, D.] Univ Chicago, Sect Endocrinol Diabet & Metab, Pediat, Chicago, IL 60637 USA. [Chirinos, J. A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Chirinos, J. A.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Katz, L. E. L.] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Pediat, Philadelphia, PA USA. [Mohler, E. R.] Univ Penn, Perelman Sch Med, Vasc Med Sect, Dept Med,Cardiovasc Div, Philadelphia, PA USA. [Gallagher, P. R.] Childrens Hosp Philadelphia, Biostat Core, Clin & Translat Res Ctr, Philadelphia, PA 19104 USA. [Mitchell, G. F.] Cardiovasc Engn Inc, Norwood, MA USA. [Marcus, C. L.] Childrens Hosp Philadelphia, Sleep Ctr, Pediat, Philadelphia, PA 19104 USA. [Marcus, C. L.] Univ Penn, Philadelphia, PA 19104 USA. RP Koren, D (reprint author), Univ Chicago, Pediat & Med, Sect Adult & Pediat Endocrinol Diabet & Metab, 5841 S Maryland Ave, Chicago, IL 60637 USA. EM dkoren@peds.bsd.uchicago.edu FU NIH [KL2 RR024132, RO1 HL58585] FX We would like to thank our research participants and their families for their time and efforts in participating in our study, the sleep technicians who oversaw and scored the polysomnography studies, and the research coordinators who helped with study recruitment. The study was supported by NIH KL2 RR024132 and NIH RO1 HL58585. NR 49 TC 11 Z9 11 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD JUL PY 2015 VL 39 IS 7 BP 1086 EP 1093 DI 10.1038/ijo.2015.67 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CM5LW UT WOS:000357730400008 PM 25913504 ER PT J AU Townsend, RR Black, HR Chirinos, JA Feig, PU Ferdinand, KC Germain, M Rosendorff, C Steigerwalt, SP Stepanek, JA AF Townsend, Raymond R. Black, Henry R. Chirinos, Julio A. Feig, Peter U. Ferdinand, Keith C. Germain, Michael Rosendorff, Clive Steigerwalt, Susan P. Stepanek, Jan A. TI Clinical Use of Pulse Wave Analysis: Proceedings From a Symposium Sponsored by North American Artery SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID CENTRAL BLOOD-PRESSURE; CARDIOVASCULAR RISK-FACTORS; ASCENDING AORTIC PRESSURE; AUGMENTATION INDEX; REPRODUCIBILITY; AMPLIFICATION; VALIDATION; VELOCITY; FORM AB The use of pulse wave analysis may guide the provider in making choices about blood pressure treatment in prehypertensive or hypertensive patients. However, there is little clinical guidance on how to interpret and use pulse wave analysis data in the management of these patients. A panel of clinical researchers and clinicians who study and clinically use pulse wave analysis was assembled to discuss strategies for using pulse wave analysis in the clinical encounter. This manuscript presents an approach to the clinical application of pulse waveform analysis, howto interpret central pressure waveforms, and how to use existing knowledge about the pharmacodynamic effect of antihypertensive drug classes in combination with brachial and central pressure profiles in clinical practice. The discussion was supplemented by case-based examples provided by panel members, which the authors hope will provoke discussion on how to understand and incorporate pulse wave analysis into clinical practice. (C) 2015 Wiley Periodicals, Inc. C1 [Townsend, Raymond R.; Chirinos, Julio A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Black, Henry R.] NYU, Sch Med, Ctr Prevent Cardiovasc Dis, New York, NY USA. [Feig, Peter U.] Weill Cornell Med Coll, New York, NY USA. [Ferdinand, Keith C.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Germain, Michael] Baystate Med Ctr, Springfield, MA USA. [Germain, Michael] Tufts Univ, Springfield, MA USA. [Rosendorff, Clive] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY USA. [Steigerwalt, Susan P.] St Clair Specialty Phys, Detroit, MI USA. [Stepanek, Jan A.] Mayo Clin, Div Prevent Occupat & Aerosp Med, Scottsdale, AZ USA. RP Townsend, RR (reprint author), Univ Penn, Renal Electrolyte & Hypertens Div, Perelman Sch Med, 122 Founders Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM townsend@exchange.upennn.edu FU AtCor Medical; National Institutes of Health FX This symposium was supported by an unrestricted grant to North American Artery from AtCor Medical, which covered travel costs and a small stipend for attendees. RRT: National Institutes of Health grant in a relevant area; HRB, JAC, PUF, KCF, MG, CR, SPS, and JAS: nothing to declare. NR 14 TC 4 Z9 4 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JUL PY 2015 VL 17 IS 7 BP 503 EP 513 DI 10.1111/jch.12574 PG 11 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CM1GI UT WOS:000357428900003 PM 26010834 ER PT J AU Apovian, CM Garvey, WT Ryan, DH AF Apovian, Caroline M. Garvey, W. Timothy Ryan, Donna H. TI Challenging Obesity: Patient, Provider, and Expert Perspectives on the Roles of Available and Emerging Nonsurgical Therapies SO OBESITY LA English DT Article ID LIFE-STYLE INTERVENTION; WEIGHT CONTROL REGISTRY; CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; CLINICAL ENDOCRINOLOGISTS; AMERICAN ASSOCIATION; BARIATRIC SURGERY; POSITION STATEMENT; CONTROLLED-RELEASE; SEROTONIN SYNDROME AB Objective: Adult obesity is recognized as a chronic disease. According to principles of chronic disease management, healthcare professionals should work collaboratively with patients to determine appropriate therapeutic strategies that address overweight and obesity, specifically considering a patient's disease status in addition to their individual needs, preferences, and attitudes regarding treatment. A central role and responsibility of healthcare professionals in this process is to inform and educate patients about their treatment options. Although current recommendations for the management of adult obesity provide general guidance regarding safe and proper implementation of lifestyle, pharmacological, and surgical interventions, healthcare professionals need awareness of specific evidence-based information that supports individualized clinical application of these therapies. More specifically, healthcare professionals should be up-to-date on approaches that promote successful lifestyle management and be knowledgeable about newer weight loss pharmacotherapies, so they can offer patients with obesity a wide range of options to personalize their treatment. Accordingly, this educational activity has been developed to provide participants with the latest information on treatment recommendations and therapeutic advances in lifestyle intervention and pharmacotherapy for adult obesity management. Design and Methods: This supplement is based on the content presented at a live CME symposium held in conjunction with ObesityWeek 2014. Results: This supplement provides an expert summary of current treatment recommendations and recent advances in nonsurgical therapies for the management of adult obesity. Patient and provider perspectives on obesity management are highlighted in embedded video clips available via QR codes, and new evidence will be applied using clinically relevant case studies. Conclusions: This supplement provides a topical update of obesity management, including clinical practice examples, for healthcare professionals who treat or provide care for adults with obesity. C1 [Apovian, Caroline M.] Boston Univ, Sch Med, Nutr & Weight Management Ctr, Dept Med, Boston, MA 02215 USA. [Apovian, Caroline M.] Boston Univ, Sch Med, Nutr & Weight Management Ctr, Dept Pediat, Boston, MA 02215 USA. [Apovian, Caroline M.] Boston Med Ctr, Nutr Support Serv, Boston, MA USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] UAB Diabet Res Ctr, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. [Ryan, Donna H.] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. RP Apovian, CM (reprint author), Boston Univ, Sch Med, Nutr & Weight Management Ctr, Dept Med, Boston, MA 02215 USA. EM Caroline.apovian@bmc.org FU Novo Nordisk Inc. FX This activity is supported by an educational grant from Novo Nordisk Inc. NR 102 TC 7 Z9 7 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD JUL PY 2015 VL 23 SU 2 BP S1 EP S26 DI 10.1002/oby.21140 PG 26 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CM6RW UT WOS:000357818500001 PM 26154880 ER PT J AU Jia, H Cong, Q Chua, JFL Liu, H Xia, X Zhang, X Lin, J Habib, SL Ao, J Zuo, Q Fu, C Li, B AF Jia, H. Cong, Q. Chua, J. F. L. Liu, H. Xia, X. Zhang, X. Lin, J. Habib, S. L. Ao, J. Zuo, Q. Fu, C. Li, B. TI p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance SO ONCOGENE LA English DT Article ID BECKWITH-WIEDEMANN-SYNDROME; IN MOUSE MODEL; CDK INHIBITORS; P57(KIP2) EXPRESSION; STEM-CELLS; CANCER; P38; P57; ATM; DIFFERENTIATION AB The DNA damage response (DDR) helps to maintain genome integrity, suppress tumorigenesis and mediate the radiotherapeutic and chemotherapeutic effects on cancer. Here we report that p57Kip2, a cyclin-dependent kinase (CDK) inhibitor implicated in the development of tumor-prone Beckwith-Wiedemann syndrome, is an effector molecule of the DNA-damage response. Genotoxic stress induces p57Kip2 expression via the bone morphogenetic protein-Smad1 and Atm-p38MAPK-Atf2 pathways in p53-proficient or -deficient cells and requires the Smad1-Atf2 complex that facilitates their recruitment to the p57Kip2 promoter. Elevated p57Kip2 induces G1/S phase cell cycle arrest but inhibits cell death in response to DNA damage and acts in parallel with p53 to suppress cell transformation and tumor formation. p57Kip2 is also upregulated in stage I and II clinical rectal tumor samples, likely due to genome instability of precancerous and/or early cancer cells. Targeting p57Kip2 in primary rectal cancer cells and tumor models resulted in increased sensitivity to doxorubicin, suggesting that p57Kip2 has a role in chemoresistance, which is consistent with its pro-survival function. These findings place p57Kip2 in DDR and uncover molecular mechanisms by which p57Kip2 suppresses tumorigenesis and causes chemoresistance. C1 [Jia, H.; Cong, Q.; Liu, H.; Xia, X.; Zhang, X.; Lin, J.; Li, B.] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai 200240, Peoples R China. [Chua, J. F. L.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore. [Habib, S. L.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Habib, S. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ao, J.] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200240, Peoples R China. [Zuo, Q.; Fu, C.] Second Mil Med Univ, Changhai Hosp, Dept Colorectal Surg, Shanghai, Peoples R China. RP Li, B (reprint author), Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Dongchuan Rd 800, Shanghai 200240, Peoples R China. EM libj@sjtu.edu.cn RI ASTAR, IMCB/E-2320-2012 FU Ministry of Science and Technology of China [2012CB966901]; National Natural Science Foundation of China [81130039, 31071229, 81121001] FX We thank Lina Gao, IH In, C Deyu, GC Hong, L Soh, J Lin and T Cheng for technical assistance and Boehringer Ingelheim, Novartis, Dr Michael D. Schneider, Dr Ye-Guang Chen, Dr Yibin Wang, Dr Nelson J Dusetti, Dr Olivier Delattre, Dr Philipp Kaldis and Dr Michael Kastan for providing constructs, reagents and mice. The work was supported by grants from the Ministry of Science and Technology of China (The National Key Scientific Program (2012CB966901 to BL) and the National Natural Science Foundation of China (81130039, 31071229 and 81121001). NR 62 TC 4 Z9 4 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 EI 1476-5594 J9 ONCOGENE JI Oncogene PD JUL PY 2015 VL 34 IS 27 BP 3568 EP 3581 DI 10.1038/onc.2014.287 PG 14 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA CM1IQ UT WOS:000357434900009 PM 25195859 ER PT J AU Bowman, C Luck, J Gale, RC Smith, N York, LS Asch, S AF Bowman, Candice Luck, Jeff Gale, Randall C. Smith, Nina York, Laura S. Asch, Steven TI A Qualitative Evaluation of Web-Based Cancer Care Quality Improvement Toolkit Use in the Veterans Health Administration SO QUALITY MANAGEMENT IN HEALTH CARE LA English DT Article ID IMPLEMENTATION; COLLABORATIVES; INNOVATION; DIFFUSION; LESSONS; PROGRAM; SYSTEM AB Background: Disease severity, complexity, and patient burden highlight cancer care as a target for quality improvement (QI) interventions. The Veterans Health Administration (VHA) implemented a series of disease-specific online cancer care QI toolkits. Objectives: To describe characteristics of the toolkits, target users, and VHA cancer care facilities that influenced toolkit access and use and assess whether such resources were beneficial for users. Methods: Deductive content analysis of detailed notes from 94 telephone interviews with individuals from 48 VHA facilities. We evaluated toolkit access and use across cancer types, participation in learning collaboratives, and affiliation with VHA cancer care facilities. Results: The presence of champions was identified as a strong facilitator of toolkit use, and learning collaboratives were important for spreading information about toolkit availability. Identified barriers included lack of personnel and financial resources and complicated approval processes to support tool use. Conclusions: Online cancer care toolkits are well received across cancer specialties and provider types. Clinicians, administrators, and QI staff may benefit from the availability of toolkits as they become more reliant on rapid access to strategies that support comprehensive delivery of evidence-based care. Toolkits should be considered as a complement to other QI approaches. C1 [Bowman, Candice; Luck, Jeff; Smith, Nina; York, Laura S.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Luck, Jeff] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA. [Gale, Randall C.; Asch, Steven] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA. [Asch, Steven] Stanford Univ, Div Gen Med Disciplines, Palo Alto, CA 94304 USA. RP Gale, RC (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 790 Willow Rd, Menlo Pk, CA 94025 USA. EM randall.gale@va.gov FU VA Office of Analytics and Business Intelligence; VA Office of Systems Redesign FX This study was funded by VA Office of Analytics and Business Intelligence and VA Office of Systems Redesign with additional in-kind support from VA Center for Applied Systems Engineering. The authors thank the following for their contributions to this evaluation and the manuscript: Sangeeta Ahluwalia, PhD; Carla S. Alvarado, MPH; Jenny Barnard, BA; Bonnie Bruce, DrPH; Danielle Cohen, MPH; Marlin Elenes, MPH; Joya Golden, MSW; Christopher J. Koenig, PhD; Andrea Nevedal, PhD; and Sabine Oishi, PhD. NR 32 TC 0 Z9 0 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1063-8628 EI 1550-5154 J9 QUAL MANAG HEALTH CA JI Qual. Manag. Health Care PD JUL-SEP PY 2015 VL 24 IS 3 BP 147 EP 161 DI 10.1097/QMH.0000000000000063 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CM8HY UT WOS:000357941400007 PM 26115063 ER PT J AU Xu, K Kranzler, HR Sherva, R Sartor, CE Almasy, L Koesterer, R Zhao, HY Farrer, LA Gelernter, J AF Xu, Ke Kranzler, Henry R. Sherva, Richard Sartor, Carolyn E. Almasy, Laura Koesterer, Ryan Zhao, Hongyu Farrer, Lindsay A. Gelernter, Joel TI Genomewide Association Study for Maximum Number of Alcoholic Drinks in European Americans and African Americans SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol Maximum Drinks; Genomewide Association; African American; European American ID WIDE ASSOCIATION; NICOTINE DEPENDENCE; COCAINE DEPENDENCE; CONSUMPTION; RISK; GENES; LOCI; DEHYDROGENASE; METAANALYSIS; METABOLISM AB BackgroundWe conducted a genomewide association study (GWAS) for maximum number of alcoholic drinks consumed in a 24-hour period (MaxDrinks), in 2 independent samples comprised of over 9,500 subjects, following up on our GWAS for alcohol dependence (AD) in European Americans (EAs) and African Americans (AAs). MethodsThe samples included our GWAS samples (Yale-UPenn) recruited for studies of the genetics of drug or AD, and a publicly available sample: the Study of Addiction: Genetics and Environment (SAGE). Genomewide association analysis was performed for similar to 890,000 single nucleotide polymorphisms (SNPs) using linear association random effects models. EAs and AAs were separately analyzed. ResultsThe results confirmed significant associations of the well-known functional loci at ADH1B with MaxDrinks in EAs (rs1229984 Arg48His p=5.96x10(-15)) and AAs (rs2066702 Arg370Cys, p=2.50x10(-10)). The region of significant association on chromosome 4 was extended to LOC100507053 in AAs but not EAs. We also identified potentially novel significant common SNPs for MaxDrinks in EAs in the Yale-UPenn sample: rs1799876 at SERPINC1 on chromosome 1 (4.00x10(-8)) and rs2309169 close to ANKRD36 on chromosome 2 (p=5.58x10(-9)). After adjusting for the peak SNP rs1229984 on ADH1B, rs1799876 was nearly significant (p=1.99x10(-7)) and rs2309169 remained highly significant (2.12x10(-9)). ConclusionsThe results provide further support that ADH1B modulates alcohol consumption. Future replications of potential novel loci are warranted. This is the largest MaxDrinks GWAS to date, the first in AAs. C1 [Xu, Ke; Sartor, Carolyn E.; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. VA CT Healthcare Ctr, West Haven, CT USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet & Neurobiol, West Haven, CT 06516 USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, VISN MIRECC 4, Philadelphia, PA USA. [Sherva, Richard; Koesterer, Ryan; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA. [Almasy, Laura] Texas Biomed Res Inst, Dept Psychiat, San Antonio, TX USA. [Zhao, Hongyu] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA. RP Gelernter, J (reprint author), Yale Univ, Sch Med, Dept Psychiat, VA CT 116A2,950 Campbell Ave, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu OI Farrer, Lindsay/0000-0001-5533-4225 FU National Institutes of Health [RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, K12 DA000167, K01 AA017921]; Robert E. Leet and Clara Guthrie Patterson Trust; VA Connecticut and Philadelphia VA MIRECCs; AbbVie; Alkermes; Ethypharm; Lilly; Lundbeck; Pfizer FX This study was supported by National Institutes of Health grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, K12 DA000167, K01 AA017921, and the Robert E. Leet and Clara Guthrie Patterson Trust; and the VA Connecticut and Philadelphia VA MIRECCs.; Dr. Kranzler has been a consultant or advisory board member for Alkermes, Lilly, Lundbeck, Pfizer, and Roche. He is also a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trial Initiative, which is supported by AbbVie, Alkermes, Ethypharm, Lilly, Lundbeck, and Pfizer. NR 36 TC 2 Z9 2 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUL PY 2015 VL 39 IS 7 BP 1137 EP 1147 DI 10.1111/acer.12751 PG 11 WC Substance Abuse SC Substance Abuse GA CM0RW UT WOS:000357387000006 PM 26036284 ER EF